<SEC-DOCUMENT>0000950170-24-097065.txt : 20240814
<SEC-HEADER>0000950170-24-097065.hdr.sgml : 20240814
<ACCEPTANCE-DATETIME>20240814162314
ACCESSION NUMBER:		0000950170-24-097065
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		73
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20240814
DATE AS OF CHANGE:		20240814

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Turnstone Biologics Corp.
		CENTRAL INDEX KEY:			0001764974
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				832909368
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41747
		FILM NUMBER:		241208358

	BUSINESS ADDRESS:	
		STREET 1:		9310 ATHENA CIRCLE, SUITE 300
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		347-897-5988

	MAIL ADDRESS:	
		STREET 1:		9310 ATHENA CIRCLE, SUITE 300
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>tsbx-20240630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-08-14T16:11:49.7910+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:calc="https://xbrl.org/2023/calculation-1.1" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:tsbx="http://www.turnstonebio.com/20240630" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-Q</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_04344c20-4f24-4f81-a6b4-dbe7d774840c" name="dei:DocumentFiscalPeriodFocus" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954">Q2</ix:nonNumeric><ix:nonNumeric id="F_2da71bec-8891-47e7-82f0-640f16d3fc7b" name="dei:AmendmentFlag" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_07e42a2d-d157-44e6-9324-6a4e16ecf7d9" name="dei:EntityCentralIndexKey" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954">0001764974</ix:nonNumeric><ix:nonNumeric id="F_00e4de9f-3d92-44e6-a456-7faa198b006c" name="dei:CurrentFiscalYearEndDate" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954">--12-31</ix:nonNumeric><ix:nonNumeric id="F_8fb38185-ea26-45ab-b107-b14eace25cd0" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954">http://fasb.org/us-gaap/2024#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric id="F_d519c220-b9c0-4efc-ae00-16610eda5851" name="us-gaap:InvestmentTypeExtensibleEnumeration" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b">http://fasb.org/us-gaap/2024#ShortTermInvestmentsMember</ix:nonNumeric><ix:nonNumeric id="F_07c37049-61be-45e2-82d2-712a7c000aaa" name="us-gaap:InvestmentTypeExtensibleEnumeration" contextRef="C_dfe46888-9d65-4c68-a853-215029dc9872">http://fasb.org/us-gaap/2024#ShortTermInvestmentsMember</ix:nonNumeric><ix:nonNumeric id="F_86aca0ff-7597-42fd-ba5f-977c1204204c" name="us-gaap:CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" contextRef="C_325b972a-88a3-49e4-a865-f3c3e4c449cb">http://fasb.org/us-gaap/2024#Revenues</ix:nonNumeric><ix:nonNumeric id="F_7a312f44-81d0-4aab-b68e-4d0c368d2aae" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" contextRef="C_d4a98e5a-d94e-4f1c-b7cf-4ba20e9be13c">http://fasb.org/us-gaap/2024#NonoperatingIncomeExpense</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="tsbx-20240630.xsd"/></ix:references><ix:resources><xbrli:context id="C_80bdbeb9-b4a1-45e1-87bb-ef7e5bd3a405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tsbx:PriceModificationAxis">tsbx:PricePreModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">tsbx:DiscoveryProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_80fd60e1-4de1-4fea-91cc-497c425d7782"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tsbx:AgreementAxis">tsbx:OperatingLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tsbx:OfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8136f853-5792-4e82-a119-8cc35daccd6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:RemainingMystHoldersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:SecondMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_82a867ab-5d5f-459b-8a82-12bbd36560a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesB1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_83258d10-36fd-47d8-8435-ebb348293175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_838eb810-3507-46b7-b156-72691850ae36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_83c6962e-9c53-4e63-b1ff-31ca5d0d2f3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">tsbx:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_862de778-6688-462a-b351-4d149c16a617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_86842d26-2e12-4042-998d-29e3bb96ed47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tsbx:SharesAvailableForIssuanceUnderPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86fd67e3-caa9-4cfa-8107-a69bd2da8aa7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tsbx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_87d12abd-fd41-4556-ab97-906718a6de21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">tsbx:DevelopmentProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tsbx:MilestoneAxis">tsbx:FirstMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_87edcac5-f97d-43c3-9877-1d9fda334fd6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">tsbx:RestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8916fdbc-eab2-44d0-8e8f-7bb4a95aae54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a2c0799-2ad0-4d20-8a89-44e9c7d5025f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a4b4f37-0658-467b-8161-438bc3405ed1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesB2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8aa8eff8-bf22-4098-92ea-223279b190c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b5fa308-adf1-4661-99fb-c63ef4adc638"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8b8a1ea1-2432-469c-84b7-3b0a47c7f036"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8eddfc98-0dbe-49c8-9be7-73a81bdcbff8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesB1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8eeaadf6-6367-4498-a18c-12b0327753e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_93377237-7cd1-48a2-b8a5-b9a2243d15e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_96148a81-8dcb-40e9-8bcc-218ebdce5605"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-31</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_971026b7-966d-464b-8792-32c68702fcf6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:H.LeeMoffittCancerCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:AllianceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9755dc24-1227-4784-baf5-a2b45b159779"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9800e42c-8612-4c53-9cab-3c07fc9a6fbb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c8cc4df-6000-4875-a29a-4d3c9dd0d7c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9d04382e-1108-4cb1-91e7-16fb7b6fd93d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d04f62a-8f18-4763-a524-2381aeebe491"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9d84a11b-47e8-4e33-b8ab-f05dc1707a83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9e1380fe-5300-44d7-addc-af012845a913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:MystHoldersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:SecondMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e6ce855-a23c-4318-9cf7-7b65d716e1a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f42a392-3c59-43e9-a2a2-d060b68b5b79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f5bac87-6928-4532-8588-a3d080f1d32d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:InitialMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:RemainingMystHoldersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a11683c6-5fef-4195-864f-a7d508bdc2d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tsbx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a12fbc8f-79f0-4426-843d-ec27ad6e7c70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a282ba00-b430-4f99-a7fb-75b6613249a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a2c92d2f-8c3a-4345-9949-14d05e745e9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a4224032-80db-4207-a62f-06fddc1f3e8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">tsbx:RestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a72293d1-c825-4856-b60c-948ad5751e42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsbx:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8118d4e-4113-40b7-b543-3bea71a014bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a8f26943-f1b9-49c8-b166-c849e9c3a34e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-15</xbrli:startDate><xbrli:endDate>2020-12-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a963c822-6da7-4671-af23-c5e6b30f3e6b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tsbx:MilestoneAxis">tsbx:SalesMilestonesOnLicensedDiscoveryProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ab5c8887-9c0a-4afb-8d68-eae695a3dd3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac0cf97a-5db0-4110-a9ce-20faacb87521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesB2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac923606-471a-43f0-8bdf-735ab3fdfba1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_adb55f11-8d4b-474a-b9d9-4cbcb3d9be20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-26</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b070210d-0df6-446b-9018-f836d7eb1564"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-30</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b169253e-4db8-48b5-a2f6-a9d18d0f3f36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1d0d042-927c-480f-9792-c14b9cf5f6d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b283014b-e73a-4c69-9931-4985a3e59add"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b34ba69f-3f68-4be6-9f1b-44db7d637865"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tsbx:TimothyLangerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b3dc0960-b79a-43dc-b52d-544a4f88fb55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">tsbx:DevelopmentProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b415a509-074d-4b97-86e2-0deee38dd0b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsbx:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tsbx:ReturningSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b49bbb74-b521-4de0-8223-a4c6342ce9da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">tsbx:DevelopmentProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tsbx:PriceModificationAxis">tsbx:PricePreModificationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4bc9727-1662-4540-9335-43dccebbd817"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsbx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b5d7d3a5-05a6-4a7d-b86b-89c61ed59b35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tsbx:PriceModificationAxis">tsbx:PriceAtModificationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b61d7932-d1b3-455d-a3a5-9627e4bd93da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tsbx:TimothyLangerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b6215fc5-849f-462e-86bf-6b597390fe38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b6c3ec3d-2d98-49dd-9189-5cbaccf94ce2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b8a7d77b-acc4-44c2-a6eb-53af2968c508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bbc99879-3c57-49b9-b3a2-7c36543a3a7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bdee48eb-7f4a-46cb-b069-06ddbd37a077"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bdf52929-1966-47f8-aeba-19d09b7e879d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tsbx:AgreementAxis">tsbx:OperatingLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tsbx:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_be0f70da-b5dc-4227-b5d4-1a3bd3c8a13d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesB1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-10-01</xbrli:startDate><xbrli:endDate>2016-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be5fa637-0934-415e-a76d-cef88c5177de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-25</xbrli:startDate><xbrli:endDate>2023-07-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bea27948-4ee5-4b9b-8b58-855991725981"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bed097c6-a12a-48ed-ab84-40a66008425b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf315150-6fec-4edf-8d74-affc42e06301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf4bea3d-6d81-4dab-a5e9-0fb7804e121d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:LangerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c0b79b4e-6d2e-4c6f-9298-ac7fa6a0af9c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c2fc5443-940d-4d73-8fd5-8bcdd4605301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c5cddb37-672e-4bc6-993b-61b085312425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-25</xbrli:startDate><xbrli:endDate>2023-07-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c5e178ae-25e5-4b12-b4f7-11636d959e09"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tsbx:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c6cfacbc-df8a-46ce-911a-93257d4940af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tsbx:PriceModificationAxis">tsbx:PricePreModificationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c6e4f9a3-9885-44ca-907d-b6658de8f0e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-15</xbrli:startDate><xbrli:endDate>2023-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c6f26a23-43b5-452a-9c94-f293c2677e84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c72ae3f1-ec49-47ae-8a52-43699c15abfc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c762659f-a398-4da4-b6b5-fb1c73edfefd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:LangerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:SecondMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c9641d36-9a68-4e01-bcd1-21dd6a75222f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ca9e9c5b-5d60-4a1b-8ad7-f5f5e30eeccd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:MystHoldersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:SecondMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cad3a30c-8bbd-41b5-8824-b6ed0ebc07b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tsbx:MystMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cada1dd4-e094-4155-bd2f-9d9d53838f8b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">tsbx:MeasurementInputLikelihoodOfOccurrenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tsbx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cb7e98d1-0ba9-403c-aa73-cc10851ec0f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cb80c5db-70c4-46c8-b391-908e60dc4392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tsbx:AgreementAxis">tsbx:OperatingLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d07e96e4-27c7-461d-87e0-bfe0e09106c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d0a34fda-1a97-4930-aa8e-a5ab1c515de5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tsbx:AgreementAxis">tsbx:OperatingLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tsbx:OfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d347b544-ac7a-4849-8e58-614bec001e25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-30</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3863644-3003-48be-ba26-f907692ad408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d4a98e5a-d94e-4f1c-b7cf-4ba20e9be13c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d7168d5d-e7a5-46ff-9b87-4e0562cb00e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:LangerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:SecondMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d917210f-1291-4dbd-86d6-3aa84bc8ab10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesB1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d92a8a59-80bf-4bc8-8d8b-2f30a155d5e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tsbx:LaboratorySpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tsbx:AgreementAxis">tsbx:OperatingLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9bf8d53-5a76-4443-ae16-8d541daf5ad2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_db72c5ee-0057-4dec-a48f-c46b4c093ae7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_db819b3e-1792-4c62-b813-10d6991af201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc19bbcb-5619-4e9c-8fd6-1b3767d599b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:H.LeeMoffittCancerCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:AllianceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dd6315d5-b691-40c0-8822-66150720e552"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:H.LeeMoffittCancerCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:AllianceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tsbx:MilestoneAxis">tsbx:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dd66f43c-636a-4989-849e-33408277fa05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dde16e3b-95a2-4acb-a8f5-4219383626cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:RemainingMystHoldersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:SecondMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ddebe139-151f-44ec-8890-0c2c9c33904a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:MystHoldersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:SecondMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_de5bd2cb-2a69-4ca4-88ea-be6ca6b3d91e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_df0e855c-ac6b-4b9c-86e6-10fbdce55a16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_df1018cd-e834-471b-a1de-7f644abc127e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tsbx:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df3730e6-4b3b-4511-9b22-d73a3cb03c8b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:LangerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df7b7c66-464a-441f-91fd-4ca59bed28ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dfe46888-9d65-4c68-a853-215029dc9872"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1930a00-b656-4b09-88f7-718672d19d95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:LangerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:SecondMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1ea96db-9cc4-4129-9e50-4fac54584f5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">tsbx:DevelopmentProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tsbx:MilestoneAxis">tsbx:SecondMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e2186eec-5e5a-4c75-b0fd-9b1fdf69034e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesB2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e3da0be9-f805-4bd4-bb62-9cbb32dda1e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-31</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e72bcdb4-17b9-4881-84a9-0f4fe4e39f0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e83e1bee-c31a-4456-a69d-f9eab649bf3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e8c17d3b-ae8b-41f1-a20f-40ff4625b247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tsbx:AgreementAxis">tsbx:OperatingLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tsbx:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ea03660c-6f74-4aa0-a083-02a3316775a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:InitialMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:MystHoldersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eab032e1-3425-462f-8d5e-286e582b438d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:LangerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:SecondMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-08</xbrli:startDate><xbrli:endDate>2022-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ecd3cf07-fefb-416f-8ca3-3ebe03141ea5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ece257ea-a6a0-437c-89a2-7ad5c9fc8aa2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-26</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed2ba762-cc53-4aa6-ad18-93928a0e9e83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ee135c52-c1b2-4ad5-911b-acfb5c8e8f2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eea7aad0-d598-4675-97e4-495ad0d5f473"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f0568106-d7a9-414e-a63d-3cea66f35a6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f13a602c-d40d-43cb-af5a-1b863d53488c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tsbx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f25cb532-a515-4fa7-abaf-0947b47f1a2d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f29d5b9e-4d61-4151-a985-c2091e0f2865"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tsbx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f3098a29-f113-4e61-967a-00d2ad37159d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tsbx:AgreementAxis">tsbx:OperatingLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tsbx:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f4165f52-0752-4cfc-8c7f-a573ebe98155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tsbx:MilestoneAxis">tsbx:ClinicalAndRegulatoryMilestonesOnLicensedDiscoveryProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6268a98-55de-42e4-b33f-cf7c0879c342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f744bbe6-544a-4cb6-9ffc-e06c7c098585"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f8d09b91-2147-483c-b5ae-6de7be334706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tsbx:AgreementAxis">tsbx:OperatingLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fa91a432-14eb-479a-ab9e-c343bfe09637"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fab6d8a7-91ff-48ba-9d83-2f673cd37dd0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fbbc94d3-e5cf-4af0-9f58-49c609a48ce9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tsbx:LaboratorySpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tsbx:AgreementAxis">tsbx:OperatingLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fde9996f-abc3-46c0-958f-c7d1eb86e821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:LangerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-14</xbrli:startDate><xbrli:endDate>2022-06-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe429d1a-4bd7-4dc5-aa72-7fe35faa4549"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tsbx:SharesAvailableForIssuanceUnderEsppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ffd72f23-b073-4049-978f-aa0c05133c6b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0041f20c-fe1a-4d2b-a3bf-ab3dc220fe5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">tsbx:DevelopmentProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_018d9f0a-f1a9-461c-a05d-3b501d8ad8bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02fa49d2-1f02-4cc7-908f-06f8c20ff1f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0532a010-4fab-45c5-a50c-f89be68e5dbd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tsbx:MilestoneAxis">tsbx:ClinicalAndRegulatoryMilestonesOnDevelopmentProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_06019969-ab1c-456b-98ef-d496be6c8d74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsbx:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tsbx:NewSharesUnderTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_076f0cb5-40e9-4509-958f-29eee0f3a275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07b24899-50be-4afd-9968-9f3387fa7317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_07beddb2-5e8d-4fd2-a982-9c19bd8f1784"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">tsbx:MeasurementInputLikelihoodOfOccurrenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tsbx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_08eea265-04df-4ba5-a0a1-6754a009edac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tsbx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_09ae6d90-7a9b-443b-bc02-068850b13217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tsbx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0acb4150-37ee-4c10-8006-d0790fa8f0f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">tsbx:DevelopmentProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tsbx:PriceModificationAxis">tsbx:PriceAtModificationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d77c486-d172-4aa4-894b-cde28b23636d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e39171b-0288-4a90-bd4c-4de866d982ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-30</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0efb3de3-c750-4eb6-95f7-ff7400831d2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tsbx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0f2177db-5b60-476f-a730-1c8f81312684"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_109f55ad-7a48-4c7f-a7ed-d02672f14dbb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10a10b4c-098b-47f2-b0cd-44fdb0c3ed0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-14</xbrli:startDate><xbrli:endDate>2022-06-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10aa115c-22ea-46be-bcba-a9a9cd88b729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_122cd3f4-302a-4c4b-acb3-5f0a4ab8924f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsbx:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1326cf13-b619-4a7a-8459-199edf00cef7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_15263df3-916f-46a0-9832-65fb7bc16128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_159402e9-c2a7-4db5-8c56-97648d7a2af3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1608bf2e-2722-4b3b-ac28-7d680ca451a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_18a36a9d-0182-4470-abc8-5f7ff7b3b4a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tsbx:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_18e0b921-32c2-4a24-b203-fed3d74f4d65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1acb574a-2c4a-4dd0-8d44-95c2caca0d22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1b2bcaaf-9d3a-490e-8d00-989c002af276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c334911-8a35-4c3d-9e49-91814e062e98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tsbx:PriceModificationAxis">tsbx:PriceAtModificationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">tsbx:DiscoveryProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ec4e76a-cfd9-4b97-8d2b-92c62767f896"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_21d1e869-620d-4a35-abc4-05dbceb24181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_221e8d7b-e069-4751-b775-170cde6f9416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_233d0f7d-f749-402b-be07-03dbe6d24916"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_234b0297-d293-4e18-9282-e7524404692b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tsbx:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23ab17bc-cbea-4436-975a-8a130aba6e62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tsbx:RemainingSharesFromTwoThousandEighteenPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsbx:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2475957a-da36-49a5-8126-8a055410a470"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_250b5a1d-34ea-4e70-805a-18bd6081b49c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_25efe362-0a08-4b30-b273-8685627ec35a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_263ddd8f-936b-4629-ac81-de82901400f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:InitialMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:LangerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-11</xbrli:startDate><xbrli:endDate>2023-09-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_264a7ac5-398e-4718-ac23-f5ff805f1954"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_277bc5e6-e420-49a1-a481-ae8acaf14f5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsbx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_278e12a5-7809-4e31-81fa-b5ac9fed8247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_29034bc0-6cf8-44cc-9ed1-c738ea64dd3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_298d2425-fd98-405f-a011-492c95c811c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2b4f6127-8d59-412e-b50f-15f6bca69e60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tsbx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d28ff08-66e3-4717-8e1b-0159fd2dae0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:ThirdMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d44f350-3d07-4146-ae3c-42824895d484"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e92c815-0887-42a5-9aa2-1aa6d38a8788"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2016-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2f446809-dc2a-40e6-9aec-438ab12cb70b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2f5ca510-92ae-4c6d-88c6-32a100f28ecc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:SecondMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2fb9dc1f-ccec-4fe3-83bb-464c06488b6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesB2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2ff3278e-16d8-4b68-bf2e-7b39955581f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesB2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_314b4149-fadb-4ae4-82c4-63f56b1c9d19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_31b4b1f9-e730-4c51-a000-a2794909b7b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_325b972a-88a3-49e4-a865-f3c3e4c449cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_334d95da-9a09-4a10-86ff-a51738440c33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_33626c55-fab2-4ed6-af8d-d98851be5b39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_33faa779-ce8f-4e4d-a219-c041b650a61c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_34b78f7b-64c0-4260-933e-8c293a3cde64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-08-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_385dcdbf-07bd-4e19-a166-84748a852d48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsbx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_390d4d0c-2d69-4485-b251-e5c588a82858"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:H.LeeMoffittCancerCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:AllianceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_392765bd-7ded-4967-8201-2e786fab388b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tsbx:SharesAvailableForIssuanceUnderEsppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3960fbc2-6191-4efe-80f0-27545067aa20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_396a19e8-3bfd-4308-a62d-934e7ca98d70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_398e0a09-f989-4f15-b8fc-2af343713b5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsbx:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tsbx:NewSharesUnderTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3bc9ea85-cac7-4114-b7e4-68f51d5ac95c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ffd6a05-a9be-4e07-b29c-81b2bc74d344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">tsbx:RestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_44bd7a65-8c40-4525-b754-f1b5eaea0d39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4519aa8e-1238-4faa-8345-635ebb5bc098"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_464ce7dd-76e3-4b22-9015-b1330a849be8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_47ec3535-df3a-4de3-bfc4-2765e79fb6a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_488ff119-253a-4f13-ab67-fcbecef54a44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_48fa1a69-511d-4e0c-b236-6692208f9dc3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:InitialMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_497bd5df-0910-478f-aa44-aeabd848571c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4bae3e9b-125f-4503-8c73-cdcf17ef0bfe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:H.LeeMoffittCancerCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:AllianceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d3b7a6e-20dc-4532-aa88-976e8d769182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:H.LeeMoffittCancerCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:AllianceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-27</xbrli:startDate><xbrli:endDate>2023-02-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d689c27-7fb0-4851-9baa-5648a27e5506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsbx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4dcd6724-0338-4288-a92d-f40147c40f0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tsbx:AgreementAxis">tsbx:OperatingLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e19f9b2-a9f6-479d-8fbf-5061721bee44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">tsbx:DiscoveryProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ed0c192-f7ce-4ccd-88a9-1326c9ea54ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4fb7b644-c91b-460a-90e4-f747ea99d23e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tsbx:LaboratorySpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tsbx:AgreementAxis">tsbx:OperatingLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_507a33a4-3fb5-40c4-b2ec-c9dcaad76c3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_50d1f298-b372-40b5-b6e4-1d4f6cc1d536"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_538d2283-b280-4bac-8832-abf9afae8b56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tsbx:LaboratorySpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tsbx:AgreementAxis">tsbx:OperatingLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5447e64a-c9af-4233-ae37-a6910517d877"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5552aea5-73b7-4fb7-83a2-8300ff05e8db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_58806346-af8a-4a1b-852a-6954a4cb63e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:InitialMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:LangerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5987e3e3-0cab-4166-bca8-581516776417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_598b88c4-d183-499c-84b9-3e796e6520bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5a226ff4-7fbd-4466-ad8e-193443f07e2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:LangerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5b06c6b4-e689-4fe0-a090-8bcd1ee5595a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5b35fa61-bbf8-46c2-a6fc-1e914819fa92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5b861034-a720-43d5-8699-9c7302265892"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5cf56eca-80aa-4857-a57f-478d4c936a9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e3f8af4-ced0-4d18-92e3-8a9b5f41b2fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5edf160a-0dd5-4113-b0b6-1b907d836f1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tsbx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ee261db-0283-4149-9229-b37f40e4e1e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5fa46bf8-b07a-4c44-a5fd-6c1dc1a9edc0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsbx:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_611eb55b-b1d8-48ea-b1bf-f13c75cd2c4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tsbx:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61b64e12-4fa9-444b-8290-e40812121809"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_622828de-17f7-43ff-8529-65876283fc2a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_624dbdac-4327-488c-b421-114825296f78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:LangerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:SecondMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_62731d6b-0b8e-473a-8756-77f4fdd3789c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6289f1e6-72be-4ab1-8d3b-4951b6ae47d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tsbx:MystMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62ccdb6f-2ce4-4c14-88c5-56ab718bbe38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62ea4f09-347c-4795-8884-5220ce935f91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_656dbf1c-1dcc-431d-8fe9-c0de04b2841b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_66ae9658-0772-4454-88b3-b788cb30a2c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tsbx:SharesAvailableForIssuanceUnderPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_686637a7-6c9d-4004-a3a1-f62abb9c5a0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tsbx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6b9ab1b4-ace1-409a-beef-b24a105df524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:H.LeeMoffittCancerCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:AllianceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6d290ced-5d11-4542-b2af-bb92860ccf5b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f6523cc-b1d2-4b30-81f0-6490c4ab9067"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:LangerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:SecondMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7442ee75-92a9-41e2-98c5-9ab8b76e128f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:H.LeeMoffittCancerCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:AllianceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_761632b7-6a3d-4167-8e38-3551f8b5bd83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_77f50463-e1af-4144-8629-1e583e752cb2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_77f8cd0f-f6c2-4b41-b3a2-ad645efbb34e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7a327960-116a-4bd1-8648-b5f38a13e8f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesB1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7a433f77-f757-4637-ac62-b0d9f32aca2c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7a615421-56cd-4cb3-983c-215b19efb667"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ab99909-780f-484a-afb9-d7fab1c3e24f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7b886516-c4ec-4600-ae2d-8f4f97019128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tsbx:MilestoneAxis">tsbx:SalesMilestonesOnDevelopmentProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c898406-56c5-4ae7-8aa8-5701d037862a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:LangerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:SecondMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d7ff18f-d96f-4bfd-81be-511ab4a4637d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">tsbx:DevelopmentProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tsbx:MilestoneAxis">tsbx:ThirdMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7faec367-2bfd-418b-b55d-ce16bab8f5a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001764974</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_CadShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_CAD"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_SquareFeet"><xbrli:measure>tsbx:SquareFeet</xbrli:measure></xbrli:unit><xbrli:unit id="U_Security"><xbrli:measure>tsbx:Security</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Y"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <div style="min-height:0.5in;"></div>
  <p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:17pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:17pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:17pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:17pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:17pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:17pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9e3567e7-8683-493e-9064-762e8fb878dd" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:17pt;font-family:Times New Roman;min-width:fit-content;">10-Q</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:17pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">(Mark One)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7%;"/>
    <td style="width:93%;"/>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:11pt;"><ix:nonNumeric id="F_7062510c-3dc9-4dec-86ca-1650883790ec" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">For the quarterly period ended </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bf285486-b975-4932-963b-446e9b88280c" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">June 30, </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f21e300d-cb9a-42b3-83e2-ec37b9b280af" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">2024</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">OR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:7%;"/>
    <td style="width:93%;"/>
   </tr>
   <tr style="height:11pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:11pt;"><ix:nonNumeric id="F_64b5d7ab-d927-4809-ad9a-6cde4feff26d" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">For the transition period from </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">                    </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">                    </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Commission File Number: </span><span style="font-size:9pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fe212df8-e168-47d7-a66c-2443d181d7b8" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">001-41747</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:23pt;font-family:Times New Roman;"><ix:nonNumeric id="F_477fdc43-ec34-4182-9453-45312af682d2" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:23pt;font-family:Times New Roman;min-width:fit-content;">Turnstone Biologics Corp.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:23pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50%;"/>
    <td style="width:50%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_84c969b8-a29a-4b99-b70c-2afe78947c91" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_8b9ff3ed-f39d-4992-8802-5c8b3ff65bd9" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">83-2909368</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5f2680dd-5fe6-42e9-8fc1-fa18a7688515" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9310 Athena Circle</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f400b547-993e-4b94-a7b7-32e475335bb7" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Suite 300</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d358db8f-ec99-487d-8f74-fdf6cab69c85" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">La Jolla</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_348947dc-9b91-4686-9f59-49a811d61049" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">California</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5199ab16-9c5d-476f-b8a1-52c761f6c6ac" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">92037</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Address of principal executive offices)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cf98e4a5-8664-4d03-96a0-25d8f49b9af7" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">347</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_336f193f-34ad-421a-a23b-8ef19987f536" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">897-5988</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Registrant&#8217;s telephone number, including area code)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:33%;"/>
    <td style="width:1%;"/>
    <td style="width:33%;"/>
    <td style="width:1%;"/>
    <td style="width:32%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_8b49a69e-4d55-4e07-a033-37cd45b500a0" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock ($0.001 par value)</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_df3b1b9b-8ead-4346-a012-5db0fab444d4" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TSBX</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_f3d13689-3043-4d22-8f61-cf3e3cf165a7" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c1a7cb8a-4555-4c73-9b59-44eda54f3422" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  &#9746;    No  &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8be84bcd-8546-4035-a73f-847e23b88361" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  &#9746;    No  &#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.084%;"/>
    <td style="width:55.011%;"/>
    <td style="width:23.905%;"/>
    <td style="width:3.001%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_43ed3bb7-83ab-4ee6-b743-d69bbee0f1bb" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_c2ae9d10-bbdd-4f93-bf48-dc23945c9b68" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:5.75pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.1in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_6d9696c7-6ff4-458b-bb37-e7b23595e292" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6e84c988-8d97-4cf7-90d1-65ddf9b1684f" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.):    Yes  &#9744;    No  </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bf0a7b76-375a-43b4-b7da-1a6e5efbe0eb" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The number of shares of Registrant&#8217;s common stock issued and outstanding as of August 12, 2024, was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1986c7f3-4df9-4fbe-bb09-bf8ac7256a5b" contextRef="C_34b78f7b-64c0-4260-933e-8c293a3cde64" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">23,128,454</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Turnstone Biologics Corp.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">FORM 10-Q</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="toc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TABLE OF CONTENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:8%;"/>
    <td style="width:84%;"/>
    <td style="width:8%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">PART I</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_i_financial_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">FINANCIAL INFORMATION</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_financial_statements"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Financial Statements</span></a></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Condensed Consolidated Balance Sheets as of June 30, 2024 (unaudited) and December 31, 2023</span></a></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_cons_stmt_of_opertios_and_comp"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2024 and 2023 (unaudited)</span></a></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_cons_stmt_of_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) for the three and six months ended June 30, 2024 and 2023 (unaudited)</span></a></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidated_stmt_of_cash_flow"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023 (unaudited)</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_the_financial_statement"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to Condensed Consolidated Financial Statements (unaudited)</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
   </tr>
   <tr style="height:4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 2</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_mda"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26</span></p></td>
   </tr>
   <tr style="height:4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 3</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_quantative_and_qualitative_disc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39</span></p></td>
   </tr>
   <tr style="height:4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 4</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_controls_and_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39</span></p></td>
   </tr>
   <tr style="height:4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">PART II</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#part_ii_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">OTHER INFORMATION</span></a></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_legal_proceeding"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
   </tr>
   <tr style="height:4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 1A</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
   </tr>
   <tr style="height:4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 2</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_unregistered_sales"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97</span></p></td>
   </tr>
   <tr style="height:4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 3</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_defaults_upon_senior_securities"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Defaults Upon Senior Securities</span></a></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97</span></p></td>
   </tr>
   <tr style="height:4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 4</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97</span></p></td>
   </tr>
   <tr style="height:4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 5</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97</span></p></td>
   </tr>
   <tr style="height:4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:top;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Item 6</span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_exhibits"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Exhibits</span></a></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98</span></p></td>
   </tr>
   <tr style="height:4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:middle;text-align:center;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:12.25pt;vertical-align:top;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="text-indent:12.25pt;vertical-align:bottom;"><p style="text-indent:-12.25pt;padding-left:12.25pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signature"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Signature</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Quarterly Report on Form 10-Q contains forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial position, business strategy, research and development costs; the anticipated timing, costs and conduct of preclinical studies and clinical trials for our Selected TIL programs and product candidates; the timing and likelihood of regulatory filings and approvals for our product candidates; our ability to commercialize our product candidates, if approved; the potential benefits of our strategic collaborations and our ability to enter into strategic arrangements; the timing and likelihood of success, plans and objectives of management for future operations; future results of anticipated product development efforts; and our expected future financing needs, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions. The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, results of operations and financial condition. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described under the sections titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in this Quarterly Report on Form 10-Q us. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we undertake no obligation to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. You should, however, review the factors and risks we describe in the reports we will file from time to time with the Securities and Exchange Commission, or SEC, after the date of this Quarterly Report on Form 10-Q.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information provides a reasonable basis for these statements, such information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely on these statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.2in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="part_i_financial_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART I. FINANCIAL</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> INFORMATION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:-11.359%;padding-left:10.2%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_financial_statements"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 1. FINANCIAL STATE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Turnstone Biologics Corp.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Condensed Consolidated</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Balance Sheets</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.353%;"/>
    <td style="width:1.52%;"/>
    <td style="width:1%;"/>
    <td style="width:13.303%;"/>
    <td style="width:1%;"/>
    <td style="width:1.52%;"/>
    <td style="width:1%;"/>
    <td style="width:13.303%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(unaudited)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Assets</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5cfd9195-5d3a-4518-a83a-b3c0c92df455" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,401</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e0f6fc40-3896-4efa-8714-2af97ba46aaf" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,798</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a36ee6b-c4b5-40fd-8475-ac909c1b195d" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20536b7a-2578-4dec-8a63-9e4b90331ae5" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c5eaf2b-08dd-4f07-828f-9d5e951ab973" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,997</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8b1ed5a-891c-44a4-828f-cd8695ad73dd" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:ShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,979</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts receivable - collaboration agreement</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_203e453e-41ef-4b91-a441-cbc80ccd77e1" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">194</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c06b7774-77c1-4ca1-9a6e-202935576b9f" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,542</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_930706d5-20c3-4e34-b110-9950053cbed6" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,655</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b074fb1-ac10-45d0-a111-e199d7f2255c" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,348</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05687719-25db-49dc-b740-97d109c35f39" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,812</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4539dd6-c526-4964-b523-61385147467f" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,404</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d57e4c6b-b517-441e-910f-563967a5bd24" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">102,554</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets, noncurrent</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95003aab-e2a7-4f96-b992-503504486e25" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,051</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_15115496-873f-4098-909a-b7c4d0f4d2e0" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,143</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease right of use assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_015e9c52-668c-4e2e-a260-1addcc2964e3" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,853</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ba143ce-d70e-43d3-9086-5e49e8814954" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,766</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c99a00bf-a1ca-4f3a-a4ae-ff0052b7d13a" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,569</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6889fed1-4fac-469b-bf29-dbb0c80e3566" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,352</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5bfb9c46-4cc2-4839-a908-d4980bd42aa7" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,877</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46b05dd6-fca5-4fd2-bf1c-34161314fb58" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112,815</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities and stockholders&#8217; equity</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_823409fe-ade6-4d85-a372-ce9d8188a5a3" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,486</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0dd95d98-b1f0-4c60-8539-b73e286b9593" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses and other current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad5de9fa-8fe3-4166-a773-c1aae8be37cd" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,354</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_53059698-1d44-4030-8c4c-4f3a0a7fda49" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,909</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability, current</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44984ff1-69b1-4de8-8084-77491fe65b57" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,793</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1dadb8e-a6b0-468f-86ef-9a5ae654b36c" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,025</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8be01f43-fe85-4d88-a12b-ac45ac17c2d4" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,633</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c689a2b9-0445-43a1-8b7d-080f98f15e1f" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,970</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability, noncurrent</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab64ce40-6bcb-47e2-bc1f-3e615b8cdbf2" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_490df26c-4a04-4171-8faa-b2684e449f88" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,189</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other liabilities, noncurrent</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d17a78be-58a6-4c83-900c-c9937c122f51" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,097</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e244cff-ae53-4989-a940-22601a983481" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">989</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_66d428fc-b365-4691-95ab-cf0421f50211" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,141</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9966797-0581-42cc-b566-9a84014449e6" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,148</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders' equity</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_174e2434-c840-4403-bf65-c530f60c8c69" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d3599fe4-bcc0-43af-a5b4-60c93a786a0d" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_36f69ebb-2d71-4f64-bd7e-0afe25744754" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b4884622-1856-4604-8c80-17976d2fd1d8" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized at June 30, 2024 and <br/>&#160;&#160;&#160;December 31, 2023, respectively, </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec434524-cf2d-4a80-b8af-af7f76342059" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6246cbcb-ae6b-4a52-bd03-41a91c31043f" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_883e15eb-10cf-4870-8997-eabb63169aa2" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1c4e5b0a-b974-4d51-8073-c58448e9330c" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares issued and outstanding as of  June 30, <br/>&#160;&#160;&#160;2024 and December 31, 2023, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4284e823-d350-4ed0-b914-4bfb76a71d7d" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8cd62986-7125-4fe6-8fe1-1978eb43f3dc" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a63507fc-3cc4-4876-99f7-04cd307131b5" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_9b98a163-3e5b-4487-ad48-ab97d1d0f384" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;par value; </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dce31fc4-6f29-481c-872a-15e5cec0d704" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7daef1de-afe4-4545-92c5-1c4d53399bcf" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">490,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares authorized at  June 30, 2024 <br/>&#160;&#160;&#160;and December 31, 2023, respectively, </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_77dce3e6-aac1-497a-bbb5-78c812278e92" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_719e5c8c-fe93-4af2-a77e-8749213435dc" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">23,128,454</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c517531-527b-4b4b-bbd8-ddc1af935379" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6b37f63f-5b85-441f-83f2-124a7cbbbd68" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">23,099,335</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;shares<br/>&#160;&#160;&#160;issued and outstanding as of June 30, 2024 and December 31, 2023, respectively</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_249398a1-6a60-416b-be16-c87a9a1347a8" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5755a02-7095-4668-8ff7-cf2313fdc2b2" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7a997c05-345f-4493-bf2d-e6f6243805b8" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">277,630</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41d4ead1-a995-41c4-8f42-454375217c20" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">275,521</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd78bacc-0db1-47ae-8f46-d690b67c1ab2" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">226</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e40bc4f8-ddaf-4254-a341-4badadea8a3c" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">119</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6fb2def4-5461-460b-a035-32aaa70b0724" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">217,691</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff49bb5b-f9a5-47b7-a2ee-77068445f2bf" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">176,758</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5eb07376-e974-4dd2-a159-2ed1f917c211" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,736</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_874d6f31-fc36-42f3-9589-75b5bdfcf569" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,667</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bad25d58-9b6b-4617-8ce5-e42c39327ddb" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,877</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a56a6a8b-45ba-411d-89e0-d7e6a6567729" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">112,815</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.2in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Turnstone Biologics Corp.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_cons_stmt_of_opertios_and_comp"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Condensed Consolidated Statements of Oper</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ations and Comprehensive Loss</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share data)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.56%;"/>
    <td style="width:1.12%;"/>
    <td style="width:1%;"/>
    <td style="width:9.24%;"/>
    <td style="width:1%;"/>
    <td style="width:1.12%;"/>
    <td style="width:1%;"/>
    <td style="width:9.24%;"/>
    <td style="width:1%;"/>
    <td style="width:1.12%;"/>
    <td style="width:1%;"/>
    <td style="width:9.24%;"/>
    <td style="width:1%;"/>
    <td style="width:1.12%;"/>
    <td style="width:1%;"/>
    <td style="width:9.24%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_21305cbf-d218-4e7d-9698-6b829eeb94d8" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,306</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51efd694-7885-40a6-a01d-bf96944b9326" contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,730</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8734e56-ca98-48d1-9e08-8538e00dff91" contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,193</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6b84be0-83c1-4978-bb57-8760977860da" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,520</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29d761a4-b2ca-4986-a17a-c2c621bf1d45" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,861</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f112f5a-5d03-4e86-8245-054fcfe70f0c" contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,327</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5513184f-feda-4cf9-850b-214698b72fdd" contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,659</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20148618-960d-4a84-b9ae-dc2288c62700" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,228</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de801798-3ca3-4dc3-89a1-a89050f2280c" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,691</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_862551f1-29d1-4570-9744-d382a5d5f738" contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,057</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cfcd5197-71a9-4846-8013-5dc6f0c40ad9" contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,852</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9b7a39d3-5165-49d1-96af-71ba93204fe5" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,748</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e4be213-05c7-4a05-a2c6-2d3263ccb1b4" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,552</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ddc371c-36f6-4938-b86b-9ff928e8d8a9" contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">22,057</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3877afe9-d15c-4aca-9881-b9778d5b85d6" contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,852</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c1306b8-c23d-447a-96fc-743d26f214a9" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">42,748</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb3a3649-08e9-4295-808c-e604749aad41" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">22,246</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b32d55e5-89ec-40b5-a39e-a98252dec2a3" contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">755</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0910ff5-2ffa-4922-9ccf-11d07077dea5" contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">347</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ccb00d69-d087-430a-93b6-1c887781fba6" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,833</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10540d3e-7529-4988-b260-9b03cf6c0036" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">727</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss before income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a7ac47c-2b5a-42b1-8bb7-bed75e9a1066" contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,302</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ca4f495-228b-4669-8a58-dd19dec0b852" contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,505</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b50047df-8b20-4cf7-8de9-3a24c5ea7374" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40,915</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5f2338e2-ea33-4c40-adfe-dc31df886571" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,519</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Benefit (Provision) for income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f36e038c-798f-487d-8e47-1c06afe5a3be" contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67665376-40a3-48ba-b3d4-829c3670b5f3" contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_deb809b0-e2d3-4e1c-a424-7085ed0cda16" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8dc17d0f-475f-4b9e-a03c-d1d12c2897a6" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">88</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff71d2d2-7f05-4b07-8ec4-8c3e2de6d132" contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,304</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb51c858-d560-4cf9-8dc9-630420b8a790" contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,499</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a89edbc5-9df9-40fa-8410-a54bf3d9a3fd" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40,933</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97f9d543-87f5-4c17-9b69-dd0508b53e55" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,431</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive loss:</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain (loss) on available-for-sale debt securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8fd37877-c7ba-4b66-877f-8ed11783eb0a" contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a50ebd5-98e2-4f13-abaa-21bcb6606073" contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7afd0ed3-cdfe-462b-a157-e2074a44e900" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">107</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed626105-7876-4c39-a30b-9d6f6077c181" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">180</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total comprehensive loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_640bee6b-f258-41ab-aa54-983eaa7ad325" contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,294</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d981916-cccd-47df-938f-47f2e862dd1f" contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,440</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea3ca55e-a5e5-4be3-bb5c-ba69f4c732e4" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,040</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b825333f-4cd5-4505-bbc5-d252669e78d4" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,251</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d12453d9-f6f3-40f1-9fb5-59b5a81c95c0" contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,304</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ea994d6-5e5e-45e8-9065-f7b08be80c7d" contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,499</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_599e97e1-568f-46f7-bd9a-9ef5d9255791" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40,933</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5382ef7-5630-435b-87f7-78a35d049ad6" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,431</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: accretion of preferred stock to redemption value</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0627cf60-6cb9-4d08-9880-ef7ee5ca33f4" contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_add4eeeb-c8ac-4144-b25c-1c01117680ca" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss attributable to common stockholders, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e77fb3d-24e6-40f3-a1b1-0680d204c227" contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_1c503748-d08a-4ce1-b46f-71ce3741f43a" contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,304</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9da3a067-40d9-4383-9204-258e25d7bfe8" contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f12f0657-4e63-4e4d-b5d0-3ab2c0971ba4" contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,518</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6e23d37-193d-42ba-9455-4a86e3f49961" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a6f87be6-1312-41a2-bdd0-5054395a1af7" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40,933</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e6eea2b-6f71-44bf-850a-21fee7e72636" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_bdc457f1-fa33-41e2-b5ff-6d8c72fb2db0" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,470</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average number of shares of common stock outstanding, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7578e036-c009-486e-b38c-e120301dac2b" contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_55c8c7e8-c9e1-40e6-8d55-f94700bc41d8" contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">23,037,714</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5f56460-91ed-4286-99c5-afc886e15692" contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6867e74a-e6c1-4485-8d2a-bcd9b4d2d2a9" contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,847,675</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d84fc9bf-b3f5-4206-a051-fa61d43d0321" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0d21aef6-f8d5-4cd5-992f-fe2432f798e2" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">23,024,754</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9124b3ec-a5ac-4efe-8e56-2491767f8ca5" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c9630a02-9e02-424f-8ee6-9728257a341d" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,817,008</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share attributable to common stockholders, basic and diluted</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca468369-79bf-4733-ad60-4e97329a8e25" contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c6c32a04-02cb-4705-a6cc-8009be838ddc" contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">0.92</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a11adf5f-083a-4481-8c76-ef1752874377" contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_77a978ae-4994-4936-86f7-6f7909527d6c" contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">7.56</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dda57c13-8997-4585-9be1-2044bbc248e9" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_06404574-9576-4373-9223-bdd242e18793" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.78</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4472a1f7-9260-4d20-aa90-e9b8630e6877" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_07f85521-7b9f-478f-83d9-97dde6798ef7" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">7.62</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Turnstone Biologics Corp.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_cons_stmt_of_equity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Condensed Consolidated Statements of Redeemable C</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">onvertible Preferred Stock and Stockholders&#8217; Equity</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.22%;"/>
    <td style="width:1%;"/>
    <td style="width:3.56%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.3%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.62%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.3%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.48%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.24%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.48%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.3%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.62%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1.74%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.56%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.96%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.04%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:4.32%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.32%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.94%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Series A Redeemable Convertible Preferred Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Series B-1 Redeemable Convertible Preferred Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Series B-2 Redeemable Convertible Preferred Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Series C Redeemable Convertible Preferred Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Series D Redeemable Convertible Preferred Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional<br/>Paid-In</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Other<br/>Comprehensive</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Stockholders&#8217;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:2.25pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Loss</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2023</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7e58068-b4d9-4b11-ad7b-da3ae9d31b2d" contextRef="C_761632b7-6a3d-4167-8e38-3551f8b5bd83" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">23,099,335</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2a64f3c5-6213-4641-8f9d-f985bf57c2a9" contextRef="C_761632b7-6a3d-4167-8e38-3551f8b5bd83" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91949c60-8411-4538-a8ae-43e4f457b25d" contextRef="C_5b861034-a720-43d5-8699-9c7302265892" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">275,521</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33f75a9e-5bd8-49c6-b763-f2b3dd328e95" contextRef="C_62ccdb6f-2ce4-4c14-88c5-56ab718bbe38" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">119</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98504a65-8973-417c-94b6-c86de803f525" contextRef="C_8eeaadf6-6367-4498-a18c-12b0327753e8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">176,758</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb1381f0-e750-4ac6-a311-41ec607fa4d1" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,667</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38da18d6-0913-428c-a1f0-5a7dabdd338f" contextRef="C_f6268a98-55de-42e4-b33f-cf7c0879c342" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">29,119</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a77c7e50-78ff-4982-9a94-65b7b7052494" contextRef="C_0d77c486-d172-4aa4-894b-cde28b23636d" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3bceb51-7f75-41e1-8ccc-610cb2eb083d" contextRef="C_93377237-7cd1-48a2-b8a5-b9a2243d15e5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c25da6b-9662-43c7-9558-21321b31d6e4" contextRef="C_0d77c486-d172-4aa4-894b-cde28b23636d" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,046</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dab80ec3-9334-4bca-a1a9-f546544a44d5" contextRef="C_93377237-7cd1-48a2-b8a5-b9a2243d15e5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,046</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized loss on available-for-sale debt securities</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f4a4d45f-1987-434d-83fe-9d028e7945bd" contextRef="C_bbc99879-3c57-49b9-b3a2-7c36543a3a7a" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">117</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_679a46be-e8fc-4bfb-bcf6-08a12e92782b" contextRef="C_93377237-7cd1-48a2-b8a5-b9a2243d15e5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">117</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_204d865a-dcab-46a0-81bd-b09e51e9fb24" contextRef="C_dd66f43c-636a-4989-849e-33408277fa05" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">19,629</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57c3a70c-2167-4d31-b487-ee1327cfa51e" contextRef="C_93377237-7cd1-48a2-b8a5-b9a2243d15e5" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">19,629</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at March 31, 2024</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a47479a9-6f45-411e-8aa5-6128fac3c208" contextRef="C_b169253e-4db8-48b5-a2f6-a9d18d0f3f36" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">23,128,454</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29278280-72c9-417a-b717-0120ec278a3b" contextRef="C_b169253e-4db8-48b5-a2f6-a9d18d0f3f36" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0fa600af-8aca-4670-9782-534252644da4" contextRef="C_df7b7c66-464a-441f-91fd-4ca59bed28ea" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">276,611</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44eb12af-ac95-4763-8556-72b0c2fddace" contextRef="C_db819b3e-1792-4c62-b813-10d6991af201" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">236</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee727958-f98d-47f2-8d59-5bdd683227e3" contextRef="C_e72bcdb4-17b9-4881-84a9-0f4fe4e39f0b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">196,387</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25c1489f-1548-4c67-9095-957fb86ffbb0" contextRef="C_18e0b921-32c2-4a24-b203-fed3d74f4d65" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,011</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec8ce985-124d-494e-aba4-c2ea9c1fcf4f" contextRef="C_7faec367-2bfd-418b-b55d-ce16bab8f5a3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,019</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd331e99-43cb-4abe-8c92-45c279955270" contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,019</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain on available-for-sale debt securities</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e9cbc5e7-f92b-49e1-81ad-cd900c577e67" contextRef="C_1acb574a-2c4a-4dd0-8d44-95c2caca0d22" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ccfa41c-a367-4e53-aae8-cd5750cc3b3a" contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c64a3e1f-0f4b-4a6a-82a8-74d4ae74272e" contextRef="C_ecd3cf07-fefb-416f-8ca3-3ebe03141ea5" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,304</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48486e4e-a97a-47ff-8d0e-e97cb0b8d000" contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,304</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at June 30, 2024</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:2.25pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea339148-375a-4011-9211-9cc31478a9a7" contextRef="C_250b5a1d-34ea-4e70-805a-18bd6081b49c" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">23,128,454</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3a4a982-d9ab-4ac9-83eb-8733f4bb120a" contextRef="C_250b5a1d-34ea-4e70-805a-18bd6081b49c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec23d125-d4f4-4654-8711-0bfb70bc63d1" contextRef="C_25efe362-0a08-4b30-b273-8685627ec35a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">277,630</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de0d9fd5-9318-43dd-a535-170f6b6bfd1c" contextRef="C_ee135c52-c1b2-4ad5-911b-acfb5c8e8f2b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">226</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f0653681-c402-4291-9f39-7426726e7148" contextRef="C_8916fdbc-eab2-44d0-8e8f-7bb4a95aae54" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">217,691</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16e58284-dbeb-46a9-b0aa-ffe8b7e2df44" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,736</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Turnstone Biologics Corp.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Deficit</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share amounts)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.22%;"/>
    <td style="width:1%;"/>
    <td style="width:3.56%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.3%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.62%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.3%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.48%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.24%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.48%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.3%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.62%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1.74%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.56%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.96%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.04%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:4.32%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.32%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:3.94%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Series A Redeemable Convertible Preferred Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Series B-1 Redeemable Convertible Preferred Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Series B-2 Redeemable Convertible Preferred Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Series C Redeemable Convertible Preferred Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Series D Redeemable Convertible Preferred Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:3.75pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Additional<br/>Paid-In</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Other<br/>Comprehensive</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Stockholders&#8217;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:3.75pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Loss</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51ee462a-374f-4ca5-a619-67680c18ee41" contextRef="C_fab6d8a7-91ff-48ba-9d83-2f673cd37dd0" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,250,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_717de24b-030e-4c2a-9d94-7c77e5e47e34" contextRef="C_fab6d8a7-91ff-48ba-9d83-2f673cd37dd0" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,643</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0df9d0da-53ee-4f10-b426-192485cae3d8" contextRef="C_82a867ab-5d5f-459b-8a82-12bbd36560a5" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,285,156</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aae87542-8a1e-489d-ba82-f8537685b790" contextRef="C_82a867ab-5d5f-459b-8a82-12bbd36560a5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,611</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6eb114be-55de-47f3-b411-70481b1a3500" contextRef="C_8a4b4f37-0658-467b-8161-438bc3405ed1" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">25,065,538</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a4b0935-bb02-4f59-90bb-c1cbdd5161d4" contextRef="C_8a4b4f37-0658-467b-8161-438bc3405ed1" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,860</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_672bca04-9fab-41ce-b685-f6ff30ac8a69" contextRef="C_838eb810-3507-46b7-b156-72691850ae36" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">17,905,288</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43cdabfe-f13e-4036-8368-fb9d19b1a7ce" contextRef="C_838eb810-3507-46b7-b156-72691850ae36" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,100</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_691b2334-a704-41ef-bbcd-6daa44103470" contextRef="C_f744bbe6-544a-4cb6-9ffc-e06c7c098585" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">29,285,356</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_953b337e-0d5a-4827-af23-c295cd1c7a2c" contextRef="C_f744bbe6-544a-4cb6-9ffc-e06c7c098585" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,730</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:3.75pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_043f27ac-7047-4a32-ab1d-ad13aed7491a" contextRef="C_9f42a392-3c59-43e9-a2a2-d060b68b5b79" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,915,757</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63114e69-3084-485e-9cc7-135a3c547be7" contextRef="C_9f42a392-3c59-43e9-a2a2-d060b68b5b79" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d280d529-249c-4f12-b53e-52e71212bb30" contextRef="C_5ee261db-0283-4149-9229-b37f40e4e1e5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,501</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55642301-02af-437a-bca7-6f4edc0cac0b" contextRef="C_a12fbc8f-79f0-4426-843d-ec27ad6e7c70" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">413</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5cab766d-12a0-401c-b5fa-2ce9fb481122" contextRef="C_2475957a-da36-49a5-8126-8a055410a470" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">121,558</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c763f5a4-a7fb-4c47-8238-b16a7d191906" contextRef="C_bed097c6-a12a-48ed-ab84-40a66008425b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">101,467</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Moffitt performance based common stock award</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:3.75pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07e98e1a-baf5-486b-86de-95fc1a0eccf2" contextRef="C_e83e1bee-c31a-4456-a69d-f9eab649bf3a" name="tsbx:StockIssuedDuringPeriodSharesMoffittPerformanceBasedCommonStockAward" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">91,721</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accretion of redeemable convertible preferred stock issuance costs</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a4599e4-b185-4fa3-8041-6e49f881687a" contextRef="C_c72ae3f1-ec49-47ae-8a52-43699c15abfc" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:3.75pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4fb7e9d-c020-42e2-b1b9-eb19057e9f23" contextRef="C_47ec3535-df3a-4de3-bfc4-2765e79fb6a6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cee728a7-bc1b-4e61-8310-2a3fc232abeb" contextRef="C_278e12a5-7809-4e31-81fa-b5ac9fed8247" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">20</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:3.75pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e031c900-4a00-47d2-a804-e0937e21c601" contextRef="C_e83e1bee-c31a-4456-a69d-f9eab649bf3a" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">20,658</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02802e97-8e62-4d15-8c96-92fc1594dfc8" contextRef="C_47ec3535-df3a-4de3-bfc4-2765e79fb6a6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c96dc68-4243-4034-9907-de1587e6024f" contextRef="C_278e12a5-7809-4e31-81fa-b5ac9fed8247" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">83</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:3.75pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0da52ef8-94e5-4b55-8809-954054baef85" contextRef="C_47ec3535-df3a-4de3-bfc4-2765e79fb6a6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">992</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d8c410f2-0d0f-41bd-a0c9-a5fe8b438cab" contextRef="C_278e12a5-7809-4e31-81fa-b5ac9fed8247" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">992</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain on available-for-sale debt securities</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:3.75pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a18dde5-b4e4-4747-a54e-e7dc1164c94b" contextRef="C_df0e855c-ac6b-4b9c-86e6-10fbdce55a16" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04486e24-289c-4e24-bb3e-a1214f633904" contextRef="C_278e12a5-7809-4e31-81fa-b5ac9fed8247" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">121</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net income</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:3.75pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af5292f1-f2a8-4f6b-9346-cffc318a977b" contextRef="C_d9bf8d53-5a76-4443-ae16-8d541daf5ad2" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dae60949-601a-41d3-80c7-18c21bffed60" contextRef="C_278e12a5-7809-4e31-81fa-b5ac9fed8247" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at March 31, 2023</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2905935f-9b9d-43b8-be24-d6e316cf926e" contextRef="C_656dbf1c-1dcc-431d-8fe9-c0de04b2841b" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,250,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a12a37e-e7e7-4f90-93a5-d845ea65f926" contextRef="C_656dbf1c-1dcc-431d-8fe9-c0de04b2841b" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,643</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ccca8a3-4002-423a-8566-406775917f45" contextRef="C_8eddfc98-0dbe-49c8-9be7-73a81bdcbff8" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,285,156</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8708c5e-e1eb-4b39-a3c3-da0a5aa7825f" contextRef="C_8eddfc98-0dbe-49c8-9be7-73a81bdcbff8" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,611</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_71348374-f280-426d-921f-ca7621fda382" contextRef="C_2ff3278e-16d8-4b68-bf2e-7b39955581f3" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">25,065,538</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b07ca3d-06ab-4787-b140-b054e23c31f6" contextRef="C_2ff3278e-16d8-4b68-bf2e-7b39955581f3" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,860</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a55a34c9-a3e8-4e42-b6c4-70eebe82d87e" contextRef="C_8aa8eff8-bf22-4098-92ea-223279b190c9" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">17,905,288</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b59de50e-fea9-4264-826c-ff6cf2831b40" contextRef="C_8aa8eff8-bf22-4098-92ea-223279b190c9" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,100</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f392bdad-f77f-4b0f-b82e-e6c89e680418" contextRef="C_ed2ba762-cc53-4aa6-ad18-93928a0e9e83" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">29,285,356</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f436732-988d-4b61-9de0-e21a5a2ea011" contextRef="C_ed2ba762-cc53-4aa6-ad18-93928a0e9e83" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,750</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:3.75pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b7f3fa2-a9ad-433f-ac47-3e99ec976509" contextRef="C_15263df3-916f-46a0-9832-65fb7bc16128" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,028,136</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1dfeb55e-e09d-4261-ab8a-35da6af6b6e8" contextRef="C_15263df3-916f-46a0-9832-65fb7bc16128" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e54f95ea-5e41-4652-b616-b3d88b8219b0" contextRef="C_07b24899-50be-4afd-9968-9f3387fa7317" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,556</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16d917f1-f90b-440e-a1cc-07a17df9dc75" contextRef="C_622828de-17f7-43ff-8529-65876283fc2a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">292</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c4ca1b17-ae22-4b5e-ab45-5c17a10ea8e7" contextRef="C_33626c55-fab2-4ed6-af8d-d98851be5b39" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">121,490</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a964d7a3-be06-46f0-b91b-d589eb6b6176" contextRef="C_1ec4e76a-cfd9-4b97-8d2b-92c62767f896" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">100,223</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accretion of redeemable convertible preferred stock issuance costs</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cba0a3db-dd83-4179-81b0-c04e0711481f" contextRef="C_497bd5df-0910-478f-aa44-aeabd848571c" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:3.75pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5956ec0-5f89-4a4c-acaa-57cdb08130a4" contextRef="C_109f55ad-7a48-4c7f-a7ed-d02672f14dbb" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e41daa48-8820-422e-911e-b34a0a668847" contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:3.75pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e90e5276-592d-4a2c-8b78-9a5a1623d564" contextRef="C_3960fbc2-6191-4efe-80f0-27545067aa20" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,122</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_982fa5a4-f2eb-4cf2-b86e-13e78575962c" contextRef="C_109f55ad-7a48-4c7f-a7ed-d02672f14dbb" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a962fa4-dfaf-4f1e-9530-6d847ed423ea" contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:3.75pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a81e440c-fa4c-46d4-bb86-587c574a8392" contextRef="C_109f55ad-7a48-4c7f-a7ed-d02672f14dbb" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,074</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_02fc8ed7-e9b3-402b-83b9-f47d5f308927" contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,074</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unrealized gain on available-for-sale debt securities</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:3.75pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19753735-9a5b-458a-acd5-5ccd939804cf" contextRef="C_ab5c8887-9c0a-4afb-8d68-eae695a3dd3b" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5626acb-30c0-4cdd-a11c-52eab31e1abb" contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:3.75pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc327435-c87c-412f-acd6-6bf9f69830f3" contextRef="C_5b06c6b4-e689-4fe0-a090-8bcd1ee5595a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,499</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7307a9c-d6fa-414f-b1a0-3233fb4f3966" contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,499</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Balance at June 30, 2023</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c2996a1-5a66-44d2-be93-b61307166996" contextRef="C_44bd7a65-8c40-4525-b754-f1b5eaea0d39" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,250,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_634773d3-a42a-41b8-8f87-0ae8ca70f3ea" contextRef="C_44bd7a65-8c40-4525-b754-f1b5eaea0d39" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,643</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e3c57e3-57d9-411b-bffa-84089c8b100e" contextRef="C_7a327960-116a-4bd1-8648-b5f38a13e8f4" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">16,285,156</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_559ee5bd-13dc-4a68-9dc8-0a4107b5c39c" contextRef="C_7a327960-116a-4bd1-8648-b5f38a13e8f4" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,611</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca9f28e1-f293-4764-ba59-0589a026c13e" contextRef="C_e2186eec-5e5a-4c75-b0fd-9b1fdf69034e" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">25,065,538</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_812e5f4a-4af4-4e65-814e-cc31233c44c8" contextRef="C_e2186eec-5e5a-4c75-b0fd-9b1fdf69034e" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,860</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7386dc9d-0eee-40a8-84b1-2bb431fc4239" contextRef="C_b6215fc5-849f-462e-86bf-6b597390fe38" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">17,905,288</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b86d7a9c-fc13-47d2-b922-553d13971050" contextRef="C_b6215fc5-849f-462e-86bf-6b597390fe38" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,100</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e25fe011-34b0-4777-9f35-85531e968c72" contextRef="C_1b2bcaaf-9d3a-490e-8d00-989c002af276" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">29,285,356</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8d5c4d3-0982-4dd4-b173-23e94a04c04e" contextRef="C_1b2bcaaf-9d3a-490e-8d00-989c002af276" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,769</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-right:3.75pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97f6349a-abe4-4b6a-95bc-78c6f13cdde2" contextRef="C_6d290ced-5d11-4542-b2af-bb92860ccf5b" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,029,258</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9275ebd9-af98-4d2e-81ec-032a6e30dd10" contextRef="C_6d290ced-5d11-4542-b2af-bb92860ccf5b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40795c48-1515-4ccc-9310-886582fc5eea" contextRef="C_2d44f350-3d07-4146-ae3c-42824895d484" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,614</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_39abc0b4-e982-43fb-91f1-65fa02c68437" contextRef="C_ffd72f23-b073-4049-978f-aa0c05133c6b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">233</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb33a5a4-8ccc-43b7-8237-fc3c866d1374" contextRef="C_1326cf13-b619-4a7a-8459-199edf00cef7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">142,989</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb1c80ed-ddcb-41f5-ac97-44643a0004b0" contextRef="C_dfe46888-9d65-4c68-a853-215029dc9872" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">120,605</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Turnstone Biologics Corp.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="condensed_consolidated_stmt_of_cash_flow"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Condensed Consolidated State</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ments of Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:63.56%;"/>
    <td style="width:1.66%;"/>
    <td style="width:1%;"/>
    <td style="width:14.56%;"/>
    <td style="width:1%;"/>
    <td style="width:1.66%;"/>
    <td style="width:1%;"/>
    <td style="width:14.56%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Operating Activities</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae3e1e2f-0291-4db6-99ae-c5934821d9ad" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40,933</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cecaba1b-2ebd-49c0-8daa-c38127f1dde9" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21,431</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stock-based compensation expense</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c3f2a65e-8fee-4070-9cde-3ee9ca0bf264" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,065</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7fcc966c-4809-498e-a266-132cb31893ce" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,066</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gain on disposal of property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2bf132a5-ba72-464e-8c20-150fbfc86298" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05ba2f39-6b47-4b2d-a370-27854406f921" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,007</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f718c7df-49dd-4441-9402-c59130d3b82e" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,439</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accretion of premium on short term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5838652-479f-46b4-b218-ccd52e0de5b9" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="tsbx:AccretionOfPremiumOnShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,385</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38db0e05-c863-4e65-a448-02c97f041b91" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="tsbx:AccretionOfPremiumOnShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">468</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in fair value of contingent consideration liability</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7274bfa-55ce-4036-a747-bd62b2bf87e5" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4de1ff1c-c498-41a8-b5e7-b08475b49bc7" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">876</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts receivable - collaboration agreement</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0292c51f-172e-4592-956f-5d33de77de57" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">194</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ed83222-a03e-4f1a-a446-946c4541cf10" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,478</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c018b29-6a0e-4841-b260-675e32ed3eff" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:IncreaseDecreaseInPrepaidExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,233</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_679775e2-c1e1-4fae-9d94-69197813bb12" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:IncreaseDecreaseInPrepaidExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">652</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_570e06d4-6da0-4253-af07-c04f12f87ade" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">464</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2bad4062-fd5f-4405-9aa0-0e84ee93318e" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">325</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ccd0083-e6b8-4856-bc4f-ffc7405f9845" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">97</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc5761f3-bcb6-4539-a1c4-64f3ddfe3c10" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">29</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4155e6a2-4fcb-47f1-87e0-9678636f960a" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,422</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a58cde81-3ba1-4438-a7cb-17bd7f7ea033" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,237</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in contingent consideration liability</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6612f81f-b099-4954-9a54-24993ef88d62" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="tsbx:IncreaseDecreaseInContingentConsiderationLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,289</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued compensation and other accrued liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1ef9fda4-e086-4d63-a2ae-8e91da30e6e6" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="tsbx:IncreaseDecreaseInAccruedCompensationAndOtherAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,445</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27a5851e-b983-4857-a0ef-c1d939f1c52a" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="tsbx:IncreaseDecreaseInAccruedCompensationAndOtherAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,002</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other non-current assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6d14709-9c68-415f-b5b7-9ce5496e9d4f" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64b4b6c6-da61-4618-aec6-201a3e671487" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">275</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51361c2c-7843-406c-bd47-b1a0c2955fc5" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">19,306</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash flows used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c99afab-6149-4757-9b7c-5b7c7a0dff81" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">33,385</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ce7ea41-95e0-48fa-87e3-897387460327" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">31,861</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Investing Activities</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from maturities of short-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff0d329f-a229-4e2f-beea-02776faa681a" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1408c1e-a569-4cf8-829e-db12ab97154e" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,500</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchase of short-term investments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe5971ac-d210-4efa-9867-cef82f7d6637" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,740</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45e048f4-d1fa-4c8f-b385-d4e0fd400725" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:PaymentsToAcquireShortTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,228</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from sale of property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd3a255a-fbc8-411f-b694-a031f783619a" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a046ff7-4e98-4ae1-93af-43854d7143c1" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af45cffe-26bc-4497-88d6-a8ca93e66890" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">249</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c6face0-69d4-49f3-9a90-6a13ca632786" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">990</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash flows provided by investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26bbc40d-4eff-4e79-8051-eb1c30bd1cd2" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,036</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2383e81-75a2-4018-92d9-418304e282d8" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,475</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financing Activities</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payments of financing costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_acd9f904-225a-43a1-a829-7261bff377f3" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:PaymentsOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payment of contingent consideration related to Myst milestone</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe7dab9d-7bd4-437e-8fb2-bde15fc5cce0" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">898</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Payment of deferred IPO costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5218805-5027-4a2f-9936-8088ca8b90c6" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">269</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from exercise of stock options</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e589444e-e79a-4d60-a789-ab3518ad9307" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_93fc8064-84d3-4a13-afb0-e82f50c9a1e7" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net cash flows used in financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4211cf56-7619-40d3-be28-c8b7ff712b59" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">48</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8840d3e9-78b1-4404-b313-3aa7cb6ba3a2" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,081</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net decrease in cash, cash equivalents and restricted cash</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_937bbdcc-579e-4682-b2fd-0106a14e57ad" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">397</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a332d678-5070-4312-b80b-40056b05a594" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">13,467</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents and restricted cash at beginning of the period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7c2ba39-df47-479b-bdb3-b6994333128c" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,914</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28570aad-ed8f-4cf9-ad90-80fa7ef1daa2" contextRef="C_bed097c6-a12a-48ed-ab84-40a66008425b" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,113</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents and restricted cash at end of the period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_708f8f84-8e54-45f2-a60e-27f81945cea3" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,517</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b484f04d-e7f7-4547-ad92-356937c77fa8" contextRef="C_dfe46888-9d65-4c68-a853-215029dc9872" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,646</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental Disclosure of Cash Flow Information:</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash paid for income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8aa1c7d4-d197-493f-ad75-ce99627fef19" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">119</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Supplemental Disclosure of Non-Cash Investing and Financing Activities:</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accretion of redeemable convertible preferred stock</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5bcaf27-3767-43fe-beae-512bb48ef70c" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="tsbx:AccretionOfRedeemableConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Equipment purchases included in accrued expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_126b27e7-413f-419e-94fb-06119dd12673" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="tsbx:EquipmentPurchasesIncludedInAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">186</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financing costs included in accounts payable</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fec40025-2dcb-42cc-8779-f86de640e59f" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred IPO costs included in accrued expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5bffcc0a-bddb-4881-9e00-6f380939d697" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="tsbx:DeferredIpoCostsIncludedInAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,286</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Turnstone Biologics Corp.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_the_financial_statement"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to the Condensed Consol</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">idated Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ad59e2c3-77c9-472a-836b-a3ee39de45c8" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of the Business and Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Organization</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Turnstone Biologics Corp. (the &#8220;Company&#8221; or &#8220;Turnstone&#8221;) is a clinical stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. Turnstone is pioneering a differentiated approach to tumor infiltrating lymphocytes (&#8220;TILs&#8221;), a clinically validated technology for treating solid tumors. The Company is developing next generation TIL therapies by selecting the most potent and tumor reactive T cells (&#8220;Selected TILs&#8221;). The Company has three ongoing Phase 1 clinical trials for TIDAL-01, including a multi-site trial for the treatment of colorectal cancer, head and neck cancer, and uveal melanoma, and two investigator sponsored trials with H. Lee Moffitt Cancer Center and Research Institute, Inc., ("Moffitt"), across colorectal cancer, head and neck cancer, and uveal melanomas. The Company&#8217;s headquarters are located in San Diego, California.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reverse Stock Split</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 14, 2023, the Company effected a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8b39f2ed-6625-4faa-a671-12e4def48b0f" contextRef="C_c5cddb37-672e-4bc6-993b-61b085312425" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1-for-7.9872</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reverse stock split (&#8220;Reverse Split&#8221;) of its issued and outstanding shares of common stock and redeemable convertible preferred stock. All share and per share amounts included in the accompanying unaudited condensed consolidated financial statements and related notes have been retroactively adjusted, where applicable, to reflect the Reverse Split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. Shares of common stock, underlying outstanding stock options, and restricted stock were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the appropriate securities agreements. Stockholders entitled to fractional shares as a result of the Reverse Split received a cash payment in lieu of receiving fractional shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Initial Public Offering</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 25, 2023, the Company completed its initial public offering ("IPO") pursuant to which it issued and sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6aa0bcf-65c0-48f5-a37e-d3922a0f6e88" contextRef="C_be5fa637-0934-415e-a76d-cef88c5177de" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,666,667</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock at a price to the public of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fe58e037-a85a-490a-9324-3bf3991e4791" contextRef="C_d3863644-3003-48be-ba26-f907692ad408" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">12.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. Aggregate net proceeds to the Company were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_901f7188-ca37-4d1e-add6-ab7ba53e69a8" contextRef="C_be5fa637-0934-415e-a76d-cef88c5177de" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">68.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting underwriting discounts and commissions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19632725-189e-49f5-96c2-081235f14c5c" contextRef="C_be5fa637-0934-415e-a76d-cef88c5177de" name="tsbx:UnderwritingDiscountsAndCommissions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and other offering expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4211929b-88fb-4e2c-aa2e-333a04c6ab03" contextRef="C_be5fa637-0934-415e-a76d-cef88c5177de" name="tsbx:OtherOfferingExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. On August 15, 2023, the underwriters exercised their option to purchase an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7e15348-c86d-4cae-9627-d82d8870e7d2" contextRef="C_c6e4f9a3-9885-44ca-907d-b6658de8f0e8" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">651,608</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4148ec17-4c4e-4080-8355-93c683d1635e" contextRef="C_b283014b-e73a-4c69-9931-4985a3e59add" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">12.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. Aggregate net proceeds to the Company were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f90f34be-1ab4-4d2a-96cd-07ba4a04c723" contextRef="C_c6e4f9a3-9885-44ca-907d-b6658de8f0e8" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting underwriting discounts and commissions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_721116c5-2fea-4b39-82ec-87c4bf52bad9" contextRef="C_c6e4f9a3-9885-44ca-907d-b6658de8f0e8" name="tsbx:UnderwritingDiscountsAndCommissions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Upon the closing of the IPO, all outstanding shares of redeemable convertible preferred stock automatically converted into shares of common stock. Subsequent to the closing of the IPO, there were no shares of redeemable convertible preferred stock outstanding.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the closing of the IPO, the Company filed its Amended and Restated Certificate of Incorporation which provides that the authorized capital stock of the Company is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ded2d0eb-fe16-4efe-b161-3a02b8b7d121" contextRef="C_c0b79b4e-6d2e-4c6f-9298-ac7fa6a0af9c" name="tsbx:SharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares consisting of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa5972b7-faae-4355-aea6-de275d7e02b2" contextRef="C_c0b79b4e-6d2e-4c6f-9298-ac7fa6a0af9c" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">490,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90ced1e5-3e15-4ec7-8002-1165c38ebc3c" contextRef="C_c0b79b4e-6d2e-4c6f-9298-ac7fa6a0af9c" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of undesignated preferred stock, both with a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3e24be3-ff3b-4677-85d0-a6e454feb511" contextRef="C_c0b79b4e-6d2e-4c6f-9298-ac7fa6a0af9c" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_97716f82-1be9-4b72-a15d-12a9487a5c51" contextRef="C_c0b79b4e-6d2e-4c6f-9298-ac7fa6a0af9c" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF" format="ixt:num-dot-decimal">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Going Concern</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of this uncertainty. Management is required to perform a two-step analysis over the Company&#8217;s ability to continue as a going concern. Management must first evaluate whether there are conditions and events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern (Step 1). If management concludes that substantial doubt is raised, management is also required to consider whether its plans alleviate that doubt (Step 2).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">However, the Company incurred a net loss and negative cash flows from operations during the six months ended June 30, 2024 and management&#8217;s cash flow forecasts indicate that based on the Company&#8217;s expected future operating losses and negative cash flows, there is substantial doubt about the Company&#8217;s ability to continue as a going concern for 12 months after the date the unaudited consolidated financial statements are filed with the SEC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s ability to continue as a going concern is dependent upon its ability to raise additional funding. Management intends to raise additional capital through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements.  However, the Company may not be able to secure additional financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div></div></ix:exclude><ix:exclude>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company&#8217;s existing stockholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its current and potential future product candidates and programs on terms that are not favorable to the Company. As a result of adverse macroeconomic and geopolitical developments, recent and potential future bank failures, actual or anticipated changes in interest rates, economic inflation and the responses by central banking authorities to control such inflation, the global credit and financial markets have experienced volatility and disruptions, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. If the equity and credit markets deteriorate in the future, it may make any additional debt or equity financing more difficult, more costly, and more dilutive. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce or eliminate its research and development programs or other operations. Even if the Company raises additional capital, it may be insufficient to continue its development as currently planned, which could have a material adverse effect on the Company&#8217;s business, operating results and financial condition, and the Company&#8217;s ability to achieve its intended business objectives. If any of these events occur, the Company&#8217;s ability to achieve the development and commercialization goals would be adversely affected.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sources of Liquidity</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since its inception, the Company has devoted substantially all of its efforts and financial resources to organizing and staffing the Company, business planning, raising capital, discovering product candidates and securing related intellectual property rights, and conducting research and development activities for its Selected TIL programs and product candidates. The Company does not have any products approved for sale, has not generated any revenue from product sales and has incurred overall net losses since commencement of the Company&#8217;s operations, including a net loss of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49e3451c-1b0f-4df1-be40-cb64db599e9f" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">40.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bae56052-054f-47df-8fbb-bd4d552a67f6" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">21.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2024 and 2023, respectively. The Company has financed its operations through the issuance and sale of shares of the Company&#8217;s redeemable convertible preferred stock, from collaboration revenue received pursuant to certain collaboration agreements, and most recently, with proceeds from the IPO completed on July 25, 2023 and the exercise of the underwriters option to purchase additional shares on August 15, 2023. As of June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d003491-522c-4f18-9b1c-289a50fb8268" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">217.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company expects to continue to generate significant operating losses for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 26, 2024 (the &#8220;Loan Closing Date&#8221;), the Company entered into a Loan and Security Agreement ("LSA") with Banc of California ("BOC") for a revolving credit facility in an aggregate principal amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f3b1076-adf5-46e7-910b-c73df340de06" contextRef="C_1608bf2e-2722-4b3b-ac28-7d680ca451a6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million with annual interest at the greater of the Prime Rate (as defined in the LSA) or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3346dd5a-b514-4367-8c44-caab2ca0c83d" contextRef="C_1608bf2e-2722-4b3b-ac28-7d680ca451a6" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">4.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.  This LSA includes a covenant requiring the Company to (i) receive positive interim Phase 1 data for TIDAL-01 (as determined by the Company&#8217;s board of directors), which was achieved in August 2024 and (ii) receive at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e28508af-e07c-438f-8b92-9841aadee1af" contextRef="C_eea7aad0-d598-4675-97e4-495ad0d5f473" name="tsbx:FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">40.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in new funding from the sale of equity, partnerships, and/or business development payments, in each case, by March 31, 2025. If the Company fails to comply with any of the foregoing covenants, the Lender may terminate the commitments to make further loans and declare all of the obligations of the Company under the LSA to be immediately due and payable. As of June 30, 2024, no amounts have been drawn under the LSA (see</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Note 8 - Term Loan</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for additional information).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company intends to fund future operations and future capital funding needs through equity and/or debt financings, as well as possible asset sales, licensing transactions, and collaborations or strategic partnerships with other companies. The sale of equity or convertible debt could result in additional dilution to stockholders. The incurrence of indebtedness would result in debt service obligations and could result in operating and financial covenants that would restrict the Company&#8217;s operations. The Company can provide no assurance that sufficient financing will be available on acceptable terms, if at all. If the Company is not able to secure adequate additional funding it may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. Any of these actions could materially harm the Company&#8217;s business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including non-clinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_011e7618-e5a4-4797-b0a1-a43fc4d6d1b7" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e9c90140-7a49-41ac-9960-cbdaee3d32ef" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation of Unaudited Condensed Consolidated Financial Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. However, such interim financial statements reflect all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the Company&#8217;s financial position and results of operations. Results shown for interim periods are not necessarily indicative of the results that may be expected for the year ended December 31, 2024 or for any other period. The condensed consolidated balance sheet as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was derived from the audited consolidated financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements, included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 22, 2024. Certain prior period amounts reported in the Company&#8217;s unaudited condensed consolidated financial statements and accompanying notes have been reclassified to conform to the current period presentation. Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_346eb260-23c8-4fd6-84b2-74e649adf6db" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Principles of Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_95a09511-6f29-4f59-949e-ce9583cfad76" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="tsbx:SignificantAccountingPoliciesPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The significant accounting policies used in preparation of these unaudited condensed consolidated financial statements are consistent with those discussed in Note 2 to the audited consolidated financial statements included in the Company&#8217;s Annual Report filed on Form 10-K filed with the SEC on March 22, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_31a3e1e7-03b6-40de-ae68-cb23595d3820" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of these unaudited condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to accrued expenses, contingent liabilities, impairment of long-lived assets, revenue recognition, the valuation of equity-based compensation, common stock, restricted common stock, and income taxes. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1742f4bc-f41f-4759-a32d-6c0bdc378f4b" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="tsbx:RestrictedCashAndInvestmentsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash and Investments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash consists of certificate of deposit accounts that are pledged as collateral for the Company&#8217;s San Diego facility lease. Restricted cash was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16f975f0-6013-43d8-9cec-c53cd9dfa8e9" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_f39017ee-4b87-4fb7-84a8-c354fc3e425e" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 and December 31, 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company invests its excess cash in investment grade, short-term, fixed income securities and recognizes purchased securities on the settlement date. All investments have been classified as &#8220;available-for-sale&#8221; in the unaudited condensed consolidated balance sheets and are carried at estimated fair value based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments at the time of purchase and re-evaluates such designation as of each balance sheet date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company assesses its available-for-sale securities under the available-for-sale security impairment model in ASC Topic 326, Financial Instruments - Credit Losses ("ASC 326") as of each reporting date in order to determine if a portion of any decline in fair value below carrying value is the result of a credit loss. The Company records credit losses in the unaudited condensed consolidated statements of operations and comprehensive loss as credit loss expense, which is limited to the difference between the fair value and the amortized cost of the security. To date, the Company has not recorded any credit losses on its available-for-sale securities. Declines in fair value below carrying value attributable to non-credit related factors are recorded as accumulated other comprehensive loss, which is a separate component of stockholders&#8217; equity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div></div></ix:exclude><ix:exclude>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Realized gains and losses are reported in other income (expense), net. Interest on short-term investments is included in other income (expense), net. The Company&#8217;s investments are classified as current assets which reflects management&#8217;s intention to use the proceeds from sales of these securities to fund its operations, as necessary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9a97a666-0745-470d-afa8-2f863adc7fe2" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, investments and restricted cash. The Company&#8217;s investment policy restricts cash investments to high credit quality, investment grade investments. The Company&#8217;s investment policy provides guidelines and limits regarding investment type, concentration, credit quality, and maturity aimed at maintaining sufficient liquidity to satisfy operating and working capital requirements along with strategic initiatives, preserving capital, and minimizing risk of capital loss while generating returns on its investments. The Company is exposed to credit risk in the event of default by the issuer or the institutions holding the cash and cash equivalents to the extent of the amounts recorded on the balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has no off-balance sheet risk, such as foreign exchange contracts, option contracts or other foreign-hedging arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c4c827b5-57ed-4d9c-85cd-65ddabeb19cc" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the unaudited condensed consolidated financial statements on a recurring basis. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy requires that an entity maximize the use of observable inputs when estimating fair value. The fair value hierarchy includes the following three-level classification which is based on the market observability of the inputs used for estimating the fair value of the assets or liabilities being measured:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Quoted market prices in active markets for identical assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3 &#8211;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Inputs that are generally unobservable and typically reflect management&#8217;s estimate of assumptions that a market participant would use in pricing the asset or liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized at fair value in the unaudited condensed consolidated financial statements on a recurring basis (at least annually). To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_47b3b454-e22d-438f-9d8c-6b983070f9a2" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for stock-based compensation expense related to stock options and restricted stock units, ("RSUs"), by estimating the fair value on the date of grant. The fair value of RSUs granted to employees is the closing price of the Company&#8217;s common stock on the date of grant. The Company estimates the fair value of stock options granted to employees and non-employees using the Black-Scholes option pricing model. The Company recognizes stock-based compensation expense, over the requisite service period, based on the vesting provisions of the individual grants. Generally, the Company issues stock-based awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. The Company accounts for forfeitures when they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a) the expected stock price volatility, (b) the expected term of the award, (c) the risk-free interest rate and (d) expected dividend yields. Due to the lack of a public market for the Company&#8217;s common stock until July 21, 2023, and lack of company- specific historical and implied volatility data, the Company has based its computation of expected volatility on the average historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term. The Company uses the simplified method as prescribed by the U.S. Securities and Exchange Commission Staff Accounting Bulletin No. 107,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div></div></ix:exclude><ix:exclude>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Share-Based </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e1fc98ff-141e-49ce-a327-7e4ddbc75600" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="tsbx:FairValueOfCommonStockPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Determination of Fair Value of Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After the Company's IPO in July 2023, the fair value of common stock is determined using the closing price of the Company's common stock on the Nasdaq Global Market. Prior to the IPO, there were significant judgments and estimates inherent in the determination of the fair value of the Company&#8217;s common stock. These estimates and assumptions include a number of objective and subjective factors, including, among other things, external market conditions, the prices at which the Company sold shares of its convertible preferred stock, the superior rights and preferences of securities senior to its common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale of the Company. The approach to estimating the fair market value of common stock is consistent with the methods outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide, Valuation of Privately-Held Company Equity Securities Issued as Compensation (the &#8220;Practice Aid&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In valuing the Company&#8217;s common stock prior to the IPO, the equity value of the business was determined using the backsolve method, a form of the subject company transaction method, wherein the equity value for a privately held company is derived from a recent transaction in the company&#8217;s own securities. The value is then allocated using the hybrid method allocation methodology. For grants made subsequent to September 30, 2018 but prior to the IPO, the Company used a hybrid method, which is a hybrid between the OPM and the probability-weighted expected return method (&#8220;PWERM&#8221;). The hybrid method is a combination of the PWERM and OPM. The OPM allocates the overall Company value to the various share classes based on differences in liquidation preferences, participation rights, dividend policy and conversion rights, using a series of call options. The call right is valued using a Black-Scholes option pricing model. The PWERM employs additional information not used in the OPM, including various market approach calculations depending upon the likelihood of various discrete future liquidity scenarios, such as an initial public offering or sale of the Company, as well as the probability of remaining a private company. In a hybrid method, various exit scenarios are analyzed. A discount for lack of marketability of the Company&#8217;s common stock was then applied to arrive at an indication of value for the common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d4d5f2a5-124c-4982-b720-af8169c1c967" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="tsbx:ContingentConsiderationPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contingent Consideration</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consideration paid related to the Myst Merger Agreement (see</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Note 7 - Asset Acquisition</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for additional information) may include potential future payments that are contingent upon the Company achieving certain milestones in the future. Contingent consideration liabilities are measured at their estimated fair value as of the date of the unaudited condensed consolidated balance sheets using a probability-based income approach based on the monetary value of the milestone payment discounted for the likelihood of achieving the milestone and a present value factor based on the timing of when the milestone is expected to be achieved. Contingent consideration liabilities expected to be settled within 12 months after the balance sheet date are presented in current liabilities, with the non-current portion recorded under other liabilities, non-current in the unaudited condensed consolidated balance sheets. Changes in the fair value of the contingent consideration are recorded as research and development expenses in the unaudited condensed consolidated statement of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fa6d629f-e9dd-4ddc-8d39-ae3ecc6ad3af" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt&#8212;Debt with Conversion and Other Options </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Subtopic 470-20) and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivatives and Hedging Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Subtopic 815-40) (&#8220;ASU 2020-06&#8221;), which reduces the number of accounting models for convertible debt instruments and convertible preferred stock as well as amends the derivatives scope exception for contracts in an entity&#8217;s own equity. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_8fb38185-ea26-45ab-b107-b14eace25cd0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ASU 2020-06</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is effective for the Company on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_16745d6e-fc8a-4a28-ad88-7bf896fa0c8c" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  The </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_28168d30-5a3b-459d-9fe9-76cafed5896e" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adoption</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1a900090-c103-49b4-8c6b-8367c18c984f" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">did not have a material impact</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on the unaudited condensed consolidated financial statements.</span></p></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_533af1a0-eed1-4c54-9d40-d802bf5dce32" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="tsbx:RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Topic 280)&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;ASU 2023-07&#8221;). ASU 2023-07 requires that an entity disclose significant segment expenses impacting profit and loss that are regularly provided to the chief operating decision maker. The update is required to be applied retrospectively to prior periods presented, based on the significant segment expense categories identified and disclosed in the period of adoption. The amendments in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div></div></ix:exclude><ix:exclude>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ASU 2023-07 are required to be adopted for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the potential impact that this standard may have on its unaudited condensed consolidated financial statements and related disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (Topic 740)&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;ASU 2023-09&#8221;). ASU 2023-09 requires that an entity disclose specific categories in the effective tax rate reconciliation as well as provide additional information for reconciling items that meet a quantitative threshold. Further, ASU 2023-09 requires certain disclosures of state versus federal income tax expense and taxes paid. The amendments in ASU 2023-09 are required to be adopted for fiscal years beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued. The amendments should be applied on a prospective basis although retrospective application is permitted. The Company is currently evaluating the potential impact that this standard may have on its unaudited condensed consolidated </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">financial statements and related disclosures.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ef8823b8-299e-44f7-9976-a6887f0d9ecd" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Fair Value of Financial Assets and Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024 and December 31, 2023, the Company&#8217;s highly liquid money market funds included within cash equivalents, restricted cash and U.S. treasury securities are valued using Level 1 inputs. The Company classifies its federal agency securities as Level 2. There were no transfers in or out of Level 1 and Level 2 during the periods presented. U.S. treasury securities are bonds issued by the U.S. government and are fully backed by the U.S. government. Given the frequency at which U.S. treasury securities trade and the accessibility of observable, quoted prices for such assets in active markets, they are recognized as Level 1 assets. Federal agency securities are bonds and notes issued by government-sponsored enterprises, including Fannie Mae, Freddie Mac and the Federal Home Loan Bank. Since Federal agency securities typically do not trade as frequently as U.S. government agency securities and no exchange exists to price such investments, they are recognized as Level 2 assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ecbc3911-dd1c-4478-80e4-8136c0a2a006" contextRef="C_6289f1e6-72be-4ab1-8d3b-4951b6ae47d2" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2668d8b8-ae1f-4bdd-8617-4a6a917e64f7" contextRef="C_cad3a30c-8bbd-41b5-8824-b6ed0ebc07b6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in contingent consideration liabilities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 and December 31, 2023, respectively, related to the Myst Merger Agreement. The contingent consideration balances are comprised of one potential milestone payment and is measured at fair value (see</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Note 7&#8212;Asset Acquisition</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for additional information). The fair value of the contingent consideration is estimated based on the monetary value of the milestone discounted for the likelihood of achieving the milestone and a present value factor based on the timing of when the milestone is expected to be achieved. The value for the contingent consideration balance is based on significant inputs not observable in the market which represents a Level 3 measurement within the fair value hierarchy. There were no transfers in or out of Level 3 during the periods presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dd290469-1025-4a1d-8127-913f62233d80" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables represent a summary of the financial assets and liabilities that are measured on a recurring basis at fair value </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.949%;"/>
        <td style="width:1.081%;"/>
        <td style="width:1%;"/>
        <td style="width:11.049%;"/>
        <td style="width:1%;"/>
        <td style="width:1.081%;"/>
        <td style="width:1%;"/>
        <td style="width:8.866999999999999%;"/>
        <td style="width:1%;"/>
        <td style="width:1.081%;"/>
        <td style="width:1%;"/>
        <td style="width:8.866999999999999%;"/>
        <td style="width:1%;"/>
        <td style="width:1.081%;"/>
        <td style="width:1%;"/>
        <td style="width:8.866999999999999%;"/>
        <td style="width:1%;"/>
        <td style="width:1.081%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="background-color:#cff0fc;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9a3ad4a-c917-450c-815d-67c3052f4cb6" contextRef="C_b8a7d77b-acc4-44c2-a6eb-53af2968c508" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,125</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5398e9bd-ebea-4b3e-8fe6-0ad928412172" contextRef="C_314b4149-fadb-4ae4-82c4-63f56b1c9d19" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,125</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb913b95-47d2-4a61-b5c8-d28e9a3a78a8" contextRef="C_b8a7d77b-acc4-44c2-a6eb-53af2968c508" name="tsbx:RestrictedCashAndCashEquivalentsAtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc0eccb3-9981-4372-980a-7fe054f55e94" contextRef="C_314b4149-fadb-4ae4-82c4-63f56b1c9d19" name="tsbx:RestrictedCashAndCashEquivalentsAtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a65ea20-477a-40c6-8b71-df561b661c44" contextRef="C_b8a7d77b-acc4-44c2-a6eb-53af2968c508" name="us-gaap:FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,997</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7776a91-7c82-4933-aa9e-c2480d02b0e7" contextRef="C_314b4149-fadb-4ae4-82c4-63f56b1c9d19" name="us-gaap:FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,997</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fc597c90-c797-473a-afe9-4432112229c0" contextRef="C_b8a7d77b-acc4-44c2-a6eb-53af2968c508" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,238</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_848a80da-b88d-47b4-9d8f-9516e90f59a7" contextRef="C_314b4149-fadb-4ae4-82c4-63f56b1c9d19" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,238</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial liabilities:</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent consideration</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d06a94b7-2062-4c83-a6bb-fdee014c458b" contextRef="C_0efb3de3-c750-4eb6-95f7-ff7400831d2b" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,024</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_45f132ba-51ff-4191-b447-87891be4845e" contextRef="C_5edf160a-0dd5-4113-b0b6-1b907d836f1c" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,024</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a9109401-e6a3-4f44-a235-dc2e8a053beb" contextRef="C_5e3f8af4-ced0-4d18-92e3-8a9b5f41b2fa" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,024</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_630ee3c2-fa90-4e49-8f19-61078cca7904" contextRef="C_314b4149-fadb-4ae4-82c4-63f56b1c9d19" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,024</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50%;"/>
        <td style="width:1.12%;"/>
        <td style="width:1%;"/>
        <td style="width:9.1%;"/>
        <td style="width:1%;"/>
        <td style="width:1.12%;"/>
        <td style="width:1%;"/>
        <td style="width:9.1%;"/>
        <td style="width:1%;"/>
        <td style="width:1.12%;"/>
        <td style="width:1%;"/>
        <td style="width:9.1%;"/>
        <td style="width:1%;"/>
        <td style="width:1.12%;"/>
        <td style="width:1%;"/>
        <td style="width:9.1%;"/>
        <td style="width:1%;"/>
        <td style="width:1.12%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="background-color:#cff0fc;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1146070-8305-4867-b0a3-3d833381321d" contextRef="C_ac923606-471a-43f0-8bdf-735ab3fdfba1" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,635</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f1bded4-f862-4876-9cde-b29531d88d0f" contextRef="C_62731d6b-0b8e-473a-8756-77f4fdd3789c" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,635</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b890de6-aa39-45b5-be06-0b65a799a78b" contextRef="C_ac923606-471a-43f0-8bdf-735ab3fdfba1" name="tsbx:RestrictedCashAndCashEquivalentsAtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3a9d075b-7e31-4515-b879-101c8634b8c8" contextRef="C_62731d6b-0b8e-473a-8756-77f4fdd3789c" name="tsbx:RestrictedCashAndCashEquivalentsAtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fef79922-149c-4db4-948b-b6758db54cac" contextRef="C_ac923606-471a-43f0-8bdf-735ab3fdfba1" name="us-gaap:FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,979</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44474980-73c3-427f-b7fd-1dd6465464b8" contextRef="C_62731d6b-0b8e-473a-8756-77f4fdd3789c" name="us-gaap:FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,979</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d702a3c-f24e-4753-bb90-bdbb3408ac6e" contextRef="C_ac923606-471a-43f0-8bdf-735ab3fdfba1" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,730</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_251c82cd-2d83-49cb-ac18-9100e506335f" contextRef="C_62731d6b-0b8e-473a-8756-77f4fdd3789c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,730</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial liabilities:</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent consideration</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6897a6c7-0c7e-498f-9432-7d407d8553ec" contextRef="C_a11683c6-5fef-4195-864f-a7d508bdc2d2" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">916</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c23f96c7-2ae6-4bb4-a775-8c7c869c6702" contextRef="C_f29d5b9e-4d61-4151-a985-c2091e0f2865" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">916</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2de0b87a-55b2-4db4-aaa3-e7694ad19b2e" contextRef="C_29034bc0-6cf8-44cc-9ed1-c738ea64dd3b" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">916</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed05d301-fb71-490e-9a5d-12dabd1adcf0" contextRef="C_62731d6b-0b8e-473a-8756-77f4fdd3789c" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">916</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash serves as deposits for the Company&#8217;s San Diego office lease. </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Included in short-term investments on the unaudited condensed consolidated balance sheets and are classified as available-for sale debt securities. </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Contingent consideration related to the Myst Merger Agreement. </span></div></div></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div></div></ix:exclude><ix:exclude>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_e41ea288-0f1f-42ab-bb9b-b05b689d136d" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following significant unobservable inputs were used in the valuation of the contingent consideration payable to the sole common stockholder of Myst Therapeutics, Inc. ("Myst") pursuant to the Myst Merger Agreement:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:29.174%;"/>
        <td style="width:1%;"/>
        <td style="width:14.077%;"/>
        <td style="width:1%;"/>
        <td style="width:19.816%;"/>
        <td style="width:19.956%;"/>
        <td style="width:1.38%;"/>
        <td style="width:13.597%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value as of</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Contingent Consideration Liability</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Valuation Technique</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unobservable Input</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">'Milestone payment for first registrational study (see Note 7 - Asset Acquisition for additional information)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43cd3d9d-035c-4c26-84c1-f18fd818a4f8" contextRef="C_09ae6d90-7a9b-443b-bc02-068850b13217" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,024</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Discounted cash flow</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Likelihood of occurrence</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_208d3a56-2f71-4652-bc03-a2920db7054c" contextRef="C_07beddb2-5e8d-4fd2-a982-9c19bd8f1784" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Discount rate</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e575ca2-2c0d-40f1-a14d-baa2c6164f4f" contextRef="C_2b4f6127-8d59-412e-b50f-15f6bca69e60" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_160853f9-bf71-49dd-908a-6890909ae23e" contextRef="C_f13a602c-d40d-43cb-af5a-1b863d53488c" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_Y" scale="0" decimals="1" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value as of</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Contingent Consideration Liability</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Valuation Technique</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unobservable Input</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">'Milestone payment for first registrational study (see Note 7 - Asset Acquisition for additional information)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_29e460a6-fb0e-4139-874f-6d7eb1b5a371" contextRef="C_86fd67e3-caa9-4cfa-8107-a69bd2da8aa7" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">916</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Discounted cash flow</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Likelihood of occurrence</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f400f6df-8323-4578-a703-90fe686f2249" contextRef="C_cada1dd4-e094-4155-bd2f-9d9d53838f8b" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Discount rate</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_19b7ec98-c26c-4e2c-b167-ef80bd11c4de" contextRef="C_611eb55b-b1d8-48ea-b1bf-f13c75cd2c4f" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ee69752-32f2-419b-b3bf-e3ab5d794e9c" contextRef="C_686637a7-6c9d-4004-a3a1-f62abb9c5a0b" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_Y" scale="0" decimals="1" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a84abb79-1974-4944-80dc-f4bb79ed171c" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table reflects the activity for the Company&#8217;s contingent consideration, measured at fair value using Level 3 inputs (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.876%;"/>
        <td style="width:2.02%;"/>
        <td style="width:1%;"/>
        <td style="width:18.104%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent consideration at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa8b9342-a0d7-4b59-9feb-200ee05ef54f" contextRef="C_86fd67e3-caa9-4cfa-8107-a69bd2da8aa7" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">916</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in the fair value of contingent consideration</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb79e74f-b46a-4c28-9244-bce3e274db19" contextRef="C_08eea265-04df-4ba5-a0a1-6754a009edac" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">108</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent consideration at June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_99c1e2c8-8638-46d2-a3c1-3c22281c2295" contextRef="C_09ae6d90-7a9b-443b-bc02-068850b13217" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,024</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f657948c-f9c6-452f-b839-bdf4c4b3a68d" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="tsbx:CompanyCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables show the Company&#8217;s cash, cash equivalents and available-for-sale securities by significant investment category </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.761%;"/>
        <td style="width:1.121%;"/>
        <td style="width:1%;"/>
        <td style="width:9.189%;"/>
        <td style="width:1%;"/>
        <td style="width:1.121%;"/>
        <td style="width:1%;"/>
        <td style="width:9.189%;"/>
        <td style="width:1%;"/>
        <td style="width:1.121%;"/>
        <td style="width:1%;"/>
        <td style="width:9.189%;"/>
        <td style="width:1%;"/>
        <td style="width:1.121%;"/>
        <td style="width:1%;"/>
        <td style="width:9.189%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1:  Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ba74156-28e3-4cae-9016-5c0b2357dd9c" contextRef="C_a282ba00-b430-4f99-a7fb-75b6613249a7" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,125</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9c2adcd-1ff2-4ded-81b3-74c2a82c0f11" contextRef="C_a282ba00-b430-4f99-a7fb-75b6613249a7" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,125</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Restricted cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a550a4e-f190-4b61-b877-2145af513f39" contextRef="C_a4224032-80db-4207-a62f-06fddc1f3e8d" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ee0feae-de47-4db7-abbd-75ee3b30b2f4" contextRef="C_a4224032-80db-4207-a62f-06fddc1f3e8d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;U.S. government securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c6d08bb7-ba5e-4048-9bb0-a2b13665ca4f" contextRef="C_598b88c4-d183-499c-84b9-3e796e6520bc" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,021</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_58813075-d4f7-4a4c-b937-a622b9a42801" contextRef="C_21d1e869-620d-4a35-abc4-05dbceb24181" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_180841d0-b158-4b70-8b51-f714eac925db" contextRef="C_598b88c4-d183-499c-84b9-3e796e6520bc" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,997</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_be3b1095-e3af-4cf4-b48a-e0b02015a93f" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,262</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_124609e1-aaea-488b-a5b0-d4225445529a" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d88ce83-7b9f-4e54-b890-e2a98bad533f" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,238</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Classified as:</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4d180956-226a-4982-bcae-59bdf833c6a7" contextRef="C_9e6ce855-a23c-4318-9cf7-7b65d716e1a5" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,125</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebe21b98-5049-4c97-b7c7-f9f7689352d7" contextRef="C_3ffd6a05-a9be-4e07-b29c-81b2bc74d344" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2fa92296-f6b4-4d80-9ee0-3929804fc422" contextRef="C_31b4b1f9-e730-4c51-a000-a2794909b7b3" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,997</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8f4e804-c2d8-482e-bbbd-91292373f7bc" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,238</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div></div></ix:exclude><ix:exclude>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.761%;"/>
        <td style="width:1.121%;"/>
        <td style="width:1%;"/>
        <td style="width:9.189%;"/>
        <td style="width:1%;"/>
        <td style="width:1.121%;"/>
        <td style="width:1%;"/>
        <td style="width:9.189%;"/>
        <td style="width:1%;"/>
        <td style="width:1.121%;"/>
        <td style="width:1%;"/>
        <td style="width:9.189%;"/>
        <td style="width:1%;"/>
        <td style="width:1.121%;"/>
        <td style="width:1%;"/>
        <td style="width:9.189%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1:  Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98dfc62f-2201-4865-a945-edfdb05a8b7b" contextRef="C_5cf56eca-80aa-4857-a57f-478d4c936a9b" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,635</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_59211168-46df-47db-90d8-32f6f47b7fb7" contextRef="C_5cf56eca-80aa-4857-a57f-478d4c936a9b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,635</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Restricted cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3fa66e03-08e6-4cb9-89f0-c1195b0d0de5" contextRef="C_83c6962e-9c53-4e63-b1ff-31ca5d0d2f3b" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf3a4c4d-f01d-4eeb-9f6f-58fbe7b6756e" contextRef="C_83c6962e-9c53-4e63-b1ff-31ca5d0d2f3b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;U.S. government securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf7e7b26-2e0a-4f3b-aed4-a3fe4b680df6" contextRef="C_9800e42c-8612-4c53-9cab-3c07fc9a6fbb" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,875</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_40f5fa14-d77b-49f2-969e-91bbd61ea377" contextRef="C_b6c3ec3d-2d98-49dd-9189-5cbaccf94ce2" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b05cdd4-42c7-46ed-a5e3-2de56c465b43" contextRef="C_9800e42c-8612-4c53-9cab-3c07fc9a6fbb" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,979</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af03debc-66dc-4ec3-97a2-d677485c82a7" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,626</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1763a897-e8cf-40be-938c-34dea866b5e0" contextRef="C_c2fc5443-940d-4d73-8fd5-8bcdd4605301" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">104</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2dd7f3e-ff79-453e-b263-6bcfa4daa727" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,730</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Classified as:</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8cd495d-5daf-41ee-9621-4c973e99ab9b" contextRef="C_396a19e8-3bfd-4308-a62d-934e7ca98d70" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,635</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbb9b01c-daf2-45b4-b7cd-3967ce3d0cf1" contextRef="C_87edcac5-f97d-43c3-9877-1d9fda334fd6" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">116</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0770f514-b46d-4868-be55-61ce8d219419" contextRef="C_3bc9ea85-cac7-4114-b7e4-68f51d5ac95c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,979</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_401c78ed-623b-47bf-9b6a-67564c49d620" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,730</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_056648d2-5eca-46a2-bd8e-b337fe2b8c1f" contextRef="C_018d9f0a-f1a9-461c-a05d-3b501d8ad8bd" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" unitRef="U_Security" decimals="INF" format="ixt:num-dot-decimal">16</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05b97161-46e6-4863-a9c0-19aeb89466d0" contextRef="C_8a2c0799-2ad0-4d20-8a89-44e9c7d5025f" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" unitRef="U_Security" decimals="INF" format="ixt:num-dot-decimal">18</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of our available-for-sale debt securities were in a gross unrealized loss position of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8477beb2-4f2f-4047-978f-b9d9836ea905" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million with an aggregate fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e884b932-de1e-4b84-9257-5fd2639cd776" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">42.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. As of December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc540191-952a-4e67-804e-29569e1405b7" contextRef="C_cb7e98d1-0ba9-403c-aa73-cc10851ec0f9" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" unitRef="U_Security" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ne out of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_536f52ac-cd96-49b3-9800-65ca2aed35c1" contextRef="C_77f8cd0f-f6c2-4b41-b3a2-ad645efbb34e" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" unitRef="U_Security" decimals="INF" format="ixt:num-dot-decimal">28</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of our available-for-sale debt securities were in a gross unrealized loss position.  While short-term investments are available-for-sale, it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be maturity. All short-term investments currently held have maturities of less than one year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews short-term investments for impairment during each reporting period. Credit losses are recognized up to the amount equal to the difference between the fair value and the amortized cost basis and recorded as an allowance for credit losses in the unaudited condensed consolidated balance sheets with a corresponding adjustment to earnings. Unrealized losses that are not related to credit losses are recognized in accumulated other comprehensive loss. Unrealized losses were not significant for the investments held in the Company&#8217;s portfolio as of June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and Company considered the decline in market value for these securities to be primarily attributable to economic and market conditions rather than credit-related factors. There were no unrealized losses in the Company's investment portfolio at December 31, 2023. The Company considered the risk-profile of the counterparties under ASC 326, noting that any credit risk associated with such entities is either zero or near zero. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af07c246-1a11-4b4e-8b5c-044cd05ffd37" contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_ea38e877-c27a-4e85-ad06-f17f05ce714f" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_9862b0ba-1445-44b4-bea7-631c78de3181" contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f12f34b3-eced-4bda-95a4-a769d34ce828" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairment losses or expected credit losses related to its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d519c220-b9c0-4efc-ae00-16610eda5851;"><span style="-sec-ix-hidden:F_07c37049-61be-45e2-82d2-712a7c000aaa;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">short-term investments</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and six months ended June 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5c395c24-636e-4050-a531-ac81f1c3b830" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. Property and Equipment, Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_24c3f55d-f8c0-400e-81c8-e10fadfe2455" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net consist of the following (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.16%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:12.92%;"/>
        <td style="width:1%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:12.92%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1a88eba-10f5-4670-94c7-f775a961f4b8" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:MachineryAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,112</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3523f446-fb47-4cbb-b215-0bc1d9a83a81" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:MachineryAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,043</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b88ae029-8a2a-41d6-811b-8b575cf69a17" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:FurnitureAndFixturesGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">690</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2c730dc-d312-4724-9def-1b7d82edd5b9" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:FurnitureAndFixturesGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">690</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d31dadd-2771-4a71-ae60-cae2a0b13e7d" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:LeaseholdImprovementsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,308</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_475c8aeb-b994-4324-95cb-b1322e33e8c2" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:LeaseholdImprovementsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,308</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7398402d-3815-4559-a1b1-837baa16aaab" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,110</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad3d5de5-96ad-43cb-8130-c40519a47f16" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,041</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3668c102-def6-4215-a4fb-b8fe7d93a273" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,541</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34cbe711-11ea-41f6-b441-7e11b1dd2b70" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,689</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d4d411f-da8b-49c2-afdd-13a6d5eda6bc" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,569</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ede64720-ba62-418c-b918-37f99c7a4e44" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,352</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment depreciation and amortization expense for the three months ended June 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa5904af-41e9-4912-ba4b-ef3a3faceea0" contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22f8c689-b631-4ca1-aa9a-debbe4bb644f" contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively and the six months ended June 30, 2024 and 2023, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5939ceb-4d17-4f44-823e-859d095823e0" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4bfebcde-585f-4b86-9d19-94a1c75fb0f0" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eb72bba7-22d1-407a-879c-58e70a93012c" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="tsbx:DisclosureOfAccruedExpensesAndOtherCurrentLiabilitiesTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. Accrued Expenses and Other Current Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7678a9f4-cbde-4b8a-8ddc-224b624ee0c4" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="tsbx:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.16%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:12.92%;"/>
        <td style="width:1%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1%;"/>
        <td style="width:12.92%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7dc8e4a5-2a26-4fdf-88bc-abbe82f16765" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="tsbx:ResearchAndDevelopmentExpenseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,187</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ab5daea9-268c-4764-bb9d-7c5b6f5c9684" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="tsbx:ResearchAndDevelopmentExpenseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,675</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional and consulting expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ccdf0e04-235c-488f-9ae0-0138db7a7989" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">753</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27f97d25-8c4e-416b-9c24-0ea17add59e9" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">641</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b2f8c4d-e631-455a-8c2a-7a7984f2e4e1" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="tsbx:AccruedCompensationCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,336</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_979a62c5-bda4-4cfa-9a3f-79ba2e2bdd94" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="tsbx:AccruedCompensationCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,593</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24488d78-65bc-4b13-92f0-456bee6c2556" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_94843045-f06a-41a5-a417-9481806deacf" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,354</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebb2857e-5205-4396-b227-f47dbf230116" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,909</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aca71098-9849-40e4-9779-95d578cd1cfe" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Takeda Pharmaceutical Company Limited</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaboration Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2019, the Company entered into a discovery, collaboration and license agreement (&#8220;Takeda Agreement&#8221;) with Millennium Pharmaceuticals, Inc. (also known as Takeda Oncology), a wholly owned subsidiary of Takeda Pharmaceutical Company Limited ("Takeda"). Under the Takeda Agreement, the Company agreed to collaborate with Takeda to co-develop and co-commercialize TBio-6517 (also known as RIVAL-01) (&#8220;Development Program&#8221;) and to conduct discovery programs to identify additional novel product candidates based on its vaccinia virus platform for independent development (&#8220;Discovery Program&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Takeda Agreement, the Company granted Takeda and its affiliates a worldwide, irrevocable, non-transferable, co-exclusive, sublicensable license under certain of the Company&#8217;s know-how and patent rights (&#8220;Turnstone Technology&#8221;) to make, use, sell, offer for sale, develop, manufacture, and commercialize, or otherwise exploit TBio-6517 (&#8220;Licensed Compound&#8221;) and products containing TBio-6517 (&#8220;Takeda Licensed Products&#8221;) in all fields. Takeda granted the Company and the Company&#8217;s affiliates an irrevocable, non-transferable, non-exclusive, sublicensable license under certain know-how and patent rights of Takeda (&#8220;Takeda Technology&#8221;) to make, use, sell, offer for sale, develop, manufacture, and commercialize, or otherwise exploit the Licensed Compound and Takeda Licensed Products in all fields in accordance with joint development, commercialization, and medical affairs plans under the Takeda Agreement. Under the Takeda Agreement, the Company also granted to Takeda and its affiliates a worldwide, non-transferable, non-exclusive, sublicensable license under Turnstone Technology to conduct joint discovery and research activities in all fields in accordance with joint research and discovery plans. Under the Takeda Agreement, Takeda granted the Company a license to Takeda Technology to conduct discovery and research activities in all fields in accordance with joint research and discovery plans. The Company also granted to Takeda and its affiliates an exclusive option to obtain a worldwide, irrevocable, non-transferable, exclusive, sublicensable license under Turnstone Technology to make, use, sell, offer for sale, develop, manufacture, and commercialize, or otherwise exploit (i) selected discovery virus candidates generated and evaluated by the parties under a joint discovery program (&#8220;Selected Discovery Candidates&#8221;), and (ii) any corresponding licensed products containing a Selected Discovery Candidate (&#8220;Licensed Discovery Products&#8221;). Takeda may exercise this option with respect to two virus candidates and within a specified option exercise period. The Company granted Takeda and its affiliates a non-exclusive, perpetual, irrevocable, worldwide, sublicensable and fully paid-up license under certain of the Company&#8217;s know-how and patents relating to manufacturing improvements developed under the Takeda Agreement solely for use in connection with the manufacture of products that do not comprise or incorporate, and that are not based on, an oncolytic virus. Takeda granted the Company and the Company&#8217;s affiliates a non-exclusive, perpetual, irrevocable, worldwide, sublicensable and fully paid-up license under certain of Takeda&#8217;s know-how and patents relating to manufacturing improvements developed under the Takeda Agreement solely for use in connection with the manufacture of any and all products. With respect to discovery virus candidates for which Takeda does not exercise its option, Takeda granted the Company a non-exclusive, perpetual, worldwide, sublicensable and royalty-bearing license under certain of its know-how and patents that is necessary or reasonably useful for the exploitation of such declined discovery virus candidates (&#8220;Declined Candidate License&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Responsibilities for the development of Licensed Compounds and Takeda Licensed Products are delineated pursuant to a joint development plan under the terms of the Takeda Agreement. The Company will be responsible for all activities under the joint development plan prior to completion of a Phase 2a clinical trial and Takeda will be responsible for all activities in the joint development plan upon and after completion of the Phase 2a clinical trial. Responsibilities relating to manufacturing, medical affairs, and commercialization of Licensed Compounds and Takeda Licensed Products are delineated pursuant to a manufacturing working plan, joint medical affairs plan and joint commercialization plan, respectively. The Company has the right to reduce or opt-out of its share of responsibilities for costs and expenses of certain development or commercialization activities for the Takeda Licensed Compounds and Takeda Licensed Products. Responsibilities for the discovery and research of Selected Discovery Candidates are delineated pursuant to joint discovery and research plans under the terms of the Takeda Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Takeda Agreement, Takeda paid the Company a non-refundable payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70141c81-1f46-4bc7-82ec-ede9861051f8" contextRef="C_0e39171b-0288-4a90-bd4c-4de866d982ec" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in November 2019 and an additional non-refundable payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d82af3f-b611-488b-b968-baa4a3ccd604" contextRef="C_d347b544-ac7a-4849-8e58-614bec001e25" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">30.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in April, 2020, for the option to license up to two Selected Discovery Candidates, with additional consideration of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_210a9c5a-a0bb-499b-88aa-2dcb98dd7b54" contextRef="C_0f2177db-5b60-476f-a730-1c8f81312684" name="tsbx:CollaborativeArrangementAdditionalConsiderationReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to be paid by Takeda to the Company for each exercise of such option.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Takeda Agreement, the Company has the right to reduce its share of funding obligations with respect to development activities for the Licensed Compound and Takeda Licensed Products (the &#8220;Development Opt-Down Right&#8221;), or to opt-out of all further funding obligations with respect to development activities for the Licensed Compound and Takeda Licensed Products (the &#8220;Development Opt-Out Right&#8221;). Unless and until the Company exercises the Development Opt-Down Right, the parties will share evenly in any operating profits or losses with respect to joint development activities, joint medical affairs activities, and joint commercialization activities. If the Company exercises its Development Opt-Down Right, then starting from the effective date of the exercise of the right, Takeda will bear (and be entitled to) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cc462a8e-9d14-4d73-83f8-8efddc6f9adc" contextRef="C_0e39171b-0288-4a90-bd4c-4de866d982ec" name="tsbx:PercentageOfOperatingProfitOrLoss" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">70</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and the Company will bear (and be entitled to) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e7c5962-6e4f-462b-b1d3-9e707901d36e" contextRef="C_b070210d-0df6-446b-9018-f836d7eb1564" name="tsbx:PercentageOfOperatingProfitOrLoss" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">30</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the operating</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div></div></ix:exclude><ix:exclude>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">profits </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or losses with respect to joint development activities, joint medical affairs activities, and joint commercialization activities. Takeda is obligated to pay the Company (i) up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_404e2a04-6dbe-49ac-9ef0-981cfc4b004b" contextRef="C_0532a010-4fab-45c5-a50c-f89be68e5dbd" name="tsbx:MilestonePaymentReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">200.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in aggregate upon achievement of certain clinical and regulatory milestones for the first Takeda Licensed Product to achieve the applicable development milestone event, (ii) up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_696ec4e2-ecca-43f1-a562-7a06b2c3e9c1" contextRef="C_7b886516-c4ec-4600-ae2d-8f4f97019128" name="tsbx:MilestonePaymentReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">150.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in aggregate for one-time payments upon achievement of certain sales milestones for each Takeda Licensed Product, (iii) up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cadc0e21-bdb0-4b4f-84ce-9ac4513490fe" contextRef="C_f4165f52-0752-4cfc-8c7f-a573ebe98155" name="tsbx:MilestonePaymentReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">240.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in aggregate (if Takeda exercises both options to Selected Discovery Candidates) upon achievement of certain clinical and regulatory milestones for the first Takeda Licensed Discovery Product to achieve applicable development milestone events, and (iv) up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ddff85e-e7fd-4afb-ae69-1d0a49673697" contextRef="C_a963c822-6da7-4671-af23-c5e6b30f3e6b" name="tsbx:MilestonePaymentReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">300.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in aggregate (if Takeda exercises both options to Selected Discovery Candidates) for one-time payments upon achievement of certain sales milestones for a Licensed Discovery Product. If the Company exercises its Development Opt-Out Right for the Takeda Licensed Products, then in lieu of the profit and loss share arrangement described above, the Company is entitled to receive tiered low- to high- teen percentage royalties on net sales of all Takeda Licensed Products by the Company or the Company&#8217;s sublicensees during the royalty term, which commences on the first commercial sale of a Takeda Licensed Product in a country and ends on the later of the expiration of all licensed patents covering such Licensed Product in such country or ten years after the date of the first commercial sale in such country (&#8220;Royalty Term&#8221;). For Licensed Discovery Products, the Company is entitled to receive tiered high-single digit to low-teen percentage royalties on net sales of all Licensed Discovery Products by the Company or the Company&#8217;s sublicensees during the Royalty Term. Royalty payments are subject to customary reductions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Takeda has the right to terminate for convenience as follows: (i) prior to the expiration of the option exercise period related to a Discovery Virus Candidate, Takeda may terminate the Takeda Agreement related to such Discovery Virus Candidate and the Discovery Program with 90 days&#8217; notice, (ii) prior to any commercial sale, Takeda may terminate the Takeda Agreement either in its entirety or on a compound-by-compound or region-by-region basis, with six months&#8217; notice and (iii) after a commercial sale, Takeda may terminate the Takeda Agreement either in its entirety or on a compound-by-compound or region-by-region basis, with 12 months&#8217; notice.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Termination of Development Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 13, 2022, Takeda provided six months&#8217; written notice to terminate the Development Program in accordance with its termination for convenience rights, with such termination being effective as of December 13, 2022. During the six months&#8217; notice period, the Company was obligated to continue providing the necessary Development Program services to wind down the program. Upon the effective termination date of December 13, 2022, Takeda&#8217;s co-exclusive license to TBio-6517 terminated and the Company is no longer obligated to pursue development of TBio-6517.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Termination of Discovery Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 6, 2023, Takeda provided six months&#8217; written notice to terminate the remainder of the Takeda Agreement, with such termination being effective as of July 6, 2023 (&#8220;Effective Termination Date&#8221;). On the Effective Termination Date, all options and licenses granted under the Takeda Agreement terminated (except for the Declined Candidate License) and Takeda granted the Company a non-exclusive license under the patent rights and know-how controlled by Takeda as of the Effective Termination Date necessary for the Company to exploit the Licensed Compound and Takeda Licensed Products in the form existing as of the Effective Termination Date for any use worldwide, subject to a royalty to be agreed upon by Takeda and the Company. As of March 31, 2023, the Company ceased all work under the Takeda Agreement and there were no remaining estimated services associated with the obligations under the Takeda Agreement as of the effective termination date of July 6, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Analysis</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company assessed the promised goods and services under the Takeda Agreement in accordance with ASC Topic 606, Revenue from Contracts with Customers ("ASC 606"), and determined that, at inception, the Takeda Agreement includes the following performance obligations: (i) research, development and manufacturing services under the Development Program for the completion of clinical trials through Phase 2a for RIVAL-01 and a co-exclusive license to exploit RIVAL-01 (&#8220;Development Program Performance Obligation&#8221;); and (ii) research and development services under the Discovery Program to identify and optimize four Selected Discovery Candidates for further development (&#8220;Discovery Program Performance Obligation&#8221;). The individual promises under the Development Program including research, development, manufacturing for clinical trials, and the co-exclusive license to RIVAL-01 are not individually distinct as they represent inputs into a combined output of advancing RIVAL-01 through the Phase 2a clinical trial. Therefore, all promises under the Development Program represent a single performance obligation. Similarly, the research and development services under the Discovery Program represent a single research program aimed at generating four Selected Discovery Candidates and therefore represents a single performance obligation. The Development Program promises are distinct from the promises under the Discovery Program, as the benefits under each program are separately identifiable. Each program has a separate work plan and the promises to be provided under the Development Program do not relate to the promises to be provided under the Discovery Program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div></div></ix:exclude><ix:exclude>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company concluded that Takeda&#8217;s license options under the Discovery Program do not represent material rights, and therefore are not performance obligations, as the Company is entitled to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa0baecd-0a15-46f7-9363-018703f8a30c" contextRef="C_77f50463-e1af-4144-8629-1e583e752cb2" name="tsbx:CollaborativeArrangementAdditionalConsiderationReceivableForLicensedOption" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million payment for each license option exercised, which approximates the estimated standalone selling price of the underlying license.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total transaction price at contract inception is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1e3822b9-9971-410d-b7b0-b3722c6bd591" contextRef="C_77f50463-e1af-4144-8629-1e583e752cb2" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">158.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, comprised of the following components:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fixed consideration of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a41ec8be-9ad8-42ae-a9b4-0ac675b49c58" contextRef="C_77f50463-e1af-4144-8629-1e583e752cb2" name="tsbx:RevenuePerformanceObligationFixedAggregateConsideration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">80.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million including a non-refundable up-front payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f51cd7c-5ed5-40b9-831c-1e9b522486c5" contextRef="C_8b5fa308-adf1-4661-99fb-c63ef4adc638" name="tsbx:RevenuePerformanceObligationFixedConsiderationNonRefundableUpfrontPaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in November 2019 and another non-refundable payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad739ac9-de6f-4109-aaec-27b67325ede4" contextRef="C_507a33a4-3fb5-40c4-b2ec-c9dcaad76c3a" name="tsbx:RevenuePerformanceObligationFixedConsiderationNonRefundablePaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">30.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million that was due on April 1, 2020 and received in April 2020. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Variable consideration related to the expense sharing under the Development Program. These amounts are determinable based on the Development Program plan and budget, and the Company has a contractual right to the payment of costs incurred under the agreed upon plan. Consistent with the expected value method, the Company estimated that it will receive $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fe003eb-0d91-4335-8762-4be072fb2f4f" contextRef="C_77f50463-e1af-4144-8629-1e583e752cb2" name="tsbx:EstimatedCompensationEarningFromProjectExpenseSharing" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">58.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million under the expense sharing through the completion of the Phase IIa clinical trial. The Company has concluded that these amounts do not require a constraint and are included in the transaction price at inception. The Company has evaluated this estimate at each reporting date and updated the estimate based on information available. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Variable consideration for the development milestones under the Development Program. The Company uses the most likely amount method to value this variable consideration as there are only two possible outcomes of achieving the individual milestones. Under the Development Program, the first milestone of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26b5445e-1b0c-4e84-8ee3-46d794cfc11e" contextRef="C_87d12abd-fd41-4556-ab97-906718a6de21" name="tsbx:MilestonePaymentReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million is due upon acceptance of an Investigational New Drug Application  ("IND") by the U.S. Food and Drug Administration ("FDA"). At inception, the Company concluded that achievement of this milestone was highly probable and therefore the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1093ca8c-7267-450a-be75-a1765cb92645" contextRef="C_87d12abd-fd41-4556-ab97-906718a6de21" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was included in the transaction price and was received in March 2020. The second milestone of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6d2e528b-e248-4d56-92a7-3aac956b260f" contextRef="C_e1ea96db-9cc4-4129-9e50-4fac54584f5a" name="tsbx:MilestonePaymentReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million under the Development Program is due upon the initiation of the first Phase 2 clinical trial for a licensed product. The Company has determined that the most likely amount is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c95be751-c0cf-4a0e-8286-80358956a096" contextRef="C_7d7ff18f-d96f-4bfd-81be-511ab4a4637d" name="tsbx:MilestonePaymentReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, however, the Company will not include this $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_441419c3-ddeb-4bec-9da1-611173110ab3" contextRef="C_7d7ff18f-d96f-4bfd-81be-511ab4a4637d" name="tsbx:MilestonePaymentReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million milestone in the transaction price until it becomes probable that a significant reversal of cumulative revenue will not occur. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional consideration to be paid to the Company includes development and sales milestones, profit and loss share, royalties and option exercise payments. These additional payments are achievable only after the completion of the Phase 2a clinical trial under the Development Program or exercise of the license options under the Discovery Program and therefore are excluded from the transaction price. Additionally, Takeda&#8217;s equity purchase commitments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c4ae4c0-4ce5-45d8-9350-ec9c65f63a95" contextRef="C_4e19f9b2-a9f6-479d-8fbf-5061721bee44" name="us-gaap:CommitmentsFairValueDisclosure" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million are at fair value and therefore no non-cash consideration has been included as a component of the transaction price.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company allocated the transaction price to the separate performance obligations based on their relative standalone selling prices. The Company determined the standalone selling price of the Development Program Performance Obligation based on the costs incurred to develop RIVAL-01 plus the estimated costs to perform the research, development and manufacturing services through the completion of the Phase 2a clinical trial, inclusive of a reasonable profit margin. The Company determined the standalone selling price of the Discovery Program Performance Obligation based on the estimated costs to discover and research four Selected Discovery Candidates, inclusive of a reasonable profit margin. Significant inputs used to determine the standalone selling prices of the performance obligations include the length of time required, the internal hours expected to be incurred on the services, and the amount of third-party expenses that will be incurred to complete the performance obligations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes the amounts associated with these performance obligations on a proportional performance basis over the contract term using input-based measurements of total cost of research and development incurred to estimate the proportion performed as compared to the estimated total cost and remeasures its progress towards completion at the end of each reporting period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2021, the transaction price was updated to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60ce74d6-53b8-46bd-b13c-07dfa47a71d5" contextRef="C_464ce7dd-76e3-4b22-9015-b1330a849be8" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">192.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to reflect an increase in the variable consideration related to the expense sharing under the Development Program from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e972cb4-5a57-4119-becd-eb73d0660cd5" contextRef="C_77f50463-e1af-4144-8629-1e583e752cb2" name="tsbx:EstimatedCompensationEarningFromProjectExpenseSharing" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">58.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million at inception to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48556180-ca46-46fc-927c-4ff953029862" contextRef="C_464ce7dd-76e3-4b22-9015-b1330a849be8" name="tsbx:EstimatedCompensationEarningFromProjectExpenseSharing" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">92.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_20d4a678-95aa-4840-9892-715f0dc9abff" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="tsbx:ScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determined that the notice of termination on June 13, 2022, represented a modification of the arrangement under ASC 606 and that the transaction price should be updated and re-allocated to the Development Program Performance Obligation and the Discovery Program Performance Obligation based on their standalone selling prices, as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.571%;"/>
        <td style="width:1.429%;"/>
        <td style="width:18.571%;"/>
        <td style="width:1.429%;"/>
        <td style="width:20%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Performance Obligations</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Price Pre-<br/>Modification</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Price at<br/>Modification</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Development Program</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b9b7d212-aa7f-47c9-95d1-1c89cf5e1b08" contextRef="C_b49bbb74-b521-4de0-8223-a4c6342ce9da" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">166.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;million</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f74c2e87-6326-4fbb-bb02-e283cc6dd6c5" contextRef="C_0acb4150-37ee-4c10-8006-d0790fa8f0f9" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">134.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;million</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Discovery Program</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fea76e95-67ff-42c3-ae44-c4701b21f4ff" contextRef="C_80bdbeb9-b4a1-45e1-87bb-ef7e5bd3a405" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">26.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;million</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_325344ff-9632-4732-9724-e953f7ae1e77" contextRef="C_1c334911-8a35-4c3d-9e49-91814e062e98" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">21.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;million</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97c0ba47-96ea-4945-8ea9-222237b0ebdb" contextRef="C_c6cfacbc-df8a-46ce-911a-93257d4940af" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">192.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;million</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1d3e7ee0-1a3f-4325-b7ee-58fa3daa6f35" contextRef="C_b5d7d3a5-05a6-4a7d-b86b-89c61ed59b35" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">155.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;million</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, the Company updated its measure of progress for each performance obligation as of the modification date and recorded a cumulative adjustment that increased collaboration revenue by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8114d2c2-e1c3-4fda-8747-27f4e6b7cae6" contextRef="C_c9641d36-9a68-4e01-bcd1-21dd6a75222f" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">31.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">on the partially satisfied remaining</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div></div></ix:exclude><ix:exclude>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">performance </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obligations, as the remaining services to be performed under each of the performance obligations are not distinct from the services prior to the modification.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs incurred relating to the Takeda Agreement consist of internal and external research and development costs, which primarily include salaries and benefits, lab supplies, and preclinical research studies. All of these costs have been included in research and development expenses in the Company&#8217;s unaudited condensed consolidated statements of operations and comprehensive loss during the three months ended March 31, 2023 and in prior years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognized the remaining deferred revenue balance during the three months ended March 31, 2023 as the Company concluded that there were no remaining estimated services to be performed associated with the obligations under the Takeda Agreement. The Company recognized </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_86aca0ff-7597-42fd-ba5f-977c1204204c;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaboration revenue</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> related to the Takeda Agreement for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c7f2c8b-6970-4157-ac2e-44cd8a6460a8" contextRef="C_325b972a-88a3-49e4-a865-f3c3e4c449cb" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad7bbd0a-e8e4-4881-8711-ecbd2107d913" contextRef="C_83258d10-36fd-47d8-8435-ebb348293175" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">19.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.  Receivables related to reimbursable costs expected to be received from Takeda for research and development services performed under the Development Program at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cfbbbdd5-e84b-4c70-ab61-3e3c5ba52640" contextRef="C_0041f20c-fe1a-4d2b-a3bf-ab3dc220fe5a" name="us-gaap:OtherReceivables" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f41f056-54e1-48e4-a6db-074a7730e09c" contextRef="C_b3dc0960-b79a-43dc-b52d-544a4f88fb55" name="us-gaap:OtherReceivables" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">H. Lee Moffitt Cancer Center</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Master Collaboration Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2021, the Company entered into an amended and restated master collaboration agreement (the &#8220;Moffitt Agreement&#8221;), with Moffitt, to amend a then-existing master collaboration agreement from November 2019, as amended March 2020, between Moffitt and the Company&#8217;s now wholly-owned subsidiary, Myst, with the intent to continue to work collaboratively in the research of cancer immunotherapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each party granted the other party a right to use its research materials for performance of the research plans agreed to by the parties (the &#8220;Research Plans&#8221;). Each party granted the other party a non-exclusive, worldwide, sublicensable, perpetual, irrevocable, royalty-free license under all inventions invented in performance of a Research Plan and invented jointly by the Company and Moffitt (the &#8220;Joint Inventions&#8221;) (with certain exclusions) to make, use, sell, offer for sale, import products and services and/or otherwise practice such inventions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company granted Moffitt a royalty free, non-sublicensable, non-transferable, perpetual, non-exclusive license to use and practice certain inventions invented solely by the Company in the performance of a Research Plan for its internal non-commercial research purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moffitt granted the Company (i) a royalty-free, sublicensable, non-transferable, perpetual, non-exclusive license to use and practice certain inventions invented solely by Moffitt in the performance of a Research Plan (&#8220;Moffitt Inventions&#8221;), (a) for internal, non-commercial research purposes outside the field of ACT and/or (b) to research, develop, make, use, sell, offer to sell, or import products and/or services in the field of ACT and (ii) a royalty free, sublicensable, non-transferable, perpetual, non-exclusive license to use and practice certain inventions invented in performance of a Research Plan or through the use of specified Moffitt research materials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moffitt granted the Company an option to obtain, with terms to be negotiated in good faith under commercially reasonable terms, a royalty-bearing, sublicensable exclusive license in the Moffitt Inventions, the TCR Inventions, and/or Moffitt&#8217;s interest in Joint Inventions. The Company can exercise this option at any time within six months after Moffitt informs the Company of any new invention, and upon the Company&#8217;s exercise, the parties will have a period of six months to negotiate the terms of such exclusive license.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Moffitt Agreement will expire upon the later of (i) four years from the effective date of the Moffitt Agreement or (ii) the termination or expiration of all Research Plans in effect under the Moffitt Agreement, unless extended upon mutual written agreement of the parties. Either party may terminate the Moffitt Agreement for cause upon any uncured breach by the other party or upon the insolvency of the other party.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Moffitt Alliance Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2022, the Company entered into a life science alliance agreement with Moffitt (the &#8220;Alliance Agreement&#8221;), in order to further expand the Company&#8217;s relationship and support the Company&#8217;s existing agreements with Moffitt (the &#8220;Underlying Agreements&#8221;). Pursuant to the Alliance Agreement, the Company will have priority access to Moffitt&#8217;s scientific research, manufacturing, and clinical capabilities for the development of novel TIL therapies, including expedited clinical trial activation, enhanced patient screening and data sharing, access to Moffitt&#8217;s cellular therapies research and development infrastructure, expanded</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div></div></ix:exclude><ix:exclude>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">molecular data sets and biospecimens for research, and allocated cGMP manufacturing capacity for the Company&#8217;s product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Alliance Agreement, the Company is obligated to use commercially reasonable efforts to further develop TIL Products, to manufacture TIL Products, to obtain regulatory approval for at least one TIL Product in the United States and to commercialize TIL Products in all countries in which regulatory approval for a TIL Product has been obtained. For purposes of the Alliance Agreement, TIL Product means any pharmaceutical, biopharmaceutical, or biotechnology TIL product that has been developed by us or Moffitt and is advanced into clinical development under an IND sponsored by Moffitt.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Alliance Agreement, the Company agreed to pay to Moffitt a total amount of at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6e0fe5b9-7d01-421c-8051-e591ad69e182" contextRef="C_4bae3e9b-125f-4503-8c73-cdcf17ef0bfe" name="tsbx:CollaborativeArrangementAggregateConsiderationPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the &#8220;Alliance Funding Amount&#8221;), for research, development and manufacturing related services that will be paid equally over five years on June 1st of each year starting on June 1, 2023. The Alliance Funding Amount will be calculated annually at the conclusion of each payment period, and, to the extent the Company&#8217;s annual aggregate payments to Moffitt of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79ff054d-1e1e-4485-be74-0f9d088f45c6" contextRef="C_971026b7-966d-464b-8792-32c68702fcf6" name="tsbx:ResearchDevelopmentAndManufacturingServicesAggregateAnnualAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million exceeds the applicable annual installment amount, the Company will receive a reduction in the amount due for future installment payments based on a predetermined formula agreed to by the parties. To the extent the aggregate annual payments are less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e089b1b8-0134-4be6-ba47-309ac2fc745a" contextRef="C_971026b7-966d-464b-8792-32c68702fcf6" name="tsbx:ResearchDevelopmentAndManufacturingServicesAggregateAnnualAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, the Company will prepay the remaining amount due. On June 28, 2024, the Alliance Agreement was amended to remove the true up of the applicable annual installment amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2fe6f06e-d45a-4720-a96e-f44032266526" contextRef="C_6b9ab1b4-ace1-409a-beef-b24a105df524" name="tsbx:ResearchDevelopmentAndManufacturingServicesAmendedToRemoveTrueUpAnnaulInstallment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.  The Alliance Funding Amount remains $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b1ae6177-138d-4a87-9dcd-5e140c43ad88" contextRef="C_7442ee75-92a9-41e2-98c5-9ab8b76e128f" name="tsbx:CollaborativeArrangementAggregateConsiderationRemains" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million over the five year term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the execution of the Alliance Agreement, the Company issued Moffitt </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fbc2eca2-0b9c-4359-adf7-bd6c20992e09" contextRef="C_390d4d0c-2d69-4485-b251-e5c588a82858" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">91,721</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock. As partial consideration under the Alliance Agreement, the Company also agreed to issue Moffitt an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da31ebe6-a3f1-473d-88a6-5f472e0f83cb" contextRef="C_dc19bbcb-5619-4e9c-8fd6-1b3767d599b1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">366,884</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock in the aggregate upon the satisfaction of certain clinical and regulatory milestones with respect to TIL Products. The issuances of common stock are treated as performance-based stock awards. On February 27, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8aba55d7-c1f6-4e09-af04-d82a8888763f" contextRef="C_4d3b7a6e-20dc-4532-aa88-976e8d769182" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">91,721</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares were issued due to the achievement of the milestone related to the start of the Phase 1 trial. In addition, upon achievement of certain thresholds for aggregate net sales of all TIL Products, the Company is required to make tiered sales-based milestones payments to Moffitt of up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65b26bfe-4c9f-43d1-ac5d-6a3d064344ec" contextRef="C_dd6315d5-b691-40c0-8822-66150720e552" name="us-gaap:OtherCommitment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. With respect to each of the equity and sales milestones described above, TIL Products include any pharmaceutical, biopharmaceutical or biotechnology TIL Product that is developed by the Company or Moffitt and is advanced into clinical development under an IND sponsored by Moffitt.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unless earlier terminated, the Alliance Agreement will remain in effect for a term of five years and may be extended for additional periods upon the mutual written consent of both parties. Either party may terminate the Alliance Agreement in the event of (i) the other party&#8217;s material breach of the Alliance Agreement that remains uncured after ninety days of receiving written notice of such breach (or in the case of breach of payment obligations, within ten days), (ii) the other party&#8217;s insolvency and (iii) a pandemic event resulting in government lockdowns or orders that legally compel such party to cease operations or that result in material disruptions in the available workforce and prevents such party from performing its contractual obligations for a period of more than six months. At any time after June 1, 2025, either party may terminate the Alliance Agreement without cause upon sixty days prior written notice to the other party (a &#8220;Termination for Convenience&#8221;). Upon a Termination for Convenience, the terminating party shall pay to the other party a termination fee in an amount equal to a low double digit percentage of the then remaining Alliance Funding Amount. Termination or expiry of one or more Underlying Agreements does not affect the term of the Alliance Agreement, which will continue to apply to the remaining ongoing Underlying Agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c2ef8e23-3454-409f-ab9b-9bc362c4ace3" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:AssetAcquisitionTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. Asset Acquisition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2020, the Company entered into the Agreement and Plan of Merger and Reorganization (the &#8220;Myst Merger Agreement&#8221;), by and among the Company, Flatiron Merger Sub I, Inc. (&#8220;Merger Sub&#8221;), Flatiron Merger Sub II, LLC (&#8220;Merger LLC&#8221;), a direct, wholly-owned subsidiary of the Company, Myst, and Timothy Langer, the sole common stockholder of Myst (&#8220;Langer&#8221;). Pursuant to the Myst Merger Agreement, the business combination (the &#8220;Merger&#8221;) was effected in two steps. The first step was the merger of Merger Sub with and into Myst. The second step was the merger of Myst with and into Merger LLC. The Merger closed on December 14, 2020, and the effective date of the Merger was January 20, 2021. As a result of the Merger, the separate existences of Merger Sub and Myst ceased, and Merger LLC became the Company&#8217;s wholly-owned subsidiary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Myst Merger Agreement, on December 15, 2020, the Company paid the former equity holders of Myst, (the &#8220;Myst Holders&#8221;), a one-time up-front payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bccae9f7-54fd-4822-9646-7d1782c2236d" contextRef="C_a8f26943-f1b9-49c8-b166-c849e9c3a34e" name="us-gaap:PaymentsToAcquireProductiveAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cash. The Company paid an additional cash consideration of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20c63314-d434-4875-972b-d7e05e280a3f" contextRef="C_10a10b4c-098b-47f2-b0cd-44fdb0c3ed0c" name="us-gaap:PaymentsToAcquireProductiveAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to the Myst Holders on June 14, 2022. The Company also issued Langer up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b8794415-fede-4ab9-9662-fa5cf67ccb71" contextRef="C_df3730e6-4b3b-4511-9b22-d73a3cb03c8b" name="tsbx:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">725,920</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock. Of these shares, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_54601acd-01f2-43e0-81da-132f757442e6" contextRef="C_df3730e6-4b3b-4511-9b22-d73a3cb03c8b" name="tsbx:AssetAcquisitionConsiderationTransferredEquityInterestIssuedShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">362,960</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock were issued upon the closing of the Merger and the remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_816b4a8c-ff3e-4131-a13f-bbfad0a64b99" contextRef="C_df3730e6-4b3b-4511-9b22-d73a3cb03c8b" name="tsbx:AssetAcquisitionConsiderationTransferredEquityInterestIssuableShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">362,960</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock were held in escrow with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b177234d-7366-4e07-8373-165154192849" contextRef="C_fde9996f-abc3-46c0-958f-c7d1eb86e821" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% vesting in December of each year that Langer remains with the Company. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, Langer is an advisor to the Company and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_78d2a1c9-5724-461a-8be5-1e6aefa164fc" contextRef="C_5a226ff4-7fbd-4466-ad8e-193443f07e2e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">272,220</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock have vested and been released from escrow with the remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ddbbfcc-3f10-4ecf-a5f6-60f0659321ce" contextRef="C_bf4bea3d-6d81-4dab-a5e9-0fb7804e121d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">90,740</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the Company&#8217;s common stock to be released at the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div></div></ix:exclude><ix:exclude>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">end </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of 2024. This restricted equity grant is accounted for as a compensatory arrangement under ASC Topic 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation &#8212; Stock Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;ASC 718&#8221;) as continued service is required under the agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, under the Myst Merger Agreement, each Myst Holder is entitled to receive certain payments as consideration based on the achievement by the Company of three predefined milestones. The initial milestone is the closing of an initial public offering, which occurred on July 25, 2023, the second milestone is the first acceptance by the FDA of an IND filed by, on behalf of or for the benefit of the Company, or the Company&#8217;s sublicensees for a product being developed by or on behalf of the Company or its sublicensees that is claimed as a product or method of making or using the product by a pending or issued Myst patent claim existing at the time of such acceptance, and the third milestone is the occurrence of the earlier of (i) the commencement of the first registration study for a product being developed by, on behalf of or for the benefit of the Company that is claimed as a product or a method of making or using the product by an issued Myst patent claim existing as of the time of such commencement or (ii) the issuance of a Myst patent claim that claims a product or method of making or using the product then being developed by, on behalf of or for the benefit of the Company, or its sublicensees, that is or was the subject of a registration study that has or had commenced. The milestones are not contingent on one another, and the milestones do not need to be achieved in any specific order.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Within 45 days of the achievement of the initial milestone, which occurred on July 25, 2023, the Company is obligated to pay the Myst Holders an aggregate amount equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b94bc050-0b53-4b1f-a8e8-7e4be5602921" contextRef="C_48fa1a69-511d-4e0c-b236-6692208f9dc3" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. At the Company&#8217;s election, the Company may pay this consideration in cash or in shares of the Company&#8217;s common stock. Pursuant to a letter agreement dated September 11, 2023 between the Company and the former equityholders of Myst regarding the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34332e78-60ff-4c71-9c59-4585360cf79d" contextRef="C_ea03660c-6f74-4aa0-a083-02a3316775a5" name="tsbx:ContingentConsiderationPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million milestone payment that became due and owing to the Myst Holders, the Company agreed to pay $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d021a049-e542-48ae-83a8-2f4263d464da" contextRef="C_9f5bac87-6928-4532-8588-a3d080f1d32d" name="tsbx:ContingentConsiderationPayableByCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cash to the former optionholders of Myst on or before September 30, 2023, with the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_88d2352f-fb4c-45a8-8351-88c4391987c4" contextRef="C_58806346-af8a-4a1b-852a-6954a4cb63e1" name="tsbx:ContingentConsiderationPayableByShares" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million payable to Langer in shares of the Company&#8217;s common stock. On September 11, 2023, the Company issued Langer </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7db16cd-9e96-4f95-91d5-f8f66cedce39" contextRef="C_263ddd8f-936b-4629-ac81-de82901400f0" name="tsbx:StockIssuedDuringThePeriodForMilestonePaymentsShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">249,992</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Within 45 days of the achievement of the second milestone, the Company is obligated to pay the Myst Holders an aggregate amount equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_722c0009-0a5b-469d-be30-ff50599f7bf8" contextRef="C_2f5ca510-92ae-4c6d-88c6-32a100f28ecc" name="tsbx:ContingentConsiderationPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. At the Company&#8217;s election, the Company may pay this consideration in cash or in shares of the Company&#8217;s common stock. In May 2022, this $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb1b15ef-fe14-44f6-ba2a-aebd9d2e9665" contextRef="C_ca9e9c5b-5d60-4a1b-8ad7-f5f5e30eeccd" name="tsbx:ContingentConsiderationPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million milestone was achieved. The Company elected to pay $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b89a90e-2f8f-4a70-af7a-f613cbd023f2" contextRef="C_ca9e9c5b-5d60-4a1b-8ad7-f5f5e30eeccd" name="tsbx:ContingentConsiderationPayableByShares" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the Company&#8217;s common stock and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_914e7f0e-4829-427a-aabf-a056ccfaa88f" contextRef="C_ca9e9c5b-5d60-4a1b-8ad7-f5f5e30eeccd" name="tsbx:ContingentConsiderationPayableByCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cash. Pursuant to a letter agreement dated July 25, 2022 between the Company and the former equityholders of Myst regarding the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f700c5af-dc0a-4cb6-819b-2a7131c2adfb" contextRef="C_9e1380fe-5300-44d7-addc-af012845a913" name="tsbx:ContingentConsiderationPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million milestone payment that became due and owing to the Myst Holders, the Company agreed to pay to the former optionholders of Myst on or before July 28, 2022, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_439a8941-f627-49ce-a161-66a407a506bf" contextRef="C_dde16e3b-95a2-4acb-a8f5-4219383626cd" name="tsbx:ContingentConsiderationPayableByCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cash, with the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80388b04-5d97-43e3-b20e-10ed9e2c70c4" contextRef="C_7c898406-56c5-4ae7-8aa8-5701d037862a" name="tsbx:ContingentConsiderationPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million payable to Langer as follows: (i) on or before July 28, 2022, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91e7becf-7687-49b5-9ff5-07f7c0ce7f29" contextRef="C_d7168d5d-e7a5-46ff-9b87-4e0562cb00e5" name="tsbx:ContingentConsiderationPayableByCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cash, (ii) on or before July 31, 2022, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_604c9618-b534-4f70-947c-cfcb9c34cb43" contextRef="C_c762659f-a398-4da4-b6b5-fb1c73edfefd" name="tsbx:ContingentConsiderationPayableByShares" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in shares of the Company&#8217;s common stock and (iii) on or before January 10, 2023, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b918b45-1c8b-4f6a-a3ab-dde52fd0cdbf" contextRef="C_e1930a00-b656-4b09-88f7-718672d19d95" name="tsbx:ContingentConsiderationPayableByCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cash. On June 8, 2022, the Company issued Langer </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57e2f052-25b2-49b2-af49-ffbc6b8716b6" contextRef="C_eab032e1-3425-462f-8d5e-286e582b438d" name="tsbx:StockIssuedDuringThePeriodForMilestonePaymentsShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">212,203</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock to settle the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5982288-0b8c-4733-9f59-bb281d967392" contextRef="C_eab032e1-3425-462f-8d5e-286e582b438d" name="tsbx:StockIssuedDuringThePeriodForMilestonePaymentsValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million obligation payable in common stock. The Company then paid the Myst Holders $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7263bbf5-400d-48b9-a306-a44685d9aaed" contextRef="C_ddebe139-151f-44ec-8890-0c2c9c33904a" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in July 2022, with $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6336d077-ad20-4ee4-9d32-7a56444395d7" contextRef="C_624dbdac-4327-488c-b421-114825296f78" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million paid to Langer and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4abfdd3c-646e-4282-869f-e4a41123089a" contextRef="C_8136f853-5792-4e82-a119-8cc35daccd6d" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million paid to the remaining Myst Holders, and the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aa2a438f-29c8-44b6-98a0-2d1b3a608014" contextRef="C_6f6523cc-b1d2-4b30-81f0-6490c4ab9067" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was paid to Langer in January 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Within 45 days of the achievement of the third milestone, the Company is obligated to pay the Myst Holders an aggregate amount equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f8eb358c-08f3-4ed7-984c-05fdcd46d348" contextRef="C_2d28ff08-66e3-4717-8e1b-0159fd2dae0a" name="tsbx:ContingentConsiderationPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. At the Company&#8217;s election, the Company may pay this consideration in cash or in shares of its common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounted for the merger with Myst pursuant to the Myst Merger Agreement as an asset acquisition as substantially all of the value received was concentrated in the acquired in-process research and development of Myst and did not have an alternate future use. The Company recognized a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f2c2f796-4a43-419e-a8dd-c45d49e8247e" contextRef="C_d4a98e5a-d94e-4f1c-b7cf-4ba20e9be13c" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">19.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million charge to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_7a312f44-81d0-4aab-b68e-4d0c368d2aae;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">research and development expense</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> at the time of the completion of the asset acquisition during the year ended December 31, 2020. The Company determined that the milestone payments are separate units of account and accounted for the initial milestone as a derivative in accordance with ASC Topic 815, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivatives and Hedging</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;ASC 815&#8221;)  and the second and third milestones as liabilities in accordance with ASC Topic 480, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Distinguishing Liabilities from Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;ASC 480&#8221;). In connection with the initial public offering, the Company reassessed its initial accounting of the milestone payments and concluded that they should be viewed as one unit of account because the milestone payments are not legally detachable from each other. The milestone payments, as one unit of account, would be classified as a liability in accordance with ASC 480 and measured at fair value, with changes in the fair value recorded in earnings. Regardless of whether the milestone payments are viewed as one unit of account or three units of account, because they are all subject to fair value measurement, the financial reporting effect of the contingent consideration arrangement as one unit of account or three units of account is substantially the same. As a liability under ASC 480, the contingent consideration will continue to be recorded at fair value until settled. The adjustment to the fair value of the contingent consideration of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fae80eb5-c918-45cf-9cf1-9e5aa4123a33" contextRef="C_9d84a11b-47e8-4e33-b8ab-f05dc1707a83" name="tsbx:AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6bf5e60f-bcec-4114-8b67-810ec8006c6a" contextRef="C_5b35fa61-bbf8-46c2-a6fc-1e914819fa92" name="tsbx:AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three months ended June 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively and was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c1dd899-8030-4c82-82d9-f5e483da459a" contextRef="C_9d04f62a-8f18-4763-a524-2381aeebe491" name="tsbx:AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80fa6991-aec2-4fcc-894e-74f65d665508" contextRef="C_7a433f77-f757-4637-ac62-b0d9f32aca2c" name="tsbx:AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the six months ended June 30, 2024 and 2023,  respectively, were included in research and development expense in the Company&#8217;s unaudited condensed consolidated statements of operations and comprehensive loss.</span></p></ix:nonNumeric></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2db5eacd-df49-48e1-a1e5-a9dee8934b86" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:DebtDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. Term Loan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 26, 2024 (the "Closing Date"), the Company entered into the LSA, by and among the Company, as borrower, the Company&#8217;s wholly owned subsidiary, Myst Therapeutics, LLC (&#8220;Myst LLC&#8221; and, together with the Company, the &#8220;Loan Parties&#8221;) and BOC, as lender. The LSA provides for a revolving credit facility in an aggregate principal amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_efecd91f-a56d-4ca8-85c5-518f77150218" contextRef="C_1608bf2e-2722-4b3b-ac28-7d680ca451a6" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the &#8220;Revolving Loans&#8221;). The Company may request advances at any time the loan is not in default and not to exceed the Revolving Loans limit and may prepay any amounts outstanding at any time with no prepayment penalty.  Upon termination of the LSA, whether in connection with acceleration, prepayment in full, or otherwise, the Company is obligated to make a nonrefundable payment of  (i) $0.4 million at any time on or prior to the first anniversary of the Closing Date, and (ii) $0.2 million at any time after the first anniversary of the Closing Date but prior to the second anniversary.  In addition, the Company is obligated to pay a fee in the event of certain corporate transactions equal to the greater of (i) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9f1824a-2137-478b-b21e-7aac486f9f6a" contextRef="C_ece257ea-a6a0-437c-89a2-7ad5c9fc8aa2" name="tsbx:DebtInstrumentSuccessFeeAmount" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">50,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8908ed9d-6641-42ee-9257-0697260cba10" contextRef="C_ece257ea-a6a0-437c-89a2-7ad5c9fc8aa2" name="tsbx:DebtInstrumentSuccessFeePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the highest aggregate principal amount outstanding prior to the transaction (the "Success Fee").  The Success Fee is due upon any merger or consolidation, any sale of substantially all of the assets of the Company, or the closing of one or more related financings where aggregate cash proceeds from the sale of equity securities and/or upfront cash proceeds from strategic partnerships is equal to at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d0336905-d479-467d-bab8-66c2783f89bc" contextRef="C_adb55f11-8d4b-474a-b9d9-4cbcb3d9be20" name="tsbx:CashProceedsFromTheSaleOfEquitySecuritiesAndOrUpfrontCashProceedsFromStrategicPartnerships" unitRef="U_USD" scale="6" decimals="INF" format="ixt:num-dot-decimal">75.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and occurs on or before the tenth anniversary of the Closing Date (each a "Success Fee Event").  If the LSA is terminated prior to the payment of the Success Fee, the Company will remain obligated to pay the Success Fee upon the occurrence of a Success Fee Event during such ten-year period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_88a204b2-03aa-47dc-9da5-a9becfc3274a" contextRef="C_ece257ea-a6a0-437c-89a2-7ad5c9fc8aa2" name="us-gaap:LineOfCreditFacilityInterestRateDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The annual interest rate applicable to the Revolving Loans is the greater of the Prime Rate (as defined in the LSA) and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a3cfc9e-5f9a-4305-aab9-8ad277b89af7" contextRef="C_1608bf2e-2722-4b3b-ac28-7d680ca451a6" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Interest under the Revolving Loans is due and payable on the first calendar day of month during the term.  The initial maturity date of the Revolving Loans is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bdd0c927-a58c-4560-bc5b-cbf4c668be6b" contextRef="C_ece257ea-a6a0-437c-89a2-7ad5c9fc8aa2" name="us-gaap:LineOfCreditFacilityExpirationDate1" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which may be extended to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c33be942-dfd7-4eb2-b646-e344505da35e" contextRef="C_ece257ea-a6a0-437c-89a2-7ad5c9fc8aa2" name="tsbx:LineOfCreditFacilityExtendedDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2027</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> subject to the satisfaction of certain terms and conditions as set forth in the LSA.  Upon maturity, all amounts outstanding will become due and payable.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The LSA contains customary representations and warranties and customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness and dividends and other distributions. The Company is also required to comply with certain covenants requiring the Company to (i) receive positive interim Phase 1 data for TIDAL-01 (as determined by the Company&#8217;s board of directors), which was satisfied in August 2024 and (ii) receive at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb20a2f3-e15d-44fa-91fb-01351b42de58" contextRef="C_eea7aad0-d598-4675-97e4-495ad0d5f473" name="tsbx:FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">40.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in new funding from the sale of equity, partnerships, and/or business development payments, in each case, by March 31, 2025. If the Company fails to comply with any of the foregoing covenants, the Lender may terminate the commitments to make further loans and declare all of the obligations of the Company under the LSA to be immediately due and payable.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The LSA also includes customary events of default, including failure to pay principal, interest or certain other amounts when due, material inaccuracy of representations and warranties, violation of covenants, specified cross-default and cross-acceleration to other material indebtedness, certain bankruptcy and insolvency events, certain undischarged judgments, material invalidity of guarantees or grant of security interest, material adverse effect and change of control, in certain cases subject to certain thresholds and grace periods. If one or more events of default occurs and continues beyond any applicable cure period, the Lender may terminate the commitments to make further loans and declare all of the obligations of the Company under the LSA to be immediately due and payable.  Additionally, upon the occurrence of an event of default, the Company is obligated to pay a fee equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9063f297-3eda-436b-91f4-5bde17ea55b7" contextRef="C_ece257ea-a6a0-437c-89a2-7ad5c9fc8aa2" name="tsbx:DebtInstrumentFeeOnEventOfDefault" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% above the interest rate then in effect on all outstanding obligations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of  June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_673e725c-caf6-4b56-bfd5-b4ee57ff17eb" contextRef="C_4ed0c192-f7ce-4ccd-88a9-1326c9ea54ba" name="us-gaap:LineOfCredit" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> amounts had been drawn under the Revolving Loans.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_310db7b6-2d72-4493-80f4-595267f5f742" contextRef="C_4ed0c192-f7ce-4ccd-88a9-1326c9ea54ba" name="us-gaap:DeferredFinanceCostsNet" unitRef="U_USD" scale="0" decimals="1" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of debt issuance costs which were recorded as part of Other Current Assets and will be amortized over the term of the LSA.</span></p></ix:nonNumeric></div>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_25c71509-bd44-4b5a-ac2a-d837a65a88d9" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Redeemable Convertible Preferred Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From October 2015 to October 2016, the Company issued a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d0d7d28-1cf0-488b-9587-b8410f5c4532" contextRef="C_2e92c815-0887-42a5-9aa2-1aa6d38a8788" name="tsbx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,250,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of series A preferred stock (the &#8220;Series A Preferred Stock&#8221;) at CDN$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_446210d7-df32-4c6e-8fe1-2ab5eac3cd17" contextRef="C_b1d0d042-927c-480f-9792-c14b9cf5f6d2" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_CadShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share (equivalent to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e344fc7-a0b4-4f87-b6cd-1f31897dd808" contextRef="C_b1d0d042-927c-480f-9792-c14b9cf5f6d2" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.74</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, based on a conversion ratio of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_599b9e4c-99a6-42c3-ad51-e172c96f9a71" contextRef="C_b1d0d042-927c-480f-9792-c14b9cf5f6d2" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" unitRef="U_pure" scale="0" decimals="3" format="ixt:num-dot-decimal">1.344</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Canadian dollars to one U.S. dollar) for total net proceeds of CDN$ </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_afaf7d6f-4153-48be-9462-528b45fc80b4" contextRef="C_2e92c815-0887-42a5-9aa2-1aa6d38a8788" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_CAD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (equivalent to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb7afa78-cf23-46df-a256-8a123f93c89e" contextRef="C_2e92c815-0887-42a5-9aa2-1aa6d38a8788" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million based on a conversion ratio of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16792cad-8c0e-49a2-96f1-8ccad897b99a" contextRef="C_b1d0d042-927c-480f-9792-c14b9cf5f6d2" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" unitRef="U_pure" scale="0" decimals="3" format="ixt:num-dot-decimal">1.344</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Canadian dollars to one U.S. dollar).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2016, the Company issued a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_532a529c-1c69-4bcc-a4d3-ea252e74c910" contextRef="C_be0f70da-b5dc-4227-b5d4-1a3bd3c8a13d" name="tsbx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">16,285,156</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of series B-1 preferred stock (the &#8220;Series B-1 Preferred Stock&#8221;) at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08add21d-89a9-4659-957c-394c8e4caccd" contextRef="C_d917210f-1291-4dbd-86d6-3aa84bc8ab10" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.77</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share for total net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae2f89d2-433a-4e7e-a25c-ae53f6099314" contextRef="C_be0f70da-b5dc-4227-b5d4-1a3bd3c8a13d" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. In November 2018, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_07b72de3-88e8-42c0-8302-d99e26665b19" contextRef="C_ac0cf97a-5db0-4110-a9ce-20faacb87521" name="tsbx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">25,065,538</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of series B-2 preferred stock (the &#8220;Series B-2 Preferred Stock&#8221;, and together with the Series B-1 Preferred Stock, the &#8220;Series B Preferred Stock&#8221;) at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c050c044-f6b7-4df4-9447-b9896b5b57ae" contextRef="C_2fb9dc1f-ccec-4fe3-83bb-464c06488b6a" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share for total net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7fe612d5-c443-4fdb-8c34-bfdd7b76eebb" contextRef="C_ac0cf97a-5db0-4110-a9ce-20faacb87521" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">28.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company issued a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_df88a50e-da0b-4742-be56-e0e49853153a" contextRef="C_33faa779-ce8f-4e4d-a219-c041b650a61c" name="tsbx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">17,905,288</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of series C preferred stock (the &#8220;Series C Preferred Stock&#8221;) at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_255c2941-db54-4e7c-bbc0-f82ee61bb7c5" contextRef="C_9d04382e-1108-4cb1-91e7-16fb7b6fd93d" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.35</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share in January 2019 for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8b53c2b5-2e5d-49e7-a02d-de12d1b3bde7" contextRef="C_33faa779-ce8f-4e4d-a219-c041b650a61c" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">41.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div></div></ix:exclude><ix:exclude>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company issued a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1c849beb-196d-42de-8dec-45f4c9f3c5be" contextRef="C_221e8d7b-e069-4751-b775-170cde6f9416" name="tsbx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">29,285,356</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of series D preferred stock (the &#8220;Series D Preferred Stock&#8221;) at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_709c17a8-1053-4a1f-a4a7-c1c4f6b162c4" contextRef="C_9755dc24-1227-4784-baf5-a2b45b159779" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.73</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share in June 2021 for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5fc4851a-3dd9-4c8a-98a0-62b55291afe6" contextRef="C_221e8d7b-e069-4751-b775-170cde6f9416" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">79.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Company's IPO, all outstanding shares of the Company's redeemable convertible preferred stock automatically converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11277a40-9eea-448a-adf7-0ae57f838cf4" contextRef="C_10aa115c-22ea-46be-bcba-a9a9cd88b729" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">12,493,879</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock.  Subsequent to the closing of the IPO, there were no shares of redeemable convertible preferred stock outstanding.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the closing of the IPO, the Company filed its Amended and Restated Certificate of Incorporation which provides that the authorized common stock of the Company is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c49e6ba7-d291-4cd1-8f81-9aa402de9839" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">490,000,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock with a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0074697e-90c9-41bd-a7e6-dd8ab1d097f6" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:num-dot-decimal">0.001</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dee8573a-be6d-4c85-bb79-db82e1da55f9" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="tsbx:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Shares of common stock reserved for future issuance consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock options outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_31ef02c0-779c-4914-b792-9d473b18c83c" contextRef="C_02fa49d2-1f02-4cc7-908f-06f8c20ff1f5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,298,558</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee1ba05f-c225-4fbe-9548-11a28701cac7" contextRef="C_5552aea5-73b7-4fb7-83a2-8300ff05e8db" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">3,374,282</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested RSUs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96abf068-cb69-4b6a-a9af-77d93bea9894" contextRef="C_234b0297-d293-4e18-9282-e7524404692b" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">108,899</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_923c1c47-279c-4adc-9b8d-6aca402faf3e" contextRef="C_df1018cd-e834-471b-a1de-7f644abc127e" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">102,945</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for issuance under the ESPP</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fdb81b7b-a187-4923-ad78-717dca6f8689" contextRef="C_fe429d1a-4bd7-4dc5-aa72-7fe35faa4549" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">453,280</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7569438e-d0ce-47cd-9c67-d5e0145163e1" contextRef="C_392765bd-7ded-4967-8201-2e786fab388b" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">222,287</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for issuance under the Plans</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c1d4d16-d177-4c25-95ea-a8e3683db016" contextRef="C_66ae9658-0772-4454-88b3-b788cb30a2c3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,946,048</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28e17b51-2f01-4fbe-8da4-cf0a2b24a290" contextRef="C_86842d26-2e12-4042-998d-29e3bb96ed47" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,755,404</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f5072291-2092-4252-b9b0-b0bc9c75c745" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,806,785</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22888131-ed48-4093-969c-d3b9a9e18322" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">5,454,918</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_692c4da3-f266-42db-87bf-b4c2cba5d41b" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. Equity Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2018 Equity Incentive Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2018, the Company adopted the 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;) which provided for the Company to grant incentive stock options or nonqualified stock options for the purchase of common stock, or restricted shares, to employees, members of the board of directors and consultants of the Company. The Company assumed all of the outstanding options under the amended and restated Equity Incentive Plan of Turnstone Biologics Inc. dated October 1, 2016 (the &#8220;2016 Plan&#8221;) in connection with the corporate reorganization in December 2018. However, there were no changes to the terms of the options requiring modification accounting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All options granted under the 2018 Plan have an exercise price, a vesting period determined by the Company&#8217;s board of directors and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_96603ff8-aed7-4f74-967b-340a805f1d87" contextRef="C_122cd3f4-302a-4c4b-acb3-5f0a4ab8924f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> term as determined and approved by the Company&#8217;s board of directors (the board of directors may delegate authority to one of the boards&#8217; committees) at the time of grant. The terms and conditions of the restricted shares are determined by the board of directors at the grant date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The majority of grants outstanding were approved with a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e7cfeaa7-bb2b-4fa0-848c-94e92fe7c6ef" contextRef="C_122cd3f4-302a-4c4b-acb3-5f0a4ab8924f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> vesting schedule with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eecf9f7f-f5ab-4fe7-91f6-57909f4ed4bc" contextRef="C_122cd3f4-302a-4c4b-acb3-5f0a4ab8924f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% vesting after one year and the remainder vesting evenly over the remaining 36 months. No further grants will be made under the 2018 Plan.  Any outstanding awards granted under these plans will remain subject to the terms of their 2016 and 2018 Plans, respectively, and applicable award agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2023 Equity Incentive Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2023, the Company's board of directors and stockholders adopted the 2023 Equity Incentive Plan (the &#8220;2023 Plan&#8221; and together with the 2018 and 2016 Plans the "Plans") which became effective upon the date of the IPO.  Under the 2023 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, performance stock awards, performance cash awards and other forms of stock awards to employees, directors and consultants. The maximum term of the stock option grants under the 2023 Plan is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7f444f36-9763-46e8-9a91-eba2dd9c5ba5" contextRef="C_5fa46bf8-b07a-4c44-a5fd-6c1dc1a9edc0" name="tsbx:MaximumTermOfOptionsUnderEquityIncentivePlan" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and, in general, the awards granted under the 2023 Plan vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_618b6c66-65fd-4769-ba95-26f3d6bf1ba3" contextRef="C_5fa46bf8-b07a-4c44-a5fd-6c1dc1a9edc0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period from the vesting commencement date. The 2023 Plan does not permit early exercises. The number of shares initially reserved for future issuance under the 2023 Plan was the sum of (1) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05551a71-9d8b-444c-82de-544e58f54665" contextRef="C_398e0a09-f989-4f15-b8fc-2af343713b5f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,889,435</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> new shares, plus (2) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9a4985ca-01c7-490b-b4e9-03e11932624b" contextRef="C_23ab17bc-cbea-4436-975a-8a130aba6e62" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">712,503</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> remaining shares of common stock reserved under the 2018 Plan that became available for issuance upon the effectiveness of the 2023 Plan, and (3) up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_48258e35-1c67-4bfe-b7ec-4e778438dd14" contextRef="C_b415a509-074d-4b97-86e2-0deee38dd0b9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">120,949</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Returning Shares (as defined in the 2023 Plan), as such shares become available from time to time. The number of shares of common stock reserved for issuance under the 2023 Plan will automatically increase on January 1 of each year, for a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7a990209-203c-43c5-9ce3-053dcaf9bc72" contextRef="C_a72293d1-c825-4856-b60c-948ad5751e42" name="tsbx:CommonStockCapitalSharesReservedForFutureIssuanceIncreaseDecreasePeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, from January 1, 2024 continuing through January 1, 2033, by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0c0c8f9-fe16-485c-88ed-07ec637c854d" contextRef="C_a72293d1-c825-4856-b60c-948ad5751e42" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as may be determined by the Company&#8217;s board of directors. As of January 1, 2024, an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60e29dc1-b7e8-4366-94a7-4909af58c433" contextRef="C_06019969-ab1c-456b-98ef-d496be6c8d74" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,154,966</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> were available for future issuance under the 2023 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div></div></ix:exclude><ix:exclude>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a57ac97f-838c-4696-a6c0-9a4ed543cafa" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of the stock option activity under the Plans is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.23%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.702%;"/>
        <td style="width:1%;"/>
        <td style="width:1.12%;"/>
        <td style="width:1%;"/>
        <td style="width:8.882%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.702%;"/>
        <td style="width:1%;"/>
        <td style="width:1.12%;"/>
        <td style="width:1%;"/>
        <td style="width:9.242%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Shares<br/>Underlying<br/>Outstanding<br/>Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average Exercise<br/>Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual Term<br/>(Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic Value<br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding &#8212; December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af0aa710-31b5-4240-bb09-13d45dfd2713" contextRef="C_bed097c6-a12a-48ed-ab84-40a66008425b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,529,982</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0b94c99-6c1b-409a-b519-ef3b74c92a2c" contextRef="C_bed097c6-a12a-48ed-ab84-40a66008425b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.86</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_7f4b9691-3ce0-4eb6-8d06-05220cd3a8e3" contextRef="C_e3da0be9-f805-4bd4-bb62-9cbb32dda1e1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.8</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83b20c7c-7598-4c44-85e2-82fd7c6457cd" contextRef="C_bed097c6-a12a-48ed-ab84-40a66008425b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,912</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_385ebc12-3b28-4330-96cb-8e11ec1dcfed" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">189,365</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2e20dd00-6dd1-4eb3-ac66-28ad44cf91ff" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.45</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4c9a4ac-a4f4-4c70-bae5-adf853218d7f" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">21,784</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1eb5ba2-f67e-4259-870c-83d277984c14" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.91</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options canceled/forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a091bbb3-e23b-4a83-9b15-1e04a5108d42" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">92,924</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4dd700b5-7768-4c57-94ca-5df0264bd311" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">10.46</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding &#8212; June 30, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_92d6a3f2-3db2-4530-8e8f-9a56f8a1c474" contextRef="C_dfe46888-9d65-4c68-a853-215029dc9872" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,604,639</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87a98f6d-8f51-4040-97d2-2713ba26461f" contextRef="C_dfe46888-9d65-4c68-a853-215029dc9872" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.42</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_2d748bd1-a49d-474f-807d-a027a3fa775f" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.8</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cbb76ed9-539d-4060-9864-5c5c0535d9e7" contextRef="C_dfe46888-9d65-4c68-a853-215029dc9872" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,605</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable &#8212; June 30, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f25149f-6439-4b99-910f-970360a41e0d" contextRef="C_dfe46888-9d65-4c68-a853-215029dc9872" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,622,615</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89eb7605-3eed-4d71-ae80-11475c2c37cf" contextRef="C_dfe46888-9d65-4c68-a853-215029dc9872" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.82</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_f8253c5c-763a-435a-aaba-e1e71262ec6e" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.7</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_331f80d4-3012-401d-b62b-ffda12536864" contextRef="C_dfe46888-9d65-4c68-a853-215029dc9872" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,100</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and expected to vest &#8212; June 30, 2023</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9bb64611-53fe-4ba6-9567-f2c96e940d1d" contextRef="C_dfe46888-9d65-4c68-a853-215029dc9872" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,604,639</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_039308af-04ab-4c76-be2b-49bcd357a35c" contextRef="C_dfe46888-9d65-4c68-a853-215029dc9872" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">9.42</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_73004762-db90-43a1-9713-0db0df69603e" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.8</span></ix:nonNumeric></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b0d4b583-726f-497b-a152-1fd27f10c563" contextRef="C_dfe46888-9d65-4c68-a853-215029dc9872" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,605</ix:nonFraction></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding &#8212; December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8829b359-1cd5-4acc-b99a-ca8e1de30dbc" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,374,282</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_912ffd11-69c7-49a9-92a3-4447d2485830" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.66</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_d955075a-1353-4673-875c-b208b632ad68" contextRef="C_96148a81-8dcb-40e9-8bcc-218ebdce5605" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.1</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5a45050-54e0-40e6-bdc2-70531f937eb2" contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">352</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ea37e1fb-d9d3-43f7-a3b0-5f6f571ba559" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">129,165</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5462e9dd-b5f8-42f2-825a-a8eb075b12eb" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.73</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a22fed73-4afd-4ee8-9d27-8dac252bc8a9" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">29,119</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b2f8d731-8197-450f-b45e-1f3164d2074e" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">1.51</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options canceled/forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e417df21-fa6c-4735-a8a0-62891da24fbc" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">175,770</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04a3f7b7-783d-4abf-88da-96c089fd85b7" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">6.97</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding &#8212; June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d757be6-99d4-4049-a458-7028500bc676" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,298,558</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd6ee7d3-6ac1-413d-8146-b5fd5c7179ee" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.56</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_ed950654-02d3-499d-a483-ba40c30dc661" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.5</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fd7821cc-2790-440a-a74e-43c1f78c43d2" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">354</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable &#8212; June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8d2111b9-8eb4-4f8f-9724-2f9fe702710a" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,955,510</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_faaab25c-2d6a-4446-88d6-4696e5bca208" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.40</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_bf70c2af-ab53-4a0f-97a5-7641de1b2a30" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.9</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8681de0e-ff96-4781-a1ed-2e2b71c6d289" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">341</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and expected to vest &#8212; June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5720d2cd-ebc3-40ae-a185-03b97b30643e" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,298,558</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1811d5ec-239b-417d-82a6-e43a4e6a9bf0" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.56</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_75379554-ccc2-4c19-99d8-fc80326398f1" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.5</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51ca545a-7cc7-4080-b5dc-f040c5d1f5e4" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">354</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_77910de8-24f0-4f85-9cdb-c232e59911dc" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of each stock option granted to employees and directors was estimated on the date of grant using the Black-Scholes option-pricing model, with the following range of assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:72.06%;"/>
        <td style="width:1.6%;"/>
        <td style="width:12.52%;"/>
        <td style="width:1.6%;"/>
        <td style="width:12.22%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dbd620e2-b366-4c2c-a578-db3c2526a4fb" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.30</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3967787-79e6-4eb4-9616-c0e4cc8fad05" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.72</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1bbe5452-2162-471c-b519-13b8d2c90083" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">3.89</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d3859148-bf3f-42cf-9c25-3b1f4fd7aaa9" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">4.48</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_472754df-87f6-495e-a497-3919691102ef" contextRef="C_bdee48eb-7f4a-46cb-b069-06ddbd37a077" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.88</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><ix:nonNumeric id="F_291f29ca-3ee3-4d32-8a8e-dbb4d8ef0e83" contextRef="C_61b64e12-4fa9-444b-8290-e40812121809" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.03</span></ix:nonNumeric></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_904aa92c-6e96-40c8-b455-16553fe91026" contextRef="C_9c8cc4df-6000-4875-a29a-4d3c9dd0d7c5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.09</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;- </span><span><ix:nonNumeric id="F_2e3685db-b63d-400a-a569-52f9a99908af" contextRef="C_862de778-6688-462a-b351-4d149c16a617" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.20</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c469e6c5-4a05-46a5-b6f1-5d88a95ce619" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_435d5150-8cf0-4cef-91b2-873f12e68d94" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Volatility</span></p></td>
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0cb40a6b-a26c-404f-bd27-6c74d8dc1fc2" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">94.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ade48ca-6bea-4f47-89b9-d0e90a745123" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">94.67</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2b364377-771d-4e10-92c1-2692825086ad" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">85.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3c080188-846a-4e46-9979-30a53090f300" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">86.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise price of stock options<br/>&#160;granted</span></p></td>
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_25db9c7b-2a9e-491a-8f03-92d2b8dc8024" contextRef="C_018d9f0a-f1a9-461c-a05d-3b501d8ad8bd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.68</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_536dd62c-89d1-40fd-9607-f669c3fcfa8b" contextRef="C_8a2c0799-2ad0-4d20-8a89-44e9c7d5025f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.88</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_284c06ad-7931-4644-b53d-5c33aa35543e" contextRef="C_7ab99909-780f-484a-afb9-d7fab1c3e24f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.18</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e16b8d34-bc64-46a7-b06b-a4e18bc83b43" contextRef="C_7a615421-56cd-4cb3-983c-215b19efb667" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.53</ix:nonFraction></span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_e0acf2e6-acdd-448f-881e-a1b9c0de9088" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 2023, the Company grants RSUs to employees. The RSU activity is summarized as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.852%;"/>
        <td style="width:2.04%;"/>
        <td style="width:1%;"/>
        <td style="width:13.563%;"/>
        <td style="width:1%;"/>
        <td style="width:2.521%;"/>
        <td style="width:1%;"/>
        <td style="width:16.023%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>RSUs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average Grant Date Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding, non-vested as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7dae5381-f760-423c-aa95-521b1f505a03" contextRef="C_fa91a432-14eb-479a-ab9e-c343bfe09637" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">102,945</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c58116e0-786a-44d4-84c0-48cc4c967935" contextRef="C_fa91a432-14eb-479a-ab9e-c343bfe09637" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.71</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_44b7bbe9-19b2-4514-8332-fb363b329134" contextRef="C_233d0f7d-f749-402b-be07-03dbe6d24916" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">16,384</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf716c60-d181-4129-912c-beabf20aaef3" contextRef="C_233d0f7d-f749-402b-be07-03dbe6d24916" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.75</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Cancelled/Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_131e623f-33e5-44a5-ba85-ece21835f3cc" contextRef="C_233d0f7d-f749-402b-be07-03dbe6d24916" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,430</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6eea22e9-67ab-42b9-95d9-97e08728e062" contextRef="C_233d0f7d-f749-402b-be07-03dbe6d24916" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.71</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Vested/Released</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding, non-vested as of June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7ba5756-8a2a-490f-9dde-b7ea6d92110c" contextRef="C_f0568106-d7a9-414e-a63d-3cea66f35a6a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">108,899</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_512dbceb-1d53-476d-9924-974a61753f50" contextRef="C_f0568106-d7a9-414e-a63d-3cea66f35a6a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.72</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6a1716d0-27fe-4b72-bd12-acbe83ed162b" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense for all stock awards, including options, restricted stock and RSUs, included in the Company&#8217;s statements of operations is as follows (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.56%;"/>
        <td style="width:1.12%;"/>
        <td style="width:1%;"/>
        <td style="width:9.24%;"/>
        <td style="width:1%;"/>
        <td style="width:1.12%;"/>
        <td style="width:1%;"/>
        <td style="width:9.24%;"/>
        <td style="width:1%;"/>
        <td style="width:1.12%;"/>
        <td style="width:1%;"/>
        <td style="width:9.24%;"/>
        <td style="width:1%;"/>
        <td style="width:1.12%;"/>
        <td style="width:1%;"/>
        <td style="width:9.24%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f5629e6-63f2-4544-8b11-92f702b201a7" contextRef="C_62ea4f09-347c-4795-8884-5220ce935f91" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">644</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74b80c1f-4348-44dc-9719-b4baa040f9aa" contextRef="C_db72c5ee-0057-4dec-a48f-c46b4c093ae7" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">507</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d17b2e6b-f8ae-457f-8aaa-bc5804065cde" contextRef="C_d07e96e4-27c7-461d-87e0-bfe0e09106c3" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,294</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_55238f35-c7d8-41bd-916a-e6a79ec95277" contextRef="C_298d2425-fd98-405f-a011-492c95c811c1" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,009</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff1572c3-db71-4fcc-8e9c-6ac1de4fac9a" contextRef="C_a8118d4e-4113-40b7-b543-3bea71a014bc" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">375</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9066e79e-48b2-4d82-a629-fcba0c2a56f9" contextRef="C_a2c92d2f-8c3a-4345-9949-14d05e745e9f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">567</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1b102fa-edc4-400b-955b-30f76c577871" contextRef="C_334d95da-9a09-4a10-86ff-a51738440c33" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">771</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80966f19-5e0d-460d-9dbf-19eebce4e495" contextRef="C_5447e64a-c9af-4233-ae37-a6910517d877" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,057</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc0fbf9c-9656-454b-ab4b-80939fc91543" contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,019</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ac24cad-e3fd-4bb1-8e58-5c3ad7d790fa" contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,074</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da193ba0-2af1-4353-96c0-6a80a04b3d71" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,065</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0998f217-54c5-4a52-ae53-567a2579c77b" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,066</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div></div></ix:exclude><ix:exclude>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The expense related to awards granted to employees and directors was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2f8fb7ba-f9aa-4173-b451-5f0a6cacc813" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3456cae0-82d9-4b2e-925f-c34ea5bcc1aa" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.1</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for each of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2024 and 2023. The weighted-average grant date Black Scholes fair market value of options granted to employees, directors and consultants during the six months ended June 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f60ea101-4424-4d8b-8e93-3cc38cd23180" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.14</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_695b03f3-87ab-40af-b74c-85933657744b" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.23</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively.  The aggregate grant date fair value of RSUs granted by the Company during the six months ended June 30, 2024 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f40f36f-6532-42a2-a67a-91a71a187b73" contextRef="C_233d0f7d-f749-402b-be07-03dbe6d24916" name="tsbx:ShareBasedCompensationArrangementAverageGrantDateFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.  </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83ad28da-e53b-4e71-a06f-4d9a6dfe2359" contextRef="C_c6f26a23-43b5-452a-9c94-f293c2677e84" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> RSUs were granted by the Company during the six months ended June 30, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had unrecognized stock-based compensation expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_badae1e4-8001-4784-8346-eea229710796" contextRef="C_50d1f298-b372-40b5-b6e4-1d4f6cc1d536" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6fc2f273-4985-4718-8bd3-61674322902c" contextRef="C_f0568106-d7a9-414e-a63d-3cea66f35a6a" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, related to stock options and RSUs, respectively, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_596793ee-a517-4fc5-8369-ed1d4fc45c9c" contextRef="C_5987e3e3-0cab-4166-bca8-581516776417" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.7</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b591b235-25d8-4cdc-b921-e4e21f57a04e" contextRef="C_233d0f7d-f749-402b-be07-03dbe6d24916" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2020, Langer received </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c1017e8-5596-4840-bcd5-3763f2eb77c1" contextRef="C_b61d7932-d1b3-455d-a3a5-9627e4bd93da" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">725,920</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares as payment related to the Myst Merger Agreement. Of the total issued, the Company restricted </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34c94df6-ae39-4ae0-80a4-ce7284abf9c5" contextRef="C_b34ba69f-3f68-4be6-9f1b-44db7d637865" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">362,960</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares to vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4a078329-a533-47a3-a8d5-edc938c1d58d" contextRef="C_bea27948-4ee5-4b9b-8b58-855991725981" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period in equal annual installments. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_112ee6f6-2362-45f7-9f7c-d554c4120b7a" contextRef="C_4519aa8e-1238-4faa-8345-635ebb5bc098" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">90,740</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares remain unvested, and the Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e6bf3eaf-b5c4-4caa-b17b-a29d6e2665e5" contextRef="C_4519aa8e-1238-4faa-8345-635ebb5bc098" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in unrecognized stock-based compensation expense related to unvested restricted stock which is expected to be recognized evenly over </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_204a9dbc-55ef-4cf6-98cf-e94ebf4f1875" contextRef="C_488ff119-253a-4f13-ab67-fcbecef54a44" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durmonth"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2023 Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2023, the Company adopted the Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), which became effective with the IPO on July 25, 2023. The ESPP was adopted by the Company&#8217;s board of directors and stockholders in June 2023. The ESPP initially provides participating employees with the opportunity to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_481ccf8f-6009-4856-86c8-8a6415eef52b" contextRef="C_385dcdbf-07bd-4e19-a166-84748a852d48" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">222,287</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. The number of shares of common stock reserved for issuance will automatically increase on January 1st of each calendar year for a period of up to</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_360230bf-ae7c-4b68-96d3-e0fc2245a0b4" contextRef="C_b4bc9727-1662-4540-9335-43dccebbd817" name="tsbx:CommonStockCapitalSharesReservedForFutureIssuanceIncreaseDecreasePeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ten years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, commencing on January 1, 2024 and ending on (and including) January 1, 2033, in an amount equal to the lesser of (i) one percent (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dd78d74e-896c-41f0-b6dc-b63e527d0372" contextRef="C_b4bc9727-1662-4540-9335-43dccebbd817" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%) of the total number of shares of capital stock outstanding on the last day of the calendar month before the date of the automatic increase, and (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_839cc2fd-9cf1-4857-a995-c4d4f0c31854" contextRef="C_385dcdbf-07bd-4e19-a166-84748a852d48" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">666,680</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. Notwithstanding the foregoing, the board may act prior to the first day of any calendar year to provide that there will be no January 1st increase in the share reserve for such calendar year or that the increase in the share reserve for such calendar year will be a lesser number of shares of common stock than would otherwise occur pursuant to the preceding sentence. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 1, 2024, the shares available for issuance under the ESPP automatically increased by an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_120ec430-d0dd-4705-a30c-67f62b712381" contextRef="C_4d689c27-7fb0-4851-9baa-5648a27e5506" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">230,993</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c91a5dae-bd03-4247-b936-914075698c9e" contextRef="C_277bc5e6-e420-49a1-a481-ae8acaf14f5e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">453,280</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> total shares available to be issued under the ESPP.  As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there was no enrollment offered to the Company's employees.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_000737a2-53f9-41c7-a046-06c04ed89dcd" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_338ba0c5-9b2f-4a38-836e-cbaa95bcc189" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c0a31911-f872-4c51-8a84-8e92e1812a7f" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t record federal income tax expense for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, as the Company expects to be in a cumulative taxable loss position in 2024 and 2023, and the net deferred tax assets are fully offset by a valuation allowance as it is not more likely than not that the benefit will be realized. The Company recorded a benefit (provision) for state income taxes of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_772a9088-e7f5-47a8-958d-f35f31c5595e" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="tsbx:ProvisionBenefitForIncomeTaxes" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e16fe49a-03e1-4e99-9b57-1fdd132ab84b" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="tsbx:ProvisionBenefitForIncomeTaxes" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_91b9b712-4b24-46a1-a5cb-6c5a6325f0ed" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12. Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company leases laboratory and office space for its corporate headquarters located in San Diego, California and office space in New York, New York and Ontario, Canada. Operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. In calculating the present value of the lease payments, the Company has elected to utilize its incremental borrowing rate based on the original lease term and not the remaining lease term. The Company determines if an arrangement is a lease by considering whether there is an identified asset, and the contract conveys the right to control its use. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company&#8217;s lease terms may include options to extend or terminate a lease. If the lease includes non-lease components (i.e., common area maintenance) that are paid separately from rent based on actual costs incurred and therefore are not included in the right-of-use asset and lease liability but are reflected as an expense in the period incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2018, the Company entered into a lease agreement for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f4f803e-ab02-4c85-88de-4292b8aae9bb" contextRef="C_d0a34fda-1a97-4930-aa8e-a5ab1c515de5" name="tsbx:NumberOfSquareFeetForLease" unitRef="U_SquareFeet" decimals="0" format="ixt:num-dot-decimal">6,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office space in New York, New York. The term of the lease is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_14ece8d6-0f21-4404-bb2a-d52044b391ce" contextRef="C_80fd60e1-4de1-4fea-91cc-497c425d7782" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seven years and three months</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">starting November 1, 2018. The lease requires the Company to share in prorated expenses and property taxes based upon actual amounts incurred. The lease contains escalating rent clauses which require higher rent payments in future years. In September 2022, the Company made the decision to sublease this space and executed a sublease in November 2022 for the remaining term of the lease. Since the Company is still responsible for making the lease payments, there was no impact to the operating lease liability from the sublease. However, since the sublease payment does not cover</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div></div></ix:exclude><ix:exclude>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">entire lease payment, the carrying value of the operating right of use asset was analyzed and determined to be impaired resulting in a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74db5c51-69b6-47f3-abda-211b4fd005c8" contextRef="C_159402e9-c2a7-4db5-8c56-97648d7a2af3" name="us-gaap:OperatingLeaseImpairmentLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million reduction in the operating right of use asset in September 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2019, the Company executed an agreement to lease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f60c102b-e56e-4e18-8f93-eacda5e37139" contextRef="C_4fb7b644-c91b-460a-90e4-f747ea99d23e" name="tsbx:NumberOfSquareFeetForLease" unitRef="U_SquareFeet" decimals="0" format="ixt:num-dot-decimal">6,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of laboratory space at Carleton University in Ontario, Canada. The initial term of the lease is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0c9aef3d-2f07-454c-a918-b7546e70e252" contextRef="C_538d2283-b280-4bac-8832-abf9afae8b56" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and started in November 2019 at a rate of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b62a9f1d-171c-457a-9138-df49363ef2de" contextRef="C_538d2283-b280-4bac-8832-abf9afae8b56" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million per year. In November 2022, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b8e01e04-9277-4ba8-b8b2-fc9d60911306" contextRef="C_d92a8a59-80bf-4bc8-8d8b-2f30a155d5e5" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the lease was extended for a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_41e67c3a-729f-4eb4-9ff8-147ef774fa7c" contextRef="C_fbbc94d3-e5cf-4af0-9f58-49c609a48ce9" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> In August 2023, the Company terminated the lease.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2019, the Company entered into a noncancelable operating lease for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_684d04ac-9795-439f-ab8a-f38690357b34" contextRef="C_cb80c5db-70c4-46c8-b391-908e60dc4392" name="tsbx:NumberOfSquareFeetForLease" unitRef="U_SquareFeet" decimals="0" format="ixt:num-dot-decimal">9,423</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet located at 12 York Street, Ontario, CA. The term of the lease is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c491e39e-4a45-48a3-a905-47258e72f900" contextRef="C_4dcd6724-0338-4288-a92d-f40147c40f0a" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, starting December 1, 2019, and includes </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_159dd3de-163f-486b-ab8d-945bc50236b9" contextRef="C_f8d09b91-2147-483c-b5ae-6de7be334706" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one renewal option for a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3e9e623a-8a6c-4674-9c02-aba4b68908a0" contextRef="C_4dcd6724-0338-4288-a92d-f40147c40f0a" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></ix:nonNumeric></span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The lease requires the Company to share in prorated expenses and property taxes based upon actual amounts incurred. The lease contains escalating rent clauses which require higher rent payments in future years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">     </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2021, the Company entered into a lease agreement for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46c37b58-8a0d-4a7e-a223-167a01fc6163" contextRef="C_e8c17d3b-ae8b-41f1-a20f-40ff4625b247" name="tsbx:NumberOfSquareFeetForLease" unitRef="U_SquareFeet" decimals="0" format="ixt:num-dot-decimal">19,474</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office and laboratory space in San Diego, California. The initial term of the lease is </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e087c3bb-2c37-4263-997f-dad3755213c8" contextRef="C_bdf52929-1966-47f8-aeba-19d09b7e879d" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38 months</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> with </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c0af435c-9f63-4d9e-bc9b-ecefc9e3fe32" contextRef="C_f3098a29-f113-4e61-967a-00d2ad37159d" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one renewal option for a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c177e416-1214-4586-8f07-ecd79ff85b48" contextRef="C_bdf52929-1966-47f8-aeba-19d09b7e879d" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and commenced in March 2022</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The lease requires the Company to share in prorated expenses and property taxes based upon actual amounts incurred. The lease contains escalating rent clauses which require higher rent payments in future years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recorded rent expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc1b8d36-de03-4275-8ae4-3d9ff12e6e3c" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:PaymentsForRent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_acb18432-f4c1-4e3c-ad1e-ab243477ef9d" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:PaymentsForRent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.  </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_71cf6fbc-3b13-459d-b3f8-7f789a76be89" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:LeaseCostTableTextBlock" escape="true" continuedAt="F_71cf6fbc-3b13-459d-b3f8-7f789a76be89_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below summarizes the Company&#8217;s total lease costs included in its unaudited condensed consolidated financial statements, as well as other required quantitative disclosures (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">). </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_71cf6fbc-3b13-459d-b3f8-7f789a76be89_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:27.826%;"/>
        <td style="width:1.86%;"/>
        <td style="width:1%;"/>
        <td style="width:14.183%;"/>
        <td style="width:1%;"/>
        <td style="width:1.86%;"/>
        <td style="width:1%;"/>
        <td style="width:14.183%;"/>
        <td style="width:1%;"/>
        <td style="width:1.86%;"/>
        <td style="width:1%;"/>
        <td style="width:14.183%;"/>
        <td style="width:1%;"/>
        <td style="width:1.86%;"/>
        <td style="width:1%;"/>
        <td style="width:14.183%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ca518a4-0072-479f-b62c-207af535f346" contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">398</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_76fe9061-68af-4890-8c2c-30b2cf109b40" contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">430</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_986851f2-2750-4b28-af8c-240b562287db" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">796</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0aecf52d-69cb-43eb-8be8-0ed6d8be6f8a" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">900</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term lease costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e6ae1e0-6854-46b3-bc7c-1aed4e270b4e" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="tsbx:ShortTermLeaseCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Variable leases costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_27e8142c-bccc-4beb-998a-473d95c83e98" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_598d7d15-77dd-48ee-ba2a-c763f7374299" contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">398</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d600589-6b52-4df3-b77c-38178e398769" contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">430</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fca1f8c3-af72-42ca-819c-1ed4165a1e14" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">796</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_34b1991e-36bb-4791-a0fd-611a7685d725" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">906</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3ba090ec-3104-4f74-9550-a4443962d96a" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="tsbx:ScheduleOfPresentValueOfOperatingLeasePayments" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The present value assumptions used in calculating the present value of the lease payments were as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:72.02%;"/>
        <td style="width:1.8%;"/>
        <td style="width:1%;"/>
        <td style="width:24.180000000000003%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average remaining lease term in years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_9bcb1ac9-4ecd-40b6-89c9-030a0ae6d54c" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span></ix:nonNumeric></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_46059433-1ae2-415e-b211-71bd0c5644f6" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">5.74</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0d1dbfc9-893d-4f00-be11-31b2239c2fe3" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The minimum aggregate future operating lease commitments at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 are as follows (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.36%;"/>
        <td style="width:1.78%;"/>
        <td style="width:1%;"/>
        <td style="width:15.860000000000001%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Minimum Lease<br/>Payments</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Remainder of 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c99d809-2af1-4e06-b4d0-8d18163d6c76" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,056</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c903273a-0a55-4e11-b90f-e1246e928e32" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,110</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f4fc657-5436-4f16-9243-ac5fd108581d" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">105</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e2cbfbce-9a22-4eb3-bbc5-1978045e5b15" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0b8f27ae-e864-427b-a63e-6218891d832c" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2029</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b0c7b0f-5365-47ef-8bf3-702720ff1529" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_60a07187-d0d3-4cc9-b841-b1c30b73b823" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,270</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2bafeac6-79ba-4eb7-9fc5-7e5c521ef91c" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_97486c4a-7b79-4d6c-a6cd-bfa2885a86b9" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,204</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: current portion of operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_522def20-8def-497d-9934-ee99b6219273" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,793</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability, noncurrent</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4112431f-22bb-41ab-ba7e-a29da1b76e2a" contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7eacee74-57e3-47bb-abaf-e7b9243ee0e0" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13. Net Loss per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic and diluted net loss per share attributed to common stockholders is calculated by dividing net loss attributed to common stockholders by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. The Company&#8217;s potentially dilutive shares, which include preferred stock, restricted stock, unvested RSUs and options to purchase common stock, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. Potentially dilutive common shares have been excluded from the diluted net loss per common share computations in all periods presented because such securities have an anti-dilutive effect on net loss per common share</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div></div></ix:exclude><ix:exclude>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></ix:exclude><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">due to the Company&#8217;s net loss. There are no reconciling items used to calculate the weighted-average number of total common shares outstanding for basic and diluted net loss per common share.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a30baf78-ef59-42ec-b7da-2ddbe3f11eaf" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following outstanding potentially dilutive shares were excluded from the computation of diluted net loss per share attributable to common stockholders:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.98%;"/>
        <td style="width:1.52%;"/>
        <td style="width:1%;"/>
        <td style="width:14.5%;"/>
        <td style="width:1%;"/>
        <td style="width:1.52%;"/>
        <td style="width:1%;"/>
        <td style="width:14.5%;"/>
        <td style="width:1%;"/>
        <td style="width:1.98%;"/>
       </tr>
       <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
        <td style="background-color:#ffffff;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
        <td style="background-color:#ffffff;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b65f654-1f50-453d-8507-d19303f13b6d" contextRef="C_8b8a1ea1-2432-469c-84b7-3b0a47c7f036" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">90,740</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_212207ac-de70-45ba-9d70-894f2e85aa12" contextRef="C_de5bd2cb-2a69-4ca4-88ea-be6ca6b3d91e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">181,480</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested RSUs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7834dc0e-9022-4cc6-b91f-833e5a12258a" contextRef="C_076f0cb5-40e9-4509-958f-29eee0f3a275" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">108,899</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_03012fc0-564f-48fd-a11c-2ac825e2db6b" contextRef="C_c5e178ae-25e5-4b12-b4f7-11636d959e09" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,298,558</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22f3020d-675f-4a5d-835a-45ab51f352bf" contextRef="C_18a36a9d-0182-4470-abc8-5f7ff7b3b4a5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">2,604,639</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Redeemable convertible preferred stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4e1f7ba-44da-4252-9b18-11c877bccd90" contextRef="C_f25cb532-a515-4fa7-abaf-0947b47f1a2d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">12,493,879</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b935a30-d7eb-4818-a556-1b76d1b72fc5" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,498,197</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c7e2212-74f1-4c4f-aca5-907f8628cf91" contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">15,279,998</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_818ba649-8f10-4c7e-b109-c2d48d3bb746" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="us-gaap:LegalMattersAndContingenciesTextBlock" escape="true"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14. Legal Proceedings</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is not a party to any material legal matters or claims and does </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ecf7099a-46c1-4b7f-817f-dc71d5b1f936" contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954" name="tsbx:LossContingencyReserveForLitigationLiabilities" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_82445838-cf0a-4347-bbb8-746b719448d2" contextRef="C_c2fc5443-940d-4d73-8fd5-8bcdd4605301" name="tsbx:LossContingencyReserveForLitigationLiabilities" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t have contingency reserves established for any litigation liabilities as of June 30, 2024 and December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_mda"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALY</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q and the audited financial statements and notes thereto as of and for the year ended December 31, 2023 and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K filed with the SEC on March 22, 2024. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Quarterly Report on Form 10-Q, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. You should carefully read the &#8220;Risk Factors&#8221; section of this Quarterly Report on Form 10-Q to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Turnstone Biologics Corp.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. Approved immunotherapies represent a significant advancement in the treatment of solid tumors, but many patients either do not respond or experience relapsed disease following an initial response. We believe the most significant challenge to creating curative immunotherapies in these patients is the low numbers of T cells that can recognize and attack the tumor, which we refer to as tumor-reactive T cells. To address this problem, we are pioneering a differentiated approach to tumor infiltrating lymphocytes, or TILs. We are developing next generation TIL therapies by selecting the most potent (meaning able to mediate an anti-tumor response) and tumor-reactive T cells, which we refer to as Selected TILs. Unlike other approaches that rely on standard &#8220;bulk TILs&#8221; that have demonstrated objective responses in clinical trials only in limited tumor types, we are developing our Selected TILs for potential treatment across the majority of solid tumors. We have three ongoing Phase 1 clinical trials for TIDAL-01, including a multi-site trial for the treatment of colorectal cancer, head and neck cancer, and uveal melanoma, and two investigator sponsored trials with H. Lee Moffitt Cancer Center and Research Institute, Inc., or Moffitt, across colorectal cancer, head and neck cancer, and uveal melanoma. On August 14, 2024, we provided preliminary data from the first 4 evaluable microsatellite stable metastatic colorectal cancer ("MSS mCRC") patients in our TIDAL-01 multi-site trial and we intend to provide the next clinical update in the first half of 2025. We are also advancing our preclinical pipeline programs including TIDAL-02, our next Selected TIL program, and our TIDAL-01 viral immunotherapy combination program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are developing next generation TIL therapies for the potential treatment of multiple solid tumors. To our knowledge, at present there are no therapies in clinical development that provide curative outcomes for the majority of patients in our chosen solid tumor indications. Our innovative Selected TIL approach focuses on selecting and expanding the most potent tumor-reactive T cells to overcome the limitations of bulk TILs. This approach expands upon work conducted in academia that demonstrated improved clinical responses for certain selected TILs in solid-tumor types where bulk TILs have not shown objective responses in clinical trials. We are leveraging this work to establish a standardized manufacturing process for large scale production of our Selected TILs.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are applying our Selected TIL approach for potential treatment of a wide range of solid tumors. We are developing a broad pipeline aimed at improving outcomes for patients, as illustrated in the chart below.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img127454107_0.jpg" alt="img127454107_0.jpg" style="width:720px;height:292px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">* Two concurrent investigator sponsored trials at Moffitt Cancer Center</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">CRC - Colorectal cancer; HNSCC - Head and neck squamous cell carcinoma</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are advancing TIDAL-01, our lead Selected TIL product candidate, for the treatment of multiple solid tumor indications. TIDAL-01 utilizes an unbiased identification and functional screening process to isolate and selectively expand the greatest breadth of tumor-reactive TILs from the patient&#8217;s tumor. Our TIDAL-01 production process is designed to deliver at least 10</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:5.025pt;font-family:Times New Roman;min-width:fit-content;">9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> cells and targets greater than 70% functional and potent tumor-reactive T cells.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have three ongoing Phase 1 clinical trials for TIDAL-01, including a multi-site trial for the treatment of colorectal cancer, head and neck cancer, and uveal melanoma, and two investigator sponsored trials with Moffitt across colorectal cancer, head and neck cancer, and uveal melanoma. In August 2024, we reported preliminary data from the first 4 evaluable patients in our TIDAL-01 multi-site trial in advanced and late line MSS mCRC. In these first 4 patients, we have seen a 25% overall response rate ("ORR") with deep and durable clinical benefit and 50% disease control rate ("DCR").  This patient population is generally unresponsive to checkpoint inhibitors, and as a point of comparison, the current standard of care treatment provides an ORR of 1 to 6% and a median progression free survival ("mPFS") of 2.0 to 5.6 months.  We observed that CRC Patient 1 has an ongoing complete response ("CR") and has been progression free for over one year.</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CRC Patient 2 had stable disease for 6 months.  These responses are notable in highly pre-treated 3</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">rd </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and 4</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> line, respectively, MSS mCRC patients with advanced disease.  Of the two other evaluable CRC patients, CRC Patient 3 showed progressive disease at 1.5 months and CRC Patient 4 showed stable disease at one month, but discontinued the study shortly after.  Additionally, no new safety observations were made specific to TIDAL-01 Selected TILs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our next Selected TIL program, TIDAL-02, is being designed to encompass a next generation streamlined manufacturing process for tumor-reactive T cells and additional modifications to enhance TIL quality and function. We believe that TIDAL-02 has the potential to address the medical need in solid tumor indications that are distinct from and complementary to TIDAL-01. TIDAL-02 is currently in preclinical development. We intend to evaluate the combination of TIDAL-01 with viral immunotherapy through two approaches: (1) treatment of the patient with viral immunotherapy prior to TIL extraction to optimize TIL harvest and broaden applicability to additional tumor types with low immune cell infiltration and (2) treatment of the patient with viral immunotherapy following treatment with TIDAL-01 to optimize TIL trafficking and infiltration into solid tumors and to support the anti-tumor functions of infiltrating immune cells. We are currently evaluating the optimal viral immunotherapy for combination with TIDAL-01 to advance into clinical development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our headquarters are located in San Diego, California and we operate as one segment. Since our inception, we have devoted substantially all of our efforts and financial resources to organizing and staffing our company, business planning, raising capital, discovering product candidates and securing related intellectual property rights and conducting research and development activities for our Selected TIL programs and product candidates. We do not have any products approved for sale and we have not generated any revenue from product sales and have incurred overall net losses since our inception through June 30, 2024. We have funded our operations primarily through the sale of our convertible preferred stock and revenue from certain of our collaboration agreements as well as our recent initial public offering, or IPO. Since our inception, we have raised an aggregate of approximately $172.0 million of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">gross proceeds from the issuance and sale of shares of our convertible preferred stock, $190.0 million in upfront, non-refundable collaboration revenue, and most recently, raised $80.0 million with gross proceeds from the IPO completed on July 25, 2023 and $7.8 million from the exercise of the underwriters option to purchase additional shares. As of June 30, 2024 and December 31, 2023, we had cash, cash equivalents and short-term investments of $62.4 million and $94.8 million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred significant operating losses in the past, and we expect to continue to incur significant operating losses for the foreseeable future. We incurred a net loss of $40.9 million and $21.4 million for the six months ended June 30, 2024 and 2023, respectively. As of June 30, 2024 and December 31, 2023, we had an accumulated deficit of $217.7 million and $176.8 million, respectively. Substantially all of our operating losses result from expenses incurred in our research and development programs and from general and administrative costs associated with our operations. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates, and on our ability to enter into collaborations, strategic partnerships and alliances or marketing, distribution or licensing arrangements with third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to incur significant expenses and increasing operating losses for the foreseeable future as we continue the preclinical development, manufacturing and clinical development of, and seek regulatory approval for, our product candidates. In addition, we may incur expenses in connection with the in-license or acquisition of additional platform technologies and the development of any such product candidates. We also expect to incur additional costs associated with operating as a public company. Furthermore, our operating losses may fluctuate significantly from quarter to quarter and year to year due to timing of preclinical activities, clinical development and regulatory approval of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We plan to fund future operations and future capital funding needs through equity and debt financings, licensing transactions, and collaborations or strategic partnerships with other companies. We can provide no assurance that financing will be available in the amounts we need or on terms acceptable to us, if at all. If we enter into licensing transactions, collaborations, strategic partnerships or similar agreements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and may reduce the value of our common stock. If we are not able to secure adequate additional funding, we may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and suspend, delay or curtail our development programs. Any of these actions could materially harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our innovative Selected TIL approach focuses on selecting and manufacturing the most potent tumor reactive T cells to overcome the limitations of bulk TILs. This approach is grounded on work conducted in academia that has demonstrated improved clinical responses for selected TILs in solid tumor types where bulk TILs have not shown benefit. We are leveraging this work to establish a standardized manufacturing process for large scale production of our Selected TILs. We intend to establish in-house tumor sequencing capabilities, expedite manufacturing and shipping of peptides, and biopsy tumor prior to resection to enable earlier sequencing and peptide synthesis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Macroeconomic and Geopolitical Trends</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We continue to actively monitor the impact of various macroeconomic and geopolitical trends, such as high rates of inflation, supply chain disruptions and geopolitical instability, and bank failures on our business. To date, we have not experienced a material financial statement impact or business disruptions, including with our vendors or third parties, as a result of these negative macroeconomic or geopolitical trends. Our business has been, and may continue to be, impacted by the negative macroeconomic and geopolitical trends wherever we have clinical trial sites, contract manufacturing organizations, or CMOs, facilities or other business operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Global economic and business activities continue to face widespread uncertainties, and global credit and financial markets have experienced extreme volatility and disruptions in the past several years, including severely diminished liquidity and credit availability, rising inflation and monetary supply shifts, rising interest rates, labor shortages, declines in consumer confidence, declines in economic growth, increases in unemployment rates, recession risks, and uncertainty about economic and geopolitical stability. Moreover, negative macroeconomic conditions could adversely impact our ability to obtain financing in the future on terms acceptable to us, or at all. In addition, the geopolitical instability and related sanctions could continue to have significant ramifications on global financial markets, including volatility in the U.S. and global financial markets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reverse Stock Split</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 14, 2023, we effected a 1-for-7.9872 reverse stock split, or Reverse Split, of our issued and outstanding shares of common stock and a proportional adjustment to the conversion ratio for each of our outstanding series of redeemable convertible</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preferred stock. All share and per share amounts have been retroactively adjusted, where applicable, to reflect the Reverse Split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. Shares of common stock underlying outstanding stock options and restricted stock were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the appropriate securities agreements. Stockholders entitled to fractional shares as a result of the Reverse Split received a cash payment in lieu of receiving fractional shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Initial Public Offering</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 25, 2023, we completed our IPO pursuant to which we issued and sold an aggregate of 6,666,667 shares of common stock at a price to the public of $12.00 per share. Aggregate net proceeds to us were $68.7 million after deducting underwriting discounts and commissions of $5.6 million and other offering expenses of $5.7 million. On August 15, 2023, the underwriters exercised their option to purchase an additional 651,608 shares of common stock at $12.00 per share. Aggregate net proceeds to us was $7.3 million after deducting underwriting discounts and commissions of $0.5 million. Upon the closing of the IPO, all outstanding shares of redeemable convertible preferred stock automatically converted into shares of common stock. Subsequent to the closing of the IPO, there were no shares of redeemable convertible preferred stock outstanding.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the closing of the IPO, we filed our Amended and Restated Certificate of Incorporation which provides that the authorized capital stock is 500,000,000 shares consisting of 490,000,000 shares of common stock and 10,000,000 shares of undesignated preferred stock, both with a par value of $0.001 per share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaboration Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Below is a summary of the key terms for certain of our collaboration agreements. For a more detailed description of our collaboration agreements, see Note 6 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Moffitt Collaboration Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Master Collaboration Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2021, we entered into an amended and restated master collaboration agreement, or the Moffitt Agreement, with Moffitt, to amend a then-existing master collaboration agreement from November 2019, as amended March 2020, between Moffitt and our now wholly-owned subsidiary, Myst Therapeutics LLC, with the intent to continue to work collaboratively in the research of cancer immunotherapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moffitt granted us (1) a royalty-free, sublicensable, non-transferable, perpetual, non-exclusive license to use and practice certain inventions invented solely by Moffitt in the performance of a research plan or through use of any data generated thereunder, or Moffitt Inventions, (a) for internal, non-commercial research purposes outside the field of adoptive cell therapy and/or (b) to research, develop, make, use, sell, offer to sell, or import products and/or services in the field of adoptive cell therapy and (2) a royalty free, sublicensable, non-transferable, perpetual, non-exclusive license to use and practice certain inventions invented in performance of a research plan or through the use of Moffitt research materials, which are (i) specifically directed to the identity of melanoma-specific T cell receptors, (ii) invented during the collaboration term or within one year after the end of the collaboration term within the field of adoptive cell therapy, and (iii) invented solely by either parties&#8217; employees or by both parties&#8217; employees jointly, to research, develop, make, use, sell, offer to sell, or import products and/or services for cancer immunotherapy involving identifying relevant tumor reactive T cells from TILs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Moffitt Alliance Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2022, we entered into a life science alliance agreement with Moffitt, or the Alliance Agreement, in order to further expand our relationship and support our existing agreements with Moffitt, or the Underlying Agreements. Pursuant to the Alliance Agreement, we will have priority access to Moffitt&#8217;s scientific research, manufacturing, and clinical capabilities for the development of novel TIL therapies, including expedited clinical trial activation, enhanced patient screening and data sharing, access to Moffitt&#8217;s cellular therapies research and development infrastructure, expanded molecular data sets and biospecimens for research, and allocated cGMP manufacturing capacity for our product candidates. Under this agreement, we have recently secured additional dedicated cleanroom capacity at Moffit&#8217;s on-site cGMP facility for manufacturing of TIDAL-01 for our multi-site solid tumor clinical trial with IND clearance from the FDA. This capacity is additive to the manufacturing capacity we have at our CDMO, Charles River Laboratories, as well as the existing capacity we have at Moffitt to support our two TIDAL-01 INDs for investigator sponsored trials.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Alliance Agreement, we are obligated to use commercially reasonable efforts to further develop TIL Products (as defined below), to manufacture TIL Products, to obtain regulatory approval for at least one TIL Product in the United States and to commercialize TIL Products in all countries in which regulatory approval for a TIL Product has been obtained. For purposes of the Alliance Agreement, TIL Product means any pharmaceutical, biopharmaceutical, or biotechnology TIL product that has been developed by us or Moffitt and is advanced into clinical development under an IND sponsored by Moffitt.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Alliance Agreement, we agreed to pay to Moffitt a total amount of at least $17.5 million, or Alliance Funding Amount, for research, development and manufacturing related services that will be paid equally over five years on June 1st of each year starting on June 1, 2023. The Alliance Funding Amount will be calculated annually at the conclusion of each payment period, and, to the extent our annual aggregate payments to Moffitt of $3.5 million exceeds the applicable annual installment amount, we will receive a reduction in the amount due for future installment payments based on a predetermined formula agreed to by the parties. To the extent the aggregate annual payments are less than $3.5 million, we will prepay the remaining amount due. On June 28, 2024, the Alliance Agreement was amended to remove the true up of the applicable annual installment amount of $3.5 million.  The Alliance Funding Amount remains $17.5 million over the five year term.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the execution of the Alliance Agreement, we issued Moffitt 91,721 shares of our common stock. As partial consideration under the Alliance Agreement, we also agreed to issue Moffitt an additional 366,884 shares of our common stock in the aggregate upon the satisfaction of certain clinical and regulatory milestones with respect to TIL Products. During the twelve months ended December 31, 2023, an additional 91,721 shares of our common stock were issued to Moffitt as a result of the achievement of the milestone related to the start of the Phase 1 clinical trial for a TIL Product. In addition, upon achievement of certain thresholds for aggregate net sales of all TIL Products, we are required to make tiered sales-based milestones payments to Moffitt of up to an aggregate of $50.0 million. With respect to each of the equity and sales milestones described above, TIL Products include any pharmaceutical, biopharmaceutical or biotechnology TIL product that is developed by us or Moffitt and is advanced into clinical development under an IND sponsored by Moffitt.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Components of Our Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaboration Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We enter into collaboration arrangements that may include the receipt of payments for up-front fees, success-based milestones, option exercises, intellectual property rights, research services, product supplies, and royalties on any future sales of commercialized products that result from the collaborations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Takeda Pharmaceutical Company Limited</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2019, we entered into a discovery, collaboration and license agreement, or the Takeda Agreement, with Millennium Pharmaceuticals, Inc. (also known as Takeda Oncology), a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, or Takeda. Under the Takeda Agreement, Takeda paid us an upfront payment of $50.0 million and an additional upfront payment of $30.0 million for the option to license up to two selected discovery candidates, with additional consideration in the low to low-mid eight figures to be paid to us by Takeda for each exercise of such option.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Takeda Agreement accounted for 100% of our total collaboration revenue for the three months ended March 31, 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 13, 2022, Takeda provided us with six months&#8217; written notice to terminate the development program in accordance with its termination for convenience rights, with such termination being effective as of December 13, 2022. Upon the effective termination date of December 13, 2022, Takeda&#8217;s co-exclusive license to TBio-6517 terminated and we are no longer obligated to pursue development of TBio-6517. On January 6, 2023, Takeda provided us with six months&#8217; written notice to terminate the remainder of the Takeda Agreement, in accordance with its termination for convenience rights, with such termination being effective as of July 6, 2023. As of March 31, 2023, we ceased all work under the Takeda Agreement and we have concluded that there are no remaining estimated services associated with the obligations under the Takeda Agreement as of the effective date of termination of the Takeda Agreement in its entirety. We will not receive any additional collaboration revenue under the Takeda Agreement in the future because this agreement has been terminated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Operating Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses consist primarily of external and internal costs incurred for our research and development activities, including adjusted development of our platform, our product discovery efforts and the development of our future product candidates. We expense research and development costs as incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">External costs include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical trial expenses, including costs of third-party contract research organizations, or CROs and costs of performing toxicity studies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expenses to acquire technologies to be used in research and development; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacturing scale-up expenses and the cost of acquiring and manufacturing preclinical and clinical materials and developing manufacturing processes; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs related to compliance with regulatory requirements. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Internal costs include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">employee-related expenses, which include salaries, benefits and stock-based compensation for employees engaged in research and development functions; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">facility-related and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation and amortization expense and expenses related to other general support services and supplies. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors and our clinical investigative sites. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our unaudited condensed consolidated financial statements as prepaid or accrued research and development expenses. Non-refundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses and expensed as the related goods are delivered or the services are performed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below summarizes our research and development expenses incurred by major development program for the periods presented </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.787%;"/>
    <td style="width:1.84%;"/>
    <td style="width:1%;"/>
    <td style="width:12.963000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.84%;"/>
    <td style="width:1%;"/>
    <td style="width:12.963000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.84%;"/>
    <td style="width:1%;"/>
    <td style="width:12.963000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.84%;"/>
    <td style="width:1%;"/>
    <td style="width:12.963000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">RIVAL-01</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">742</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TIDAL-01</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,404</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,218</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,473</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,263</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TIDAL-02</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">544</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,320</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,621</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,260</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other research programs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">782</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,557</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,426</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,596</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,730</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,193</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,520</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,861</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The successful development of our product candidates is highly uncertain. We plan to substantially increase our research and development expenses for the foreseeable future as we continue our existing clinical trials, initiate future clinical trials for our product candidates, continue to discover and develop additional product candidates, improve the efficiency and scalability of our manufacturing processes and supply chain and build our in-house process development, analytical and manufacturing capabilities. Therefore, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development and commercialization of any of our product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from the sale of our current or any future product candidates, if approved. This is due to the numerous risks and uncertainties associated with developing product candidates, including the uncertainty of:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope, rate of progress and expenses of our planned clinical trials and other research and development activities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">successful patient enrollment in, and the initiation and completion of, clinical trials including the impact of patient discontinuations and the number and location of clinical sites; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establishing an appropriate safety profile of our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether our product candidates show safety and efficacy in our clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">receipt of marketing approvals from applicable regulatory authorities; </span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">31</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">making arrangements with third-party manufacturers for the supply of materials to support our planned clinical trials and establishing commercial manufacturing capabilities for the potential manufacture of approved products, if any; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining, maintaining, protecting and enforcing patent and trade secret protection and regulatory exclusivity for our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">commercializing product candidates, if and when approved, whether alone or in collaboration with others; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">acceptable safety profile of the products following any regulatory approval. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any changes in the outcome of any of these variables with respect to the development of our product candidates in preclinical and clinical development could mean a significant change in the costs and timing associated with the development of these product candidates. We may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on others. For example, if the U.S. Food and Drug Administration, or FDA, or comparable foreign regulatory authority were to delay our planned clinical trials or require us to conduct pre-clinical or clinical trials beyond those that we currently expect or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development of that product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses consist primarily of personnel costs, allocated expenses and other expenses for outside professional services, including legal, intellectual property, human resources, audit and accounting services. Personnel costs consist of salaries, bonuses, benefits and stock-based compensation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect our general and administrative expenses will increase during the next few years to support our continued research and development activities of our product candidates and associated expenses with operating as a public company, including expenses related to compliance with the rules and regulations of the SEC and the Nasdaq Stock Market LLC, or Nasdaq, insurance expenses, audit expenses, investor relations activities, Sarbanes-Oxley Act compliance expenses, increased costs related to the hiring of additional personnel and fees to outside consultants, lawyers and accountants, among other administrative expenses and professional services.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income, Net</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other income, net consists primarily of interest income earned on our short-term investments and foreign currency remeasurement gains and losses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comparison of the Three Months Ended June 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables set forth our results of operations (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:35.774%;"/>
    <td style="width:1.941%;"/>
    <td style="width:1%;"/>
    <td style="width:17.467%;"/>
    <td style="width:1%;"/>
    <td style="width:1.941%;"/>
    <td style="width:1%;"/>
    <td style="width:17.467%;"/>
    <td style="width:1%;"/>
    <td style="width:1.941%;"/>
    <td style="width:1%;"/>
    <td style="width:17.467%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change ($)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,730</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,193</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(537</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,327</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,659</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">332</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,057</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,852</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(205</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(22,057</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(21,852</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(205</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">755</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">347</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">408</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(2</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(8</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(21,304</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(21,499</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">195</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaboration Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There was no collaboration revenue during the three months ended June 30, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">32</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our research and development expenses </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:61.76%;"/>
    <td style="width:1.38%;"/>
    <td style="width:1%;"/>
    <td style="width:15.74%;"/>
    <td style="width:1%;"/>
    <td style="width:1.38%;"/>
    <td style="width:1%;"/>
    <td style="width:15.74%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-clinical research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,130</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,027</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Manufacturing</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,195</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,500</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Clinical and regulatory</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,017</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,374</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Personnel related</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,388</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,292</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,730</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,193</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses were $17.7 million and $17.2 million during the three months ended June 30, 2024 and 2023, respectively, an increase of $0.5 million, or 2.9%. The increase was due primarily to an increase of $1.7 million in manufacturing expenses and $0.6 million in clinical and regulatory costs as we continue TIDAL-01 clinical trials offset by a decrease of $0.9 million in personnel related costs and $0.9 million in pre-clinical research and development costs due to the termination of the Takeda Agreement and winding down activities related to the RIVAL-01 platform during the three months ended March 31, 2023.  We expect research and development expenses to continue to increase as we advance the development of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses were $4.3 million and $4.7 million during the three months ended June 30, 2024 and 2023, respectively, a decrease of $0.4 million, or 8.5%. The decrease was due primarily to a reduction in personnel costs of $0.4 million.  We anticipate that general and administrative expenses will remain stable as we support public company operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income, Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other income (expense), net was $0.8 million and $0.3 million during the three months ended June 30, 2024 and 2023, respectively, an increase of $0.5 million, or 166.7% due to interest income earned on the net proceeds from our IPO as well as an increase in interest rates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comparison of the Six Months Ended June 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables set forth our results of operations (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:62.26%;"/>
    <td style="width:1.38%;"/>
    <td style="width:1%;"/>
    <td style="width:9.200000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.38%;"/>
    <td style="width:1%;"/>
    <td style="width:9.200000000000001%;"/>
    <td style="width:1%;"/>
    <td style="width:1.38%;"/>
    <td style="width:1%;"/>
    <td style="width:9.200000000000001%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change ($)</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,306</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(19,306</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,520</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,861</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(659</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,228</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,691</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(537</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42,748</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41,552</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,196</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(42,748</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(22,246</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(20,502</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,833</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">727</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,106</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provision for income taxes</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(18</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(106</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(40,933</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(21,431</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(19,502</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaboration Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaboration revenue was $0.0 million and $19.3 million during the six months ended June 30, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our research and development expenses </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.3%;"/>
    <td style="width:2.22%;"/>
    <td style="width:1%;"/>
    <td style="width:20.02%;"/>
    <td style="width:1%;"/>
    <td style="width:2.22%;"/>
    <td style="width:1%;"/>
    <td style="width:20.02%;"/>
    <td style="width:1%;"/>
    <td style="width:2.22%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-clinical research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,496</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,015</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Manufacturing</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,329</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,197</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Clinical and regulatory</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,297</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,579</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Personnel related</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,398</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,070</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total research and development</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,520</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,861</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research and development expenses were $33.5 million and $32.9 million during the six months ended June 30, 2024 and 2023, respectively, an increase of $0.6 million, or 1.8%. The increase was due primarily to an increase of $4.1 million in manufacturing expenses related to our increased clinical activities for TIDAL-01 offset by decreases of $2.5 million in pre-clinical research and development, $0.3 million in clinical and regulatory expenses and $0.7 million in personnel related expenses due to the termination of the Takeda agreement and winding down activities related to the RIVAL-01 platform. We expect our research and development expenses to increase in the long term as we advance the development of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General and administrative expenses were $9.2 million and $8.7 million during the six months ended June 30, 2024 and 2023, respectively, an increase of $0.5 million, or 6.2%. The increase was due primarily to an increase in compensation costs as we transition to being a public company. We anticipate that general and administrative expenses will continue to increase in the future due to an increase in expenses related to activities associated with operating as a public company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Income, Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other income, net was $1.8 million and $0.7 million during the six months ended June 30, 2024 and 2023, respectively, an increase of $1.1 million, or 157.1%. due to interest income earned on the net proceeds from our IPO as well as an increase in interest rates.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Going Concern</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on our expected operating losses and negative cash flows, we believe there is substantial doubt about our ability to continue as a going concern for 12 months after the date of these unaudited interim consolidated financial statements are filed with the SEC. If we cannot continue as a going concern, our stockholders may lose some or all of their investment in us. Our ability to continue as a going concern is dependent upon our ability to raise additional funding. We intend to raise additional capital through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may not be able to secure additional financing in a timely manner or on favorable terms, if at all. Furthermore, if we issue equity securities to raise additional funds, our existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of our existing stockholders. If we raise additional funds through collaboration, licensing or other similar arrangements, we may need to relinquish valuable rights to our potential products on terms that are not favorable to us.  If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may need to significantly delay, scale back or discontinue the development or future commercialization of one or more of our product candidates, if approved. Any of the above events could adversely affect our business, results of operations and financial condition and cause the price of our common stock to decline.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sources of Liquidity</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our headquarters are located in San Diego, California and we operate as one segment. Since our inception, we have devoted substantially all of our efforts and financial resources to organizing and staffing our company, business planning, raising capital, discovering product candidates and securing related intellectual property rights and conducting research and development activities for our Selected TIL programs and product candidates. We do not have any products approved for sale, we have not generated any revenue from product sales, and we have incurred overall net losses since our inception through June 30, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to our IPO and since our inception, we have funded our operations primarily through the sale of our convertible preferred stock and revenue from certain of our collaboration agreements. Since our inception, we have raised an aggregate of approximately $172.0 million of gross proceeds from the issuance and sale of shares of our convertible preferred stock, $190.0 million in upfront, nonrefundable collaboration revenue, and most recently, with gross proceeds of $80.0 million from the IPO completed on July 25,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">34</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023 and $7.8 million from the exercise of the underwriters&#8217; option to purchase additional shares. As of June 30, 2024 and  December 31, 2023, we had cash, cash equivalents and short-term investments of $62.4 million and $94.8 million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 26, 2024, or the Loan Closing Date, we entered into a Loan and Security Agreement, or LSA, with Banc of California, or BOC, for a revolving credit facility in an aggregate principal amount of up to $20 million with annual interest equal to the greater of the Prime Rate (as defined in the LSA) or 4.25%.  This LSA includes a covenant requiring us to (i) receive positive interim Phase 1 data for TIDAL-01 (as determined by our board of directors), which was achieved in August 2024 and (ii) receive at least $40.0 million in new funding from the sale of equity, partnerships, and/or business development payments, in each case, by March 31, 2025. If we fail to comply with any of the foregoing covenants, BOC may terminate the commitments to make further loans and declare all of our obligations  under the LSA to be immediately due and payable. As of June 30, 2024, no amounts were drawn and outstanding under the LSA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have incurred significant operating losses in the past, and we expect to continue to incur significant operating losses for the foreseeable future. We incurred a net loss of $40.9 million and $21.4 million for the six months ended June 30, 2024 and 2023, respectively. As of June 30, 2024 and December 31, 2023, we had an accumulated deficit of $217.7  million and $176.8 million, respectively. Substantially all of our operating losses result from expenses incurred in our research and development programs and from general and administrative costs associated with our operations. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates, and on our ability to enter into collaborations, strategic partnerships and alliances or marketing, distribution or licensing arrangements with third parties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect that our existing cash, cash equivalents and short-term investments will not enable us to fund our operating expenses and capital expenditure requirements into the third quarter of 2025. We have based this estimate on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Funding Requirements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we continue to advance our product candidates and programs through preclinical and clinical development. Furthermore, as a result of the completion of the IPO on July 25, 2023, we expect to have incurred additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs which could materially harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future capital requirements will depend on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of conducting clinical trials, including the clinical development of our TIDAL-01 product candidate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the progress of preclinical development and clinical trials of our current earlier-stage and future product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of manufacturing; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope, progress, results and costs of discovery, preclinical development, laboratory testing and clinical trials for other potential product candidates we may develop, if any; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs, timing and outcome of regulatory review of our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to establish and maintain collaborations and partnerships on favorable terms, if at all; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the achievement of milestones or occurrence of other developments that trigger payments under any collaboration agreements we might have at such time; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of operating as a public company; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of future commercialization activities, if any, including product sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to achieve sufficient market acceptance, adequate coverage and reimbursement from third-party payors and adequate market share; and </span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">35</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of  June 30, 2024 and December 31, 2023, we had cash, cash equivalents and short-term investments of $62.4 million and $94.8 million, respectively. We believe that our existing cash, cash equivalents and short-term investments, will enable us to fund our operating expenses and capital expenditures into the third quarter of 2025. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. We anticipate that we will require additional capital as we seek regulatory approval of our product candidates and if we choose to pursue in-licenses or acquisitions of other product candidates. If we need to raise additional capital to fund our operations, funding may not be available to us on acceptable terms, or at all. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend one or more of our preclinical studies, clinical trials, research and development programs, or commercialization efforts. If we receive regulatory approval for our current or future product candidates, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interests may be diluted, and the terms of these securities may include liquidation or other preferences that could adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may need to significantly delay, scale back or discontinue the development or future commercialization of one or more of our product candidates, if approved. Any of the above events could adversely affect our business, results of operations and financial condition and cause the price of our common stock to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our cash flows </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.313%;"/>
    <td style="width:1.5%;"/>
    <td style="width:1%;"/>
    <td style="width:12.843%;"/>
    <td style="width:1%;"/>
    <td style="width:1.5%;"/>
    <td style="width:1%;"/>
    <td style="width:12.843%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash used in operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(33,385</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(31,861</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash provided by investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,036</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,475</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash used in financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(48</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(1,081</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net decrease in cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(397</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(13,467</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows from Operating Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash used in operating activities for the six months ended June 30, 2024 was $33.4 million, primarily due to our net loss of $40.9 million and accretion of the premium on short-term investments of $1.4 million which was partially offset by the decrease in our net operating assets and liabilities of $5.8 million, changes in stock-based compensation of $2.1 million, and depreciation and amortization expense of $1.0 million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash used in operating activities for the six months ended June 30, 2023 was $31.9 million, primarily due to our net loss of $21.4 million and the decrease in our net operating assets and liabilities of $14.3 million, which included changes in deferred revenue of $19.3 million, accretion of the premium on short-term investments of $0.5 million and partially offset by changes in stock-based compensation of $2.1 million, depreciation and amortization expense of $1.4 million, and change in the fair value of contingent consideration liabilities of $0.9 million.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows from Investing Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash provided by investing activities for the six months ended June 30, 2024 was $33.0 million, due primarily to $40.0 million in maturities of short-term investments offset by the purchases of $6.7 million of short-term investments and $0.3 million in purchases of property and equipment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash provided by investing activities for the six months ended June 30, 2023 was $19.5 million, due primarily to the maturities of $35.5 million of short-term investments, $0.2 million of proceeds from the sale of property and equipment, and offset by $1.0 million in purchases of property and equipment and $15.2 million in purchases of short-term investments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows from Financing Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Net cash used in financing activities for the six months ended June 30, 2023 was $1.1 million, due primarily to the $0.9 million cash payment of contingent consideration related to Myst&#8217;s achievement of the second milestone under the Myst Merger Agreement due to the acceptance by the FDA of an IND filed by, on behalf of or for the benefit of us and $0.3 million in payments of deferred IPO costs offset by $0.1 million in proceeds from the exercise of stock options.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Contractual Obligations and Commitments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We enter into contracts in the normal course of business with CROs and CMOs for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. These contracts provide for termination at the request of either party with less than one year notice, and therefore we believe that our non-cancellable obligations under these agreements are not material. We additionally have contractual obligations for our operating leases for our corporate headquarters and office and laboratory spaces. These obligations are further described in Note 12 to our unaudited condensed consolidated financial statements. We are also party to certain collaboration and license agreements, which contain a number of contractual obligations. Those contractual obligations may entitle us to receive, or may obligate us to make, certain payments. The amount and timing of those payments are unknown or uncertain as we are unable to estimate the timing or likelihood of the events that will obligate those payments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have milestones, royalties, and/or other payments due to third parties under our existing license and collaboration agreements. See Note 6 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q. We can&#8217;t estimate when such payments will be due and none of these events were probable to occur as of June 30, 2024 and December 31, 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Critical Accounting Polices and Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of our financial statements and related disclosures in conformity with generally accepted accounting principles in the United States and our discussion and analysis of our financial condition and operating results require us to make judgments, assumptions and estimates that affect the amounts reported in our unaudited condensed consolidated financial statements and accompanying notes. Our significant accounting policies and methods used in preparation of our unaudited condensed consolidated financial statements are described in Note 2 to our unaudited condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q. We base our estimates on historical experience and on various other assumptions we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates, and such differences may be material.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been no material changes to our critical accounting policies from those described under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8211; Critical Accounting Policies and Estimates&#8221; included in our Annual Report on Form 10-K filed with the SEC on March 22, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Pronouncements Recently Adopted</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have reviewed all recently issued standards and have determined that, other than as disclosed in Note 2 to our unaudited condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q, such standards will not have a material impact on our unaudited condensed consolidated financial statements or do not otherwise apply to our current operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging Growth and Smaller Reporting Company Status</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The JOBS Act permits an &#8220;emerging growth company&#8221; such as us to take advantage of reduced reporting requirements that are otherwise applicable to public companies and also an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected to not &#8220;opt out&#8221; of this provision and, as a result, we will adopt new or revised accounting standards at the time private companies adopt the new or revised accounting standard and will do so until such time that we either (i) irrevocably elect to &#8220;opt out&#8221; of such extended transition period or (ii) no longer qualify as an emerging growth company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will remain an emerging growth company until the earliest of (i) the last day of the fiscal year following the fifth anniversary of the IPO, (ii) the last day of the fiscal year in which we have total annual gross revenues of $1.235 billion or more, (iii) the date on which we have issued more than $1.0 billion in non-convertible debt during the previous rolling three-year period or (iv) the date on which we are deemed to be a large accelerated filer under the Exchange Act.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our ordinary shares held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and our ordinary shares held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_quantative_and_qualitative_disc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 3. QUANTITATIVE AND QUAL</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITATIVE DISCLOSURES ABOUT MARKET RISK</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not required for smaller reporting companies.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_controls_and_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 4. CONTROLS </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AND PROCEDURES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024, management, with the participation and supervision of our Chief Executive Officer and our Chief Financial Officer, have evaluated our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of June 30, 2024, our disclosure controls and procedures were effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There has been no change in our internal control over financial reporting during the quarter ended June 30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="part_ii_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PART II. OTHE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">R INFORMATION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1_legal_proceeding"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 1. LEGA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">L PROCEEDINGS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we have been or may become involved in material legal proceedings or be subject to claims arising in the ordinary course of our business. We are currently not party to any legal proceedings material to our operations or of which any of our property is the subject, nor are we aware of any such proceedings that are contemplated by a government authority. Regardless of outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources, and other factors, and there can be no assurances that favorable outcomes will be obtained.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 1A. RI</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SK FACTORS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business involves significant risks, some of which are described below. You should carefully consider the risks described below, as well as the other information in this Quarterly Report on Form 10-Q, including our unaudited condensed consolidated financial statements and the related notes, and the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;. The occurrence of any of the events or developments described below could adversely affect our business, results of operations and financial condition. In any such event, the market price of our common stock could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial also may impair our business, results of operations and financial condition.  The risk factors set forth below that are marked with an asterisk (*) contain substantive changes to the similarly titled risk factors included in, or did not appear as separate risk factors in, Item 1A of our Annual Report on Form 10-K filed with the SEC on March 22, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risk Factor Summary</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Below is a summary of material factors that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks that we face. Additional discussion of the risks and uncertainties summarized in this risk factor summary, as well as other risks that we face, follows this summary. This summary is qualified in its entirety by that more complete discussion of such risks and uncertainties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have limited operating history, have incurred substantial net losses and anticipate that we will continue to incur net losses for the foreseeable future. We have no products approved for commercial sale, have never generated any revenue from product sales and may never be profitable. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We will require additional capital to fund our operations, and if we fail to obtain necessary capital on acceptable terms, or at all, we will not be able to complete the development and future commercialization of our current and any future product candidates. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our business is highly dependent on the success of our lead Selected TIL product candidate TIDAL-01, as well as our other current and any future product candidates. All of our product candidates will require significant additional preclinical or clinical development before we are able to seek regulatory approval for and launch a product commercially. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail to develop and receive approval for our existing or any additional future product candidates, our commercial opportunity could be limited which could adversely affect our business, results of operations and financial condition. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unfavorable global economic conditions, including any adverse macroeconomic conditions or geopolitical events, including the conflict between Ukraine and Russia, conflict in the Middle East, and recent bank failures affecting the financial services industry, could adversely affect our business, financial condition, results of operations or liquidity, either directly or through adverse impacts on certain of the third parties on which we rely to conduct certain aspects of our preclinical studies or clinical trials. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical development involves a lengthy and expensive process, with uncertain outcomes. We may incur significant costs and/or experience delays in completing, or ultimately be unable to complete, the development of our current and future product candidates, including our lead product candidates. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Preclinical development is uncertain. Our preclinical programs may experience delays or generate unfavorable data, and may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all, and any of these events would adversely affect our business, results of operations and financial condition. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates are based on a novel approach to the treatment of cancer, which makes it difficult to predict the time and cost of product candidate development. </span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">40</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The manufacture of our product candidates is complex, and we may encounter difficulties in production, particularly with respect to process development, quality control, or scaling-up of any future manufacturing capabilities. If we, or any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face significant competition and if we fail to compete effectively, our business, results of operations and financial condition could be adversely affected. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Negative developments in the fields of immuno-oncology and TIL-based immunotherapy could damage public perception of our product candidates and adversely affect our business, results of operations and financial condition. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have relied and expect to continue to rely on third parties to conduct certain aspects of our preclinical studies, to conduct our clinical trials and to conduct investigator sponsored clinical trials of our product candidates. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, comply with regulatory requirements or terminate the relationship, we may not be able to obtain regulatory approval of or commercialize any potential product candidates. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The regulatory approval process for our product candidates in the United States, and other jurisdictions is currently uncertain and will be lengthy, time-consuming and inherently unpredictable, and we may experience significant delays in the clinical development and regulatory approval, if any, of our product candidates. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats to our business. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall. </span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Business</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have limited operating history, have incurred substantial net losses and anticipate that we will continue to incur net losses for the foreseeable future. We have no products approved for commercial sale, have never generated any revenue from product sales and may never be profitable.*</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a clinical stage biotechnology company with a limited operating history. We were formed in 2014 and we have devoted substantially all of our efforts and financial resources to organizing and staffing our company, business planning, raising capital, discovering product candidates and securing related intellectual property rights, and conducting research and development activities for our Selected TIL programs and product candidates. Consequently, we have no meaningful operations upon which to evaluate our business and predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing program candidates. Investment in biotechnology product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become commercially viable. We have not yet demonstrated the ability to progress any product candidate through clinical trials, we have no products approved for commercial sale and we have not generated any revenue from product sales to date. We continue to incur significant research and development and other expenses related to our ongoing operations. As a result, we are not profitable and we have incurred overall net losses since our inception through June 30, 2024. We had net loss of $40.9 million and $21.4 million for the six months ended June 30, 2024 and 2023, respectively. As of June 30, 2024 and December 31, 2023, we had an accumulated deficit of $217.7 million and $176.8 million, respectively. Additionally, we will not receive any additional collaboration revenue under the Takeda Agreement in the future because the agreement has been terminated. We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of our Selected TIL programs, and seek regulatory approvals for our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We anticipate that our expenses will increase substantially if, and as, we:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">advance the development of our lead Selected TIL product candidate TIDAL-01 through two Phase 1 clinical trials and, if the results are favorable, into further clinical development; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">actively advance our other preclinical pipeline programs, including TIDAL-02, our next Selected TIL program and our TIDAL-01 and viral immunotherapy combination program; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seek regulatory approvals for any product candidates that successfully complete clinical trials, if any; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increase the amount of research and development activities to identify and develop Selected TIL product candidates; </span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">41</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">hire additional clinical, quality control and scientific personnel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a public company; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">maintain, expand and protect our intellectual property portfolio; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expand our external manufacturing relationships; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">oversee and maintain our manufacturing infrastructure; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any products for which we may obtain marketing approval and intend to commercialize on our own or jointly with third parties; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">invest in or in-license enabling technologies. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To become and remain profitable, we and any current or potential future collaborators must develop and eventually commercialize products with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials, obtaining marketing approval for product candidates, manufacturing, marketing and selling products if we obtain marketing approval, obtaining market acceptance for such products and satisfying any post-marketing requirements. We may never succeed in any or all of these activities and, even if we do, we may never generate revenue that is significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and the price or of common stock, and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company also could cause you to lose all or part of your investment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. We also may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; (deficit) equity and working capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will require additional capital to fund our operations, and if we fail to obtain necessary capital on acceptable terms, or at all, we will not be able to complete the development and future commercialization of our current and any future product candidates.*</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our operations have consumed substantial amounts of cash since our inception. We expect to continue to spend substantial amounts of cash to conduct further research and development, preclinical studies and clinical trials of our current and future product candidates, to seek regulatory approvals for our product candidates and to launch and commercialize any products if we receive regulatory approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have three ongoing Phase 1 clinical trials for our lead Selected TIL product candidate, TIDAL-01, including a multi-site trial for the treatment of colorectal cancer, head and neck cancer and uveal melanoma, and two investigator sponsored trials with Moffitt across colorectal cancer, head and neck cancer and uveal melanomas. In August 2024, we provided preliminary data from the first 4 evaluable MSS mCRC patients in our TIDAL-01 multi-site trial and intend to provide the next clinical update in the first half of 2025.  We are also developing TIDAL-02, our next Selected TIL program, which is currently in preclinical development and we intend to evaluate the combination of TIDAL-01 with viral immunotherapy. We are currently evaluating the optimal viral immunotherapy for combination with TIDAL-01 to advance into clinical development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024, we had approximately $62.4 million in cash, cash equivalents and short-term investments. Based on our current operating plan, there is substantial doubt about the Company&#8217;s ability to continue as a going concern for 12 months after the date the unaudited consolidated financial statements are filed with the SEC. Our future capital requirements and the period for which our existing resources will support our operations may vary significantly from what we expect, and we will in any event require additional capital in order to complete clinical development of any of our current programs. Our monthly spending levels will vary based on new and ongoing development and corporate activities. Because the length of time and activities associated with development of our programs and product candidates is highly uncertain, we are unable to estimate the actual funds we will require for development and any approved marketing and future commercialization activities, if any. Our future capital requirements will depend on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of conducting clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the progress of preclinical development for our programs and clinical trials of our current earlier-stage product candidates; </span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">42</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of manufacturing; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope, progress, results and costs of discovery, preclinical development, laboratory testing and clinical trials for other potential product candidates we may develop, if any; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs, timing and outcome of regulatory review of our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to establish and maintain collaborations and partnerships on favorable terms, if at all; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the achievement of milestones or occurrence of other developments that trigger payments to us or by us under any collaboration agreements we might have at such time; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our headcount growth and associated costs as we expand our business operations and research and development activities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of operating as a public company; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to mitigate the impact of adverse macroeconomic conditions or geopolitical events, including the ongoing conflict between Ukraine and Russia, the ongoing conflict in the Middle East, recent bank failures or other factors on our preclinical and clinical development or operations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs and timing of future commercialization activities, if any, including product sales, marketing, manufacturing and distribution, if we receive marketing approval for any of our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to achieve sufficient market acceptance, adequate coverage and reimbursement from third-party payors and adequate market share; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the amount of revenue, if any, received from commercial sales of our product candidates, if any of our product candidates receive marketing approval. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We do not have any committed external source of funds or other support for our development efforts and additional funding may not be available on acceptable terms, or at all. Market volatility resulting from adverse macroeconomic conditions or geopolitical events, including the ongoing conflict between Ukraine and Russia and in the Middle East, recent bank failures or other factors may further adversely impact our ability to access capital as and when needed. Until we can generate sufficient product or royalty revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other arrangements. If we raise additional funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. Further, to the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, your ownership interest will be diluted. In addition, any debt financing may subject us to fixed payment obligations and covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. We also could be required to seek collaborators for our current or future product candidates at an earlier stage than otherwise would be desirable or relinquish our rights to product candidates or technologies that we otherwise would seek to develop or commercialize ourselves. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may need to significantly delay, scale back or discontinue the development or future commercialization of one or more of our product candidates, if approved.  Any of the above events could adversely affect our business, results of operations and financial condition and cause the price of our common stock to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our business is highly dependent on the success of our lead Selected TIL product candidate TIDAL-01, as well as our other current and any future product candidates. All of our product candidates will require significant additional preclinical or clinical development before we are able to seek regulatory approval for and launch a product commercially.*</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are very early in our development efforts. If TIDAL-01 or any future product candidates encounter safety or efficacy problems, manufacturing failures, development delays or regulatory issues or other problems, our development plans and business may be significantly harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have three ongoing Phase 1 clinical trials for our lead Selected TIL product candidate, TIDAL-01, including a multi-site trial for the treatment of colorectal cancer, head and neck cancer, and uveal melanoma, and two investigator sponsored trials with Moffitt across colorectal cancer, head and neck cancer and uveal melanomas. On August 14, 2024, we provided preliminary data from</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">43</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the first 4 evaluable MSS mCRC patients in our TIDAL-01 multi-site trial and intend to provide the next clinical update in the first half of 2025. We are also developing TIDAL-02, our next Selected TIL program, which is currently in preclinical development and we intend to evaluate the combination of TIDAL-01 with viral immunotherapy. We are currently evaluating the optimal viral immunotherapy for combination with TIDAL-01 to advance into clinical development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current and any future product candidates will require additional preclinical or clinical development, regulatory review and approval in one or more jurisdictions, substantial investment, and access to sufficient commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from product sales. We may not have the financial resources to continue development of, or to modify existing or enter into new collaborations for, any product candidate if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, our product candidates, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">negative or inconclusive results from our preclinical studies or clinical trials or the clinical trials of others for product candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product-related side effects experienced by subjects in our clinical trials or by individuals using products or immunotherapies similar to our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in submitting INDs or comparable foreign applications or delays or failure in obtaining the necessary authorizations or approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conditions imposed by the FDA or comparable foreign regulatory authorities regarding the scope or design of our clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays in enrolling subjects in clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">high drop-out rates of subjects from clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inadequate supply or quality of product candidates or other materials necessary for the conduct of our clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">greater than anticipated clinical trial costs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">poor effectiveness of or safety issues associated with our product candidates during clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unfavorable FDA or comparable foreign regulatory authorities&#8217; inspection and review of a clinical trial site; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential disruptions caused by health pandemics or epidemics, including difficulties in initiating clinical sites, enrolling and retaining participants, diversion of healthcare resources away from clinical trials, travel or quarantine policies that may be implemented, and other factors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">varying interpretations of data by the FDA or comparable foreign regulatory authorities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacturing failures, including our TIL selection process, resulting in a less effective product candidate in the tumor indications we are pursuing; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unsuccessful improvements to our internal manufacturing processes. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The occurrence of any of the above events could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to develop and receive approval for our existing or any additional future product candidates, our commercial opportunity could be limited which could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Developing, obtaining marketing approval for, and commercializing any product candidates will require substantial additional funding and will be subject to the risks of failure inherent in medical product development. We may not be able to successfully advance any of our existing product candidates or any additional product candidates through the development process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we obtain approval from the FDA or comparable foreign regulatory authorities to market our existing or any additional product candidates for the treatment of solid tumors or any other indication, any such product candidates may not be successfully</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">44</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">commercialized, widely accepted in the marketplace, or more effective than other commercially available alternatives. If we are unable to successfully develop and commercialize our existing or any additional product candidates, our commercial opportunity may be limited and our business, results of operations and financial condition may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unfavorable global economic conditions, including any adverse macroeconomic conditions or geopolitical events, including the conflict between Ukraine and Russia, the conflict in the Middle East and recent bank failures affecting the financial services industry, could adversely affect our business, financial condition, results of operations or liquidity, either directly or through adverse impacts on certain of the third parties on which we rely to conduct certain aspects of our preclinical studies or clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. Global economic and business activities continue to face widespread uncertainties, and global credit and financial markets have experienced extreme volatility and disruptions in the past several years, including severely diminished liquidity and credit availability, rising inflation and monetary supply shifts, rising interest rates, labor shortages, declines in consumer confidence, declines in economic growth, increases in unemployment rates, recession risks, and uncertainty about economic and geopolitical stability. A severe or prolonged economic downturn, or additional global financial or political crises, could result in a variety of risks to our business, including delayed clinical trials or preclinical studies, delayed approval of our product candidates, delayed ability to obtain patents and other intellectual property protection, weakened demand for our product candidates, if approved, or our ability to raise additional capital when needed on acceptable terms, if at all. The extent of the impact of these conditions on our operational and financial performance, including our ability to execute our business strategies and initiatives in the expected timeframe, as well as that of third parties upon whom we rely, will depend on future developments which are uncertain and cannot be predicted. A weak or declining economy also could strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business. Furthermore, our stock price may decline due in part to the volatility of the stock market and the general economic downturn.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, on March 10, 2023, Silicon Valley Bank was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation, or FDIC, as receiver. Similarly, on March 12, 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership, and on May 1, 2023, First Republic Bank was also swept into receivership. Although a statement by the Department of the Treasury, the Federal Reserve and the FDIC indicated that all depositors of Silicon Valley Bank would have access to all of their money after only one business day of closure, including funds held in uninsured deposit accounts, borrowers under credit agreements, letters of credit and certain other financial instruments with Silicon Valley Bank, Signature Bank or any other financial institution that is placed into receivership by the FDIC may be unable to access undrawn amounts thereunder. If any of the banks which hold our cash deposits were to be placed into receivership, we may be unable to access such funds. As of June 30, 2024, all of our cash on deposit was maintained at two financial institutions in the United States, and our current deposits are in excess of federally insured limits. If further failures in financial institutions occur where we hold deposits, we could experience additional risk. Any such loss or limitation on our cash, cash equivalents and short-term investments would adversely affect our business. In addition, if any of the third parties on which we rely to conduct certain aspects of our preclinical studies or clinical trials are unable to access funds pursuant to such instruments or lending arrangements with such a financial institution, such parties&#8217; ability to fulfill their obligations to us could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may evaluate various acquisitions and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">increased operating expenses and cash requirements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the assumption of additional indebtedness, contractual obligations or contingent liabilities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the issuance of our equity securities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel; </span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party, their regulatory compliance status, and their existing products or product candidates and marketing approvals; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, if we undertake acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business. Any of the foregoing may adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not realize the expected benefits from our recent workforce reduction and it could result in total costs and expenses that are greater than expected and could disrupt our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2023, we conducted a reduction in our workforce. The changes to our operations and the reduction in workforce may yield unintended consequences and costs, such as the loss of institutional knowledge and expertise, attrition beyond our intended reductions in force, and a reduction in morale among our remaining employees, all of which may have an adverse effect on our development activities, our business, results of operations or financial condition. If we are unable to realize the expected operational efficiencies, our business, results of operations and financial condition would be adversely affected. In addition, to the extent we do not realize such anticipated operational efficiencies, we may need to undertake workforce reductions or restructuring activities in the future. Furthermore, our reductions in force may be disruptive to our operations. For example, our workforce reductions could yield unanticipated consequences, such as attrition beyond planned staff reductions, increased difficulties in our day-to-day operations and reduced employee morale. If employees who were not affected by the reductions in force seek alternative employment, this could result in our seeking contractor support at unplanned additional expense or harm our productivity. Our workforce reductions could also harm our ability to attract and retain qualified management, scientific, clinical, and manufacturing personnel who are critical to our business. Any failure to attract or retain qualified personnel could prevent us from successfully developing our potential product candidates. We may also discover that the reductions in workforce could make it difficult for us to pursue new opportunities and initiatives and require us to hire qualified replacement personnel, which may require us to incur additional and unanticipated costs and expenses. Our failure to successfully accomplish any of the above activities and goals may have a material adverse impact on our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our ability to use our net operating loss carryforwards to offset future income could be subject to limitation.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we had approximately $43.0 million of U.S. federal and $81.9 million of state net operating loss, or NOL, carryforwards. Our U.S. federal NOL carryforwards can be carried forward indefinitely, but use of such carryforwards is limited to 80% of taxable income. If not utilized, our state NOL carryforwards will begin to expire at various dates beginning in 2038. These NOL carryforwards could expire unused and be unavailable to offset future income tax liabilities if we are not able to generate sufficient taxable income to utilize our state NOL carryforwards before they expire. We have recorded a full valuation allowance related to our carryforwards due to the uncertainty of the ultimate realization of the future benefits of those assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, under Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, the amount of benefits from our NOL carryforwards may be impaired or limited if we incur a cumulative ownership change of more than 50% over a three-year period. Any future offerings of our securities may trigger such an ownership change. In addition, because we will need to raise substantial additional funding to finance our operations, we may in the future undergo further ownership changes. We have not conducted an analysis as to whether such a change of ownership has occurred, but if such a change has occurred or occurs in the future, we will be limited regarding the amount of NOL carryforwards that can be utilized annually in the future to offset taxable income. Any such annual limitation may significantly reduce the value of our NOL carryforwards before they expire, which could result in greater tax liabilities than we would incur in the absence of such a limitation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may have exposure to greater-than-anticipated tax liabilities, which could seriously harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The tax laws applicable to our international business activities, including the laws of the United States and other jurisdictions, are subject to change and uncertain interpretation. The U.S. government may enact significant changes to the taxation of business</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">46</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">entities including, among others, the imposition of additional minimum taxes and an increase in the corporate tax rate. Any such change could have a significant impact on our cash flow.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our income tax obligations are based on our corporate operating structure and third-party and intercompany arrangements, including the manner in which we develop, value, and use our intellectual property and the valuations of our intercompany transactions. The taxing authorities of the jurisdictions in which we operate may challenge our methodologies for valuing developed technology, intercompany arrangements, or transfer pricing, which could increase our worldwide effective tax rate and the amount of taxes we pay and seriously harm our business. Taxing authorities also may determine that the manner in which we operate our business is not consistent with how we report our income, which could increase our effective tax rate and the amount of taxes we pay and seriously harm our business. In addition, our future income taxes could fluctuate because of earnings being lower than anticipated in jurisdictions that have lower statutory tax rates and higher than anticipated in jurisdictions that have higher statutory tax rates, by changes in the valuation of our deferred tax assets and liabilities. We are subject to regular review and audit by U.S. federal and state and foreign tax authorities. Any adverse outcome from a review or audit could seriously harm our business. In addition, determining our worldwide provision for income taxes and other tax liabilities requires significant judgment by management, and there are many transactions where the ultimate tax determination is uncertain. Although we believe that our estimates are reasonable, the ultimate tax outcome may differ from the amounts recorded in our financial statements for such period or periods and may seriously harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exchange rate fluctuations may adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have operations, including employing a portion of our workforce, in Ottawa, Canada. Owing to the international scope of our operations, fluctuations in exchange rates between the U.S. dollar and the Canadian dollar may adversely affect our business, results of operations and financial condition. As a result, our business and the price of our common stock may be affected by fluctuations in foreign exchange rates, which may have a significant impact on our results of operations and cash flows from period to period. Currently, we do not have any exchange rate hedging arrangements in place.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will need to grow the size of our organization, and we may experience difficulties in managing this growth, which could adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024, we had 82 full-time employees. As our clinical development and future commercialization plans and strategies develop, and as we transition into operating as a public company, we may need to hire additional managerial, clinical, regulatory, sales, marketing, financial, legal and other personnel. Future growth would impose significant added responsibilities on members of management, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identifying, recruiting, integrating, maintaining and motivating additional employees; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">managing our development efforts effectively, including the clinical and FDA or comparable foreign regulatory authorities review process for our current product candidates and any future product candidates, while complying with our contractual obligations to contractors and other third parties; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developing and managing our internal manufacturing operations effectively and in a cost-effective manner while increasing production capabilities for our product candidates to commercial levels; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">identifying and establishing additional facilities for our operations; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">improving our operational, financial and management controls, reporting systems and procedures. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future financial performance and our ability to commercialize our product candidates, if approved, will depend, in part, on our ability to effectively manage any future growth. Our management may have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services, including contract manufacturers and companies focused on antibody development and discovery activities. The services of independent organizations, advisors and consultants may not continue to be available to us on a timely or cost-efficient basis when needed, and we may not be able to find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality, accuracy or quantity of the services provided is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain, or may be substantially delayed in obtaining, regulatory approval of our product candidates or otherwise advance our business. We may not be</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">47</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are not able to effectively expand our organization by hiring new employees, consultants and contractors as necessary, we may not be able to successfully implement the tasks necessary to further develop and commercialize our current or any future product candidates, if approved, and, accordingly, may not achieve our research, development and future commercialization goals, which could adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we lose key management or other scientific or medical personnel, or if we fail to recruit additional highly skilled personnel, our business, results of operations and financial condition could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our executive officers and other members of our management team, including our President and Chief Executive Officer, Sammy Farah, M.B.A., Ph.D. We do not currently maintain &#8220;key person&#8221; life insurance on the lives of our executives or any of our employees. This lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals. The loss of the services of any of our executive officers or other members of our management team, including our scientific and medical personnel, and our inability to find suitable replacements in a timely manner could result in delays in product development and adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We conduct our operations at our facility in San Diego, California. This region is headquarters to many other biopharmaceutical and biotechnology companies and many academic and research institutions. Competition for skilled personnel in our industry is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options that vest over time. The value to employees of stock options that vest over time may be significantly affected by movements in our stock price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Generally, employment agreements with our key employees provide for at-will employment, which means that such employee could leave our employment at any time, with or without notice. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior scientific and medical personnel.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our internal information technology systems, or those of our third-party CROs, CMOs and other contractors and consultants, may fail or suffer security breaches, loss or leakage of data and other disruptions, which could result in a material disruption of our development programs, compromise sensitive information related to our business or prevent us from accessing critical information, potentially exposing us to liability, and could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are increasingly dependent upon information technology systems to operate our business. In the ordinary course of business, we collect, store and transmit confidential information (including, but not limited to, intellectual property, confidential and proprietary business information and personal information). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of all such information. We also have outsourced elements of our operations to third parties, and as a result we manage a significant number of third-party contractors who have access to our confidential information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Despite the implementation of security measures, given the size and complexity and the increasing amounts of confidential information that our information technology systems maintain, such systems and those of our third-party CROs, and CMOs and other contractors and consultants are potentially vulnerable to attack, breakdown, damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, contractors, consultants, business partners and/or other third parties, or from cyberattacks by malicious third parties (including the deployment of harmful malware, ransomware, malicious code, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information), which may compromise our information technology system infrastructure or lead to data leakage. We may face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">48</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and reputational damage and the further development and future commercialization of our current product candidates or any future product candidates could be delayed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We and certain of our service providers are from time to time subject to cyberattacks and security incidents. While we do not believe that we have experienced any significant system failure, accident or security breach, our data protection efforts and our investment in information technology may not in the future prevent significant cyber incidents in our systems and those of our third-party CROs and CMOs and other contractors and consultants that could adversely affect our business, results of operations and financial condition. For example, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs and the development of our product candidates could be delayed. In addition, the loss of clinical trial data for any of our product candidates could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. Furthermore, significant disruptions of or security breaches in our internal information technology systems and those of our third-party CROs and CMOs and other contractors and consultants could result in the loss, misappropriation and/or unauthorized access, use, or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information and personal information), which could result in financial, legal, business and reputational harm to us. For example, any such event that leads to unauthorized access, use, or disclosure of personal information, including personal information regarding our clinical trial subjects or employees, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages that could adversely affect our business, results of operations and financial condition. Further, we do not currently maintain cybersecurity liability insurance coverage.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to the risk of employee fraud or other illegal activity by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to (1) comply with the laws of the FDA or comparable foreign regulatory authorities, (2) provide true, complete and accurate information to the FDA or comparable foreign regulatory authorities, (3) comply with manufacturing standards we have established, (4) comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws, or (5) report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA or comparable foreign regulatory authorities&#8217; approval of any of our product candidates and begin commercializing those products in the United States or abroad, our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. These laws may impact, among other things, our current activities with principal investigators and research patients, as well as proposed and future sales, marketing and education programs. It is not always possible to identify and deter misconduct by our employees, independent contractors, consultants, commercial partners and vendors. The precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in any of the following: the imposition of civil, criminal and administrative penalties, damages, monetary fines, individual imprisonment, disgorgement, possible exclusion from participation in government healthcare programs, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings and the curtailment of our operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">49</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit future commercialization of our product candidates, if approved, which could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face an inherent risk of product liability as a result of testing our product candidates, including our current and any of our future product candidates in clinical trials and will face an even greater risk if we commercialize any products, if approved. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical trials, manufacturing, marketing or sale. Any such product liability claims could include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims also could be asserted under state consumer protection acts. Product liability claims could delay or prevent completion of our development programs. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit future commercialization of our product candidates, if approved. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">inability to bring a product candidate to the market, if approved; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">decreased demand for our products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injury to our reputation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">withdrawal of clinical trial participants and inability to continue clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">initiation of investigations by U.S. and foreign regulators; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">costs to defend the related litigation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">diversion of management&#8217;s time and our resources; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">substantial monetary awards or settlements to trial participants; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product recalls, withdrawals or labeling, marketing or promotional restrictions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">loss of revenue; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">exhaustion of any available insurance and our capital resources; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inability to commercialize any product candidate, if approved; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">decline in our stock price. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the future commercialization, if approved, of products we develop alone or with collaborators. We need to obtain additional insurance for clinical trials as our current pre-clinical and any future pre-clinical programs enter the clinical development phase. However, we may be unable to obtain, or may obtain on unfavorable terms, clinical trial insurance in amounts adequate to cover any liabilities from any of our clinical trials. Our insurance policies also may have various deductibles and exclusions, and we may be subject to a product liability claim for which we have no coverage. We may need to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, enforcing such indemnification provisions may cause diversion of management&#8217;s time and our resources and such indemnification may not be available or adequate should any claim arise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our research and development activities involve the use of biological and hazardous materials and produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials, which could cause an interruption of our future commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, this may not be the case and we may not eliminate the risk of accidental contamination or injury from these</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes or our future compliance. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against potential liabilities. Although we have environmental liability insurance for our San Diego facility as required by the related lease agreement, we do not currently carry specific biological waste or hazardous waste insurance coverage, workers compensation or property and casualty and general liability insurance policies that include coverage for damages and fines arising from biological or hazardous waste exposure or contamination.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our insurance policies may be inadequate and potentially expose us to unrecoverable risks.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have limited director and officer insurance and commercial insurance policies. Any significant insurance claims would have a material adverse effect on our business, results of operations and financial condition. Insurance availability, coverage terms and pricing continue to vary with market conditions. We endeavor to obtain appropriate insurance coverage for insurable risks that we identify; however, we may fail to correctly anticipate or quantify insurable risks, we may not be able to obtain appropriate insurance coverage, and insurers may not respond as we intend to cover insurable events that may occur. We have observed rapidly changing conditions in the insurance markets relating to nearly all areas of traditional corporate insurance. Such conditions have resulted in higher premium costs, higher policy deductibles and lower coverage limits. For some risks, we may not have or maintain insurance coverage because of cost or availability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our operations are concentrated in one location, and we or the third parties upon whom we depend may be adversely affected by earthquakes, pandemics or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current operations are predominantly located in San Diego, California. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, health epidemic, power shortage, telecommunication failure or other natural or manmade accidents or incidents that result in us being unable to fully utilize our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our product candidates or interruption of our business operations. Earthquakes, pandemics or other natural disasters could further disrupt our operations and have a material and adverse effect on our business, results of operations and financial condition. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research facilities or the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, the amounts of insurance may not be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities of our third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed and our clinical trials may be delayed. Any business interruption may adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">51</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Research and Development</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The successful development of biopharmaceuticals is highly uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The successful development of biotechnology is highly uncertain and is dependent on numerous factors, many of which are beyond our control. Product candidates that appear promising in the early phases of development may fail to reach the market for several reasons including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preclinical study results may show the product candidate to be less effective than desired or to have harmful or problematic side effects; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical trial results may show the product candidates to be less effective than expected (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">e.g.,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> a clinical trial could fail to meet its primary endpoint(s)), to have unacceptable side effects or toxicities or to have effects in humans that differ from previously observed effects in lab animals; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">failure to receive the necessary regulatory approvals or a delay in receiving such approvals. Among other things, such delays may be caused by slow enrollment in clinical trials, patients withdrawing from clinical trials, length of time to achieve trial endpoints, additional time requirements for data analysis, or BLA, or comparable foreign application, preparation, discussions with the FDA or comparable foreign regulatory authorities and any such request for additional preclinical or clinical data, or unexpected safety or manufacturing issues or failures; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacturing costs, formulation issues, pricing or reimbursement issues, or other factors that make a product candidate uneconomical; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the proprietary rights of others and their competing products and technologies that may prevent or otherwise make it uneconomical for one or more of our product candidates from being commercialized, if approved. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The length of time necessary to complete clinical trials and to apply for marketing approval for a final decision by a regulatory authority varies significantly from one product candidate to the next and may be difficult to predict. Even if we are successful in getting market approval, commercial success of any approved products also will depend in large part on the availability of coverage and adequate reimbursement from third-party payors, including government payors such as the Medicare and Medicaid programs, commercial insurers, and managed care organizations, which may be affected by existing and future healthcare reform measures designed to reduce the cost of healthcare. Third-party payors could require us to conduct additional studies, including post-marketing studies related to the cost effectiveness of a product, to qualify for reimbursement, which could be costly and divert our resources. If third-party payors were to decide to not provide coverage and adequate reimbursement levels for any of our products, if approved, market acceptance and commercial success would be reduced.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, if any of our product candidates are approved for marketing, we will be subject to significant regulatory obligations regarding the submission of safety and other post-marketing information and reports and registration, and will need to continue to comply (or ensure that our third-party providers comply) with cGMPs or similar foreign requirements and good clinical practices, or GCPs, for any clinical trials that we conduct post-approval. GCPs are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, clinical investigators and trial sites. In addition, there always is the risk that we or a regulatory authority might identify previously unknown problems with a product post-approval, such as adverse events of unanticipated severity or frequency. Compliance with these requirements is costly, and any failure to comply or other issues with our product candidates following approval, if any, could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical development involves a lengthy and expensive process, with uncertain outcomes. We may incur significant costs and/or experience delays in completing, or ultimately be unable to complete, the development of our current and future product candidates, including our lead product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To obtain the requisite regulatory approvals to commercialize any product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our product candidates are safe, pure and potent or effective in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Differences in trial design between early-stage clinical trials and later-stage clinical trials make it difficult to extrapolate the results of earlier clinical trials to later clinical trials. Moreover, clinical data often are susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in clinical trials have nonetheless failed to obtain marketing approval of their products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">52</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Successful completion of clinical trials is a prerequisite to submitting a BLA, to the FDA, a Marketing Authorization Application, or MAA, to the European Medicines Agency, or EMA, and similar marketing applications to comparable foreign regulatory authorities, for each product candidate and, consequently, the ultimate approval and commercial marketing of any product candidates. We do not know whether any of our clinical trials will be completed on schedule, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may experience delays in initiating or completing clinical trials. We also may experience numerous unforeseen events during, or as a result of, any future clinical trials that we could conduct that could delay or prevent our ability to receive marketing approval or commercialize our current product candidates or any future product candidates, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulators or institutional review boards, or IRBs, may not authorize or ethics committees may not issue favorable opinions permitting us or our investigators to commence or continue a clinical trial or conduct a clinical trial at a prospective trial site; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective CROs the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical trials of any product candidates may fail to show safety, purity or potency, or produce negative or inconclusive results and we may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials or we may decide to abandon product development programs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may experience manufacturing failures, including in our TIL selection process, resulting in a less effective product candidate in the tumor indications we are pursuing; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number of subjects required for clinical trials of any product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or subjects may drop out of these clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may elect to, or regulators, or IRBs or ethics committees may require that we or our investigators, suspend, vary, or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cost of clinical trials of any product candidates may be greater than we anticipate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate to initiate or complete a given clinical trial; for example, the process development for TILs is very complicated and requires significant logistics, and any issues with this process could delay our trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators, or IRBs or ethics committees to suspend or terminate the trials, or reports from clinical testing of other therapies may raise safety or efficacy concerns about our product candidates; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may require us to submit additional data such as long-term toxicology studies, or impose other requirements before permitting us to initiate a clinical trial. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also could encounter delays if a clinical trial is suspended or terminated by us, the IRBs or ethics committees of the institutions in which such trials are being conducted, or the FDA or comparable foreign regulatory authorities, or recommended for suspension or termination by the Data Safety Monitoring Board, or DSMB, or foreign equivalent for such trial. A suspension or termination may be imposed by the FDA or comparable foreign regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product or treatment, failure to establish or achieve clinically meaningful trial endpoints, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials also may ultimately lead to the denial of regulatory approval of our product candidates. Further, the FDA or comparable foreign regulatory authorities may disagree with our clinical trial design and our interpretation of data from clinical trials, or may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">53</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product development costs will increase if we experience delays in clinical testing or marketing approvals. We do not know whether any of our clinical trials will need to be restructured or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates and may allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates and harming our business and results of operations. Any delays in our clinical development programs may adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the FDA&#8217;s and comparable foreign regulatory authorities&#8217; policies with respect to clinical trials may change and additional government regulations may be enacted. For instance, the regulatory landscape related to clinical trials in the European Union, or EU, evolved. The EU Clinical Trials Regulation, or CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. </span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The CTR allows sponsors to make a single submission to both the competent authority and an ethics committee in each EU Member State, leading to a single decision for each EU Member State. The assessment procedure for the authorization of clinical trials has been harmonized as well, including a joint assessment by all EU Member States concerned, and a separate assessment by each EU Member State with respect to specific requirements related to its own territory, including ethics rules. Each EU Member State&#8217;s decision is communicated to the sponsor via the centralized EU portal. Once the clinical trial approved, clinical study development may proceed. The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies.  For clinical trials in relation to which application for approval was made on the basis of the Clinical Trials Directive before January 31, 2023, the Clinical Trials Directive will continue to apply on a transitional basis until</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> January 31, 2025</span><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. By that date, all ongoing trials will become subject to the provisions of the CTR. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The CTR will apply to clinical trials from an earlier date if the related clinical trial application was made on the basis of the CTR or if the clinical trial has already transitioned to the CTR framework before January 31, 2025. Compliance with the CTR requirements by us and our third-party service providers, such as CROs, may impact our developments plans.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In light of the entry into application of the CTR on January 31, 2022, we may be required to transition clinical trials for which we have obtained regulatory approvals in accordance with the CTD to the regulatory framework of the CTR. Transition of clinical trials governed by the CTD to the CTR will be required for clinical trials which will have at least one site active in the E.U. on January 30, 2025. A transitioning application would need to be submitted to the competent authorities of E.U. Member States through the Clinical Trials Information Systems and related regulatory approval obtained to continue the clinical trial past January 30, 2025. This would require financial, technical and human resources. If we are unable to transition our clinical trials in time, the conduct of those clinical trials may be negatively impacted</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The regulatory framework in the United Kingdom, or UK, in relation to clinical trials is derived from existing EU legislation (as implemented into UK law, through secondary legislation). On January 17, 2022, the UK Medicines and Healthcare products Regulatory Agency, or MHRA, launched an eight-week consultation on reframing the UK legislation for clinical trials. The consultation closed on March 14, 2022. The reframe aims to streamline clinical trials approvals, enable innovation, enhance clinical trials transparency, enable greater risk proportionality, and promote patient and public involvement in clinical trials. On March 21, 2023, the MHRA published the outcome of the consultation with its responses confirming that it would bring forward changes to the legislation. These resulting legislative amendments will determine how closely the UK regulations will align with the CTR. Failure of the UK to closely align its regulations with the EU may have an effect on the cost of conducting clinical trials in the UK as opposed to other countries and/or make it harder to seek a marketing authorization for the Company's product candidates on the basis of clinical trials conducted in the United Kingdom.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preclinical development is uncertain. Our preclinical programs may experience delays or generate unfavorable data, and may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all, and any of these events would adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before we can commence clinical trials for any product candidate in our preclinical programs, we must complete extensive preclinical studies that support our planned INDs in the United States, or similar applications in other jurisdictions. Our preclinical studies may not be completed on a timely basis and have an unfavorable outcome, and the FDA and comparable foreign regulatory authorities may not accept our proposed clinical programs, or the outcome of our preclinical studies may not ultimately support the further development of our preclinical programs. As a result, we may not be able to submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and submission of INDs or similar applications may not result in the FDA or comparable foreign regulatory authorities allowing clinical trials to begin.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">54</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our product candidates are based on a novel approach to the treatment of cancer, which makes it difficult to predict the time and cost of product candidate development.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have concentrated substantially all of our recent research and development efforts on product candidates based on our Selected TIL approach, and our future success depends largely on the successful development of these approaches. Any development problems we experience in the future may cause significant delays or unanticipated costs, and such development problems may not be solved. Should we encounter development problems, including unfavorable preclinical or clinical trial results, the FDA and comparable foreign regulatory authorities may refuse to authorize us to conduct additional clinical trials, and even if they do, they may not approve our product candidates, or may require additional information, tests, or trials, which could significantly delay product development and significantly increase our research and development costs. Moreover, even if we are able to provide to the FDA or comparable foreign regulatory authorities the requested information or trials, the FDA or comparable foreign regulatory authorities may not accept them and may not approve our product candidates. We also may experience delays in developing a sustainable, reproducible and scalable manufacturing process, or developing or qualifying and validating product release assays, other testing and manufacturing methods, and our equipment and facilities in a timely manner. This may prevent us from completing our clinical trials or commercializing our product candidates on a timely or profitable basis, if at all.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the clinical trial requirements of the FDA and comparable foreign regulatory authorities and the criteria these regulators use to evaluate the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The FDA and comparable foreign regulatory authorities have limited experience with the approval of Selected TIL immunotherapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The manufacture of our product candidates is complex, and we may encounter difficulties in production, particularly with respect to process development, quality control, or scaling-up of any future manufacturing capabilities. If we, or any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates are biologics and the process of manufacturing our product candidates is complex, highly regulated and subject to multiple risks. The manufacture of our product candidates involves complex processes, including harvesting tumor fragments from patients, isolating the T-cells from the tumor fragments, multiplying the T-cells to obtain the desired dose, and ultimately infusing the T-cells back into a patient. As a result of the complexities, the cost to manufacture biologics is generally higher than traditional small molecule chemical compounds, and the manufacturing process is less reliable and is more difficult to reproduce. Further, as a result of the complexities, we may not be able to successfully manufacture Selected TILs, which could result in any of our product candidates not being differentiated from a bulk TIL product, and as a result, any of our product candidates may not be effective in the tumor indications that we are pursuing. Moreover, our manufacturing process is susceptible to product loss or failure due to logistical issues associated with the collection of tumor fragments, or starting material, from the patient, shipping such material to the manufacturing site, shipping the final product back to the patient, and infusing the patient with the product, manufacturing issues associated with the differences in patient starting material, interruptions in the manufacturing process, contamination, equipment failure, assay failures, improper installation or operation of equipment, vendor or operator error, inconsistency in cell growth, meeting pre-specified release criteria, and variability in product characteristics. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects, and other supply disruptions. If for any reason we lose a patient&#8217;s starting material, or later developed product at any point in the process, or if any product does not meet the applicable specifications, the manufacturing process for that patient will need to be restarted, including resection of the proper amount of tumor fragment and the resulting delay may adversely affect that patient&#8217;s outcome. If microbial, viral, environmental or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because our product candidates are manufactured specifically for each individual patient, we will be required to maintain a chain of identity with respect to the patient&#8217;s tumor as it moves from the patient to the manufacturing facility, through the manufacturing process, and back to the patient. Maintaining such a chain of identity is difficult and complex, and failure to do so could result in adverse patient outcomes, loss of product, or regulatory action including withdrawal of our products from the market. Further, as product candidates are developed through preclinical studies to late-stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered along the way to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials or otherwise necessitate the conduct of additional studies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a result of these challenges, we may experience delays in our clinical development and/or commercialization plans, if approved. Furthermore, we may ultimately be unable to reduce the cost of goods for our product candidates to levels that will allow for an attractive return on investment if and when those product candidates are commercialized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">55</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The manufacture of cell therapy products requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of cell therapy products often encounter difficulties in production, particularly in scaling up initial production. These problems include difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel, and compliance with strictly enforced federal, state, local and foreign regulations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Externally, to support both TIDAL-01 and TIDAL-02, we have formed deep partnerships across a global network of contract development and manufacturing organizations, or CDMOs, that specialize in bioprocess development, testing, cGMP manufacturing, formulation and filling, packaging, controlled temperature storage, and distribution. For TIDAL-01, this includes a close partnership with the Cell Therapy Facility at Moffitt Cancer Center, responsible for cGMP manufacturing, testing, release, and distribution of Selected TIL to the clinical investigators at Moffitt under our investigator sponsored clinical trial. We have separate partnerships, fully controlled and supervised by us, for the sequencing and peptide manufacturing portions of the TIDAL-01 manufacturing process. In parallel, we have completed a technology transfer of the TIDAL-01 Selected TIL manufacturing process to a U.S.-based CDMO, Charles River Laboratories. Any problems or delays we, Moffitt or our CDMOs experience in preparing for commercial scale manufacturing of a product candidate or component may result in a delay in the FDA or comparable foreign regulatory authority approval of the product candidate or may impair our ability to manufacture commercial quantities or such quantities at an acceptable cost, which could result in the delay, prevention, or impairment of clinical development and commercialization of our product candidates, if approved, and could adversely affect our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, we may not succeed in maintaining our relationships with our current CDMOs or establishing relationships with additional or alternative CDMOs. Our product candidates may compete with other products and product candidates for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that are both capable of manufacturing for us and willing to do so. If our CDMOs should cease manufacturing for us, we would experience delays in obtaining sufficient quantities of our product candidates for clinical trials and, if approved, commercial supply. Further, our CDMOs may breach, terminate, or not renew its agreements with us. If we were to need to find alternative manufacturing facilities it would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. The commercial terms of any new arrangement could be less favorable than our existing arrangements and the expenses relating to the transfer of necessary technology and processes could be significant.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are ultimately responsible for the manufacture of our product candidates. A failure to comply with these requirements may result in regulatory enforcement actions against our manufacturers or us, including fines and civil and criminal penalties, which could result in imprisonment, suspension or restrictions of production, injunctions, delay or denial of product approval or supplements to approved products, clinical holds or termination of clinical trials, warning or untitled letters, regulatory authority communications warning the public about safety issues with the biologic, refusal to permit the import or export of the products, product seizure, detention, or recall, operating restrictions, suits under the civil False Claims Act, corporate integrity agreements, consent decrees, or withdrawal of product approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidate, impair commercialization efforts, increase our cost of goods, and have an adverse effect on our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cell-based therapies and biologics rely on the availability of reagents, specialized equipment, and other specialty materials, which may not be available to us on acceptable terms or at all. For some of these reagents, equipment, and materials, we rely or may rely on sole source vendors or a limited number of vendors, which could impair our ability to manufacture and supply our products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturing our product candidates requires many reagents, which are substances used in our manufacturing processes to bring about chemical or biological reactions, and other specialty materials and equipment, some of which are manufactured or supplied by small companies with limited resources and experience to support commercial biologics production. We currently depend on a limited number of vendors for certain materials and equipment used in the manufacture of our product candidates. Some of these suppliers may not have the capacity to support clinical trials and commercial products manufactured under cGMPs by biopharmaceutical firms or may otherwise be ill-equipped to support our needs. We also do not have supply contracts with many of these suppliers and may not be able to obtain supply contracts with them on acceptable terms or at all. Accordingly, we may experience delays in receiving key materials and equipment to support clinical or commercial manufacturing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">56</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For some of these reagents, equipment, and materials, we rely and may in the future rely on sole source vendors or a limited number of vendors. An inability to continue to source product from any of these suppliers, which could be due to a number of issues, including regulatory actions or requirements affecting the supplier, adverse financial or other strategic developments experienced by a supplier, labor disputes or shortages, unexpected demands, or quality issues, could adversely affect our ability to satisfy demand for our product candidates, which could adversely and materially affect our product sales and operating results or our ability to conduct clinical trials, either of which could significantly harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in product candidate manufacturing, formulation or analytical methods may result in additional costs or delay, which could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As product candidates are developed through preclinical studies to later-stage clinical trials towards approval and future commercialization, it is common that various aspects of the development program, such as manufacturing methods, formulation or analytical methods, are altered throughout the development process in an effort to optimize processes and results. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials or utilizing different analytical methods. Such changes also may require additional testing, or notification to, or authorization by the FDA or a comparable foreign regulatory authority. This could delay completion of clinical trials, require the conduct of bridging clinical trials or studies, require the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and/or jeopardize our ability to commence product sales and generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of our product candidates could be associated with side effects, adverse events or other properties or safety risks, which could cause us to suspend or discontinue clinical trials, abandon a product candidate, delay or preclude approval, prevent market acceptance, limit the commercial profile of an approved label or result in other significant negative consequences that could severely harm our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Before obtaining regulatory approvals for the commercial sale of any of our products, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our current product candidates, including our lead product candidates, and any future product candidate are both safe, pure and potent, or effective for use in such product candidate&#8217;s target indication. Clinical testing is expensive, can take many years to complete and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product candidates in later stages of clinical trials may fail to generate desired safety and efficacy data despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence clinical trials are never approved and there can be no assurance that any of our clinical trials will ultimately be successful or support further clinical development of our current product candidates or any of our future product candidates or ultimately their approval.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, results of operations and financial condition significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our product candidates are associated with undesirable side effects or have unexpected characteristics in preclinical studies or clinical trials we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial, or result in potential product liability claims. Any of these occurrences may prevent us from achieving or maintaining market acceptance of the affected product candidate and may harm our business, results of operations and financial condition significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patients in our ongoing and planned clinical trials may in the future suffer significant adverse events or other side effects not observed in our preclinical studies or previous clinical trials. In addition, if our product candidates are used in combination with other therapies, our product candidates may exacerbate adverse events associated with the therapy. Patients treated with our product candidates may also be undergoing surgical, radiation or chemotherapy treatments, which can cause side effects or adverse events that</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">57</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">are unrelated to our product candidate, but may still impact the success of our clinical trials. The inclusion of critically ill patients in our clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using or due to the gravity of such patients&#8217; illnesses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If significant adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting patients to the clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of that product candidate altogether. We, the FDA, other comparable foreign regulatory authorities or an IRB or ethics committee may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance due to its tolerability versus other therapies. Any of these developments could materially harm our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, if any of our product candidates receives regulatory approval, and we or others later identify undesirable side effects caused by such product, a number of potentially significant negative consequences could result. For example, the FDA could require us to adopt a Risk Evaluation and Mitigation Strategy, or REMS, to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a communication plan to health care practitioners, patient education, extensive patient monitoring or distribution systems and processes that are highly controlled, restrictive and more costly than what is typical for the industry. Other potentially significant negative consequences include that:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be forced to suspend marketing of that product, or decide to remove the product from the marketplace, if approved; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may withdraw or change their approvals of that product; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">regulatory authorities may require additional warnings on the label or limit access of that product to selective specialized centers with additional safety reporting and with requirements that patients be geographically close to these centers for all or part of their treatment; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to create a medication guide outlining the risks of the product for patients, or to conduct post-marketing studies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be required to change the way the product is administered; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we could be subject to fines, injunctions, or the imposition of criminal or civil penalties, or be sued and held liable for harm caused to subjects or patients; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the product may become less competitive, and our reputation may suffer. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any of these events could diminish the usage or otherwise limit the commercial success of our product candidates and prevent us from achieving or maintaining market acceptance of the affected product candidate, if approved by applicable regulatory authorities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected, which could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. The enrollment of patients depends on many factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the patient eligibility and exclusion criteria defined in the protocol; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the proximity of patients to trial sites; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the design of the trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain and maintain patient consents; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the risk that patients enrolled in clinical trials will withdraw from the trials before completion. </span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">58</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, our clinical trials will compete with other clinical trials for patient participation for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. For example, we will compete with various other cancer therapies including combinations studies. Public perception of TIL-based immunotherapies also may adversely influence willingness of subjects to participate in clinical trials. Furthermore, because the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such sites.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, if we implement improvements to our manufacturing process, we may decide to slow or limit enrollment while we are implementing such improvements. While we would expect such implementation to only be temporary, any resulting enrollment delays may adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our future clinical trials, which could prevent completion of these trials and adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interim, initial, "top-line" and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data, and results in one indication may not be predictive of results to be expected for the same product candidate in another indication.*</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may publicly disclose preliminary or topline data from our clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the topline or preliminary data we previously published. As a result, topline and preliminary data should be viewed with caution until the final data are available.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From time to time, we may also disclose initial or interim data from our clinical trials, such as the initial clinical update for our TIDAL-01 trial. Initial or interim data from these trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as subject enrollment continues and more data become available, or that results in one indication may be materially different in another indication for the same product candidate.  If later-stage clinical trials do not produce favorable results, our ability to achieve regulatory approval for any of our product candidates may be adversely impacted.  Even if clinical trials show promising early results, clinical trials of the same product candidate in another indication may fail to show similar results, and market acceptance of our product candidate, if approved, may be limited. Adverse differences between interim or initial data and top-line, preliminary, or final data could significantly harm our business prospects. Further, disclosure of interim or initial data by us or by our competitors could result in volatility in the price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, others, including regulatory authorities, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product, and our company in general. In addition, the information we choose to publicly disclose regarding a particular clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the interim, initial, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize our product candidates may be harmed, which could harm our business, results of operations or financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Due to our limited resources and access to capital, we must prioritize development of certain programs and product candidates; these decisions may prove to be wrong and may adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because we have limited financial and human resources, we intend to initially focus on research programs and product candidates for a limited set of indications. For example, we are initially focused on the development of our lead Selected TIL product candidate TIDAL-01 in colorectal cancer, head and neck cancer, and uveal melanoma. Because TIL therapy is a relatively new and expanding area of novel therapeutic interventions, there are many uncertainties related to development, marketing, reimbursement and the commercial potential for our product candidates. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success. Our</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">59</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may for a number of reasons fail to identify viable new product candidates for clinical development from our current or future research programs. If we fail to identify additional potential product candidates, our business, results of operations and financial condition could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Research programs to pursue the development of our existing and planned product candidates for additional indications and to identify new product candidates and disease targets require substantial technical, financial and human resources whether they are ultimately successful or not. Our research programs may initially show promise in identifying potential indications and/or product candidates, yet fail for a number of reasons to yield results for clinical development, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the research methodology used may not be successful in identifying potential indications and/or product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">potential product candidates may, after further study, be shown to have harmful adverse effects or other characteristics that indicate they are unlikely to be effective products against the indicated disease; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it may take greater human and financial resources than we will possess to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, thereby limiting our ability to develop, diversify and expand our product portfolio. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, we may never be able to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, which could materially adversely affect our future growth and prospects. We may focus our efforts and resources on potential product candidates or other potential programs that ultimately prove to be unsuccessful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may seek orphan drug designation for our product candidates, but we may be unable to obtain such designation or to obtain or maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our product revenue, if any, to be reduced.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Regulatory authorities in some jurisdictions, including the United States and the EU, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a biologic as an orphan drug if it is intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population of 200,000 or more in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, orphan drug designation entitles a party to financial incentives such as tax advantages and user fee waivers. Opportunities for grant funding toward clinical trial costs may also be available for clinical trials of drugs or biologics for rare diseases, regardless of whether the biologics are designated for the orphan use. In addition, if a biologic with an orphan drug designation subsequently receives the first marketing approval for the disease or condition for which it has such designation, the product is entitled to a seven-year period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug for the same disease or condition for that time period, except in limited circumstances. If our competitors are able to obtain orphan drug exclusivity prior to us, for products that constitute the &#8220;same drug&#8221; and treat the same diseases or conditions as our product candidates, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, the European Commission, following a related opinion of the EMA Committee for Orphan Medicinal Products, may grant orphan drug designation for medicinal products to be developed (i) for the diagnosis, prevention or treatment of diseases that are life-threatening or chronically debilitating, for which (ii) either (a) such conditions affect not more than 5 in 10,000 persons in the EU when the application is made, or (b) the product without the benefits derived from orphan status, would not generate sufficient return in the EU to justify the necessary investment in developing the medicinal product; and (iii) there exists no satisfactory authorized method of diagnosis, prevention, or treatment of the condition that has been authorized in the EU, or even if such method exists, the product will be of significant benefit to those affected by that condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a drug with orphan designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug may be entitled to a period of marketing exclusivity. This precludes the FDA or the EMA from accepting another marketing application for the same drug or, in the case of the EMA, accept an application to extend for a similar product and the European Commission cannot grant a marketing authorization, for the same indication during this time period. The applicable</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">60</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">period is seven years in the United States and ten years in the EU. The period which may be extended by six months in the United States and two years in the EU for products that have complied with the respective regulatory authority&#8217;s agreed upon pediatric investigation plan. The exclusivity period in the EU can be reduced to six years if at the end of the fifth year a drug no longer meets the criteria for orphan drug designation, including where it can be demonstrated on the basis of available evidence that  the drug is sufficiently profitable that market exclusivity is no longer justified or where the prevalence of the condition has increased above the threshold.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may seek orphan designation for certain of our product candidates. However, we may be unsuccessful in obtaining orphan drug designation for these and may be unable to maintain the benefits associated with orphan drug designation, even if we do obtain such designation. Even if we obtain orphan drug designation and obtain orphan drug exclusivity for any of our product candidates, that exclusivity may not effectively protect those product candidates from competition because different products can be approved for the same disease or condition. Even after an orphan drug is granted orphan exclusivity and approved, the FDA can subsequently approve a later application for the same drug for the same disease or condition before the expiration of the seven-year exclusivity period if the FDA concludes that the later drug is clinically superior in that it is shown to be safer in a substantial portion of the target populations, more effective or makes a major contribution to patient care. Similarly, the European Commission can approve a similar drug for the same therapeutic indication during the 10-year-exclusivity if the original applicant consents thereto, if the manufacturer of the original orphan medicinal product is unable to supply sufficient quantities of the drug in the EU, or if the similar product is demonstrated to be safer, more effective or otherwise clinically superior to ours. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Moreover, orphan-drug-exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to manufacture sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may attempt to secure approval from the FDA or comparable foreign regulatory authorities through the use of accelerated approval pathways. If we are unable to obtain such approval, we may be required to conduct additional clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA or comparable foreign regulatory authorities, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA or comparable foreign regulatory authorities may seek to withdraw accelerated approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may in the future seek an accelerated approval for our one or more of our product candidates. However, because our product candidates are in early development, there can be no assurance that the FDA would approve any form of application for expedited review for any of our product candidates. Under the accelerated approval program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful clinical benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product&#8217;s clinical benefit. If such post-approval studies fail to confirm the product&#8217;s clinical benefit, the FDA may withdraw its approval. Furthermore, the FDA&#8217;s accelerated approval pathways do not guarantee an accelerated review by the FDA, and even if our product candidates could be granted a designation or qualify for expedited development, it would not increase the likelihood that such product candidate will receive FDA approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the EU, under the centralized procedure, the EMA&#8217;s Committee for Medicinal Products for Human Use may perform an accelerated assessment of a marketing authorization application. Applicants requesting an accelerated assessment procedure must justify that the product candidate targeting an unmet medical need is expected to be of major public health interest, particularly from the point of view of therapeutic innovation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to seeking accelerated approval for any of our product candidates, we intend to seek feedback from the FDA or similar foreign regulatory authorities and will otherwise evaluate our ability to seek and receive accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit a BLA or similar application</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">61</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">for accelerated approval or any other form of expedited development or review. Similarly, there can be no assurance that after subsequent FDA or similar foreign regulatory authorities&#8217; feedback we will continue to pursue or apply for accelerated approval or any other form of expedited development or review, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval or other expedited development or review for our product candidates, there can be no assurance that such submission or application will be accepted or that any expedited development or review will be granted on a timely basis, or at all. The FDA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development or review for our product candidate would result in a longer time period to commercialization of such product candidate, if any, could increase the cost of development of such product candidate, and could harm our competitive position in the marketplace.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The FDA and other regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA and other foreign regulatory authorities strictly regulate the promotional claims that may be made about prescription products, such as our product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other foreign regulatory authorities as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The government has also required companies to enter into consent decrees or imposed permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to the Biotechnology Industry</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We face significant competition and if we fail to compete effectively, our business, results of operations and financial condition could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The biotechnology and pharmaceutical industries are characterized by intense competition, fierce defense of intellectual property and rapidly advancing technologies. Our competitors may be able to develop other therapies or drugs that are able to achieve similar or better results than our product candidates. Our competitors include major pharmaceutical, specialty pharmaceutical and existing or emerging biotechnology companies, academic institutions, governmental agencies, and public and private research institutions. Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations and well-established sales forces, and other biopharmaceutical companies may compete by establishing collaborative arrangements with these large companies. Smaller or early-stage companies also may prove to be significant competitors, particularly as they develop novel approaches to treating disease indications that our product candidates also are focused on treating. Established biotechnology companies may also invest heavily to accelerate discovery and development of novel therapeutics or to in-license novel therapeutics that could make the product candidates that we develop obsolete. Mergers and acquisitions in the biotechnology industry may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors, either alone or with collaborative partners, may succeed in developing, acquiring or licensing on an exclusive basis drug or biologic products that are more effective, safer, more easily commercialized or less costly than our product candidates or may develop proprietary technologies or secure patent protection that we may need for the development of our technologies and products. We believe the key competitive factors that will affect the development and commercial success of our product candidates are efficacy, safety, tolerability, reliability, durability, convenience of use, price and reimbursement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We anticipate competing with other companies that are focused on treating disease indications that our product candidates also are focused on treating. A competitor may develop technologies focused on the same disease pathway as our technology or may focus on treating the targeted disease in a completely different manner. Our competitors may also seek and obtain patent rights to their technologies that are similar to ours, and such patent rights may in the future affect the direction of our product development or require us to negotiate a license to such patent rights. To the extent a new drug is developed by a competitor that is more efficacious than any product candidate developed by us, this could reduce or negate the need for our product candidate. In addition, while we believe our product candidates may be used in conjunction with existing or emerging standard of care in certain disease indications, as companies continue to improve upon existing standards of care, more efficacious drug therapies could become available, reducing or completely negating the benefit of our product candidates. Our competitors also may include companies that are or will be developing therapies for the same therapeutic areas that we are targeting within our early pipeline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">62</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face competition from segments of the pharmaceutical, biotechnology and other related markets that pursue the development of TIL or other cell therapies for the treatment of solid tumors. Our competitors include, among others:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">companies with approved TIL therapies like Iovance Biotherapeutics, Inc. or those that are developing TIL therapies such as Achilles Therapeutics plc, Instil Bio, Inc., KSQ Therapeutics, Inc., Lyell Immunopharma, Inc., Obsidian Therapeutics, Inc., Intima Bioscience, Inc. and others; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">companies focused on CAR-T and TCR-T cell therapies for solid-tumors, such as Adaptimmune Therapeutics PLC, Adicet Bio, Inc., Alaunos Therapeutics, Inc., Atara Biotherapeutics, Inc., and Immatics N.V. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, we are aware of other privately held biotechnology companies are evaluating neoantigen directed T cell approaches. Further, there are companies utilizing other cell-based approaches that may be competitive to our product candidates. More effective small molecules, cancer vaccines and other approaches may be developed and used as first line or second line treatments, which would reduce the opportunity for our Selected TIL therapies. Furthermore, we also face competition more broadly across the oncology market for cost-effective and reimbursable cancer treatments.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The most common methods of treating patients with cancer are surgery, radiation, and drug therapy, including chemotherapy, hormone therapy, biologic therapy, such as monoclonal and bispecific antibodies, immunotherapy, cell-based therapy and targeted therapy, or a combination of any such methods. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. While our Selected TIL product candidates, if any are approved, may compete with these existing drugs and other therapies, to the extent they are ultimately used in combination with or as an adjunct to these therapies, our Selected TIL product candidates may not be competitive with them.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Even if we obtain regulatory approval of our product candidates, the availability and price of our competitors&#8217; products as well as limits on health insurance reimbursements for our product candidates could limit the demand and the price we are able to charge for our product candidates. We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug or biologic products or choose to reserve our product candidates for use in limited circumstances. We believe our ability to successfully compete will depend on our ability to rapidly develop new product candidates, manufacture product supply, successfully enroll patients in clinical trials, gain regulatory approval in target indications, establish collaborations, successfully market and commercialize, and secure and protect intellectual property rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Negative developments in the fields of immuno-oncology and TIL-based immunotherapy could damage public perception of our product candidates and adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The commercial success of our product candidates will depend in part on public acceptance of the use of cancer immunotherapies and TIL-based immunotherapies. Adverse events in clinical trials of our product candidates or in clinical trials of others developing similar products and the resulting publicity, as well as any other negative developments in the field of immuno-oncology and TIL-based immunotherapy that may occur in the future, could result in a decrease in demand for any product candidates that we may develop. These events also could result in the suspension, discontinuation, or clinical hold of or modification to our clinical trials. If public perception is influenced by claims that the use of cancer immunotherapies and TIL-based immunotherapies is unsafe, whether related to our therapies or those of our competitors, our product candidates may not be accepted by the general public or the medical community and potential clinical trial subjects may be discouraged from enrolling in our clinical trials. As a result, we may not be able to continue or may be delayed in conducting our development programs.  For example, administration of certain approved CAR-T therapies has been associated with a risk of secondary malignancies.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Future negative developments in the field of immuno-oncology or the biotechnology industry also could result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approvals of our products. Any increased scrutiny could delay or increase the costs of obtaining marketing approval for any of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if a product candidate we develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success and any revenue that we generate from its sales could be limited.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have never commercialized a product candidate for any indication. If our current product candidates, including our lead product candidates, or any future product candidate we develop receives marketing approval, whether as a single agent or in combination with other therapies, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors, and others in the medical community. If the product candidates we develop do not achieve an adequate level of acceptance, we</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">63</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">may not generate significant product revenues and we may not become profitable. The degree of market acceptance of any of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">efficacy and potential advantages compared to alternative treatments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to offer our products, if approved, for sale at competitive prices; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">convenience and ease of administration compared to alternative treatments; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the strength of marketing and distribution support; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ability to obtain sufficient third-party payor coverage and adequate reimbursement; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the prevalence and severity of any side effects. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our product candidates, if approved, do not achieve an adequate level of market acceptance, our business, results of operations and financial condition may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The size of the potential commercial opportunities for our product candidates is difficult to estimate and, if any of our assumptions are inaccurate, the actual markets for our product candidates may be smaller than our estimates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The potential commercial opportunities for our product candidates are difficult to estimate and will depend in large part on the drugs with which our product candidates are co-administered and the success of competing therapies and therapeutic approaches. In particular, the commercial opportunity for TIL-based therapies is hard to estimate given that it is an emerging field with no approved TIL therapies. Our estimates of the potential commercial opportunities are predicated on many assumptions, which may include industry knowledge and publications, third-party research reports, and other surveys. The number of patients in the United States and other major markets and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our product candidates or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our business, results of operations and financial condition. Although we believe that our internal assumptions are reasonable, these assumptions involve the exercise of significant judgment on the part of our management, are inherently uncertain, and their reasonableness has not been assessed by an independent source. If any of the assumptions proves to be inaccurate, the actual markets for our product candidates could be smaller than our estimates of the potential commercial opportunities, which could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Reliance on Third Parties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have relied and expect to continue to rely on third parties to conduct certain aspects of our preclinical studies, to conduct our clinical trials and to conduct investigator sponsored clinical trials of our product candidates. If these third parties do not successfully carry out their contractual duties, meet expected deadlines, comply with regulatory requirements or terminate the relationship, we may not be able to obtain regulatory approval of or commercialize any potential product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We depend upon on a significant number of third parties, including independent investigators, to conduct certain aspects of our preclinical studies and our clinical trials under agreements with universities, medical institutions, CROs, strategic partners and others. Pursuant to our collaboration agreement with Moffitt, Moffitt&#8217;s TIDAL-01 IND utilizes product candidate produced by Moffitt, which will be supporting the trial with dedicated cleanroom capacity and manufacturing priority at its on-site facility for TIDAL-01 production. We also utilize CROs to manage certain aspects of our studies, which are conducted at third party clinical sites by third party investigators.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to need to negotiate budgets and contracts with such third parties, which may result in delays to our development timelines and increased costs. We will rely especially heavily on third parties over the course of our clinical trials, and, as a result, will have limited control over and limited visibility into their day-to-day activities, including with respect to their compliance with the clinical protocol. Nevertheless, we are responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with GCP requirements. Upon inspection, such regulatory authorities may determine that any of our clinical trials do not comply with the GCP requirements. If we or any of these third parties fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to suspend or terminate these trials or perform additional preclinical studies or clinical trials before approving our marketing applications if at all. In addition, our clinical trials must be conducted with biologic product produced under cGMP or similar foreign requirements and may require a large number of patients, whom we may not be able to recruit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">64</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal, state, or foreign fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any third parties conducting aspects of our preclinical studies or our current and future clinical trials will not be our employees and, except for remedies that may be available to us under our agreements with such third parties and the ability to enforce them, we cannot control whether or not they devote sufficient time and resources to our preclinical studies and clinical programs. These third parties also may have relationships with other commercial entities, including our competitors, for whom they also may be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the preclinical or clinical data they obtain is compromised due to the failure to adhere to our protocols or regulatory requirements or for other reasons, our development timelines, including clinical development timelines, may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of our relationships with these third-party CROs or other similar organizations expires or is terminated, we may not be able to enter into arrangements with alternative CROs or other third parties or to do so on commercially reasonable terms, if at all. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a sometime lengthy transition period when a new CRO begins work. As a result, delays may occur, which can materially impact our ability to meet our desired development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, we have relied on, and in the future may rely on, separate institutions to conduct and sponsor clinical trials relating to our product candidates. We will not control the design or conduct of the investigator sponsored trials, and it is possible that the FDA or comparable foreign regulatory authorities will not view these investigator sponsored trials as providing adequate support for future clinical trials, whether controlled by us or third parties, for any one or more reasons, including elements of the design or execution of the trials or safety concerns or other trial results.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Such arrangements will provide us certain information rights with respect to the investigator sponsored trials, including access to and the ability to use and reference the data, including for our own regulatory filings, resulting from the investigator sponsored trials. However, we do not have control over the timing and reporting of the data from investigator sponsored trials, nor do we own the data from the investigator sponsored trials. If we are unable to confirm or replicate the results from the investigator sponsored trials or if negative results are obtained, we would likely be further delayed or prevented from advancing further clinical development of our product candidates. Further, if investigators or institutions breach their obligations with respect to the clinical development of our product candidates, or if the data proves to be inadequate compared to the firsthand knowledge we might have gained had the investigator sponsored trials been sponsored and conducted by us, then our ability to design and conduct any future clinical trials ourselves may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, the FDA or comparable foreign regulatory authorities may disagree with the sufficiency of our right of reference to the preclinical, manufacturing, or clinical data generated by these investigator sponsored trials, or our interpretation of preclinical, manufacturing, or clinical data from these investigator sponsored trials. If so, the FDA or comparable foreign regulatory authorities may require us to obtain and submit additional preclinical, manufacturing, or clinical data before we may initiate our planned trials and/or may not accept such additional data as adequate to initiate our planned trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Because we currently rely on third-party manufacturing and supply partners, our supply of research and development, preclinical and clinical development materials may become limited or interrupted or may not be of satisfactory quantity or quality.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have relied and expect to continue to rely on third-party CDMOs to manufacture some of our preclinical product candidate supplies and to manufacture all of our clinical trial product supplies. Externally, to support TIDAL-01, we have formed deep partnerships across a global network of CDMOs that specialize in bioprocess development, testing, cGMP manufacturing, formulation and filling, packaging, controlled temperature storage, and distribution. For TIDAL-01, this includes a close partnership with the Cell Therapy Facility at Moffitt Cancer Center, responsible for cGMP manufacturing, testing, release, and distribution of Selected TIL to the clinical investigators at Moffitt under our investigator sponsored clinical trial. We have separate partnerships, fully controlled and supervised by us, for the sequencing and peptide manufacturing portions of the TIDAL-01 manufacturing process. In parallel, we have</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">65</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">completed a technology transfer of the TIDAL-01 Selected TIL manufacturing process to a U.S.-based CDMO, Charles River Laboratories.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our preclinical and clinical development product supplies may be limited, interrupted, or not of satisfactory quality or may not continue to be available at acceptable prices. In particular, any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements; this could be particularly problematic where we rely on one CDMO for the manufacture of TIDAL-01.  Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as cGMP or similar foreign requirements outside the United States. We, or our contract manufacturers, any future collaborators and their contract manufacturers could be subject to periodic unannounced inspections by the FDA, competent authorities of EU Member States or other comparable foreign regulatory authorities, to monitor and ensure compliance with cGMP. Despite our efforts to audit and verify regulatory compliance, one or more of our third-party manufacturing vendors may be found on regulatory inspection by the FDA, competent authorities of EU Member States or other comparable foreign regulatory authorities to be noncompliant with cGMP regulations. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including shutdown of the third-party vendor or invalidation of drug product lots or processes, fines, injunctions, civil penalties, delays, suspension, variation or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products</span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#404040;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if approved, </span><span style="color:#ff0000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and significantly harm our business, financial condition, results of operations and prospects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the event that any of our manufacturers</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third-party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third-party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third-party manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget. Moreover, changes to the manufacturer or manufacturing process may be subject to the prior review by the FDA and comparable foreign regulatory authorities, and the FDA and comparable foreign regulatory authorities may not authorize us to utilize product candidates produced by different manufacturers or, if we obtain approval, to commercialize such product produced by different manufacturers than those identified in our marketing applications.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third-party manufacturing for product candidates, or to do so on commercially reasonable terms, if at all, we may not be able to develop and commercialize our product candidates successfully, if approved. Also, our or a third-party&#8217;s failure to execute on our manufacturing requirements and comply with cGMPs or similar requirements could adversely affect our business in a number of ways, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an inability to initiate or continue clinical trials of product candidates under development; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">delay in submitting regulatory applications, or receiving regulatory approvals, for product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">loss of the cooperation of an existing or future collaborator; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">requirements to cease distribution or to recall batches of our product candidates; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Failure to maintain cGMPs or similar requirements can result in a contractor receiving FDA or comparable foreign regulatory authorities sanctions, which can impact our ability to operate, obtain or maintain regulatory approvals, or lead to delays in any clinical development programs or future commercialization of any approved products. In addition, any delay in contracting for fill and finish services, or failure of the contract manufacturer to perform the services as needed, may delay any clinical trials, registration and launches, which could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">66</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our current and future collaborations are and will be important to our business. If we are unable to enter into new collaborations, or if these or any of our current collaborations are not successful, our business, results of operations and financial condition could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A part of our strategy is to strategically evaluate and, as we deem appropriate, enter into additional partnerships in the future, including potentially with major biotechnology or pharmaceutical companies. For example, we entered into a collaboration agreement with Moffitt in connection for the development of TIDAL-01 and an alliance agreement with Moffitt in order to further expand our relationship and support our existing agreements with Moffitt. We have limited capabilities for product development and do not yet have any capability for commercialization. Accordingly, we may continue to enter into collaborations with other companies in the future to provide us with important technologies and funding for our programs and technology.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our current collaborations and any future collaborations we enter into may pose a number of risks, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators have significant discretion in determining the efforts and resources that they will apply; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not perform their obligations as expected; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs or license arrangements based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as a strategic transaction that may divert resources or create competing priorities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products and product candidates if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates, if approved; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution or marketing of a product candidate or product; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval, if any, may not commit sufficient resources to the marketing and distribution of such product or products; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or terminations of the research, development or future commercialization of product candidates, if approved, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may seek to amend or modify the terms of any collaboration; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if a collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate the development or future commercialization of any product candidate licensed to it by us; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaborations may be terminated by the collaborator, and, if terminated, we could be required to raise additional capital to pursue further development or future commercialization of the applicable product candidates. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our collaborations do not result in the successful discovery, development and future commercialization of product candidates, if approved, or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under such collaboration. All of the risks relating to product development, regulatory approval and future commercialization described in this &#8220;Risk Factors&#8221; section and elsewhere in this Quarterly Report on Form 10-Q also apply to</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">67</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the activities of our therapeutic collaborators. Additionally, if one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our perception in the business and financial communities could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We face significant competition in seeking appropriate partners for our product candidates, and the negotiation process is time-consuming and complex. In order for us to successfully partner our product candidates, potential partners must view these product candidates as economically valuable in markets they determine to be attractive in light of the terms that we are seeking and other available products for licensing by other companies. Collaborations are complex, expensive and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Additionally, our collaboration agreements may contain non-competition provisions that could limit our ability to enter into strategic collaborations with future collaborators or restrict our ability to commercialize products on our own, if approved.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization, if approved, or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or future commercialization activities at our own expense. If we elect to increase our expenditures to fund development or future commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms, or at all. If we fail to enter into collaborations or do not have sufficient funds or expertise to undertake the necessary development and future commercialization activities, we may not be able to further develop our product candidates, bring them to market, if approved, and generate revenue from sales of drugs or continue to develop our technology, and our business, results of operations and financial condition could be adversely affected. Even if we are successful in our efforts to establish new strategic partnerships, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such strategic partnerships if, for example, development or approval of a product candidate is delayed or sales of any approved product are disappointing. Any delay in entering into new strategic partnership agreements related to our product candidates could delay the development and future commercialization of our product candidates, if approved, and reduce their competitiveness even if they reach the market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our reliance on third parties, such as manufacturers, may subject us to risks relating to manufacturing scale-up and may cause us to undertake substantial obligations, including financial obligations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As we continue to grow and advance our product candidates through preclinical and clinical trials, we will need to scale our operations accordingly. For example, as we conduct clinical trials of our product candidates, we need to manufacture them in large quantities. We, or any manufacturing partners, may be unable to successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. If we, or any manufacturing partners, are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development, testing, and clinical trials of that product candidate may be delayed or infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The regulatory approval process for our product candidates in the United States and other jurisdictions is currently uncertain and will be lengthy, time-consuming and inherently unpredictable, and we may experience significant delays in the clinical development and regulatory approval, if any, of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The research, testing, manufacturing, labeling, approval, selling, import, export, marketing and distribution of drug products, including biologics like immunotherapies and, cell therapies, are subject to extensive regulation by the FDA in the United States and other regulatory authorities. We are not permitted to market any such products in the United States until we obtain approval of a BLA from the FDA or comparable marketing applications from comparable foreign regulatory authorities. We have not previously submitted a BLA to the FDA, or similar marketing application to comparable foreign authorities. A BLA and similar foreign applications must include extensive preclinical and clinical data and supporting information to establish that the product candidate is safe, pure and potent (or effective) for each desired indication. A BLA and similar foreign application also must include significant information regarding the chemistry, manufacturing and controls for the product, and the manufacturing facilities must complete a successful pre-license inspection.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA also has the authority to require a panel of experts, referred to as an Advisory Committee, to deliberate on the adequacy of the safety and efficacy data to support approval. The opinion of the Advisory Committee, although not binding, could</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">68</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">have a significant impact on our ability to obtain approval of any product candidates that we develop based on the completed clinical trials. Similar decisions may also be taken by foreign regulatory authorities and have similar impact.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, clinical trials can be delayed or terminated for a variety of reasons, including delays or failures related to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining regulatory authorization to begin a clinical trial, if applicable; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the availability of financial resources to begin and complete the planned trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obtaining approval at each clinical trial site by an independent IRB or positive ethics committee opinions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">recruiting suitable patients in sufficient number to participate in a trial in a timely manner; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">having patients complete a trial or return for post-treatment follow-up; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">clinical trial sites deviating from trial protocol, not complying with GCP requirements or dropping out of a trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">addressing any patient safety concerns that arise during the course of a clinical trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">addressing any conflicts with new or existing laws or regulations; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to obtain and maintain patient consents; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adding new clinical trial sites; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">manufacturing qualified materials under cGMPs or similar regulations for use in clinical trials. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patient enrollment is a significant factor in the timing of clinical trials and is affected by many factors. Further, a clinical trial may be suspended or terminated by us, the IRBs or ethics committees for the institutions in which such trials are being conducted, or the FDA or comparable foreign regulatory authorities, or recommended for suspension or termination by the DSMB for such trial, due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects for our product candidates will be adversely affected, and our ability to generate product revenue will be delayed or terminated. In addition, any delays in completing any clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may fail to obtain regulatory approval of our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The general approach for FDA and equivalent foreign approval of a new biologic is to obtain dispositive data from two well-controlled, Phase 3 clinical trials of the relevant biologic in the relevant patient population. Phase 3 clinical trials typically involve hundreds of patients, have significant costs and take years to complete.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our clinical trials results may not support approval. In addition, our product candidates could fail to receive regulatory approval for many reasons, including the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our product candidates are safe and effective for any of their proposed indications; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may be unable to demonstrate that our product candidates&#8217; clinical and other benefits outweigh their safety risks; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">69</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the FDA and comparable foreign regulatory authorities may change their approval policies and new regulations may be enacted, which could delay or prevent our ability to obtain approval. If any of our product candidates fail to achieve regulatory approval due to the above factors, or otherwise, any such failure would adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our relationships with healthcare providers and physicians and third-party payors may be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Healthcare providers, physicians and third-party payors in the United States and elsewhere play a primary role in the recommendation and prescription of pharmaceutical products. Our current and future arrangements with healthcare providers, third-party payors and customers can expose us to broadly applicable fraud and abuse and other healthcare laws and regulations, which may constrain the business or financial arrangements and relationships through which we research, and if approved, sell, market and distribute our products. In particular, the research of our product candidates, as well as the promotion, sales and marketing of our product candidates is subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials. The applicable federal, state and foreign healthcare laws and regulations laws that may affect our ability to operate include, but are not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity can be found guilty of violating the statute without actual knowledge of the statute or specific intent to violate it. The federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal civil and criminal false claims laws, including the federal False Claims Act or FCA, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent claims for payment to, or approval by Medicare, Medicaid, or other federal healthcare programs, knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim or an obligation to pay or transmit money to the federal government, or knowingly and improperly avoiding or decreasing or concealing an obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government healthcare programs if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">e.g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">., public or private), and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating the health care fraud statute under HIPAA without actual knowledge of the statute or specific intent to violate it; </span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">70</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the federal Physician Payments Sunshine Act and its implementing regulations, which require some manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the United States Department of Health and Human Services, or HHS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician practitioners (such as physician assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">analogous state and foreign laws and regulations, such as state and foreign anti-kickback and false claims laws, which may apply to claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, and may be broader in scope than their federal equivalents; state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and local laws that require the registration of pharmaceutical sales representatives. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Outside the United States, interactions between pharmaceutical companies and health care professionals are also governed by strict laws, such as national anti-bribery laws of European countries, national sunshine rules, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal, state and foreign enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions, significant fines and penalties and settlements in the healthcare industry. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and may divert our management&#8217;s attention from the operation of our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in federal and state funded healthcare programs, or comparable foreign programs, contractual damages and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Any action for violation of these laws, even if successfully defended, could cause us to incur significant legal expenses and divert management&#8217;s attention from the operation of our business. Prohibitions or restrictions on sales or withdrawal of future marketed products could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, or comparable regulatory authorities in foreign jurisdictions also must approve the manufacturing, marketing and promotion of the product candidate in those jurisdictions. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In some jurisdictions outside the United States a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products also is subject to approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">71</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also may submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed, which could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Even if we receive regulatory approval of any product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If any of our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post- marketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. In addition, we will be subject to continued compliance with cGMPs and similar requirements outside the United States and GCP requirements for any clinical trials that we conduct post-approval.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMPs or similar regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMPs or similar requirements and adherence to commitments made in any BLA, other marketing application, and previous responses to inspection observations. Accordingly, we and others with which we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production and quality control.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 (post-approval) clinical trials and surveillance to monitor the safety and efficacy of the product candidate. The FDA or comparable foreign regulatory authorities may also require a REMS program, or comparable foreign strategies, as a condition of approval of our product candidates or similar risk management measures, which could entail requirements for long-term patient follow-up, a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, we will need to comply with requirements of any such programs including submissions of safety and other post-marketing information and reports and registration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA or comparable foreign regulatory authorities may impose consent decrees or withdraw or vary approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information or a &#8220;black box&#8221; warning; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program or comparable foreign strategies. Other potential consequences include, among other things:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">fines, warning letters or holds on clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">refusal by the FDA or comparable foreign regulatory authorities to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">product seizure or detention or refusal to permit the import or export of our product candidates; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Failure to comply with EU and EU Member State laws that apply to the conduct of clinical trials, manufacturing approval, marketing authorization of medicinal products and marketing of such products, both before and after grant of the marketing authorization, or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials, or to grant marketing authorization, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the marketing authorization, total or partial</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">72</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The FDA and comparable foreign regulatory authorities strictly regulate marketing, labeling, advertising, and promotion of products that are placed on the market. Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and comparable foreign regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses and a company that is found to have improperly promoted off-label uses may be subject to significant civil, criminal and administrative liability. The policies of the FDA and comparable regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and our business, results of operations and financial condition could be adversely affected. For example, on April 26, 2023, the European Commission adopted a proposal for a new Directive and Regulation to revise the existing pharmaceutical legislation. If adopted in the form proposed, the recent European Commission proposals to revise the existing EU laws governing authorization of medicinal products may result in a decrease in data and market exclusivity opportunities for our product candidates in the EU and make them open to generic or biosimilar competition earlier than is currently the case with a related reduction in reimbursement status.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, if approved, which could make it difficult for us to sell any product candidates profitably.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The success of our product candidates, if approved, depends on the availability of coverage and adequate reimbursement from third-party payors. We cannot be certain that coverage and reimbursement will be available for, or accurately estimate the potential revenue from, our product candidates or assure that coverage and reimbursement will continue to be available for any product that we may develop that receives coverage and adequate reimbursement from one or more third-party payors. Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Accordingly, coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs and treatments they will cover and the amount of reimbursement. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use of a product is:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a covered benefit under its health plan; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">safe, effective and medically necessary; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">appropriate for the specific patient; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">cost-effective; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">neither experimental nor investigational. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. As a result, obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our products on a payor-by-payor basis, with no assurance that coverage and adequate reimbursement will be obtained. Even if we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate for us to achieve or sustain profitability or may require co-payments that patients find unacceptably high. Additionally, third-party payors may not cover, or provide adequate reimbursement for, long-term follow-up evaluations required following the use of product candidates. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates. There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. There has been increasing legislative and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">73</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to President Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect to experience pricing pressures in connection with the sale of all of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, cost containment initiatives and additional legislative changes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Ongoing healthcare legislative and regulatory reform measures may adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (1) changes to our manufacturing arrangements; (2) additions or modifications to product labeling; (3) the recall or discontinuation of our products; (4) post-marketing approvals or compliance programs or (5) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, was passed by Congress, which substantially changes the way health care is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. The ACA, among other things, subjected biological products to potential competition by lower-cost biosimilars, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs, and created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since its enactment, certain provisions the ACA have been subject to executive, judicial and congressional challenges. On June 17, 2021, the U.S. Supreme Court dismissed the most recent challenge to the ACA on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, President Biden issued an executive order that initiated a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental authorities to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program. It is unclear how other healthcare reform measures of the Biden administration, if any, will impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011, among other things included aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect on April 1, 2013, and, due to subsequent legislative amendments, will stay in effect through 2032 unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">74</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2024. Further, the IRA, among other things, (1) directs HHS to negotiate the price of certain single-source drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023.  On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs are implemented. It is currently unclear how the IRA will be implemented but it is likely to have a significant effect on the pharmaceutical industry. In response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the Centers for Medicare &amp; Medicaid Services, or CMS, Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These laws, and future state and federal healthcare reform measures may be adopted in the future, any of which may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EU drug marketing and reimbursement regulations may materially affect our ability to market and receive coverage for our products in the EU member states.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We intend to seek approval to market our product candidates in the United States and we may also seek to do so in selected foreign jurisdictions, including the EU. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in the EU, the pricing of medicinal products is subject to governmental control and other market regulations which could put pressure on the pricing and usage of our product candidates. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. Some countries provide that products may be marketed only after a reimbursement decision has been taken by the relevant regulatory authority. In addition, market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for our product candidates and may be affected by existing and future health care reform measures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Payments made to physicians and healthcare organizations in certain EU member states must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and/or approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU member states. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU member states. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, in most foreign countries, including the EU, the requirements governing drug pricing and reimbursement vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Reference pricing used by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced EU member states, can further reduce prices. An EU member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Many EU Member States also periodically review their reimbursement procedures for medicinal products, which could have an adverse impact on reimbursement status.  In some countries, we may be required to conduct a clinical study or other studies that compare the cost-effectiveness of any of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. This Health Technology Assessment (&#8220;HTA&#8221;) of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some EU Member States, including those representing the larger markets. The HTA process is the procedure to assess therapeutic, economic and societal impact of a given medicinal product in the national healthcare systems of the individual country. The outcome of an HTA will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU Member States. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product currently varies between EU Member States. In December 2021, Regulation No. 2021/2282 on Health Technology Assessment, or HTA, amending Directive 2011/24/EU, was adopted. This regulation which will apply from January 12, 2025 intends to boost cooperation among EU member states in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">75</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">assessing health technologies, including new medicinal products, and providing the basis for cooperation at the EU level for joint clinical assessments in these areas. The regulation foresees a three-year transitional period and will permit EU member states to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the most potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technologies, and making decisions on pricing and reimbursement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the EU do not follow price structures of the United States and generally prices tend to be significantly lower. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales by us or our strategic partners and the potential profitability of any of our product candidates in those countries would be negatively affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Disruptions at the FDA and other national and foreign government and regulatory authorities caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ability of the FDA and comparable foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s and foreign regulatory authorities&#8217; ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s and comparable foreign regulatory authorities&#8217; ability to perform routine functions. Average review times at the FDA and comparable foreign regulatory authorities have fluctuated in recent years as a result. In addition, government funding of other government authorities that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other national and foreign authorities also may slow the time necessary for new biologics or modifications to approved biologics to be reviewed and/or approved by necessary government authorities, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory authorities, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There is a risk that any of our product candidates approved as a biological product under a BLA would not qualify for the 12-year period of exclusivity or that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. If competitors are able to obtain marketing approval for biosimilars referencing our candidates, if approved, our products may become subject to competition from such biosimilars, with the attendant competitive pressure and potential adverse consequences.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">76</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal information, such as information that we may collect in connection with clinical trials. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulations, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our business, results of operation, and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the United States, HIPAA as amended by the Health Information Technology for Economic and Clinical Health Act, or collectively, HIPAA, imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. Most healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA. While we do not believe that we are currently acting as a covered entity or business associate under HIPAA and thus are not directly regulated under HIPAA, we could face substantial criminal penalties if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain states have also adopted comparable privacy and security laws and regulations. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. For example, the California Consumer Privacy Act of 2018, or CCPA, went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Further, the California Privacy Rights Act, or CPRA, generally went into effect on January 1, 2023 and significantly amends the CCPA and imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It also creates a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. Similar laws have passed in Virginia, Colorado, Utah, Iowa and Connecticut and have been proposed in other states and at the federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also or may become subject to rapidly evolving data protection laws, rules and regulations in foreign jurisdictions. For example, in Europe, the EU and the UK General Data Protection Regulations (respectively, the EU GDPR and UK GDPR; together, the GDPR) each impose strict requirements for processing the personal data of individuals within the European Economic Area, or EEA, and/or the UK. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million under the EU GDPR and &#163;17.5 million under the UK GDPR or 4% of the annual global revenues of the noncompliant company, whichever is greater. In addition to these fines, supervisory authorities have extensive audit and inspection rights, and powers to order temporary or permanent bans on all or some processing of personal data carried out by noncompliant actors; the GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR. We could be subject to potentially overlapping or divergent enforcement actions for certain actual or perceived violations. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States. In July 2020, the Court of Justice of the EU, or CJEU, limited how organizations could lawfully transfer personal data from the EU/EEA to the United States by invalidating the Privacy Shield for purposes of international transfers. To facilitate such transfers a new set of standard contractual clauses, or SCCs, was issued by the European Commission but these apply only to transfers of personal data outside the EEA under the EU GDPR. Organizations are now required to comply with onerous obligations to determine the additional measures that need to be implemented and maintained to supplement such safeguards to protect the transferred personal data effectively. In March 2022, the US and EU announced a new regulatory regime intended to replace the invalidated regulations; however, this new EU-US Data Privacy Framework has not been implemented beyond an executive order signed by President Biden on October 7, 2022 on Enhancing Safeguards for United States Signals Intelligence Activities. European court and regulatory decisions subsequent to the CJEU decision of July 2020 have taken a restrictive approach to international data transfers. As</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">77</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">supervisory authorities issue further guidance on personal data export mechanisms, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations. The GDPR may impose additional responsibility and liability in relation to personal data that we process and we may be required to put in place additional mechanisms, at significant cost and diversion of management attention, to ensure compliance with the new data protection rules. This may be onerous and adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, and adversely affect our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Additional laws and regulations governing international operations could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we further expand our operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. The Foreign Corrupt Practices Act, or the FCPA prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate and other related parties for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our research and development costs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Among other matters, U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, which are collectively referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government authorities or government-affiliated hospitals, universities, and other organizations. We also expect our non-U.S. activities to increase over time. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals, and we can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">78</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we own or exclusively license 11 issued U.S. patents and 78 issued foreign patents in 19 countries. We currently own or exclusively license 17 pending U.S. patent applications, three U.S. provisional applications, two pending international PCT applications, and 74 pending foreign patent applications in 11 other countries. Our commercial success will depend in large part on obtaining and maintaining patent, trademark and trade secret protection of our proprietary technologies and our product candidates, their respective components, formulations, combination therapies, methods used to manufacture them and methods of treatment, as well as successfully defending these patents against third-party challenges. Our ability to stop unauthorized third parties from making, using, selling, offering to sell or importing our product candidates is dependent upon the extent to which we have rights under valid and enforceable patents that cover these activities. If we are unable to secure and maintain patent protection for any product or technology we develop, or if the scope of the patent protection secured is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to commercialize any product candidates we may develop may be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The patenting process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications in all jurisdictions at a reasonable cost or in a timely manner. Moreover, obtaining such protection in a timely manner, or at all, may be affected by factors or events beyond our control, such as a prolonged economic downturn, or global financial or political crises, or the ongoing political unrest between Russia and Ukraine. In addition, we may not pursue or obtain patent protection in all relevant markets. It also is possible that we will fail to identify and file on patentable aspects of our research and development output before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CMOs, consultants, advisors and other third parties, any of these parties may breach these agreements and disclose such results before a patent application is filed, thereby jeopardizing our ability to seek patent protection. If we delay in filing a patent application, and a competitor files a patent application on the same or a similar technology before we do, we may face a limited ability to secure patent rights. Or we may not be able obtain a patent on such technology at all. Even if we can patent the technology, we may be able to patent only a limited scope of the technology, and the limited scope may be inadequate to protect our product candidates, or to block competitor products or product candidates that are similar to ours. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or license to third parties and are reliant on our licensors or licensees.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Composition of matter patents for biological and pharmaceutical product candidates often provide a strong form of intellectual property protection for those types of products, as such patents provide protection without regard to any method of use. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#8220;off-label.&#8221; Although off-label prescriptions may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain of our programs may involve combination therapies. Composition of matter and method of use patents directed to combination therapies may be subject to heightened patentability standards and, therefore, may be difficult to issue worldwide.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. If the breadth or strength of protection provided by the patent applications we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since patent applications in the United States and most other countries are confidential for a period of time after filing, we may not have been the first to file any patent application related to our product candidates. Furthermore, for United States applications in which all claims are entitled to a priority date before March 16, 2013, an interference proceeding can be provoked by a third-party or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">79</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">instituted by the United States patent office, or USPTO, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be the first to invent the inventions covered by pending patent applications and, if we are not, we may be subject to priority disputes. We may be required to disclaim part or all of the term of certain patents or all of the term of certain patent applications. There may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. No assurance can be given that if challenged, our patents would be declared by a court to be valid or enforceable or that even if found valid and enforceable, a competitor&#8217;s technology or product would be found by a court to infringe our patents. We may analyze patents or patent applications of our competitors that we believe are relevant to our activities, and consider that we are free to operate in relation to our product candidates, but our competitors may achieve issued claims, including in patents we consider to be unrelated, which block our efforts or may potentially result in our product candidates or our activities infringing such claims. The possibility exists that others will develop products which have the same effect as our products on an independent basis which do not infringe our patents or other intellectual property rights, or will design around the claims of patents that we have had issued that cover our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent or future changes in patent-related case law and/or patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. For example, under the enacted Leahy-Smith America Invents Act, or America Invents Act, enacted in 2013, the United States moved from a &#8220;first to invent&#8221; to a &#8220;first-to-file&#8221; system. Under a &#8220;first-to-file&#8221; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. The America Invents Act includes a number of other significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted, redefine prior art and establish a new post-grant review system. The effects of these changes are currently unclear as the USPTO only recently developed new regulations and procedures in connection with the America Invents Act and many of the substantive changes to patent law, including the &#8220;first-to-file&#8221; provisions, became effective in March 2013. In addition, the courts have yet to address many of these provisions and the applicability of the act and new regulations on specific patents discussed herein have not been determined and would need to be reviewed. However, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Recent changes in European law have caused uncertainty regarding our European patent portfolios. In particular, in 2012, the European Patent Package, or EU Patent Package, regulations were passed with the goal of providing for a single pan-European Unitary Patent, and a new European Unified Patent Court, or UPC, for litigation of European patents. The EU Patent Package was ratified in February 2023 and currently covers 17 member states. On June 1, 2023, all European patents, including those issued prior to ratification, will by default automatically fall under the jurisdiction of the UPC and allow for the possibility of obtaining pan-European injunctions, and further will be at risk of a central revocation proceeding at the UPC in participating UPC states. Under the EU Patent Package, patent holders are permitted to &#8220;opt-out&#8221; of the UPC on a patent-by-patent basis during an initial seven-year period after the EU Patent Package is ratified, with the proviso that an &#8220;opt-out&#8221; is no longer available for EP patents for which a revocation has been initiated before the UPC. Owners of European patent applications who receive notice of grant after the EU Patent Package is ratified could, for the UPC contracting states, either obtain a Unitary Patent or validate the patent nationally and file an opt-out demand. The EU Patent Package may increase the uncertainties and costs surrounding the enforcement or defense of our issued European patents and pending applications. The full impact on future European patent filing strategy and the enforcement or defense of our issued European patents in member states and/or the UPC is not known.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats to our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may be able to make or use compounds or cells that are similar to the biological compositions of our product candidates but that are not covered by the claims of our patents; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the active biological ingredients in our current product candidates will eventually become commercially available in biosimilar drug products, and no patent protection may be available with regard to formulation or method of use; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we or our licensors, as the case may be, may fail to meet our obligations to the U.S. government in regards to any in-licensed patents and patent applications funded by U.S. government grants, leading to the loss of patent rights; </span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">80</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we or our licensors, as the case may be, might not have been the first to file patent applications for the inventions we own or control; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is possible that our pending patent applications will not result in issued patents; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is possible that there are prior public disclosures that could invalidate our or our licensors&#8217; patents, as the case may be, or parts of our or their patents; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is possible that a court could find the disclosure of our owned or -in-licensed patents is not sufficient to support the scope of issued claims, thereby invalidating the claims; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is possible that others may circumvent our owned or in-licensed patents; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering our products or technology similar to ours; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the laws of foreign countries may not protect our or our licensors&#8217;, as the case may be, proprietary rights to the same extent as the laws of the United States; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our competitors might conduct research and development activities in the United States and other foreign countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights and then use the information learned from such activities to develop competitive product candidates for sale in our major commercial markets; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the claims of our owned or in-licensed issued patents or patent applications, if and when issued, may not cover our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our owned or in-licensed issued patents may not provide us with any competitive advantages, may be narrowed in scope, or be held invalid or unenforceable as a result of legal challenges by third parties; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which will be costly whether we win or lose; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the inventors of our owned or in-licensed patents or patent applications may become involved with competitors, develop products or processes which design around our patents, or become hostile to us or the patents or patent applications on which they are named as inventors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is possible that our owned or in-licensed patents or patent applications omit individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we have engaged in scientific collaborations in the past, and will continue to do so in the future. Such collaborators may develop adjacent or competing products to ours that are outside the scope of our patents; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">we may not develop additional proprietary technologies for which we can obtain patent protection; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">it is possible that product candidates or diagnostic tests we develop may be covered by third parties&#8217; patents or other exclusive rights; or </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the patents of others may have an adverse effect on our business, including if others obtain patents claiming subject matter similar to or improving that covered by our patents and patent applications. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any difficulties we encounter in defending, or resulting inability to protect, our proprietary rights and technology, may adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">81</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are dependent on patents, know-how and proprietary technology, both our own and licensed from others. Any termination of these licenses could result in the loss of significant rights and could harm our ability to commercialize our product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disputes also may arise between us and our licensors regarding intellectual property subject to a license agreement, including:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope of rights granted under the license agreement and other interpretation-related issues; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our right to sublicense patent and other rights to third parties under collaborative development relationships; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the priority of invention of patented technology; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our diligence obligations with respect to the use of the licensed technology in relation to our development and future commercialization of our product candidates, and what activities satisfy those diligence obligations; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the ownership of and rights to use inventions and know-how resulting from the joint or individual creation or use of intellectual property by our licensors and us and our partners. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, certain of our current and future agreements with third parties may limit or delay our ability to consummate certain transactions, may impact the value of those transactions, or may limit our ability to pursue certain activities. For example, we may enter into license agreements that are not assignable or transferable, or that require the licensor&#8217;s express consent in order for an assignment or transfer to take place. If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We generally also are subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own, which are described in this &#8220;Risk Factors&#8221; section. If we or our licensors fail to adequately protect this intellectual property, our business, results of operations and financial condition could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to comply with our obligations under our patent licenses with third parties, we could lose license rights that are important to our business, which could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are a party to license agreements pursuant to which we in-license patent and patent applications, know-how, trade secrets and data rights for our product candidates. These existing licenses impose on us various diligence, milestone payment, royalty, insurance and other obligations. If we fail to comply with these obligations, our licensors may have the right to terminate the license, in which event we would not be able to develop or market the products covered by such licensed intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our licensors retain certain rights under their agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may also enter into license agreements with third parties under which we are a sublicensee. If our sublicensor fails to comply with its obligations under its upstream license agreement with its licensor, the licensor may have the right to terminate the upstream license, which may terminate our sublicense. If this were to occur, we would no longer have rights to the applicable intellectual property unless we are able to secure our own direct license with the owner of the relevant rights, which we may not be able to do on reasonable terms, or at all, which may impact our ability to continue to develop and commercialize our product candidates incorporating the relevant intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may have limited control over the maintenance and prosecution of these in-licensed patents and patent applications, activities or any other intellectual property that may be related to our in-licensed intellectual property. For example, such activities by these licensors may not have been or may not be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. Our licensors may not successfully prosecute the patent applications to which we are licensed in a manner consistent with the best interests of our business. We have limited control over the manner in which our licensors initiate an infringement proceeding against a third-party infringer of the intellectual property rights, or defend certain of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">82</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the intellectual property that is licensed to us. It is possible that the licensors&#8217; infringement proceeding or defense activities may be less vigorous than had we conducted them ourselves.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business, results of operations and financial condition could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition to patent and other intellectual property protection, we rely heavily upon know-how and trade secret protection, as well as non-disclosure agreements and invention assignment agreements with our employees, consultants and third parties, to protect our confidential and proprietary information, especially where we do not believe patent protection is appropriate or obtainable. Elements of our product candidates, including processes for their preparation and manufacture, may involve proprietary know-how, information, or technology that is not covered by patents and that may not be patentable, and thus for these aspects we may consider trade secrets and know-how to be our primary intellectual property. We may also rely on trade secret protection as temporary protection for concepts that may be included in a future patent filing. In addition to contractual measures, we try to protect the confidential nature of our proprietary information using physical and technological security measures. Such measures may not, for example, in the case of misappropriation of a trade secret by an employee or third-party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may be expensive and not provide an adequate remedy to protect our interests fully. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, our competitive position could be harmed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, courts outside the United States are sometimes less willing to protect trade secrets. We may need to share our proprietary information, including trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or foreign actors, and those affiliated with or controlled by state actors. If we choose to go to court to stop a third-party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees, consultants and current and potential business partners, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors and current and potential business partners to execute confidentiality agreements upon the commencement of employment, consulting or other applicable relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual or entity during the course of the party&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. Any disclosure, either intentional or unintentional, by our employees or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Because we expect to rely on third parties in the development and manufacture of our product candidates, we must, at times, share trade secrets with them, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our sole and exclusive property. We also have adopted policies and conduct training that provides guidance on our expectations, and our advice for best practices, in protecting our trade secrets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We cannot prevent other companies from licensing some of the same intellectual properties that we have licensed or from otherwise duplicating our business model and operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since parties we have licenses with are developing therapies to similar technologies, they may make their methods and data available to third parties, who may want to enter into our line of business and compete against us. We currently do not have any exclusive rights to our entire product portfolio that could be used to prevent third parties from duplicating our business plan or from otherwise directly competing against us. No assurance can be given that our existing exclusive rights are or will be sufficient to prevent others from competing with us and developing substantially similar products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">83</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our commercial success depends in part on our ability to research, develop, manufacture, market and sell our current and any future product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review, post grant review, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product candidates and/or proprietary technologies infringe their intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. We are further aware of certain patents, and patent applications in the United States and elsewhere that contain claims that, if issued in their present form, may cover our TIL products or their methods of use or manufacture. We, along with a number of third parties in the TIL cell therapy field, have been involved in opposition proceedings in Europe with respect to some of these patents. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties may allege they have patent rights encompassing our product candidates, technologies or methods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If a third-party claims that we infringe its intellectual property rights, we may face a number of issues, including, but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">infringement and other intellectual property claims which, regardless of merit, may be expensive and time-consuming to litigate and may divert our management&#8217;s attention from our core business; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">substantial damages for infringement, which we may have to pay if a court decides that the product candidate or technology at issue infringes on or violates the third-party&#8217;s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent owner&#8217;s attorneys&#8217; fees; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">a court prohibiting us from developing, manufacturing, marketing or selling our product candidates, or from using our proprietary technologies, unless the third-party licenses its product rights to us, which it is not required to do; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">if a license is available from such third-party (and no such license may be available), we may have to pay substantial royalties, upfront fees and other amounts, and/or grant cross-licenses to intellectual property rights for our products; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">redesigning our product candidates or processes so they do not infringe, which may not be possible or may require substantial monetary expenditures and time. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Third parties may assert that we are employing their proprietary technology without authorization. Generally, conducting clinical trials and other development activities in the United States is protected under the Safe Harbor exemption as set forth in 35 U.S.C. &#167; 271. If and when one of our product candidates is approved by the FDA, that certain third-party may then seek to enforce its patent by filing against us a patent infringement lawsuit. In this regard, patents issued in the United States by law enjoy a presumption of validity that can be rebutted only with evidence that is &#8220;clear and convincing,&#8221; a heightened standard of proof. There may be third-party patents of which we currently are unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. We have conducted freedom to operate analyses with respect to only certain of our products and services and we cannot guarantee that our analyses are complete and thorough, nor can we be sure that we have identified each and every patent and pending application in the United States and abroad that is relevant or necessary to the commercialization of our products and services. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our product candidates, constructs or molecules used in or formed during the manufacturing process, or any final product itself, the holders of any such patents may be able to block our ability to commercialize the product candidate unless we obtained a license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">84</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business. Even if we obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other intellectual property related proceedings could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. In addition, if our product candidates are found to infringe the intellectual property rights of third parties, these third parties may also assert infringement claims against our licensees and other parties with whom we have business relationships, and we may be required to indemnify those parties for any damages they suffer as a result of these claims. If any of these claims succeed, we may be required to pay damages on behalf of those parties or may be required to obtain licenses for the products they use. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. Any such license may not be available at all or may not be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow future commercialization of our product candidates, if approved. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Third parties may assert that our employees, consultants or other third parties have wrongfully used, disclosed confidential information, misappropriated trade secrets or are in breach of non-competition or non-solicitation agreements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously employed at universities or other biopharmaceutical or pharmaceutical companies, including our competitors or potential competitors. Although no material claims against us currently are pending or threatened, and although we try to ensure that our employees, consultants and other third parties do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants, independent contractors or current or potential business partners have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third parties, or are in breach of any non-competition or non-solicitation agreements. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may be subject to claims that former employees, collaborators, or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding co-ownership of potential joint inventions. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">85</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other intellectual property related proceedings could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may not be successful in obtaining or maintaining necessary rights to develop current and any future product candidates on acceptable terms.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates also may require specific formulations to work effectively and efficiently and these rights may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which would harm our business. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and expenses and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, we sometimes collaborate with academic institutions and governmental authorities to accelerate our preclinical research or development under written agreements with these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our program. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business, results of operations and financial condition could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The licensing and acquisition of third-party intellectual property rights is a highly competitive area, and companies, which may be more established, or have greater resources than we do, also may be pursuing strategies to license or acquire third-party intellectual property rights that we consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or insufficient written description. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. For the patents and patent</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">86</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">applications that we have licensed, we may have limited or no right to participate in the defense of any licensed patents against challenge by a third party. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future product candidates. Such a loss of patent protection could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. Moreover, our ability to successfully pursue infringement claims or otherwise enforce intellectual property that we license from or co-own with another party may require the participation and co-operation of the co-owner or licensor, and may be impaired or prohibited if such participation or co-operation is insufficient or cannot be secured.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may choose to challenge the patentability of claims in a third-party&#8217;s U.S. patent by requesting that the USPTO review the patent claims in an</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> ex-parte</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> re-exam,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review or post-grant review proceedings. These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third-party&#8217;s patent in patent opposition proceedings in the European Patent Office, or EPO, or another foreign patent office. The costs of these opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed to litigation by a third-party alleging that the patent may be infringed by our product candidates or proprietary technologies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, and publications in the scientific literature often lag behind actual discoveries, others may have filed patent applications for technology covered by our owned and in-licensed issued patents or our pending applications, and we or, if applicable, a licensor may not have been the first to invent the technology. Our competitors may have filed, and may in the future file, patent applications covering our products or technology similar to ours. Any such patent application may have priority over our owned and in-licensed patent applications or patents, which could require us to obtain rights to issued patents covering such technologies. For applications that have claims entitled to a priority date before March 16, 2013, if another party has filed a U.S. patent application on inventions similar to those owned by or in-licensed to us, we or, in the case of in-licensed technology, the licensor may have to participate in an interference proceeding declared by the USPTO to determine priority of invention in the United States. If we or one of our licensors is a party to an interference proceeding involving a U.S. patent application on inventions owned by or in-licensed to us, we may incur substantial costs, divert management&#8217;s time and expend other resources, even if we are successful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Interference proceedings provoked by third parties or brought by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Litigation or interference proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Periodic maintenance fees, renewal fees, annuity fees, and various other governmental fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent application process and following the issuance of a patent. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">87</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we or one of our licensing partners initiate legal proceedings against a third-party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third-party can assert invalidity or unenforceability of a patent. Third parties also may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review, post grant review, derivation proceedings and equivalent proceedings in foreign jurisdictions (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">e.g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, there may be invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if we are otherwise unable to adequately protect our rights, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changes in patent law in the United States and in other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. In addition, the United States has enacted and is currently implementing the America Invents Act. Moreover, recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in other situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in the case of</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Assoc. for Molecular Pathology v. Myriad Genetics, Inc.,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> the U.S. Supreme Court held that certain claims to DNA molecules are not patentable. We cannot predict how these decisions or any future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents. Similarly, any adverse changes in the patent laws of other jurisdictions could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have limited intellectual property rights outside the United States. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can have a different scope and strength than those in the United States. Moreover, obtaining such protection in a timely manner, or at all, may be affected by factors or events beyond our control, such as a prolonged economic downturn, or global financial or political crises, whether or not related to the ongoing political unrest between Russia and Ukraine and in the Middle East. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">88</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">difficult for us to stop the infringement of our patents or marketing of competing products against third parties in violation of our proprietary rights generally. The initiation of proceedings by third parties to challenge the scope or validity of our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. Proceedings to enforce our patent and other intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Similarly, if our trade secrets are disclosed in a foreign jurisdiction, competitors worldwide could have access to our proprietary information and we may be without satisfactory recourse. Such disclosure could have a material adverse effect on our business. Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. In addition, certain countries, including China and India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled to grant a license to a third party, which could materially diminish the value of those patents. In addition, many countries limit the enforceability of patents against government authorities or government contractors. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We may incur substantial costs as a result of litigation or other proceedings relating to patents, and we may be unable to protect our rights to our products and technology.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we or our licensors choose to go to court to stop a third-party from using the inventions claimed in our owned or in-licensed patents, that third-party may ask the court to rule that the patents are invalid and/or should not be enforced against that third-party. These lawsuits are expensive and would consume time and other resources even if we or they, as the case may be, were successful in stopping the infringement of these patents. In addition, there is a risk that the court will decide that these patents are not valid and that we or they, as the case may be, do not have the right to stop others from using the inventions. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us. An unfavorable result at the USPTO, EPO or other patent office may result in the loss of our right to exclude others from practicing one or more of our inventions in the relevant country or jurisdiction, which could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There also is the risk that, even if the validity of these patents is upheld, the court will refuse to stop the third-party on the ground that such third-party&#8217;s activities do not infringe our owned or in-licensed patents. In addition, the U.S. Supreme Court recently has changed some legal principles that affect patent applications, granted patents and assessment of the eligibility or validity of these patents. As a consequence, issued patents may be found to contain invalid claims according to the newly revised eligibility and validity standards. Some of our owned or in-licensed patents may be subject to challenge and subsequent invalidation or significant narrowing of claim scope in proceedings before the USPTO, or during litigation, under the revised criteria which also could make it more difficult to obtain patents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We, or our licensors, may not be able to detect infringement against our owned or in-licensed patents, as the case may be, which may be especially difficult for manufacturing processes or formulation patents. Even if we or our licensors detect infringement by a third-party of our owned or in-licensed patents, we or our licensors, as the case may be, may choose not to pursue litigation against or settlement with the third-party. If we, or our licensors, later sue such third-party for patent infringement, the third-party may have certain legal defenses available to it, which otherwise would not be available except for the delay between when the infringement was first detected and when the suit was brought. Such legal defenses may make it impossible for us or our licensors to enforce our owned or in-licensed patents, as the case may be, against such third-party.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If another party questions the patentability of any of our claims in our owned or in-licensed U.S. patents, the third-party can request that the USPTO review the patent claims such as in an</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> inter partes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> review,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> ex parte</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> re-exam or post-grant review proceedings. These proceedings are expensive and may result in a loss of scope of some claims or a loss of the entire patent. In addition to potential USPTO review proceedings, we may become a party to patent opposition proceedings at the EPO or similar proceedings in other foreign patent offices, where either our owned or in-licensed foreign patents are challenged.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the future, we may be involved in similar proceedings challenging the patent rights of others, and the outcome of such proceedings is highly uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">An adverse determination in any such proceeding may result in our inability to manufacture or commercialize products without infringing third-party patent rights. The costs of these opposition or similar proceedings could be substantial, and may result in a loss of scope of some claims or a loss of the entire patent.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">89</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional application filing date. Various extensions such as patent term adjustments and/or extensions, may be available, but the life of a patent, and the protection it affords, is limited. For instance, a patent term extension based on regulatory delay may be available in the United States. However, only a single patent can be extended for each marketing approval, and any patent can be extended only once, for a single product. Moreover, the scope of protection during the period of the patent term extension does not necessarily extend to all claims, but instead only to claims that cover the product as approved. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, we own or in-license patent applications covering our proprietary technologies and our product candidates that if issued as patents are expected to expire between 2039 and 2044, without taking into account any possible patent term adjustments or extensions. However, the USPTO or relevant foreign patent offices may not grant any of these patent applications. If issued, the patents may expire before, or soon after, our first product achieves marketing approval in the United States or foreign jurisdictions. Further, if issued, the patents may expire before, or soon after, any regulatory protection afforded our first approved product through data and/or market exclusivity in the United States or foreign jurisdictions. Upon the expiration of any such patents, if issued, we may lose the right to exclude others from practicing these inventions. The expiration of these patents also could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business, results of operations and financial condition could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our trademarks or trade names may be challenged, opposed, infringed, circumvented, invalidated, cancelled, declared generic, determined not to entitled to registration, or determined to be infringing on other marks. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in foreign jurisdictions. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. Any trademark litigation could be expensive. In addition, we could be found liable for significant monetary damages, including treble damages, disgorgement of profits and attorneys&#8217; fees, if we are found to have willfully infringed a trademark.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moreover, any name we propose to use with our product candidates in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of our proposed proprietary product names, it may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We may not be able to protect our rights to our trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business, results of operations and financial condition could be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Risks Related to Our Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The price of our common stock may be volatile, and you could lose all or part of your investment.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading price of our common stock is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this Quarterly Report on Form 10-Q, these factors include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the progress, conduct, enrollment or results of our two Phase 1 clinical trials for TIDAL-01; </span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">90</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any termination of, loss of rights or disputes or disagreements arising under our collaboration, partnership and strategic alliance agreements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any delay in identifying additional product candidates from our current and future development programs; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse results or delays in future clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse regulatory decisions, including failure to receive regulatory approval of our current product candidates or any future product candidate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in laws or regulations applicable to our current product candidates or any future product candidate, including but not limited to clinical trial requirements for approvals; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse development concerning our competitors, particularly those developing TIL-based therapies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse developments concerning our manufacturers; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse developments concerning our manufacturing process, including manufacturing failures; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our inability to establish collaborations or other strategic relationships, if needed; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to successfully develop and the costs associated with the development of our internal manufacturing processes; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our failure to commercialize our product candidates, if approved; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">additions or departures of key scientific or management personnel; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unanticipated serious safety concerns related to the use of our current product candidates or any future product candidate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">introduction of new products or services offered by us or our competitors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to effectively manage our growth; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">actual or anticipated variations in quarterly operating results; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our cash position; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">publication of research reports about us or our industry, or our or a competitor&#8217;s product candidates in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the market valuations of similar companies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">volatility and instability in the financial and capital markets; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">overall performance of the equity markets, including the effects of geopolitical events; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sales of our common stock by us, our insiders, or other stockholders in the future, or issuances by us of shares of our common stock in connection with strategic transactions; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">expiration of market standoff or lock-up agreements described in the section titled &#8220;Underwriting&#8221;; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">conditions and trends in the biotechnology and other industries; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">trading volume of our common stock; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in accounting practices; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ineffectiveness of our internal controls; </span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">91</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">disputes or other developments relating to intellectual property and other proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">significant lawsuits, including patent or stockholder litigation; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">changes in the structure of healthcare payment systems, including coverage and adequate reimbursement for any approved drug; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">global or regional public health emergencies, including pandemics, natural disasters, or major catastrophic events; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adverse macroeconomic conditions or geopolitical events, including the conflict between Ukraine and Russia, the conflict in the Middle East and recent bank failures; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the occurrence of any of the risks described in this section titled &#8220;Risk Factors&#8221;; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">other events or factors, many of which are beyond our control. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the stock market in general, and the market for biotechnology companies in particular, have experienced extreme price and volume fluctuations that often have been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, securities class action litigation often has been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which could adversely affect our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently anticipate that we will retain future earnings for the research, development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any future debt or other financing arrangements may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Any return to stockholders therefore will be limited to the appreciation of the price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2023, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially held, in the aggregate, approximately 51.0% of our outstanding common stock. These stockholders, acting together, would be able to significantly influence all matters requiring stockholder approval. For example, these stockholders would be able to significantly influence elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This level of control may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors&#8217; perception that conflicts of interest may exist or arise.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We are an emerging growth company and a smaller reporting company, and the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are an emerging growth company, as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. We will remain an emerging growth company until the earlier of (1) (a) December 31, 2027, (b) the last day of the fiscal year in which we have total annual gross revenue of at least $1.235 billion and (c) the last day of the fiscal year in which we are deemed to be a large accelerated filer, which requires the market value of our common stock that is held by non-affiliates to exceed $700.0 million as of the prior June 30th, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the JOBS Act, emerging growth companies also can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to avail ourselves of this exemption, and, as a result, our operating</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">92</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">results and financial statements may not be comparable to the operating results and financial statements of companies who have adopted the new or revised accounting standards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also are a &#8220;smaller reporting company,&#8221; meaning that the market value of our stock held by non-affiliates is less than $700.0 million and our annual revenue is less than $100.0 million during the most recently completed fiscal year. We will continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250.0 million or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700.0 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our annual report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Conflicts of interest may arise because some members of our board of directors are representatives of our principal stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain of our principal stockholders or their affiliates are venture capital funds or other investment vehicles that could invest in entities that directly or indirectly compete with us. As a result of these relationships, when conflicts arise between the interests of the principal stockholders or their affiliates and the interests of other stockholders, members of our board of directors that are representatives of the principal stockholders may not be disinterested.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If our stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline. In addition, shares of common stock that are either subject to outstanding options or reserved for future issuance under our existing equity compensation plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, future lock-up agreements and Rule 144 under the Securities Act of 1933, as amended, or the Securities Act and Rule 701 under the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Certain holders of approximately 13.3 million shares of our common stock are entitled to rights with respect to the registration of their shares under the Securities Act as provided under the terms of the Second Amended and Restated Investors&#8217; Rights Agreement, or the Rights Agreement, between us and certain of our stockholders, or the Myst Merger Agreement.  Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of our company more difficult, limit attempts by our stockholders to replace or remove our current management and limit the market price of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Provisions in our amended and restated certificate of incorporation and our amended and restated bylaws may have the effect of delaying or preventing a change of control or changes in our board of directors and management. Our amended and restated certificate of incorporation and amended and restated bylaws include provisions that:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">authorize our board of directors to issue, without further action by the stockholders, shares of undesignated preferred stock with terms, rights and preferences determined by our board of directors that may be senior to our common stock; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">specify that special meetings of our stockholders can be called only by directors representing a majority of the total authorized size of our board of directors, the chairperson of our board of directors, our chief executive officer or our president; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish an advance notice procedure for stockholder proposals to be brought before an annual meeting, including proposed nominations of persons for election to our board of directors; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">establish that our board of directors is divided into three classes, with each class serving three-year staggered terms; </span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">93</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">prohibit cumulative voting in the election of directors, therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide that our directors may be removed for cause only upon the vote of at least 66 2/3% of our outstanding shares of voting stock; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">require the approval of our board of directors or the holders of at least 66 2/3% of our outstanding shares of voting stock to amend our bylaws and certain provisions of our certificate of incorporation. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, or DGCL, which generally, subject to certain exceptions, prohibits a Delaware corporation from engaging in any of a broad range of business combinations with any &#8220;interested&#8221; stockholder for a period of three years following the date on which the stockholder became an &#8220;interested&#8221; stockholder. Any of the foregoing provisions could limit the price that investors might be willing to pay in the future for shares of our common stock, and they could deter potential acquirers of our company, thereby reducing the likelihood that holders of our common stock would receive a premium for their shares of our common stock in an acquisition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district court for the District of Delaware of the United States will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any derivative action or proceeding brought on our behalf; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any action asserting a breach of fiduciary duty; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any action asserting a claim against us arising under the DGCL, our amended and restated certificate of incorporation, or our amended and restated bylaws; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any action seeking to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation, or our amended and restated bylaws; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any action to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; and </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">any action asserting a claim against us that is governed by the internal-affairs doctrine. </span></div></div>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation further provides that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid and several state trial courts have enforced such provisions and required that suits asserting Securities Act claims be filed in federal court, there is no guarantee that courts of appeal will affirm the enforceability of such provisions and a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and the provisions may not be enforced by a court in those other jurisdictions. This exclusive forum provision may result in increased costs to stockholders to bring a claim. Further, this exclusive forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">94</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">may incur further significant additional costs associated with litigating Securities Act claims in state court, or both state and federal court, which could seriously harm our business, results of operations and financial condition.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">General Risk Factors</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As a public company, we will incur significant legal, accounting, compliance and other expenses that we did not incur as a private company. We will be subject to the reporting requirements of the Exchange Act, which will require, among other things, that we file with the SEC annual, quarterly, and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#8220;say on pay&#8221; and proxy access. Emerging growth companies and smaller reporting companies are exempted from certain of these requirements, but we may be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, results of operations and financial condition. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements also makes it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are not currently required to comply with the rules of the SEC implementing Section 404 of the Sarbanes-Oxley Act and are therefore not required to make a formal assessment of the effectiveness of our internal control over financial reporting for that purpose. Upon becoming a public company, we will be required to comply with the SEC&#8217;s rules implementing Sections 302 and 404 of the Sarbanes-Oxley Act, which will require management to certify financial and other information in our quarterly and annual reports and provide an annual management report on the effectiveness of internal control over financial reporting. Although we will be required to disclose changes made in our internal control over financial reporting on a quarterly basis, we will not be required to make our first annual assessment of our internal control over financial reporting until our second annual report on Form 10-K. However, as an emerging growth company, our independent registered public accounting firm will not be required to formally attest to the effectiveness of our internal control over financial reporting until the later of the year following our first annual report required to be filed with the SEC or the date we are no longer an emerging growth company. When we lose our status as an &#8220;emerging growth company&#8221; and reach an accelerated filer threshold, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for our management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we may need to upgrade our information technology systems; implement additional financial and management controls, reporting systems and procedures; and hire additional accounting and finance staff. If we or, if required, our auditors are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There may be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begins its Section 404 reviews, investors may lose confidence in the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">95</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to the periodic reporting requirements of the Exchange Act and must design our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. Any disclosure controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make any related party transaction disclosures. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. In addition, we do not have a formal risk management program for identifying and addressing risks to our business in other areas.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">We could be subject to securities class action litigation, which is expensive and could divert management attention.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The market price of our common stock is likely to be volatile. The stock market in general, and Nasdaq and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of companies. In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs (including the cost to defend against, and any potential adverse outcome resulting from any such proceeding), damage to our reputation, and a diversion of management&#8217;s attention and resources from other business concerns, which could harm our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our failure to meet Nasdaq&#8217;s continued listing requirements could result in a delisting of our common stock.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If we fail to satisfy the continued listing requirements of Nasdaq, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with the listing requirements of Nasdaq.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no securities or industry analysts commence coverage of our company, the trading price for our stock would likely be negatively impacted. In the event securities or industry analysts initiate coverage, if one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which would likely cause our stock price and trading volume to decline.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">96</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_2_unregistered_sales"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 2. UNREGISTERED SALES OF</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> EQUITY SECURITIES AND USE OF PROCEEDS</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Unregistered Sales of Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">None.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Proceeds</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 20, 2023, our registration statement on Form S-1 (File No. 333-272600) was declared effective by the SEC for our IPO. At the closing of the IPO on July 25, 2023, we sold 6,666,667 shares of common stock, at an IPO price of $12.00 per share and received gross proceeds of $80.0 million, which resulted in net proceeds to us of approximately $68.7 million, after deducting underwriting discounts and commissions of $5.6 million and other offering costs totaling approximately $5.7 million. On August 15, 2023, the underwriters exercised their option to purchase an additional 651,608 shares of common stock at $12.00 per share. Aggregate net proceeds to the Company were $7.3 million after deducting underwriting discounts and commissions of $0.5 million. None of the expenses associated with the IPO were paid to directors, officers, persons owning ten percent or more of any class of equity securities, or to their associates, or to our affiliates, other than payments from our net proceeds in the ordinary course of business to officers for salaries and to non-employee directors as compensation for service on the board of directors or committees of the board of directors. BofA Securities, Inc., Leerink Partners LLC, and Piper Sandler &amp; Co. acted as joint book-running managers for the IPO.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There has been no material change in the planned use of IPO proceeds from that described in our final prospectus filed with the SEC pursuant to Rule 424(b)(4) on July 24, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_3_defaults_upon_senior_securities"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 3. DEFAULTS UPON </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SENIOR SECURITIES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 4. MINE SAFET</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Y DISCLOSURES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_5_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 5. OTHE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">R INFORMATION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Trading Arrangements of Section 16 reporting progress.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the three months ended June 30, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7d9913e7-a350-4f0e-b4af-f188c651d696" contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_3d184698-485a-4f06-9514-ce0220ad69f6" contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_10961851-7d38-47ac-b6e6-70a46ff0cb4e" contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_df7f33b6-f91b-452e-8c79-5650032a7fa8" contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> director of officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement", as each term is defined in Item 408(a) of regulation S-K.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">97</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_6_exhibits"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ITEM 6. </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">EXHIBITS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="background-color:#ffffff;font-weight:bold;visibility:collapse;">
    <td style="width:8%;"/>
    <td style="width:1%;"/>
    <td style="width:51%;"/>
    <td style="width:8%;"/>
    <td style="width:13%;"/>
    <td style="width:7%;"/>
    <td style="width:12%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="4" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Incorporated by Reference</span></p></td>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">No.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Form</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">File No.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Filing<br/>Date</span></p></td>
   </tr>
   <tr style="height:4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1764974/000119312523165338/d574486dex21.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Agreement and Plan of Merger and Reorganization, dated December  11, 2020, between Turnstone Biologics Corp., Flatiron Merger Sub I, Inc., Flatiron Merger Sub II, LLC, Myst Therapeutics, Inc. and Timothy Langer</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">S-1/A</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">333-272600</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July  17, 2023</span></p></td>
   </tr>
   <tr style="height:4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1764974/000119312523193445/d878456dex31.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Certificate of Incorporation of the Company</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-41747</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.1</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July  25, 2023</span></p></td>
   </tr>
   <tr style="height:4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1764974/000119312523193445/d878456dex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Amended and Restated Bylaws of the Company.</span></a></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8-K</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-41747</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.2</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">July  25, 2023</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1764974/000095017024058818/tsbx-ex10_1.htm" style="-sec-extract:exhibit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Loan and Security Agreement by and among the Company, Myst Therapeutics, LLC and Bank of California, dated April 26, 2024</span></a></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10-Q</span></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">001-41747</span></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">May 13, 2024</span></p></td>
   </tr>
   <tr style="height:4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.1*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="tsbx-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31.2*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="tsbx-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32.1*+</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="tsbx-ex32_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.INS*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">101.SCH*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:4pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:4pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104*</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">* Filed herewith.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">+ Furnished herewith and not deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">98</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="signature"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGN</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ATURE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of The Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of La Jolla, State of California, on the 14th day of August, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Turnstone Biologics Corp.</span></p></td>
   </tr>
   <tr style="height:12.25pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">/s/ </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Venkat Ramanan</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Venkat Ramanan, Ph.D.</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Chief Financial Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">99</span></p></div></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>tsbx-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION  302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Sammy Farah, certify that:</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Form 10-Q of Turnstone Biologics Corp.;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:46.52%;"></td>
    <td style="width:3%;"></td>
    <td style="width:50.48%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: August 14, 2024</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Sammy Farah</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sammy Farah, M.B.A., Ph.D.</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>tsbx-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION  302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I, Venkat Ramanan, certify that:</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I have reviewed this Form 10-Q of Turnstone Biologics Corp.;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.646%;padding-left:4.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47%;"></td>
    <td style="width:3%;"></td>
    <td style="width:50%;"></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: August 14, 2024</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</font></p></td>
    <td style="vertical-align:top;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Venkat Ramanan</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Venkat  Ramanan, Ph.D.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial  Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>tsbx-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION  1350, AS ADOPTED PURSUANT TO SECTION  906</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#x201c;Exchange Act&#x201d;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Sammy Farah, Chief Executive Officer of Turnstone Biologics Corp. (the &#x201c;Company&#x201d;), and Venkat Ramanan, Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:</font></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#x2019;s Quarterly Report on Form 10-Q for the period ended June 330, 2024, to which this Certification is attached as Exhibit 32.1 (the &#x201c;Periodic Report&#x201d;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and</font></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="text-indent:-4.646%;padding-left:4.44%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dated: August 14, 2024</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:47%;"></td>
    <td style="width:3%;"></td>
    <td style="width:50%;"></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Sammy Farah</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid #ffffff03;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Venkat Ramanan</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sammy Farah, M.B.A., Ph.D.</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Venkat Ramanan, Ph.D.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Principal Financial Officer</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Turnstone Biologics Corp. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>img127454107_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img127454107_0.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 9:#Z # 2(  A$! Q$!_\0
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MO]C2<_\ ;>&O)?C-G_A;GC3//_$YN_\ T<U<L?XTO0U?\-''4445U&04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %?6_PS^7]B_Q0>F5O/;NOT_K_2ODBOK?
MX9_+^QAXH.,';>=>.Z_3^O3\*YJ^R]4:T]WZ'R1111729!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 ?6W[6WR_!OX? 'C,6/3_ (]A_GI7R37UO^UN?^+-_#\'(.Z+@G_I
MV_SVKY(KFP_\,UJ_$%%%%=)D%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?3?["H!\8>)O7[!'_P"C!7S_ ..&
MW>-?$!SG.H7!_P#(C5] _L*Y_P"$N\3\'_CQC^G^LKY^\<?\CKX@YS_Q,+C_
M -&-7-'^-+Y&LO@1B4445TF04444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5];?M;?+\&_A\ >,Q8]/^/8?YZ5\
MDU];_M;G_BS?P_!R#NBX)_Z=O\]JYJG\2!K#X9'R1111729!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7TW^
MPJ ?&'B;U^P1_P#HP5\R5].?L*Y_X2[Q/P?^/&/Z?ZRN?$?PV:4_C1\_>.&W
M>-?$!SG.H7!_\B-6)6WXX_Y'7Q!SG_B87'_HQJQ*VCLB'N%%%%4(**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M^MOVMN/@U\/P#QNBZ=/^/8?YZ5\DU];?M;X_X4W\/L8ZQ8QC_GV%?)-<V'_A
MFM7X@HHHKI,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?Q(&L/AD?)%%%%=)D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %?3G["O_(W^)_\ KQC[?]-/6OF.OIS]A7_D
M;_$Q_P"G&/M_TT]:Y\1_"9I3^-'S]XX.?&WB GK_ &A<=?\ KHU8E;?CC_D=
M/$'?_B87'3'_ #T;TK$K:.R,WN%%%%4 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!];_M<<?!OX?C./FB^7C_
M )]O\]J^2*^MOVN/^2.?#\=/FBXX_P"?<?YXKY)KFP_\,UJ_$%%%%=)D%3VM
MA=7[,MM;37!49(B0MCZXJ"NH\ _%+QA\*]2>_P#!_B;5/#=U)M\UM-NGA$P4
MY59%!PZ@D_*P(YZ4G?H!C_\ ".ZK_P! R\_\!W_PJM=6-S8N$N;>6W9AD+*A
M4D>O-?NQ^Q=\>-3_ &B/@/I?BG6[6.WUF*>33[QX!B.>2+;^]5?X=P8$KT!S
MCC%0_MB?LMZ9^T_\,Y-. AL_%FFA[C1-2D&/+E(&Z%SC/E28 /H0K8.W!X?K
M5I<LE8Z?8W5TS\)JNV^BZA=0K+!874T3?=DCA9E/.."!ZBIO$WAG5/!OB#4=
M"UNQFTW5]/G:VNK2<8>*13@J?\1P>HKV;]FS]K#XC?!CQIX7MK#Q1J=UX5AN
MXH)_#]W<M+9FW:4&1(XVW"(G<Q#( 03GGD'LDW:\3G5KV9XJWA_5$4LVFWBJ
MHR28' 'Z50K[^_X*6?M1>/M+^-5_\._#_B*^\.^']+LH!<1Z7.T$EY)-$LC>
M8ZD,5VNJ[,XZY!S7P#2IR<HJ30Y)1=D%%%%:$A1110 4444 %%%>Q?LJ_L[:
MK^TI\6M.\-VL<T6BPLMSK.H1C M;4'YL$\;W^Z@YY.<85B)E)15V-)MV1X[1
M7=_'CPKIW@7XV^/O#FCQ&#2=)UV]L;2)I"Y2&.=T12Q))(4 9)SZUPE-.ZN(
M****8!5N32;Z'2K?4Y+.X33;B:2WAO&C8122QJC2(KXP642QD@<@.N>HJ.PL
M;C5+ZVLK.%[F[N)%AAAC7<TCL0%4#N22!7ZV_&C]BRVL?V![/P3IUJLWBGPI
M;?V\LL0RUQ>A6>[4$<L&5I%4?[$0_A%8U*BIM)]2XP<KV/R+HHHK8@**** "
MBBB@ HHKM/@Y\)=?^.'Q%T?P=X<MS-J&H2A6E()CMHA_K)I#V1%R3Z\ 9) *
M;LKL-]#BZ4 L0 ,D]!7L_P"V)\)]$^!_[0/B#P5X=$W]E:9;V*HUQ)OD=WLX
M7D=CZL[,V. ,X  Q1^QGX@\+^%?VGOA]JOC&2V@T"WOV,D]YCR893$ZV\CD\
M*%F,3;CPNW)QC-3S>[S(JVMF<-XK^#WCSP)H]MJWB3P7K^@:7<D+#>:GIDUO
M$['. &=0,D D#J1STKD*_>G]L#Q9X0T/]FCQW)XJNK-M,U#1[BVM(IF5C=7+
MQG[.L(_B??L8$?=V[N I(_!:LJ-5U4VT74AR.P4445T&05N>#_ OB/XA:N-*
M\+Z#J7B+4MGF&UTNTDN) @(!8J@)"@D98\#-8=?J+_P2#\3>%(? _C301/:0
M^-I=3%W)"Y"SW%B(46/;GEU23S\XSM\P9QN&<JLW3BY)%PCS2L?F;XD\+ZSX
M-UB?2=?TF^T358,>;8ZC;O!-'D9&Y' (R"#T[UF5^AO_  5\\3>$]4\6>!-*
ML)[6Z\7:=#=?VE]G*M)!;N8C#'*1WR)&53R Q. '!/YY44Y<\5)H4H\LK!11
M16I(4444 %%%% !1110 45]._LP_LF2?%+X7?$OXD^)+:>'POX>T#4)-,^<Q
M_;-0CMW=6!XS'$0">0"Q49(#BOF*H4E)M+H-II7"BBBK$%%%% !5BTTZ[U#?
M]EM9KG9C=Y,9;&>F<#V-5Z[KX3_&[QO\$=<CU/P=XCO]&;SHYKBT@G86UWL)
MVK/%G;(N&888'&XXQFD[VT#U.5_X1W5?^@9>?^ [_P"%4'1HW9'4JRG!5A@@
M^E?TI5_.U\8/^2M>-O\ L.7W_I0]<U&M[5M6L;5*?)U.1HHHKJ,0HHHH ^K/
MV#_^/SQM_P!<K3'3_IO_ )_#\_V@L/\ CQM^W[M?Y"OQ?_8/_P"/SQL<$CR[
M//'7F;C^=?M!8@K8VX(P1&O3Z"O%Q'\5GH4O@13\3?\ (MZM_P!>DO\ Z :_
M&#]NMMWB'PG_ ->DQ_\ 'UK]G_$__(MZM_UZ3?\ H!K\8/V[/^1B\)C/_+I/
MW_VU]Z>&_B(5;X&?+U%%%>R< 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]%_L._\E.UK
M@$_V.^,_]=X:\E^,O_)7/&?_ &&+O_T<U>M?L._\E.UH_P#4&D_]'PUY-\9O
M^2N>-/\ L,W?_HYJY8_QI>AJ_P"&CC:***ZC(**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "OK?X9\?L8>*,?W;SV[K]/Z_TKY(KZV^&G_)E_BC/3;>=O=?SK
MFK[+U1K3W?H?)-%%%=)D%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!];?M<<?!OX?C_ &HN
MV/\ EV':ODFOK?\ :WX^#?P_'3YHN.?^?8>O^%?)%<V'_AFM7X@HHHKI,@HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/XD#6'PR/DFBBBNDR"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "OIS]A7_D</$W_7C'SC_IIZU\QU]-_L*_\
M(W^)O^O"/_T97/B/X;-*?QH^?_''_(Z:_P#]A"XZ?]=&K$K;\<'/C7Q >O\
MQ,+C_P!&-6)6T=D9O<****H HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#ZV_:W_Y(W\/QR/FB^7_MV'^>E?)-
M?6_[6^1\&_A^#Q\T7&,?\N_I7R17-A_X9K5^(****Z3(**** /M3P7\5-?\
M@O\ L*_#WQ?X8O/L>K:?\2IF ;F.=#92[XG'=&7@C\1@@$?IG^SS\>_#W[1G
MPTL/%N@/Y1?]S?:>[!I;*Y !>)O7J"&XW*0<#.!^3WB1L?\ !-CPF,@9^(L_
M'_;E+7"_LF_M.:S^S!\3(=;M?-O?#][MM]9TI2,7,&?O*#P)4R64\=U)PS5P
M3H^T3:WNSIC4Y6D]C]!O^"C7[&O_  MSP_-\1_!UB&\::3!_I]G OSZI:H.H
M ^]-&!QW91MY(05^3_AO_D8M*_Z^XO\ T,5_1-X+\9:-\0O"NE^)/#U_%J>C
M:E MQ;74)X=3_(@Y!!Y!!!Y%?FC_ ,% /V-?^$!\=6GQ5\&V./#.HZC"=:L;
M=/ET^Y>10)E':*1CR.BN?1P%C#UK?NY%58?:1XE_P4G_ .3R/''3_5:?_P"D
M,'O7S-;6TUY<16]O$\\\KB..*-2S.Q. H Y))[5],_\ !2@_\9D>..<XBT_O
M_P!.,'O_ (?U/K7_  2=^!UCXP^(&O\ Q#U>U6YA\-+';:8DJY3[9*&+2C_:
MC1<#/0S CE01U*?LZ*D^R,>7FFT<#8_\$_+GP3\.8?&_QJ\?:?\ "?2)V1(+
M.2R?4;YW;E8S#&RX<J"VU2[* 2P7:<,\?_\ !/?5[?X5Q?$?X7>,;+XK>$FA
M:X=K*S>TNPBDAV6%F?=L*D,N0X(^X><>H_\ !8+Q;=W'Q"\!>&//86-KI<NI
M>2.%,DLS1[CZG$&!GIDXZFO6?^"0>M3W7P7\9:7)*SPV>O>=&C?P>9!&" ?3
M,><>N3WK!U)JFJM_D:<L7+DL?EQX/T2Q\2>)++3=2UZS\,V5P6#ZKJ$<TD$&
M%)&X0H[\D!<A3@L"< $C[*T7_@D[X\\2:19ZKI7C[P9J.FWD2SVUW:SW$D4T
M;#*LK"+!!'<5Y-^W]\*;/X2?M0>*+'3+=+32-4$>L6EO& JQK,,R* . HE67
M ' 7 [5]/?\ !*+]I%_,O?@[KET64B34/#S2$G&,O<6PYZ=95 ':8D\@5K4G
M/D]I B,8\W+(^7/VB?V/;S]F>.RA\4^/?#DVL7JK+;:58QW<DTD1DV-+GR=B
MJO)^9@3M. 3Q776/_!/F]U#X6P_$B/XM>!8_!$L9D36+F6[@B.',97#P!@^\
M%=A&[=QC-?H+^W1^R:?VG_!>A#2KFUTWQ+HU\IAO;K(C^R2LJW"L1V4!9!_U
MS(&-V:_,7]JSXT:;XMOM%^'7@>XD7X6^!XOL&D+OXU"89\Z^DQPS2.7*G'"L
M2 N]A44ZDJB5GKU*E%0;NM#G?A7^SKJ'QH^+4W@SPCXATG4[&W03W'B.0R6U
MG';C;ND"3(DI(9@@79DGT7+#]IOV=?V>_"G[./P^MO#GAB(3/(%FO]5D4>??
MS8_UCD=!_=4<*/4DD_S^U_19\+_^29^$O^P1:?\ HE*SQ7,DE?0JC:[T/SA^
M.G_!-[Q7XX^+'CGQ;;^/?!]G::KJ]YJ*6UW<S":)))6<(X$9^8 X(![<5^>-
M>I?M4<?M,?%7_L:-2[8_Y>9*\MKLIJ26KN82:OH@HHHK4@^I/V O ^CM\1-8
M^*GBXB'P7\-[/^V+J5E#;[LY%K&JGJ^Y6=<?QQH/XA7[3Z??V^JV%M>V<RW%
MI<Q+-#-&<JZ, 58'T((-?CI^T O_  SI^R?X!^#D6;?Q1XL9?%WBI02'16P+
M:V<=L;%RO0/;Y'WJ^TO^"8GQM_X6=^S^GAJ^N/-UKP;*NGL&)+-9L"ULQ]@
M\0'I"/6O+Q$7->TZ'92?*^0_./\ ;6^!_P#PH7]H3Q'HEK;F#0KY_P"U-)PN
M%%M,2=B^T;AX_P#@ />O":_7S_@J=\#_ /A8'P5M?&^GV_F:QX0E,DVQ<M)8
MRE5E& .=C"-^>%42'N:_(.NRA/VD$SGJ1Y9'J?[/_P "U^/WBH>&K3QEH?AG
M79V"V-GK0N%^VG:Q81ND;(" H^5F!;<-H/-?1/BC_@E#\1O"OAG5];N/%OA>
M:WTVSFO)(XGN=[+&A<@9BZD+7S_^R+_R=!\+,?\ 0Q67_HU:_=OQUKTGA;P1
MXAUJ*%+B73=.N+Q(I/NN8XF<*?8XQ6->K.G)*)I3A&2;9^37P#_X)=^/?BQX
M?MM?\4ZO!X TN[C$MK!<6K75](I *LT.Y!&I!XW/N]5'&<;]J3_@G/XL_9W\
M*OXKTS6XO&GAJWVB^GAM#:W%GDX#M%O<-'D@%@V03RH'-<9\#?CEXY\9?MD?
M#_Q7JWB.]NM:U3Q+9VEQ*TK;/L]Q<)') JYPL>QRH0< 8QTK]H/BYHT'B+X5
M>,M+N8UEM[S1KRW='&00T+CG\ZFI4J4YJ[T8XPC.+LC\ OAC\-=;^+OCC2_"
MGAZ.!]4U!RJ-=3K##&JJ6>1W;@*JAF.,DXP 20#^UG[(?[)_AC]F7P2$L)8=
M;\3ZDBG4]?51^^[B*+^[$I[=6(R>P'X55^\7[$/_ ":=\,O^P4O_ *&U/%74
M5KH%&USY>_:Z_8"\3?'+X^>(O&>F^-/"VDVFH):JEGJ=Q*D\?EV\<1W (1R4
MR,=B*^/OA/\ LCS?%SXB:YX$T_XA>%[#Q;IFH7EBFFW@NP;Q+<X>>&182C*<
M,0N[?A&)4#FMS_@I-_R>1XY_ZYZ?V_Z<8*QOV 9#'^V!\-RK%&-W<+P>N;2;
M(_+-:1YHTKWZ$2Y7.UNIZ=\2/^"7OQ#^'/P^\0>*=1\7^'+O3] TZXU"2WA>
MY+F.)&D94!BP"<'J0,GD]Z^+J_?[]JW_ )-E^*W./^*8U'K_ ->SU^,?[(_P
M6C^/OQ]\,>$KO<-(DE:[U)E)!^RQ*7=<CD%\",'L7!I4:KE%RGT'4@HM*)V'
MP!_85\:_&KPO+XSU+4+#P'X MXVGE\0:T2 \*!C)+%'QN5-IRSLB]<,<''JW
M@C_@FSX;^,_A&[UKX7?''3?%AM7>VD6YT.6S03@$A7S*SQJ05YV-D9(STKZV
M_P""E6M'P/\ L@:EI>D(NG6E]=V6DK#:H(TC@#;_ "U P%7;"%P.,<=#7QM_
MP3'_ &C_  O\$_&WBG0_&.J)HND^(H('@U"Y.((KB R85S_ &65OF/&4 /45
M"J5*D'./W%<L8R46?+OQ:^$/BGX'^.+OPIXPTUM+U:W"R#Y@\4T39VRQN.'0
MX/(Z$$$!@0/I#X3_ /!.+Q!\9?#,7BCP/\3O".LZ3Y[0BZ@%[$\<J$$JR/ K
MHPR#R <%2."#73_\%3/C5X ^+'B3P+9>#=9L_$5]H\-W]NU#3I!+;A93#Y<8
MD7Y7(,<A..!N'/)Q[Q_P2#=C\#_&2DML'B(D+V!-M#D_H/R%7.I/V2GLR8QC
MS\I\)?M1_LD^)?V5;CPY'XCUG2M7?75N'A.FF4[/),>[=O1>OFC&,]#G'%=E
M\#/V!]5_:(\,OK/@SXC^$KX6XC6^LY!>1SV4CIN\N16@'^T-RY4E6VDXKWG_
M (+($?VG\*!GGR=3_P#0K6C_ ((WL?[2^+ YQY.EGV/S7?\ G\:7M)>QY[ZA
MRQ]IRGBOQ._X)I?$_P"'5QX9M+:\TGQ1J&OZC_9UO:Z4TN8SY;R-+(TD:JL:
MJA);/%>M>&_^"0=[K'A\7%U\6-,75E)26WTW2VNK:.0=4\XS(QYQR4!'I7T+
M_P %//BSK_PO_9_MK;P]=/I]SXAU)=+N+V%RDL=N8WD=4(Y!?8JD_P!TL._'
MP9_P3A^*6I?#W]J#PYID-V\>C^)2^EZA:[ODE)1S V.FY90N#UPSC^(U,959
MT^=.UBG&$9\MCS?]HC]F'QO^S-XEATSQ7:1R6=V&:PU:R8O:W:CJ%8@%6&1E
M& (R#R""?):_>3]M#X1VWQF_9Q\8:,]OY^HV5H^JZ80/F6Z@5G0+Z%UWQ_20
MU^._[)-YX3T_]I#P!=>.)K>W\-0ZDLEQ-=X\E) K& R$\!!-Y6XGY0,D\9K6
ME6YX-O=$3I\LK'=>%OV&?$D/@6W\;_$SQ+H_PC\*7#*MO-KY9[VXW#</+M4^
M8D@,=C%7P"=N.:]<\!_\$T_"/QB\,W&I_#KX]:;XI>V.R55T0Q!'.2@D7[07
MBR >JG.#CI7UE_P4EL/!6O?LLZK=^(;^UAO;>2*[\/S+*OFS718*%B'5U9';
M<!D!?F_A!'S/_P $>8[L>.OB)(J3?8&TVV5W"GRS()6V@GINP6P/0FL?:SE3
M=1.UC3DBI*-CXZ^.O[/_ (R_9U\8GP[XQL$@GD3S;6]M6,EK=Q]"\3D#(!X(
M(##N!D5ZS^Q?^QC=?M*:TFKZUJ4&C>![.Z$%PRSJ+N^D #-! F<C@KEV&!N&
MT,00/LO_ (*[:+:77P!\+:J\$9OK/Q)'!%.P&]8Y;:X,B ^C&*,D?[ ]*^ O
MV)?^3KOAC_V%T_\ 06K6-252ES;,S<5&=C]IO%?POTZ/X%^(/A_X9M[+P]IT
MV@W>DV*8*6]J)('C5FQS@%MS'J>3R37Y'?'#]@/Q+\#/AMJGC+4O&OA75K2P
M:%6L]-N)6N)#)*L8VAHP#@OD\] :_6W]HSG]GOXG@_\ 0KZIVS_RZ2U_/?6&
M%4G=IFM:RLK'2_#OX;^)/BQXNL?#/A/29]9UJ\;$5O#@8 ZNS$A44=V8@#N:
M^H/$W["/@KX1W&CZ1\6/CSHW@WQ1JD?F1:79:--J"1*3@/)*'38A.1N=54E6
MP2%./L;_ ()@_ ZQ^'GP%M_&5Q;*?$?BYFN7G=?GBLT<I#$I_NG:9>.OF#/W
M1C\YOVWO%UWXR_:K^(]U=3M/]CU6338@>B1V^(0H Z#Y#^))/)-;JHZE1QB[
M)&7*HQ4GU-C]I[]B'QO^S+;P:O=SVWB7PC<.(XM<TY6"QL?NK-&<F,MV(+*>
M!NSQ7SK7[K_L_P"B6'QH_8M\%Z'XDC_M"PU?PO#IUUY@!8JL?E!@2/OKM#!N
MH8!NM?E/^R[^SZ?B-^U?I7P^UV#SK'2M1N&UF,'Y6BM2QD0_[+NBQ\<_/VZT
M4ZUU+FW03IZKEZG<?LX_\$W?B!\=_#]IXEU2^M_ _AF\7?:SW\#S7=RG:6.W
M!7]V><,[KD8*@J0:T/B5_P $[6TVQU5_AA\3_#_Q3UC1XFFU'P[I[11ZE"J\
M,5B2:7<0?X3M/8;C@'])_P!K_P <7/PO_9A^(.N:8[6EY;Z6;6VEARK0O,ZP
M(ZXZ%3*"#V(%?ACX!\>:W\,?&6D>*?#E])IVM:7.MQ;SH>XZJP_B5AE64\,I
M(/!J*4ZE6\KV*G&,+*Q_1G7\[7Q?S_PMKQMGK_;E]_Z4/7]$M?SL_%[_ )*S
MXVX(_P")Y?=?^OAZRP>[+K[(Y*BBBO3.0**** /JS]@__C]\:=/]79X]>LW3
M_/I7[/Z>-NGVPQC]TO [<#VK\8/V#S_IGC;U\JS)X]YL?Y]Z_9_3QML;8 8
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MXM?3Y-0O+%=0B;39FEC\MI'C )95^;,;<8Z8KS"J34E=$M6T84444P"BBB@
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M+ZC:S3!?DC=Q;-&I/JP23'^X:SO^"-__ "%/BOU_U.E]^/O759?\PW]=R_\
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M7Y&>&_V ?B'I?C*Z_P"%D6<?@CP'HKF?6O$]S<QFW%JI^8P$$F1W'" +U89
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M\)_LU? /4/B=\6=%U'XA:]:PQR2>%=+O&M;.U,CJH$LT?[QMA8;G4[1D@*X
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M4TPFGOU(M&A9G 4;55G  48R>,YI*IJDU:X<FC:>Q\;4445L0%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'UM^UO_P D;^'_ /O1
M<'K_ ,>U?)-?6_[6_P#R1OX?\'&Z+K_U["ODBN7#_P ,UJ_$%%%%=1D%%%%
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M3YM0T6^L)-+OUM0#/%$[QR"2,$@$AXDR"1D%N^*^H/VWO^"A7@;XL?!J_P#
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M2ZKX;U.)KK2=0F4+(T8;#Q2 <>8A(!( #!E8!<[1,:RE+D>C'*FTN;H>K?\
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M@%Q(K1J7>$MW20*5(/ )5NJU\7?\$B_AUJ&I_%KQ1XU>V/\ 8^E:4VG+<,,
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M2:JC+VJ3?3\PJ1Y+I=3Z4_X)F_\ )X'A3_KUO_\ TEEK],_V[_\ DT?XE?\
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MATX-<M;]W54T;4_?@XGPE^PSXRTC]G72_A)\/]2ABCU_XI0WGB&ZFD.'MHR
MNG#/=94ADP/[S\5]!_M]?"/_ (6]^S'XIM;>'SM5T5!KEB ,GS( 3( .Y:$S
M*!ZL*_*3]HWXW2^*?VG-1\8^&)EM;'P_?P6_AWR?]7!;V15;=D'928_,QZN:
M_;GX9^.M.^+7PV\/>*[%4?3]<T^*[$)(<)O4;XV]2K;E/NIJ*T7!QJ%4VI)P
M/QT\*_\ %G?V'?$VND^1KWQ0U9-$L3R'&F6A+W,B'^Z\I\EAW&/P^8:^HO\
M@H+XAT>U^+FG?#;PM&+;PG\/M.32+2!'W+Y[_O;A\_WBS*K>\9KY=KT:>JYN
MYR2WMV"BBBM20HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OK?X
M9Y_X8O\ %'7[MYZ'NM?)%?6WPT_Y,O\ %';Y;SMCNOYUS5]EZHUI[OT/DFBB
MBNDR"BBB@#]QO^"=YS^QO\.N<_NKW_TNN*J_M6?M4Z)^S'\1OAE)K/AR#4+3
M6VO+>\UH<W.G6JF$/Y2A2S N\;,,\B+ !."MK_@G><_L;_#KG/[J]_\ 2ZXK
MY9_X+( _VG\)SC@PZIS_ ,"M:\>,5.LXOS.YMQIIKR/TCM;K3/%>@Q7$#VVJ
MZ/J5N'1UVRPW,,BY![AE93]"#7XT?MZ?L?S_ +./CC^W- MI'^'NN3L;)QEA
MI\YRQM'8Y., E">2H(Y*,3ZS_P $T_VR#X1U.T^$?C*\_P"))?3;=!OYWP+.
M=R2;9B?^6<C'Y?[KDCD/\OZ4?$KX<Z#\6O ^K^$O$UDM]HVIP^5-'T93G*NA
M_A=6 93V(!IIRPU2SV!VK1\S^=*OJ3_@FO\ #VT\?_M5Z#+?1+/;:!;3ZWY3
MKD&2/:D3>Q666-P?5!7F'[2G[/>O?LU_$Z^\*ZP&N;,DSZ9J83:E]:DD+(!V
M88PRY^5@>2,$^T?\$LO$D.@_M66UI+(D9UC1KRP3<0-S#9/@>_[@_E7H5)7I
MMQ[')%6FDS[^_P""@WPQU[XN? .+P_X?N=,M;EM8MIYI-6O4M(?*5)> [\;M
MQ3CZU\M_L,?LZ^(OV?\ X[1^*/%7B+P?;Z,=-N+21K;Q#;RON?:5PH;U7]*^
MO_V[/AC?_%C]EWQGI&DVWVO6+:.+4K2$#+,T$JR.JCNQB650.Y85^%-<E"+G
M3<;G14?+).Q^G/\ P5IF\+^+/ASX&U[2M9TO4]2T[5I+$K97<<L@BGA9R2%8
MG:&MUYQP6]Z\:_X):?'#_A7OQNN/!6H7&S1O&$0ABWMA8[Z(,T)YZ;U,D?')
M9H_2OC[_ (1G5CX;/B'^SKG^PQ=BP.H>6?)^T%"_E;NF_8"V.N*@T76+WP[K
M%AJNFW,EEJ-C/'=6US$</%*C!D=3ZA@#^%=2I)4W3N8N?O\ ,?M[^WM\$6^.
M'[.>O6=E 9M=T3_B=::J#+/)$K;XP!R2\32*!_>*'M7YA?L.Z#8VGQ/U7XD:
MY )?#GPYTJ?Q%<*W FN54K:PJW:1I6#+GJ8S7[$_ ?XKV7QO^$/A?QK9;$&J
MV:R3PH>(;A<I-'_P&17'N #WK\X?VXO!F@_LJ_#K6OAWX7EC%Q\1?$<FOW<<
M2[3;:7!M-M9D?W%G=RAY_P!6<UQT9.SI/^NYO42TF?#?BCQ)?^,?$NK:]JLW
MVC4]4NY;VZF_ORR.7<_B6-9E%%>F<85]X_\ !(/_ )+AXR_[%T_^E,-?!U?>
M/_!(/_DN'C+_ +%T_P#I3#6-?^&S2G\:/T$_:\_Y-=^*7_8O7G_HHU^!5?OK
M^U[_ ,FN_%+_ +%Z\[?],S7X%5SX3X6:U]T?KY_P23'_ !C/K/\ V-%U_P"D
MUK[?X_TKP/\ X+!7EPWQ2\!6K3R-:QZ-+*D!<E%=IR&8+V)"J">^T>E>^?\
M!),?\8SZSQC/BBZ[?].UK[?X_P!!\^?\%@/^2O>!O^P$W_I0]1#_ 'AE2_A(
M][_X)$_\FV^)/^QMN?\ TCLZ\6_X+$1J/'?PX<*-[:;=*6[D"5,#]3^=>T_\
M$B?^3;?$G_8VW/\ Z1V=>,?\%B!_Q7'PW/\ U#KO_P!&QTH_[RPE_".K_P""
M/?@.VCT/X@>-)(U>\EN8-'@D*\QHB^;* ?1B\.?^N8J?_@L9K$T/A/X8Z4&(
M@N;Z^NG7/!:*.%5/7TF;MWK3_P""/OB:&X^%_CSP]YJ_:+/6([\Q9&[;- J
MXZXS;FL__@L5H\TW@[X::JH;R+6_O;5V[;I8XF7](6_(T?\ ,3K_ %H'_+G0
M^4O^"<+$?MG?#W!QG^T<_P#@NN:_5;]L[_DU7XH<9_XD<_ ^E?E3_P $X?\
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M%^W+\(;GX._M*>+K)H3'IFKW+ZUISXPK07#LY5?9'\R/_@%>"(C2.J(I9F.
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MC0Y9\]S:53FCRV"OT$_X)\_MX:-\,= A^&OQ&O'LM#CE9M'UIP7CM=[9:";
MR$W$LK\A=Q!PN"/S[HK:<%4CRLSC)Q=T?H!^T=^Q#>?&?XVZQXW^''C;P;J'
MA#Q%-_:%Q?3:U'LL96&92Q3=O4L"P*Y^\00 ,GW[XH?ME?#7]D7X+:1X$\$Z
MY8^-_%ND:7%IEC#8NLT$<B($,]TZ-M7Y@6,:MN).,*#N'Y T5BZ/-92=TB_:
M6NTMSN/ YB^)OQM\/?\ "87\D\/B#Q#;#6+^5\.ZSW*B>1F'0X=B3VK]K?VC
MOV4?#'[1'PPTGP7/=3^&+/1YXY]-?2XUV0;(VC$9B/RE-K=!@C P0,@_BW\
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MCG4Y]T?OEX/^/?P<\)^$]$T-/B[X(G73+&"R$I\168+B.-4W8\WC.W-?E/\
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M%:5*<:D>5D1FXNY^K/[77['?PB^(OCBX^*>J?%C3? 6GWD<<NJ1JL5PMZ44
MO ?-4B1D51A5DW-SM))!]<_99^/GPCTOX"V4FF:CI?@+P9I=W<:=ID6O:E##
M<3Q1L"9Y-S#]Y*[.Y SRV*_$JBL7A^:/+*1I[6SND??O_!1OQU\$OC?=Z=XB
M\-_$R.[\7:/9-9#2[339[B"]C+ET N,*D94M)DY;.X<#'/S7^Q]\=+?]GCX\
M:%XLU&*6;1=LEEJ20+F3[/*N"RCN58(^.^S'>O%J*VC348<FZ,W-N7,?O3\3
MV^%G[47P-U?1[GQGI<WA;5H4?^U++4(E-NZ.)$?+'Y65T&58#H0<<U\O_LK^
M-OV<_P!FWXL7W@OPKXKL=4N+BPEGUCX@Z_?P6]J&1HQ%96LAVH5)9W8J3DJ/
MF? $?Y;45BL/:+CS:&CJW:=C]J_VL_B!\,?CK^SWXP\$Z)\7OA_#J^H1P/;-
M=>)+,1F2&XBG"$B3Y=PCVY[;L]*_&P2ZCX#\7>997\46K:-?;H+_ $VY2:-9
MH9/EEBE0E7&Y0RNI(/!!(K'HK6E2]FK7(G/G=S]K/V7?V^O 7QP\+V5KXBUC
M3_"7C>*,)>:=J$ZP17#@8\RW=R%8-UV9W+R,$ ,<K]IS]F?]FSQYK%SXV\=Z
M_:^$M1*^;>WVG:O%;->[0 -T;!P[87;\BAVSCDXQ^-%%9?5E&5X2L7[6ZM)7
M/H']I'XR>!M3TV#X=?!W0VT'X<:?=F[GO)BYN]=N@"BW$Q?YPBJ7\M#C&]B5
M7(5?;_\ @FC^UQX7^#$>N> O&U^NBZ/JMXNH6&J3 ^1%<%%CD25A]T,J188_
M*-K9(R*^#Z*VE34H<C,U-J7,?KC^W!H_[/OQNTOP[XD\4?%[3M-&@B4+#X=O
M;>^N;^&3:QBCB5F.[*C#X*C<=PQ@C\M_BAXHTGQAXZU34] T*W\-:$S)#I^E
MVR@>1;QHL<>\_P <I5 SN>7=F8]:Y:BBG3]FK7N$I<VM@HHHK8@^E?V/?VV?
M$/[+NJ3:?<6\OB'P/>OON='\[8\$AP#/ Q!"MCJIX? R0<,/LOX[WOP'_P""
M@W@?2O[$^(VE^%_'.F*TFGMK1%K,H< R6TT;E?,4E0=T9?802I(+!OR?HKGE
M14I<ZT9I&HTN5ZH^LX?^":WQ)^W8G\2^!K?21AO[8.N VS(<?,OR;R,'/*BO
MKCX8_$;X ?\ !/GX8WFB)XUM?&/B^Z(N-2&A[;FXO)U&%C&PE(40$X61QU8\
MEL5^2E%$J3GI*6@U-1UBCW+]JK]K+Q/^U+XNBOM2C_LCP]8Y73=#AE+QP ]9
M'; WRGNV!P  !W\-HHK:,5%61FVV[LT?#OB"_P#"?B#3-;TNX:TU/3;J*\M;
MA.L<L;AT8?1@#7Z;_MP?MA:;XJ_8]\)CPY=QQZG\1(5^TV\,F7M+>+!NXR1T
M/FA8>?O R>E?EO143IJ;3?0J,G%-+J%=9\)_B5JWP>^)'A[QGHC+_:6CW:W*
M(Y(25>0\38YVNA9#CG#&N3HK1JZLR#]Y/@C^V#\+?CUX?M9]-\2:?IVKS1J+
MGP_JMPD-W$YP"@5\>:N2!N3(.1T/%?-?QZ_9(_9)\'ZE>^+?$7BR?PI 9//?
MP_H>JP%)F.&*16_EO* <_=C*JH;C:,8_*^BN2.'Y7>,K&[J\RU1Z=\?/C#;_
M !:\46:Z)HT?ACP5H=M_9V@:#"<K:6P8L6?^]+(S%W?DDGDG&:_0W_@G;J'@
M+]GGX4ZS%XO^*O@"UUG7-06[^QP^)[-S;PB)519#YF Y)?*C.!CG.0/RDHK6
M=/GCR)V1$9\KYC]1_P#@HU#X._:,\+>$)_!GQ5^'UWJ&@3W)EL;CQ590F6.9
M8_F1FEVY4Q#@XR&XZ8/Y<4455.'LX\MQ2ES.X5VWP4^*%]\%_BMX8\:Z=N:?
M1[U)WB4X,T)RLL6?1XV=/^!5Q-%:-75F1MJ?I'_P5,_:2TWQ-X-\$^!_"VIQ
MWMAK,$?B*^FMWR'MR/\ 14./[Q+N5/(V1GO7YN445G3@J<>5%2DY.[/LW_@G
M#X9T+PC\5K#XE>+/'O@WPSI%G:W4-O9ZIX@M8+V65U,7,#.&10"YRV,_+@$'
M(^]_VB/BA\*/C%\$?&?@VQ^+W@*WO]6TZ2&UDN/$=H(Q,,-&'(D)"EE4$@$@
M$G!QBOP[HK*=#GESMFD:G*N6QZ'X3\3:Y^S?\:-+US3+[3-0UCP[>1SK-I=_
M'>6=PI4;XQ-"Q5E='9&VG(RPX(K]H?@E^V#\+?CUX?M9M,\2:?IVK31J+G0-
M5N$ANXG. 4".1YJY(&Y,@Y'0\5^#=%54HJK:^XH5'#8_5#X]?LC_ +)7@_5+
M[Q9XC\63^$X3)Y[^']#U6 I,QPQ2*V\MY0#G[J$!0W&T8Q^?OQ\^,-O\6O%%
MFNAZ-'X7\%:';?V=X?T"%LK:6P8L68Y^:61F+N_))/);&:\QHJH4^7=W)E+F
MV5@K]/\ X?\ [84>E_\ !-G4+UM1$?C'1H&\(6R[\3&1@$MY4&<_);N&W'@M
M"WTK\P**=2FJEK] C)QV"OTW_P""</[3VF^$/V;_ !]H_B&[C4>!DFU>SADE
M"--:R*\ABC!ZGSE?IWG45^9%%%2FJD>5A&3B[HTO$OB&^\7>(]5US4YC<:EJ
M=W+>W4Q_CED<N[?BS$UFT45H0%%%%, HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "OK;X9_\F8>*?\ =O.A]UKY)KZW^&>?^&+_ !1U^[>>A[K7
M-7V7JC6GN_0^2****Z3(*['X=_#"^^)4UVEGK7AO15M6C$DGB+7;73%(<M@I
MY[J9 -IW; Q&1GJ,\=12=^@'[>?LV?$/X2? WX'^$? UW\8_ =]>Z5:L+B>'
MQ':;&E>1Y9-F9,E0TA ) R .!TKPW_@HAIO@G]ICPUX0O?!GQ=^'DVJ^'9+K
M.GW7BBRA%S'<"+)20R;0RF!>&P"&)R" #^6M%<D</RSYT]3=U;QY;&[9^$;J
MZ\9_\(VE]I45XMVUI]MEU.!+$,K$%_M1?RO+XR)-VTC!!.17[:_!7]HCP3H/
MPG\+Z=X[^,O@"_\ %MI81Q:C=0>)K-E=UR Q8R#<VT#<W=@QK\+:*TJTO:I)
MLB$^0_;/]H[4/V=OVE_ ,OAGQ%\5?!%O<Q-Y^GZK!XALC/8S8QO7,O*D##(>
M&'H0K#\JO%_@G5OV9/B%H6O:#XW\)>*IK"^6[T[4_"^LPWR[HF5E\V)&WQ@\
M AA@_, 6YKR&BBG2]FK7NARGS:V/W/\ V>_VWOAI\>/#=E+_ &]8^&_$Q0"[
MT'5+E(94DQ\WE%R!,G!(9><8W!3Q7BO[1'[(_P"RI;ZQJ'C'Q1XM/@;S7\^X
ML-$U6!$N')R?+MC'(^6Y.V(#N0!UK\FJ*S6'Y97C*Q3JW5FCU_\ :*^,6B_$
M?5M+T+P1HG_"+_#?PVDEOHFE$YD?>P,MU.<G=-*0I)). JC)P2?(**^]H_\
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M5$HSM)!QD=.HK\9/B3\%[[X:R0>;XH\'>)(9Y_(CF\-^(K6_!.,[F5'WHO\
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M3ZE<16GB:SD2'>L:*F_S,,=L2DD<<XYQD_C[16E2G[1<M[$PERNY^B?_  5
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MXKEL?JE^QG^VA\&K'Q1XC\$:5H.E_"7PCF*;0IK^;;)?/\PE:\N'=AYI'E;
MS' #+O.!FS_P44\<? ;QMX-T*^UOQ:OB77M&%T=)T/POJ4,IN9)T5<SNH?RX
MU:)&+9!(5@ 2>/RDHH^KKGYTQ^U?+RV/NW_@F?H?ASX:^.+OXC^,?B%X)\.V
M-QI,UC9Z;?>(K6.^9WFC)=XB^8U B;A\,=RD#'-?7?[6WCWX8?'G]GGQ9X+T
M7XN?#Z/5M0C@EM'NO$MH(S)#<1S!21(<;A&5![%@:_%>BB5#FGSW"-3ECRV+
M^O:++X=UJ\TR>>SNIK60Q/-874=U Y'=)8V*.ONI(JA11728A1113 **** "
MBBB@#Z;_ &%?^1N\3]?^/"/_ -&5\_\ CC_D=?$&>O\ :%Q_Z,:OH#]A7_D;
MO$__ %X1_P#HROG_ ,<8_P"$T\08Y']H7'_HQJY8_P :7R-9? C$HHHKJ,@H
MHHH **** "BBB@ HHHH **** .G\ _#Z]^(FI365GJF@Z2T,8D>;7]9MM-BP
M6 PKSNH8\YVKDX!.*_7[]D7Q9\+/V>_@/H'@W5?C'X!O=6MVFN;R6U\1VAB$
MLLC.50F0$A00N<#."<#.*_%JBL*M/VJLWH:0GR:V/U3_ ."AFG^!/VEO!_AB
M?PA\7?A[)K?AZ>X86%UXGLHA<Q3+&&VR&7 93$G!P"">1@ _F!XG\/3^%-=N
M])N;FPO)[9@K3Z7>Q7EN^5!^2:)F1QS_  DX.1U%9=%.G3]FN6^@I2YG>P5]
M2_\ !/SPQH]G\;="\?\ B7QQX3\(Z#X?GF:2/7-;M[2ZN7,#*HBA=@Q7,JDN
M<+PP!)&*^6J*N4>:+1,79W/W;^+?QG^$/Q*^%?C+PG!\7_ =M<:WI%WIL<\O
MB*T*122PLBNP$N< L#CVK\T/V-_AGIWA']IK3M8\4>/_  +HVC>$+WSKB\G\
M2VHCO6,3&,6K!\3#<R[F! 4 @_,-I^4Z*PA1Y(N*>YK*IS-.Q^]/Q"^.7P?\
M<> ?$OAP?%WP-;G6-,N=/$S>(K,A/-B:/=CS>V[-?BSI*O\  ;XW>'KZ]N-)
M\2#PYJ]EJ;2:'J$5]:72Q2I+M26,E3D+C'4'@@&O/**JG15.ZON*=3F/WV\/
M?M7?!OQAX1CUV'XB>&X=-GBW20ZEJ,-O-&".4DAD8,K=MI'/;((KX8L?VHOV
M:O@%\>-'G^%7@.WDL9KXQ:UXMG%Q(+6!P5;[#%*Q90"Q+,JKE595#!AC\\**
MSCAHQOJ5*LWT/W:^+OQH^"'Q ^#/B33M:^*'AV+P]K&FRV\UQ8ZI!+<*KJ1F
M.)2S-(#R%VDY&,5^8G[*^O>#-%_;D\%WWA07FF^#[>ZEA@N-=G0S,GV*2-YY
M2 JH7)9]HX7=C)Q7S!150H*$7&^Y,JG,T['W=\;OV3_AS\>O&FH^)_@%\2/"
M,LE],\UYX4OK[[(\<I/S/;!QN*,Q)VE0JD_*VTA5^@?A[\6/"7_!/O\ 9BM_
M#'BGQAI7BSQQ$]S<V^@:+="<B:1B4BXYCB!&6D<#DOM#' /Y(44W1YDHR>@*
MI9W2U-/Q-XBOO%_B35M=U.7S]2U2[FO;J7^_+(Y=V_%F-?KC^QM_P4 \'?$G
MP/I'ASQYK]IX<\<V$*6DDVJ3"&#4PH"K,LK?*)&XW(2"6)*@@X'X]T5=2E&H
MK,F,W!W1^T'[3'[,/[/'QBOO^$S\8^([3PG?O"&GUK2]7MK7[6B@;6D\Q71R
M!@!@NX@J,D!0/SH_:*^*'P\TGP^/A;\%K2=/!,-REWJOB&\)^V:_<H"(RY*J
M?)CW-M7:HW,6"CJ?G:BIIT>3=W*E/FV5@HHHKH,CLOA_\+=0^(RW;6>L^&M(
M2V=$<^(-?L]-W;L\H)Y%+@8YV@XR/6OUP_9#\3?"G]G7X%Z+X/U+XR> ;_5D
M>6[O9;?Q%:>4)I6W%$S+DJHPN[ SC.!G%?B[16%2G[16;T-(3Y-4C]._^"B7
MAWP7^TA;^%-9\%?%KX>7&JZ*D]O/IUWXILH3/'(496C<R;0RE#D,1D-UXP?S
M7\2:#-X7UR[TJXN;&\FM6V-/IMY%=V[G .4FB9D<<]5)'6LRBJIP]FN6XI2Y
MG<****U("BBB@ HHHH **** "BBB@ HHHH *^M_VM_\ DC?P_P#]Z+KU_P"/
M:ODBOK;]K?'_  IOX?\ KNBZG_IV%<M3^) UA\,CY)HHHKJ,@HHHH **** "
MBBB@ HHHH **** "OLC]B/X.Z3X,^,WA?Q_XT^)?P_\ #VCZ4K7L=I)XKL9+
MN>1X65$*+*?+P7RV\@C;C'.1\;T5$XN2M<<79W/Z"/\ AIKX/?\ 15_ _P#X
M4=G_ /'*_%KXW_ %/AOJ>MW^C^.O!7C#P[#<G[+<:+XBLY[J6-WPF;59#)N
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M#/7^T+C_ -&-6)6WXXQ_PFGB#'(_M"X_]&-6)6T=D0]PHHHJA!1110 4444
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M]6*&[TK2;BYBW X*[D0C(]*Y;4M-O-&U"XL=0M)[&]MW,<UM<QM')&PZJRL
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MU%%%=1D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M***]DX HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#Z+_8=_P"2GZSU_P"0._\ Z/AYKR7X
MR\_%SQH?^HQ=_P#HYJ]9_8=_Y*=K6!S_ &,__H^"O)OC-_R5SQI_V&;O_P!'
M-7+'^-+T-7_#1QU%%%=1D%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7UO\
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MGQ)IFEPBWT_4M/E5;J.%0 D+H^%<*/E#;E(  (/6N0_:<_;LT?XJ+KD'P]\
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M9!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5];_#/C]B_P 4<X^6\[>ZU\D5
M];_#/_DR_P 4<?PWG3ZK7-7V7JC6GN_0^2****Z3(**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#ZW_:W_Y(W\/^#C=%U_Z]A7R17UO^UO\ \D;^'_\ O1=>O_'M7R17+A_X
M9K5^(****ZC(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KZ;_ &%?^1N\3]?^/"/_ -&5\R5]
M-_L*_P#(W>)_^O"/_P!&5SXC^&S2G\:/G_QQ_P CKX@SU_M"X_\ 1C5B5M^.
M,?\ ":>(,<C^T+C_ -&-6)6T=D0]PHHHJA!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'_@*G^->E]9I=SC]E/L?&]%?9'_#"6C?]#3J'_@*G^-'_#"6C?\ 0TZA_P"
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M]G?\,"Z=_P!##JG_ (!K_C1_PP+IW_0PZI_X!K_C1]9I=P]E/L?&-%?9W_#
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MX!K_ (T?\,"Z=_T,.J?^ :_XT?6:7</93['QC7UO\,_^3+_%'?Y;S^:UL?\
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MQ:I_X!+_ (T?\,"Z;_T,6J_^ 2_XT?6:7</93['QC17V=_PP+IO_ $,6J_\
M@$O^-'_# NG?]#%JG_@$O^-'UFEW#V4^Q\8T5]G?\,"Z;_T,6J_^ 2_XT?\
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M+IO_ $,6J_\ @$O^-'UFEW#V4^Q\8T5]G?\ # NF_P#0Q:K_ . 2_P"-'_#
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M'_0Q:K_X K_C1_PP'8?]#%JO_@"O^-'UFEW#V4^Q\8T5]G?\,!V'_0Q:K_X
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M_P## >G_ /0PZK_X K_C1_PP'I__ $,.K?\ @$O^-'UFEW#V4^Q\845]G_\
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M_0PZM_X!+_C1_P ,!Z?_ -##JO\ X K_ (T?6:7</93['QA17V?_ ,,!Z?\
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MO_ )?\:/K-+N'LI]CXPHK[/_ .& ]/\ ^AAU7_P!7_&C_A@/3_\ H8=6_P#
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M .& ]/\ ^AAU;_P"7_&C_A@/3_\ H8=6_P# )?\ &CZS2[A[*?8^,**^S_\
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M?_ %?\:/K-+N'LI]CXPHK[/_ .& ]/\ ^AAU;_P"7_&C_A@/3_\ H8=6_P#
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MZ?\ ]##JW_@$O^-'UFEW#V4^Q\845]G_ /# >G_]##JW_@$O^-'_  P'I_\
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M_C1_PP'I_P#T,.J_^ *_XT?6:7</93['QA17V?\ \,!Z?_T,.K?^ 2_XT?\
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M-%?9W_# NG?]##JG_@&O^-'_  P+IW_0PZI_X!K_ (T?6:7</93['.?L(?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'D7[2W_ ")FG?\ 807_ -%R5W?P[_Y$+P[_ -@^
M#_T 5PG[2W_(F:=_V$%_]%R5W?PY_P"1!\._]>$/_H H Z*BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *\$\9-_QD5HV/[]O_(U[W7@?C'_ ).*T?\
MW[?^5 'OE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 >"? ,_\ %P/%'IM?_P!&U[W7
M@?P#_P"2@>*,= KC_P C5[Y0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% '@GP#/_%P/%'8;7_]&U[W
M7@?P"_Y*!XG_ -Q__1M>^4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "O _&/_ "<5H_\ OV_\J]\KP/QC_P G%:/_ +]O_*@#WRBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** / _@'_R4+Q0?]F3M_TVKWRO _@&/^+A>*#C^!__
M $=_G_/3WR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** / _@%_R4#Q/CIL?_T;7OE>!_ +_DH'B?\
MW'[Y_P"6M>^4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KP/QC_ ,G%:/\ []O_ "KWRO _&/\ R<5H_P#OV_\ *@#WRBBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** / _@&/\ BX7B@X_@?M_TV^G]:]\KP/X!_P#)
M0O%!_P!F09Z_\MO6O?* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH \#^ /_(_^)_\ <?\ ]&U[Y7@?
MP"S_ ,+ \3YR3L?K_P!=:]\H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KP/QC_P G%:/_ +]O_*O?*\#\8_\ )Q6C
M_P"_;_RH ]\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#P/X!C_BX7B@X_@?G_ +;?
M2O?*\#^ ?_)0O%!Q_!)SC_IM7OE !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 >!_ +_DH'B?C'R/T_
MZZU[Y7@?P"_Y*!XGQTV/_P"C:]\H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_G_/?Z4G\/U';Z 4 +_GM]/Z_P">YZ=?\G_]5'\1^H[^_P#G\Z.G;I]?3/\
MGZ?D &[;R.".?R__ %?I^1VP.>>!GKQC'^<?X'L3QT/Y'/\ GV%&3RV.>?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7@?C'_DXK1_]^W_ )5[Y7@?C'_D
MXK1_]^W_ )4 >^4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X'\ _^2A>*/]Q__1WK
MBO?*\#^ ?_)0O%'^X_\ Z.^G]:]\H **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#P/X!?\ )0/$_P#N
M/WS_ ,M:]\KP/X _\C_XG_W'_P#1M>^4 %%%% !1110 4444 %%%% !1110
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M** / _@'_P E!\4<?PR=O^FU>^5X'\ _^2A>*#C^!^?^VQ[X_K7OE !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK5C_ -.DW_H!KY(\*G]S<]\,._LW^?\ ]5 &\O4?A_6F_P /_ ?Z?Y_ST?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-_X#GW_V/I0?BA;\XU1O_ <^_P#L?2O):*/J=(/K$SUH_%"WYQJC?^ Y]_\
M8^E!^*%OSC5&_P# <^_^Q]*\EHH^IT@^L3/6C\4+?G&J-_X#GW_V/I0?BA;\
MXU1O_ <^_P#L?2O):*/J=(/K$SUH_%"WYQJC?^ Y]_\ 8^E!^*%OSC5&_P#
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M&45D>']6^W0>7(VZ=!U_O#UK7KP9)Q=F>FG=704445(PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \#^ 7_)0/$^.FQ__1M>
M^5X'\ O^2@>)_P#<?OG_ ):U[Y0 4444 %%%% !1110 4444 %%%% !1110
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MO\_Y_/\ SW/?M_DTG;\!_7_/^<4-]UOH?_010 OJ/T_3_/\ G)_//]?\2/\
M/5?XO^!?Y_S[_FU?NK]!_P"@F@!?3\._N/\ /^<D';\O\_Y_^L>GX?S'^?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *2EHH [WP'XFD!2W=_\ 2(.8G8\L
MH'*G]![CZ5['8WB7]LDT?1N"/0CJ*^889GMYDEC8I(AW*PZ@^M>P>!_%B7,:
M3GY0WR3Q@_=/]['?I^1KQL9A_MQ._#U?LL]&HI%8,H(.0>12UXIZ(4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >!_ '_ )'_
M ,3XZ;'_ /1M>^5X'\ ?^1_\3\8^1_\ T;7OE !1110 4444 %%%% !1110
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MO^/2+_KIVZ'C_P"O_P#JKZL\#\>"] [?\2^W_P#1:U\I^*CFSCZ']YV_W?\
M/^>GU9X'X\%Z!V_XE]O_ .BUH VZ*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH \B_:6_P"1,T[_ +""_P#HN2N[^'/_ "(/AW_KPA_]
M %<)^TM_R)FG?]A!?_1<E=W\.?\ D0?#O_7A#_Z * .BHHHH **** "BBB@
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M%,\3'G*E&7@X;L/T!JEJFBZ=KMN;?4K"UU" @@Q74*RK@C!&&!'(H ^<K?\
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MTHR-IF@Z;;Z9;--@R-'#&L:LQ  +$+DG'))H Z*BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /GSP;_ ,BOXK_Z_;OV_@!_S_6N:KI?!O\ R*_BH_\
M3]=_^BU_Q_SWYJOHL#_#/*Q/Q!1117HG(%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !6CH.L/HNH+.,F)OEE7U7U^HZ_
M_KK.HJ6E)68T[.Z/H+PGKD=S!'#YBM$Z[X&]0>U=-7@/@GQ"UG<+92MA';,+
M9^Z_)Q]"?UKV[1M2&I6NXG]ZG#\?D?QKYO%472E?H>M1J<Z-"BBBN(Z0HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#P/X!9_X6!XGR
M<G8^><_\M:]\KP/X _\ (_\ B?'38_\ Z-KWR@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH \B_:6_Y$S3O^P@O_HN2N[^'/_(@^'?^O"'_ - %
M<)^TM_R)FG?]A!?_ $7)7=_#G_D0?#O_ %X0_P#H H Z*BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *\#\8_P#)Q6C_ ._;_P J]\KP/QC_ ,G%:/\
M[]O_ "H ]\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% '@?P!_Y'_Q/QCY'_\ 1M>^5X'\ L_\+ \3Y.3L?/.?^6M>^4 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\Z.O7GN?U_P_G2@_./K_ %_S_GJW^'_@/?Z?Y_ST %XY_K]/_K_K^1[9]O\
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MN2N[^'/_ "(/AW_KPA_] %<)^TM_R)FG?]A!?_1<E=W\.?\ D0?#O_7A#_Z
M* .BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O _&/_)Q6C_[]O_*O
M?*\#\8_\G%:/_OV_\J /?**** "O-_C!X4^)/B"Q>;X=^.['PGJ$5NPBMM2T
M9+VWGF&2N]MP9 >%RN<==K=*](HH _*?]C#]L?\ :1_:V^,EQX+/C#0/#=GI
M^GS:G?WW_"/QSNL<<D<>R--P!=GE0<L  &/.-I_4#2-,U6S\,QV-]K7]HZNL
M3(VJFU2+<YSM?RE^48R..AQ7Y ?\$8\?\-3>/,=/^$7N>O/_ "_6O>OV7H _
M-K]O3]HS]HC]C;4/"UQ8^/-$\3Z'XA^T+$]QX=B@GMI(?+)1\.0X82@AAC[K
M @8!/T3^SQ9?''XG?!GPOXR\3_%73K*_\2:7;ZI!9Z9X:@,=K%,JRQ@N[Y=O
M+9<\* 6(YP"?EO\ X+C?\BQ\(NN?MFI=^/N6_:OO/]F!1'^S3\)5"J@7PCI(
M"KT'^AQ<"@#X._; _:@_:G_8P\::$=8\0>&?&'A#5)"]CJ,>BI;&Y\LJ9;>6
M,.6B;##D,00P(;(8+]Y_L[_'[PQ^TM\+-+\;^%I\VMR/*NK.1@9K&Y4#S()!
M_>7(.>C*RL.&%?,W_!1_P%I'Q3^)'[-W@_7XI)M&UOQ-<V-TD,AC?RWBC4E6
M'1AG(.",CGCK\3^#?$GCS_@D[^U3=:)KB3:UX!U<J;@PJ%35+#<1'<Q DA9X
MB6RA/4,N=K*] '[4^)+'4=3T.[M=)U3^Q=1D7$-_]G6?R3D<^6W#<9'/K7Q'
MKOCW]I+3?VS](^"EO\2-!DT74=&/B(:Y)X:B$T=H'D1H_*\S#2>9'MR& PP;
M'\-?:_A#Q=H_C[POI?B/P]J$.JZ)JENEU9WEN24EC89!&>1[@@$'((!%?,.N
MC/\ P5,\-?*QQ\+)CN!X'_$R?_/XB@#WW6_%]O\ !/X3ZCXD\?\ B47]KH=K
M+=ZAK#6J6YD4,2JK$AQNP5C51RQQW-?)_P '_'7[1O[;6DW'CGP_XPT_X$_#
M.XEEM]'@M]'AU;4]11'V/*[386,9#J&3!W(?E( <^K?\%&O ^N_$+]C7XBZ3
MX=ADNM12"WOC:PC+3PV]S%/*H'4D)&S #DE0!UKY)_X)E_\ !0;P3X9^'.B_
M![XA7L/A>[TMI8](UR[8)97,;RM)Y4S](74NP#-A& &6#8W 'K_QC^(7[57[
M'GA._P#%6I:IX=^/G@VV4O>7LFDC2=2T\'@2-%;G8T()&X@,PZG:H)KZ)_9!
M\>:W\3OV:?A_XK\27?V[7-6T[[5=7&P)O<NW10  ,8 ]A7JFI:=8^)-&NK"]
MABO],O[=H)H7PT<T+J593ZJRDCZ&O/\ ]F_X9W7P2^!7A+P5J5Q#-<:%:-;2
M3PN3&RB1R&R0/X2#STH YK]JW]KSP3^R3X+35O$LKW^LWJNNDZ!:,!<7TBXS
MR>(XP2-TC<#/ 9L*?(_ARO[67[1FEV_BO4_%VC_ #P[>Q^98Z%9: FJ:HT9;
MY6N/M7RQDKR",'&,QJ:^'_A/KS_M^?\ !3"SUK70VJ>#]/NY[ZULK@'RX],M
M-S6L93IAY#$74\$ROG.<']KJ /E[4O G[3_PMM)]5\._$W1/C(D(S_PC7BC0
M8=*GDC Z0WELP4RG  \U-O)R:YK]@W]K3Q9^U)\0_C0WB726\+0>'Y],MK/P
MU(XD?3F*W*3J\AC1G<R0DME1MP!@8Y^QJ\F\(? Z/P5^T7X\^(VFM;PV/C#2
M=/AO[52WF-?6S3+YV,;0K0O&.N=R$X^;- '8?$[XG^&?@WX'U/Q=XPU6+1M
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MS'I&KQNR0WD82:)TD:.2-P"1E71AD$@XR"0: .^HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW_ZW^?Y_YZGIV[\>_P#^O_/9.P_SV_\ KC_/%+[]O7\<_P"?\Y #]/\ ]?\
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M/_9?_K?IVKZL\#\>"] [?\2^W_\ 1:T ;=%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 >1?M+?\B9IW_807_P!%R5W?PY_Y$'P[_P!>
M$/\ Z *X3]I;_D3-._[""_\ HN2N[^'/_(@^'?\ KPA_] % '14444 %%%%
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MUL3+F1O"5X(#Z/\ :K0D_P#?(?\ .OVTK\0?%/AK4O\ @FE^W]IGB2?39W\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3HY'AD62-BCJ=
MRLO4&FU/86,NI7<=O",NYQ[ =R?H*3VU ]8\#^*OM,27!7G_ %=Q&.Q]1ZCG
M/XXKT@'< ?Z5Q?@OPS%:PQC;^XA[,/\ 6-ZG\@:[6OEL0XN;Y3VJ2DHZA111
M7,;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X'\ L_\+ \3Y.3L
M?/.?^6M>^5X'\ ?^1_\ $^.FQ_\ T;7OE !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MPBC J2BBO!/3"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \
M#^ /_(_^)^,?(_\ Z-KWRO _@%G_ (6!XGR<G8^><_\ +6O?* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_ &H!^Y\.$?WKCG_O
MU[5[9I^!I]L ,#REXQCL*\2_:A_U/ASC/-QV_P"N7M7MNGC%C;#_ *9K_(4
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M_KCZ<?S/^<TK?F?FZ\]\^_UZ_P#UP#$\5#_1(CC!\ST]O\0?7_'ZL\#\>"]
M[?\ $OM__1:U\I^*ABTBX_C[XST/M[5]6>!^/!>@=O\ B7V__HM: -NBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /(OVEO^1,T[_L(
M+_Z+DKN_AS_R(/AW_KPA_P#0!7"?M+?\B9IW_807_P!%R5W?PY_Y$'P[_P!>
M$/\ Z * .BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBOXK_P"OV[_]%C_/:N:KZ' _PSRL1\04445Z1R!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %:.A:.^M7RPC*Q+
M\TC@?=7_ !JA##)<2I%$A>1R%51W)KV'P/X22WB$6,A2'GDQ]]O[OTQ^GUKF
MKUE2C?J;4Z;FSH?"FAQV=O',8@B*H6!/[J^M=)2 !0 !@#H*6OF)2<W=GL1B
MHJR"BBBH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \#^
M/_(_^)\=-C_^C:]\KP/X _\ (_\ B?C'R/\ ^C:]\H **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#PO]J#_ %/ASM\UQSC_ *Y>W^<5
M[9IXVZ?;#&/W2\#MP/:O$_VH!F'PYQDYN/\ VE[5[9I__(/MO^N2]1CL/84
M5/$^?^$;U;'7[)-_Z :^2/"9S#/_ +P[_7W_ ,YKZW\3G'AO5CG'^B3<_P#
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M+_Z+DKN_AS_R(/AW_KPA_P#0!0!T5%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5X'XQ_P"3BM'_ -^W_E7OE>!^,?\ DXK1_P#?M_Y4 >^4444 %<A\
M8=%LO$GPE\::5J-NEU8WFC7D$T,@!5E:%P1S77USWQ$_Y)_XG_[!=U_Z*:@#
M\G?^"(^AV5U\6/B-JLMLDE]9:-!#!.RY,2RS$N >V?+7\J_8.OR*_P""'_\
MR4#XIG!_Y!=ESV_ULE?KK0!Y1^UEI-GK?[+_ ,6;6_MXKJW_ .$5U*7RYEW*
M'2VD=&^JNJL#V*@UQW_!/GP[I_AO]C?X71:?:1VJW6E+?3[% ,LTK,[NQ[DD
M]3V '0"N\_:>_P"3:_BS_P!BEJW_ *1RUQ7[%NF)K/[%'PQT^2:YM8[OPQ%
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MI\07<NJ?$+6&;5-0DW10XMK.-W!#<$O-(PV!UV!F)* 'Z<45^//[2'_"Z?\
M@F[\:/!?BBT^+OB+XB>&==>5WM?$%Y-,+@0O'Y\$\;NZDE)5VRKA@2V-N.?L
M#QU\$?C5^UWI\>N7OQ2U'X)>$;E/,TCPOX>B,EZ\+ &.>_N(YDS(WWO(0LB#
M:-Q;<2 ?8U%?F%^P3\9OB=\)_P!KSQ7^SE\1_%%YXQMHOM(L;R^N'N'BFB3S
ME>-W)81RPY8HQPIVXP=V[WK_ (*:?M2>+?V9?@]HS^"$^R^(/$5^UC'J[PB5
M;%%3>Q56!4R-P%W C <XR!@ ^PZ*^-?%G[$]Q>? >XOE^*/Q,A^)L.D?;O\
MA()_%=[N-ZL7F;6@\S8L>\;=J@,J]&R,UB_\$I?VGO&'[0OPN\4:9XWU!M;U
MGPO>011ZK-@33V\R.467 ^9E:)QOZD$9R020#[DHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ^?/!O_(K^*_^OV[_ /18_P ]JYJNE\&_\BOXK_Z_;O\ ]%C_ #VKFJ^A
MP/\ #/*Q'Q!1117I'(%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !116[X3T$ZQ>>9(O^C0GYN/OMV6HE)15V-)R=D=#X
M!\+R.R73Q_Z1+E8@<_(IX+'T[_A]:]CL;-+&V6&/HO)/J3R36?X?TD:?!YCI
MMG<=/[J^E:]?,XBLZLCV*5/D04445RFX4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU9X'X\%Z!V_XE]O_ .BUH VZ*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH \B_:6_P"1,T[_ +""_P#HN2N[^'/_ "(/AW_KPA_] %<)
M^TM_R)FG?]A!?_1<E=W\.?\ D0?#O_7A#_Z * .BHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %<__P %N-4U!?B?\+;65?,TBWTNYN($8Y1IFG42C'^ZD/YUSFE?&_PY;_\
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MF38%F1@"I+HZCC!*\9% 'P5X-;_C=]J?\/\ I%T,*.O_ !)&ZU][?M6?M'>
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/GSP;_R*_BO_ *_;O_T6/\]JYJNE\&_\BOXK_P"OV[_]%C_/:N:KZ' _PSRL
M1\04445Z1R!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !111R>@R?:@"SINGRZI>1VT(R[GKV ]37MW@WPU%:V\7RDV\/"!A]]
MN['_ #U^E<UX#\(M"JB08N)>9FZ^6N/NUZG#"MO$D:#"*, 8KPL9B.9\D3TL
M/2M[S'T445Y)W!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 >1?M+?\ (F:=_P!A!?\ T7)7=_#G_D0?#O\ UX0_^@"N
M$_:6_P"1,T[_ +""_P#HN2N[^'/_ "(/AW_KPA_] % '14444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !7@?C'_DXK1_]^W_E7OE>!^,?^3BM'_W[?^5
M'OE%%% !1110 5F2>&='FOEO9-)L7O%)9;AK9#("2"2&QG)*J?\ @(]*TZ*
M"BBB@ I@AC69I0BB5E"L^/F(!) )]!D_F:?10 4444 5X-/M;6>6:&VAAFEY
MDDCC"L_)/)'7DG\ZL444 %%%% !1110 4444 %%%% !1110 4V2-)HVCD57C
M8%65AD$'J"*=10!#:V<%C"(K:".WB!)$<2!5R3DG ]ZFHHH **** "BBB@ H
MHHH **** *EYI%CJ$B275E;W,B#"M-$KD#.>"1ZU;HHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M +]?_7_SS1_PB'_3V/\ OU_]?_/-'U^';^ON#ZK(^>J*^A?^$0_Z>Q_WZ_\
MK_YYH_X1#_I['_?K_P"O_GFCZ_#M_7W!]5D?/5%?0O\ PB'_ $]C_OU_]?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\_A0 GM_GH?\_A2^GX=/P_\ K?Y-''X?3_/;'^>:.>PR>.WN?\_YQ0 ?R_\
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MAS_R(/AW_KPA_P#0!7"?M+?\B9IW_807_P!%R5W?PY_Y$'P[_P!>$/\ Z *
M.BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O _&/\ R<5H_P#OV_\
M*O?*\#\8_P#)Q6C_ ._;_P J /?**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \#^ ?
M_)0?%!QCY'_]&_3ZU[Y7@?P#'_%P?%!Q_ _./^FH]O\ ./R]\H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /(OVEO\ D3-.
M_P"P@O\ Z+DKN_AS_P B#X=_Z\(?_0!7"?M+?\B9IW_807_T7)7=_#G_ )$'
MP[_UX0_^@"@#HJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP/QC_R<
M5H_^_;_RKWRO _&/_)Q6C_[]O_*@#WRBBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
M_@&/^+@^*#C^!^<?]-1[?YQ^7OE>!_ ,?\7!\4''\#\X_P"FH]O\X_+WR@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *\#\8_\ )Q6C_P"_;_RKWRO _&/_ "<5H_\
MOV_\J /?**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH \#^ 8_XN#XH./X'YQ_TU'M_G
M'Y>^5X'\ Q_Q<'Q0<?P/SC_IJ/;_ #C\O?* "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/_K=O\^G^>*.F/\ /^?\^V  ]!_GH:/3\.O/<#_/^<IZ^G_UO_U?YXI3U/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP/QC_P G%:/_ +]O
M_*O?*\#\8_\ )Q6C_P"_;_RH ]\HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#P/X!C
M_BX/B@X_@?G'_34>W^<?E[Y7@?P#'_%P?%!Q_ _./^FH]O\ ./R]\H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS_SW_P ]#^?7_/\ GT-'![\?TX_IC_/4Z]OP_#_]?^<T '4'GKW_  '/\O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7>G:II=H@2WAO/L-S+')$@X0.B2Y50%4Q @?,: /OZBBB@ KS/XT?M*?#/\
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M\"OB-H^A6K7NN:AX;U*TL+5'"--<26LB1(&) !+%1DD 9ZT ><?\/ /V=_\
MHJ^@_P#?4G_Q%'_#P#]G?_HJ^@_]]2?_ !%:7P5_8T^$_P %? ^C:'8^"-!U
M+4+.!!<ZUJ&FPSW=W.%^>5I'4L,MN(4':H.  *_-3]J_PUH^G_\ !6'P#I-K
MI5C;Z5)KWAE)+&&W18&5IH RE -I!!.1CG- 'Z,_\/ /V=_^BKZ#_P!]2?\
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M*** "BBB@ HHHH *\#\8_P#)Q6C_ ._;_P J]\KP/QC_ ,G%:/\ []O_ "H
M]\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#P/X!C_ (N#XH./X'YQ_P!-1[?YQ^7O
ME>!_ ,?\7!\4''\#\X_Z:CV_SC\O?* "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \#^ 7_ "4#Q1Z;
M&Y_[:U[Y7@7P!Q_PL#Q/C_GF_./^FM>^T %%%% !1110 4444 %%%% !1110
M 4444 8/C[P3I/Q*\$Z]X3UV W.C:U93:?=QJ=K&.1"C%3_"P!R#V(![5^/'
MPEU;Q=_P2?\ VI]1TKQQ9WFI?#;Q#']FDU2R@S'?0*Q,%U$,X\V(LP>(MD"2
M3&<HQ_:6L'QMX"\-_$KP_/H7BO0=.\1Z-,0SV.J6R7$18=&VL" P[,.0>010
M!1^&_P 5_!WQ>\/Q:WX+\2:;XETR0 ^=I\ZR%"?X77[R-ZJP!'<5B?%OX^>%
M?@_#;VNH7#ZMXHOV$6E>%=)VSZKJ4I!PL, .=O!S(V$4#+,!7B-]_P $L?V<
MKG5UU"W\'7VF2"0R&*QUN\1,D=!F0E1GG"D8Z=.*]D^#?[,'PL_9_2;_ (0'
MP5IV@7$VX27PWW%VZDY*FXF9Y2N?X=V/:@#;^$6G^+K7PB+SQU=I-XGU.9KZ
MZL;9@UMIF\ )9PD ;EC554N<EWWOP& 'YH^ =:LF_P""VFMLD\4J37-Y:K(K
M@@2KI)5ESZAD9<>H(K]4O$7A^R\5:+=Z3J(G:RNEV2BVN9;>0C(/$D3*Z]/X
M2*\'C_X)Z_L]PZHNIQ_#FWCU)9A<+>)J5Z)EE#;A('$VX-NYW9SGF@#V[QU>
MP:;X)\0W=S,EM;6^G7$LLTC!5C58F)8D]  "<U^:7_!#B_@.D_%^RW*+E9]+
MFVY&XH5NAG'H"/U%?H-XR^ /@?X@^#]/\+>(=,O-4T&QA:".SEU:\ DC( *R
MLLH:;[H_UA;]37&^!?V'O@E\,?$5MKWA3P0N@:O;NKQW5CJ=Y&WRNKA6Q-AT
MW*I*,"IQ@@B@#Y%_X+?7,2_#7X86YE43R:O=2+&6^9E6%0Q SR 67_OH>M?>
MGP%N(KOX&_#J>!UE@E\.:<\;IRK*;6,@CCIBN+^('[%/P8^*GB"?6_%_@P>(
M=4F=W,]_J=[)MW,68(OG81<D_*H"CL!6]X._9G^'?P^\*ZAX;\.:/>:/H=\B
M1RV5KK-\J*JOO'E?OLQ?,228RN<G.: /SL\.ZU82?\%P+V:.\C:%KF>T$@8;
M?.70S&T>?4.I7'7<,>U?>?[<5Y!8?L@_%R6XF2"-O#MU$&D;:"SIL1?J68 #
MN2!6*O\ P3S_ &>UU9=4'PZ@_M-9OM O?[3O?.\W=N\S?Y^[?NYW9SGG-=MX
M]_9?^&WQ0T73='\5Z%<Z[I>GV\=K!9W>KWK1[$)*%U\[]XX)/SON;U- 'S!_
MP1COX+G]E+6+>-E\ZV\4W:RH"-PW6]LP)'N#^AKQ3_@KE\+_ !3\._C'X%^/
MWAAI(X;86UI+=0QY^PWUO*TMO(Y_NN#M'&,Q8/W@*^_?A?\ LA?"3X*Z^NM>
M!_"0\.:@/O/9ZC=[)?E91YD9E*28#MC<#@G(P>:]1\0>'=+\6:)>Z-K>G6NK
MZ3>Q&&YL;V%989HSU5T8$,/8T ?*/PF_X*D? OQU\/;+6_$GBF#P5KJP@ZAH
M=]%-))!*/O"-DC(F0XRI7G!&0IXKN?V;_C!JG[3'B[6OB/IMIJ6C_"ZUMCH_
MAE+PM$VLR&4-=WSPYP$5HHHHB<L!Y_W2S*,#3?\ @F+^S;I?B%=7C^'4<TBR
M"5+6YU.\EME;.?\ 5-*58?[+ KCC%?3UC8VVEV4%G9V\5I:6\:Q0V\"!(XT4
M8554<     =* /R*_8G^.6A^%_\ @H'\7]6^,6J6VA^)M4DOK&TU+7)MD5I,
MEV ;4228$8\M B9P-L00$9 /1_\ !7+X_>"_BU\+/#6C>"M1/BJ#2?$*O?:[
MI*&?2X)6M9=EO]J7]V\S*2VQ"V%0Y*\ _=/Q5_8F^"/QL\7?\)1XR^']CJNO
MD*)+V.XN+5I]O ,HAD02D# RX)P .@ K?\7_ +,/PK\=?"VU^'&K^"-+?P3:
MS)<6^CV:-:1P2KG$D;0E&1_F?+ @MO;).XY .3_9!^-W@_XC?"?P'X?\-:JF
MMW^E^$M,DU-K(>;#I\GD1QBWGD7Y4G++)^Z^\!&Q( QGX8\ ZU9-_P %M-;9
M)XI4FN;RU617! E722K+GU#(RX]017Z3^$_@3X%\!_#5O /AK0(_#WA9@0]I
MI=Q-;2.QQEVG1Q*7.U<N7W$  FO,H_\ @GK^SW#JBZG'\.;>/4EF%PMXFI7H
MF64-N$@<3;@V[G=G.>: /HJBJ&@Z':>&]&L]+L!,MG:1B*(3SR3R;1TW22,S
ML?=B35^@#\I_^"PT5UX-^./P1\>/;R2:;:JR[D 8>9;7,<Q7!. 2L@QG&<'T
M./NN^_;/^#<?ANPU72_'6E^)KG4@@TW0]!N$O-4OI7P$ABM$/F>86(7#!0I/
MS%0"1W/Q<^#7@WX[>#;CPMXYT*WU[1IF$@BFRKQ2 $"2.12&C< D;E(."1T)
M%<%\#?V*O@Y^SKK4VL^"/!\-EK<BF,:G>7$MW<1H1@K&TK-Y8(R#MP2#@YH
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M(LGN0@)[UZY\+?@_X+^"?AE/#_@;PW8>&M)5M[0V4>&E?&-\CG+R-C W.2<
M#/% 'Y^_\%I/@7J_B3PKX0^*&E6OVJS\/B33=7\M"9(H975H93_L"3<A]#*O
MJ<?1G[''[<W@;X^_"+1[C6_%.E:/XYT^T2'6].U&ZCMI&F1</<1AR-T;XWY7
M(7=M/(KZAO+.#4+2>UNH([FUG1HI89D#I(C##*RG@@@D$'UKYAF_X)C_ +-M
MQXBEUA_AS&))',AM$U.\2U#$YR(EE"@?[(^49Z=* /@O]M#X\^"]=_X*1?"G
MQCI/B""_\+^&Y]%BO]7MP7M@L&I2R7#1OC;(BJS LF1N# '(->Y_\%=?BQ_P
MEW[,?A*?P)X@M-=\$ZKXA-OJ>J:%?+/;3/%$[10.\3%'7>&<J2?FA0]1Q]<:
M_P#L6?!3Q3XST7Q-JWP^TF_O-%TZ+2M/LY4/V"WMXW=T06@/DG!D;JAZUZ3X
MN^&_A;Q[X+N?"/B#0-/U7PS<0B"32YX%,&P8VA5'W2N 5*X*D @@@4 ?._P)
M_;"^!/AS]FOP'<6?C+1=-BM=(M+%?#=M*)-32Y6-$:W6S3,TDGF<?*IW$A@2
M#FOAC]@3XW>%/AG^VI\<->\;7_\ PA5GJ%OJDB6^M#R;A9O[1C?[*8N6:XQN
M'E+N8E& !-?I1\(_V+_@I\"]=_MOP5\/].TK6!GR[^>6:\GAR"#Y3SNYCR"0
M=A&0<=*LZ?\ L?\ P<TOXO77Q0M_ 6G#QS<W+7CZG(\L@%P2"9UA9S$DI8;O
M,5 VXDYR2: /C?\ X+1+-K?P#^&&O+:7=I;-K)#PW4?ER0M-:LZI(N?E<"-P
M1V(:OJ+]GK]JCX<>./!/PK\/>'_$-KKWB75](MTDT?2Y4FN-.\JUS,]V@(\A
M$9-F6QN9D"AMPKV?Q]\/_#GQ2\)W_ACQ9H]KKV@7RJMQ8W:[D?:P93Z@A@""
M""" 17+?!G]F[X9_L]V=W;_#[PA8>'/MA!N+B+?-<3 =%::5FD*CJ%+8!)('
M)H _*?XA^)O%?_!-C_@H#XB\6/IT^I^"_%5S=7XMH3Y,5_87,ID:-&.X>;;R
MD#GD[!G:LN:^Z_\ AZE^S@?"CZR/&ET;A8]_]C_V1="\+XSY8!3RRW;._9_M
M5]!_%?X,^"/CEX9;P_X[\-V7B32MV](KI2'B;^_'(I#QMCC<C X)&<5Y)\,?
M^"=_P!^$GB:T\0Z'X"AFUFS<2VUSJEY<7HA<8PZQRNR!@1N#;=RGD$8% '9_
MLSZOXP\8>!+SQIXSMKK2+WQ5?MJUAH%U(6;2-/,<<=M;D$#:Y2/SG&/OS/G'
M0>N444 %%%% !1110 4444 %%%% !1110 4444 >%_M0#,/ASC)S<?\ M+VK
MVS3_ /D'VW_7)>HQV'L*\3_:A&8/#G&1FXZ#_KE[5[9I_P#QXVV1@^6O'X"@
M"IXH_P"1:U;G'^B3?^@&ODCPGCR;GV<?U_IG_P"O7UOXH;;X:U8YQBTFY]/D
M-?)'A7_4W(_V@,?]]=/\]N] &][]Q_G_  _ST/N]."#]/\_Y]\'WCU]?YC_/
MX_C2=AV[]?8_Y_SP 'KZ8QR?P_QI?\3_ #_S_GJ'OVZ]O?\ _5_GH?Q#Z_U_
MS_GJ 'IG]?S_ ,?THZX_SVQ_G_ZV*3^'/L.WL/\ #_/9?\?_ &:@ Z],^WXG
M_P"M_GLF1SVX_I_]<&C'X>_^?I^GY+^GM^?O]?\ /0 .F.PSQSTZ=\^^>/Y&
MCGD8]L*.>N/YC_/%&[D-G'?/X@GO]._O]#A<YP/FQ@\=\^GOCI^7<  ?NG!Z
M]%YZ'']>.<XX]*%S[D@#[O4]L CW _SU3&5QR05XX[]!^/MSCGIV7ABPR2/3
M'/(X/\@/Z9H Q/%7-G$<@_O.HZ?=_P __6KZL\#\>"] [?\ $OM__1:U\I^*
MCFSA)ZEP>G^R1_3_ /57U9X'X\%Z!V_XE]O_ .BUH VZ*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH \B_:6_P"1,T[_ +""_P#HN2N[
M^'/_ "(/AW_KPA_] %<)^TM_R)FG?]A!?_1<E=W\.?\ D0?#O_7A#_Z * .B
MHHHH **** /QU^,'/_!:NPXS_P 5#H?;_J&VGM_GVK]BJ_'7XP<_\%J[#C/_
M !4.A]O^H;:>W^?:OV*H ^+/^"EVAZ_X!^!?B/XH^#OB%XR\*:_IUU9[[73=
M<G2RGCDEBMRGD;ML>-P?* 9;=G.XUZ+^P'XHUOXF?L9> M7\3ZUJ&L:SJ-O?
M)<ZG=7+M=28O+B-3YN=VX*J@'.1@>E<O_P %5/\ DQWQ[_UWTW_TOMZU?^"9
M/_)C?PP_ZXWW_IPN: /DW]J+Q)X]_9^_;Q^$/@WPS\4O'%QX3\0W>CW=QI6J
M:]/=(/-U%X)(<LV6C98QP^3\S#)&,?:_[97_  M33_@SXJU_X;>-]/\ ![:'
MHUWJ=PLNC"[N[KR8VD,<4S2;(<HK#)B<Y(P5ZU\2?\%&'6/_ (*1?L\LYPJK
MH9))Q@?VQ-7Z%?M/X_X9I^+6=H'_  B.K9W=/^/.7K0!^?\ _P $[?%OQS^/
M'P=\=Z=HOC*XTO4K_P 0F74_B!X@8ZG/:QFVC"P6=NS_ #2DCDN42-"-NYCA
M.-_:R\+_ !S_ ."?7C7P?\0-%^-GB;QYH^J7313QZ_=S2(TR ,8)X6E9)(Y$
MW8889=K8VD*Q]J_X(E_\D#\=<C_D9CQCG_CU@H_X+:?\D#\"_P#8S#_TEGH
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MXU?!#PGXLTSXP>+U\3BXOHWTB$ZA+?M;JJL)7\V0!@DA,9"?P[&. 6->/_\
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M0_"#XQ?LR^'_ (C7?QQ^($.M^&H=MW92W&J37HMHX5E:XN3)*H,<;($.W/\
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MK^,7Q)O?B-<0![GQ)IOB>YM8[>X*G(M[="L2Q!CPI7) ZC-?"/[(]MXQL?\
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MI:O _&''[16C]OGM_P"5 $?_  T9K_\ T+T'_D2D_P"&C-?_ .A>A_\ '_\
M/_ZJ^@:* /G[_AHS7_\ H7H?_'_\_P#ZJ/\ AHS7_P#H7H?_ !__ #_^JOH&
MB@#Y^_X:,U__ *%Z'_Q__/\ ^JC_ (:,U_\ Z%Z'_P ?_P __JKZ!HH ^?O^
M&C-?_P"A>A_\?_S_ /JH_P"&C-?_ .A>A_\ '_\ /_ZJ^@:* /G[_AHS7_\
MH7H?_'_\_P#ZJ/\ AHS7_P#H7H?_ !__ #_^JOH&B@#Y^_X:,U__ *%Z'_Q_
M_/\ ^JC_ (:,U_\ Z%Z'_P ?_P __JKZ!HH ^?O^&C-?_P"A>A_\?_S_ /JH
M_P"&C-?_ .A>A_\ '_\ /_ZJ^@:* /G[_AHS7_\ H7H?_'_\_P#ZJ/\ AHS7
M_P#H7H?_ !__ #_^JOH&B@#Y^_X:,U__ *%Z'_Q__/\ ^JC_ (:,U_\ Z%Z'
M_P ?_P __JKZ!HH ^?O^&C-?_P"A>A_\?_S_ /JH_P"&C-?_ .A>A_\ '_\
M/_ZJ^@:* /G[_AHS7_\ H7H?_'_\_P#ZJ/\ AHS7_P#H7H?_ !__ #_^JOH&
MB@#Y^_X:,U__ *%Z'_Q__/\ ^JC_ (:,U_\ Z%Z'_P ?_P __JKZ!HH ^?O^
M&C-?_P"A>A_\?_S_ /JH_P"&C-?_ .A>A_\ '_\ /_ZJ^@:* /G[_AHS7_\
MH7H?_'_\_P#ZJ/\ AHS7_P#H7H?_ !__ #_^JOH&B@#Y^_X:,U__ *%Z'_Q_
M_/\ ^JC_ (:,U_\ Z%Z'_P ?_P __JKZ!HH ^?O^&C-?_P"A>A_\?_S_ /JH
M_P"&C-?_ .A>A_\ '_\ /_ZJ^@:* /G[_AHS7_\ H7H?_'_\_P#ZJ/\ AHS7
M_P#H7H?_ !__ #_^JOH&B@#Y^_X:,U__ *%Z'_Q__/\ ^JC_ (:,U_\ Z%Z'
M_P ?_P __JKZ!HH ^?O^&C-?_P"A>A_\?_S_ /JH_P"&C-?_ .A>A_\ '_\
M/_ZJ^@:* /G[_AHS7_\ H7H?_'_\_P#ZJ/\ AHS7_P#H7H?_ !__ #_^JOH&
MB@#Y^_X:,U__ *%Z'_Q__/\ ^JC_ (:,U_\ Z%Z'_P ?_P __JKZ!HH ^?O^
M&C-?_P"A>A_\?_S_ /JH_P"&C-?_ .A>A_\ '_\ /_ZJ^@:* /G[_AHS7_\
MH7H?_'_\_P#ZJ/\ AHS7_P#H7H?_ !__ #_^JOH&B@#Y^_X:,U__ *%Z'_Q_
M_/\ ^JC_ (:,U_\ Z%Z'_P ?_P __JKZ!HH ^?O^&C-?_P"A>A_\?_S_ /JH
M_P"&C-?_ .A>A_\ '_\ /_ZJ^@:* /G[_AHS7_\ H7H?_'_\_P#ZJ/\ AHS7
M_P#H7H?_ !__ #_^JOH&B@#Y^_X:,U__ *%Z'_Q__/\ ^JC_ (:,U_\ Z%Z'
M_P ?_P __JKZ!HH ^?O^&C-?_P"A>A_\?_S_ /JH_P"&C-?_ .A>A_\ '_\
M/_ZJ^@:* /G[_AHS7_\ H7H?_'_\_P#ZJ/\ AHS7_P#H7H?_ !__ #_^JOH&
MB@#Y^_X:,U__ *%Z'_Q__/\ ^JC_ (:,U_\ Z%Z'_P ?_P __JKZ!HH ^?O^
M&C-?_P"A>A_\?_S_ /JH_P"&C-?_ .A>A_\ '_\ /_ZJ^@:* /G[_AHS7_\
MH7H?_'_\_P#ZJ/\ AHS7_P#H7H?_ !__ #_^JOH&B@#Y^_X:,U__ *%Z'_Q_
M_/\ ^JC_ (:,U_\ Z%Z'_P ?_P __JKZ!HH ^?O^&C-?_P"A>A_\?_S_ /JH
M_P"&C-?_ .A>A_\ '_\ /_ZJ^@:* /G[_AHS7_\ H7H?_'_\_P#ZJ/\ AHS7
M_P#H7H?_ !__ #_^JOH&B@#Y^_X:,U__ *%Z'_Q__/\ ^JC_ (:,U_\ Z%Z'
M_P ?_P __JKZ!HH ^?O^&C-?_P"A>A_\?_S_ /JH_P"&C-?_ .A>A_\ '_\
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M$'_0O6_?O)^%?0-% 'S]_P -&:__ -"];XS_ --*3_AHSQ!_T+MO^<E?05%
M'S]_PT9X@_Z%ZW[]Y/PH_P"&C-?_ .A>M\9_Z:5] T4 ?/O_  T9X@_Z%VW_
M #DI?^&C/$'_ $+UOW[R?A7T#10!\_?\-&:__P!"];XS_P!-*3_AHSQ!_P!"
M[;_G)7T%10!\_?\ #1GB#_H7K?OWD_"C_AHS7_\ H7K?&?\ II7T#10!\^_\
M-&>(/^A=M_SDI?\ AHSQ!_T+UOW[R?A7T#10!\_?\-&:_P#]"];XS_TTI/\
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M/W_#1GB#_H7K?OWD_"C_ (:,U_\ Z%ZWQG_II7T#10!\^_\ #1GB#_H7;?\
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M_AHSQ!_T+MO^<E?05% 'S]_PT9X@_P"A>M^_>3\*/^&C-?\ ^A>M\9_Z:5]
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M)^%?0-% 'S]_PT9K_P#T+UOC/_32D_X:,\0?]"[;_G)7T%10!\_?\-&>(/\
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MUN1DV^?:M*W7@^:IQ_X\?RKZ(KP/X!Y_X6#XH_W'[Y_Y:U[Y0 4444 %%%%
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M/]?S $[9_'^O^?\ .%_B'U/\S_G_ #RG1?PQU]/_ -7^>R_Q#ZG^9_S_ )Y
M$_A'T'\O\_YZ+_C_ .S4@^Z/H/\ /^?3\E_Q_P#9J  ?Y_I_GZ?@=>#@_7/O
M_C]?SI.WI_G_ #^7Y+WP.!T_I_7]* #[V<[LXQ[G...G?G]?>C/4YSWRN1G
M'3_/&.@I!\P.!@XP!Z9./\\#K^!7.<'&%]#CH<<?S/X9XH /X\X!.<'C\,8_
M/CVZ8I!RN <C@#//Z8]\GJ>?K2X[#@\C'3C)SC@?Y'X4;CU]_7UX'Z=N/IC-
M &)XJ_X\X2!QO&.>VTX_K^7:OJSP/QX+T#M_Q+[?_P!%K7RGXJ'^B1#'23'/
M7H0/Y5]6>!^/!>@=O^)?;_\ HM: -NBBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#P/X!C_ (N!XHXZ*_\ Z-'M_A]*]\KP/X!C_BX'BCCHK_\ HT>W^'TK
MWR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^'?P)^)GANT\1^$?"/@+Q!HMP3Y-_IVD6<L993@C(3A@>"#R#UKU^@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5X'XQ_Y.*T?_ '[?^5>^5X'X
MQ_Y.*T?_ '[?^5 'OE%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >!_ ,?\7 \4<=%?
M_P!&CV_P^E>^5X'\ Q_Q<#Q1QT5__1H]O\/I7OE !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC']/\*7U/T/\C_C0 @]/?^A_S_G%+[_GW],_Y_#ZG^?\_@1_GHG7/'./Z?\
MUC_G-  ??(&.3CIG&3V]1^7H:=N.1GDD^IZY^OJ>W/YTAQN.?7O]?\_YZ&>Y
M]/KGDY/OR#[?3B@ 'RX Z=NG8X)_+TS^-)PJCC(7_$_7T/M^M+_%CN0,]#]2
M?7KGKCC\C./F Z<?@.1^GK[<<4 8GBH;;.$?]-,?EG_/^<U]6>!^/!>@=O\
MB7V__HM:^4_%7%G#W^?'Y#_/^<5]6>!^/!>@=O\ B7V__HM: -NBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /(OVEO^1,T[_L(+_Z+
MDKN_AS_R(/AW_KPA_P#0!7"?M+?\B9IW_807_P!%R5W?PY_Y$'P[_P!>$/\
MZ * .BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O _&/\ R<5H_P#O
MV_\ *O?*\#\8_P#)Q6C_ ._;_P J /?**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \
M#^ 8_P"+@>*..BO_ .C1[?X?2O?*\#^ 8_XN!XHXZ*__ *-'M_A]*]\H ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_+_)_K_GL>OX]_P_E_GU,]_?K^ _S_G- !_G^G]*#D]1S_\ 6_\ KDTG^?\
M/YG\J7U_S[?Y^OY@![?Y_P \_K^9[GZ\_0?Y_*DR!].O'^?Q_'\U''?D=Q^'
M/]?P% !]W(Z'IZ=__K=?I1SS@<]L CG)Q^/I_P#6I.=N.G8CIVP>_O\ YY%*
MV&&3@_>Y_'^?X_\ UP .,D$93K[8'H/K_7GJ:,G@L,'C.3W!&3QWZ?YYH[MG
MUY!]S@_Y/MSZ@XVMV^4YQ[Y[?C_D< &)XJXLX/\ ? _(&OJSP/QX+T#M_P 2
M^W_]%K7RGXJXLX/]\#\@:^K/ _'@O0.W_$OM_P#T6M &W1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'D7[2W_(F:=_V$%_]%R5W?PY
M_P"1!\._]>$/_H KA/VEO^1,T[_L(+_Z+DKN_AS_ ,B#X=_Z\(?_ $ 4 =%1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %>!^,?^3BM'_P!^W_E7OE>!
M^,?^3BM'_P!^W_E0![Y1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '@?P#'_%P/%''1
M7_\ 1H]O\/I7OE>!_ ,?\7 \4<=%?_T:/;_#Z5[Y0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '@?P
M"_Y*!XGQT\MN/^VM>^5X'\ _^2@^*,C#;&SQC_EK7OE !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \B_:6_P"1,T[_ +""
M_P#HN2N[^'/_ "(/AW_KPA_] %<)^TM_R)FG?]A!?_1<E=W\.?\ D0?#O_7A
M#_Z * .BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O _&/_)Q6C_[]
MO_*O?*\#\8_\G%:/_OV_\J /?**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \#^ 8_X
MN!XHXZ*__HT>W^'TKWRO _@&/^+@>*..BO\ ^C1[?X?2O?* "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*O\ CSA_W^OX'^H_SFOJSP/QX+T#M_Q+[?\ ]%K7RGXJ_P"/.'N=X_\ 0?\
M/^37U9X'X\%Z!V_XE]O_ .BUH VZ*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH \B_:6_P"1,T[_ +""_P#HN2N[^'/_ "(/AW_KPA_]
M %<)^TM_R)FG?]A!?_1<E=W\.?\ D0?#O_7A#_Z * .BHHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7:*C6C)V1W%%%%<AT!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-._[""_^BY*[OX<_\B#X=_Z\(?\ T 4 =%1110 4444 %%%% !1110 4444
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M  @5]VU5_LJR&J'4A9VXU%H1;F\\I?.,08L(]^,[=Q)VYQDYH M45\(_MV?
MC]ICXG_'+P'J_P '_%%QI7A:SMXXY!;ZQ]BCT^[$SE[F>(L//0HT8PJR'",N
MS!^;[LC5EC4.V]P &8#&3ZX[4 .HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#Y\\&\>%_%78?;;OVQ^[7_ #_GGFJZ7P;G_A%_%6/^?Z[_ /1:_P"?
M\\\U7T6!_AGE8GX@HHHKT3D"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "M;PYKAT6^#.2;:3B5>O']['J*R:*F45)68TVG='T
M5X8U874*V[-N(7,;YR&6MZO"? OB)K>1+&1]K+\UO)Z'^[_A^5>U:7J"ZE:B
M0#:XX=?0U\UB:+I2\CUZ-3G1<HHHKC.@**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** / _@%_R4#Q/CIY;<?\ ;6O?*\#^ ?\
MR4'Q1D8;8V>,?\M:]\H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXT:KXJ\&^'[SXD_"+5B(KP6B/))]E5BR"Y$8_<SQ@L%F*F,[STWE%^M_!?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!59E8,I*L#D$=0
M?6O5O GBPW$8D;'GQC9.@'##^\./QKRBK>EZE)I-]'<Q\E3AE[,I/(/^>U<]
M:DJL;&M.?([GTU%*DT:R(VY&&0:?7(>#O$4=U#$@??;S?-&W]UB3\N/K^M=?
M7S$X.$K,]F,E)704445F4%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU]@?\$\_&_B&X\)>+OAUXJ65=4\$WR6JQW#!FAB?S%\C(ZA'ADP<GAU"\ 4
M?6_\OKG/(!_PSQGGFCGG/7H?PS_/GMZY[Y&ST[\Y_7K^ /IG]:/X@3]?_K?I
MZ=OPH Q?%6?L<6>OF$=_?UKZK\#\>"] [?\ $OM__1:U\I>*/^/*#V88[]C7
MU;X'X\%Z!V_XE]O_ .BUH VZ*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH \B_:6_P"1,T[_ +""_P#HN2N[^'/_ "(/AW_KPA_] %<)
M^TM_R)FG?]A!?_1<E=W\.?\ D0?#O_7A#_Z * .BHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#P/X!?\E \3XZ>6W'_ &UKWRO _@'_ ,E!\49&
M&V-GC'_+6O?* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[6$?A7Z]5^7_ /P6*:/_ (2SX9*/]:+&^+<?P^9#CG\&KCPS_>(WK? >2_\
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M_/I\IKCJ:5&O,WC\*/YMOPQ7]#7P)_Y(?\//^Q=T[_TFCK^>7\,5_0U\"?\
MDA_P\_[%W3O_ $FCKNQ?PHYZ&[.YHHHKS#K"BBB@#R+]I;_D3-._[""_^BY*
M[OX<_P#(@^'?^O"'_P! %<)^TM_R)FG?]A!?_1<E=W\.?^1!\._]>$/_ * *
M .BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O _&0S^T5HO&?GM^WL
M?;_/M7OE>!^,AG]HK1>,_/;]O8^W^?:@#WRBBB@ HHHH _&G_@C)G_AJ;QY_
MV+%S_P"EUK7[+5^%W_!,/P;XS\;?M">,K3P/\0IOAQJD>@W$LNIPZ/;:F9HO
MM=N#$8YP5 +%6W#GY,9P37Z=_P#"@/V@L_\ )U.H8S_T(>D=,?[OK0!\J_\
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M222: -VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOA< GO& G)Y:-O6O/P<G2G*C(Z<1'GBJD3(_:FQ\7O'&O^&1^^\/?#SPK?\
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MZ[UCN[E(F*\\@,1QP?RHTGQ1HVO2O%IFKV.HRQC<Z6ERDI49QDA2<#-?-_\
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M+IL=DUJ/M<\'EF0S[_\ 52+G.Q>N>G%8U*E3ZS&"_K0TA&'L7)GVU^T5X'\
M_M!?#W_A&-8\8:=I3B:._L;^*\A9H90K*K["XWH59@1D9SP00#6-^R/^SGX3
M^ VGZX=$\60^,M8OVC%Y?P>6B1QKN\M%C5WV<ER26.X@=,5XY_P4(^$?@_P!
M^SOX6'A_0;73GTS6(;&UG4-).ENT5P[1&5B79=P!^8GD"L?_ ()1_P#-4?\
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MHHHK U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#P/X!?\E \3CM
MY;<_]M:]\KP/X!?\E \3XZ>6W'_;6O?* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH \+_:@_U/ASM\UQSC_KE[?YQ7MFGC;I]L,8_=
M+P.W ]J\3_:@&8?#G&3FX_\ :7M7MFG_ /(/MO\ KDO48[#V% %3Q1_R+6K<
MX_T2;_T U\D>%?\ 57(_VQ_7^F?_ *]?6_BC_D6M6[?Z)-WQ_ :^2/"G,5S_
M +ZG'YG_ !_^O0!O?_7_ ,_R_G0.V?Y?Y]Z/\?\ /Z_R_"C'M[=_I_GZ_F "
M]OPY_P _YY_/#\+^,=.\72:W%IS2,^CZ@^EW7F)MQ.D<;D ]QB5.?KZ9K<SW
MY/U]_P#Z_P#GU^#K/]LG3/V>?CW\6_#GB32;_4M$O=>>_AN-+$;3Q3&*-'!5
MV4,K!$YWC!4\'/ !]X^OY]/?_/ZT;<_+[X7//;'?\/0^W3'R!_P\_P#A9_T
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MB&) <-9VTJSDY'W2=IC!_P"FN,'-?K[#Y/BKP\\>H:9-;VU]"\-QI]^JA]C
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M!GIC..0/MO\ 9GDU[3?A+X8\-^(_"^I>'=5T738;&;[686BE,:A R-'(V<@
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MU\9/!OB*Y?R;73M5@DNF(^[#O"R_^.%J_<1)%D171@Z,,AE.01ZU\6?M3_\
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M\FWJ8O[<GPYTWX7_ !FMM(T^[U'4GDTB"YN]0U:Z:YNKN=I)0TLCL>I"J,
M8 X[G]&_V0?^39_AYU_Y!B]?]]J^-OVN/V3OC%KWB+2/%$LTWQ'U"ZL5AU&;
M3;=(ELYE=R(HH1@^2$(PV"2P<MMW 'ZP_8YT#XC^%_A/I>C^.]+T_0[;3K=;
M:PLHR7O&7>[&28ABB?*RJ$'/!)QTJ</%PQ$O=:3*JM2I+4_,;]H>01_M'_$-
MW.U5\2WI+8Z 7#\U^T^LS+:Z3?2MG;'!(Q]<!2:_,GQ_^Q5\4?BU\6?BGXAT
MS2(].T\:U?3V1U:0V[:CF=B! "#D%3D.VU#QAO3Z6\>?M ?$#7/A'?>&K/X.
M^.XO'VI:8UA+-_9>=/@E=?+DE%PK8( +,O'7 .!S4X:]%S<UOM^(ZUJBBHO8
M_/G]F'1+GQ!^T1\.;2T1GE77;2Z;9U$<,JRR-^"1L?PKU;_@I!975K^TI/)<
M,6AN=)M);?/:,!D(_P"^T<_C7T_^Q+^QK>?!6XF\9>,U@;Q;/"8+2QB995TZ
M-OODN,J96'&5)"KD9.X@=?\ MG_LMR?M#^$K"[T-[>V\7Z,7-JTYVI=0MR\#
M-_"<@,K'@'<. Q(SCA9_5VK:WO8IUH^U3Z'9?LD2))^S7\.S&1M_LJ-25&.0
M2#^N:_)O28)]>^/UE#9_+=7OB=$AQSAWNP%^O)%?=OP,^+'Q$^!_P1'@;6?A
M%XWO_%FCK<1:5-IVDM<V4P=G>+S)D.%"NQ!(S\H4C-8G[%_[%&O^$?&4/Q"^
M(MNME?6N]]-T=F6243,"#/-C*K@$[5&3DY.TJ ;J1=?V<(K;?R)BU3YY,]=_
MX*%'_C%SQ&/^GJS_ /2F.OE__@EO8Q2?%[Q7>,N9H=#,2'C@/<1$_P#H _6O
MJ;]M_P /^*_B%\)+CP9X2\*:AK]]J,T$TES!)#'! D<@<@EY%8N2H  4C!)S
MP*\&_8A^$/Q,^ ?Q'U:^\3_#[5!I>J:?]D^U6L]M(8'$B."R^;DJ0&SCGIQB
MM*L6\5&5M%_P28->Q:OJ?H)7@_[6'[1WA3X$>%K6/6=)M_$^M7Y+V&B3!"IV
M\&:0L#L09(R 22<#^(K[Q7P7_P %!OV:_'OQ(\?:-XO\*Z5/XCLETU-.FM+7
M!FMF221P=A.65O,/*YP0<XR,]F(E.--N"NS"E&,II2V(;[POXQ^.O[-/B[XJ
M?$S79_L3:1<W7A[PGI3M:Z?;+&KA)Y8P<R-N&4#,V!@DG<%'C'_!./\ Y.8L
M>O\ R#+OI_N"O;OA%\ _VA?$WP-U/P/XEUZ+P?X673[B"PTN:&&2]N"RL8X7
MD4$Q0&0C=DE]N5 "D8\M_9D^ 'QW^%7QJM-1L/ RV4\4<UI->:XP6QB1U*F3
M?&W[S:<'$>XG'H<CRW&7M*<^5^9V)KEG&Z/IS_@I-_R;>W_88M/Y25Y!_P $
MI_\ D(?$O_KEIW\[FOJ?]J/X,7_QT^".I>%[.ZABUQ6AN[65U*123QG)4C)V
MJP+#J<$C.<'/QW^RC\.?C[\!_&FOV.G?#:-VU:%+:6]UFX$5I:M&S%9O-1CY
MBC<^53);(Q[]%52CBHU+:&4&I47&^I[9_P %.?\ DWO2O7_A(K;O_P!.]S7G
M'_!*/I\4N<?\@O\ ]O*]"_;.^'OQ"^(7PE\-^ -!\/ZMXQU6RN[>]U#Q"S6T
M$$[)!(C%5,@8%GDSC;A0 ,G-<M^P3\,?B-\"/$WB6R\5^!-4M-/UY;55OXIK
M:2.W>)I<&11+NVD2GE0>G3G(4E+ZVIV=O^ -6]@XWU/DK]L:RNK#]ISXA17C
M%I6U'S5)_P">;QH\8_!&6OU;U*[CB^ %U<QX,2^&'D7&%! M"?P&*\ _;D_8
M_P!2^-$MGXR\%Q0R>*+.#[->:>[B,WT*Y*%&)"B1<D8.-RD#(V@'-F^,'Q&F
M_9K_ .%=K\(_'/\ PGSZ./#[71T=O[/VF,0F?[1G',1STQOX/'-%.+H5*G-U
MV"352,;=#XW_ &-[&XU']ISX?16QVR+J!F)QGY$C=W_\=5J^P?\ @J9_R3'P
M9_V&)/\ T2U;G[#_ .QYJ'P3ENO&/C)85\57<'V>UT^)UD%A"Q!<LXR#*Q '
MRG"J",G<0(/V_?A_X\^,UAX>\.>#_!FHZK%IMT]W<:AYEO' Q:,!5CW2AB>6
MSE1R!C.:B%*5/"R36K*E.,JR:>B,K_@EG_R3'QG_ -AA/_1"U\;_ +7O_)R_
MQ#_[";?^@K7VQ^P5X"\??!'2?%6A^+_!&J6$5[(M_;7<<MO(C,D9#1D"3(8X
M7;Q@DG)&*^;?C7^S#\9_B=\6/%?BJU^'6H6UIJE_)<00S75KYBQDX0-B4C=M
M R 3SG!-9U8R>'A%)W]"H22JR=]#]2O#O'A_3!C'^C1]L?PBM&N4^%^J:EJW
M@72'UC0[WP]J<-O'!<6-\8V<2(BAF5HV964G.#D$]P.E=77MQU5SSGN%%%%4
M(**** "BBB@ HHHH **** "BBB@ J[H^ERZQ?1V\8(!Y=\<*O<U356D954%F
M8@ #N37K7@3PC]FC6-U_>,0]Q)CIZ*#_ )]>U<]:JJ4;FM.#G*QT7@_P_':6
M\3A-L,(VQ)ZD=6_/O_@*ZNFQQK%&J(-J*, #L!3J^7G)S=V>S&/*K(****@H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** / _@'_R4'Q1D8;8V>,?
M\M:]\KP/X!?\E \3CMY;<_\ ;6O?* "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/_T";'_P&3_"M.B@#,_X1G1_^@38_P#@,G^%7K>VALX5A@B2")?NQQJ%4=^
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MZ5#(DD>F6<;HP966W0%2.A!QP:T**=V 4444@"BBB@#R']I?_D3=-_Z_U_\
M1;UWGPY_Y$'P[_UX0_\ H K@_P!I?_D3=-_Z_P!?_1;UWGPY_P"1!\._]>$/
M_H H Z*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGE8GX@HHHKT3D"BBB@ HHHH ,XZ<4444 %%%% !1110 4444 %%%% !1110
M4444 )12T4 %%%% !1110 4444 %)2T4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !24M% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 445K^&M#.M7P#C%K'S(WKZ*/K4RDHJ[&DV
M[(W_  'X:DN)H[QT)D8[8%_FQ_#],GTKV?3=/33K58U&6ZNW=C6=X:T=;. 3
ML@5V&$7&-B__ %^*W*^9Q%9U9'L4::@@HHHKD-PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0PR,$>G!ZGIT[Y_2CG;P<D8P?PP,=?3V_P  8'0@<C'8?7Z<8_F10!B>*O\
MCSA]-X[8['_/_P"NOJSP/QX+T#M_Q+[?_P!%K7RGXJQ]C@Q_>';V/^?\X'U9
MX'X\%Z!V_P")?;_^BUH VZ*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH \A_:7_Y$W3?^O\ 7_T6]=Y\.?\ D0?#O_7A#_Z *X/]I?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#Y\\&_P#(K^*NW^FW?;_IFO\ G_\ 7SS5=+X-P/"_BK/_ #_77M_RS7_/
M^>>:KZ+ _P ,\K$_$%%%%>B<@4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% $UG9RW]U';PKNDD. /ZU[3X)\+Q6M
MO&NW,$1RS8_UK^ON./Y"N:\ ^$W4(\B?Z3. Q)'^JCX_7O\ D*]9MK:.TA6*
M)=JK_G->)C,1?W(GHX>E]IDM%%%>.=X4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!X'\ O^2@>)QV\MN?^VM>^5X'\ O\ DH'B?'3R
MVX_[:U[Y0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@OXZ?]"0O8?\ABP[_P#;>OU]]N .FWMSR!UZ#K_.C<>I;/4\GKP<]_XL<]Z
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]H+X+^$_B#IMNUI;ZW:>:]LQSY$R.T4T>?X@LJ2*&P,@ X&:\\O/^"?7[/\
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M_8/^,?Q-^#_[8OBG]G'XA^*+[QE9AKE;&[U"X>9X9HHS<++&SEF5)8<L8RV
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M+ _PSRL3\04445Z)R!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5TW@SP^VH72W<L9:&-OW:XSYC]L?3^?XUCZ-I,NL7
MR01_*O5W/15]:]R\(Z!'9P12A-D,8VPQX[#C/\_U/>N'%5U2C9;G11I\[N;&
MCZ6--M_F ,[\NW7\![5H445\VVY.[/72MH@HHHI#"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** / _@'_R4'Q1D8;8V>,?\M:]\KP/X
M!?\ )0/$X[>6W/\ VUKWR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS6]@K EV;:O)P>JLJJ23]T:'HMGX;T73])TZ'[/I]A;QVMO""3LC10J+D\G
M '-7J* (KJUAOK6:VN(DGMYD,<D4@RKJ1@@CN"*_)/\ 96_9"U[P7^WUXO\
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MPT\)"..6R3Q(ZQ7S1!?WL\\8R(HRYVQ@G<RKO( =17YB>$OC=X;L?^"KE_\
M%"5[R/P%=W]Q:#6I+";R@&L#;+*?ER(S*!\Q'"G)P,U^S%% %#0=>T_Q1H]G
MJVDW<5_IMY&);>ZA.4E0]&4]Q5B^OK?2[&XO+N9+>UMXVFFFD.%1%!+,3V
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MD*H+.T>P#+9'[(T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY_8VH?\ /C<_]^6_PH_L;4/^?&Y_[\M_A1S+N%F4Z*N?V-J'_/C<_P#?EO\
M"C^QM0_Y\;G_ +\M_A1S+N%F4Z*N?V-J'_/C<_\ ?EO\*/[&U#_GQN?^_+?X
M4<R[A9E.BKG]C:A_SXW/_?EO\*/[&U#_ )\;G_ORW^%',NX693HJY_8VH?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!X'\ O^2@>)\=/+;C_ +:U[Y7@
M?P#_ .2@^*,C#;&SQC_EK7OE !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 >%_M0?ZGPYV^:XYQ_P!<O;_.*]LT\;=/MAC'[I>!VX'M
M7B?[4 S#X<XR<W'_ +2]J]LT_P#Y!]M_UR7J,=A["@"IXH_Y%K5N<?Z)-_Z
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M_G_.!]6>!^/!>@=O^)?;_P#HM: -NBBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /(?VE_\ D3=-_P"O]?\ T6]=Y\.?^1!\._\ 7A#_
M .@"N#_:7_Y$W3?^O]?_ $6]=Y\.?^1!\._]>$/_ * * .BHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "O _&2Y_:*T;C^.W[9[?3Z_G7OE>!^,ES^T
M5HW'\=OVSV^GU_.@#WRBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK6+2QP7&NVNK00SQQE@IEDB4LLK*-QVHJ$]O4_1A7?P$P6Z@)CD@$=CU(_\
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MJSP/QX+T#M_Q+[?_ -%K0!MT444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!Y#^TO_P B;IO_ %_K_P"BWKO/AS_R(/AW_KPA_P#0!7!_
MM+_\B;IO_7^O_HMZ[SX<_P#(@^'?^O"'_P! % '14444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7@?C)<_M%:-Q_';]L]OI]?SKWRO _&2Y_:*T;C^.W
M[9[?3Z_G0![Y1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% '@?P#'_%P?%''\#]O^FH]
MO\_R]\KP/X!C_BX/BCC^!^W_ $U'M_G^7OE !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >!_ /_DH/
MBC(PVQL\8_Y:U[Y7@?P"_P"2@>)QV\MN?^VM>^4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 >0_M+_P#(FZ;_ -?Z_P#HMZ[SX<_\B#X=
M_P"O"'_T 5P?[2__ ")NF_\ 7^O_ *+>N\^'/_(@^'?^O"'_ - % '14444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7@?C)<_M%:-Q_';]L]OI]?SKWR
MO _&2Y_:*T;C^.W[9[?3Z_G0![Y1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '@?P#'
M_%P?%''\#]O^FH]O\_R]\KP/X!C_ (N#XHX_@?M_TU'M_G^7OE !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 >!_ +_ )*!XGQT\MN/^VM>^5X'\ _^2@^*,C#;&SQC_EK7OE !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >%_M0#,/ASC)S<
M?^TO:O;-/_Y!]M_UR7J,=A["O$_VH1F#PYQD9N.@_P"N7M7MFG_\>-MD8/EK
MQ^ H J>*./#.KDG ^R3<YQ_ :^2/"G^JN?\ ?'\R?Z?_ *Z^M_%!QX:U8_\
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M4 %>!^,ES^T5HW'\=OVSV^GU_.O?*\#\9+G]HK1N/X[?MGM]/K^= 'OE%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 >!_ ,?\7!\4<?P/V_Z:CV_P _R]\KP/X!C_BX
M/BCC^!^W_34>W^?Y>^4 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!X'\ O^2@>)QV\MN?^VM>^5X'\
M O\ DH'B?'3RVX_[:U[Y0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% 'A?[4 _<^'"/[UQS_P!^O:O;-/P-/M@!@>4O&,=A7B7[4/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M '@?P#_Y*#XHR,-L;/&/^6M>^5X'\ O^2@>)QV\MN?\ MK7OE !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?^1*/^&C-?\ ^A>@_P#(E 'T#17S]_PT9K__ $+T'_D2C_AHS7_^A>@_\B4
M?0-%?/W_  T9K_\ T+T'_D2C_AHS7_\ H7H/_(E 'T#17S]_PT9K_P#T+T'_
M )$H_P"&C-?_ .A>@_\ (E 'T#17S]_PT9K_ /T+T'_D2C_AHS7_ /H7H/\
MR)0!] T5\_?\-&:__P!"]!_Y$H_X:,U__H7H/_(E 'T#17S]_P -&:__ -"]
M!_Y$H_X:,U__ *%Z#_R)0!] T5\_?\-&:_\ ]"]!_P"1*/\ AHS7_P#H7H/_
M ")0!] T5\_?\-&:_P#]"]!_Y$H_X:,U_P#Z%Z#_ ,B4 ?0-%?/W_#1FO_\
M0O0?^1*/^&C-?_Z%Z#_R)0!] T5\_?\ #1FO_P#0O0?^1*/^&C-?_P"A>@_\
MB4 ?0-%?/W_#1FO_ /0O0?\ D2C_ (:,U_\ Z%Z#_P B4 ?0-%?/W_#1FO\
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M_AHS7_\ H7H/_'_\_P#ZZ /H"BOG_P#X:,U__H7H/_'_ //_ .NC_AHS7_\
MH7H/_'_\_P#ZZ /H"BOG_P#X:,U__H7H/_'_ //_ .NC_AHS7_\ H7H/_'_\
M_P#ZZ /H"BOG_P#X:,U__H7H/_'_ //_ .NC_AHS7_\ H7H/_'_\_P#ZZ /H
M"BOG_P#X:,U__H7H/_'_ //_ .NC_AHS7_\ H7H/_'_\_P#ZZ /H"BOG_P#X
M:,U__H7H/_'_ //_ .NC_AHS7_\ H7H/_'_\_P#ZZ /H"BOG_P#X:,U__H7H
M/_'_ //_ .NC_AHS7_\ H7H/_'_\_P#ZZ /H"BOG_P#X:,U__H7H/_'_ //_
M .NC_AHS7_\ H7H/_'_\_P#ZZ /H"BOG_P#X:,U__H7H/_'_ //_ .NC_AHS
M7_\ H7H/_'_\_P#ZZ /H"BOG_P#X:,U__H7H/_'_ //_ .NC_AHS7_\ H7H/
M_'_\_P#ZZ /H"BOG_P#X:,U__H7H/_'_ //_ .NC_AHS7_\ H7H/_'_\_P#Z
MZ /H"BOG_P#X:,U__H7H/_'_ //_ .NC_AHS7_\ H7H/_'_\_P#ZZ /H"BOG
M_P#X:,U__H7H/_'_ //_ .NC_AHS7_\ H7H/_'_\_P#ZZ /H"BOG_P#X:,U_
M_H7H/_'_ //_ .NC_AHS7_\ H7H/_'_\_P#ZZ /H"BOG_P#X:,U__H7H/_'_
M //_ .NC_AHS7_\ H7H/_'_\_P#ZZ /H"BOG_P#X:,U__H7H/_'_ //_ .NC
M_AHS7_\ H7H/_'_\_P#ZZ /H"BOG_P#X:,U__H7H/_'_ //_ .NC_AHS7_\
MH7H/_'_\_P#ZZ /H"BOG_P#X:,U__H7H/_'_ //_ .NC_AHS7_\ H7H/_'_\
M_P#ZZ /H"BOG_P#X:,U__H7H/_'_ //_ .NC_AHS7_\ H7H/_'_\_P#ZZ /H
M"BOG_P#X:,U__H7H/_'_ //_ .NC_AHS7_\ H7H/_'_\_P#ZZ /H"BOG_P#X
M:,U__H7H/_'_ //_ .NC_AHS7_\ H7H/_'_\_P#ZZ /H"BOG_P#X:,U__H7H
M/_'_ //_ .NC_AHS7_\ H7H/_'_\_P#ZZ /H"BOG_P#X:,U__H7H/_'_ //_
M .NC_AHS7_\ H7H/_'_\_P#ZZ /H"BOG_P#X:,U__H7H/_'_ //_ .NC_AHS
M7_\ H7H/_'_\_P#ZZ /H"BOG_P#X:,U__H7H/_'_ //_ .NC_AHS7_\ H7H/
M_'_\_P#ZZ /H"BOG_P#X:,U__H7H/_'_ //_ .NC_AHS7N_AV$_0O0!)\ Q_
MQ<'Q1Q_ _;_IJ/;_ #_+WROD7P-\1+[P=KVI:E::>EW+>*P>-LX4%MV1CGM^
MOY=S_P -&:_G_D78/_(GO_G\: /H&BOG[_AHSQ!C_D7;?/UD].WX^N*/^&C/
M$'/_ !3UO[<R4 ?0-%?/W_#1GB#_ *%V#\Y/6C_AHSQ!_P!"];_G)Z_X4 ?0
M-%?/W_#1GB#C/AV ?C)Q1_PT9X@Q_P B[;Y^LGIV_'UQ0!] T5\_?\-&>(.?
M^*>M_;F2C_AHSQ!_T+L'YR>M 'T#17S]_P -&>(/^A>M_P Y/7_"C_AHSQ!Q
MGP[ /QDXH ^@:*^?O^&C/$&/^1=M\_63T[?CZXH_X:,\0<_\4];^W,E 'T#1
M7S]_PT9X@_Z%V#\Y/6C_ (:,\0?]"];_ )R>O^% 'T#17S]_PT9X@XSX=@'X
MR<4?\-&>(,?\B[;Y^LGIV_'UQ0!] T5\_?\ #1GB#G_BGK?VYDH_X:,\0?\
M0NP?G)ZT ?0-%?/W_#1GB#_H7K?\Y/7_  H_X:,\0<9\.P#\9.* /H&BOG[_
M (:,\08_Y%VWS]9/3M^/KBC_ (:,\0<_\4];^W,E 'T#17S]_P -&>(/^A=@
M_.3UH_X:,\0?]"];_G)Z_P"% 'T#17S]_P -&>(.,^'8!^,G%'_#1GB#'_(N
MV^?K)Z=OQ]<4 ?0-%?/W_#1GB#G_ (IZW]N9*/\ AHSQ!_T+L'YR>M 'T#17
MS]_PT9X@_P"A>M_SD]?\*/\ AHSQ!QGP[ /QDXH ^@:*^?O^&C/$&/\ D7;?
M/UD].WX^N*/^&C/$'/\ Q3UO[<R4 ?0-%?/W_#1GB#_H78/SD]:/^&C/$'_0
MO6_YR>O^% 'T#17S]_PT9X@XSX=@'XR<4?\ #1GB#'_(NV^?K)Z=OQ]<4 ?0
M-%?/W_#1GB#G_BGK?VYDH_X:,\0?]"[!^<GK0!] T5\_?\-&>(/^A>M_SD]?
M\*/^&C/$'&?#L _&3B@#Z!HKY^_X:,\08_Y%VWS]9/3M^/KBC_AHSQ!S_P 4
M];^W,E 'T#17S]_PT9X@_P"A=@_.3UH_X:,\0?\ 0O6_YR>O^% 'T#17S]_P
MT9X@XSX=@'XR<4?\-&>(,?\ (NV^?K)Z=OQ]<4 ?0-%?/W_#1GB#G_BGK?VY
MDH_X:,\0?]"[!^<GK0!] T5\_?\ #1GB#_H7K?\ .3U_PH_X:,\0<9\.P#\9
M.* /H&BOG[_AHSQ!C_D7;?/UD].WX^N*/^&C/$'/_%/6_MS)0!] T5\_?\-&
M>(/^A=@_.3UH_P"&C/$'_0O6_P"<GK_A0!] T5\_?\-&>(.,^'8!^,G%'_#1
MGB#'_(NV^?K)Z=OQ]<4 ?0-%?/W_  T9X@Y_XIZW]N9*/^&C/$'_ $+L'YR>
MM 'T#17S]_PT9X@_Z%ZW_.3U_P */^&C/$'&?#L _&3B@#Z!HKY^_P"&C/$&
M/^1=M\_63T[?CZXH_P"&C/$'/_%/6_MS)0!] T5\_?\ #1GB#_H78/SD]:/^
M&C/$'_0O6_YR>O\ A0!] T5\_?\ #1GB#C/AV ?C)Q1_PT9X@Q_R+MOGZR>G
M;\?7% 'T#17S]_PT9X@Y_P"*>M_;F2C_ (:,\0?]"[!^<GK0!] T5\_?\-&>
M(/\ H7K?\Y/7_"C_ (:,\0<9\.P#\9.* /H&BOG[_AHSQ!C_ )%VWS]9/3M^
M/KBC_AHSQ!S_ ,4];^W,E 'T#17S]_PT9X@_Z%V#\Y/6C_AHSQ!_T+UO^<GK
M_A0!] T5\_?\-&>(.,^'8!^,G%'_  T9X@Q_R+MOGZR>G;\?7% 'T#17S]_P
MT9X@Y_XIZW]N9*/^&C/$'_0NP?G)ZT ?0-%?/W_#1GB#_H7K?\Y/7_"C_AHS
MQ!QGP[ /QDXH ^@:*^?O^&C/$&/^1=M\_63T[?CZXH_X:,\0<_\ %/6_MS)0
M!] T5\_?\-&>(/\ H78/SD]:/^&C/$'_ $+UO^<GK_A0!] T5\_?\-&>(.,^
M'8!^,G%'_#1GB#'_ "+MOGZR>G;\?7% 'T#17S]_PT9X@Y_XIZW]N9*/^&C/
M$'_0NP?G)ZT ?0-%?/W_  T9X@_Z%ZW_ #D]?\*/^&C/$'&?#L _&3B@#Z!H
MKY^_X:,\08_Y%VWS]9/3M^/KBC_AHSQ!S_Q3UO[<R4 ?0-%?/W_#1GB#_H78
M/SD]:/\ AHSQ!_T+UO\ G)Z_X4 ?0-%?/W_#1GB#C/AV ?C)Q1_PT9X@Q_R+
MMOGZR>G;\?7% 'T#17S]_P -&>(.?^*>M_;F2C_AHSQ!_P!"[!^<GK0!] T5
M\_?\-&>(/^A>M_SD]?\ "C_AHSQ!QGP[ /QDXH ^@:*^?O\ AHSQ!C_D7;?/
MUD].WX^N*/\ AHSQ!S_Q3UO[<R4 ?0-%?/W_  T9X@_Z%V#\Y/6C_AHSQ!_T
M+UO^<GK_ (4 ?0-%?/W_  T9X@XSX=@'XR<4?\-&>(,?\B[;Y^LGIV_'UQ0!
M] T5\_?\-&>(.?\ BGK?VYDH_P"&C/$'_0NP?G)ZT ?0-%?/W_#1GB#_ *%Z
MW_.3U_PH_P"&C/$'&?#L _&3B@#Z!HKY^_X:,\08_P"1=M\_63T[?CZXH_X:
M,\0<_P#%/6_MS)0!] T5\_?\-&>(/^A=@_.3UH_X:,\0?]"];_G)Z_X4 ?0-
M%?/W_#1GB#C/AV ?C)Q1_P -&>(,?\B[;Y^LGIV_'UQ0!] T5\_?\-&>(.?^
M*>M_;F2C_AHSQ!_T+L'YR>M 'T#17S]_PT9X@_Z%ZW_.3U_PH_X:,\0<9\.P
M#\9.* /H&BOG[_AHSQ!C_D7;?/UD].WX^N*/^&C/$'/_ !3UO[<R4 ?0-%?/
MW_#1GB#_ *%V#\Y/6C_AHSQ!_P!"];_G)Z_X4 ?0-%?/W_#1GB#C/AV ?C)Q
M1_PT9X@Q_P B[;Y^LGIV_'UQ0!] T5\_?\-&>(.?^*>M_;F2C_AHSQ!_T+L'
MYR>M 'T#17S]_P -&>(/^A>M_P Y/7_"C_AHSQ!QGP[ /QDXH ^@:*^?O^&C
M/$&/^1=M\_63T[?CZXH_X:,\0<_\4];^W,E 'T#17S]_PT9X@_Z%V#\Y/6C_
M (:,\0?]"];_ )R>O^% 'T#17S]_PT9X@XSX=@'XR<4?\-&>(,?\B[;Y^LGI
MV_'UQ0!] T5\_?\ #1GB#G_BGK?VYDH_X:,\0?\ 0NP?G)ZT ?0-%?/W_#1G
MB#_H7K?\Y/7_  H_X:,\0<9\.P#\9.* /H&BOG[_ (:,\08_Y%VWS]9/3M^/
MKBC_ (:,\0<_\4];^W,E 'T#17S]_P -&>(/^A=@_.3UH_X:,\0?]"];_G)Z
M_P"% 'T#17S]_P -&>(.,^'8!^,G%'_#1GB#'_(NV^?K)Z=OQ]<4 ?0-%?/W
M_#1GB#G_ (IZW]N9*/\ AHSQ!_T+L'YR>M 'T#17S]_PT9X@_P"A>M_SD]?\
M*/\ AHSQ!QGP[ /QDXH ^@:*^?O^&C/$&/\ D7;?/UD].WX^N*/^&C/$'/\
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M_0O6_P"<GK_A0!] T5\_?\-&>(.,^'8!^,G%'_#1GB#'_(NV^?K)Z=OQ]<4
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M ,B4?\-&:_\ ]"]!_P"1* /H&BOG[_AHS7_^A>@_\B4?\-&:_P#]"]!_Y$H
M^@:*^?O^&C-?_P"A>@_\B4?\-&:__P!"]!_Y$H ^@:*^?O\ AHS7_P#H7H/_
M ")1_P -&:__ -"]!_Y$H ^@:*^?O^&C-?\ ^A>@_P#(E'_#1FO_ /0O0?\
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M+KT!;D$'USV Z]OUI#\HZ] >2?7CU]^G^2[.6/< YV;@PX+'@#CL>V.2>,T
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M - % '14444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7@GC+/_#16C$#^
M.WYQ['V_S[5[W7@?C(#_ (:*T;(S\]OCZX/^?\.M 'OE%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >"? //_"P/%)]5?\ ]'?2O>Z\#^ 8_P"+@>)S_L/V_P"FOT_S
M_+WR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /!/@&3_PL#Q1R?N/_P"C:][KP/X!?\E \3_[C_\
MHVO?* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.PK]C/B!^R3\)?B-?3WNM>#+-;]R&>ZL&>SD9NY;RF4,3DY+ \@=>M</:_\
M!.KX,6]Y'(VDZK=HIW&&34I=CC=C'R8/Y-Z\], 'Y6^&_#>J^,-<L]'T2PN-
M3U2[<1P6MLA=W;Z>G<D\  D\5^OW[(_P%;]GWX3VVDWSQR>(;^;^T-3D0@JL
MA7:(D;NJ*H7(/+;B.HQO>&_#'PI^ %UI.BZ78Z+X/OM:WP68D"I/?,JIE/-?
M+NV63"LQR6XP<UZ=N^8Y;G.2Q)&3USUSS@=N_P!* #;MR.P^OJ/;L ,\?_6-
MW4]P23GJ.?Y_CVZ]J0\*W&.>1@>F><#_  [_ (+_ '?0$_AR!U^F.X_Q ,3Q
M5_QYP^F_(QTYS[?Y_0?5G@?CP7H';_B7V_\ Z+6OE/Q5_P ><'^\O\C_ )_S
M@?5G@?CP7H';_B7V_P#Z+6@#;HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#R']I?\ Y$W3?^O]?_1;UWGPZ_Y$'P[_ ->$/_H K@_V
ME_\ D3=-_P"O]?\ T6]=Y\.O^1!\._\ 7A#_ .@"@#HJ*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KP/QE_R<5HW?Y[?^7_ .O_ .M7OE>!^,L_\-%:
M-_OVX]>Q_P _A[YH ]\HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#P/X!C_BX/B?CG
M8_;_ *:CV^GY?E[Y7@?P#_Y*!XGXXV/_ .C?I_G^7OE !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2\4_\><''.X?7[M?5O@?CP7H';_B7V__ *+6@#;HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#R']I?_D3=-_Z_U_\ 1;UWGPZ_Y$'P
M[_UX0_\ H K@_P!I?_D3=-_Z_P!?_1;UW?PY_P"1!\._]>$/_H H Z.BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *\#\9?-^T5HW'\=OVSV/^/_ .KD
MU[Y7@?C+YOVB]%[_ #VXY^A/'Z_Y.: /?**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M \#^ 8_XN!XG/^P_;_IK]/\ /\O?*\#^ 8_XN#XGXYV/V_Z:CV^GY?E[Y0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% '@?P"_Y*!XG_P!Q_P#T;7OE>!_ +_DH'B?_ ''_ /1M>^4
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MN\^'/_(@^'?^O"'_ - % '14444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7@?C+_ ).*T;O\]M_(_P"?\.M>^5X'XR_Y.*T;O\]M_(_Y_P .M 'OE%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 >!_ /_DH'B?CC8__ *-^G^?Y>^5X'\ Q_P 7
M \3G_8?M_P!-?I_G^7OE !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 >!_ +_DH'B?_ ''_ /1M>^5X
M'\ O^2@>)_\ <?\ ]&U[Y0 4444 %%%% !1110 4444 %%%% !1110 4444
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M -%O7>?#G_D0?#O_ %X0_P#H H Z*BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *\#\9?\G%:-W^>V_D?\_X=:]\KP/QE_R<5HW?Y[;^1_S_ (=: /?*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH \#^ 8_P"+@^)^.=C]O^FH]OI^7Y>^5X'\
M _\ DH'B?CC8_P#Z-^G^?Y>^4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!X'\ O\ DH'B?_<?_P!&
MU[Y7@?P"_P"2@>)_]Q__ $;7OE !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 >%_M0?ZGPX2. ;CG'_ %R_7_"O;-/&W3[88Q^Z7@=N
M![5XE^U N8?#GUN0,#D9$?.<<?\ UZ]MT_\ X\+; VCREX QC@=J *GB?CPW
MJW;_ $2;_P! -?)'A/\ U5P/]M3_ #/]/;^H^M_%''AG5R3@?9)N<X_@-?)'
MA7_57/\ O@_J3_3_ /70!O#''X?U_P ?\]*/3\/Y_P#UO\]S./;^F/\ )_7M
M1[#Z?Y_+^7I0 >N><]<_3_\ 5^=(WR@Y'3_]?<?Y_/*^_P"-(1A3^(_G_A_G
ML +TQ\W'(+#!XZ>OH?7T^M<?\4_A+X6^,WA67P_XLTM-1L6/F1-N*2V\@&!)
M$X.48=,]",@A@2*[!CW/OG'N1GGGW[]/U\/_ &DOVM/"O[.5K#;WD3ZWXFNT
M\ZVT:UD"G9N($DSD$1H<$ X8DYP" < 'RG\1?^"7OB.QO))O!/BG3]4L6RT=
MKK0:VN!T 4.BLCG.?F.P<'@5P=E_P3?^,5U<11/#H=JKD RRZD&5<XZA%9CU
M[ ]#3O%G_!1[XNZ[/(=)GTKPS;DMM2RLEF?!Z;FFW@D GD  Y/%?IE\,]7O/
M$/PY\*ZG?S-<7U[H]G<3R% IDD>W1V8@;<?-S@#:.PQQ0!\J_ C_ ()O^'O!
M>I6NL^/=3A\6W\+!XM+MXV6P1P1@ON^>8=/E*JO4$.*^S5PF"O[M>J@8&,'I
MQCC"]N/I7SU\5/C%XV_9W\5MK7BNVA\4?"C4[OREO[&#RKS06? 1)4'$T? P
MPPQ)Y.=JM[MH>OZ=XJT:RUG2;R.^TR^A%Q;7<)&V6-@<,.AZ=LGG(/)- &@/
MO8YZ;#C\1T_3UQGB@9QTSTX'3KVXQUR.!_7(WRL<\!3A@>GWCQ[?3'X4*OS
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#P/X!?\E \3_P"X_P#Z-KWRO _@%_R4#Q/_
M +C_ /HVO?* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M -%K0!MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y
M#^TO_P B;IO_ %_K_P"BWKO/AS_R(/AW_KPA_P#0!7!_M+_\B;IO_7^O_HMZ
M[SX<_P#(@^'?^O"'_P! % '14444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7@?C+_DXK1N_SVW\C_G_#K7OE>!^,O^3BM&[_ #VW\C_G_#K0![Y1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH \#^ 7_)0/$_\ N/\ ^C:]\KP/X!?\
ME \3_P"X_P#Z-KWR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** /"OVH?\ 4^'>_-R<#D_\LN@]:]MT]=MA;# &(E'R].@KQ/\ :@YB
M\-C_ &KC_P!I>W2O;-/_ .0?;?\ 7)>HQV'L* *GB?\ Y%O5O^O2;_T U\D>
M%#^YN3_M@_S/^>GXU];^*/\ D6=7_P"O2;_T U\D>%?]7<#_ &Q_[-_A_P#K
MH WNA&>.G\S_ )_SBD'0<=.WX#_/X4OW?;T[=O\ ZW^>M'3((]N?K[_YZ4 '
M/XCOC]?U_4B@#H!QG&._^>WY#UH_SS]#_C7F'B3]IKX6^$=<O-&UGQKI=AJE
MG)Y5Q:S.VZ-A@[3@=>?Y^^0#TX'^(<=QV]\9SVX_/VKRO]H']G'PM^T5X9CT
MW7%>SU*T#-I^L6J@SVC$$GY?XXR0-R' .,AE.&%0?M??!O</^+A:03QSO?/4
M'KM'J>_\LT?\-@?!I=I_X6#I!Q@XWOV&?[N,]1SGKT] #X"\??\ !.WXM>$[
MZ1=&LK/Q=8Y!CGT^Z2&0J>FZ*4J0?9=PY')KA;7]CGXT7EQ'"GP^U16D.T/,
M8XT_%V<*/J3V/I7Z;?\ #7GP:&%/Q"T@C[IPS^N,_=&>>?P]*#^V!\&F;?\
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MHH **** "BBB@ HHHH \A_:7_P"1-TW_ *_U_P#1;UWGPY_Y$'P[_P!>$/\
MZ *X/]I?_D3=-_Z_U_\ 1;UWGPY_Y$'P[_UX0_\ H H Z*BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *\#\9?\ )Q6C=_GMOY'_ #_AUKWRO _&7_)Q
M6C=_GMOY'_/^'6@#WRBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MESQ.W#U;>ZSUFBHX)EN(4E0Y1QD5)7A'IA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '@?P"_Y*!XG
M_P!Q_P#T;7OE>!_ +_DH'B?_ ''_ /1M>^4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!X5^U#GR/#N!WN>W!.(^#_ )[5[;8<6-L.
M?]6O48/05XG^U!_J?#A(X!N.<?\ 7+]?\*]LT\;=/MAC'[I>!VX'M0!4\4';
MX9U<YQ_HDW/_   ^]?)'A7B&Y_W@?Y_Y_'O7UOXG./#>K'./]$FY_P" &ODC
MPK_J;D'^\/ZY_K_]>@#?Q\WX^G^?;_/5J\*#TX'//'&?Z?Y[+W!]_P#/^?\
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M &Q_&?Q M]3\-:7X:T71(+2:PM[222:XS*TH82RL0K_ZL8VQIWZU]H5^4_\
MP1@C$7Q/^."!=@5;-0H[#S[GC_)K]6* "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KP/QE_R<5HW?Y[;^1_S_AUKWRO _&7_)Q6
MC=_GMOY'_/\ AUH ]\HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6?;Z5[IX=U87D/D2.#,@X/\ >'_UJ^=Q5#V<KK8]6A4YE9FS1117GG6%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!X'\ O^2@>)_P#<?_T;7OE>!_ +_DH'B?\ W'_]&U[Y0 4444 %%%%
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M>Y(]3TYY]?HGJH&<$?+CIR3[^N/\\@&)XHQ]EBX /F=,=.M?5?@;_D2?#_\
MV#[?_P!%+7RKXHXM(0#D>8,?3!_KFOJKP-_R)/A__L'V_P#Z*6@#<HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R']I?\ Y$W3?^O]
M?_1;UWGPY_Y$'P[_ ->$/_H K@_VE_\ D3=-_P"O]?\ T6]=Y\.?^1!\._\
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M_LK^(?%O@;PJGAG7_#7V::*XAO;B3[1$]Q'%)'+YKL&XD+!OO;D49P2#R/\
MP30;=^WY^T(=S-D:H<D=?^)JG)]Z^P/^"D6?^&)/BEC/_'G;],?\_D'K0!%_
MP3;^(.K_ !(_8W\ ZEKMU)?:E:I<::]U,<O)'!<21Q9/<B-8U)/)*Y/)KX,;
MPKKGCK_@KKXTT+0/$DWA*\OKB\@EUJT0-=6UN=/ F-N2<),8]RI)SL+;@"5
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ME1&!M7S(VC8<<OYAQP:_8:OE[_@I)\$3\</V4?%-O:6YN-;\/ >(-."C+%X
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M3JH=P2B$AB>47T%<;_P1CRWQ2^.3?>XL_F'3_7W->K_\%J_^36?"W_8YVO\
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MOXK_ .OV[_\ 18_SVKFJ^AP/\,\K$?$%%%%>D<@4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 E=[X"\32*T=H[[9X<F%_5?[I_/\OI7!TZ
M*5X)4EC8I(A#*PZ@CO652FJD>5EPDXNZ/IW3[Y=0M5F48SP5]#Z59KS;P/XL
M6XA6?&/X)XE/3'<<<UZ0K!E!!R#R"*^7JTW3E9GLTYJ:N+1116)H%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '@?
MP"_Y*!XG_P!Q_P#T;7OE>!_ +_DH'B?_ ''_ /1M>^4 %%%% !1110 4444
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MQ?!?7?AMX$^'']J'7K>V%QK%]K%I;P6VV5)618R^]W!C"Y(5?FR"V,5]444
M?'G_  3M^'OQ:^ ?POM_AK\0/ @T^RM;NYNK;7;76+6XC"2'?Y;Q*Y<'?NP5
MR/FYQC)\Q^-7[&?QG^'?[7%S^T-\&9=%\87]W.TT_AO5G%K(H>#R9(U=G".K
M*#AMZ%2PX(!-?HC10!\B^)?B;^T[\8?"MWX6\.?!B'X2ZMJ$36USXJU_Q-;W
M<.G(PPSVZ0+YDLFTG:V %8#(->J?LI_LN^&/V3_A?#X3\/N]_>32?:M4UB=
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M-EYT4%P3M5&9\,R83K@-M/W<\?J#10!6TZXFN]/M9[BU>QN)8E>2UD96:%B
M2A*DJ2#QD$CC@U9HHH Q_&'A33/'?A/6?#>LVXN](U>SFL;N _QQ2(4<>W!/
M-?''_!-7]BO5_P!EQ?B'JWBVWC_X2'4-3;2]/G4HV_38&)2=2I)43N=Q0\@1
M1Y /%?;]% #78JC$*7(&0JXR?;FOS#_;#_9U_:+_ &B_VA_"7Q$\/?#.WT:Q
M\+P6J6-KJ6OV1EEDBN&N"TGERD+EF"X5CPN<Y.!^GU% 'E>L_$3XD1_#E=3T
MSX3W4WB^7?$NA3ZW9"*!PF5DDG$FUHR_'RC?QG:*^%/V"?V=?VB_V/\ QQXF
MO]8^&=OXAT+Q%;1QW<5CX@LDN8I8F9HY$WR;6'[R12I(^\#GC!_3^B@#F_B5
MX&L_B=\._%'@_4))(+'7],N=+GEB +QI-$T99<\;@&R/<5^:G[,?[._[9?['
MOBCQ%X6\%:!X3\0>$M4N!(=0UO45.G+* %%RD:2I<HVT*&78<A ,$A37ZGT4
M ?EU^V%^PE^T!XV^('P\^(&@:[_PLOQI;L'U.2:>VL++2I8YA+ MK!(RXMUR
M1C+R,49FY? ^W=&E^+GP_P#AG-J6L:=%\3?B-JDYN)]+T>YAT_2]-8PX2&!K
MAPWD*T:@L2\C-(S8 PJ^T44 ?F-^P7^SG^T+^R?\2?%6L^(OAK#KFD^)+98[
MH:?KUDDT,JR%T=5:4*R_.X(R#R"#P0?TYHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "O _&7_)Q6C=_GMOY'_/\ AUKWRO _
M&7_)Q6C=_GMOY'_/^'6@#WRBBB@ KG/B-\0=#^%/@76_%_B6]73]"T>U>[NI
MR,D*H^ZH_B9CA54<EF ')KHZ^:_^"C7@?7?B%^QK\1=)\.PR76H)!;WS6L(R
MT\-O<Q3RJ!U)"1LP Y)4 =: /*O@_P".OVC?VVM)N/'/A_QAI_P)^&=Q++;Z
M/!;:/#JVJ:C&CE'ED>;"QC(=0Z8.4("D .R?&/XA?M5?L>>$[_Q5J6J>'?CY
MX-ME+WE[)I(TG4M/!X$C16YV-""1N(#,.IVJ":\A_P""9G_!0?P3X:^'.B?!
M[XAWL7AB[TQI(M(URZ8+9W,<DK2"*9^D+J78!FPC*!E@V-WZ=:AI]AXFT6YL
MKN*'4-+U"W:&:)L/'/#(I#*?564GZ@T >6?L@^/-;^)_[-/P_P#%?B.\^WZY
MJVG?:KNXV! [EVZ    # _"O8:\T_9M^&-Y\%_@;X1\#W\T5Q=:':&T::%MR
MN!(Q5LX'52">.N:=\;/VA/!/P!TFPNO%FHR+>ZG.+72]&T^!KK4-1F) $<$"
M99SD@9X4%E!(+#(!Z317R=XR_P""@5M\,+.QUGQW\%_B9X.\*7<BH-<U#3;=
MX[?<<*9TCG9HB?[I^;T!KZ,^'/Q(\,_%KP?I_BKPAK%OKN@7ZEK>\M2=IP<,
MI! *L"""K $$$$"@#X$_X*G?%;X_?!GPWIFHZ%XZT_P_X-UK4)=.2#P]:O;:
ME'A#)&9+IG9MQ57R8?*QM ^;.:^Y_@1J%WJWP/\ AY?7]S->WUUX=TZ:XN;F
M1I)99&MHV9W9N68DDDGDDU\1_P#!;3_D@?@7@?\ (S#Z_P#'K/7V7\"=1M-%
M_9N^'E_J%S!86%IX3TZ>XN;B01Q0QI9QLSNQP%50"23@ "@#PKXX?#']I+7O
MVQO 'B/P/XN:Q^$MI]E.J6*WHA@1%E)NDFMLYN&D085L':6 RFW=7U_7R=J7
M_!3#X.3?%KPM\//"E]>>-M9US5[;2/MFDQ 6-LTLJQ[VF<CS -V?W0<''45]
M8T %?G1_P5,^*GQ\^"_A'3M7\/\ CG3_  _X/U?4WTQ(- LWM]2CS$TD9DNF
M=CDA),F(1;=JCYLDU],>-OVRO#&B_$>\^'W@[P]X@^*7C:P&[4=,\)V\<D>G
M '!%S<2R)'&0>-NXD$@$ U\'?\%3/VH-$^+7PGT?P/=^&O$O@7QSI'B&WO[C
M0/$UDL4DEJUK<K]HADC=XY(][!<[@2>@X. #])?V9=6OM>_9M^%&IZG>7&HZ
ME>^$M)N;J\NY6EFGE>SB9Y'=B2S,Q)+$Y)))KTNO*OV3O^36?@W_ -B9HW_I
M##7JM %+6M9L?#NCW^K:G<QV6FV%O)=75S,<)#$BEG=CV 4$GZ4FAZU9^)-$
MT_5].F^T:?J%O'=VTVQDWQ.H9&VL 1D$'! ([U^:/_!5C]KSQ9IOA6Z^&GAC
MPOXFT#P_J$\EAK'BK5-)N+*VOPN0UI:22*!*C8):1>'4 *65B3])_L\_M4+K
M'@GP5X9M_A#\5HKFWT"!%OKKPN;:PF:&T#82YDD6/#[,(6*ABRC(R* /JFBO
MES0_^"AOP^U;XY6/PCO/#7C/P]XWNKQ;'['J^F0Q+%(R;U+LL[?*5(8,H(((
M(R#FO8_C)\7X_@OX;;7;OPGXE\3:9#%+/=R>&[2*Y:TCC 8O(C2HV""3\H;&
MULX[@'H%%>'_ +,/[7_@;]K2Q\07?@FWUBWBT.2&*Z_M:V2$DRARNS;(^>(S
MG..U><?&/_@I[\$_A7K$>B:9J\WCW7I)D@^S^&PLUO&S-C+W)(CP/1"Y!ZB@
M#ZWHKYD_:(_X*#?#/]GG7+SP_<0ZQXQ\26,8EU#3?#-JMQ_9R'&&N9&94CSD
M?+DMRN0 0:V?V<?VX_A?^TKX/US7=&U*3P^V@1>?J]CX@,=O)90X)\]F#%#%
M\K?.&XQ\P7(R ?05%?"GB[_@L'\'O#.OK;6F@>+M<T0RF)=?M;"..VFP<,T0
MED5G Z\A3[5]D_#WX@:!\5/!.C^+?"^HQZKH&K6XN;2[C! =3D$$$ JP(*E2
M 0000"* .BHKS;XV?M">"?@#I-A=>+-1D6]U.<6NEZ-I\#76H:C,2 (X($RS
MG) SPH+*"06&?%_&7_!0*V^&%G8ZSX[^"_Q,\'>%+N14&N:AIMN\=ON.%,Z1
MSLT1/]T_-Z T ?6-%<S\._B5X8^+'@W3_%?A'6;;7/#]\A>"]MF.TX.&5@0"
MK*0058 @@@@5\X?%3_@IU\$OAYKUIH&CZS+X^UVZN8[58?#86:VC9W"[GN21
M&0/^F9<]..] 'UK17Q]\=O\ @J+\(?@1\3I? ][%K'B+4+&40:I=:+#%)!82
M9PT;,TBEW7^)5!VD%2=P('N/Q6_:,\'_  C\-Z!JE^]_K-WXC=8M!T30[1KG
M4=6D9 X6"'C/RD$LQ55R-Q&1D ]0HKY>^(W[=EK\%=#;5_B/\(_B#X.TR3*V
M]]-;65W;2/MRD3R6]R_E.W0!P!P>>#7T3X-\1Q^,/".AZ_% ]M%JEC!?)#(<
MM&)8U<*3ZC=C\* -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** /GSP;_R*_BO_ *_;O_T6/\]JYJNE\&_\BOXK_P"OV[_]%C_/:N:K
MZ' _PSRL1\04445Z1R!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!?T36)-%OEG7YHSQ)'_>7/\_\]Z]Q\):Y'<0QP^8'BD&Z%\]O
M[O\ GUKY_KJ/!?B V,XLIG(BD;]T?[CGL/8D_G]:X,5052-UN=-&IR.Q] 45
MG:+J@U&WPQ'GIPP]?>M&OG&FG9GK)WU04444AA1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_HI: -RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /(
M?VE_^1-TW_K_ %_]%O7>?#G_ )$'P[_UX0_^@"N#_:7_ .1-TW_K_7_T6]=Y
M\.?^1!\._P#7A#_Z * .BHHHH ***PY?'7AJ#Q9#X6E\0Z5'XFFA-Q%HK7L0
MO9(AUD6'=O*CU Q0!N4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8/8X.01R" 1R*_*3_@EOXVU;X(_M=_$/X$W-\;S19[G4+95<;<7UC(R>:HY
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M[N9'C]C$?49YK_@M@ZC]G+P6NX;CXKB(7/) L[K)_4?G0!];_LG?\FL_!O\
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M;>'_ (OPALRK=:6[+CHI2Z .?^ G\JS/^"STBQ_$_P"!S.0J*MX23T \^VH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /GSP;_ ,BOXK_Z_;O_ -%C_/:N:KI?!O\
MR*_BO_K]N_\ T6/\]JYJOH<#_#/*Q'Q!1117I'(%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !24M=-X,\/G4;H74L9:",X10/OO_
M %Q_/%1.2A'F948N3LCOO [:DT-F9/\ CYV_/G^YZM[X"UZ)6=HNEC3;?YP#
M._+L.WL/:M&OE:TU.3:/:IQY8V84445B:!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% '@?P"_Y*!XG_P!Q_P#T;7OE>!_
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MMTS<QQR6\D4EK+&VUX=Y,3_,HSY*XR*2WTWX7_MW?#_Q%IWB_P *66IKX?\
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MQK\,V7AOQ]"9A9OI\3(KRQ(99()%WNI/E!I%D5MC*O?*D^L_MI?M6>,_V8?
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M#L,D=R9R3*KIYP&UMQX&,8&,8%?==% 'AGQ_^ WC?X[?#D^#/^%G1^&=+O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M23@#.  .M\&_L?\ QD\#Z+9Z+IO[4OB1-'M84MH[>3PY93.D*@ (DDI=EP
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MH7\4-W%/;PK"X$&=[!C&67:IW C% 'S%KV?^'XVGX'>+W_Y@!KZL_P""H_\
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MLMO<6D%KI/@_12MQJY?:J1V<=C&3+Y@.U,;0HX)(4YK\^/\ @EC\;?"7P?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KP/QE_P G%:-W^>V_D?\ /^'6O?*\#\9?
M\G%:-W^>V_D?\_X=: /?**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** / _@&/^+@>)^/X'[?\ 37Z?Y_E[Y7@?P#'_ !<#Q/Q_ _;_
M *:_3_/\O?* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH \*_:A_P!3X=[\W)P.3_RRZ#UKVW3UVV%L, 8B4?+TZ"O$_P!J#F+PV/\
M:N/_ &E[=*]LT_\ Y!]M_P!<EZC'8>PH J>*./#.KDG ^R3<YQ_ :^2?"?\
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M:D\.LX</':ZI>>2Y9-A9HFF*,VW@,02.Q%<OK_[ 7P$\5:G)J6M^ (]8U&0
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MGBLCXL?LO_#/XY7R7?COPX_B-HPH2&YU*[6!-H(!6%)1&&^8_,%R<\FO5**
M/'_A;^R/\)O@GKRZSX'\)_\ ".7XSN:TU&[\N3*,G[R-I2CX#MC<IP3D8(!K
MMOB7\+?"?QB\)77AGQIH-GXBT.X(9[2\3(# $!T8$,CC)PZD,,G!KJJ* /'O
M@W^R%\'O@!J4FI> _ FGZ)JCH8_[0>26[N54_>599W=T!SR%(!XSTI?"?[(?
MP>\#_%'4/B-HO@33[3QG?3R74NJ,\LI2:0DR211N[)"S;FR8U4_,1T->P44
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X'XR_Y.*T;O
M\]M_(_Y_PZU[Y7@?C+_DXK1N_P ]M_(_Y_PZT >^4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!X'\ Q_Q<#Q/Q_ _;_IK]/\_P O?*\#
M^ 8_XN!XGX_@?M_TU^G^?Y>^4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!X5^U#GR/#N!WN>W!.(^#_GM7MMAQ8VPY_U:]1@]!7B?
M[4'^I\.$C@&XYQ_UR_7_  KVS3QMT^V&,?NEX';@>U %3Q1_R+6K<X_T2;_T
M U\D>%?]5<CMN'_LW^?\:^M_%'_(LZO_ ->DW?'\!]Q7R1X5_P!5<X_OCC\3
M_7'_ ->@#>/ZY_I_G_/-)Q[8_P _Y_#\E]!^7;_/_P!;\@<X_P ]2?\ /XT
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MQ_$5]5>!O^1)\/\ _8/M_P#T4M &Y1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'D/[2_\ R)NF_P#7^O\ Z+>N\^'/_(@^'?\ KPA_
M] %<'^TO_P B;IO_ %_K_P"BWKO/AS_R(/AW_KPA_P#0!0!T5%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5X'XR_P"3BM&[_/;?R/\ G_#K7OE>!^,O
M^3BM&[_/;?R/^?\ #K0![Y1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'SYX-_Y%?Q7
M_P!?MW_Z+'^>U<U72^#?^17\5_\ 7[=_^BQ_GM7-5]#@?X9Y6(^(****](Y
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***OZ'I$FM7RP*=J#YI)/[J
M^M)M15V-*[LC:\$^'6U"Z2\E0O&CA8DQ]]\C]!_GI7M^CZ6NFVP! ,S<NW7\
M*RO">A)9V\<QCV*J[8H\=!Z__7_^M72U\UBJSJRMT/6HT^1!1117$=(4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!X'\ Q_P 7 \3\?P/V_P"FOT_S_+WRO _@&/\ BX'B?C^!^W_3
M7Z?Y_E[Y0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 >0_M+_\B;IO_7^O_HMZ[SX<_P#(@^'?^O"'_P! %<'^TO\ \B;IO_7^
MO_HMZ[SX<_\ (@^'?^O"'_T 4 =%1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %>!^,O^3BM&[_/;?R/^?\ #K7OE>!^,O\ DXK1N_SVW\C_ )_PZT >
M^4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!X#X"MVNM!\2P(0'DU"Y0%N "44#^=1?
M\(#J'_/:U_[[;_XFK'P(8W'C;Q-;2DR6R[Y!"_*!_,QNQC&<<9KW+^S;3_GU
MA_[]C_"N^EBG2CRHY9T5-W9X+_P@.H?\]K7_ +[;_P")H_X0'4/^>UK_ -]M
M_P#$U[W_ &=:?\^L/_?L?X4?V=:?\^L/_?L?X5M]?EV,_JJ/!/\ A =0_P">
MUK_WVW_Q-'_" ZA_SVM?^^V_^)KWO^SK3_GUA_[]C_"C^SK3_GUA_P"_8_PH
M^OR[!]51X)_P@.H?\]K7_OMO_B:/^$!U#_GM:_\ ?;?_ !->]_V=:?\ /K#_
M -^Q_A1_9UI_SZP_]^Q_A1]?EV#ZJCP3_A =0_Y[6O\ WVW_ ,31_P (#J'_
M #VM?^^V_P#B:][_ +.M/^?6'_OV/\*/[.M/^?6'_OV/\*/K\NP?54>"?\(#
MJ'_/:U_[[;_XFC_A =0_Y[6O_?;?_$U[W_9UI_SZP_\ ?L?X4?V=:?\ /K#_
M -^Q_A1]?EV#ZJCP3_A =0_Y[6O_ 'VW_P 31_P@.H?\]K7_ +[;_P")KWO^
MSK3_ )]8?^_8_P */[.M/^?6'_OV/\*/K\NP?54>"?\ " ZA_P ]K7_OMO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** / _@&/^+@>)^/X'[?\
M37Z?Y_E[Y7@?P#'_ !<#Q/Q_ _;_ *:_3_/\O?* "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M /V#[?\ ]%+7RIXH&VUB Q_K!T^AKZK\#?\ (D^'_P#L'V__ **6@#<HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R']I?_D3=-_Z_
MU_\ 1;UWGPY_Y$'P[_UX0_\ H K@_P!I?_D3=-_Z_P!?_1;UWGPY_P"1!\._
M]>$/_H H Z*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\#\9?\G%:-
MW^>V_D?\_P"'6O?*\#\9?\G%:-W^>V_D?\_X=: /?**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH \#^ 8_XN#XGXYV/V_Z:CV^GY?E[Y7@?P#_Y*!XG/^P_;_IK]/\
M/\O?* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%+7RKXJS]DASU\STZ?+T_3_]5?57@;_D2?#_ /V#[?\ ]%+0!N4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y#^TO_ ,B;IO\ U_K_
M .BWKO/AS_R(/AW_ *\(?_0!7!_M+_\ (FZ;_P!?Z_\ HMZ[SX<_\B#X=_Z\
M(?\ T 4 =%1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>!^,O\ DXK1
MN_SVW\C_ )_PZU[Y7@?C+_DXK1N_SVW\C_G_  ZT >^4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!X'\ Q_P 7 \3<?P2=O^FH]O\ /\O?*\#^ 8_XN!XFX_@D[?\
M34>W^?Y>^4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#8&#Z<@_3IS^?<?H!35^2-2,97!R#T/)]?3'I],BG$ 'V'RYP/7'7/<9[G_
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M_P"O"'_T 4 =%1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>!^,O^3B
MM&[_ #VW\C_G_#K7OE>!^,O^3BM&[_/;?R/^?\.M 'OE%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >!_ ,?\7 \3<?P2=O^FH]O\_R]\KP/X!C_BX'B;C^"3M_TU'M
M_G^7OE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 >!_ ,?\7 \3\?P/V_Z:_3_ #_+WRO _@&/^+@>
M)^/X'[?]-?I_G^7OE !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGG_]>/U-'WFR,X8Y_P#U_@#W[_4TGH<#(P0>G<].F,_AQV[T 8WBHYMXCZR
M]/4?Y_SS7U5X&_Y$GP__ -@^W_\ 12U\J^*AMM8L9'[WTQZ^P_R.U?57@;_D
M2?#_ /V#[?\ ]%+0!N4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!Y#^TO_ ,B;IO\ U_K_ .BWKO/AS_R(/AW_ *\(?_0!7!_M+_\
M(FZ;_P!?Z_\ HMZ[SX<_\B#X=_Z\(?\ T 4 =%1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %>!^,O\ DXK1N_SVW\C_ )_PZU[Y7@?C+_DXK1N_SVW\
MC_G_  ZT >^4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!X'\ Q_P 7 \3<?P2=O^FH
M]O\ /\O?*\#^ 8_XN!XFX_@D[?\ 34>W^?Y>^4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X'\ Q_
MQ<#Q/Q_ _;_IK]/\_P O?*\#^ 8_XN!XGX_@?M_TU^G^?Y>^4 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!X5^U#_J?#O?FY.!R?\
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MF1P::N1L;:01M/<8Z<]AZ=_XA]:7JV63YEYVGDC&>/7@+C!!%(B?= 'S8QG
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M[?\ ]%+7RKXJ_P"/6'O^\Z@>Q_SUQP:^JO W_(D^'_\ L'V__HI: -RBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /(?VE_^1-TW_K_
M %_]%O7>?#G_ )$'P[_UX0_^@"N#_:7_ .1-TW_K_7_T6]=Y\.?^1!\._P#7
MA#_Z * .BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O _&7_)Q6C=_
MGMOY'_/^'6O?*\#\9?\ )Q6C=_GMOY'_ #_AUH ]\HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#P/X!C_BX'B;C^"3M_TU'M_G^7OE>!_ ,?\ %P/$W'\$G;_IJ/;_
M #_+WR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** / _@&/^+@>)^/X'[?]-?I_G^7OE>!_ ,?\7 \3
M\?P/V_Z:_3_/\O?* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/_(E?0-% 'S]_P -&:__ -"]!_Y$H_X:,U__ *%Z#_R)7T#10!\_?\-&:_\
M]"]!_P"1*/\ AHS7_P#H7H/_ ")7T#10!\_?\-&:_P#]"]!_Y$H_X:,U_P#Z
M%Z#_ ,B5] T4 ?/W_#1FO_\ 0O0?^1*/^&C-?_Z%Z#_R)7T#10!\_?\ #1FO
M_P#0O0?^1*/^&C-?_P"A>@_\B5] T4 ?/W_#1FO_ /0O0?\ D2C_ (:,U_\
MZ%Z#_P B5] T4 ?/W_#1FO\ _0O0?^1*/^&C-?\ ^A>@_P#(E?0-% 'S]_PT
M9K__ $+T'_D2C_AHS7_^A>@_\B5] T4 ?/W_  T9K_\ T+T'_D2C_AHS7_\
MH7H/_(E?0-% 'S]_PT9K_P#T+T'_ )$H_P"&C-?_ .A>@_\ (E?0-% 'S]_P
MT9K_ /T+T'_D2C_AHS7_ /H7H/\ R)7T#10!\_?\-&:__P!"]!_Y$H_X:,U_
M_H7H/_(E?0-% 'S]_P -&:__ -"]!_Y$H_X:,U__ *%Z#_R)7T#10!\_?\-&
M:_\ ]"]!_P"1*/\ AHS7_P#H7H/_ ")7T#10!\_?\-&:_P#]"]!_Y$H_X:,U
M_P#Z%Z#_ ,B5] T4 ?/W_#1FO_\ 0O0?^1*/^&C-?_Z%Z#_R)7T#10!\_?\
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M_P#]"]!_Y$KZ!HH ^?O^&C-?_P"A>@_\B4?\-&:__P!"]!_Y$KZ!HH ^?O\
MAHS7_P#H7H/_ ")1_P -&:__ -"]!_Y$KZ!HH ^?O^&C-?\ ^A>@_P#(E'_#
M1FO_ /0O0?\ D2OH&B@#Y^_X:,U__H7H/_(E'_#1FO\ _0O0?^1*^@:* /G[
M_AHS7_\ H7H/_(E'_#1FO_\ 0O0?^1*^@:* /G[_ (:,U_\ Z%Z#_P B4?\
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MB@#Y^_X:,U__ *%Z'_R)1_PT9K__ $+T/_D2OH&B@#Y^_P"&C-?_ .A>A_\
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M$KZ!HH ^?O\ AHS7_P#H7H?_ ")1_P -&:__ -"]#_Y$KZ!HH ^?O^&C-?\
M^A>A_P#(E'_#1FO_ /0O0_\ D2OH&B@#Y^_X:,U__H7H?_(E'_#1FO\ _0O0
M_P#D2OH&B@#Y^_X:,U__ *%Z'_R)1_PT9K__ $+T/_D2OH&B@#Y^_P"&C-?_
M .A>A_\ (E'_  T9K_\ T+T/_D2OH&B@#Y^_X:,U_P#Z%Z'_ ,B4?\-&:_\
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M]?0-% 'S[_PT9K__ $+L&/\ MI1_PT9X@_Z%ZW_\B?C7T%10!\_?\-&>(/\
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M]?0-% 'S[_PT9K__ $+L&/\ MI1_PT9X@_Z%ZW_\B?C7T%10!\_?\-&>(/\
MH7;?/UD_S_GO2?\ #1FO_P#0NP8_[:5]!44 ?/O_  T9X@_Z%ZW_ /(GXTO_
M  T9X@_Z%VWS]9/\_P">]?0-% 'S[_PT9K__ $+L&/\ MI1_PT9X@_Z%ZW_\
MB?C7T%10!\_?\-&>(/\ H7;?/UD_S_GO2?\ #1FO_P#0NP8_[:5]!44 ?/O_
M  T9X@_Z%ZW_ /(GXTO_  T9X@_Z%VWS]9/\_P">]?0-% 'S[_PT9K__ $+L
M&/\ MI1_PT9X@_Z%ZW_\B?C7T%10!\_?\-&>(/\ H7;?/UD_S_GO2?\ #1FO
M_P#0NP8_[:5]!44 ?/O_  T9X@_Z%ZW_ /(GXTO_  T9X@_Z%VWS]9/\_P">
M]?0-% 'S[_PT9K__ $+L&/\ MI1_PT9X@_Z%ZW_\B?C7T%10!\_?\-&>(/\
MH7;?/UD_S_GO2?\ #1FO_P#0NP8_[:5]!44 ?/O_  T9X@_Z%ZW_ /(GXTO_
M  T9X@_Z%VWS]9/\_P">]?0-% 'S[_PT9K__ $+L&/\ MI1_PT9X@_Z%ZW_\
MB?C7T%10!\_?\-&>(/\ H7;?/UD_S_GO2?\ #1FO_P#0NP8_[:5]!44 ?/O_
M  T9X@_Z%ZW_ /(GXTO_  T9X@_Z%VWS]9/\_P">]?0-% 'S[_PT9K__ $+L
M&/\ MI1_PT9X@_Z%ZW_\B?C7T%10!\_?\-&>(/\ H7;?/UD_S_GO2?\ #1FO
M_P#0NP8_[:5]!44 ?/O_  T9X@_Z%ZW_ /(GXTO_  T9X@_Z%VWS]9/\_P">
M]?0-% 'S[_PT9K__ $+L&/\ MI1_PT9X@_Z%ZW_\B?C7T%10!\_?\-&>(/\
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M]?0-% 'S[_PT9K__ $+L&/\ MI1_PT9X@_Z%ZW_\B?C7T%10!\_?\-&>(/\
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M]?0-% 'S[_PT9K__ $+L&/\ MI1_PT9X@_Z%ZW_\B?C7T%10!\_?\-&>(/\
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M]?0-% 'S[_PT9K__ $+L&/\ MI1_PT9X@_Z%ZW_\B?C7T%10!\_?\-&>(/\
MH7;?/UD_S_GO2?\ #1FO_P#0NP8_[:5]!44 ?/O_  T9X@_Z%ZW_ /(GXTO_
M  T9X@_Z%VWS]9/\_P">]?0-% 'S[_PT9K__ $+L&/\ MI1_PT9X@_Z%ZW_\
MB?C7T%10!\_?\-&>(/\ H7;?/UD_S_GO2?\ #1FO_P#0NP8_[:5]!44 ?/O_
M  T9X@_Z%ZW_ /(GXTO_  T9X@_Z%VWS]9/\_P">]?0-% 'S[_PT9K__ $+L
M&/\ MI1_PT9X@_Z%ZW_\B?C7T%10!\_?\-&>(/\ H7;?/UD_S_GO2?\ #1FO
M_P#0NP8_[:5]!44 ?/O_  T9X@_Z%ZW_ /(GXTO_  T9X@_Z%VWS]9/\_P">
M]?0-% 'S[_PT9K__ $+L&/\ MI1_PT9X@_Z%ZW_\B?C7T%10!\_?\-&>(/\
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M]?0-% 'S[_PT9K__ $+L&/\ MI1_PT9X@_Z%ZW_\B?C7T%10!\_?\-&>(/\
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M]?0-% 'S[_PT9K__ $+L&/\ MI1_PT9X@_Z%ZW_\B?C7T%10!\_?\-&>(/\
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M]?0-% 'S[_PT9K__ $+L&/\ MI1_PT9X@_Z%ZW_\B?C7T%10!\_?\-&>(/\
MH7;?/UD_S_GO2?\ #1FO_P#0NP8_[:5]!44 ?/O_  T9X@_Z%ZW_ /(GXTO_
M  T9X@_Z%VWS]9/\_P">]?0-% 'S[_PT9K__ $+L&/\ MI1_PT9X@_Z%ZW_\
MB?C7T%10!\_?\-&>(/\ H7;?/UD_S_GO2?\ #1FO_P#0NP8_[:5]!44 ?/O_
M  T9X@_Z%ZW_ /(GXTO_  T9X@_Z%VWS]9/\_P">]?0-% 'S[_PT9K__ $+L
M&/\ MI1_PT9X@_Z%ZW_\B?C7T%10!\_?\-&>(/\ H7;?/UD_S_GO2?\ #1FO
M_P#0NP8_[:5]!44 ?/O_  T9X@_Z%ZW_ /(GXTO_  T9X@_Z%VWS]9/\_P">
M]?0-% 'S[_PT9K__ $+L&/\ MI1_PT9X@_Z%ZW_\B?C7T%10!\_?\-&>(/\
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M]"2*,G@YSCJ<D^YZ?3U]?P ,3Q5S9PG^\X;]#_A_GFOJSP/QX+T#M_Q+[?\
M]%K7RIXJS]CBS_ST_I]/3%?5?@?CP7H';_B7V_\ Z+6@#;HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R+]I;_ )$W3?\ K_7_ -%R
M5W?PY_Y$'P[SG_B7P#_QP5P?[2__ ")VF_\ 7^O_ *+>N\^'/_(@^'?^O"'O
MG^ 4 =%1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>!^,AG]HK1>,_/
M;=O8^W^?:O?*\#\9#/[16B\9^>V[>Q]O\^U 'OE%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 >!_ /_ )*!XH_W&_\ 1HKWRO _@'_R4#Q1_N-_Z-%>^4 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!X'\ O^2@>)_P#<?_T;7OE>!_ +_DH'B?\ W'_]&U[Y0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A7[47^H\.GWN/\ VE7M
MUA_QXV_;]VO\A7B/[47^H\.GWN/_ &E7MUA_QXV_;]VO\A0!3\4''AK5C_TZ
M3?\ H!KY(\*_ZFY[_./Z_P"/_P"NOK?Q1_R+6K<X_P!$F_\ 0#7R1X4_U=QV
M^<?U_IG_ .O0!O' YZ@?_K_/_/K1C.1U'U]/S[=/J>>*%SD$?>R",<?R_P _
MI2<;?5?;G_/'TZ>U !G=PQP>/PZ],GU.<?RI5PV6P#D9(!QD<G! [9 [=ATI
M"2J\_=R21G@]..HSDX_#%+(?E8DEP.,DYSG=SGD?Y_&@ PS(%RS' &#NP<@D
M#Z\+CIT'7K2$94E,#<3@CW'3@=>",'UX'>E;:K@G;C/WBHP1N/H"/Y]".>E$
M:[MJ'YCG;U![D$#J?XNWY'K0 O\ K)N.K#@]SEOSZ'_:_P &[BREN,\L.>G(
M/7/T_EVQ0K;<,1_" <\ XP>_7CU![>U'W<*&Y&<=,=<9ZX[#IGZT *6VXP>/
MF Y&/09Y]/?_ .N;0/E 8#..F3@>WU^G/Z*&SRI/7&?;(([]@.Y_EFF\<\=B
M<?B>V/0\''_U@!1EMPSDG.?FSDD=>I]#S_\ 6P=<'IR",]AZ\?EV''Y+RVY3
MR>XY/.6'3GU],_U0?-GU;'H>>OXG'TSS[Y ,3Q2/]#B.,?.#V[@GTKZL\#\>
M"] [?\2^W_\ 1:U\I^*2&LXR#G,G]&_SS7U9X'X\%Z!V_P")?;_^BUH VZ**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \A_:7_Y$W3?
M^O\ 7O\ ],WKO/AS_P B#X=_Z\(>V/X!7!_M+_\ (FZ;_P!?Z]O^F;UW?PY_
MY$'P[_UX0_\ H H Z.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\#\
M9#/[16B\9^>V[>Q]O\^U>^5X'XR&?VBM%XS\]MV]C[?Y]J /?**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH \#^ ?\ R4#Q1_N-_P"C17OE>!_ /_DH'BC_ '&_]&BO
M?* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH \#^ 7_ "4#Q/\ [C_^C:]\KP/X!?\ )0/$_P#N/_Z-
MKWR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"OVH
MO]1X=/O<?^TJ]NL/^/&W[?NU_D*\1_:B_P!1X=/O<?\ M*O;K#_CQM^W[M?Y
M"@"GXH_Y%G5_^O2;OC^ ^XKY)\*<1W/./G'X<GG]/TKZV\4?\BSJ_P#UZ3=\
M?P'W%?)'A4[8KGG'SC\.3S^GZ4 ;O7H.V .O8X_K_GBE/J#@*<CG.!@8/7Z?
MYX!@\K^'7_/M_G%(QRK'D Y//OS]/3TZT #,-IP=IQ_"1TY&.N>X[].QZTLF
M&W$GC=RW7NW^>OYTI;=O 8\Y/RL?]KW/^>_<HV6R3R6RV<$@@;CZ9P?KV.:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %>!^,AG]HK1>,_/;=O8^W^?:O?*\#\9#/[16B\9^>V[>Q]O
M\^U 'OE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 >!_ /_ )*!XH_W&_\ 1HKWRO _
M@'_R4#Q1_N-_Z-%>^4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!X'\ O^2@>)_P#<?_T;7OE>!_ +
M_DH'B?\ W'_]&U[Y0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% 'A7[47^H\.GWN/\ VE7MUA_QXV_;]VO\A7B/[47^H\.GWN/_ &E7
MMUA_QXV_;]VO\A0!3\3_ /(MZM_UZ3?^@&ODCPK_ *BY[?-_//\ G_&OK?Q1
M_P BSJ__ %Z3?^@&ODCPK_J;G!QAQ^&<_P"?\: -YNYQG_9/?GI_G_\ 6O\
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M -?Z_P#HMZ[SX<_\B#X=_P"O"'OG^ 4 =%1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %>!^,AG]HK1>,_/;=O8^W^?:O?*\#\9#/[16B\9^>V[>Q]O\
M^U 'OE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 >!_ /\ Y*!XH_W&_P#1HKWRO _@
M'_R4#Q1_N-_Z-%>^4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!X'\ O\ DH'B?_<?_P!&U[Y7@?P"
M_P"2@>)_]Q__ $;7OE !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 >%?M1?ZCPZ?>X_]I5[=8?\>-OV_=K_ "%>(_M1?ZCPZ?>X_P#:
M5>W6'_'C;]OW:_R% %/Q0=OAK5B.#]DF_P#0#7R1X5_U-P.VX#'MST_SV[U]
M;^*/^1:U;G'^B3?^@&ODCPI_JKD?[8_F?Z9_^O0!N]>_^&?\\_A[T>N/E[CM
M@\X[CN?\X-+_ )_E_G\/QI&)52<D?YSZ^N/R'M0 [.XKCOD#GCIQW.>.,9]L
M>K05P0" #TR1Z$<\?3M[Y&:63[K'KU'!.#AA@=^,8[^GXJVX*V-S<-_>P>HS
MU.?XCZ=>3TH "S*#G<!CJPXZD@'/7G(QZCO2!=NY!T5R/FYQRO)S_4#Z]J1B
MGS$!3]XCD=\^WL../;KPI]!M^7D9(('.,G'!^Z/0G/>@ _B0XY[#G)&T8'(_
M^M[>J;=H8?PG'8^A&>GOGIT[YIP7;(%"D=@I!!/S$=/S'?\ P8OW20?FQGC
MZ 8Z'Z]O_K "Y^4'V(Y(]!QGOP/7OT]7'AFR-W0GWQR3Z9Y_R.J-@<YX]3S\
MOIGOP/;H12]SN&>03[]_?/'?'_UP!%7:P4C##CI@^A[>Q]>OK2<;1VX)P/3J
M?7W'YYQSD7*@+T/3'O\ +VZ>G')XYI>Q R20?4Y).,_I[\]_0 Q?%?\ QZQY
MZ^9SP1V/^>>>#7U7X'_Y$KP__P!@^W_]%K7RGXK_ ./6+O\ O.H'L?\ /IP:
M^K/ _P#R)7A__L'V_P#Z+6@#;HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#R']I?\ Y$W3?^O]>_\ TS>N\^'/_(@^'?\ KPA[8_@%
M<'^TO_R)NF_]?Z]O^F;UW?PY_P"1!\._]>$/_H H Z.BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** / _@%_R4#Q/_ +C_
M /HVO?*\#^ 7_)0/$_\ N/\ ^C:]\H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#PK]J+_ %'AT^]Q_P"TJ]NL/^/&W[?NU_D*\1_:
MB_U'AT^]Q_[2KVZP_P"/&W[?NU_D* *?BC_D6=7_ .O2;OC^ ^XKY(\*_P"I
MNO\ >_QQ_G^=?6_BC_D6M6YQ_HDW_H!KY(\*?ZNX[?./Z_TS_P#7H WCR>#Q
MV_/_ /5_D\AQ^?O@GITXZD?Y]3^$Y!QCGV_SG_/<_BZXSR1GCM[CL3^9'O0
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ML4;#^Z[JWM0!]*456TV^CU33[6\B#+%<1+,@<88!@",^_-6: "BBB@ HHHH
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MS^T5HO&?GMNWL?;_ #[4 >^4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X'\ _^2@>
M*/\ <;_T:*]\KP3X2;-%O/$6LJX69KN6V?S2/+5%*MGL0<GN>@KT+_A8T/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
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M<&YSD$\X]![_ -.WY#C"L/3.,Y],=QUX]NGTPI;=GYB<$?Q=/F/?)Q]??\P
MZL-N#R0I^O/^/'Z#-)PP[?,NW\^WX<>I_HN1D,>A_+'8?H.IXP>O2CD9W<\9
MY/)P>>O_ .K^8 ,3Q5_QYQ'_ *:8!^F?<^WZ5]6>!_\ D2O#_P#V#[?_ -%K
M7RGXI_X\H><_O,9]?E_S_P#6KZL\#_\ (E>'_P#L'V__ *+6@#;HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ"CHE];K,J-]H09 8$ XK]FZ_'7_ ((C_P#):OB$<?\ ,OIV_P"GF/V_K_\
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M^?:O?*\#\9#/[16B\9^>V[>Q]O\ /M0![Y1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#P/X!?\E \3_[C_P#HVO?*\#^
M7_)0/$_^X_\ Z-KWR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y#^TO_ ,B;IO\
MU_KW_P"F;UWGPY_Y$'P[_P!>$/;'\ K@_P!I?_D3=-_Z_P!>W_3-Z[OX<_\
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MYS_RW]S^9KY;_P""IW[(/BWQ9X@T/XW?#*ROK[Q'HZ11:I::9N:[58FWV]W
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MK^U!\2-:\82W'AC2?$MI<&QOM3MI(XMYNUE6-WVD(Q0D@L0,KC))4$ ^X/\
M@JH%/[#OCW/43Z;CCO\ ;[?_ .O6K_P3)_Y,;^&')/[F^ZC'_,0N:\V_X*K?
M&'PM)^S/XB\ 6>H+J?BW5KG3Q%IEDC2RQ()HKCS'"@[5*(,$]2ZXK8_X)8_%
M?P[JG[,7A#P ;YK;QEH:WPO-(NH7BF$9O))5D0,!O39-'EAG!)!Y% 'VE111
M0 4444 %%%% !1110 5X'XR&?VBM%XS\]MV]C[?Y]J]\KP/QD,_M%:+QGY[;
MM['V_P ^U 'OE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 ?/G@W_D5_%?;_3KOG'_3
M-?\ ]?X^_/-5TO@W'_"+^*^P^W7??I^[7\O\_CS5?18'^&>5B?B"BBBO1.0*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!T<CPR+)&Q1U.Y67J#7
MKG@?Q<+B)9SPW"7$8]>/F'KU)'U(KR&KVBZM)HM^MPG*_=D3^\M<U>BJL;=3
M6G-P9],JP90P.01D&EKEO".N17$,<(??#(-T,@Z'V_G74U\Q.+@[,]F,E)70
M4445!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% '@?P"_Y*!XG_ -Q__1M>^5X'\ O^2@>)_P#<?_T;7OE
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M "YY"Y) VX7)Z8Z8/]XY]../2D. V<8!W8P,<<G&>.>G;O\ A0Q\R/KUZ9/
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M3_)_ 5]6>!_^1*\/_P#8/M__ $6M?*?BK'V.'!S\X&?7Y?\ ]7_UJ^K/ _\
MR)7A_P#[!]O_ .BUH VZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#';PI%$BQ11J%1$&%4 8  ["GT4 %%%% !1110 4444 %%%% !1110 4444
M5X]/M8;N2Z2VA2YD&UYEC =AZ%NIJQ110 4444 ,,,;3+*44RJI57Q\P!()
M/H<#\A3Z** &10QP*5C18U+,Q"C R223]222?<T^BB@ HHHH **** "BBB@
MHHHH **** "BBB@"M:Z;:6+S/;6L-NTS;I&BC"ESZM@<GD]?6K-%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X'\ O^2@>)_P#<
M?_T;7OE>!_ +_DH'B?\ W'_]&U[Y0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P#7^O\ Z+>N[^'/_(@^'?\ KPA_] % '1T444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !117RK^UI^T[K7@SXH_#OX)^ +JWL/'WCBXC\W6+F$3K
MH]B7*M.L1&V24[)=@;*CRSN'(H ^JJ*_/G]J[]GGX_\ P=TFU^(7P3^+_P 2
MO&NIV<ZMJ?AO5[U=1,JG_EK!;+&L; -]Z$1-PV5P%Q7V7\"?$?BWQ=\'?"&L
M^.]&'A_QA>Z='-J>FJI3R9B.?D/*$C#%#RI;:>10!W=%%% !1110 445A^#_
M !MHGC[29M3\/WZ:E817EUI[7$:,J^?;SO!,HW 9"R1NNX95L94D$$@&Y111
M0 4444 %%%<[\1K'7]4^'_B:S\*7L.F^)[C3+F+2[RX&8X+IHF$+M[!RI[].
MAZ4 =%17S#^P1\/_ (Y_#WX<Z[9_'+7IM:U6;4C+IR7FH"_N((2@W[I]S94M
M]U,G;@] 0!]/4 %%%% !1110 4444 %%%% !1110 4444 %%%% !17BW[5U_
M\5-%^$WB'6?A?KFAZ'>:5I5WJ$\NJ:>UW<2>5&9%2#+B-&(5AF1'&<<=2/G3
M_@D?\6_&GQB^&OQ"U?QMXHU3Q1J":ZB1RZE<M*(5,"DI&I.V-<\[5 &>U 'W
MI117R5^V)\4?CEH_Q<^%_P /_@<NFG5O$-KJ%WJ$FJVHD@MX8&@ FD<@[$7S
M&!P"264 $D @'UK17Q'X^L_VQ/AO\+_%?C+6/BA\/I4\/Z3=ZM+9V.A22&5(
M(&E9%=E7!.P@9&.<^U>3_L=_M!?M3?MB:+XDU+1_'WA#P]'HEQ#;R)?>'_,,
MAD5F!4J<<!3^E 'Z:45^?_C7XA?M@_ KXG?#0>-M7\)^)?A_KWB?3M'U'4O#
M^F_-;)/<QQE90ZJT9=68*Z[ER "02H/N_P"UM-\7_ _PZ\8>/OAYX[T[3X=
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M;B S#J=J@F@#[JHKQ[]D'QYK?Q/_ &:?A_XK\1WGV_7-6T[[5=W&P('<NW0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '@?P"_Y*!XG_W'_P#1
MM>^5X'\ O^2@>)_]Q_\ T;7OE !1110 4444 %%%% !1110 4444 %%%>&_M
M-VOQ8T7P3XD\6?#CQS8:1+HVF2WRZ'J6B1W4=T88V=E$V\,C,!@$@@$#@9)
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MZD8QC\.AZX^A]W;G@_*#SCIV_EW_ /K 'S;<#)SV[]N._(/;OCGI0!B>*O\
MCSBP!]\9Q]#_ (5]6>!_^1*\/_\ 8/M__1:U\I^*/^/*'@@;QV]C_0BOJSP/
M_P B5X?_ .P?;_\ HM: -NBBB@ K&U3P=HVM>(M$UZ^L([G5]$\\Z==.3NMO
M.0)*5&<991CD=/K6S10 5^(/_!1[_D\[XA_]P[_TW6M?M]7X@?\ !1T8_;.^
M(GO_ &=_Z;K6NW"?&_0YZ_PGTK_P1K_YJ_\ ]P?_ -O:_2JOS5_X(U_\U?\
M^X/_ .WM?I56>(_BLNE\",GPKX5TGP3H=OHVAV,>G:9;M(T5M$3M0N[2/C)/
M5G8_C7Y4_P#!7D_\9!>%!G_F5X>,_P#3W=>_]/S[?K97Y)_\%>3_ ,9!>%!G
M_F5X>,_]/=U[_P!/S[5AOXA-;X#$_P""4&?^&HKKT_X1V[_]&P5^P]?CO_P2
MA'_&45T=H/\ Q3MWSGD?O;>OV(HQ7\0*/PGX[_\ !5[_ ).BM3@_\B[:<YX_
MUMQ73?\ !(/_ )+AXR_[%T_^E,-<S_P5>_Y.BM3@_P#(NVG.>/\ 6W%=-_P2
M#_Y+AXR_[%T_^E,-=;_W?Y&/_+T_6*OR%_X*R>!K?P[^T-I>OVL0C'B#1HIK
MA@/OSPNT1;_OVL(_"OUZK\OO^"Q31_\ "6_#)1CSA8WQ;CG:9(L?J&KCPS_>
M(WK? >3?\$Q?BM<^ ?VEK'02S'2_%EO)IUQ'V$J*TL,GU!5D^DK5^S5?@7^Q
M_P#:#^U'\+?LQVR?\)!:9XS\GF#?W_N[J_?2KQ:M-,FB_=(YIX[6&2::18HH
MU+O(Y 55 R22>@ K\7OVMM,\4?'ZS\2?M#J6?P4=?/AO2K=HSN2RB4B*XZ\(
M\FX'TDD(K]#OV]/B1J7AOX2VG@;PPQ?QK\0KU/#NEQ1MM81R$"XD]E",(RP^
MZ9E/:NZN/V;?#TG[,K?!E HT?^Q?[,6X,8SYX&X7.W^_YW[[_>J*4O96F^OY
M%37/[I^-O[(OQL;X _'SPSXIEE,>CM+]AU9><-9RX61B!R=AVR =S&HK][8Y
M%EC5T8.C#*LIR"#W%?S@>)O#M_X/\2:KH6JP&UU/3+J6RNH3UCEC<HZ_@P-?
ML[_P3G^-_P#PN#]G72["]G\W7?"I71[O)RSQ(O\ H\AX[QX7/.3&Q[UT8J%T
MIHRHR^RSZDKYR_X*(''[&_Q%YQ^ZL^^/^7ZW]Q_GUZ5]&U\Y?\%$#C]C?XB\
MX_=6??'_ "_6_N/\^O2N&G\<?4Z)_"S\.#R",X]Z_I*TOC2[, 8'DIQ_P$5_
M-JV-IR,BOZ2M+XTRT'3$2#]!7=C/LG/0ZEJBBBO-.L**\I\;?M4_"7X<>*+[
MPYXE\=:7H^N6.S[38W#-YD6^-9%SA3U1U;Z$5A_\-P? G_HINB_]]/\ _$U?
M))ZI$\R[GN5?SH?$KQA-\0OB)XG\47!)FUG4[G4&SV\V5GQ[ ;L8]J_>3PS\
M;/!GQF\+^)V\ ^);+Q%-I]JPF-KN(B>1'\O=D#J4;IZ5_/L&# $'(/0UWX16
M<KG-7>UC^@G]F,[OV;/A.?\ J4M)[?\ 3G%7X@_M-#'[2/Q8_P"QMU;_ -+)
M:_<7]G%E;]GKX7LI#*?"VED$="/LD5?AU^TUG_AI'XL9Y_XJW5O_ $LEI8;X
MY#K?"C]>_P!BO4K;XQ?L7>"K3Q#;1:E9RZ9-H=W:S#*2P0226RHW3(,4:9^M
M?1-K:PV-M%;V\,=O;PH(XX8E"HB@8"@#@ #C KY4_P""8,4T?[(^A-*<H^H7
MS1>R^<P_]"#5]85QU-)M>9O#X4?)W_!3[3].O/V2-=FO8U>ZM-0L9K%F4$K,
M9E0D'L?*>49'J1WK\\/^"=_P]NO'_P"U;X1:&+?::&TFLW<F/]6D2X0_C*\2
M_P# L]J^G?\ @J]\7WUZ_P#"/P;\/^9J&J2W*:EJ%I:*9)&E8&.T@ 7)+MO=
MMF,\Q'G(KZ-_88_91B_9F^&K/JJ1S>-]<"3ZK,I#"W4#Y+5&'!"9))'WF)Y(
M"XZXR]E0UW9@USU/0^EJ***\\Z@HHHH \A_:7_Y$W3?^O]?_ $6]=W\.?^1!
M\._]>$/_ * *X3]I?_D3=-_Z_P!?_1;UW?PY_P"1!\._]>$/_H H Z.BBB@#
MG_'?Q \-?#'PU<^(?%NN6/AW1+; EOM0G6*,$G"KD]6)X"CD]A7SU\*_^"C'
MPH^-'Q8U#P=X5GO9M.TW2;K6+WQ-J$8L[".&$H&(\PA\8<L6=4 "]\\?4;*K
M8W*&P<C(Z'UK\>?V4_AIX:\8?\%1OC#H.KZ5#=Z%:WVO3KI,F1:R[-00HDD0
M^22-20PC<%<HAQE1@ ^H_&G_  5[^#WA/78K>VT'QAKFAO*T2>(+/3HX[.?:
M<,T'FR(T@!SG*KTXS7O?B[]L;X3^"_@OH_Q1O/%$5QX6UI =)^R(9+J_DS@P
MQ0_>,BL"K*0-A!#;<&L7]OKP?I/BS]COXGVVI64-Q'I^C2ZC:[E&8)X!YD;H
M?X2"N..H)'0D5\[_ /!'3P#H=]\ YO&-[8B_\1VFL7>F65]>,TQL;4)%(T5L
M&XA#/*[/Y8&\D;B=H  .]^$'_!5/X6?%/XH6/@6]T;Q'X*U74)UM;277[>)(
MGG8X2)]DC&-F)4#(QD@9'&?LV21(8VDD94C4%F9C@ #J2:_*W_@N!X<L+=_A
M+XCAMTAUB0ZA92W4:8DDB3R'C5F]$9Y"!_TT:OT7\>>#KCXP? S7?"\FI/I-
MUXF\/S6#ZA''N,#SVY0OLR,@%\E<C(XR.M 'DFE_MSZ)\0M4UFV^%/@#QC\5
M['1YOL]YKF@V]O#IOFC[T<<US-&97&5.$4@JP8$@@U?_ &>?VY/ '[0WC'5?
M!=K9ZWX0\=Z7YGVKPWXFM!;W/[MMLFW:S*2AZJ2&')VX!(Y#]GSPUX&_X)Q_
M NU\'^._B!IL^K7^HSZB(X8F^TWDDFR-4MK5-TTN!&@R%)R>W%?&^C^*E\4?
M\%DM \06.@:UX4&I3H_V'7;+['=[3I#1M(\))*"106PV&PV6 .10!^B7Q]_;
M,^$G[-8>W\:>*H8]:$8D30M/4W-^X/*YB7[@(Y#2%5..M<79_P#!1#X7Q_ +
M0?BGK']H:5;Z_/=PZ3X<5$N-6O?(G>)BD*-C^ $L6V+N4%LD9S_^"IMA;7'[
M#7Q&FEMXI)H)-,EBD9 6C?\ M&V3<I[':[+D=F([URO_  2;^&?A[3?V5_"W
MC0:<LWB;4FOK=M3NB998;=+V=1!"6SY46X,Y1,!G=F.2: .E_9M_X*7_  O_
M &COB O@FUL=:\*>))PWV.WUR*-4NV4$M&CH[8D #':P&<<$GBO6_CW^T=I_
M[/&D7&M:_P"#_%FK>';6!)[K6="LX+BWMMSLNV0-,L@(V@EMFT!URW/'Y\?\
M%'=(M? __!0GX'^*M)MTM-2OY-*N+J2$;3/+#J!178XY)CV)GGY4 [<_H'^V
M)_R:?\8>,_\ %)ZG_P"DTE %K]FW]I3PG^U-X!NO%W@Z#4X-+M]0DTUUU6W6
M&7S4CC<D!78%<2KSGKGTKRSXU?\ !1/P/^SSKL.E>/?!/CW0I[G>;2:33+=X
M;M5(#-%(MP58#<N1G(W#(&:\R_X(O_\ )J.N\D_\5;=]1_TZVE>4_P#!<I1_
M9_P9..1+JXS^%G_G\* /T?\ B+\0X_AWX%NO% \/Z_XHB@$1&F>&=/-[?RB1
MU0&.$$%L;MS8Z*">U?DGX^^/:Z]_P5+\,>.I/ GCE(-.CACC\,W&@R+K;A;*
M3[EF3N.6<N.?N_-7[':1C^R;+' \A/\ T$5^6?CXC_A]MX>SSS;=&_ZA#?E]
M/\: /T)^#/QUA^,TNKI%X$\=>#/[.$1+>,] DTP7.\N/W)<G?MV?-Z;U]:X3
M6?VUO#5W\1=:\"_#[PIXG^*_B30\KJP\+V\/V/3Y 2#'-<SRQIOX8 +NR49>
MH('T+<1>?!)'O>+>I7?&<,N1U!]:^,OV6_@+X4_X)M>"?&=_\0?B;I+Q^(;^
M.2.]NT%INCA5PB(C,SR2GS7)5-V.,9Y) .W^%_[?'@CQW\8)?A7XAT'Q'\-_
MB )/*BTCQ1:)&+A]N]5CDC=U)9?F7. PQM+9&?IJOQM_;.^)5C\2/V^/@7XK
MT/0=?T"W,NC);WFN:8^GO?A-3=DN8HY,2&/YP SJI.W@;<$_I%^VQ\8+[X%?
MLN^/_&&E2/#K%M9+:V$T8!:&XN)$MXY1GC*-*'Y_N=#T(!!XZ_:^\-^'_'EY
MX%\(^'O$/Q1\:6&/[0TOPE;),FFY. +JXD=(HCU^4L3D8(%<Q\,?^"@7@'QQ
M\6#\,?$>B^(_AEX^:188-(\6V:0?:9'&Y$CD1V7<R[2N_:'W*$+$BN?_ ."5
MG@BQ\,_L>^'-<C'FZQXIO+W5M4O&<R//+]IDA3+'GB.%,C^\7/4FIOVK?^">
M6A_M0_&#PI\0)/%M[X5OM)AAM;R&SM%D-Y%%*TL923>IBD!=AO(?@+P-O(!3
M_P""B'[6WBC]G[X8ZM8>"/"GB*YUVX@5)O%BZ1/_ &3HL<K",2&Z*^6TY9E5
M%!(#,"W("-Y=_P $WOVE(_"?[-GP_P#!TOPT^)>LRRWUU$?$&D^&9;G229K^
M8^8;H-C8F[#M_"5;TKVO_@J/_P F)_$W_N&?^G2TJI_P2K'_ !@YX"YSF?4O
MP_T^XH ?\5O^"D'@/X'>);/0/'G@CQ]X:U.\C66".ZTRV=98R<;E=+EE8 \'
M:201@@5])^./%4_@WP_-JEOX?U?Q,\1&=/T..*2Y8<Y95DD0'&.F[)[ FOS(
M_P""VQ_XJCX(]CC5/F49/W[.OU6H ^<?@'^WA\/OVB/BEJOP^\/Z5XFTKQ+I
M=K/=7=OKNGI;"+R94BDC;$K,)%>0 J0.C<TO[07[?WP:_9QN+G3=>\1_VQXE
MMR5?0-!075W&P&=LG(CB/3B1U/.0#7QK^Q"JK_P5=^/@VD?-X@/7O_:D'->K
M_P#!:;3;6;]E_P ,WC0Q"ZM_%MNL4VP;PKVEWO4'J 2JD@=2@STH [_XJ?\
M!3SX7_"/P+X$UG5K'5K_ %OQ9H]MK<7A_2Q%+/96\R!U,[LZJN<D #).,X Y
MKT*7]NKX,Z?\%_#GQ-U?Q9%H>A^(+:2XL+&]0_VA,8W,<L:VZ;F8I(I1F7*
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M)TGB;([K)$C?\!KA/VL?^36?C)_V)FL_^D,U>JUY5^UC_P FL_&3_L3-9_\
M2&:@#X>_X(>J/^$$^*K;>3J5B-V/^F4O?'OZ]_S_ $@\69_X176<'!^Q38.<
M?\LV[U^<'_!#W_D0_BH<?\Q.Q[?],I?;^O\ ]?\ 1_Q<-WA36@.ILIAR<?\
M+-J /R5_X(A_\E5^)7_8%M__ $?7[ 5^/_\ P1#_ .2J_$K_ + MO_Z/K]@*
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH[X7:3XX\*7!DL;Q=D]K(?WUE<*!YEO*.SJ2/8@JPR&!/Y__ ++7CP?M3?\
M!4CQYXLUM_MNG^$-+OH_#=M*=RVT<-S%:QNJGH66::0^CR_2@#Z4\9?\% K;
MX86=CK/COX+_ !,\'>%+N14&N:AIMN\=ON.%,Z1SLT1/]T_-Z U]&?#GXD>&
M?BUX/T_Q5X0UBWUW0+]2UO>6I.TX.&4@@%6!!!5@""""!5KQOX-TCXB>#]:\
M+Z_:+?:+K%I)97=NW&^-U*M@]C@Y!'((!'(K\I/^"6_C;5O@C^UU\0_@3<WQ
MO-%GN=0ME5_EQ?6,C)YJKR!OB20,.^U.?EY /8?^"VG_ "0/P+P/^1F'/?\
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M3\H;&ULX[_F]\<N?^"S7@CD?\?&E]A_SZFOU*\7JK>$];5_N&QG!XSQY;=J
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M)%>*?\$;=4N-0_9'O8)I&>.Q\3WEO K=$0PV\I ]MTCGZDT ?47QL_:$\$_
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_![S-)\.'4%N76S7*Z+>L<%"G3[--N90I&P;FC( 9 0#]*_VQO\ DT_XP_\
M8IZG_P"DTE7/V3O^36?@W_V)FC?^D,-> R_M5:!^UG_P3W^*_B;31'8Z[:>%
M-1MM;T?=EK*Y^R2'C/)B< LC=QD'YE8#W[]D[_DUGX-_]B9HW_I##0!\ ?\
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MS]H;P%HWB_\ X+ :)H-]!(FFZPUC_:$=E.UN]P#8D.K.A# .JA&P02I([YH
M^IOC%_P5<^#_ ,*?$EQI%C9Z]XV2TF-O=:IH%O$UC'*.L:322*)&'^QE?1J^
ME?@C\;?"?[0GPZT[QKX,OFO='O-R%9D\N:WE7AX94_A=3UY(.002I!-7XH_#
M?PS>? /Q7X,71+&T\,-H5U:)IEK;)'!#&(FVB.-0 I4X9<8P0",$9KX1_P""
M'^K7,WP_^*6F,Y-G;:I97,:9X#R12*Y_$0I^5 'Z:4444 %%%% !1110 444
M4 %%%% !1110!X5^U%_J/#I][C_VE7MUA_QXV_;]VO\ (5XC^U%_J/#I][C_
M -I5[=8?\>-OV_=K_(4 4_%#;?#6K'.,6DW/I\AKY(\)@>7.I&!O4$>WS?Y[
M?6OK?Q0<>&M6/_3I-_Z :^2/"G^KNAU^8<?]]?SZ?B.: -Y<_+U4#;S@Y7OG
M..!RW3T_&AAD'<NWC/0\<D>G09Q_P'Z4F RX SQD''LQ]#^G_P!<*?ED'\!Z
M@X YW$=>/\C\@!"1M4G!Z 9QSPO&<'^?X#H7)\K!3[#G/."HZ$^WH>G3T0$X
M++G&/X<G^'C/T*^OT&*51B7IA3TXZ_,#Z#/!'8_3T &J/E<8[ XQ_L'G'_UO
MQ'6@-NC(SGY3QG/9?<_R[?D*/E<8[ XQ_L'G'_UOQ'6G+\^U2<Y '7)YVC'4
M_P OP] !#\OF=MI;. >/3C(QR1V'0?2@_P!Y1GC.1N/3!&.>G'Z'VI%;Y5?I
MA@20,8.2<CGK@>WT[TN =N<8XR< ]/?]._TZ"@ X&1U'4>X!R3Z=<CCW]\HN
M,8R#QSCI[\9],>GZ4O*Y+94CD\'CK^H/'X]>E'.TJ3_#C&>.@ /4^G\O;  A
M.W'.T[<>^0#Q_+OZ<=@O&\IP,D@@'I^'X#MQZ=* 1P0< D=^G?M_];_ [$=B
M/N@<\GT_+M_2@#$\4_\ 'G"<<EQSZ\'G_)[5]6>!_P#D2O#_ /V#[?\ ]%K7
MRGXJ_P"/2,]S)DXY'3Z>N>_^-?5G@?\ Y$KP_P#]@^W_ /1:T ;=%%% !111
M0 5^('_!1T8_;.^(GO\ V=_Z;K6OV4\??%?P9\*[2"Y\8>*=(\-17 <VXU.\
MCA:?9MW^6K'<Y&Y<A0<;AZU^'W[9/Q+T;XO_ +3'CGQ9X>F:YT:]N(8K:X*E
M1,L-M%!Y@!Y"L8BPS@X(X%=V$3YV['-6:Y;'V%_P1K_YJ_\ ]P?_ -O:_2JO
MR+_X)=_'_P &?!GQ9XXTKQEK</A^#7X+-[6\O/EM_,@:;*,^/E)$^03A?E/.
M<9_6+P[XFTCQAHMMJ^@ZK8ZWI-SN\B_TZX2X@EVL5;;(A*MAE8'!X(([5GB4
M_:-ET6N5(TJ_)/\ X*\G_C(+PH,_\RO#QG_I[NO?^GY]OU1\7>-_#O@#2AJ?
MBC7]+\-Z:9!"+S5[R.UA+D$A=\C 9(!.,YX-?CQ_P4J^,GA7XR?'RPN?"&J1
MZUIND:-%ITM];DF&2<332-Y;='4"1!N'!.>H -5A4_:7%6?NFU_P2A'_ !E%
M=':#_P 4[=\YY'[VWK]B*_$#_@GS\8/#/P5_:*M-9\6W@TS1[W3KC36OW5F2
MW=RCJS[02%)C"DXP-P)P 2/V B_:"^&$WAI/$*_$7PJ-">Y^Q#4FUFW6#[1L
MW^3O+X$FSYMGWL<XIXJ+Y[V%1:Y3\MO^"KW_ "=%:G!_Y%VTYSQ_K;BNF_X)
M!_\ )</&7_8NG_TIAKR/_@H1\8/#?QH_:,O-7\*WO]IZ18Z?!IBWR B*X="[
M,T?JN9-N[ SM)'&"9_\ @G[^T-X7_9S^,>IZQXPDNX-%U/2)-/\ /M(/.\F4
MS0R*[J/FVXC<?*"<D<=QU\K]A:VMC&Z]I<_;>OQ[_P""K7CR#Q1^TC:Z':RF
M2/PYH\-K.N<A;B1GF;'/_/.2$'W!KZI^)'_!4+P:^F3:;\*-#UCQYXNN(RMG
M%_9\B6R.> SKQ*^"0=JKSTW+UKY*^%O_  3]^-/[0WC*Y\1^.K>X\'6.I73W
M>H:KKR;;V9W8L^RUR'W$G^,(N#P3C%<U&'LWSU-#6I+G7+'4T_\ @E?\%[OQ
MM\=)/'5Q 1HGA*!V65U^66\F1HXT&>I5&D<X^Z0G]X5^OM<7\'_A#X9^!G@'
M3O"'A.R-II5F"Q>0[IKB5N7EE?'S.QZGH    H 'SS^VM^W+X8^"W@[7O#'A
M?68M2^)%PCV4<%DV_P#LMF7#32L.%= <JG)W;<C -8SDZ]3W32*5..IYUJ'A
MGQY^V!^U)XF\<> /&=MX.T;X:S?\(]HNJ7.F)J$<]T5?[6\<<F8\@MC?C[IA
M(]1ZO_PI']J+_HY.Q_\ "+L?_B:\Y_X)N_M!?"SP[\ -"\'7_B?2] \7C4+K
M[79ZE.+=KN:6=C$Z,^ Y,9B3@YRN/3/W=3J2<'RVT7D**4E>Y^+'[>_[-OCC
MX0^+[#QCXP\3V_C2X\5._P!IU:TTU+%5N(E1=CQQ_("R;2",;BKDC()+?^";
M_P <#\(?VB-/TN]G\K0?%@72+H,?E6<MFVD^HD.ST E8]J^W_P#@H]\0?A=K
MW[/?BSPMJ7BW19_%]A<6\UCI-O>QS7T%XKK]Z%6+)F)Y 2P&%<GTK\>89GMY
M4EB=HY$8,KH<%2.00>QKNI7JTK2.:?N3NC^E"OG+_@H@<?L;_$7G'[JS[X_Y
M?K?W'^?7I53]C?\ ;&\,?M ^!=!TO4=:M;;XD0VWDW^DS.$FNGC7YIX0<;U9
M1O(7.S)!X )\W_X*'?M.?#;4/V;_ !)X0T+QCH_B/Q#K4EM;Q6FCWJ79B$=S
M'+(TAC8A %C(PQ!)(X(S7GPA*-1)K9G5*2<&S\C/TK^DG2_^09:8Y'DI_P"@
MBOYMNO!Y%?L9X%_X*??!2X\':,^MZIJ>CZL+:-+NSDTR:7RY0H#8>,,K+D'!
MSG!&0.0.S%1E*UD849)7N?8]?/WQ^^,%YH?QL^#'PWT'46M=5\0:R;_4DA8;
M_P"SH(W9D88X61@1[B)A7F'CS_@JU\'_  ]I,TGAV#6O%>IF/,-O':&UAW\X
M$DDN"HX&2JOU'!YQ\P?L8_$;Q#^TA_P4!L/'?B:42W\-I>W2P0@B&UA%N\,<
M48.<(HF'N222222>6%&23E):(VE45TD>R?M5_P#!.+QS\>OCWXH\=Z/XE\/Z
M?INK?9?*M[YIQ,GE6L,+;ML9'+1DC!Z$5Y/_ ,.@_B7W\8^%/^^[G_XS7ZQT
M4EB*D4D@=*+=SY2_81_9%\1_LJVGC6+Q%J^E:NVNO9F'^S?,(00B8,&WHO7S
M1CKT/2OR,^,W@.;X7_%GQ?X4FB:$Z1JEQ:QAOXHE<^6WT9-K#V(K^B"OSP_X
M*8?L<ZMXXOE^*_@C37U+4HK=8-=TVTCW33)&,)=*HY=E4*C*,G:J$#"L:VH5
MOWC<NI%2G[ON]#[#_9AD63]FOX3LIR/^$3TH?^2<5?B%^TUG_AI'XL9Y_P"*
MMU;_ -+):_2;]D7]M[X8>&?V6] L_%_BBVT;7O"]FUA<Z7(&^T3+$6\DPIC,
MFZ,(..C9!QU/R;^R[^RWXA_:]^-5_P"._$.EW&G> +C5I]5U&\G!"WK/,TAM
M86P-Y+':S#A5W<AMH-T5[.4Y2V)G[ZBD?I5^Q;X$;X<_LM_#G1I(VBG;3%OY
MD=<,LERS7+*PQU!FQ[8Q5W]I[]HK2?V;_AM/KMU&-0UV\8VFBZ.AS)?71'RC
M:#G8I(+D=!@#YF4'N/B)\0- ^$?@75?%7B.[33M"TF#S9I,<XR%5$7NS,555
M'4L!7X5_M,_M%:]^TM\3+OQ/JY:UL(\P:7I:N3'96X/"CU<_>9NY/8  84J;
MK3<GL:3G[.-EN?I;^QC^R+J_A_Q!>?&;XM[M2^)VN2/=PVMT-QTP2=68=!,5
M.T*.(U^4<Y ^C?CA\;?#7P$^'^J>*?$=[!$MK SVMBTRI-?3 ?)#$#R68X'
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M@],5]K_M_>!+GXN?LB_$[P[HD*ZGK5K:0WJ6D!#3*]O-%<E0O)WM&C87JVX
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M+RXGAD 5EC=I4$>4\Q3\K$[^""* /CO_ ((ER(?@-X\0']X/$N2,]C:PXX_
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK/Q$^)WAGQU\;/&UOX]NO"[&;0_#VEZ0-.TJTG)&9Y$:25YWRL;#+* 4'!%
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M/B[H*>&/BW\>)=8\'2*JZAIGA;P_#I-QJ@ 'RS7(9\(2#N1$ 8$]., 'S?\
M\$3_ (17^G:'X]^)5[ UO8ZH\6C::6!'FB(F2=QGJNYHE!]4<=0:Q_C#(J?\
M%HO!9=@HW6"_,>YLF '7U/MU_&OTRT/P)I_@/X?0^%/!%M9^%[*PLFM-+2.V
M\V"T;:=CM'N4R88[FRP+G.6R2:^.O%7_  35\2^+_CU'\8KWXYWL?CB&\AO(
M+J#PY"(H#$JK$B1&8KL"J!M.=W.<EB: /LKXB<?#_P 3?]@NZ_\ 135^;_\
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M(].^#U_^N +N^9-QPP8$Y//7GOZY[CKGZ$8^Z<?> &!WY7CT/Y$^H[T;BDA
M.T9)')'\6,\XYZ=/0>](PRV.,D$!2"3QP.N/[OZ].HH %'RN/8''_ #V_P#K
M?B.M.C;<RC.<[1C.?[O;)_D?IZ)]Y6*C*Y)( R/XL<#'OUP?04,2R-AMPZ9R
M3D98_P#U^WT[T )&,JBG!' ['O\ C_>[?EWI0Q^5VY/).>O(Z?CR>?R]1L;O
M1>W;(R1UZXQGUZ"A?O@'KGD8'?MCMR>@_+B@!"NS*$[3TYX[$>G&2/\ $CFE
M;.[/W1D\X[D^Y_J>GI2*=JC''0=0.1CN,9Y ^F<^]*5QD@>H^[CC/?VSQGCK
M^% !U5>P/\B,9Z^^.H' SWP;@3S_ !$$@X]/<^X_7GO0IS@@ECNSGKSW/7CC
MG.1S],@7@C&<=@>G?^A]/KU- &)XJS]CB![.!^0(KZL\#_\ (E>'_P#L'V__
M *+6OE/Q2/\ 0H>N-XZCV/\ 3'YU]6>!_P#D2O#_ /V#[?\ ]%K0!MT444 %
M%%% %:\TRSU+9]KM(+K9G;YT:OMSUQD<=*J_\(SH_P#T";'_ ,!D_P *TZ*
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M_"I(- TNUF66'3;2&53E7C@56'T(%7Z*=V 4444@"BBB@#R']I?_ )$W3?\
MK_7_ -%O7=_#G_D0?#O_ %X0_P#H KA/VE_^1-TW_K_7_P!%O7=_#G_D0?#O
M_7A#_P"@"@#HZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^&OVVOV*_B1\
M2/C!X?\ C9\'/%J:5X^T&SCMXM/OI-BMY;2%3 [!D!82NK1R 1MDY/S,#S_A
M_P#:"_;MT/R-*USX :%KMZL>W[;#>10B1L@;G=+IH@>>0-OKP!7Z"T4 ?)GA
MGX4_'7]H?['_ ,+^N?#OA/P3#*D\O@+PJ#*VJ,CAE2_N'>0&'(YBC.UQ@-C'
M/UDJA5  P!P *6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ KP/QDN?VB=&XS\]OV^GM_G^7OE>!^,ES^T3HW&?GM^WT]O\_P @
M#WRBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /GSP;C_A%_%?8?;KOOT_=K^7^?QYJN
MF\&Y'A?Q7P<_;KO_ - 7^OY_SYFOHL#_  SRL3\04445Z)R!1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !114MI:R7US'!"NZ20X I :/A
MO0VUJ^"D$6Z?-(WMZ#W->Z^&='6S@6=D",5VHF,;5_IT_*N?\$^%([:W2,J'
MACYD;&/-?'^?PQ7>U\_B\1[1\JV/5H4^5784445YIUA1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X'\ Q_Q<#Q/Q
M_ _;_IK]/\_R]\KP/X!C_BX'B?C^!^W_ $U^G^?Y>^4 %%%% !1110 4444
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M^Z,'Y>WWNN,#CCT/3\@_)D@8Z_A@*0#C'?CK^ -*%&XC'\6#_P!]'V_3VZ4
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MI;8I^_0!]*456TV9[C3K660[I'B1F.,9) )JS0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>!^,ES^T3HW
M&?GM^WT]O\_R]\KP/QDN?VB=&XS\]OV^GM_G^0![Y1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHGWD_O8'U_@_'T]NGMPL;;F49SD*,9S_ '>V3_(_3T (U/R1G./E<=?8^_\
MGT]7GY9F_A_3^/\ X#_GT[,4_)&<X^5QU]C[_P"?3U>?DF?^']/X_P#@/^?3
ML &WYA\N.>>,<9(ST''0=?\ ZPN6V]6W<< GK@$>V/IW Y%)MW*Z@<[CVZ<K
MVQ_0?TIQ.[G'OR,\9SZ'MD_G^( D?WAZM@XQC.<]L^Y[=AQS3> C8Z8Z8QU'
M4_D.W?K3D!5@I&T\ CIG@@\?IT/X]TQPH.5'^( /IZ_H/K0 K=5P<\G;U[=
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M_P!C/PSX5^*7PD^(_C32B-632[_2-4UZXU*TEWQR2QR&.X9PP!B965MP.Y<
M$$G[[^!OQ$?XM?!GP1XTFMTM+C7M&M-1FMXR2L4LD2LZ*3R0&+ 'N *_//\
MX*@?";QEH/[,MEXH\??$K5?&&OR:_:P_V78Q)I^AV:M%,3Y5JN6=@5P)97=L
M$X"Y(K[9_8G_ .31_A#SG_BF;'_T4M 'PGX^8?\ #[;P]UX:U!Y_ZA!_*OT@
M^+F@^/?$7A26S^'OBS2_!NM/N_XF.I:.=1P-IVA%\Y%1MV/F99!C/R&OS?\
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MAT45]!_L#Z+?>+M!\<?'/7H)(=<^*.L/J%M#,/GMM)@)AL83QV0,V1PRLAH
M^H]-L5TS3[6S26:9+>)85DN96EE<*  7=B2S''+$Y)Y-2W%Q%:P2332)##&I
M=Y)&"JJ@9))/0 5)7G'[25Y?Z?\ L[_%&YTM6?4H?"VJ26RKU\P6DI7'OG%
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M?*\#\9+G]HG1N,_/;]OI[?Y_D >^4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\^^#
M<CPOXKX.?MUW_P"@+_7\_P"?,UTO@W_D5_%?;_3KOG'_ $S7_P#7^/OSS5?1
M8'^&>5B?B"BBBO1.0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH \#^ 8_XN!XGX_@?M_TU^G^?
MY>^5X'\ Q_Q<#Q/Q_ _;_IK]/\_R]\H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#PK]J+_4>'3[W'_M*O;K#_ (\;?M^[7^0KQ']J
M+_4>'3[W'_M*O;K#_CQM^W[M?Y"@"GXG_P"1;U;G'^B3<YQ_ :^1_"K8@N3C
MH5;!&>I/J/7';ZU]<^)CCPWJISC_ $27G_@!KY%\+?\ 'K=#_<_F?\]/\" =
M!M"L5!PI!Y'IN()X]L_WO\%3)V<<' "KS_$#@=?7IS[CO22?ZQSURK'Z_,?S
M_7Z^BKC<6Z@]>_&0<''& !Z?AQP -7E03SCU.[L#Z''3T_D:<"57G)(P"&SV
M&>G/ICGCCIZ(BY*H1R" 1@=>A&.N>1T';H>M-#!D/3)R?X>./3\#QQVZ\4 +
M]SY?[H8 YQV.>N.__P"HDTX_(['[HY![<ALX_A[?TZ<8;N'S;3\OS8Y]0?<>
MW;\.Q61=K$XV_/@\8[MQT']/\  ^[N4C)#$[>/4=L<?=/8?THV[5P 'QD8QD
M'D#MGL?7T]LHRE5;Y2!SVP/XO4#^7Y4K<]<,,D$]?XAW_P#K]_S !<*V!]WV
M[X!!/Z^A[]><I'A3U '&>1Z$=C_0_CW7KC)X*Y/]3^GO^G!D\9.T^YQZ#U'?
M_P!!'O0  D<$Y;TSR3U]?4_I]:.R\Y"]\],8[C\/?H!VI>58\>IQD]!D8Q^)
M[?UIO3CNH]@1@_H<'^?UH Q?%7_'I%Q@[\?H?;US7U9X'_Y$KP__ -@^W_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!X'\ Q_Q<#Q/Q_ _;_IK]/\_R]\KP/X!C_BX'B?C^
M!^W_ $U^G^?Y>^4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!X5^U%_J/#I][C_P!I5[=8?\>-OV_=K_(5XC^U%_J/#I][C_VE7MUA
M_P >-OV_=K_(4 5/$QQX;U4YQ_HDO/\ P U\B^%O^/6Z'^Y_,_YZ?X'ZZ\3'
M'AO53G'^B2\_\ -?(OA;_CUNA_N?S/\ GI_@0#H)/]8YZY5C]?F/Y_K]?0/S
M1_WL#Z_P?CZ>W3\B3_6.>N58_7YC^?Z_7T1F'EY)'3'//\'X_P!/\ !VT[L
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M$CA6("J/1L?,&KZ$HH I:+HNG^&])L]*TFQM],TRSB6"VL[.)8H88U&%1$4
M*H'  %7:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP/
MQDN?VB=&XS\]OV^GM_G^7OE>!^,ES^T3HW&?GM^WT]O\_P @#WRBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#P/X!C_BX'B?C^!^W_37Z
M?Y_E[Y7@?P#'_%P/$_'\#]O^FOT_S_+WR@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /"OVHO]1X=/O<?^TJ]NL/\ CQM^W[M?Y"O$
M?VHO]1X=/O<?^TJ]NL/^/&W[?NU_D* *GB8X\-ZJ<X_T27G_ ( :^1?"W_'K
M=#_<_F?\]/\  _77B8X\-ZJ<X_T27G_@!KY%\+?\>MT/]S^9_P ]/\" =!)_
MK'/7*L?K\Q_/]?KZ+R&'+#Y@IW$@]3P>>.1DY(YZ>M#$%V.01DY/7N3@\^G/
M4]!@TW<%48;:5Z'(].W4CD?KVS0 H;#)DXVA3D]>@.1DCMQQZ#ZTDBGRSD9(
M'/'3A?8_S_+H7+\L@4< GA03S\WMU' Z9/ _!A7='PN?ER,+]/\ 9]C^1_$
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M?_[!]O\ ^BUKY4\5+MLXN,?O,<#'./\ /7FOJOP/_P B5X?_ .P?;_\ HM:
M-NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /(?VE_^
M1-TW_K_7_P!%O7=_#G_D0?#O_7A#_P"@"N$_:7_Y$W3?^O\ 7_T6]=W\.?\
MD0?#O_7A#_Z * .CHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O _&2
MY_:)T;C/SV_;Z>W^?Y>^5X'XR7/[1.C<9^>W[?3V_P _R /?**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH \#^ ?_)0?%''\+_^C?I7OE>!_ ,?\7"\4<?P/V_Z:CV_
MS[]O?* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH \#^ 8_XN!XGX_@?M_TU^G^?Y>^5X'\ Q_Q<#Q/
MQ_ _;_IK]/\ /\O?* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVZP_X\;?M^[7^0H I^*./#.KDG ^R3<YQ_ :^2/"O^INL]-PR/\ OKG'X_\
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MQ=OG''IP<=O0U]6>!_\ D2O#_P#V#[?_ -%K0!MT444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!Y#^TO_P B;IO_ %_K_P"BWKN_AS_R
M(/AW_KPA_P#0!7"?M+_\B;IO_7^O_HMZ[OX<_P#(@^'?^O"'_P! % '1T444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7@?C)<_M$Z-QGY[?M]/;_ #_+
MWRO _&2Y_:)T;C/SV_;Z>W^?Y 'OE%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >!_
M,?\ %PO%''\#]O\ IJ/;_/OV]\KP/X!C_BX7BCC^!^W_ $U'M_GW[>^4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!X'\ Q_Q<#Q/Q_ _;_IK]/\_R]\KP/X!C_BX'B?C^!^W_ $U^
MG^?Y>^4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 >0_M+_\B;IO_7^O_HMZ[OX<_P#(@^'?^O"'_P! %<)^TO\ \B;IO_7^
MO_HMZ[OX<_\ (@^'?^O"'_T 4 ='1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %>!^,ES^T3HW&?GM^WT]O\_P O?*\#\9+G]HG1N,_/;]OI[?Y_D >^
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!X'\ Q_Q<+Q1Q_ _;_IJ/;_/OV]\KP/X!
MC_BX7BCC^!^W_34>W^??M[Y0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% '@?P#'_%P/$_'\#]O^FOT
M_P _R]\KP/X!C_BX'B?C^!^W_37Z?Y_E[Y0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'A7[47^H\.GWN/_:5>W6'_ !XV_;]VO\A7
MB/[47^H\.GWN/_:5>W6'_'C;]OW:_P A0!3\3L%\-ZL3P!:3=\?P&ODCPD-L
M5P,9P4XX[$^HP.O4C'\J^L_%\IA\)ZW(HW,EC.P'/.(V]*^.]*OKBSAF6&V:
M<L<G /'!Y_' _ =: .NC8*H&[CCJ?_K_ .T>W;IUH7Y5S]T$8/(_N^Q&>"?T
M!ZUB?V]?[LBPD49SP&XY//7T/UZ'UIO]N7^T$V#@A<?<;^[CZ_KCM0!O'Y58
M^QR5Z>_3(') XZCTS2Y*G ['&%)QP6..N>H'<'V-8!UR_+9_L]\YXRIROXC'
MH/I_)#KE]\V-.?D$#"GW/H/;_/0 WU^]W/"J1@\\@C\^W7IT]"/+;<G.<#KG
MGKZ\_E_$>.E8+:Y>X/\ Q+F R2!L/.<CT..W;_ZQ_;E]P?L#YZ<JV?3^0'7W
MXYX -T#Y1\N<#. .G\7<'L/\\Y<HY0>^WH.W(&.?Q'KV]<#^W+[ !TYAC_9)
M]\=^_P#/ZT#7+['_ "#W'&.5.>GK^7Y'L: -SA1V!QUZ'E?P_P _JL@&6) P
M<\G'H"/\Y/X]\(:[?]/[/D SV##C!_Q/;\.N1M=OSD_V>X;GHIYRN/\ .3Z^
MN: -]OO$G.W.<]NW.?H>O/7WS2+E>#P>XQCGN.O7IV[?G@MKE\S,?[/;))_A
M;O[_ )=?0^M']N7W4:>Z_16'\O\ /'TH ?XJ_P"/.(?[8_+:?_K_ .>3]6>!
M_P#D2O#_ /V#[?\ ]%K7R%JU_<WD*K+:M"@;.=I'//\ B:]+T;X^:WI.CV%C
M%H,,L5K!'"LA\S+!5 !_(4 ?1M%?/W_#1FO_ /0O0?\ D2C_ (:,U_\ Z%Z#
M_P B4 ?0-%?/W_#1FO\ _0O0?^1*/^&C-?\ ^A>@_P#(E 'T#17S]_PT9K__
M $+T'_D2C_AHS7_^A>@_\B4 ?0-%?/W_  T9K_\ T+T'_D2C_AHS7_\ H7H/
M_(E 'T#17S]_PT9K_P#T+T'_ )$H_P"&C-?_ .A>@_\ (E 'T#17S]_PT9K_
M /T+T'_D2C_AHS7_ /H7H/\ R)0!] T5\_?\-&:__P!"]!_Y$H_X:,U__H7H
M/_(E 'T#17S]_P -&:__ -"]!_Y$H_X:,U__ *%Z#_R)0!] T5\_?\-&:_\
M]"]!_P"1*/\ AHS7_P#H7H/_ ")0!] T5\_?\-&:_P#]"]!_Y$H_X:,U_P#Z
M%Z#_ ,B4 ?0-%?/W_#1FO_\ 0O0?^1*/^&C-?_Z%Z#_R)0!] T5\_?\ #1FO
M_P#0O0?^1*/^&C-?_P"A>@_\B4 ?0-%?/W_#1FO_ /0O0?\ D2C_ (:,U_\
MZ%Z#_P B4 ?0-%?/W_#1FO\ _0O0?^1*/^&C-?\ ^A>@_P#(E 'T#17S]_PT
M9K__ $+T'_D2C_AHS7_^A>@_\B4 ?0-%?/W_  T9K_\ T+T'_D2C_AHS7_\
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M_P#]"]!_Y$H ^@:*^?O^&C-?_P"A>@_\B4?\-&:__P!"]!_Y$H ^@:*^?O\
MAHS7_P#H7H/_ ")1_P -&:__ -"]!_Y$H ^@:*^?O^&C-?\ ^A>@_P#(E'_#
M1FO_ /0O0?\ D2@#Z!HKY^_X:,U__H7H/_(E'_#1FO\ _0O0?^1* /H&BOG[
M_AHS7_\ H7H/_(E'_#1FO_\ 0O0?^1* /H&BOG[_ (:,U_\ Z%Z#_P B4?\
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MA>A_\B?Y_P _2@#Z!HKY^_X:,U__ *%Z'_R)_G_/TH_X:,U__H7H?_(G^?\
M/TH ^@:*^?O^&C-?_P"A>A_\B?Y_S]*/^&C-?_Z%Z'_R)_G_ #]* /H&BOG[
M_AHS7_\ H7H?_(G^?\_2C_AHS7_^A>A_\B?Y_P _2@#Z!HKY^_X:,U__ *%Z
M'_R)_G_/TH_X:,U__H7H?_(G^?\ /TH ^@:*^?O^&C-?_P"A>A_\B?Y_S]*/
M^&C-?_Z%Z'_R)_G_ #]* /H&BOG[_AHS7_\ H7H?_(G^?\_2C_AHS7_^A>A_
M\B?Y_P _2@#Z!HKY^_X:,U__ *%Z'_R)_G_/TH_X:,U__H7H?_(G^?\ /TH
M^@:*^?O^&C-?_P"A>A_\B?Y_S]*/^&C-?_Z%Z'_R)_G_ #]* /H&BOG[_AHS
M7_\ H7H?_(G^?\_2C_AHS7_^A>A_\B?Y_P _2@#Z!HKY^_X:,U__ *%Z'_R)
M_G_/TH_X:,U__H7H?_(G^?\ /TH ^@:*^?O^&C-?_P"A>A_\B?Y_S]*/^&C-
M?_Z%Z'_R)_G_ #]* /H&BOG[_AHS7_\ H7H?_(G^?\_2C_AHS7_^A>A_\B?Y
M_P _2@#Z!HKY^_X:,U__ *%Z'_R)_G_/TH_X:,U__H7H?_(G^?\ /TH ^@:*
M^?O^&C-?_P"A>A_\B?Y_S]*/^&C-?_Z%Z'_R)_G_ #]* /H&BOG[_AHS7_\
MH7H?_(G^?\_2C_AHS7_^A>A_\B?Y_P _2@#Z!HKY^_X:,U__ *%Z'_R)_G_/
MTH_X:,U__H7H?_(G^?\ /TH ^@:*^?O^&C-?_P"A>A_\B?Y_S]*/^&C-?_Z%
MZ'_R)_G_ #]* /H&BOG[_AHS7_\ H7H?_(G^?\_2C_AHS7_^A>A_\B?Y_P _
M2@#Z!HKY^_X:,U__ *%Z'_R)_G_/TH_X:,U__H7H?_(G^?\ /TH ^@:*^?O^
M&C-?_P"A>A_\B?Y_S]*/^&C-?_Z%Z'_R)_G_ #]* /H&BOG[_AHS7_\ H7H?
M_(G^?\_2C_AHS7_^A>A_\B?Y_P _2@#Z!HKY^_X:,U__ *%Z'_R)_G_/TH_X
M:,U__H7H?_(G^?\ /TH ^@:*^?O^&C-?_P"A>A_\B?Y_S]*/^&C-?_Z%Z'_R
M)_G_ #]* /H&BOG[_AHS7_\ H7H?_(G^?\_2C_AHS7_^A>A_\B?Y_P _2@#Z
M!HKY^_X:,U__ *%Z'_R)_G_/TH_X:,U__H7H?_(G^?\ /TH ^@:*^?O^&C-?
M_P"A>A_\B?Y_S]*/^&C-?_Z%Z'_R)_G_ #]* /H&BOG[_AHS7_\ H7H?_(G^
M?\_2C_AHS7_^A>A_\B?Y_P _2@#Z!HKY^_X:,U__ *%Z'_R)_G_/TH_X:,U_
M_H7H?_(G^?\ /TH ^@:*^?O^&C-?_P"A>A_\B?Y_S]*/^&C-?_Z%Z'_R)_G_
M #]* /H&BOG[_AHS7_\ H7H?_(G^?\_2C_AHS7_^A>A_\B?Y_P _2@#Z!HKY
M^_X:,U__ *%Z'_R)_G_/TH_X:,U__H7H?_(G^?\ /TH ^@:*^?O^&C-?_P"A
M>A_\B?Y_S]*4?M&:]QGP[#U_VZ )/@&/^+A>*./X'[?]-1[?Y]^WOE?(W@;X
MA7_@[7M2U*TTY+J:\!#QOG"98-VY]OP^E=Q_PT9K^<?\(];_ /D2@#Z!HKY^
M_P"&C/$'_0NV^?K)_G_/>D_X:,U__H78,?\ ;2@#Z"HKY]_X:,\0?]"];_\
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MK)_G_/>@#Z!HKY]_X:,U_P#Z%V#'_;2C_AHSQ!_T+UO_ .1/QH ^@J*^?O\
MAHSQ!_T+MOGZR?Y_SWI/^&C-?_Z%V#'_ &TH ^@J*^??^&C/$'_0O6__ )$_
M&E_X:,\0?]"[;Y^LG^?\]Z /H&BOGW_AHS7_ /H78,?]M*/^&C/$'_0O6_\
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M&C/$'_0O6_\ Y$_&@#Z"HKY^_P"&C/$'_0NV^?K)_G_/>D_X:,U__H78,?\
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MSQ!_T+MOGZR?Y_SWH ^@:*^??^&C-?\ ^A=@Q_VTH_X:,\0?]"];_P#D3\:
M/H*BOG[_ (:,\0?]"[;Y^LG^?\]Z3_AHS7_^A=@Q_P!M* /H*BOGW_AHSQ!_
MT+UO_P"1/QI?^&C/$'_0NV^?K)_G_/>@#Z!HKY]_X:,U_P#Z%V#'_;2C_AHS
MQ!_T+UO_ .1/QH ^@J*^?O\ AHSQ!_T+MOGZR?Y_SWI/^&C-?_Z%V#'_ &TH
M ^@J*^??^&C/$'_0O6__ )$_&E_X:,\0?]"[;Y^LG^?\]Z /H&BOGW_AHS7_
M /H78,?]M*/^&C/$'_0O6_\ Y$_&@#Z"HKY^_P"&C/$'_0NV^?K)_G_/>D_X
M:,U__H78,?\ ;2@#Z"HKY]_X:,\0?]"];_\ D3\:7_AHSQ!_T+MOGZR?Y_SW
MH ^@:*^??^&C-?\ ^A=@Q_VTH_X:,\0?]"];_P#D3\: /H*BOG[_ (:,\0?]
M"[;Y^LG^?\]Z3_AHS7_^A=@Q_P!M* /H*BOGW_AHSQ!_T+UO_P"1/QI?^&C/
M$'_0NV^?K)_G_/>@#Z!HKY]_X:,U_P#Z%V#'_;2C_AHSQ!_T+UO_ .1/QH ^
M@J*^?O\ AHSQ!_T+MOGZR?Y_SWI/^&C-?_Z%V#'_ &TH ^@J*^??^&C/$'_0
MO6__ )$_&E_X:,\0?]"[;Y^LG^?\]Z /H&BOGW_AHS7_ /H78,?]M*/^&C/$
M'_0O6_\ Y$_&@#Z"HKY^_P"&C/$'_0NV^?K)_G_/>D_X:,U__H78,?\ ;2@#
MZ"HKY]_X:,\0?]"];_\ D3\:7_AHSQ!_T+MOGZR?Y_SWH ^@:*^??^&C-?\
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M_?\ SF@#Z HKY_\ ^&C-?Y_XIV$_]]^_O_G-'_#1FO\ /_%.PG_OOW]_\YH
M^@**^?\ _AHS7^?^*=A/_??O[_YS1_PT9K_/_%.PG_OOW]_\YH ^@**^?_\
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M_?\ SF@#Z HKY_\ ^&C-?Y_XIV$_]]^_O_G-'_#1FO\ /_%.PG_OOW]_\YH
M^@**^?\ _AHS7^?^*=A/_??O[_YS1_PT9K_/_%.PG_OOW]_\YH ^@**^?_\
MAHS7^?\ BG83_P!]^_O_ )S1_P -&:_S_P 4["?^^_?W_P YH ^@**^?_P#A
MHS7^?^*=A/\ WW[^_P#G-'_#1FO\_P#%.PG_ +[]_?\ SF@#Z HKY_\ ^&C-
M?Y_XIV$_]]^_O_G-'_#1FO\ /_%.PG_OOW]_\YH ^@**^?\ _AHS7^?^*=A/
M_??O[_YS1_PT9K_/_%.PG_OOW]_\YH ^@**^?_\ AHS7^?\ BG83_P!]^_O_
M )S1_P -&:_S_P 4["?^^_?W_P YH ^@**^?_P#AHS7^?^*=A/\ WW[^_P#G
M-'_#1FO\_P#%.PG_ +[]_?\ SF@#Z HKY_\ ^&C-?Y_XIV$_]]^_O_G-'_#1
MFO\ /_%.PG_OOW]_\YH ^@**^?\ _AHS7^?^*=A/_??O[_YS1_PT9K_/_%.P
MG_OOW]_\YH ^@**^?_\ AHS7^?\ BG83_P!]^_O_ )S1_P -&:_S_P 4["?^
M^_?W_P YH ^@**^?_P#AHS7^?^*=A/\ WW[^_P#G-'_#1FO\_P#%.PG_ +[]
M_?\ SF@#Z HKY_\ ^&C-?Y_XIV$_]]^_O_G-'_#1FO\ /_%.PG_OOW]_\YH
M^@**^?\ _AHS7^?^*=A/_??O[_YS1_PT9K_/_%.PG_OOW]_\YH ^@**^?_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+%%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>tsbx-20240630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-08-14T16:11:52.9871+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.turnstonebio.com/20240630" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:tsbx="http://www.turnstonebio.com/20240630" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:calc="https://xbrl.org/2023/calculation-1.1" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" namespace="http://xbrl.sec.gov/ecd/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage" id="CoverPage">
        <link:definition>100000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureLeasesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetail2" id="DisclosureLeasesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetail2">
        <link:definition>100020 - Disclosure - Leases - Schedule of Minimum Aggregate Future Operating Lease Commitments (Detail) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss2" id="StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss2">
        <link:definition>100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureLeasesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetail3" id="DisclosureLeasesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetail3">
        <link:definition>100050 - Disclosure - Leases - Schedule of Minimum Aggregate Future Operating Lease Commitments (Detail) 3</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100060 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" id="StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100070 - Statement - Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows" id="CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>100080 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentation" id="NatureOfTheBusinessAndBasisOfPresentation">
        <link:definition>995455 - Disclosure - Nature of the Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>995465 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilities" id="FairValueOfFinancialAssetsAndLiabilities">
        <link:definition>995475 - Disclosure - Fair Value of Financial Assets and Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
        <link:definition>995485 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/AccruedExpensesAndOtherCurrentLiabilities" id="AccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>995495 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/Agreements" id="Agreements">
        <link:definition>995505 - Disclosure - Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisition" id="AssetAcquisition">
        <link:definition>995515 - Disclosure - Asset Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoan" id="DisclosureTermLoan">
        <link:definition>995525 - Disclosure - Term Loan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquity" id="DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquity">
        <link:definition>995535 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensation" id="EquityBasedCompensation">
        <link:definition>995545 - Disclosure - Equity Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>995555 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/Leases" id="Leases">
        <link:definition>995565 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>995575 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/LegalProceedings" id="LegalProceedings">
        <link:definition>995585 - Disclosure - Legal Proceedings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995595 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesTables" id="FairValueOfFinancialAssetsAndLiabilitiesTables">
        <link:definition>995605 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
        <link:definition>995615 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" id="AccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>995625 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsTables" id="AgreementsTables">
        <link:definition>995635 - Disclosure - Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityTables" id="DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityTables">
        <link:definition>995645 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationTables" id="EquityBasedCompensationTables">
        <link:definition>995655 - Disclosure - Equity Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/LeasesTables" id="LeasesTables">
        <link:definition>995665 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>995675 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail" id="NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail">
        <link:definition>995685 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>995695 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisAtFairValueDetail" id="FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisAtFairValueDetail">
        <link:definition>995705 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of financial assets and liabilities measured on recurring basis at fair value (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputOfContingentConsiderationValuationDetail" id="FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputOfContingentConsiderationValuationDetail">
        <link:definition>995715 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of unobservable input of contingent consideration valuation (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysContingentConsiderationMeasuredAtFairValueLevel3Detail" id="FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysContingentConsiderationMeasuredAtFairValueLevel3Detail">
        <link:definition>995725 - Disclosure - Fair Value of Financial Assets and Liabilities -  Schedule of company's contingent consideration measured at fair value level 3 (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysCashCashEquivalentsAndAvailableForSaleSecuritiesDetail" id="FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysCashCashEquivalentsAndAvailableForSaleSecuritiesDetail">
        <link:definition>995735 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of company's cash, cash equivalents and available-for-sale securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail" id="FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail">
        <link:definition>995745 - Disclosure - Fair Value of Financial Assets and Liabilities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetConsistDetail" id="PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetConsistDetail">
        <link:definition>995755 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net Consist (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail" id="PropertyAndEquipmentNetAdditionalInformationDetail">
        <link:definition>995765 - Disclosure - Property and Equipment, Net - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesDetail" id="AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesDetail">
        <link:definition>995775 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Liabilities and Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationDetail" id="AgreementsScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationDetail">
        <link:definition>995785 - Disclosure - Agreements - Schedule Of Transaction Price Allocated To Programs Performance Obligation (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail" id="AgreementsAdditionalInformationDetail">
        <link:definition>995795 - Disclosure - Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail" id="AssetAcquisitionAdditionalInformationDetail">
        <link:definition>995805 - Disclosure - Asset Acquisition - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails" id="DisclosureTermLoanAdditionalInformationDetails">
        <link:definition>995815 - Disclosure - Term Loan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetail" id="DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetail">
        <link:definition>995825 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquitySummaryOfSharesOfCommonStockReservedForFutureIssuanceDetail" id="DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquitySummaryOfSharesOfCommonStockReservedForFutureIssuanceDetail">
        <link:definition>995835 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Summary Of Shares Of Common Stock Reserved For Future Issuance (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail" id="DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail">
        <link:definition>995845 - Disclosure - Equity Based Compensation - Schedule of Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfFairValueAssumptionOfStockOptionActivityDetail" id="EquityBasedCompensationScheduleOfFairValueAssumptionOfStockOptionActivityDetail">
        <link:definition>995855 - Disclosure - Equity Based Compensation - Schedule of Fair Value Assumption of Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRsuActivityDetail" id="DisclosureEquityBasedCompensationSummaryOfRsuActivityDetail">
        <link:definition>995865 - Disclosure - Equity Based Compensation - Summary of RSU Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfStockBasedCompensationForStockAwardsDetail" id="EquityBasedCompensationScheduleOfStockBasedCompensationForStockAwardsDetail">
        <link:definition>995875 - Disclosure - Equity Based Compensation - Schedule of Stock Based Compensation for Stock Awards (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail" id="EquityBasedCompensationAdditionalInformationDetail">
        <link:definition>995885 - Disclosure - Equity Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/IncomeTaxesAdditionalInformationDetail" id="IncomeTaxesAdditionalInformationDetail">
        <link:definition>995895 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/LeasesAdditionalInformationDetail" id="LeasesAdditionalInformationDetail">
        <link:definition>995905 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfInformationAboutLeaseCostsDetail" id="LeasesScheduleOfInformationAboutLeaseCostsDetail">
        <link:definition>995915 - Disclosure - Leases - Schedule of Information about Lease Costs (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfPresentValueOfOperatingLeasePaymentsDetail" id="LeasesScheduleOfPresentValueOfOperatingLeasePaymentsDetail">
        <link:definition>995925 - Disclosure - Leases - Schedule of Present Value of Operating Lease Payments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetail" id="LeasesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetail">
        <link:definition>995935 - Disclosure - Leases - Schedule of Minimum Aggregate Future Operating Lease Commitments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetail" id="DisclosureNetLossPerShareScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetail">
        <link:definition>995945 - Disclosure - Net Loss per Share - Schedule of Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/LegalProceedingsAdditionalInformationDetail" id="LegalProceedingsAdditionalInformationDetail">
        <link:definition>995955 - Disclosure - Legal Proceedings - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage" xlink:href="tsbx-20240630.xsd#CoverPage" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets" xlink:href="tsbx-20240630.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="tsbx-20240630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="tsbx-20240630.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="tsbx-20240630.xsd#StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="tsbx-20240630.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:href="tsbx-20240630.xsd#NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="tsbx-20240630.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisAtFairValueDetail" xlink:href="tsbx-20240630.xsd#FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisAtFairValueDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputOfContingentConsiderationValuationDetail" xlink:href="tsbx-20240630.xsd#FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputOfContingentConsiderationValuationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysContingentConsiderationMeasuredAtFairValueLevel3Detail" xlink:href="tsbx-20240630.xsd#FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysContingentConsiderationMeasuredAtFairValueLevel3Detail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysCashCashEquivalentsAndAvailableForSaleSecuritiesDetail" xlink:href="tsbx-20240630.xsd#FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysCashCashEquivalentsAndAvailableForSaleSecuritiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail" xlink:href="tsbx-20240630.xsd#FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetConsistDetail" xlink:href="tsbx-20240630.xsd#PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetConsistDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationDetail" xlink:href="tsbx-20240630.xsd#AgreementsScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail" xlink:href="tsbx-20240630.xsd#AgreementsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail" xlink:href="tsbx-20240630.xsd#AssetAcquisitionAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails" xlink:href="tsbx-20240630.xsd#DisclosureTermLoanAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetail" xlink:href="tsbx-20240630.xsd#DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquitySummaryOfSharesOfCommonStockReservedForFutureIssuanceDetail" xlink:href="tsbx-20240630.xsd#DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquitySummaryOfSharesOfCommonStockReservedForFutureIssuanceDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail" xlink:href="tsbx-20240630.xsd#DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfFairValueAssumptionOfStockOptionActivityDetail" xlink:href="tsbx-20240630.xsd#EquityBasedCompensationScheduleOfFairValueAssumptionOfStockOptionActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRsuActivityDetail" xlink:href="tsbx-20240630.xsd#DisclosureEquityBasedCompensationSummaryOfRsuActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfStockBasedCompensationForStockAwardsDetail" xlink:href="tsbx-20240630.xsd#EquityBasedCompensationScheduleOfStockBasedCompensationForStockAwardsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail" xlink:href="tsbx-20240630.xsd#EquityBasedCompensationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/LeasesAdditionalInformationDetail" xlink:href="tsbx-20240630.xsd#LeasesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetail" xlink:href="tsbx-20240630.xsd#DisclosureNetLossPerShareScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentation" xlink:href="tsbx-20240630.xsd#NatureOfTheBusinessAndBasisOfPresentation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPolicies" xlink:href="tsbx-20240630.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilities" xlink:href="tsbx-20240630.xsd#FairValueOfFinancialAssetsAndLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNet" xlink:href="tsbx-20240630.xsd#PropertyAndEquipmentNet" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="tsbx-20240630.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/Agreements" xlink:href="tsbx-20240630.xsd#Agreements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisition" xlink:href="tsbx-20240630.xsd#AssetAcquisition" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoan" xlink:href="tsbx-20240630.xsd#DisclosureTermLoan" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquity" xlink:href="tsbx-20240630.xsd#DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensation" xlink:href="tsbx-20240630.xsd#EquityBasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/IncomeTaxes" xlink:href="tsbx-20240630.xsd#IncomeTaxes" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/Leases" xlink:href="tsbx-20240630.xsd#Leases" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShare" xlink:href="tsbx-20240630.xsd#DisclosureNetLossPerShare" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/LegalProceedings" xlink:href="tsbx-20240630.xsd#LegalProceedings" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="tsbx-20240630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesTables" xlink:href="tsbx-20240630.xsd#FairValueOfFinancialAssetsAndLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNetTables" xlink:href="tsbx-20240630.xsd#PropertyAndEquipmentNetTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="tsbx-20240630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsTables" xlink:href="tsbx-20240630.xsd#AgreementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityTables" xlink:href="tsbx-20240630.xsd#DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationTables" xlink:href="tsbx-20240630.xsd#EquityBasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/LeasesTables" xlink:href="tsbx-20240630.xsd#LeasesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="tsbx-20240630.xsd#DisclosureNetLossPerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail" xlink:href="tsbx-20240630.xsd#PropertyAndEquipmentNetAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesDetail" xlink:href="tsbx-20240630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/IncomeTaxesAdditionalInformationDetail" xlink:href="tsbx-20240630.xsd#IncomeTaxesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfInformationAboutLeaseCostsDetail" xlink:href="tsbx-20240630.xsd#LeasesScheduleOfInformationAboutLeaseCostsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfPresentValueOfOperatingLeasePaymentsDetail" xlink:href="tsbx-20240630.xsd#LeasesScheduleOfPresentValueOfOperatingLeasePaymentsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetail" xlink:href="tsbx-20240630.xsd#LeasesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/LegalProceedingsAdditionalInformationDetail" xlink:href="tsbx-20240630.xsd#LegalProceedingsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureLeasesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetail2" xlink:href="tsbx-20240630.xsd#DisclosureLeasesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetail2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss2" xlink:href="tsbx-20240630.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureLeasesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetail3" xlink:href="tsbx-20240630.xsd#DisclosureLeasesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetail3" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ContingentConsiderationPayableByCash" xlink:label="tsbx_ContingentConsiderationPayableByCash"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SharesAvailableForIssuanceUnderEsppMember" xlink:label="tsbx_SharesAvailableForIssuanceUnderEsppMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_TakedaAgreementMember" xlink:label="tsbx_TakedaAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_PaymentOfLoanFirstAnniversaryClosingDateMember" xlink:label="tsbx_PaymentOfLoanFirstAnniversaryClosingDateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_CollaborativeArrangementAdditionalConsiderationReceivableForLicensedOption" xlink:label="tsbx_CollaborativeArrangementAdditionalConsiderationReceivableForLicensedOption"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_NumberOfTradingDays" xlink:label="tsbx_NumberOfTradingDays"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SignificantAccountingPoliciesLineItems" xlink:label="tsbx_SignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGross" xlink:label="us-gaap_AccountsReceivableGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_StockIssuedDuringPeriodValueNewIssuesOnMilestoneAchievement" xlink:label="tsbx_StockIssuedDuringPeriodValueNewIssuesOnMilestoneAchievement"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_PaymentOfLoanSecondAnniversaryClosingDateMember" xlink:label="tsbx_PaymentOfLoanSecondAnniversaryClosingDateMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_StockIssuedDuringThePeriodForMilestonePaymentsValue" xlink:label="tsbx_StockIssuedDuringThePeriodForMilestonePaymentsValue"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesCRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:label="us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ShortTermLeaseCosts" xlink:label="tsbx_ShortTermLeaseCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_TwoThousandAndEighteenEquityIncentivePlanMember" xlink:label="tsbx_TwoThousandAndEighteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SecondMilestonePaymentMember" xlink:label="tsbx_SecondMilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_RevenuePerformanceObligationFixedAggregateConsideration" xlink:label="tsbx_RevenuePerformanceObligationFixedAggregateConsideration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_CollaborativeArrangementAdditionalConsiderationReceivable" xlink:label="tsbx_CollaborativeArrangementAdditionalConsiderationReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_LossContingencyReserveForLitigationLiabilities" xlink:label="tsbx_LossContingencyReserveForLitigationLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue" xlink:label="us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_DisclosureOfAccruedExpensesAndOtherCurrentLiabilitiesTextBlock" xlink:label="tsbx_DisclosureOfAccruedExpensesAndOtherCurrentLiabilitiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_DebtInstrumentSuccessFeeAmount" xlink:label="tsbx_DebtInstrumentSuccessFeeAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_CommonStockCapitalSharesReservedForFutureIssuanceIncreaseDecreasePeriod" xlink:label="tsbx_CommonStockCapitalSharesReservedForFutureIssuanceIncreaseDecreasePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SharesAvailableForIssuanceUnderPlansMember" xlink:label="tsbx_SharesAvailableForIssuanceUnderPlansMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_BusinessDescriptionAndBasisOfPresentationAbstract" xlink:label="tsbx_BusinessDescriptionAndBasisOfPresentationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AccretionOfRedeemableConvertiblePreferredStock" xlink:label="tsbx_AccretionOfRedeemableConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_DebtInstrumentFeeOnEventOfDefault" xlink:label="tsbx_DebtInstrumentFeeOnEventOfDefault"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_FirstMilestonePaymentMember" xlink:label="tsbx_FirstMilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_UnvestedRestrictedStockUnitsMember" xlink:label="tsbx_UnvestedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_DeferredIpoCostsIncludedInAccruedExpenses" xlink:label="tsbx_DeferredIpoCostsIncludedInAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_MaximumTermOfOptionsUnderEquityIncentivePlan" xlink:label="tsbx_MaximumTermOfOptionsUnderEquityIncentivePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_RestrictedCashMember" xlink:label="tsbx_RestrictedCashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfPresentValueOfOperatingLeasePayments" xlink:label="tsbx_ScheduleOfPresentValueOfOperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_CollaborativeArrangementAggregateConsiderationRemains" xlink:label="tsbx_CollaborativeArrangementAggregateConsiderationRemains"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SalesMilestonesOnLicensedDiscoveryProductMember" xlink:label="tsbx_SalesMilestonesOnLicensedDiscoveryProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_StockIssuedDuringPeriodSharesNewIssuesOnMilestoneAchievement" xlink:label="tsbx_StockIssuedDuringPeriodSharesNewIssuesOnMilestoneAchievement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AgreementAxis" xlink:label="tsbx_AgreementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="tsbx_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock" xlink:label="tsbx_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityTable" xlink:label="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AllianceAgreementMember" xlink:label="tsbx_AllianceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundablePaymentReceived" xlink:label="tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundablePaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_PricePreModificationMember" xlink:label="tsbx_PricePreModificationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="us-gaap_AssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ContingentConsiderationMember" xlink:label="tsbx_ContingentConsiderationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuableShares" xlink:label="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuableShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments" xlink:label="tsbx_FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_OptionsToPurchaseCommonStockMember" xlink:label="tsbx_OptionsToPurchaseCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_CollaborativeArrangementAggregateConsiderationPayable" xlink:label="tsbx_CollaborativeArrangementAggregateConsiderationPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_OfficeAndLaboratorySpaceMember" xlink:label="tsbx_OfficeAndLaboratorySpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_PriceAtModificationMember" xlink:label="tsbx_PriceAtModificationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_PercentageOfOperatingProfitOrLoss" xlink:label="tsbx_PercentageOfOperatingProfitOrLoss"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_TimothyLangerMember" xlink:label="tsbx_TimothyLangerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ResearchDevelopmentAndManufacturingServicesAmendedToRemoveTrueUpAnnaulInstallment" xlink:label="tsbx_ResearchDevelopmentAndManufacturingServicesAmendedToRemoveTrueUpAnnaulInstallment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ContingentConsiderationCurrent" xlink:label="tsbx_ContingentConsiderationCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_RemainingMystHoldersMember" xlink:label="tsbx_RemainingMystHoldersMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_NumberOfSquareFeetForLease" xlink:label="tsbx_NumberOfSquareFeetForLease"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_StockIssuedDuringPeriodValueMoffittPerformanceBasedCommonStockAward" xlink:label="tsbx_StockIssuedDuringPeriodValueMoffittPerformanceBasedCommonStockAward"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundableUpfrontPaymentReceived" xlink:label="tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundableUpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_EstimatedCompensationEarningFromProjectExpenseSharing" xlink:label="tsbx_EstimatedCompensationEarningFromProjectExpenseSharing"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_DevelopmentProgramMember" xlink:label="tsbx_DevelopmentProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ClinicalAndRegulatoryMilestonesOnLicensedDiscoveryProductMember" xlink:label="tsbx_ClinicalAndRegulatoryMilestonesOnLicensedDiscoveryProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ProvisionBenefitForIncomeTaxes" xlink:label="tsbx_ProvisionBenefitForIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="us-gaap_LiabilitiesAssumed1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ResearchAndDevelopmentExpenseLiabilities" xlink:label="tsbx_ResearchAndDevelopmentExpenseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AgreementsAbstract" xlink:label="tsbx_AgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_OperatingLeaseAgreementMember" xlink:label="tsbx_OperatingLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_MeasurementInputLikelihoodOfOccurrenceMember" xlink:label="tsbx_MeasurementInputLikelihoodOfOccurrenceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ThirdMilestonePaymentMember" xlink:label="tsbx_ThirdMilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SignificantAccountingPoliciesTable" xlink:label="tsbx_SignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SharesAuthorized" xlink:label="tsbx_SharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AgreementDomain" xlink:label="tsbx_AgreementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_StockIssuedDuringPeriodSharesMoffittPerformanceBasedCommonStockAward" xlink:label="tsbx_StockIssuedDuringPeriodSharesMoffittPerformanceBasedCommonStockAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_DebtInstrumentNonrefundablePrepaymentFeeInSecondAnniversary" xlink:label="tsbx_DebtInstrumentNonrefundablePrepaymentFeeInSecondAnniversary"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="us-gaap_MachineryAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_NewSharesUnderTwoThousandTwentyThreeMember" xlink:label="tsbx_NewSharesUnderTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesB2RedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesB2RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SalesBasedMilestonesMember" xlink:label="tsbx_SalesBasedMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_RestrictedCashAndCashEquivalentsAtFairValue" xlink:label="tsbx_RestrictedCashAndCashEquivalentsAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="tsbx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_CompanyCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryTableTextBlock" xlink:label="tsbx_CompanyCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement" xlink:label="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ContingentConsiderationPolicyPolicyTextBlock" xlink:label="tsbx_ContingentConsiderationPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:label="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationLineItems" xlink:label="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ShareBasedCompensationArrangementAverageGrantDateFairValue" xlink:label="tsbx_ShareBasedCompensationArrangementAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="tsbx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationAbstract" xlink:label="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_TwoThousandAndTwentyThreeEquityIncentivePlanMember" xlink:label="tsbx_TwoThousandAndTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:label="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_IncreaseDecreaseInContingentConsiderationLiability" xlink:label="tsbx_IncreaseDecreaseInContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_DebtInstrumentNonrefundablePrepaymentFeeInFirstAnniversary" xlink:label="tsbx_DebtInstrumentNonrefundablePrepaymentFeeInFirstAnniversary"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_EmployeeStockPurchasePlanMember" xlink:label="tsbx_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentDomain" xlink:label="dei_DocumentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_RemainingSharesFromTwoThousandEighteenPlanMember" xlink:label="tsbx_RemainingSharesFromTwoThousandEighteenPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_LaboratorySpaceMember" xlink:label="tsbx_LaboratorySpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationTable" xlink:label="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesB1RedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesB1RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeExtensibleEnumeration" xlink:label="us-gaap_InvestmentTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesDRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_MilestonePaymentReceivable" xlink:label="tsbx_MilestonePaymentReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_StockIssuedDuringThePeriodForMilestonePaymentsShares" xlink:label="tsbx_StockIssuedDuringThePeriodForMilestonePaymentsShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_FairValueDisclosuresLineItems" xlink:label="tsbx_FairValueDisclosuresLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_UnderwritingDiscountsAndCommissions" xlink:label="tsbx_UnderwritingDiscountsAndCommissions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AccruedCompensationCurrent" xlink:label="tsbx_AccruedCompensationCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ContingentConsiderationPayable" xlink:label="tsbx_ContingentConsiderationPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationTableTextBlock" xlink:label="tsbx_ScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ReturningSharesMember" xlink:label="tsbx_ReturningSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_FairValueDisclosuresTable" xlink:label="tsbx_FairValueDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_CollaborativeArrangementDisclosureAbstract" xlink:label="tsbx_CollaborativeArrangementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsFairValueDisclosure" xlink:label="us-gaap_CommitmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AccretionOfPremiumOnShortTermInvestments" xlink:label="tsbx_AccretionOfPremiumOnShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationDocumentAxis" xlink:label="dei_DocumentInformationDocumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ResearchDevelopmentAndManufacturingServicesAggregateAnnualAmount" xlink:label="tsbx_ResearchDevelopmentAndManufacturingServicesAggregateAnnualAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="us-gaap_AssetAcquisitionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_MystMember" xlink:label="tsbx_MystMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ClinicalAndRegulatoryMilestonesOnDevelopmentProgramMember" xlink:label="tsbx_ClinicalAndRegulatoryMilestonesOnDevelopmentProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_LineOfCreditFacilityExtendedDate" xlink:label="tsbx_LineOfCreditFacilityExtendedDate"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:label="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfPresentValueOfOperatingLeasePaymentsAbstract" xlink:label="tsbx_ScheduleOfPresentValueOfOperatingLeasePaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_DebtInstrumentSuccessFeePercentage" xlink:label="tsbx_DebtInstrumentSuccessFeePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ContingentConsiderationPayableByShares" xlink:label="tsbx_ContingentConsiderationPayableByShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:label="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability" xlink:label="tsbx_AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_PriceModificationAxis" xlink:label="tsbx_PriceModificationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_MilestoneDomain" xlink:label="tsbx_MilestoneDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_H.LeeMoffittCancerCenterMember" xlink:label="tsbx_H.LeeMoffittCancerCenterMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" xlink:label="tsbx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_LangerMember" xlink:label="tsbx_LangerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesARedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_MystMergerAgreementMember" xlink:label="tsbx_MystMergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_RestrictedCashAndInvestmentsPolicyPolicyTextBlock" xlink:label="tsbx_RestrictedCashAndInvestmentsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_OtherOfferingExpenses" xlink:label="tsbx_OtherOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_FairValueOfCommonStockPolicyPolicyTextBlock" xlink:label="tsbx_FairValueOfCommonStockPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_MilestoneAxis" xlink:label="tsbx_MilestoneAxis"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_InitialMilestonePaymentMember" xlink:label="tsbx_InitialMilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_OfficeSpaceMember" xlink:label="tsbx_OfficeSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:label="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_UnpaidLiabilityMilestoneAchievement" xlink:label="tsbx_UnpaidLiabilityMilestoneAchievement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SignificantAccountingPoliciesPolicyPolicyTextBlock" xlink:label="tsbx_SignificantAccountingPoliciesPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="us-gaap_CapitalizedComputerSoftwareGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SalesMilestonesOnDevelopmentProgramMember" xlink:label="tsbx_SalesMilestonesOnDevelopmentProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_DiscoveryProgramMember" xlink:label="tsbx_DiscoveryProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_IncreaseDecreaseInAccruedCompensationAndOtherAccruedLiabilities" xlink:label="tsbx_IncreaseDecreaseInAccruedCompensationAndOtherAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="tsbx_TakedaPharmaceuticalCompanyLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_EquipmentPurchasesIncludedInAccruedExpenses" xlink:label="tsbx_EquipmentPurchasesIncludedInAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_CashProceedsFromTheSaleOfEquitySecuritiesAndOrUpfrontCashProceedsFromStrategicPartnerships" xlink:label="tsbx_CashProceedsFromTheSaleOfEquitySecuritiesAndOrUpfrontCashProceedsFromStrategicPartnerships"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedShares" xlink:label="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedShares"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_MystHoldersMember" xlink:label="tsbx_MystHoldersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_PriceModificationDomain" xlink:label="tsbx_PriceModificationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_BusinessDescriptionAndBasisOfPresentationTable" xlink:label="tsbx_BusinessDescriptionAndBasisOfPresentationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ContingentConsiderationPayableByCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration payable by cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ContingentConsiderationPayableByCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Payable By Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ContingentConsiderationPayableByCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent consideration payable by cash.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SharesAvailableForIssuanceUnderEsppMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for issuance under the ESPP [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SharesAvailableForIssuanceUnderEsppMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Available For Issuance Under ESPP [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SharesAvailableForIssuanceUnderEsppMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares available for issuance under ESPP.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable - collaboration agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inflow From Issuance Of Intangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_TakedaAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Takeda Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_TakedaAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Takeda Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_TakedaAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Takeda agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_PaymentOfLoanFirstAnniversaryClosingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of loan first anniversary closing date [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_PaymentOfLoanFirstAnniversaryClosingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Loan First Anniversary Closing Date [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_PaymentOfLoanFirstAnniversaryClosingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of loan first anniversary closing date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based payment arrangement, non-vested award, excluding option, cost not yet recognized, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of the reverse stock split arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Indexed to Issuer's Equity, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_CollaborativeArrangementAdditionalConsiderationReceivableForLicensedOption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative arrangement additional consideration receivable for license option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_CollaborativeArrangementAdditionalConsiderationReceivableForLicensedOption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Additional Consideration Receivable for Licensed Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_CollaborativeArrangementAdditionalConsiderationReceivableForLicensedOption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement additional consideration receivable for license option.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remainder of 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_NumberOfTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of trading days</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_NumberOfTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Trading Days</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_NumberOfTradingDays_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of trading days.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock, Class of Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Company's Contingent Consideration Measured at Fair Value Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Property and equipment depreciation and amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based compensation arrangement by share-based payment award, award vesting rights, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of vesting of award under share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Disclosure of Non-Cash Investing and Financing Activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing and Financing Items [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments to acquire productive assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Productive Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Productive Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Redeemable Convertible Preferred Stock and Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross unrealized losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, before Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_StockIssuedDuringPeriodValueNewIssuesOnMilestoneAchievement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon Myst milestone achievement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_StockIssuedDuringPeriodValueNewIssuesOnMilestoneAchievement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues on Milestone Achievement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_StockIssuedDuringPeriodValueNewIssuesOnMilestoneAchievement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value new issues on milestone achievement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_PaymentOfLoanSecondAnniversaryClosingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of loan second anniversary closing date [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_PaymentOfLoanSecondAnniversaryClosingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Loan Second Anniversary Closing Date [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_PaymentOfLoanSecondAnniversaryClosingDateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of loan second anniversary closing date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_StockIssuedDuringThePeriodForMilestonePaymentsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issued during the period for milestone payments value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_StockIssuedDuringThePeriodForMilestonePaymentsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During the Period for Milestone Payments Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_StockIssuedDuringThePeriodForMilestonePaymentsValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during the period for milestone payments value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C redeemable convertible preferred stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SeriesCRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options canceled/forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueDiscountedCashFlowMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation technique discounted cash flow [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueDiscountedCashFlowMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Technique, Discounted Cash Flow [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares, issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Risk-free interest rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of the Business and Basis of Presentation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description and Basis of Presentation [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ShortTermLeaseCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ShortTermLeaseCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Lease, Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ShortTermLeaseCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short-term lease, costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss before income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_TwoThousandAndEighteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2018 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_TwoThousandAndEighteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Eighteen Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_TwoThousandAndEighteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and eighteen equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SecondMilestonePaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Milestone Payment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SecondMilestonePaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second Milestone Payment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SecondMilestonePaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second milestone payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_RevenuePerformanceObligationFixedAggregateConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, performance obligation fixed aggregate consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_RevenuePerformanceObligationFixedAggregateConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Performance Obligation Fixed Aggregate Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_RevenuePerformanceObligationFixedAggregateConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue, performance obligation fixed aggregate consideration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for issuance automatically increased by additional shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Unrealized Loss Position, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale debt securities an aggregate unrealized loss position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of credit maturity date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue from collaborative arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_CollaborativeArrangementAdditionalConsiderationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative arrangement additional consideration receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_CollaborativeArrangementAdditionalConsiderationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Additional Consideration Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_CollaborativeArrangementAdditionalConsiderationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement additional consideration receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, option to extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_LossContingencyReserveForLitigationLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss contingency reserve for litigation liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_LossContingencyReserveForLitigationLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Reserve For Litigation Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_LossContingencyReserveForLitigationLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loss contingency reserve for litigation liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments, Owned, US Government and Agency Obligations, at Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. government securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable write-off</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_DisclosureOfAccruedExpensesAndOtherCurrentLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_DisclosureOfAccruedExpensesAndOtherCurrentLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of Accrued Expenses and Other Current Liabilities [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_DisclosureOfAccruedExpensesAndOtherCurrentLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accrued expenses and other current liabilities [Text Block].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_DebtInstrumentSuccessFeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument success fee amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_DebtInstrumentSuccessFeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Success Fee Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_DebtInstrumentSuccessFeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument success fee amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Allocated share based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_CommonStockCapitalSharesReservedForFutureIssuanceIncreaseDecreasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, capital shares reserved for future issuance increase decrease period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_CommonStockCapitalSharesReservedForFutureIssuanceIncreaseDecreasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved for Future Issuance Increase Decrease Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_CommonStockCapitalSharesReservedForFutureIssuanceIncreaseDecreasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock capital shares reserved for future issuance increase decrease period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares Underlying Outstanding Options, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares Underlying Outstanding Options, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, capital shares reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SharesAvailableForIssuanceUnderPlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for issuance under the Plans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SharesAvailableForIssuanceUnderPlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Available For Issuance Under Plans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SharesAvailableForIssuanceUnderPlansMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares available for issuance under plans.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash flows used in operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs Cancelled/Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, term of contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_BusinessDescriptionAndBasisOfPresentationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description And Basis Of Presentation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_BusinessDescriptionAndBasisOfPresentationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business description and basis of presentation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value recurring basis [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Assets and Liabilities Measured on Recurring Basis at Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par or stated value per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AccretionOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of redeemable convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AccretionOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Of Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AccretionOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accretion of redeemable convertible preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_DebtInstrumentFeeOnEventOfDefault_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, fee on the event of default</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_DebtInstrumentFeeOnEventOfDefault_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Fee On Event of Default</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_DebtInstrumentFeeOnEventOfDefault_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument, fee on event of default.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_FirstMilestonePaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Milestone Payment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_FirstMilestonePaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Milestone Payment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_FirstMilestonePaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First milestone payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_UnvestedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested Restricted Stock Units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_UnvestedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_UnvestedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested RSUs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_DeferredIpoCostsIncludedInAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred IPO costs included in accrued expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_DeferredIpoCostsIncludedInAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred IPO Costs Included In Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_DeferredIpoCostsIncludedInAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred IPO costs included in accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of RSUs granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_MaximumTermOfOptionsUnderEquityIncentivePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum term of options issued under equity incentive plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_MaximumTermOfOptionsUnderEquityIncentivePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Term of Options Under Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_MaximumTermOfOptionsUnderEquityIncentivePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum term of options under equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Approach and Technique [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_RestrictedCashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_RestrictedCashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_RestrictedCashMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted cash [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration input range</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of dilutive securities excluded from computation of diluted net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revolving credit facility, aggregate principal amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross unrealized gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accretion of preferred stock to redemption value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accretion of preferred stock to redemption value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Accretion to Redemption Value, Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based compensation arrangement by share-based payment award, equity instruments other than options, nonvested, number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of non-vested equity-based payment instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Outstanding RSUs, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Outstanding RSUs, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development asset acquired other than through business combination, write-off</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liability, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ScheduleOfPresentValueOfOperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of present value of operating lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ScheduleOfPresentValueOfOperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Present Value Of Operating Lease Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ScheduleOfPresentValueOfOperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of present value of operating lease payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net income (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_CollaborativeArrangementAggregateConsiderationRemains_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative arrangement aggregate consideration remains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_CollaborativeArrangementAggregateConsiderationRemains_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Aggregate Consideration Remains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_CollaborativeArrangementAggregateConsiderationRemains_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement aggregate consideration remains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SalesMilestonesOnLicensedDiscoveryProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Milestones on Licensed Discovery Product [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SalesMilestonesOnLicensedDiscoveryProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales Milestones On Licensed Discovery Product Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale of Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_StockIssuedDuringPeriodSharesNewIssuesOnMilestoneAchievement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon Myst milestone achievement (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_StockIssuedDuringPeriodSharesNewIssuesOnMilestoneAchievement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues On Milestone Achievement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_StockIssuedDuringPeriodSharesNewIssuesOnMilestoneAchievement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares new issues on milestone achievement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Commitment, Excluding Long-Term Commitment [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Noncontrolling Interest, Equity, Carrying Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Redeemable Noncontrolling Interest, Equity, Carrying Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares, issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AgreementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AgreementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement Axis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recently Issued Accounting Pronouncements Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recently issued accounting pronouncements policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Risk-free interest rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options canceled/forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from Issuance of redeemable convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable convertible preferred stock policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of share based compensation stock options activity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration by Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AllianceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Alliance Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AllianceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Alliance Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AllianceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Alliance agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundablePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, performance obligation fixed consideration Non refundable payment received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundablePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Performance Obligation Fixed Consideration Non Refundable Payment Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundablePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue, performance obligation fixed consideration Non refundable upfront payment received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, par or stated value per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock par value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_PricePreModificationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price Pre-Modification [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_PricePreModificationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Price Pre Modification [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_PricePreModificationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Price pre modification.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accretion of preferred stock to redemption value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of redeemable convertible preferred stock issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Accretion to Redemption Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Business acquisition, equity interest issued or issuable, number of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument nonrefundable prepayment fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent Consideration [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash at beginning of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash at end of the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series D redeemable convertible preferred stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Project [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuableShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset acquisition consideration transferred equity interest issuable shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuableShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Consideration Transferred Equity Interest Issuable Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuableShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition consideration transferred equity interest issuable shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Estimated fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding From Sale Of Equity Partnerships And Or Business Development Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funding From Sale Of Equity Partnerships And Or Business Development Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funding from sale of equity partnerships and or business development payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to purchase common stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options To Purchase Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options To Purchase Common Stock Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of minimum aggregate future operating lease commitments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_CollaborativeArrangementAggregateConsiderationPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative arrangement aggregate consideration payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_CollaborativeArrangementAggregateConsiderationPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Aggregate Consideration Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_CollaborativeArrangementAggregateConsiderationPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement aggregate consideration payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based compensation arrangement by share-based payment award, number of shares available for grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation arrangement by share-based payment award, number of shares available for grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate grant date fair value of RSUs granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based payment arrangement, non-vested award, cost not yet recognized, period for recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_OfficeAndLaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office and laboratory space [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_OfficeAndLaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office And Laboratory Space [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_OfficeAndLaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office And Laboratory Space Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Federal income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Federal Income Tax Expense (Benefit), Continuing Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Federal Income Tax Expense (Benefit), Continuing Operations, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Cash payment of Myst milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_PriceAtModificationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price at Modification [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_PriceAtModificationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Price At Modification [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_PriceAtModificationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Price&#160;at&#160;modification.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock ,shares authorized, issued and outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Noncontrolling Interest, Equity, Preferred, Carrying Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_PercentageOfOperatingProfitOrLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of share of operating profit or loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_PercentageOfOperatingProfitOrLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Operating Profit Or Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_PercentageOfOperatingProfitOrLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of operating profit or loss.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_TimothyLangerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Timothy Langer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_TimothyLangerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Timothy Langer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_TimothyLangerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Timothy Langer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of equity-based payment instruments vested during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Vested/Released</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ResearchDevelopmentAndManufacturingServicesAmendedToRemoveTrueUpAnnaulInstallment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research development and manufacturing services amended to remove the true up annual installment amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ResearchDevelopmentAndManufacturingServicesAmendedToRemoveTrueUpAnnaulInstallment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Development And Manufacturing Services Amended to Remove True Up Annaul Installment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ResearchDevelopmentAndManufacturingServicesAmendedToRemoveTrueUpAnnaulInstallment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research development and manufacturing services amended to remove true up annaul installment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of deferred IPO costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">RSUs Cancelled/Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs Cancelled/Forfeited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ContingentConsiderationCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ContingentConsiderationCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ContingentConsiderationCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent consideration, current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_RemainingMystHoldersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining Myst Holders [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_RemainingMystHoldersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Myst Holders [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_RemainingMystHoldersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining myst holders.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_NumberOfSquareFeetForLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of square feet for lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_NumberOfSquareFeetForLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Square Feet For Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_NumberOfSquareFeetForLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of square feet for lease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_StockIssuedDuringPeriodValueMoffittPerformanceBasedCommonStockAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Moffitt performance based common stock award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_StockIssuedDuringPeriodValueMoffittPerformanceBasedCommonStockAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Moffitt Performance Based Common Stock Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_StockIssuedDuringPeriodValueMoffittPerformanceBasedCommonStockAward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value moffitt performance based common stock award.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundableUpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, performance obligation fixed consideration Non refundable upfront payment received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundableUpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Performance Obligation Fixed Consideration Non Refundable Upfront Payment Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundableUpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue, performance obligation fixed consideration Non refundable upfront payment received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Charges, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares authorized for issuance under share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation arrangement by share-based payment award, number of shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series A redeemable convertible preferred stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_EstimatedCompensationEarningFromProjectExpenseSharing_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated compensation earning from project expense sharing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_EstimatedCompensationEarningFromProjectExpenseSharing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Compensation Earning from Project Expense Sharing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_EstimatedCompensationEarningFromProjectExpenseSharing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated compensation earning from project expense sharing.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_DevelopmentProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_DevelopmentProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_DevelopmentProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of redeemable convertible preferred stock issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ClinicalAndRegulatoryMilestonesOnLicensedDiscoveryProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical and Regulatory Milestones on Licensed Discovery Product [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ClinicalAndRegulatoryMilestonesOnLicensedDiscoveryProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical And Regulatory Milestones On Licensed Discovery Product Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from initial public offering, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ProvisionBenefitForIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Benefit (provision) for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ProvisionBenefitForIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Benefit (provision) for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ProvisionBenefitForIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Provision Benefit For Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ProvisionBenefitForIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Provision benefit for income taxes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAssumed1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development contract obligation assumed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAssumed1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Assumed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Taxes Paid, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. government and agency securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ResearchAndDevelopmentExpenseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ResearchAndDevelopmentExpenseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ResearchAndDevelopmentExpenseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expense liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset impairment charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Impairment Charges</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Asset Impairment Charges, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of information about lease costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_OperatingLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_OperatingLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_OperatingLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Lease Agreement Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_MeasurementInputLikelihoodOfOccurrenceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement input likelihood of occurrence [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_MeasurementInputLikelihoodOfOccurrenceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Likelihood Of Occurrence [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_MeasurementInputLikelihoodOfOccurrenceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Measurement input likelihood of occurrence [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation arrangement by share-based payment award, percentage of outstanding stock maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ThirdMilestonePaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third Milestone Payment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ThirdMilestonePaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third Milestone Payment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ThirdMilestonePaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third milestone payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property plant and equipment gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement input expected term [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Expected Term [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of fair value assumption of stock option activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Proceedings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Matters and Contingencies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments for rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Rent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares Authorized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of RSU activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign exchange rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Exchange Rate, Translation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AgreementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AgreementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement Domain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash flows used in financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_StockIssuedDuringPeriodSharesMoffittPerformanceBasedCommonStockAward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Moffitt performance based common stock award (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_StockIssuedDuringPeriodSharesMoffittPerformanceBasedCommonStockAward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Moffitt Performance Based Common Stock Award</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_StockIssuedDuringPeriodSharesMoffittPerformanceBasedCommonStockAward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares moffitt performance based common stock award.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_DebtInstrumentNonrefundablePrepaymentFeeInSecondAnniversary_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument nonrefundable prepayment fee in second anniversary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_DebtInstrumentNonrefundablePrepaymentFeeInSecondAnniversary_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Nonrefundable Prepayment Fee In Second Anniversary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_DebtInstrumentNonrefundablePrepaymentFeeInSecondAnniversary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument nonrefundable prepayment fee in second anniversary.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash received on stock transaction after deduction of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise price of stock options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Benefit (Provision) for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MachineryAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MachineryAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Machinery and Equipment, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Disposition of Property Plant Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain on disposal of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_NewSharesUnderTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Shares Under 2023 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_NewSharesUnderTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Shares Under Two Thousand Twenty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_NewSharesUnderTwoThousandTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New Shares Under Two Thousand Twenty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SeriesB2RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series B-2 Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SeriesB2RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B-2 redeemable convertible preferred stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SeriesB2RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B2 Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SeriesB2RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B-2 redeemable convertible preferred stock [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SalesBasedMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Based Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SalesBasedMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Based Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SalesBasedMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_RestrictedCashAndCashEquivalentsAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_RestrictedCashAndCashEquivalentsAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents At Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_RestrictedCashAndCashEquivalentsAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted cash and cash equivalents at fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Liabilities and Other Current Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities And Other Current Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of accrued liabilities and other current liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unvested RSUs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable leases costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_CompanyCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Company's Cash, Cash Equivalents and Available-for-Sale Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_CompanyCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Company Cash, Cash Equivalents And Available For Sale Securities By Significant Investment Category [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_CompanyCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Company cash, cash equivalents and&#160;available for sale&#160;securities by significant investment category [Table Text Block].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Equity issuance related to milestone achievement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity issuance related to milestone achievement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based payment arrangement, nonvested award, cost not yet recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of stock based compensation for stock awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement input discount rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in the fair value of contingent consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based payment arrangement, non-vested award, option, cost not yet recognized, amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity, aggregate amount of redemption requirement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Aggregate Amount of Redemption Requirement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration risk, percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ContingentConsiderationPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ContingentConsiderationPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ContingentConsiderationPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent consideration policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Volatility, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other commitment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitment to spend for cell therapy infrastructure and continued research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Commitment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset acquisition, consideration transferred, equity interest issued and issuable shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Consideration Transferred Equity Interest Issued And Issuable Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition consideration transferred equity interest issued and issuable shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value by Liability Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Transaction Price Allocatied To Programs Performance Obligation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of transaction price allocatied to programs performance obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ShareBasedCompensationArrangementAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation Arrangement Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ShareBasedCompensationArrangementAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ShareBasedCompensationArrangementAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate grant date fair value of RSUs granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of stock classified as temporary equity issued during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares new issues.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Transaction Price Allocatied To Programs Performance Obligation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of transaction price allocatied to programs performance obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_TwoThousandAndTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_TwoThousandAndTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Three Equity Incentive Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_TwoThousandAndTwentyThreeEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty three equity incentive plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of share based payment award stock options valuation assumptions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_IncreaseDecreaseInContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in contingent consideration liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_IncreaseDecreaseInContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Contingent Consideration Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_IncreaseDecreaseInContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in contingent consideration liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right of use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid Expense, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Disclosure of Cash Flow Information:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value of financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Liabilities Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_DebtInstrumentNonrefundablePrepaymentFeeInFirstAnniversary_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument nonrefundable prepayment fee in first anniversary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_DebtInstrumentNonrefundablePrepaymentFeeInFirstAnniversary_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Nonrefundable Prepayment Fee In First Anniversary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_DebtInstrumentNonrefundablePrepaymentFeeInFirstAnniversary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument nonrefundable prepayment fee in first anniversary.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Interest Rate Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash flows provided by investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forecast [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from initial public offering, net of issuance costs (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of new stock issued during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of contingent consideration related to Myst milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Payment for contingent consideration liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment for Contingent Consideration Liability, Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award vesting period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common stockholders, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net income (loss) attributable to common stockholders, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_RemainingSharesFromTwoThousandEighteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining Shares From 2018 Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_RemainingSharesFromTwoThousandEighteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Shares From Two Thousand Eighteen Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_RemainingSharesFromTwoThousandEighteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining Shares From Two Thousand Eighteen Plan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, par or stated value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-Based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate Intrinsic Value Outstanding , Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic Value Outstanding , Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_LaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory space [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_LaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Space [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_LaboratorySpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory Space Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of computation of basic and diluted net loss per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Transaction Price Allocatied To Programs Performance Obligation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of transaction price allocatied to programs performance obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Contingent consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Contingent Consideration, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SeriesB1RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series B-1 Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SeriesB1RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B-1 redeemable convertible preferred stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SeriesB1RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B1 Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SeriesB1RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B-1 redeemable convertible preferred stock [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Type [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average number of shares of common stock outstanding, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average number of basic shares used in computing net earnings (loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SeriesDRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D redeemable convertible preferred stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SeriesDRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SeriesDRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series D Redeemable Convertible Preferred Stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_MilestonePaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_MilestonePaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_MilestonePaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of contingent consideration liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Volatility, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Value of new stock classified as temporary equity issued during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Sublease income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_StockIssuedDuringThePeriodForMilestonePaymentsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issued during the period for milestone payments shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_StockIssuedDuringThePeriodForMilestonePaymentsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During the Period for Milestone Payments Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_StockIssuedDuringThePeriodForMilestonePaymentsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during the period for milestone payments shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_FairValueDisclosuresLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_FairValueDisclosuresLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value disclosures [Lineitems].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing costs included in accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted- Average Remaining Contractual Term (Years) Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts and commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Discounts and Commissions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_UnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting discounts and commissions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">General and administrative [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AccruedCompensationCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AccruedCompensationCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Compensation Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AccruedCompensationCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued compensation current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ContingentConsiderationPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ContingentConsiderationPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ContingentConsiderationPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent consideration payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale debt securities an aggregate fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series C redeemable convertible preferred stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of stock option plan activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-Term Line of Credit, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Line of Credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts drawn and outstanding under credit facility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity (deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Transaction Price Allocated To Programs Performance Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Transaction Price Allocated To Programs Performance Obligation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of transaction price allocated to programs performance obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Transition Option Elected [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ReturningSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Returning Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ReturningSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Returning Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ReturningSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Returning Shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_FairValueDisclosuresTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_FairValueDisclosuresTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value disclosures [Table].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award requisite service period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Current Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash, cash equivalents and restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_CollaborativeArrangementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_CollaborativeArrangementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative Arrangement Disclosure Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (loss) per share attributable to common stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivables related to reimbursable costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity purchase commitments by counter party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AccretionOfPremiumOnShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accretion of premium on short term investments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AccretionOfPremiumOnShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion of premium on short term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AccretionOfPremiumOnShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accretion of premium on short term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AccretionOfPremiumOnShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion of premium on short term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued, price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationDocumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information, Document [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional and consulting expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ResearchDevelopmentAndManufacturingServicesAggregateAnnualAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research development and manufacturing services aggregate annual amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ResearchDevelopmentAndManufacturingServicesAggregateAnnualAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Development And Manufacturing Services Aggregate Annual Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ResearchDevelopmentAndManufacturingServicesAggregateAnnualAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research development and manufacturing services aggregate annual amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Unobservable Input of Contingent Consideration Valuation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalents, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash and Cash Equivalents, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common stockholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (loss) attributable to common stockholders, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_MystMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Myst [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_MystMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Myst [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_MystMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Myst [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Contract with Customer, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents, and short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration, liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Contingent Consideration, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Asset Acquisition, Contingent Consideration, Liability, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value; 10,000,000 shares authorized, at June 30, 2024 and December 31, 2023, respectively, 0 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ClinicalAndRegulatoryMilestonesOnDevelopmentProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical and Regulatory Milestones On Development Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ClinicalAndRegulatoryMilestonesOnDevelopmentProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical And Regulatory Milestones On Development Program Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_LineOfCreditFacilityExtendedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line Of Credit Facility Extended Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_LineOfCreditFacilityExtendedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line Of Credit Facility Extended Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_LineOfCreditFacilityExtendedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Line of credit facility extended date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of share based compensation stock options activity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ScheduleOfPresentValueOfOperatingLeasePaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Present Value of Operating Lease Payments [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ScheduleOfPresentValueOfOperatingLeasePaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of Present Value Of Operating Lease Payments Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_DebtInstrumentSuccessFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument success fee percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_DebtInstrumentSuccessFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Success Fee Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_DebtInstrumentSuccessFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument success fee percentage.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized loss on available-for-sale debt securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on available-for-sale debt securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ContingentConsiderationPayableByShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration payable by shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ContingentConsiderationPayableByShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Payable By Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ContingentConsiderationPayableByShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent consideration payable by shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of share based payment award stock options valuation assumptions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock into common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Impairment of ROU asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, impairment loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Impairment Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares, outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset acquisition contingent consideration arrangements change in amount of contingent consideration, liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Contingent Consideration Arrangements Change in Amount of Contingent Consideration Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition contingent consideration arrangements change in amount of contingent consideration liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional&#160;paid-in&#160;capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Commitment, Excluding Long-Term Commitment [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_PriceModificationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Price Modification [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_PriceModificationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Price modification.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Liabilities Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Issuance Costs, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Amortized Cost, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_MilestoneDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_MilestoneDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: current portion of operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_H.LeeMoffittCancerCenterMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">H. Lee Moffitt Cancer Center [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_H.LeeMoffittCancerCenterMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">H. Lee Moffitt Cancer Center [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_H.LeeMoffittCancerCenterMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">H. Lee moffitt cancer center.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of shares of common stock reserved for future issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Stock Shares Reserved For Future Issuance [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of common stock shares reserved for future issuance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Stated Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_LangerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Langer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_LangerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Langer [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_LangerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Langer.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Approach and Technique [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A redeemable convertible preferred stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A Redeemable Convertible Preferred Stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_MystMergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Myst Merger Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_MystMergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Myst Merger Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_MystMergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Myst Merger Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_MystMergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Myst merger agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Grant Date Fair Value, Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Grant Date Fair Value, Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Investments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_RestrictedCashAndInvestmentsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash and Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_RestrictedCashAndInvestmentsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Investments Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_RestrictedCashAndInvestmentsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted cash and investments policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets, noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_OtherOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_OtherOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Offering Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_OtherOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other Offering Expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_FairValueOfCommonStockPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Determination of Fair Value of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_FairValueOfCommonStockPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Common Stock Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_FairValueOfCommonStockPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of common stock policy text block.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PerformanceSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Shares [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments of financing costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Financing Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments of Financing Costs, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_MilestoneAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_MilestoneAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_InitialMilestonePaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Milestone Payment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_InitialMilestonePaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Milestone Payment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_InitialMilestonePaymentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial milestone payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_OfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office space [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_OfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Space [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_OfficeSpaceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office Space Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description And Basis Of Presentation [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business Description And Basis Of Presentation [Line Item]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation of Unaudited Condensed Consolidated Financial Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, $0.001 par value; 490,000,000 shares authorized at June 30, 2024 and December 31, 2023, respectively, 23,128,454 and 23,099,335 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inflow From Issuance Of Intangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_UnpaidLiabilityMilestoneAchievement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unpaid liability on milestone acheivement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_UnpaidLiabilityMilestoneAchievement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unpaid Liability Milestone Achievement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_UnpaidLiabilityMilestoneAchievement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unpaid liability milestone achievement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SignificantAccountingPoliciesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SignificantAccountingPoliciesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SignificantAccountingPoliciesPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average number of shares of common stock outstanding, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted-average number of diluted shares used in computing net earnings (loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer equipment and software</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Computer Software, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable - collaboration agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Receivable, after Allowance for Credit Loss, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, renewal term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Vested and expected to vest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, liability, to be paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SalesMilestonesOnDevelopmentProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Milestones On Development Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_SalesMilestonesOnDevelopmentProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales Milestones On Development Program Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_DiscoveryProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discovery Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_DiscoveryProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Discovery Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_DiscoveryProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Discovery program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_IncreaseDecreaseInAccruedCompensationAndOtherAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and other accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_IncreaseDecreaseInAccruedCompensationAndOtherAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Compensation And Other Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_IncreaseDecreaseInAccruedCompensationAndOtherAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in accrued compensation and other accrued liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProjectMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Project [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Additional revenue recognized on change in contract modification</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenues, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock split, conversion ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revolving Loans [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revolving Credit Facility [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_TakedaPharmaceuticalCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Takeda Pharmaceutical Company Limited [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_TakedaPharmaceuticalCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Takeda Pharmaceutical Company Limited [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_TakedaPharmaceuticalCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Takeda pharmaceutical company limited.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted- Average Exercise Price Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted- Average Exercise Price Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_EquipmentPurchasesIncludedInAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equipment purchases included in accrued expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_EquipmentPurchasesIncludedInAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment Purchases Included In Accrued Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_EquipmentPurchasesIncludedInAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment purchases included in accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_CashProceedsFromTheSaleOfEquitySecuritiesAndOrUpfrontCashProceedsFromStrategicPartnerships_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Proceeds From The Sale of Equity Securities And/Or Upfront Cash Proceeds From Strategic Partnerships</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_CashProceedsFromTheSaleOfEquitySecuritiesAndOrUpfrontCashProceedsFromStrategicPartnerships_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Proceeds From The Sale of Equity Securities And/Or Upfront Cash Proceeds From Strategic Partnerships</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_CashProceedsFromTheSaleOfEquitySecuritiesAndOrUpfrontCashProceedsFromStrategicPartnerships_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash proceeds from the sale of equity securities and/or upfront cash proceeds from strategic partnerships.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of available-for-sale debt securities in gross unrealized loss position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate cash proceeds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from (Repayments of) Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from (Repayments of) Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset acquisition consideration transferred equity interest issued shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Consideration Transferred Equity Interest Issued Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition consideration transferred equity interest issued shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_MystHoldersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Myst Holders [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_MystHoldersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Myst Holders [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_MystHoldersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Myst holders.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Concentration Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term in years</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_PriceModificationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Price Modification [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_PriceModificationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Price modification.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_BusinessDescriptionAndBasisOfPresentationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Description And Basis Of Presentation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tsbx_BusinessDescriptionAndBasisOfPresentationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business Description And Basis Of Presentation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of short-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Short-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for doubtful accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accounts Receivable, Allowance for Credit Loss, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accounts Receivable, Allowance for Credit Loss, Ending Balance</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_ContingentConsiderationPayableByCash" xlink:to="tsbx_ContingentConsiderationPayableByCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_SharesAvailableForIssuanceUnderEsppMember" xlink:to="tsbx_SharesAvailableForIssuanceUnderEsppMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="us-gaap_ProceedsFromSaleOfIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_TakedaAgreementMember" xlink:to="tsbx_TakedaAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_PaymentOfLoanFirstAnniversaryClosingDateMember" xlink:to="tsbx_PaymentOfLoanFirstAnniversaryClosingDateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_CollaborativeArrangementAdditionalConsiderationReceivableForLicensedOption" xlink:to="tsbx_CollaborativeArrangementAdditionalConsiderationReceivableForLicensedOption_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_NumberOfTradingDays" xlink:to="tsbx_NumberOfTradingDays_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_SignificantAccountingPoliciesLineItems" xlink:to="tsbx_SignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ClassOfStockDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGross" xlink:to="us-gaap_AccountsReceivableGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_StockIssuedDuringPeriodValueNewIssuesOnMilestoneAchievement" xlink:to="tsbx_StockIssuedDuringPeriodValueNewIssuesOnMilestoneAchievement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_PaymentOfLoanSecondAnniversaryClosingDateMember" xlink:to="tsbx_PaymentOfLoanSecondAnniversaryClosingDateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_StockIssuedDuringThePeriodForMilestonePaymentsValue" xlink:to="tsbx_StockIssuedDuringThePeriodForMilestonePaymentsValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:to="tsbx_SeriesCRedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:to="us-gaap_ValuationTechniqueDiscountedCashFlowMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_ShortTermLeaseCosts" xlink:to="tsbx_ShortTermLeaseCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_TwoThousandAndEighteenEquityIncentivePlanMember" xlink:to="tsbx_TwoThousandAndEighteenEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_SecondMilestonePaymentMember" xlink:to="tsbx_SecondMilestonePaymentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_RevenuePerformanceObligationFixedAggregateConsideration" xlink:to="tsbx_RevenuePerformanceObligationFixedAggregateConsideration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityExpirationDate1" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_CollaborativeArrangementAdditionalConsiderationReceivable" xlink:to="tsbx_CollaborativeArrangementAdditionalConsiderationReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_LossContingencyReserveForLitigationLiabilities" xlink:to="tsbx_LossContingencyReserveForLitigationLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue" xlink:to="us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_DisclosureOfAccruedExpensesAndOtherCurrentLiabilitiesTextBlock" xlink:to="tsbx_DisclosureOfAccruedExpensesAndOtherCurrentLiabilitiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_DebtInstrumentSuccessFeeAmount" xlink:to="tsbx_DebtInstrumentSuccessFeeAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_CommonStockCapitalSharesReservedForFutureIssuanceIncreaseDecreasePeriod" xlink:to="tsbx_CommonStockCapitalSharesReservedForFutureIssuanceIncreaseDecreasePeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_SharesAvailableForIssuanceUnderPlansMember" xlink:to="tsbx_SharesAvailableForIssuanceUnderPlansMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationAbstract" xlink:to="tsbx_BusinessDescriptionAndBasisOfPresentationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_AccretionOfRedeemableConvertiblePreferredStock" xlink:to="tsbx_AccretionOfRedeemableConvertiblePreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_DebtInstrumentFeeOnEventOfDefault" xlink:to="tsbx_DebtInstrumentFeeOnEventOfDefault_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_FirstMilestonePaymentMember" xlink:to="tsbx_FirstMilestonePaymentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_UnvestedRestrictedStockUnitsMember" xlink:to="tsbx_UnvestedRestrictedStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_DeferredIpoCostsIncludedInAccruedExpenses" xlink:to="tsbx_DeferredIpoCostsIncludedInAccruedExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_MaximumTermOfOptionsUnderEquityIncentivePlan" xlink:to="tsbx_MaximumTermOfOptionsUnderEquityIncentivePlan_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_RestrictedCashMember" xlink:to="tsbx_RestrictedCashMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_ScheduleOfPresentValueOfOperatingLeasePayments" xlink:to="tsbx_ScheduleOfPresentValueOfOperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_CollaborativeArrangementAggregateConsiderationRemains" xlink:to="tsbx_CollaborativeArrangementAggregateConsiderationRemains_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_SalesMilestonesOnLicensedDiscoveryProductMember" xlink:to="tsbx_SalesMilestonesOnLicensedDiscoveryProductMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_StockIssuedDuringPeriodSharesNewIssuesOnMilestoneAchievement" xlink:to="tsbx_StockIssuedDuringPeriodSharesNewIssuesOnMilestoneAchievement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_AgreementAxis" xlink:to="tsbx_AgreementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="tsbx_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock" xlink:to="tsbx_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityTable" xlink:to="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_AllianceAgreementMember" xlink:to="tsbx_AllianceAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundablePaymentReceived" xlink:to="tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundablePaymentReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_PricePreModificationMember" xlink:to="tsbx_PricePreModificationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="us-gaap_AssetAcquisitionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_ContingentConsiderationMember" xlink:to="tsbx_ContingentConsiderationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuableShares" xlink:to="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuableShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments" xlink:to="tsbx_FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_OptionsToPurchaseCommonStockMember" xlink:to="tsbx_OptionsToPurchaseCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_CollaborativeArrangementAggregateConsiderationPayable" xlink:to="tsbx_CollaborativeArrangementAggregateConsiderationPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_OfficeAndLaboratorySpaceMember" xlink:to="tsbx_OfficeAndLaboratorySpaceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_PriceAtModificationMember" xlink:to="tsbx_PriceAtModificationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_PercentageOfOperatingProfitOrLoss" xlink:to="tsbx_PercentageOfOperatingProfitOrLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_TimothyLangerMember" xlink:to="tsbx_TimothyLangerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_ResearchDevelopmentAndManufacturingServicesAmendedToRemoveTrueUpAnnaulInstallment" xlink:to="tsbx_ResearchDevelopmentAndManufacturingServicesAmendedToRemoveTrueUpAnnaulInstallment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_ContingentConsiderationCurrent" xlink:to="tsbx_ContingentConsiderationCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_RemainingMystHoldersMember" xlink:to="tsbx_RemainingMystHoldersMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_NumberOfSquareFeetForLease" xlink:to="tsbx_NumberOfSquareFeetForLease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_StockIssuedDuringPeriodValueMoffittPerformanceBasedCommonStockAward" xlink:to="tsbx_StockIssuedDuringPeriodValueMoffittPerformanceBasedCommonStockAward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundableUpfrontPaymentReceived" xlink:to="tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundableUpfrontPaymentReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_EstimatedCompensationEarningFromProjectExpenseSharing" xlink:to="tsbx_EstimatedCompensationEarningFromProjectExpenseSharing_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_DevelopmentProgramMember" xlink:to="tsbx_DevelopmentProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_ClinicalAndRegulatoryMilestonesOnLicensedDiscoveryProductMember" xlink:to="tsbx_ClinicalAndRegulatoryMilestonesOnLicensedDiscoveryProductMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_ProvisionBenefitForIncomeTaxes" xlink:to="tsbx_ProvisionBenefitForIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAssumed1" xlink:to="us-gaap_LiabilitiesAssumed1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_ResearchAndDevelopmentExpenseLiabilities" xlink:to="tsbx_ResearchAndDevelopmentExpenseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_AgreementsAbstract" xlink:to="tsbx_AgreementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_OperatingLeaseAgreementMember" xlink:to="tsbx_OperatingLeaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_MeasurementInputLikelihoodOfOccurrenceMember" xlink:to="tsbx_MeasurementInputLikelihoodOfOccurrenceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_ThirdMilestonePaymentMember" xlink:to="tsbx_ThirdMilestonePaymentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="us-gaap_LegalMattersAndContingenciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_SignificantAccountingPoliciesTable" xlink:to="tsbx_SignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_SharesAuthorized" xlink:to="tsbx_SharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_AgreementDomain" xlink:to="tsbx_AgreementDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_StockIssuedDuringPeriodSharesMoffittPerformanceBasedCommonStockAward" xlink:to="tsbx_StockIssuedDuringPeriodSharesMoffittPerformanceBasedCommonStockAward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_DebtInstrumentNonrefundablePrepaymentFeeInSecondAnniversary" xlink:to="tsbx_DebtInstrumentNonrefundablePrepaymentFeeInSecondAnniversary_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentGross" xlink:to="us-gaap_MachineryAndEquipmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_NewSharesUnderTwoThousandTwentyThreeMember" xlink:to="tsbx_NewSharesUnderTwoThousandTwentyThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_SeriesB2RedeemableConvertiblePreferredStockMember" xlink:to="tsbx_SeriesB2RedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_SalesBasedMilestonesMember" xlink:to="tsbx_SalesBasedMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_RestrictedCashAndCashEquivalentsAtFairValue" xlink:to="tsbx_RestrictedCashAndCashEquivalentsAtFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="tsbx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_CompanyCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryTableTextBlock" xlink:to="tsbx_CompanyCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement" xlink:to="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_ContingentConsiderationPolicyPolicyTextBlock" xlink:to="tsbx_ContingentConsiderationPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitment" xlink:to="us-gaap_OtherCommitment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:to="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationLineItems" xlink:to="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_ShareBasedCompensationArrangementAverageGrantDateFairValue" xlink:to="tsbx_ShareBasedCompensationArrangementAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="tsbx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationAbstract" xlink:to="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_TwoThousandAndTwentyThreeEquityIncentivePlanMember" xlink:to="tsbx_TwoThousandAndTwentyThreeEquityIncentivePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_IncreaseDecreaseInContingentConsiderationLiability" xlink:to="tsbx_IncreaseDecreaseInContingentConsiderationLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_DebtInstrumentNonrefundablePrepaymentFeeInFirstAnniversary" xlink:to="tsbx_DebtInstrumentNonrefundablePrepaymentFeeInFirstAnniversary_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_EmployeeStockPurchasePlanMember" xlink:to="tsbx_EmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentDomain" xlink:to="dei_DocumentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_RemainingSharesFromTwoThousandEighteenPlanMember" xlink:to="tsbx_RemainingSharesFromTwoThousandEighteenPlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_LaboratorySpaceMember" xlink:to="tsbx_LaboratorySpaceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationTable" xlink:to="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_SeriesB1RedeemableConvertiblePreferredStockMember" xlink:to="tsbx_SeriesB1RedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeExtensibleEnumeration" xlink:to="us-gaap_InvestmentTypeExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_SeriesDRedeemableConvertiblePreferredStockMember" xlink:to="tsbx_SeriesDRedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_MilestonePaymentReceivable" xlink:to="tsbx_MilestonePaymentReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_StockIssuedDuringThePeriodForMilestonePaymentsShares" xlink:to="tsbx_StockIssuedDuringThePeriodForMilestonePaymentsShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_FairValueDisclosuresLineItems" xlink:to="tsbx_FairValueDisclosuresLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_UnderwritingDiscountsAndCommissions" xlink:to="tsbx_UnderwritingDiscountsAndCommissions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_AccruedCompensationCurrent" xlink:to="tsbx_AccruedCompensationCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_ContingentConsiderationPayable" xlink:to="tsbx_ContingentConsiderationPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_ScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationTableTextBlock" xlink:to="tsbx_ScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_ReturningSharesMember" xlink:to="tsbx_ReturningSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_FairValueDisclosuresTable" xlink:to="tsbx_FairValueDisclosuresTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_CollaborativeArrangementDisclosureAbstract" xlink:to="tsbx_CollaborativeArrangementDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsFairValueDisclosure" xlink:to="us-gaap_CommitmentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_AccretionOfPremiumOnShortTermInvestments" xlink:to="tsbx_AccretionOfPremiumOnShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationDocumentAxis" xlink:to="dei_DocumentInformationDocumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_ResearchDevelopmentAndManufacturingServicesAggregateAnnualAmount" xlink:to="tsbx_ResearchDevelopmentAndManufacturingServicesAggregateAnnualAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTextBlock" xlink:to="us-gaap_AssetAcquisitionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_MystMember" xlink:to="tsbx_MystMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_ClinicalAndRegulatoryMilestonesOnDevelopmentProgramMember" xlink:to="tsbx_ClinicalAndRegulatoryMilestonesOnDevelopmentProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_LineOfCreditFacilityExtendedDate" xlink:to="tsbx_LineOfCreditFacilityExtendedDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_ScheduleOfPresentValueOfOperatingLeasePaymentsAbstract" xlink:to="tsbx_ScheduleOfPresentValueOfOperatingLeasePaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_DebtInstrumentSuccessFeePercentage" xlink:to="tsbx_DebtInstrumentSuccessFeePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_ContingentConsiderationPayableByShares" xlink:to="tsbx_ContingentConsiderationPayableByShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:to="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseImpairmentLoss" xlink:to="us-gaap_OperatingLeaseImpairmentLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability" xlink:to="tsbx_AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_PriceModificationAxis" xlink:to="tsbx_PriceModificationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_MilestoneDomain" xlink:to="tsbx_MilestoneDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_H.LeeMoffittCancerCenterMember" xlink:to="tsbx_H.LeeMoffittCancerCenterMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" xlink:to="tsbx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_LangerMember" xlink:to="tsbx_LangerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_SeriesARedeemableConvertiblePreferredStockMember" xlink:to="tsbx_SeriesARedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_MystMergerAgreementMember" xlink:to="tsbx_MystMergerAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsMember" xlink:to="us-gaap_ShortTermInvestmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_RestrictedCashAndInvestmentsPolicyPolicyTextBlock" xlink:to="tsbx_RestrictedCashAndInvestmentsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_OtherOfferingExpenses" xlink:to="tsbx_OtherOfferingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_FairValueOfCommonStockPolicyPolicyTextBlock" xlink:to="tsbx_FairValueOfCommonStockPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_MilestoneAxis" xlink:to="tsbx_MilestoneAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_InitialMilestonePaymentMember" xlink:to="tsbx_InitialMilestonePaymentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_OfficeSpaceMember" xlink:to="tsbx_OfficeSpaceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_UnpaidLiabilityMilestoneAchievement" xlink:to="tsbx_UnpaidLiabilityMilestoneAchievement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_SignificantAccountingPoliciesPolicyPolicyTextBlock" xlink:to="tsbx_SignificantAccountingPoliciesPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="us-gaap_ContingentConsiderationTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareGross" xlink:to="us-gaap_CapitalizedComputerSoftwareGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_SalesMilestonesOnDevelopmentProgramMember" xlink:to="tsbx_SalesMilestonesOnDevelopmentProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_DiscoveryProgramMember" xlink:to="tsbx_DiscoveryProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_IncreaseDecreaseInAccruedCompensationAndOtherAccruedLiabilities" xlink:to="tsbx_IncreaseDecreaseInAccruedCompensationAndOtherAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProjectMember" xlink:to="us-gaap_ProjectMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_TakedaPharmaceuticalCompanyLimitedMember" xlink:to="tsbx_TakedaPharmaceuticalCompanyLimitedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_EquipmentPurchasesIncludedInAccruedExpenses" xlink:to="tsbx_EquipmentPurchasesIncludedInAccruedExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_CashProceedsFromTheSaleOfEquitySecuritiesAndOrUpfrontCashProceedsFromStrategicPartnerships" xlink:to="tsbx_CashProceedsFromTheSaleOfEquitySecuritiesAndOrUpfrontCashProceedsFromStrategicPartnerships_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedShares" xlink:to="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_MystHoldersMember" xlink:to="tsbx_MystHoldersMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditConcentrationRiskMember" xlink:to="us-gaap_CreditConcentrationRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_PriceModificationDomain" xlink:to="tsbx_PriceModificationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationTable" xlink:to="tsbx_BusinessDescriptionAndBasisOfPresentationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationDocumentAxis" xlink:label="dei_DocumentInformationDocumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentDomain" xlink:label="dei_DocumentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationDocumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationDocumentAxis" xlink:to="dei_DocumentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentInformationTable" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesARedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesB1RedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesB1RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesB2RedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesB2RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesCRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesDRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesARedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesB1RedeemableConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesB2RedeemableConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesCRedeemableConvertiblePreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesDRedeemableConvertiblePreferredStockMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAbstract" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesARedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesB1RedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesB1RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesB2RedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesB2RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesCRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement" xlink:label="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesDRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesARedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesB1RedeemableConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesB2RedeemableConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesCRedeemableConvertiblePreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesDRedeemableConvertiblePreferredStockMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_10"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss_10" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesB1RedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesB1RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesB2RedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesB2RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_StockIssuedDuringPeriodSharesNewIssuesOnMilestoneAchievement" xlink:label="tsbx_StockIssuedDuringPeriodSharesNewIssuesOnMilestoneAchievement"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_StockIssuedDuringPeriodValueNewIssuesOnMilestoneAchievement" xlink:label="tsbx_StockIssuedDuringPeriodValueNewIssuesOnMilestoneAchievement"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_StockIssuedDuringPeriodSharesMoffittPerformanceBasedCommonStockAward" xlink:label="tsbx_StockIssuedDuringPeriodSharesMoffittPerformanceBasedCommonStockAward"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_StockIssuedDuringPeriodValueMoffittPerformanceBasedCommonStockAward" xlink:label="tsbx_StockIssuedDuringPeriodValueMoffittPerformanceBasedCommonStockAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_16"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_17"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_18"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_19"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesB1RedeemableConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesB2RedeemableConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tsbx_StockIssuedDuringPeriodSharesNewIssuesOnMilestoneAchievement" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tsbx_StockIssuedDuringPeriodValueNewIssuesOnMilestoneAchievement" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tsbx_StockIssuedDuringPeriodSharesMoffittPerformanceBasedCommonStockAward" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tsbx_StockIssuedDuringPeriodValueMoffittPerformanceBasedCommonStockAward" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_16" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_17" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_18" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_19" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AccretionOfRedeemableConvertiblePreferredStock" xlink:label="tsbx_AccretionOfRedeemableConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_EquipmentPurchasesIncludedInAccruedExpenses" xlink:label="tsbx_EquipmentPurchasesIncludedInAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_DeferredIpoCostsIncludedInAccruedExpenses" xlink:label="tsbx_DeferredIpoCostsIncludedInAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AccretionOfPremiumOnShortTermInvestments" xlink:label="tsbx_AccretionOfPremiumOnShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_IncreaseDecreaseInContingentConsiderationLiability" xlink:label="tsbx_IncreaseDecreaseInContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_IncreaseDecreaseInAccruedCompensationAndOtherAccruedLiabilities" xlink:label="tsbx_IncreaseDecreaseInAccruedCompensationAndOtherAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="tsbx_AccretionOfRedeemableConvertiblePreferredStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="tsbx_EquipmentPurchasesIncludedInAccruedExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="tsbx_DeferredIpoCostsIncludedInAccruedExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="tsbx_AccretionOfPremiumOnShortTermInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="tsbx_IncreaseDecreaseInContingentConsiderationLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="tsbx_IncreaseDecreaseInAccruedCompensationAndOtherAccruedLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_BusinessDescriptionAndBasisOfPresentationAbstract" xlink:label="tsbx_BusinessDescriptionAndBasisOfPresentationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_DisclosureOfAccruedExpensesAndOtherCurrentLiabilitiesTextBlock" xlink:label="tsbx_DisclosureOfAccruedExpensesAndOtherCurrentLiabilitiesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="tsbx_DisclosureOfAccruedExpensesAndOtherCurrentLiabilitiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/Agreements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AgreementsAbstract" xlink:label="tsbx_AgreementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_AgreementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisition" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="us-gaap_AssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="us-gaap_AssetAcquisitionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="us-gaap_AssetAcquisitionTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoan" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/IncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/Leases" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/LegalProceedings" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LegalMattersAndContingenciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SignificantAccountingPoliciesPolicyPolicyTextBlock" xlink:label="tsbx_SignificantAccountingPoliciesPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_RestrictedCashAndInvestmentsPolicyPolicyTextBlock" xlink:label="tsbx_RestrictedCashAndInvestmentsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_FairValueOfCommonStockPolicyPolicyTextBlock" xlink:label="tsbx_FairValueOfCommonStockPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock" xlink:label="tsbx_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ContingentConsiderationPolicyPolicyTextBlock" xlink:label="tsbx_ContingentConsiderationPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="tsbx_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tsbx_SignificantAccountingPoliciesPolicyPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tsbx_RestrictedCashAndInvestmentsPolicyPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tsbx_FairValueOfCommonStockPolicyPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tsbx_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tsbx_ContingentConsiderationPolicyPolicyTextBlock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tsbx_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_CompanyCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryTableTextBlock" xlink:label="tsbx_CompanyCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="tsbx_CompanyCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="tsbx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="tsbx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_CollaborativeArrangementDisclosureAbstract" xlink:label="tsbx_CollaborativeArrangementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationTableTextBlock" xlink:label="tsbx_ScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_CollaborativeArrangementDisclosureAbstract" xlink:to="tsbx_ScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" xlink:label="tsbx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="tsbx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/LeasesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfPresentValueOfOperatingLeasePayments" xlink:label="tsbx_ScheduleOfPresentValueOfOperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="tsbx_ScheduleOfPresentValueOfOperatingLeasePayments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_BusinessDescriptionAndBasisOfPresentationAbstract" xlink:label="tsbx_BusinessDescriptionAndBasisOfPresentationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_BusinessDescriptionAndBasisOfPresentationTable" xlink:label="tsbx_BusinessDescriptionAndBasisOfPresentationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:label="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_UnderwritingDiscountsAndCommissions" xlink:label="tsbx_UnderwritingDiscountsAndCommissions"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_OtherOfferingExpenses" xlink:label="tsbx_OtherOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SharesAuthorized" xlink:label="tsbx_SharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments" xlink:label="tsbx_FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationAbstract" xlink:to="tsbx_BusinessDescriptionAndBasisOfPresentationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationTable" xlink:to="srt_StatementScenarioAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationTable" xlink:to="us-gaap_CreditFacilityAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="tsbx_UnderwritingDiscountsAndCommissions" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationTable" xlink:to="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="tsbx_OtherOfferingExpenses" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="tsbx_SharesAuthorized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="tsbx_FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SignificantAccountingPoliciesLineItems" xlink:label="tsbx_SignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SignificantAccountingPoliciesTable" xlink:label="tsbx_SignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGross" xlink:label="us-gaap_AccountsReceivableGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCash" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tsbx_SignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountsReceivableGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_SignificantAccountingPoliciesTable" xlink:to="tsbx_SignificantAccountingPoliciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisAtFairValueDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ContingentConsiderationMember" xlink:label="tsbx_ContingentConsiderationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_RestrictedCashAndCashEquivalentsAtFairValue" xlink:label="tsbx_RestrictedCashAndCashEquivalentsAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue" xlink:label="us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="tsbx_ContingentConsiderationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="tsbx_RestrictedCashAndCashEquivalentsAtFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputOfContingentConsiderationValuationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_MeasurementInputLikelihoodOfOccurrenceMember" xlink:label="tsbx_MeasurementInputLikelihoodOfOccurrenceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ContingentConsiderationMember" xlink:label="tsbx_ContingentConsiderationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:label="us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="tsbx_MeasurementInputLikelihoodOfOccurrenceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="tsbx_ContingentConsiderationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDiscountedCashFlowMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysContingentConsiderationMeasuredAtFairValueLevel3Detail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ContingentConsiderationMember" xlink:label="tsbx_ContingentConsiderationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="tsbx_ContingentConsiderationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysCashCashEquivalentsAndAvailableForSaleSecuritiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_FairValueDisclosuresTable" xlink:label="tsbx_FairValueDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_FairValueDisclosuresLineItems" xlink:label="tsbx_FairValueDisclosuresLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_RestrictedCashMember" xlink:label="tsbx_RestrictedCashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="tsbx_FairValueDisclosuresTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_FairValueDisclosuresLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_FairValueDisclosuresTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="tsbx_RestrictedCashMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_FairValueDisclosuresLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_FairValueDisclosuresTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_FairValueDisclosuresLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_FairValueDisclosuresTable" xlink:to="tsbx_FairValueDisclosuresLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_FairValueDisclosuresLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_ShortTermInvestmentsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_FairValueDisclosuresTable" xlink:label="tsbx_FairValueDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_MystMember" xlink:label="tsbx_MystMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_FairValueDisclosuresLineItems" xlink:label="tsbx_FairValueDisclosuresLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_UnpaidLiabilityMilestoneAchievement" xlink:label="tsbx_UnpaidLiabilityMilestoneAchievement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeExtensibleEnumeration" xlink:label="us-gaap_InvestmentTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="tsbx_FairValueDisclosuresTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tsbx_MystMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_FairValueDisclosuresLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_FairValueDisclosuresTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_FairValueDisclosuresLineItems" xlink:to="tsbx_UnpaidLiabilityMilestoneAchievement" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_FairValueDisclosuresTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_FairValueDisclosuresLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_FairValueDisclosuresTable" xlink:to="tsbx_FairValueDisclosuresLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_FairValueDisclosuresLineItems" xlink:to="us-gaap_InvestmentTypeExtensibleEnumeration" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_FairValueDisclosuresLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_FairValueDisclosuresLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_FairValueDisclosuresLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetConsistDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="us-gaap_CapitalizedComputerSoftwareGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="us-gaap_MachineryAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_CapitalizedComputerSoftwareGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_MachineryAndEquipmentGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_FurnitureAndFixturesGross" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_LeaseholdImprovementsGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ResearchAndDevelopmentExpenseLiabilities" xlink:label="tsbx_ResearchAndDevelopmentExpenseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AccruedCompensationCurrent" xlink:label="tsbx_AccruedCompensationCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ContingentConsiderationCurrent" xlink:label="tsbx_ContingentConsiderationCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="tsbx_ResearchAndDevelopmentExpenseLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="tsbx_AccruedCompensationCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="tsbx_ContingentConsiderationCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationLineItems" xlink:label="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationAbstract" xlink:label="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationTable" xlink:label="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationTable"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_PriceModificationAxis" xlink:label="tsbx_PriceModificationAxis"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_PriceModificationDomain" xlink:label="tsbx_PriceModificationDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_DevelopmentProgramMember" xlink:label="tsbx_DevelopmentProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_PricePreModificationMember" xlink:label="tsbx_PricePreModificationMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_DiscoveryProgramMember" xlink:label="tsbx_DiscoveryProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_PriceAtModificationMember" xlink:label="tsbx_PriceAtModificationMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationAbstract" xlink:to="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationTable" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_PriceModificationAxis" xlink:to="tsbx_PriceModificationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProjectMember" xlink:to="tsbx_DevelopmentProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_PriceModificationDomain" xlink:to="tsbx_PricePreModificationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationTable" xlink:to="tsbx_PriceModificationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProjectMember" xlink:to="tsbx_DiscoveryProgramMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_PriceModificationDomain" xlink:to="tsbx_PriceAtModificationMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationTable" xlink:to="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_TakedaAgreementMember" xlink:label="tsbx_TakedaAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="tsbx_TakedaPharmaceuticalCompanyLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_CollaborativeArrangementDisclosureAbstract" xlink:label="tsbx_CollaborativeArrangementDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_MilestoneDomain" xlink:label="tsbx_MilestoneDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SalesBasedMilestonesMember" xlink:label="tsbx_SalesBasedMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_MilestoneAxis" xlink:label="tsbx_MilestoneAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_DevelopmentProgramMember" xlink:label="tsbx_DevelopmentProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AllianceAgreementMember" xlink:label="tsbx_AllianceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_H.LeeMoffittCancerCenterMember" xlink:label="tsbx_H.LeeMoffittCancerCenterMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_FirstMilestonePaymentMember" xlink:label="tsbx_FirstMilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_PercentageOfOperatingProfitOrLoss" xlink:label="tsbx_PercentageOfOperatingProfitOrLoss"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_DiscoveryProgramMember" xlink:label="tsbx_DiscoveryProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SecondMilestonePaymentMember" xlink:label="tsbx_SecondMilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_MilestonePaymentReceivable" xlink:label="tsbx_MilestonePaymentReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ClinicalAndRegulatoryMilestonesOnDevelopmentProgramMember" xlink:label="tsbx_ClinicalAndRegulatoryMilestonesOnDevelopmentProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SalesMilestonesOnDevelopmentProgramMember" xlink:label="tsbx_SalesMilestonesOnDevelopmentProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsFairValueDisclosure" xlink:label="us-gaap_CommitmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ClinicalAndRegulatoryMilestonesOnLicensedDiscoveryProductMember" xlink:label="tsbx_ClinicalAndRegulatoryMilestonesOnLicensedDiscoveryProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SalesMilestonesOnLicensedDiscoveryProductMember" xlink:label="tsbx_SalesMilestonesOnLicensedDiscoveryProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ThirdMilestonePaymentMember" xlink:label="tsbx_ThirdMilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ResearchDevelopmentAndManufacturingServicesAggregateAnnualAmount" xlink:label="tsbx_ResearchDevelopmentAndManufacturingServicesAggregateAnnualAmount"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_CollaborativeArrangementAdditionalConsiderationReceivable" xlink:label="tsbx_CollaborativeArrangementAdditionalConsiderationReceivable"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_CollaborativeArrangementAdditionalConsiderationReceivableForLicensedOption" xlink:label="tsbx_CollaborativeArrangementAdditionalConsiderationReceivableForLicensedOption"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_RevenuePerformanceObligationFixedAggregateConsideration" xlink:label="tsbx_RevenuePerformanceObligationFixedAggregateConsideration"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundableUpfrontPaymentReceived" xlink:label="tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundableUpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundablePaymentReceived" xlink:label="tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundablePaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_EstimatedCompensationEarningFromProjectExpenseSharing" xlink:label="tsbx_EstimatedCompensationEarningFromProjectExpenseSharing"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_CollaborativeArrangementAggregateConsiderationPayable" xlink:label="tsbx_CollaborativeArrangementAggregateConsiderationPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_CollaborativeArrangementAggregateConsiderationRemains" xlink:label="tsbx_CollaborativeArrangementAggregateConsiderationRemains"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ResearchDevelopmentAndManufacturingServicesAmendedToRemoveTrueUpAnnaulInstallment" xlink:label="tsbx_ResearchDevelopmentAndManufacturingServicesAmendedToRemoveTrueUpAnnaulInstallment"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tsbx_TakedaAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tsbx_TakedaPharmaceuticalCompanyLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_CollaborativeArrangementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_MilestoneDomain" xlink:to="tsbx_SalesBasedMilestonesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_MilestoneAxis" xlink:to="tsbx_MilestoneDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromSaleOfIntangibleAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProjectMember" xlink:to="tsbx_DevelopmentProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tsbx_AllianceAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tsbx_H.LeeMoffittCancerCenterMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_MilestoneDomain" xlink:to="tsbx_FirstMilestonePaymentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsbx_PercentageOfOperatingProfitOrLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProjectMember" xlink:to="tsbx_DiscoveryProgramMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_MilestoneDomain" xlink:to="tsbx_SecondMilestonePaymentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsbx_MilestonePaymentReceivable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="tsbx_MilestoneAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_MilestoneDomain" xlink:to="tsbx_ClinicalAndRegulatoryMilestonesOnDevelopmentProgramMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_MilestoneDomain" xlink:to="tsbx_SalesMilestonesOnDevelopmentProgramMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommitmentsFairValueDisclosure" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_AwardTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_MilestoneDomain" xlink:to="tsbx_ClinicalAndRegulatoryMilestonesOnLicensedDiscoveryProductMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_MilestoneDomain" xlink:to="tsbx_SalesMilestonesOnLicensedDiscoveryProductMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_MilestoneDomain" xlink:to="tsbx_ThirdMilestonePaymentMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherReceivables" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsbx_ResearchDevelopmentAndManufacturingServicesAggregateAnnualAmount" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsbx_CollaborativeArrangementAdditionalConsiderationReceivable" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsbx_CollaborativeArrangementAdditionalConsiderationReceivableForLicensedOption" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsbx_RevenuePerformanceObligationFixedAggregateConsideration" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundableUpfrontPaymentReceived" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundablePaymentReceived" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsbx_EstimatedCompensationEarningFromProjectExpenseSharing" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsbx_CollaborativeArrangementAggregateConsiderationPayable" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherCommitment" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsbx_CollaborativeArrangementAggregateConsiderationRemains" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsbx_ResearchDevelopmentAndManufacturingServicesAmendedToRemoveTrueUpAnnaulInstallment" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="us-gaap_AssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_LangerMember" xlink:label="tsbx_LangerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_MystMergerAgreementMember" xlink:label="tsbx_MystMergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_InitialMilestonePaymentMember" xlink:label="tsbx_InitialMilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_MystHoldersMember" xlink:label="tsbx_MystHoldersMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:label="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SecondMilestonePaymentMember" xlink:label="tsbx_SecondMilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_RemainingMystHoldersMember" xlink:label="tsbx_RemainingMystHoldersMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedShares" xlink:label="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ThirdMilestonePaymentMember" xlink:label="tsbx_ThirdMilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuableShares" xlink:label="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuableShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_NumberOfTradingDays" xlink:label="tsbx_NumberOfTradingDays"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ContingentConsiderationPayable" xlink:label="tsbx_ContingentConsiderationPayable"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ContingentConsiderationPayableByShares" xlink:label="tsbx_ContingentConsiderationPayableByShares"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ContingentConsiderationPayableByCash" xlink:label="tsbx_ContingentConsiderationPayableByCash"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_StockIssuedDuringThePeriodForMilestonePaymentsShares" xlink:label="tsbx_StockIssuedDuringThePeriodForMilestonePaymentsShares"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_StockIssuedDuringThePeriodForMilestonePaymentsValue" xlink:label="tsbx_StockIssuedDuringThePeriodForMilestonePaymentsValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="us-gaap_LiabilitiesAssumed1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability" xlink:label="tsbx_AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="us-gaap_AssetAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tsbx_LangerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="tsbx_MystMergerAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="tsbx_InitialMilestonePaymentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tsbx_MystHoldersMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="tsbx_SecondMilestonePaymentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tsbx_RemainingMystHoldersMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AwardTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="tsbx_ThirdMilestonePaymentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuableShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tsbx_NumberOfTradingDays" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tsbx_ContingentConsiderationPayable" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tsbx_ContingentConsiderationPayableByShares" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tsbx_ContingentConsiderationPayableByCash" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tsbx_StockIssuedDuringThePeriodForMilestonePaymentsShares" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tsbx_StockIssuedDuringThePeriodForMilestonePaymentsValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_LiabilitiesAssumed1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_OtherCommitment" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tsbx_AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_PaymentOfLoanFirstAnniversaryClosingDateMember" xlink:label="tsbx_PaymentOfLoanFirstAnniversaryClosingDateMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_DebtInstrumentNonrefundablePrepaymentFeeInFirstAnniversary" xlink:label="tsbx_DebtInstrumentNonrefundablePrepaymentFeeInFirstAnniversary"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_PaymentOfLoanSecondAnniversaryClosingDateMember" xlink:label="tsbx_PaymentOfLoanSecondAnniversaryClosingDateMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_DebtInstrumentNonrefundablePrepaymentFeeInSecondAnniversary" xlink:label="tsbx_DebtInstrumentNonrefundablePrepaymentFeeInSecondAnniversary"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_DebtInstrumentSuccessFeeAmount" xlink:label="tsbx_DebtInstrumentSuccessFeeAmount"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_DebtInstrumentSuccessFeePercentage" xlink:label="tsbx_DebtInstrumentSuccessFeePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_CashProceedsFromTheSaleOfEquitySecuritiesAndOrUpfrontCashProceedsFromStrategicPartnerships" xlink:label="tsbx_CashProceedsFromTheSaleOfEquitySecuritiesAndOrUpfrontCashProceedsFromStrategicPartnerships"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_DebtInstrumentFeeOnEventOfDefault" xlink:label="tsbx_DebtInstrumentFeeOnEventOfDefault"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_LineOfCreditFacilityExtendedDate" xlink:label="tsbx_LineOfCreditFacilityExtendedDate"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments" xlink:label="tsbx_FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LineOfCreditFacilityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_CreditFacilityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="tsbx_PaymentOfLoanFirstAnniversaryClosingDateMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tsbx_DebtInstrumentNonrefundablePrepaymentFeeInFirstAnniversary" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_StatementScenarioAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="tsbx_PaymentOfLoanSecondAnniversaryClosingDateMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tsbx_DebtInstrumentNonrefundablePrepaymentFeeInSecondAnniversary" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tsbx_DebtInstrumentSuccessFeeAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tsbx_DebtInstrumentSuccessFeePercentage" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ProceedsFromRepaymentsOfDebt" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tsbx_CashProceedsFromTheSaleOfEquitySecuritiesAndOrUpfrontCashProceedsFromStrategicPartnerships" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDescription" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tsbx_DebtInstrumentFeeOnEventOfDefault" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tsbx_LineOfCreditFacilityExtendedDate" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tsbx_FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCredit" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesARedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="tsbx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesB1RedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesB1RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesB2RedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesB2RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesCRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesDRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesARedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tsbx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesB1RedeemableConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesB2RedeemableConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesCRedeemableConvertiblePreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesDRedeemableConvertiblePreferredStockMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquitySummaryOfSharesOfCommonStockReservedForFutureIssuanceDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_UnvestedRestrictedStockUnitsMember" xlink:label="tsbx_UnvestedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SharesAvailableForIssuanceUnderEsppMember" xlink:label="tsbx_SharesAvailableForIssuanceUnderEsppMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SharesAvailableForIssuanceUnderPlansMember" xlink:label="tsbx_SharesAvailableForIssuanceUnderPlansMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tsbx_UnvestedRestrictedStockUnitsMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tsbx_SharesAvailableForIssuanceUnderEsppMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tsbx_SharesAvailableForIssuanceUnderPlansMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_TwoThousandAndEighteenEquityIncentivePlanMember" xlink:label="tsbx_TwoThousandAndEighteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityTable" xlink:label="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:label="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_18"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tsbx_TwoThousandAndEighteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityTable" xlink:to="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_18" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfFairValueAssumptionOfStockOptionActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:label="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:label="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:to="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRsuActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:label="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfStockBasedCompensationForStockAwardsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_TwoThousandAndEighteenEquityIncentivePlanMember" xlink:label="tsbx_TwoThousandAndEighteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_TimothyLangerMember" xlink:label="tsbx_TimothyLangerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_MystMergerAgreementMember" xlink:label="tsbx_MystMergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_TwoThousandAndTwentyThreeEquityIncentivePlanMember" xlink:label="tsbx_TwoThousandAndTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_EmployeeStockPurchasePlanMember" xlink:label="tsbx_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_NewSharesUnderTwoThousandTwentyThreeMember" xlink:label="tsbx_NewSharesUnderTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_RemainingSharesFromTwoThousandEighteenPlanMember" xlink:label="tsbx_RemainingSharesFromTwoThousandEighteenPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ReturningSharesMember" xlink:label="tsbx_ReturningSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_MaximumTermOfOptionsUnderEquityIncentivePlan" xlink:label="tsbx_MaximumTermOfOptionsUnderEquityIncentivePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ShareBasedCompensationArrangementAverageGrantDateFairValue" xlink:label="tsbx_ShareBasedCompensationArrangementAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_CommonStockCapitalSharesReservedForFutureIssuanceIncreaseDecreasePeriod" xlink:label="tsbx_CommonStockCapitalSharesReservedForFutureIssuanceIncreaseDecreasePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tsbx_TwoThousandAndEighteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tsbx_TimothyLangerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tsbx_MystMergerAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tsbx_TwoThousandAndTwentyThreeEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tsbx_EmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tsbx_NewSharesUnderTwoThousandTwentyThreeMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tsbx_RemainingSharesFromTwoThousandEighteenPlanMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tsbx_ReturningSharesMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="tsbx_MaximumTermOfOptionsUnderEquityIncentivePlan" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="tsbx_ShareBasedCompensationArrangementAverageGrantDateFairValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="tsbx_CommonStockCapitalSharesReservedForFutureIssuanceIncreaseDecreasePeriod" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/IncomeTaxesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ProvisionBenefitForIncomeTaxes" xlink:label="tsbx_ProvisionBenefitForIncomeTaxes"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="tsbx_ProvisionBenefitForIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/LeasesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AgreementAxis" xlink:label="tsbx_AgreementAxis"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AgreementDomain" xlink:label="tsbx_AgreementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_NumberOfSquareFeetForLease" xlink:label="tsbx_NumberOfSquareFeetForLease"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_OperatingLeaseAgreementMember" xlink:label="tsbx_OperatingLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_OfficeSpaceMember" xlink:label="tsbx_OfficeSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_LaboratorySpaceMember" xlink:label="tsbx_LaboratorySpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_OfficeAndLaboratorySpaceMember" xlink:label="tsbx_OfficeAndLaboratorySpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_AgreementAxis" xlink:to="tsbx_AgreementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="tsbx_NumberOfSquareFeetForLease" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_AgreementDomain" xlink:to="tsbx_OperatingLeaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tsbx_OfficeSpaceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="tsbx_AgreementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tsbx_LaboratorySpaceMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tsbx_OfficeAndLaboratorySpaceMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForRent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfInformationAboutLeaseCostsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ShortTermLeaseCosts" xlink:label="tsbx_ShortTermLeaseCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="tsbx_ShortTermLeaseCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_SubleaseIncome" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfPresentValueOfOperatingLeasePaymentsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfPresentValueOfOperatingLeasePaymentsAbstract" xlink:label="tsbx_ScheduleOfPresentValueOfOperatingLeasePaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfPresentValueOfOperatingLeasePaymentsAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tsbx_ScheduleOfPresentValueOfOperatingLeasePaymentsAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_OptionsToPurchaseCommonStockMember" xlink:label="tsbx_OptionsToPurchaseCommonStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="tsbx_OptionsToPurchaseCommonStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/LegalProceedingsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_LossContingencyReserveForLitigationLiabilities" xlink:label="tsbx_LossContingencyReserveForLitigationLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="tsbx_LossContingencyReserveForLitigationLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationDocumentAxis" xlink:label="dei_DocumentInformationDocumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentDomain" xlink:label="dei_DocumentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentDomain" xlink:label="dei_DocumentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationDocumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_DocumentInformationDocumentAxis" xlink:to="dei_DocumentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_DocumentInformationDocumentAxis" xlink:to="dei_DocumentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesARedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesB1RedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesB1RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesB2RedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesB2RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesCRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesDRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesARedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesB1RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesB2RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesCRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesDRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesARedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesB1RedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesB1RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesB2RedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesB2RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesCRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement" xlink:label="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesDRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesARedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesB1RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesB2RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesCRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesDRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesB1RedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesB1RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesB2RedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesB2RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_StockIssuedDuringPeriodSharesNewIssuesOnMilestoneAchievement" xlink:label="tsbx_StockIssuedDuringPeriodSharesNewIssuesOnMilestoneAchievement"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_StockIssuedDuringPeriodValueNewIssuesOnMilestoneAchievement" xlink:label="tsbx_StockIssuedDuringPeriodValueNewIssuesOnMilestoneAchievement"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_StockIssuedDuringPeriodSharesMoffittPerformanceBasedCommonStockAward" xlink:label="tsbx_StockIssuedDuringPeriodSharesMoffittPerformanceBasedCommonStockAward"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_StockIssuedDuringPeriodValueMoffittPerformanceBasedCommonStockAward" xlink:label="tsbx_StockIssuedDuringPeriodValueMoffittPerformanceBasedCommonStockAward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesB1RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesB2RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tsbx_StockIssuedDuringPeriodSharesNewIssuesOnMilestoneAchievement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tsbx_StockIssuedDuringPeriodValueNewIssuesOnMilestoneAchievement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tsbx_StockIssuedDuringPeriodSharesMoffittPerformanceBasedCommonStockAward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tsbx_StockIssuedDuringPeriodValueMoffittPerformanceBasedCommonStockAward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AccretionOfRedeemableConvertiblePreferredStock" xlink:label="tsbx_AccretionOfRedeemableConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_EquipmentPurchasesIncludedInAccruedExpenses" xlink:label="tsbx_EquipmentPurchasesIncludedInAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_DeferredIpoCostsIncludedInAccruedExpenses" xlink:label="tsbx_DeferredIpoCostsIncludedInAccruedExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AccretionOfPremiumOnShortTermInvestments" xlink:label="tsbx_AccretionOfPremiumOnShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_IncreaseDecreaseInContingentConsiderationLiability" xlink:label="tsbx_IncreaseDecreaseInContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_IncreaseDecreaseInAccruedCompensationAndOtherAccruedLiabilities" xlink:label="tsbx_IncreaseDecreaseInAccruedCompensationAndOtherAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="tsbx_AccretionOfRedeemableConvertiblePreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="tsbx_EquipmentPurchasesIncludedInAccruedExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="tsbx_DeferredIpoCostsIncludedInAccruedExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="tsbx_AccretionOfPremiumOnShortTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="tsbx_IncreaseDecreaseInContingentConsiderationLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="tsbx_IncreaseDecreaseInAccruedCompensationAndOtherAccruedLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:label="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_BusinessDescriptionAndBasisOfPresentationTable" xlink:label="tsbx_BusinessDescriptionAndBasisOfPresentationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_UnderwritingDiscountsAndCommissions" xlink:label="tsbx_UnderwritingDiscountsAndCommissions"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_OtherOfferingExpenses" xlink:label="tsbx_OtherOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SharesAuthorized" xlink:label="tsbx_SharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments" xlink:label="tsbx_FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="tsbx_BusinessDescriptionAndBasisOfPresentationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="tsbx_UnderwritingDiscountsAndCommissions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="tsbx_OtherOfferingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="tsbx_SharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="tsbx_FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SignificantAccountingPoliciesLineItems" xlink:label="tsbx_SignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SignificantAccountingPoliciesTable" xlink:label="tsbx_SignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGross" xlink:label="us-gaap_AccountsReceivableGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tsbx_SignificantAccountingPoliciesLineItems" xlink:to="tsbx_SignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tsbx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountsReceivableGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tsbx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredOfferingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisAtFairValueDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ContingentConsiderationMember" xlink:label="tsbx_ContingentConsiderationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_RestrictedCashAndCashEquivalentsAtFairValue" xlink:label="tsbx_RestrictedCashAndCashEquivalentsAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue" xlink:label="us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="tsbx_ContingentConsiderationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="tsbx_RestrictedCashAndCashEquivalentsAtFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputOfContingentConsiderationValuationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_MeasurementInputLikelihoodOfOccurrenceMember" xlink:label="tsbx_MeasurementInputLikelihoodOfOccurrenceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ContingentConsiderationMember" xlink:label="tsbx_ContingentConsiderationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:label="us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="tsbx_MeasurementInputLikelihoodOfOccurrenceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="tsbx_ContingentConsiderationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDiscountedCashFlowMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ValuationTechniqueAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysContingentConsiderationMeasuredAtFairValueLevel3Detail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ContingentConsiderationMember" xlink:label="tsbx_ContingentConsiderationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="tsbx_ContingentConsiderationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysCashCashEquivalentsAndAvailableForSaleSecuritiesDetail">
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_FairValueDisclosuresLineItems" xlink:label="tsbx_FairValueDisclosuresLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_FairValueDisclosuresTable" xlink:label="tsbx_FairValueDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_RestrictedCashMember" xlink:label="tsbx_RestrictedCashMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tsbx_FairValueDisclosuresLineItems" xlink:to="tsbx_FairValueDisclosuresTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_FairValueDisclosuresLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tsbx_FairValueDisclosuresTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="tsbx_RestrictedCashMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_FairValueDisclosuresLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tsbx_FairValueDisclosuresTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_FairValueDisclosuresLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_FairValueDisclosuresLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_ShortTermInvestmentsMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_FairValueDisclosuresLineItems" xlink:label="tsbx_FairValueDisclosuresLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_FairValueDisclosuresTable" xlink:label="tsbx_FairValueDisclosuresTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_MystMember" xlink:label="tsbx_MystMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_UnpaidLiabilityMilestoneAchievement" xlink:label="tsbx_UnpaidLiabilityMilestoneAchievement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeExtensibleEnumeration" xlink:label="us-gaap_InvestmentTypeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tsbx_FairValueDisclosuresLineItems" xlink:to="tsbx_FairValueDisclosuresTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tsbx_MystMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_FairValueDisclosuresLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tsbx_FairValueDisclosuresTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_FairValueDisclosuresLineItems" xlink:to="tsbx_UnpaidLiabilityMilestoneAchievement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tsbx_FairValueDisclosuresTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_FairValueDisclosuresLineItems" xlink:to="us-gaap_AssetImpairmentCharges" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_FairValueDisclosuresLineItems" xlink:to="us-gaap_InvestmentTypeExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_FairValueDisclosuresLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_FairValueDisclosuresLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_FairValueDisclosuresLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetConsistDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="us-gaap_CapitalizedComputerSoftwareGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="us-gaap_MachineryAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_CapitalizedComputerSoftwareGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_MachineryAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_FurnitureAndFixturesGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_LeaseholdImprovementsGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationDetail">
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationLineItems" xlink:label="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationTable" xlink:label="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_PriceModificationAxis" xlink:label="tsbx_PriceModificationAxis"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_PriceModificationDomain" xlink:label="tsbx_PriceModificationDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_PriceModificationDomain" xlink:label="tsbx_PriceModificationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_DevelopmentProgramMember" xlink:label="tsbx_DevelopmentProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_PricePreModificationMember" xlink:label="tsbx_PricePreModificationMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_DiscoveryProgramMember" xlink:label="tsbx_DiscoveryProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_PriceAtModificationMember" xlink:label="tsbx_PriceAtModificationMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationLineItems" xlink:to="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationTable" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tsbx_PriceModificationAxis" xlink:to="tsbx_PriceModificationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="tsbx_PriceModificationAxis" xlink:to="tsbx_PriceModificationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProjectMember" xlink:to="tsbx_DevelopmentProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_PriceModificationDomain" xlink:to="tsbx_PricePreModificationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationTable" xlink:to="tsbx_PriceModificationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProjectMember" xlink:to="tsbx_DiscoveryProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_PriceModificationDomain" xlink:to="tsbx_PriceAtModificationMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_TakedaAgreementMember" xlink:label="tsbx_TakedaAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProjectMember" xlink:label="us-gaap_ProjectMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="tsbx_TakedaPharmaceuticalCompanyLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" xlink:label="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_MilestoneDomain" xlink:label="tsbx_MilestoneDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SalesBasedMilestonesMember" xlink:label="tsbx_SalesBasedMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_MilestoneAxis" xlink:label="tsbx_MilestoneAxis"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_MilestoneDomain" xlink:label="tsbx_MilestoneDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_DevelopmentProgramMember" xlink:label="tsbx_DevelopmentProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AllianceAgreementMember" xlink:label="tsbx_AllianceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_H.LeeMoffittCancerCenterMember" xlink:label="tsbx_H.LeeMoffittCancerCenterMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_FirstMilestonePaymentMember" xlink:label="tsbx_FirstMilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_PercentageOfOperatingProfitOrLoss" xlink:label="tsbx_PercentageOfOperatingProfitOrLoss"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_DiscoveryProgramMember" xlink:label="tsbx_DiscoveryProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SecondMilestonePaymentMember" xlink:label="tsbx_SecondMilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_MilestonePaymentReceivable" xlink:label="tsbx_MilestonePaymentReceivable"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ClinicalAndRegulatoryMilestonesOnDevelopmentProgramMember" xlink:label="tsbx_ClinicalAndRegulatoryMilestonesOnDevelopmentProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SalesMilestonesOnDevelopmentProgramMember" xlink:label="tsbx_SalesMilestonesOnDevelopmentProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsFairValueDisclosure" xlink:label="us-gaap_CommitmentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ClinicalAndRegulatoryMilestonesOnLicensedDiscoveryProductMember" xlink:label="tsbx_ClinicalAndRegulatoryMilestonesOnLicensedDiscoveryProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SalesMilestonesOnLicensedDiscoveryProductMember" xlink:label="tsbx_SalesMilestonesOnLicensedDiscoveryProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ThirdMilestonePaymentMember" xlink:label="tsbx_ThirdMilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:label="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherReceivables" xlink:label="us-gaap_OtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ResearchDevelopmentAndManufacturingServicesAggregateAnnualAmount" xlink:label="tsbx_ResearchDevelopmentAndManufacturingServicesAggregateAnnualAmount"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_CollaborativeArrangementAdditionalConsiderationReceivable" xlink:label="tsbx_CollaborativeArrangementAdditionalConsiderationReceivable"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_CollaborativeArrangementAdditionalConsiderationReceivableForLicensedOption" xlink:label="tsbx_CollaborativeArrangementAdditionalConsiderationReceivableForLicensedOption"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_RevenuePerformanceObligationFixedAggregateConsideration" xlink:label="tsbx_RevenuePerformanceObligationFixedAggregateConsideration"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundableUpfrontPaymentReceived" xlink:label="tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundableUpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundablePaymentReceived" xlink:label="tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundablePaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_EstimatedCompensationEarningFromProjectExpenseSharing" xlink:label="tsbx_EstimatedCompensationEarningFromProjectExpenseSharing"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_CollaborativeArrangementAggregateConsiderationPayable" xlink:label="tsbx_CollaborativeArrangementAggregateConsiderationPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_CollaborativeArrangementAggregateConsiderationRemains" xlink:label="tsbx_CollaborativeArrangementAggregateConsiderationRemains"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ResearchDevelopmentAndManufacturingServicesAmendedToRemoveTrueUpAnnaulInstallment" xlink:label="tsbx_ResearchDevelopmentAndManufacturingServicesAmendedToRemoveTrueUpAnnaulInstallment"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tsbx_TakedaAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_ProjectMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tsbx_TakedaPharmaceuticalCompanyLimitedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_MilestoneDomain" xlink:to="tsbx_SalesBasedMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tsbx_MilestoneAxis" xlink:to="tsbx_MilestoneDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="tsbx_MilestoneAxis" xlink:to="tsbx_MilestoneDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromSaleOfIntangibleAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProjectMember" xlink:to="tsbx_DevelopmentProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tsbx_AllianceAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tsbx_H.LeeMoffittCancerCenterMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_MilestoneDomain" xlink:to="tsbx_FirstMilestonePaymentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsbx_PercentageOfOperatingProfitOrLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProjectMember" xlink:to="tsbx_DiscoveryProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_MilestoneDomain" xlink:to="tsbx_SecondMilestonePaymentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsbx_MilestonePaymentReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="tsbx_MilestoneAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_MilestoneDomain" xlink:to="tsbx_ClinicalAndRegulatoryMilestonesOnDevelopmentProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_MilestoneDomain" xlink:to="tsbx_SalesMilestonesOnDevelopmentProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommitmentsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_MilestoneDomain" xlink:to="tsbx_ClinicalAndRegulatoryMilestonesOnLicensedDiscoveryProductMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_MilestoneDomain" xlink:to="tsbx_SalesMilestonesOnLicensedDiscoveryProductMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_MilestoneDomain" xlink:to="tsbx_ThirdMilestonePaymentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherReceivables" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsbx_ResearchDevelopmentAndManufacturingServicesAggregateAnnualAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsbx_CollaborativeArrangementAdditionalConsiderationReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsbx_CollaborativeArrangementAdditionalConsiderationReceivableForLicensedOption" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsbx_RevenuePerformanceObligationFixedAggregateConsideration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundableUpfrontPaymentReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundablePaymentReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsbx_EstimatedCompensationEarningFromProjectExpenseSharing" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsbx_CollaborativeArrangementAggregateConsiderationPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherCommitment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsbx_CollaborativeArrangementAggregateConsiderationRemains" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tsbx_ResearchDevelopmentAndManufacturingServicesAmendedToRemoveTrueUpAnnaulInstallment" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_LangerMember" xlink:label="tsbx_LangerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_MystMergerAgreementMember" xlink:label="tsbx_MystMergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_InitialMilestonePaymentMember" xlink:label="tsbx_InitialMilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_MystHoldersMember" xlink:label="tsbx_MystHoldersMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" xlink:label="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SecondMilestonePaymentMember" xlink:label="tsbx_SecondMilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_RemainingMystHoldersMember" xlink:label="tsbx_RemainingMystHoldersMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedShares" xlink:label="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedShares"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ThirdMilestonePaymentMember" xlink:label="tsbx_ThirdMilestonePaymentMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuableShares" xlink:label="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuableShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_NumberOfTradingDays" xlink:label="tsbx_NumberOfTradingDays"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ContingentConsiderationPayable" xlink:label="tsbx_ContingentConsiderationPayable"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ContingentConsiderationPayableByShares" xlink:label="tsbx_ContingentConsiderationPayableByShares"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ContingentConsiderationPayableByCash" xlink:label="tsbx_ContingentConsiderationPayableByCash"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_StockIssuedDuringThePeriodForMilestonePaymentsShares" xlink:label="tsbx_StockIssuedDuringThePeriodForMilestonePaymentsShares"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_StockIssuedDuringThePeriodForMilestonePaymentsValue" xlink:label="tsbx_StockIssuedDuringThePeriodForMilestonePaymentsValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="us-gaap_LiabilitiesAssumed1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment" xlink:label="us-gaap_OtherCommitment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability" xlink:label="tsbx_AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tsbx_LangerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="tsbx_MystMergerAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="tsbx_InitialMilestonePaymentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tsbx_MystHoldersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="tsbx_SecondMilestonePaymentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="tsbx_RemainingMystHoldersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="tsbx_ThirdMilestonePaymentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuableShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tsbx_NumberOfTradingDays" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tsbx_ContingentConsiderationPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tsbx_ContingentConsiderationPayableByShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tsbx_ContingentConsiderationPayableByCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tsbx_StockIssuedDuringThePeriodForMilestonePaymentsShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tsbx_StockIssuedDuringThePeriodForMilestonePaymentsValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_LiabilitiesAssumed1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_OtherCommitment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="tsbx_AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_PaymentOfLoanFirstAnniversaryClosingDateMember" xlink:label="tsbx_PaymentOfLoanFirstAnniversaryClosingDateMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_DebtInstrumentNonrefundablePrepaymentFeeInFirstAnniversary" xlink:label="tsbx_DebtInstrumentNonrefundablePrepaymentFeeInFirstAnniversary"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_PaymentOfLoanSecondAnniversaryClosingDateMember" xlink:label="tsbx_PaymentOfLoanSecondAnniversaryClosingDateMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_DebtInstrumentNonrefundablePrepaymentFeeInSecondAnniversary" xlink:label="tsbx_DebtInstrumentNonrefundablePrepaymentFeeInSecondAnniversary"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_DebtInstrumentSuccessFeeAmount" xlink:label="tsbx_DebtInstrumentSuccessFeeAmount"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_DebtInstrumentSuccessFeePercentage" xlink:label="tsbx_DebtInstrumentSuccessFeePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRepaymentsOfDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_CashProceedsFromTheSaleOfEquitySecuritiesAndOrUpfrontCashProceedsFromStrategicPartnerships" xlink:label="tsbx_CashProceedsFromTheSaleOfEquitySecuritiesAndOrUpfrontCashProceedsFromStrategicPartnerships"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityInterestRateDescription" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_DebtInstrumentFeeOnEventOfDefault" xlink:label="tsbx_DebtInstrumentFeeOnEventOfDefault"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityExpirationDate1" xlink:label="us-gaap_LineOfCreditFacilityExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_LineOfCreditFacilityExtendedDate" xlink:label="tsbx_LineOfCreditFacilityExtendedDate"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments" xlink:label="tsbx_FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_RevolvingCreditFacilityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="tsbx_PaymentOfLoanFirstAnniversaryClosingDateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tsbx_DebtInstrumentNonrefundablePrepaymentFeeInFirstAnniversary" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="tsbx_PaymentOfLoanSecondAnniversaryClosingDateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tsbx_DebtInstrumentNonrefundablePrepaymentFeeInSecondAnniversary" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tsbx_DebtInstrumentSuccessFeeAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tsbx_DebtInstrumentSuccessFeePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_ProceedsFromRepaymentsOfDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tsbx_CashProceedsFromTheSaleOfEquitySecuritiesAndOrUpfrontCashProceedsFromStrategicPartnerships" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tsbx_DebtInstrumentFeeOnEventOfDefault" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityExpirationDate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tsbx_LineOfCreditFacilityExtendedDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="tsbx_FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCredit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesARedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="tsbx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesB1RedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesB1RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesB2RedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesB2RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesCRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SeriesDRedeemableConvertiblePreferredStockMember" xlink:label="tsbx_SeriesDRedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesARedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tsbx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesB1RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesB2RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesCRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tsbx_SeriesDRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquitySummaryOfSharesOfCommonStockReservedForFutureIssuanceDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_UnvestedRestrictedStockUnitsMember" xlink:label="tsbx_UnvestedRestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SharesAvailableForIssuanceUnderEsppMember" xlink:label="tsbx_SharesAvailableForIssuanceUnderEsppMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_SharesAvailableForIssuanceUnderPlansMember" xlink:label="tsbx_SharesAvailableForIssuanceUnderPlansMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tsbx_UnvestedRestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tsbx_SharesAvailableForIssuanceUnderEsppMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tsbx_SharesAvailableForIssuanceUnderPlansMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail">
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:label="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityTable" xlink:label="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_TwoThousandAndEighteenEquityIncentivePlanMember" xlink:label="tsbx_TwoThousandAndEighteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tsbx_TwoThousandAndEighteenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfFairValueAssumptionOfStockOptionActivityDetail">
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:label="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:label="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRsuActivityDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:label="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfStockBasedCompensationForStockAwardsDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_TwoThousandAndEighteenEquityIncentivePlanMember" xlink:label="tsbx_TwoThousandAndEighteenEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_TimothyLangerMember" xlink:label="tsbx_TimothyLangerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_MystMergerAgreementMember" xlink:label="tsbx_MystMergerAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_TwoThousandAndTwentyThreeEquityIncentivePlanMember" xlink:label="tsbx_TwoThousandAndTwentyThreeEquityIncentivePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_NewSharesUnderTwoThousandTwentyThreeMember" xlink:label="tsbx_NewSharesUnderTwoThousandTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_EmployeeStockPurchasePlanMember" xlink:label="tsbx_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_RemainingSharesFromTwoThousandEighteenPlanMember" xlink:label="tsbx_RemainingSharesFromTwoThousandEighteenPlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ReturningSharesMember" xlink:label="tsbx_ReturningSharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_MaximumTermOfOptionsUnderEquityIncentivePlan" xlink:label="tsbx_MaximumTermOfOptionsUnderEquityIncentivePlan"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ShareBasedCompensationArrangementAverageGrantDateFairValue" xlink:label="tsbx_ShareBasedCompensationArrangementAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_CommonStockCapitalSharesReservedForFutureIssuanceIncreaseDecreasePeriod" xlink:label="tsbx_CommonStockCapitalSharesReservedForFutureIssuanceIncreaseDecreasePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tsbx_TwoThousandAndEighteenEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="tsbx_TimothyLangerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tsbx_MystMergerAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tsbx_TwoThousandAndTwentyThreeEquityIncentivePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tsbx_NewSharesUnderTwoThousandTwentyThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tsbx_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tsbx_RemainingSharesFromTwoThousandEighteenPlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tsbx_ReturningSharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="tsbx_MaximumTermOfOptionsUnderEquityIncentivePlan" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="tsbx_ShareBasedCompensationArrangementAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="tsbx_CommonStockCapitalSharesReservedForFutureIssuanceIncreaseDecreasePeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/LeasesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AgreementAxis" xlink:label="tsbx_AgreementAxis"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AgreementDomain" xlink:label="tsbx_AgreementDomain"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AgreementDomain" xlink:label="tsbx_AgreementDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_NumberOfSquareFeetForLease" xlink:label="tsbx_NumberOfSquareFeetForLease"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_OperatingLeaseAgreementMember" xlink:label="tsbx_OperatingLeaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_OfficeSpaceMember" xlink:label="tsbx_OfficeSpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_LaboratorySpaceMember" xlink:label="tsbx_LaboratorySpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="us-gaap_OperatingLeaseImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_OfficeAndLaboratorySpaceMember" xlink:label="tsbx_OfficeAndLaboratorySpaceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tsbx_AgreementAxis" xlink:to="tsbx_AgreementDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="tsbx_AgreementAxis" xlink:to="tsbx_AgreementDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="tsbx_NumberOfSquareFeetForLease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tsbx_AgreementDomain" xlink:to="tsbx_OperatingLeaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tsbx_OfficeSpaceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="tsbx_AgreementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tsbx_LaboratorySpaceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseImpairmentLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tsbx_OfficeAndLaboratorySpaceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForRent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_OptionsToPurchaseCommonStockMember" xlink:label="tsbx_OptionsToPurchaseCommonStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="tsbx_OptionsToPurchaseCommonStockMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="us-gaap_ShortTermInvestmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdateTransitionMethodAbstract" xlink:label="us-gaap_AccountingStandardsUpdateTransitionMethodAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingStandardsUpdateTransitionMethodAbstract" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount" xlink:label="us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureLeasesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetail2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureLeasesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetail3">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfFinancingCosts" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tsbx_AccretionOfPremiumOnShortTermInvestments" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="11" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="14" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="15" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tsbx_IncreaseDecreaseInContingentConsiderationLiability" order="16" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tsbx_IncreaseDecreaseInAccruedCompensationAndOtherAccruedLiabilities" order="17" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="18" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="19" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:label="us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AccretionOfPremiumOnShortTermInvestments" xlink:label="tsbx_AccretionOfPremiumOnShortTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_IncreaseDecreaseInContingentConsiderationLiability" xlink:label="tsbx_IncreaseDecreaseInContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_IncreaseDecreaseInAccruedCompensationAndOtherAccruedLiabilities" xlink:label="tsbx_IncreaseDecreaseInAccruedCompensationAndOtherAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisAtFairValueDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="tsbx_RestrictedCashAndCashEquivalentsAtFairValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_RestrictedCashAndCashEquivalentsAtFairValue" xlink:label="tsbx_RestrictedCashAndCashEquivalentsAtFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue" xlink:label="us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetConsistDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_CapitalizedComputerSoftwareGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_MachineryAndEquipmentGross" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_FurnitureAndFixturesGross" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_LeaseholdImprovementsGross" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="us-gaap_CapitalizedComputerSoftwareGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="us-gaap_MachineryAndEquipmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="tsbx_AccruedCompensationCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="tsbx_ContingentConsiderationCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="tsbx_ResearchAndDevelopmentExpenseLiabilities" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_AccruedCompensationCurrent" xlink:label="tsbx_AccruedCompensationCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ContingentConsiderationCurrent" xlink:label="tsbx_ContingentConsiderationCurrent"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ResearchAndDevelopmentExpenseLiabilities" xlink:label="tsbx_ResearchAndDevelopmentExpenseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfInformationAboutLeaseCostsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="tsbx_ShortTermLeaseCosts" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_SubleaseIncome" order="3" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="tsbx-20240630.xsd#tsbx_ShortTermLeaseCosts" xlink:label="tsbx_ShortTermLeaseCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="tsbx_RemainingSharesFromTwoThousandEighteenPlanMember" name="RemainingSharesFromTwoThousandEighteenPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_FairValueDisclosuresTable" name="FairValueDisclosuresTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_ContingentConsiderationCurrent" name="ContingentConsiderationCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tsbx_CollaborativeArrangementDisclosureAbstract" name="CollaborativeArrangementDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_DebtInstrumentNonrefundablePrepaymentFeeInFirstAnniversary" name="DebtInstrumentNonrefundablePrepaymentFeeInFirstAnniversary" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tsbx_PricePreModificationMember" name="PricePreModificationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_SecondMilestonePaymentMember" name="SecondMilestonePaymentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_OperatingLeaseAgreementMember" name="OperatingLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundablePaymentReceived" name="RevenuePerformanceObligationFixedConsiderationNonRefundablePaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tsbx_SeriesARedeemableConvertiblePreferredStockMember" name="SeriesARedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_MeasurementInputLikelihoodOfOccurrenceMember" name="MeasurementInputLikelihoodOfOccurrenceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_LangerMember" name="LangerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_CollaborativeArrangementAdditionalConsiderationReceivable" name="CollaborativeArrangementAdditionalConsiderationReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tsbx_BusinessDescriptionAndBasisOfPresentationTable" name="BusinessDescriptionAndBasisOfPresentationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_ShareBasedCompensationArrangementAverageGrantDateFairValue" name="ShareBasedCompensationArrangementAverageGrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tsbx_ReturningSharesMember" name="ReturningSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_LineOfCreditFacilityExtendedDate" name="LineOfCreditFacilityExtendedDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tsbx_TwoThousandAndEighteenEquityIncentivePlanMember" name="TwoThousandAndEighteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" name="ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tsbx_DeferredIpoCostsIncludedInAccruedExpenses" name="DeferredIpoCostsIncludedInAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tsbx_MilestoneAxis" name="MilestoneAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_ContingentConsiderationPolicyPolicyTextBlock" name="ContingentConsiderationPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tsbx_AccruedCompensationCurrent" name="AccruedCompensationCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tsbx_RestrictedCashAndInvestmentsPolicyPolicyTextBlock" name="RestrictedCashAndInvestmentsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tsbx_MystMember" name="MystMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_ContingentConsiderationPayableByShares" name="ContingentConsiderationPayableByShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tsbx_DebtInstrumentSuccessFeeAmount" name="DebtInstrumentSuccessFeeAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tsbx_SharesAuthorized" name="SharesAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationAbstract" name="ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" name="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_AgreementsAbstract" name="AgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_RemainingMystHoldersMember" name="RemainingMystHoldersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_ScheduleOfPresentValueOfOperatingLeasePaymentsAbstract" name="ScheduleOfPresentValueOfOperatingLeasePaymentsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability" name="AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tsbx_IncreaseDecreaseInContingentConsiderationLiability" name="IncreaseDecreaseInContingentConsiderationLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tsbx_CompanyCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryTableTextBlock" name="CompanyCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tsbx_DebtInstrumentFeeOnEventOfDefault" name="DebtInstrumentFeeOnEventOfDefault" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tsbx_PaymentOfLoanFirstAnniversaryClosingDateMember" name="PaymentOfLoanFirstAnniversaryClosingDateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_DebtInstrumentNonrefundablePrepaymentFeeInSecondAnniversary" name="DebtInstrumentNonrefundablePrepaymentFeeInSecondAnniversary" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tsbx_UnvestedRestrictedStockUnitsMember" name="UnvestedRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_UnderwritingDiscountsAndCommissions" name="UnderwritingDiscountsAndCommissions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tsbx_OfficeSpaceMember" name="OfficeSpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_ContingentConsiderationMember" name="ContingentConsiderationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_SeriesCRedeemableConvertiblePreferredStockMember" name="SeriesCRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_StockIssuedDuringThePeriodForMilestonePaymentsShares" name="StockIssuedDuringThePeriodForMilestonePaymentsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tsbx_FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments" name="FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tsbx_OtherOfferingExpenses" name="OtherOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tsbx_PercentageOfOperatingProfitOrLoss" name="PercentageOfOperatingProfitOrLoss" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tsbx_OfficeAndLaboratorySpaceMember" name="OfficeAndLaboratorySpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_ThirdMilestonePaymentMember" name="ThirdMilestonePaymentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_StockIssuedDuringPeriodSharesMoffittPerformanceBasedCommonStockAward" name="StockIssuedDuringPeriodSharesMoffittPerformanceBasedCommonStockAward" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tsbx_OptionsToPurchaseCommonStockMember" name="OptionsToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_IncreaseDecreaseInAccruedCompensationAndOtherAccruedLiabilities" name="IncreaseDecreaseInAccruedCompensationAndOtherAccruedLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tsbx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" name="ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tsbx_BusinessDescriptionAndBasisOfPresentationAbstract" name="BusinessDescriptionAndBasisOfPresentationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_RevenuePerformanceObligationFixedAggregateConsideration" name="RevenuePerformanceObligationFixedAggregateConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tsbx_SalesMilestonesOnDevelopmentProgramMember" name="SalesMilestonesOnDevelopmentProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_AccretionOfRedeemableConvertiblePreferredStock" name="AccretionOfRedeemableConvertiblePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tsbx_AllianceAgreementMember" name="AllianceAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_SharesAvailableForIssuanceUnderEsppMember" name="SharesAvailableForIssuanceUnderEsppMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_SignificantAccountingPoliciesLineItems" name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_SalesBasedMilestonesMember" name="SalesBasedMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_MilestonePaymentReceivable" name="MilestonePaymentReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tsbx_SeriesB2RedeemableConvertiblePreferredStockMember" name="SeriesB2RedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_TakedaAgreementMember" name="TakedaAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock" name="RedeemableConvertiblePreferredStockPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityTable" name="ScheduleOfShareBasedCompensationStockOptionsActivityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationLineItems" name="ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_TakedaPharmaceuticalCompanyLimitedMember" name="TakedaPharmaceuticalCompanyLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_NumberOfSquareFeetForLease" name="NumberOfSquareFeetForLease" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tsbx_AgreementDomain" name="AgreementDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_SignificantAccountingPoliciesPolicyPolicyTextBlock" name="SignificantAccountingPoliciesPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tsbx_ContingentConsiderationPayableByCash" name="ContingentConsiderationPayableByCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tsbx_PaymentOfLoanSecondAnniversaryClosingDateMember" name="PaymentOfLoanSecondAnniversaryClosingDateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_CollaborativeArrangementAggregateConsiderationPayable" name="CollaborativeArrangementAggregateConsiderationPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tsbx_MilestoneDomain" name="MilestoneDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_FirstMilestonePaymentMember" name="FirstMilestonePaymentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" name="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_NewSharesUnderTwoThousandTwentyThreeMember" name="NewSharesUnderTwoThousandTwentyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_InitialMilestonePaymentMember" name="InitialMilestonePaymentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_FairValueOfCommonStockPolicyPolicyTextBlock" name="FairValueOfCommonStockPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tsbx_ScheduleOfPresentValueOfOperatingLeasePayments" name="ScheduleOfPresentValueOfOperatingLeasePayments" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" name="ScheduleOfShareBasedCompensationStockOptionsActivityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_AccretionOfPremiumOnShortTermInvestments" name="AccretionOfPremiumOnShortTermInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tsbx_PriceAtModificationMember" name="PriceAtModificationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_DisclosureOfAccruedExpensesAndOtherCurrentLiabilitiesTextBlock" name="DisclosureOfAccruedExpensesAndOtherCurrentLiabilitiesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tsbx_TimothyLangerMember" name="TimothyLangerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_TwoThousandAndTwentyThreeEquityIncentivePlanMember" name="TwoThousandAndTwentyThreeEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_DebtInstrumentSuccessFeePercentage" name="DebtInstrumentSuccessFeePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tsbx_FairValueDisclosuresLineItems" name="FairValueDisclosuresLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_ClinicalAndRegulatoryMilestonesOnDevelopmentProgramMember" name="ClinicalAndRegulatoryMilestonesOnDevelopmentProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_EstimatedCompensationEarningFromProjectExpenseSharing" name="EstimatedCompensationEarningFromProjectExpenseSharing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tsbx_SeriesB1RedeemableConvertiblePreferredStockMember" name="SeriesB1RedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_CommonStockCapitalSharesReservedForFutureIssuanceIncreaseDecreasePeriod" name="CommonStockCapitalSharesReservedForFutureIssuanceIncreaseDecreasePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tsbx_PriceModificationDomain" name="PriceModificationDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_DiscoveryProgramMember" name="DiscoveryProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_RestrictedCashMember" name="RestrictedCashMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_RestrictedCashAndCashEquivalentsAtFairValue" name="RestrictedCashAndCashEquivalentsAtFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tsbx_DevelopmentProgramMember" name="DevelopmentProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_CollaborativeArrangementAdditionalConsiderationReceivableForLicensedOption" name="CollaborativeArrangementAdditionalConsiderationReceivableForLicensedOption" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tsbx_MystHoldersMember" name="MystHoldersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_MystMergerAgreementMember" name="MystMergerAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_ScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationTableTextBlock" name="ScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundableUpfrontPaymentReceived" name="RevenuePerformanceObligationFixedConsiderationNonRefundableUpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tsbx_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" name="RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tsbx_ResearchDevelopmentAndManufacturingServicesAggregateAnnualAmount" name="ResearchDevelopmentAndManufacturingServicesAggregateAnnualAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tsbx_NumberOfTradingDays" name="NumberOfTradingDays" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tsbx_ContingentConsiderationPayable" name="ContingentConsiderationPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tsbx_ShortTermLeaseCosts" name="ShortTermLeaseCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tsbx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuableShares" name="AssetAcquisitionConsiderationTransferredEquityInterestIssuableShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tsbx_ClinicalAndRegulatoryMilestonesOnLicensedDiscoveryProductMember" name="ClinicalAndRegulatoryMilestonesOnLicensedDiscoveryProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_AgreementAxis" name="AgreementAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedShares" name="AssetAcquisitionConsiderationTransferredEquityInterestIssuedShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tsbx_LossContingencyReserveForLitigationLiabilities" name="LossContingencyReserveForLitigationLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tsbx_UnpaidLiabilityMilestoneAchievement" name="UnpaidLiabilityMilestoneAchievement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" name="AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tsbx_LaboratorySpaceMember" name="LaboratorySpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_BusinessDescriptionAndBasisOfPresentationLineItems" name="BusinessDescriptionAndBasisOfPresentationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_CollaborativeArrangementAggregateConsiderationRemains" name="CollaborativeArrangementAggregateConsiderationRemains" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tsbx_StockIssuedDuringPeriodValueNewIssuesOnMilestoneAchievement" name="StockIssuedDuringPeriodValueNewIssuesOnMilestoneAchievement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tsbx_EquipmentPurchasesIncludedInAccruedExpenses" name="EquipmentPurchasesIncludedInAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tsbx_MaximumTermOfOptionsUnderEquityIncentivePlan" name="MaximumTermOfOptionsUnderEquityIncentivePlan" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tsbx_SignificantAccountingPoliciesTable" name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationTable" name="ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_SalesMilestonesOnLicensedDiscoveryProductMember" name="SalesMilestonesOnLicensedDiscoveryProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_ResearchAndDevelopmentExpenseLiabilities" name="ResearchAndDevelopmentExpenseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tsbx_StockIssuedDuringThePeriodForMilestonePaymentsValue" name="StockIssuedDuringThePeriodForMilestonePaymentsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tsbx_PriceModificationAxis" name="PriceModificationAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_StockIssuedDuringPeriodSharesNewIssuesOnMilestoneAchievement" name="StockIssuedDuringPeriodSharesNewIssuesOnMilestoneAchievement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tsbx_SharesAvailableForIssuanceUnderPlansMember" name="SharesAvailableForIssuanceUnderPlansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_CashProceedsFromTheSaleOfEquitySecuritiesAndOrUpfrontCashProceedsFromStrategicPartnerships" name="CashProceedsFromTheSaleOfEquitySecuritiesAndOrUpfrontCashProceedsFromStrategicPartnerships" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tsbx_H.LeeMoffittCancerCenterMember" name="H.LeeMoffittCancerCenterMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_SeriesDRedeemableConvertiblePreferredStockMember" name="SeriesDRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tsbx_ProvisionBenefitForIncomeTaxes" name="ProvisionBenefitForIncomeTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tsbx_ResearchDevelopmentAndManufacturingServicesAmendedToRemoveTrueUpAnnaulInstallment" name="ResearchDevelopmentAndManufacturingServicesAmendedToRemoveTrueUpAnnaulInstallment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tsbx_StockIssuedDuringPeriodValueMoffittPerformanceBasedCommonStockAward" name="StockIssuedDuringPeriodValueMoffittPerformanceBasedCommonStockAward" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249631811248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Aug. 12, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Turnstone Biologics Corp.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001764974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-2909368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9310 Athena Circle<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">La Jolla<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">897-5988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock ($0.001 par value)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TSBX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,128,454<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249637042432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 17,401<span></span>
</td>
<td class="nump">$ 17,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">44,997<span></span>
</td>
<td class="nump">76,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">3,542<span></span>
</td>
<td class="nump">4,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">2,348<span></span>
</td>
<td class="nump">2,812<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">68,404<span></span>
</td>
<td class="nump">102,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, noncurrent</a></td>
<td class="nump">1,051<span></span>
</td>
<td class="nump">1,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">1,853<span></span>
</td>
<td class="nump">2,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">5,569<span></span>
</td>
<td class="nump">6,352<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">76,877<span></span>
</td>
<td class="nump">112,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,486<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">12,354<span></span>
</td>
<td class="nump">9,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">1,793<span></span>
</td>
<td class="nump">2,025<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">15,633<span></span>
</td>
<td class="nump">11,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, noncurrent</a></td>
<td class="nump">411<span></span>
</td>
<td class="nump">1,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities, noncurrent</a></td>
<td class="nump">1,097<span></span>
</td>
<td class="nump">989<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">17,141<span></span>
</td>
<td class="nump">14,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized, at June 30, 2024 and December 31, 2023, respectively, 0 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 490,000,000 shares authorized at June 30, 2024 and December 31, 2023, respectively, 23,128,454 and 23,099,335 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional&#160;paid-in&#160;capital</a></td>
<td class="nump">277,630<span></span>
</td>
<td class="nump">275,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(226)<span></span>
</td>
<td class="num">(119)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(217,691)<span></span>
</td>
<td class="num">(176,758)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">59,736<span></span>
</td>
<td class="nump">98,667<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 76,877<span></span>
</td>
<td class="nump">$ 112,815<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249637317888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par or stated value per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">490,000,000<span></span>
</td>
<td class="nump">490,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="nump">23,128,454<span></span>
</td>
<td class="nump">23,099,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued</a></td>
<td class="nump">23,128,454<span></span>
</td>
<td class="nump">23,099,335<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249632560848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 17,730<span></span>
</td>
<td class="nump">$ 17,193<span></span>
</td>
<td class="nump">$ 33,520<span></span>
</td>
<td class="nump">32,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,327<span></span>
</td>
<td class="nump">4,659<span></span>
</td>
<td class="nump">9,228<span></span>
</td>
<td class="nump">8,691<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">22,057<span></span>
</td>
<td class="nump">21,852<span></span>
</td>
<td class="nump">42,748<span></span>
</td>
<td class="nump">41,552<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(22,057)<span></span>
</td>
<td class="num">(21,852)<span></span>
</td>
<td class="num">(42,748)<span></span>
</td>
<td class="num">(22,246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">755<span></span>
</td>
<td class="nump">347<span></span>
</td>
<td class="nump">1,833<span></span>
</td>
<td class="nump">727<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">(21,302)<span></span>
</td>
<td class="num">(21,505)<span></span>
</td>
<td class="num">(40,915)<span></span>
</td>
<td class="num">(21,519)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit (Provision) for income taxes</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,304)<span></span>
</td>
<td class="num">(21,499)<span></span>
</td>
<td class="num">(40,933)<span></span>
</td>
<td class="num">(21,431)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Unrealized gain (loss) on available-for-sale debt securities</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="num">(107)<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Total comprehensive loss</a></td>
<td class="num">(21,294)<span></span>
</td>
<td class="num">(21,440)<span></span>
</td>
<td class="num">(41,040)<span></span>
</td>
<td class="num">(21,251)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,304)<span></span>
</td>
<td class="num">(21,499)<span></span>
</td>
<td class="num">(40,933)<span></span>
</td>
<td class="num">(21,431)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Less: accretion of preferred stock to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders, basic</a></td>
<td class="num">(21,304)<span></span>
</td>
<td class="num">(21,518)<span></span>
</td>
<td class="num">(40,933)<span></span>
</td>
<td class="num">(21,470)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common stockholders, diluted</a></td>
<td class="num">$ (21,304)<span></span>
</td>
<td class="num">$ (21,518)<span></span>
</td>
<td class="num">$ (40,933)<span></span>
</td>
<td class="num">$ (21,470)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares of common stock outstanding, basic</a></td>
<td class="nump">23,037,714<span></span>
</td>
<td class="nump">2,847,675<span></span>
</td>
<td class="nump">23,024,754<span></span>
</td>
<td class="nump">2,817,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares of common stock outstanding, diluted</a></td>
<td class="nump">23,037,714<span></span>
</td>
<td class="nump">2,847,675<span></span>
</td>
<td class="nump">23,024,754<span></span>
</td>
<td class="nump">2,817,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic</a></td>
<td class="num">$ (0.92)<span></span>
</td>
<td class="num">$ (7.56)<span></span>
</td>
<td class="num">$ (1.78)<span></span>
</td>
<td class="num">$ (7.62)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted</a></td>
<td class="num">$ (0.92)<span></span>
</td>
<td class="num">$ (7.56)<span></span>
</td>
<td class="num">$ (1.78)<span></span>
</td>
<td class="num">$ (7.62)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249634589728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss) [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th">
<div>Series A redeemable convertible preferred stock [Member] </div>
<div>Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Series B-1 Redeemable Convertible Preferred Stock [Member] </div>
<div>Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Series B-2 Redeemable Convertible Preferred Stock [Member] </div>
<div>Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Series C redeemable convertible preferred stock [Member] </div>
<div>Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Series D redeemable convertible preferred stock [Member] </div>
<div>Preferred Stock [Member]</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,250,000<span></span>
</td>
<td class="nump">16,285,156<span></span>
</td>
<td class="nump">25,065,538<span></span>
</td>
<td class="nump">17,905,288<span></span>
</td>
<td class="nump">29,285,356<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,643<span></span>
</td>
<td class="nump">$ 12,611<span></span>
</td>
<td class="nump">$ 28,860<span></span>
</td>
<td class="nump">$ 42,100<span></span>
</td>
<td class="nump">$ 79,730<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,915,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="num">$ (101,467)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 20,501<span></span>
</td>
<td class="num">$ (413)<span></span>
</td>
<td class="num">$ (121,558)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of redeemable convertible preferred stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock', window );">Accretion of redeemable convertible preferred stock issuance costs</a></td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_StockIssuedDuringPeriodSharesMoffittPerformanceBasedCommonStockAward', window );">Moffitt performance based common stock award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Unrealized gain (loss) on available-for-sale debt securities</a></td>
<td class="nump">121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,250,000<span></span>
</td>
<td class="nump">16,285,156<span></span>
</td>
<td class="nump">25,065,538<span></span>
</td>
<td class="nump">17,905,288<span></span>
</td>
<td class="nump">29,285,356<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,643<span></span>
</td>
<td class="nump">$ 12,611<span></span>
</td>
<td class="nump">$ 28,860<span></span>
</td>
<td class="nump">$ 42,100<span></span>
</td>
<td class="nump">$ 79,750<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,028,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="num">(100,223)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">21,556<span></span>
</td>
<td class="num">(292)<span></span>
</td>
<td class="num">(121,490)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,250,000<span></span>
</td>
<td class="nump">16,285,156<span></span>
</td>
<td class="nump">25,065,538<span></span>
</td>
<td class="nump">17,905,288<span></span>
</td>
<td class="nump">29,285,356<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,643<span></span>
</td>
<td class="nump">$ 12,611<span></span>
</td>
<td class="nump">$ 28,860<span></span>
</td>
<td class="nump">$ 42,100<span></span>
</td>
<td class="nump">$ 79,730<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,915,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="num">$ (101,467)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">20,501<span></span>
</td>
<td class="num">(413)<span></span>
</td>
<td class="num">(121,558)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">21,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Unrealized gain (loss) on available-for-sale debt securities</a></td>
<td class="nump">$ 180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(21,431)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,250,000<span></span>
</td>
<td class="nump">16,285,156<span></span>
</td>
<td class="nump">25,065,538<span></span>
</td>
<td class="nump">17,905,288<span></span>
</td>
<td class="nump">29,285,356<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,643<span></span>
</td>
<td class="nump">$ 12,611<span></span>
</td>
<td class="nump">$ 28,860<span></span>
</td>
<td class="nump">$ 42,100<span></span>
</td>
<td class="nump">$ 79,769<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,029,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="num">(120,605)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">22,614<span></span>
</td>
<td class="num">(233)<span></span>
</td>
<td class="num">(142,989)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,250,000<span></span>
</td>
<td class="nump">16,285,156<span></span>
</td>
<td class="nump">25,065,538<span></span>
</td>
<td class="nump">17,905,288<span></span>
</td>
<td class="nump">29,285,356<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Beginning balance at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,643<span></span>
</td>
<td class="nump">$ 12,611<span></span>
</td>
<td class="nump">$ 28,860<span></span>
</td>
<td class="nump">$ 42,100<span></span>
</td>
<td class="nump">$ 79,750<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,028,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2023</a></td>
<td class="num">(100,223)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">21,556<span></span>
</td>
<td class="num">(292)<span></span>
</td>
<td class="num">(121,490)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of redeemable convertible preferred stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock', window );">Accretion of redeemable convertible preferred stock issuance costs</a></td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Unrealized gain (loss) on available-for-sale debt securities</a></td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(21,499)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,499)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,250,000<span></span>
</td>
<td class="nump">16,285,156<span></span>
</td>
<td class="nump">25,065,538<span></span>
</td>
<td class="nump">17,905,288<span></span>
</td>
<td class="nump">29,285,356<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,643<span></span>
</td>
<td class="nump">$ 12,611<span></span>
</td>
<td class="nump">$ 28,860<span></span>
</td>
<td class="nump">$ 42,100<span></span>
</td>
<td class="nump">$ 79,769<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,029,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="num">$ (120,605)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">22,614<span></span>
</td>
<td class="num">(233)<span></span>
</td>
<td class="num">(142,989)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">23,099,335<span></span>
</td>
<td class="nump">23,099,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 98,667<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">275,521<span></span>
</td>
<td class="num">(119)<span></span>
</td>
<td class="num">(176,758)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Unrealized gain (loss) on available-for-sale debt securities</a></td>
<td class="num">(117)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(117)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(19,629)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,629)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,128,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">$ 80,011<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">276,611<span></span>
</td>
<td class="num">(236)<span></span>
</td>
<td class="num">(196,387)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">23,099,335<span></span>
</td>
<td class="nump">23,099,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 98,667<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">275,521<span></span>
</td>
<td class="num">(119)<span></span>
</td>
<td class="num">(176,758)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">29,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Unrealized gain (loss) on available-for-sale debt securities</a></td>
<td class="num">$ (107)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (40,933)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2024</a></td>
<td class="nump">23,128,454<span></span>
</td>
<td class="nump">23,128,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="nump">$ 59,736<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">277,630<span></span>
</td>
<td class="num">(226)<span></span>
</td>
<td class="num">(217,691)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,128,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2024</a></td>
<td class="nump">80,011<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">276,611<span></span>
</td>
<td class="num">(236)<span></span>
</td>
<td class="num">(196,387)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Unrealized gain (loss) on available-for-sale debt securities</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (21,304)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,304)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2024</a></td>
<td class="nump">23,128,454<span></span>
</td>
<td class="nump">23,128,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="nump">$ 59,736<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 277,630<span></span>
</td>
<td class="num">$ (226)<span></span>
</td>
<td class="num">$ (217,691)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_StockIssuedDuringPeriodSharesMoffittPerformanceBasedCommonStockAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares moffitt performance based common stock award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_StockIssuedDuringPeriodSharesMoffittPerformanceBasedCommonStockAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease (increase) in additional paid in capital (APIC) for the increase in carrying amount of redeemable preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 3.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (12)(c)<br> -Section S99<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Subparagraph (16)(c)<br> -Paragraph 3A<br> -Section S99<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (15)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (14)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249632510976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (40,933)<span></span>
</td>
<td class="num">$ (21,431)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,065<span></span>
</td>
<td class="nump">2,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on disposal of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,007<span></span>
</td>
<td class="nump">1,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_AccretionOfPremiumOnShortTermInvestments', window );">Accretion of premium on short term investments</a></td>
<td class="num">(1,385)<span></span>
</td>
<td class="num">(468)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration liability</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable - collaboration agreement</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">8,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">1,233<span></span>
</td>
<td class="nump">652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">464<span></span>
</td>
<td class="num">(325)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(97)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,422<span></span>
</td>
<td class="num">(3,237)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_IncreaseDecreaseInContingentConsiderationLiability', window );">Change in contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,289)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_IncreaseDecreaseInAccruedCompensationAndOtherAccruedLiabilities', window );">Accrued compensation and other accrued liabilities</a></td>
<td class="nump">2,445<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">92<span></span>
</td>
<td class="num">(275)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,306)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows used in operating activities</a></td>
<td class="num">(33,385)<span></span>
</td>
<td class="num">(31,861)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from maturities of short-term investments</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">35,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchase of short-term investments</a></td>
<td class="num">(6,740)<span></span>
</td>
<td class="num">(15,228)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(249)<span></span>
</td>
<td class="num">(990)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows provided by investing activities</a></td>
<td class="nump">33,036<span></span>
</td>
<td class="nump">19,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments of financing costs</a></td>
<td class="num">(92)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment of contingent consideration related to Myst milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(898)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of deferred IPO costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(269)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows used in financing activities</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(1,081)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(397)<span></span>
</td>
<td class="num">(13,467)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of the period</a></td>
<td class="nump">17,914<span></span>
</td>
<td class="nump">35,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of the period</a></td>
<td class="nump">17,517<span></span>
</td>
<td class="nump">21,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosure of Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosure of Non-Cash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_AccretionOfRedeemableConvertiblePreferredStock', window );">Accretion of redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_EquipmentPurchasesIncludedInAccruedExpenses', window );">Equipment purchases included in accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Financing costs included in accounts payable</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_DeferredIpoCostsIncludedInAccruedExpenses', window );">Deferred IPO costs included in accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,286<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_AccretionOfPremiumOnShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion of premium on short term investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_AccretionOfPremiumOnShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_AccretionOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion of redeemable convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_AccretionOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_DeferredIpoCostsIncludedInAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred IPO costs included in accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_DeferredIpoCostsIncludedInAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_EquipmentPurchasesIncludedInAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equipment purchases included in accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_EquipmentPurchasesIncludedInAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_IncreaseDecreaseInAccruedCompensationAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued compensation and other accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_IncreaseDecreaseInAccruedCompensationAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_IncreaseDecreaseInContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in contingent consideration liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_IncreaseDecreaseInContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249631795360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (21,304)<span></span>
</td>
<td class="num">$ (19,629)<span></span>
</td>
<td class="num">$ (21,499)<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
<td class="num">$ (40,933)<span></span>
</td>
<td class="num">$ (21,431)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249629563328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249633514208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_BusinessDescriptionAndBasisOfPresentationAbstract', window );"><strong>Business Description And Basis Of Presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of the Business and Basis of Presentation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Nature of the Business and Basis of Presentation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Organization</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Turnstone Biologics Corp. (the &#8220;Company&#8221; or &#8220;Turnstone&#8221;) is a clinical stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. Turnstone is pioneering a differentiated approach to tumor infiltrating lymphocytes (&#8220;TILs&#8221;), a clinically validated technology for treating solid tumors. The Company is developing next generation TIL therapies by selecting the most potent and tumor reactive T cells (&#8220;Selected TILs&#8221;). The Company has three ongoing Phase 1 clinical trials for TIDAL-01, including a multi-site trial for the treatment of colorectal cancer, head and neck cancer, and uveal melanoma, and two investigator sponsored trials with H. Lee Moffitt Cancer Center and Research Institute, Inc., ("Moffitt"), across colorectal cancer, head and neck cancer, and uveal melanomas. The Company&#8217;s headquarters are located in San Diego, California.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Reverse Stock Split</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 14, 2023, the Company effected a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1-for-7.9872</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reverse stock split (&#8220;Reverse Split&#8221;) of its issued and outstanding shares of common stock and redeemable convertible preferred stock. All share and per share amounts included in the accompanying unaudited condensed consolidated financial statements and related notes have been retroactively adjusted, where applicable, to reflect the Reverse Split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. Shares of common stock, underlying outstanding stock options, and restricted stock were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the appropriate securities agreements. Stockholders entitled to fractional shares as a result of the Reverse Split received a cash payment in lieu of receiving fractional shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Initial Public Offering</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 25, 2023, the Company completed its initial public offering ("IPO") pursuant to which it issued and sold an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,666,667</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock at a price to the public of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. Aggregate net proceeds to the Company were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">68.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting underwriting discounts and commissions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and other offering expenses of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. On August 15, 2023, the underwriters exercised their option to purchase an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">651,608</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share. Aggregate net proceeds to the Company were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million after deducting underwriting discounts and commissions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Upon the closing of the IPO, all outstanding shares of redeemable convertible preferred stock automatically converted into shares of common stock. Subsequent to the closing of the IPO, there were no shares of redeemable convertible preferred stock outstanding.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the closing of the IPO, the Company filed its Amended and Restated Certificate of Incorporation which provides that the authorized capital stock of the Company is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">500,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares consisting of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">490,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of undesignated preferred stock, both with a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Going Concern</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of this uncertainty. Management is required to perform a two-step analysis over the Company&#8217;s ability to continue as a going concern. Management must first evaluate whether there are conditions and events that raise substantial doubt about the Company&#8217;s ability to continue as a going concern (Step 1). If management concludes that substantial doubt is raised, management is also required to consider whether its plans alleviate that doubt (Step 2).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">However, the Company incurred a net loss and negative cash flows from operations during the six months ended June 30, 2024 and management&#8217;s cash flow forecasts indicate that based on the Company&#8217;s expected future operating losses and negative cash flows, there is substantial doubt about the Company&#8217;s ability to continue as a going concern for 12 months after the date the unaudited consolidated financial statements are filed with the SEC.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s ability to continue as a going concern is dependent upon its ability to raise additional funding. Management intends to raise additional capital through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements.  However, the Company may not be able to secure additional financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company&#8217;s existing stockholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its current and potential future product candidates and programs on terms that are not favorable to the Company. As a result of adverse macroeconomic and geopolitical developments, recent and potential future bank failures, actual or anticipated changes in interest rates, economic inflation and the responses by central banking authorities to control such inflation, the global credit and financial markets have experienced volatility and disruptions, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. If the equity and credit markets deteriorate in the future, it may make any additional debt or equity financing more difficult, more costly, and more dilutive. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce or eliminate its research and development programs or other operations. Even if the Company raises additional capital, it may be insufficient to continue its development as currently planned, which could have a material adverse effect on the Company&#8217;s business, operating results and financial condition, and the Company&#8217;s ability to achieve its intended business objectives. If any of these events occur, the Company&#8217;s ability to achieve the development and commercialization goals would be adversely affected.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sources of Liquidity</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since its inception, the Company has devoted substantially all of its efforts and financial resources to organizing and staffing the Company, business planning, raising capital, discovering product candidates and securing related intellectual property rights, and conducting research and development activities for its Selected TIL programs and product candidates. The Company does not have any products approved for sale, has not generated any revenue from product sales and has incurred overall net losses since commencement of the Company&#8217;s operations, including a net loss of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">40.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">21.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2024 and 2023, respectively. The Company has financed its operations through the issuance and sale of shares of the Company&#8217;s redeemable convertible preferred stock, from collaboration revenue received pursuant to certain collaboration agreements, and most recently, with proceeds from the IPO completed on July 25, 2023 and the exercise of the underwriters option to purchase additional shares on August 15, 2023. As of June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had an accumulated deficit of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">217.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. The Company expects to continue to generate significant operating losses for the foreseeable future.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 26, 2024 (the &#8220;Loan Closing Date&#8221;), the Company entered into a Loan and Security Agreement ("LSA") with Banc of California ("BOC") for a revolving credit facility in an aggregate principal amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million with annual interest at the greater of the Prime Rate (as defined in the LSA) or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.  This LSA includes a covenant requiring the Company to (i) receive positive interim Phase 1 data for TIDAL-01 (as determined by the Company&#8217;s board of directors), which was achieved in August 2024 and (ii) receive at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">40.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in new funding from the sale of equity, partnerships, and/or business development payments, in each case, by March 31, 2025. If the Company fails to comply with any of the foregoing covenants, the Lender may terminate the commitments to make further loans and declare all of the obligations of the Company under the LSA to be immediately due and payable. As of June 30, 2024, no amounts have been drawn under the LSA (see</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Note 8 - Term Loan</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for additional information).</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company intends to fund future operations and future capital funding needs through equity and/or debt financings, as well as possible asset sales, licensing transactions, and collaborations or strategic partnerships with other companies. The sale of equity or convertible debt could result in additional dilution to stockholders. The incurrence of indebtedness would result in debt service obligations and could result in operating and financial covenants that would restrict the Company&#8217;s operations. The Company can provide no assurance that sufficient financing will be available on acceptable terms, if at all. If the Company is not able to secure adequate additional funding it may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. Any of these actions could materially harm the Company&#8217;s business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including non-clinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_BusinessDescriptionAndBasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business description and basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_BusinessDescriptionAndBasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249638808416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2. Summary of Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation of Unaudited Condensed Consolidated Financial Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. However, such interim financial statements reflect all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the Company&#8217;s financial position and results of operations. Results shown for interim periods are not necessarily indicative of the results that may be expected for the year ended December 31, 2024 or for any other period. The condensed consolidated balance sheet as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was derived from the audited consolidated financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements, included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 22, 2024. Certain prior period amounts reported in the Company&#8217;s unaudited condensed consolidated financial statements and accompanying notes have been reclassified to conform to the current period presentation. Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Principles of Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The significant accounting policies used in preparation of these unaudited condensed consolidated financial statements are consistent with those discussed in Note 2 to the audited consolidated financial statements included in the Company&#8217;s Annual Report filed on Form 10-K filed with the SEC on March 22, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of these unaudited condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to accrued expenses, contingent liabilities, impairment of long-lived assets, revenue recognition, the valuation of equity-based compensation, common stock, restricted common stock, and income taxes. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash and Investments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash consists of certificate of deposit accounts that are pledged as collateral for the Company&#8217;s San Diego facility lease. Restricted cash was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 and December 31, 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company invests its excess cash in investment grade, short-term, fixed income securities and recognizes purchased securities on the settlement date. All investments have been classified as &#8220;available-for-sale&#8221; in the unaudited condensed consolidated balance sheets and are carried at estimated fair value based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments at the time of purchase and re-evaluates such designation as of each balance sheet date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company assesses its available-for-sale securities under the available-for-sale security impairment model in ASC Topic 326, Financial Instruments - Credit Losses ("ASC 326") as of each reporting date in order to determine if a portion of any decline in fair value below carrying value is the result of a credit loss. The Company records credit losses in the unaudited condensed consolidated statements of operations and comprehensive loss as credit loss expense, which is limited to the difference between the fair value and the amortized cost of the security. To date, the Company has not recorded any credit losses on its available-for-sale securities. Declines in fair value below carrying value attributable to non-credit related factors are recorded as accumulated other comprehensive loss, which is a separate component of stockholders&#8217; equity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Realized gains and losses are reported in other income (expense), net. Interest on short-term investments is included in other income (expense), net. The Company&#8217;s investments are classified as current assets which reflects management&#8217;s intention to use the proceeds from sales of these securities to fund its operations, as necessary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, investments and restricted cash. The Company&#8217;s investment policy restricts cash investments to high credit quality, investment grade investments. The Company&#8217;s investment policy provides guidelines and limits regarding investment type, concentration, credit quality, and maturity aimed at maintaining sufficient liquidity to satisfy operating and working capital requirements along with strategic initiatives, preserving capital, and minimizing risk of capital loss while generating returns on its investments. The Company is exposed to credit risk in the event of default by the issuer or the institutions holding the cash and cash equivalents to the extent of the amounts recorded on the balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has no off-balance sheet risk, such as foreign exchange contracts, option contracts or other foreign-hedging arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the unaudited condensed consolidated financial statements on a recurring basis. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy requires that an entity maximize the use of observable inputs when estimating fair value. The fair value hierarchy includes the following three-level classification which is based on the market observability of the inputs used for estimating the fair value of the assets or liabilities being measured:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Quoted market prices in active markets for identical assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3 &#8211;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Inputs that are generally unobservable and typically reflect management&#8217;s estimate of assumptions that a market participant would use in pricing the asset or liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized at fair value in the unaudited condensed consolidated financial statements on a recurring basis (at least annually). To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for stock-based compensation expense related to stock options and restricted stock units, ("RSUs"), by estimating the fair value on the date of grant. The fair value of RSUs granted to employees is the closing price of the Company&#8217;s common stock on the date of grant. The Company estimates the fair value of stock options granted to employees and non-employees using the Black-Scholes option pricing model. The Company recognizes stock-based compensation expense, over the requisite service period, based on the vesting provisions of the individual grants. Generally, the Company issues stock-based awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. The Company accounts for forfeitures when they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a) the expected stock price volatility, (b) the expected term of the award, (c) the risk-free interest rate and (d) expected dividend yields. Due to the lack of a public market for the Company&#8217;s common stock until July 21, 2023, and lack of company- specific historical and implied volatility data, the Company has based its computation of expected volatility on the average historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term. The Company uses the simplified method as prescribed by the U.S. Securities and Exchange Commission Staff Accounting Bulletin No. 107,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Share-Based </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Determination of Fair Value of Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After the Company's IPO in July 2023, the fair value of common stock is determined using the closing price of the Company's common stock on the Nasdaq Global Market. Prior to the IPO, there were significant judgments and estimates inherent in the determination of the fair value of the Company&#8217;s common stock. These estimates and assumptions include a number of objective and subjective factors, including, among other things, external market conditions, the prices at which the Company sold shares of its convertible preferred stock, the superior rights and preferences of securities senior to its common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale of the Company. The approach to estimating the fair market value of common stock is consistent with the methods outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide, Valuation of Privately-Held Company Equity Securities Issued as Compensation (the &#8220;Practice Aid&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In valuing the Company&#8217;s common stock prior to the IPO, the equity value of the business was determined using the backsolve method, a form of the subject company transaction method, wherein the equity value for a privately held company is derived from a recent transaction in the company&#8217;s own securities. The value is then allocated using the hybrid method allocation methodology. For grants made subsequent to September 30, 2018 but prior to the IPO, the Company used a hybrid method, which is a hybrid between the OPM and the probability-weighted expected return method (&#8220;PWERM&#8221;). The hybrid method is a combination of the PWERM and OPM. The OPM allocates the overall Company value to the various share classes based on differences in liquidation preferences, participation rights, dividend policy and conversion rights, using a series of call options. The call right is valued using a Black-Scholes option pricing model. The PWERM employs additional information not used in the OPM, including various market approach calculations depending upon the likelihood of various discrete future liquidity scenarios, such as an initial public offering or sale of the Company, as well as the probability of remaining a private company. In a hybrid method, various exit scenarios are analyzed. A discount for lack of marketability of the Company&#8217;s common stock was then applied to arrive at an indication of value for the common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contingent Consideration</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consideration paid related to the Myst Merger Agreement (see</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Note 7 - Asset Acquisition</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for additional information) may include potential future payments that are contingent upon the Company achieving certain milestones in the future. Contingent consideration liabilities are measured at their estimated fair value as of the date of the unaudited condensed consolidated balance sheets using a probability-based income approach based on the monetary value of the milestone payment discounted for the likelihood of achieving the milestone and a present value factor based on the timing of when the milestone is expected to be achieved. Contingent consideration liabilities expected to be settled within 12 months after the balance sheet date are presented in current liabilities, with the non-current portion recorded under other liabilities, non-current in the unaudited condensed consolidated balance sheets. Changes in the fair value of the contingent consideration are recorded as research and development expenses in the unaudited condensed consolidated statement of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt&#8212;Debt with Conversion and Other Options </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Subtopic 470-20) and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivatives and Hedging Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Subtopic 815-40) (&#8220;ASU 2020-06&#8221;), which reduces the number of accounting models for convertible debt instruments and convertible preferred stock as well as amends the derivatives scope exception for contracts in an entity&#8217;s own equity. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_8fb38185-ea26-45ab-b107-b14eace25cd0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ASU 2020-06</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is effective for the Company on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  The </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adoption</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">did not have a material impact</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on the unaudited condensed consolidated financial statements.</span></p></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Topic 280)&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;ASU 2023-07&#8221;). ASU 2023-07 requires that an entity disclose significant segment expenses impacting profit and loss that are regularly provided to the chief operating decision maker. The update is required to be applied retrospectively to prior periods presented, based on the significant segment expense categories identified and disclosed in the period of adoption. The amendments in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ASU 2023-07 are required to be adopted for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the potential impact that this standard may have on its unaudited condensed consolidated financial statements and related disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (Topic 740)&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;ASU 2023-09&#8221;). ASU 2023-09 requires that an entity disclose specific categories in the effective tax rate reconciliation as well as provide additional information for reconciling items that meet a quantitative threshold. Further, ASU 2023-09 requires certain disclosures of state versus federal income tax expense and taxes paid. The amendments in ASU 2023-09 are required to be adopted for fiscal years beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued. The amendments should be applied on a prospective basis although retrospective application is permitted. The Company is currently evaluating the potential impact that this standard may have on its unaudited condensed consolidated </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">financial statements and related disclosures.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249633791264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Assets and Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3. Fair Value of Financial Assets and Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024 and December 31, 2023, the Company&#8217;s highly liquid money market funds included within cash equivalents, restricted cash and U.S. treasury securities are valued using Level 1 inputs. The Company classifies its federal agency securities as Level 2. There were no transfers in or out of Level 1 and Level 2 during the periods presented. U.S. treasury securities are bonds issued by the U.S. government and are fully backed by the U.S. government. Given the frequency at which U.S. treasury securities trade and the accessibility of observable, quoted prices for such assets in active markets, they are recognized as Level 1 assets. Federal agency securities are bonds and notes issued by government-sponsored enterprises, including Fannie Mae, Freddie Mac and the Federal Home Loan Bank. Since Federal agency securities typically do not trade as frequently as U.S. government agency securities and no exchange exists to price such investments, they are recognized as Level 2 assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in contingent consideration liabilities as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 and December 31, 2023, respectively, related to the Myst Merger Agreement. The contingent consideration balances are comprised of one potential milestone payment and is measured at fair value (see</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Note 7&#8212;Asset Acquisition</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for additional information). The fair value of the contingent consideration is estimated based on the monetary value of the milestone discounted for the likelihood of achieving the milestone and a present value factor based on the timing of when the milestone is expected to be achieved. The value for the contingent consideration balance is based on significant inputs not observable in the market which represents a Level 3 measurement within the fair value hierarchy. There were no transfers in or out of Level 3 during the periods presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables represent a summary of the financial assets and liabilities that are measured on a recurring basis at fair value </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.949%;"></td>
        <td style="width:1.081%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.049%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.081%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.866999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.081%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.866999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.081%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.866999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.081%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="background-color:#cff0fc;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,125</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,125</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,997</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,997</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,238</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,238</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial liabilities:</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent consideration</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,024</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,024</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,024</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,024</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="background-color:#cff0fc;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,635</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,635</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,979</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,979</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92,730</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92,730</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial liabilities:</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent consideration</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">916</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">916</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">916</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">916</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash serves as deposits for the Company&#8217;s San Diego office lease. </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Included in short-term investments on the unaudited condensed consolidated balance sheets and are classified as available-for sale debt securities. </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Contingent consideration related to the Myst Merger Agreement. </span></div></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following significant unobservable inputs were used in the valuation of the contingent consideration payable to the sole common stockholder of Myst Therapeutics, Inc. ("Myst") pursuant to the Myst Merger Agreement:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:29.174%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.077%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.816%;"></td>
        <td style="width:19.956%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:13.597%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value as of</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Contingent Consideration Liability</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Valuation Technique</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unobservable Input</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">'Milestone payment for first registrational study (see Note 7 - Asset Acquisition for additional information)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,024</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Discounted cash flow</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Likelihood of occurrence</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Discount rate</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value as of</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Contingent Consideration Liability</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Valuation Technique</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unobservable Input</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">'Milestone payment for first registrational study (see Note 7 - Asset Acquisition for additional information)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">916</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Discounted cash flow</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Likelihood of occurrence</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Discount rate</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table reflects the activity for the Company&#8217;s contingent consideration, measured at fair value using Level 3 inputs (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.876%;"></td>
        <td style="width:2.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.104%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent consideration at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">916</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in the fair value of contingent consideration</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent consideration at June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,024</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables show the Company&#8217;s cash, cash equivalents and available-for-sale securities by significant investment category </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.761%;"></td>
        <td style="width:1.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.189%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.189%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.189%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.189%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1:  Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,125</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,125</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Restricted cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;U.S. government securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,021</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,997</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,262</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,238</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Classified as:</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,125</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,997</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,238</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.761%;"></td>
        <td style="width:1.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.189%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.189%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.189%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.189%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1:  Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,635</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,635</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Restricted cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;U.S. government securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,875</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,979</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92,626</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92,730</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Classified as:</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,635</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,979</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92,730</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">16</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">18</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of our available-for-sale debt securities were in a gross unrealized loss position of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million with an aggregate fair value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">42.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. As of December 31, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ne out of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of our available-for-sale debt securities were in a gross unrealized loss position.  While short-term investments are available-for-sale, it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be maturity. All short-term investments currently held have maturities of less than one year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company reviews short-term investments for impairment during each reporting period. Credit losses are recognized up to the amount equal to the difference between the fair value and the amortized cost basis and recorded as an allowance for credit losses in the unaudited condensed consolidated balance sheets with a corresponding adjustment to earnings. Unrealized losses that are not related to credit losses are recognized in accumulated other comprehensive loss. Unrealized losses were not significant for the investments held in the Company&#8217;s portfolio as of June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and Company considered the decline in market value for these securities to be primarily attributable to economic and market conditions rather than credit-related factors. There were no unrealized losses in the Company's investment portfolio at December 31, 2023. The Company considered the risk-profile of the counterparties under ASC 326, noting that any credit risk associated with such entities is either zero or near zero. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> impairment losses or expected credit losses related to its </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d519c220-b9c0-4efc-ae00-16610eda5851;"><span style="-sec-ix-hidden:F_07c37049-61be-45e2-82d2-712a7c000aaa;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">short-term investments</span></span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and six months ended June 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249633771888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4. Property and Equipment, Net</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net consist of the following (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.16%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,112</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,043</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">690</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">690</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,308</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,308</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,110</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,041</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,541</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,689</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,569</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,352</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment depreciation and amortization expense for the three months ended June 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively and the six months ended June 30, 2024 and 2023, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249632996016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_DisclosureOfAccruedExpensesAndOtherCurrentLiabilitiesTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5. Accrued Expenses and Other Current Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.16%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,187</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,675</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional and consulting expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">753</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">641</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,336</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,593</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,354</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,909</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_DisclosureOfAccruedExpensesAndOtherCurrentLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accrued expenses and other current liabilities [Text Block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_DisclosureOfAccruedExpensesAndOtherCurrentLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249633791264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_AgreementsAbstract', window );"><strong>Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Agreements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6. Agreements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Takeda Pharmaceutical Company Limited</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaboration Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2019, the Company entered into a discovery, collaboration and license agreement (&#8220;Takeda Agreement&#8221;) with Millennium Pharmaceuticals, Inc. (also known as Takeda Oncology), a wholly owned subsidiary of Takeda Pharmaceutical Company Limited ("Takeda"). Under the Takeda Agreement, the Company agreed to collaborate with Takeda to co-develop and co-commercialize TBio-6517 (also known as RIVAL-01) (&#8220;Development Program&#8221;) and to conduct discovery programs to identify additional novel product candidates based on its vaccinia virus platform for independent development (&#8220;Discovery Program&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Takeda Agreement, the Company granted Takeda and its affiliates a worldwide, irrevocable, non-transferable, co-exclusive, sublicensable license under certain of the Company&#8217;s know-how and patent rights (&#8220;Turnstone Technology&#8221;) to make, use, sell, offer for sale, develop, manufacture, and commercialize, or otherwise exploit TBio-6517 (&#8220;Licensed Compound&#8221;) and products containing TBio-6517 (&#8220;Takeda Licensed Products&#8221;) in all fields. Takeda granted the Company and the Company&#8217;s affiliates an irrevocable, non-transferable, non-exclusive, sublicensable license under certain know-how and patent rights of Takeda (&#8220;Takeda Technology&#8221;) to make, use, sell, offer for sale, develop, manufacture, and commercialize, or otherwise exploit the Licensed Compound and Takeda Licensed Products in all fields in accordance with joint development, commercialization, and medical affairs plans under the Takeda Agreement. Under the Takeda Agreement, the Company also granted to Takeda and its affiliates a worldwide, non-transferable, non-exclusive, sublicensable license under Turnstone Technology to conduct joint discovery and research activities in all fields in accordance with joint research and discovery plans. Under the Takeda Agreement, Takeda granted the Company a license to Takeda Technology to conduct discovery and research activities in all fields in accordance with joint research and discovery plans. The Company also granted to Takeda and its affiliates an exclusive option to obtain a worldwide, irrevocable, non-transferable, exclusive, sublicensable license under Turnstone Technology to make, use, sell, offer for sale, develop, manufacture, and commercialize, or otherwise exploit (i) selected discovery virus candidates generated and evaluated by the parties under a joint discovery program (&#8220;Selected Discovery Candidates&#8221;), and (ii) any corresponding licensed products containing a Selected Discovery Candidate (&#8220;Licensed Discovery Products&#8221;). Takeda may exercise this option with respect to two virus candidates and within a specified option exercise period. The Company granted Takeda and its affiliates a non-exclusive, perpetual, irrevocable, worldwide, sublicensable and fully paid-up license under certain of the Company&#8217;s know-how and patents relating to manufacturing improvements developed under the Takeda Agreement solely for use in connection with the manufacture of products that do not comprise or incorporate, and that are not based on, an oncolytic virus. Takeda granted the Company and the Company&#8217;s affiliates a non-exclusive, perpetual, irrevocable, worldwide, sublicensable and fully paid-up license under certain of Takeda&#8217;s know-how and patents relating to manufacturing improvements developed under the Takeda Agreement solely for use in connection with the manufacture of any and all products. With respect to discovery virus candidates for which Takeda does not exercise its option, Takeda granted the Company a non-exclusive, perpetual, worldwide, sublicensable and royalty-bearing license under certain of its know-how and patents that is necessary or reasonably useful for the exploitation of such declined discovery virus candidates (&#8220;Declined Candidate License&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Responsibilities for the development of Licensed Compounds and Takeda Licensed Products are delineated pursuant to a joint development plan under the terms of the Takeda Agreement. The Company will be responsible for all activities under the joint development plan prior to completion of a Phase 2a clinical trial and Takeda will be responsible for all activities in the joint development plan upon and after completion of the Phase 2a clinical trial. Responsibilities relating to manufacturing, medical affairs, and commercialization of Licensed Compounds and Takeda Licensed Products are delineated pursuant to a manufacturing working plan, joint medical affairs plan and joint commercialization plan, respectively. The Company has the right to reduce or opt-out of its share of responsibilities for costs and expenses of certain development or commercialization activities for the Takeda Licensed Compounds and Takeda Licensed Products. Responsibilities for the discovery and research of Selected Discovery Candidates are delineated pursuant to joint discovery and research plans under the terms of the Takeda Agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Takeda Agreement, Takeda paid the Company a non-refundable payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in November 2019 and an additional non-refundable payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">30.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in April, 2020, for the option to license up to two Selected Discovery Candidates, with additional consideration of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to be paid by Takeda to the Company for each exercise of such option.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Takeda Agreement, the Company has the right to reduce its share of funding obligations with respect to development activities for the Licensed Compound and Takeda Licensed Products (the &#8220;Development Opt-Down Right&#8221;), or to opt-out of all further funding obligations with respect to development activities for the Licensed Compound and Takeda Licensed Products (the &#8220;Development Opt-Out Right&#8221;). Unless and until the Company exercises the Development Opt-Down Right, the parties will share evenly in any operating profits or losses with respect to joint development activities, joint medical affairs activities, and joint commercialization activities. If the Company exercises its Development Opt-Down Right, then starting from the effective date of the exercise of the right, Takeda will bear (and be entitled to) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">70</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and the Company will bear (and be entitled to) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">30</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the operating</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">profits </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">or losses with respect to joint development activities, joint medical affairs activities, and joint commercialization activities. Takeda is obligated to pay the Company (i) up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">200.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in aggregate upon achievement of certain clinical and regulatory milestones for the first Takeda Licensed Product to achieve the applicable development milestone event, (ii) up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">150.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in aggregate for one-time payments upon achievement of certain sales milestones for each Takeda Licensed Product, (iii) up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">240.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in aggregate (if Takeda exercises both options to Selected Discovery Candidates) upon achievement of certain clinical and regulatory milestones for the first Takeda Licensed Discovery Product to achieve applicable development milestone events, and (iv) up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">300.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in aggregate (if Takeda exercises both options to Selected Discovery Candidates) for one-time payments upon achievement of certain sales milestones for a Licensed Discovery Product. If the Company exercises its Development Opt-Out Right for the Takeda Licensed Products, then in lieu of the profit and loss share arrangement described above, the Company is entitled to receive tiered low- to high- teen percentage royalties on net sales of all Takeda Licensed Products by the Company or the Company&#8217;s sublicensees during the royalty term, which commences on the first commercial sale of a Takeda Licensed Product in a country and ends on the later of the expiration of all licensed patents covering such Licensed Product in such country or ten years after the date of the first commercial sale in such country (&#8220;Royalty Term&#8221;). For Licensed Discovery Products, the Company is entitled to receive tiered high-single digit to low-teen percentage royalties on net sales of all Licensed Discovery Products by the Company or the Company&#8217;s sublicensees during the Royalty Term. Royalty payments are subject to customary reductions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Takeda has the right to terminate for convenience as follows: (i) prior to the expiration of the option exercise period related to a Discovery Virus Candidate, Takeda may terminate the Takeda Agreement related to such Discovery Virus Candidate and the Discovery Program with 90 days&#8217; notice, (ii) prior to any commercial sale, Takeda may terminate the Takeda Agreement either in its entirety or on a compound-by-compound or region-by-region basis, with six months&#8217; notice and (iii) after a commercial sale, Takeda may terminate the Takeda Agreement either in its entirety or on a compound-by-compound or region-by-region basis, with 12 months&#8217; notice.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Termination of Development Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 13, 2022, Takeda provided six months&#8217; written notice to terminate the Development Program in accordance with its termination for convenience rights, with such termination being effective as of December 13, 2022. During the six months&#8217; notice period, the Company was obligated to continue providing the necessary Development Program services to wind down the program. Upon the effective termination date of December 13, 2022, Takeda&#8217;s co-exclusive license to TBio-6517 terminated and the Company is no longer obligated to pursue development of TBio-6517.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Termination of Discovery Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 6, 2023, Takeda provided six months&#8217; written notice to terminate the remainder of the Takeda Agreement, with such termination being effective as of July 6, 2023 (&#8220;Effective Termination Date&#8221;). On the Effective Termination Date, all options and licenses granted under the Takeda Agreement terminated (except for the Declined Candidate License) and Takeda granted the Company a non-exclusive license under the patent rights and know-how controlled by Takeda as of the Effective Termination Date necessary for the Company to exploit the Licensed Compound and Takeda Licensed Products in the form existing as of the Effective Termination Date for any use worldwide, subject to a royalty to be agreed upon by Takeda and the Company. As of March 31, 2023, the Company ceased all work under the Takeda Agreement and there were no remaining estimated services associated with the obligations under the Takeda Agreement as of the effective termination date of July 6, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Accounting Analysis</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company assessed the promised goods and services under the Takeda Agreement in accordance with ASC Topic 606, Revenue from Contracts with Customers ("ASC 606"), and determined that, at inception, the Takeda Agreement includes the following performance obligations: (i) research, development and manufacturing services under the Development Program for the completion of clinical trials through Phase 2a for RIVAL-01 and a co-exclusive license to exploit RIVAL-01 (&#8220;Development Program Performance Obligation&#8221;); and (ii) research and development services under the Discovery Program to identify and optimize four Selected Discovery Candidates for further development (&#8220;Discovery Program Performance Obligation&#8221;). The individual promises under the Development Program including research, development, manufacturing for clinical trials, and the co-exclusive license to RIVAL-01 are not individually distinct as they represent inputs into a combined output of advancing RIVAL-01 through the Phase 2a clinical trial. Therefore, all promises under the Development Program represent a single performance obligation. Similarly, the research and development services under the Discovery Program represent a single research program aimed at generating four Selected Discovery Candidates and therefore represents a single performance obligation. The Development Program promises are distinct from the promises under the Discovery Program, as the benefits under each program are separately identifiable. Each program has a separate work plan and the promises to be provided under the Development Program do not relate to the promises to be provided under the Discovery Program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company concluded that Takeda&#8217;s license options under the Discovery Program do not represent material rights, and therefore are not performance obligations, as the Company is entitled to an additional $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million payment for each license option exercised, which approximates the estimated standalone selling price of the underlying license.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The total transaction price at contract inception is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">158.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, comprised of the following components:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fixed consideration of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">80.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million including a non-refundable up-front payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in November 2019 and another non-refundable payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">30.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million that was due on April 1, 2020 and received in April 2020. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Variable consideration related to the expense sharing under the Development Program. These amounts are determinable based on the Development Program plan and budget, and the Company has a contractual right to the payment of costs incurred under the agreed upon plan. Consistent with the expected value method, the Company estimated that it will receive $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">58.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million under the expense sharing through the completion of the Phase IIa clinical trial. The Company has concluded that these amounts do not require a constraint and are included in the transaction price at inception. The Company has evaluated this estimate at each reporting date and updated the estimate based on information available. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Variable consideration for the development milestones under the Development Program. The Company uses the most likely amount method to value this variable consideration as there are only two possible outcomes of achieving the individual milestones. Under the Development Program, the first milestone of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million is due upon acceptance of an Investigational New Drug Application  ("IND") by the U.S. Food and Drug Administration ("FDA"). At inception, the Company concluded that achievement of this milestone was highly probable and therefore the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was included in the transaction price and was received in March 2020. The second milestone of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million under the Development Program is due upon the initiation of the first Phase 2 clinical trial for a licensed product. The Company has determined that the most likely amount is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, however, the Company will not include this $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million milestone in the transaction price until it becomes probable that a significant reversal of cumulative revenue will not occur. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional consideration to be paid to the Company includes development and sales milestones, profit and loss share, royalties and option exercise payments. These additional payments are achievable only after the completion of the Phase 2a clinical trial under the Development Program or exercise of the license options under the Discovery Program and therefore are excluded from the transaction price. Additionally, Takeda&#8217;s equity purchase commitments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million are at fair value and therefore no non-cash consideration has been included as a component of the transaction price.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company allocated the transaction price to the separate performance obligations based on their relative standalone selling prices. The Company determined the standalone selling price of the Development Program Performance Obligation based on the costs incurred to develop RIVAL-01 plus the estimated costs to perform the research, development and manufacturing services through the completion of the Phase 2a clinical trial, inclusive of a reasonable profit margin. The Company determined the standalone selling price of the Discovery Program Performance Obligation based on the estimated costs to discover and research four Selected Discovery Candidates, inclusive of a reasonable profit margin. Significant inputs used to determine the standalone selling prices of the performance obligations include the length of time required, the internal hours expected to be incurred on the services, and the amount of third-party expenses that will be incurred to complete the performance obligations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes the amounts associated with these performance obligations on a proportional performance basis over the contract term using input-based measurements of total cost of research and development incurred to estimate the proportion performed as compared to the estimated total cost and remeasures its progress towards completion at the end of each reporting period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2021, the transaction price was updated to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">192.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to reflect an increase in the variable consideration related to the expense sharing under the Development Program from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">58.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million at inception to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">92.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determined that the notice of termination on June 13, 2022, represented a modification of the arrangement under ASC 606 and that the transaction price should be updated and re-allocated to the Development Program Performance Obligation and the Discovery Program Performance Obligation based on their standalone selling prices, as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.571%;"></td>
        <td style="width:1.429%;"></td>
        <td style="width:18.571%;"></td>
        <td style="width:1.429%;"></td>
        <td style="width:20%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Performance Obligations</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Price Pre-<br/>Modification</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Price at<br/>Modification</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Development Program</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">166.3</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;million</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">134.3</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;million</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Discovery Program</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26.3</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;million</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.2</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;million</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">192.6</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;million</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">155.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;million</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, the Company updated its measure of progress for each performance obligation as of the modification date and recorded a cumulative adjustment that increased collaboration revenue by $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">31.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">on the partially satisfied remaining</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">performance </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">obligations, as the remaining services to be performed under each of the performance obligations are not distinct from the services prior to the modification.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Costs incurred relating to the Takeda Agreement consist of internal and external research and development costs, which primarily include salaries and benefits, lab supplies, and preclinical research studies. All of these costs have been included in research and development expenses in the Company&#8217;s unaudited condensed consolidated statements of operations and comprehensive loss during the three months ended March 31, 2023 and in prior years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognized the remaining deferred revenue balance during the three months ended March 31, 2023 as the Company concluded that there were no remaining estimated services to be performed associated with the obligations under the Takeda Agreement. The Company recognized </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_86aca0ff-7597-42fd-ba5f-977c1204204c;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">collaboration revenue</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> related to the Takeda Agreement for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.  Receivables related to reimbursable costs expected to be received from Takeda for research and development services performed under the Development Program at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 and December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">H. Lee Moffitt Cancer Center</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Master Collaboration Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2021, the Company entered into an amended and restated master collaboration agreement (the &#8220;Moffitt Agreement&#8221;), with Moffitt, to amend a then-existing master collaboration agreement from November 2019, as amended March 2020, between Moffitt and the Company&#8217;s now wholly-owned subsidiary, Myst, with the intent to continue to work collaboratively in the research of cancer immunotherapies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Each party granted the other party a right to use its research materials for performance of the research plans agreed to by the parties (the &#8220;Research Plans&#8221;). Each party granted the other party a non-exclusive, worldwide, sublicensable, perpetual, irrevocable, royalty-free license under all inventions invented in performance of a Research Plan and invented jointly by the Company and Moffitt (the &#8220;Joint Inventions&#8221;) (with certain exclusions) to make, use, sell, offer for sale, import products and services and/or otherwise practice such inventions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company granted Moffitt a royalty free, non-sublicensable, non-transferable, perpetual, non-exclusive license to use and practice certain inventions invented solely by the Company in the performance of a Research Plan for its internal non-commercial research purposes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moffitt granted the Company (i) a royalty-free, sublicensable, non-transferable, perpetual, non-exclusive license to use and practice certain inventions invented solely by Moffitt in the performance of a Research Plan (&#8220;Moffitt Inventions&#8221;), (a) for internal, non-commercial research purposes outside the field of ACT and/or (b) to research, develop, make, use, sell, offer to sell, or import products and/or services in the field of ACT and (ii) a royalty free, sublicensable, non-transferable, perpetual, non-exclusive license to use and practice certain inventions invented in performance of a Research Plan or through the use of specified Moffitt research materials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Moffitt granted the Company an option to obtain, with terms to be negotiated in good faith under commercially reasonable terms, a royalty-bearing, sublicensable exclusive license in the Moffitt Inventions, the TCR Inventions, and/or Moffitt&#8217;s interest in Joint Inventions. The Company can exercise this option at any time within six months after Moffitt informs the Company of any new invention, and upon the Company&#8217;s exercise, the parties will have a period of six months to negotiate the terms of such exclusive license.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Moffitt Agreement will expire upon the later of (i) four years from the effective date of the Moffitt Agreement or (ii) the termination or expiration of all Research Plans in effect under the Moffitt Agreement, unless extended upon mutual written agreement of the parties. Either party may terminate the Moffitt Agreement for cause upon any uncured breach by the other party or upon the insolvency of the other party.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Moffitt Alliance Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2022, the Company entered into a life science alliance agreement with Moffitt (the &#8220;Alliance Agreement&#8221;), in order to further expand the Company&#8217;s relationship and support the Company&#8217;s existing agreements with Moffitt (the &#8220;Underlying Agreements&#8221;). Pursuant to the Alliance Agreement, the Company will have priority access to Moffitt&#8217;s scientific research, manufacturing, and clinical capabilities for the development of novel TIL therapies, including expedited clinical trial activation, enhanced patient screening and data sharing, access to Moffitt&#8217;s cellular therapies research and development infrastructure, expanded</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">molecular data sets and biospecimens for research, and allocated cGMP manufacturing capacity for the Company&#8217;s product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Alliance Agreement, the Company is obligated to use commercially reasonable efforts to further develop TIL Products, to manufacture TIL Products, to obtain regulatory approval for at least one TIL Product in the United States and to commercialize TIL Products in all countries in which regulatory approval for a TIL Product has been obtained. For purposes of the Alliance Agreement, TIL Product means any pharmaceutical, biopharmaceutical, or biotechnology TIL product that has been developed by us or Moffitt and is advanced into clinical development under an IND sponsored by Moffitt.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Alliance Agreement, the Company agreed to pay to Moffitt a total amount of at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the &#8220;Alliance Funding Amount&#8221;), for research, development and manufacturing related services that will be paid equally over five years on June 1st of each year starting on June 1, 2023. The Alliance Funding Amount will be calculated annually at the conclusion of each payment period, and, to the extent the Company&#8217;s annual aggregate payments to Moffitt of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million exceeds the applicable annual installment amount, the Company will receive a reduction in the amount due for future installment payments based on a predetermined formula agreed to by the parties. To the extent the aggregate annual payments are less than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, the Company will prepay the remaining amount due. On June 28, 2024, the Alliance Agreement was amended to remove the true up of the applicable annual installment amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.  The Alliance Funding Amount remains $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million over the five year term.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the execution of the Alliance Agreement, the Company issued Moffitt </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">91,721</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock. As partial consideration under the Alliance Agreement, the Company also agreed to issue Moffitt an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">366,884</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of its common stock in the aggregate upon the satisfaction of certain clinical and regulatory milestones with respect to TIL Products. The issuances of common stock are treated as performance-based stock awards. On February 27, 2023, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">91,721</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares were issued due to the achievement of the milestone related to the start of the Phase 1 trial. In addition, upon achievement of certain thresholds for aggregate net sales of all TIL Products, the Company is required to make tiered sales-based milestones payments to Moffitt of up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. With respect to each of the equity and sales milestones described above, TIL Products include any pharmaceutical, biopharmaceutical or biotechnology TIL Product that is developed by the Company or Moffitt and is advanced into clinical development under an IND sponsored by Moffitt.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unless earlier terminated, the Alliance Agreement will remain in effect for a term of five years and may be extended for additional periods upon the mutual written consent of both parties. Either party may terminate the Alliance Agreement in the event of (i) the other party&#8217;s material breach of the Alliance Agreement that remains uncured after ninety days of receiving written notice of such breach (or in the case of breach of payment obligations, within ten days), (ii) the other party&#8217;s insolvency and (iii) a pandemic event resulting in government lockdowns or orders that legally compel such party to cease operations or that result in material disruptions in the available workforce and prevents such party from performing its contractual obligations for a period of more than six months. At any time after June 1, 2025, either party may terminate the Alliance Agreement without cause upon sixty days prior written notice to the other party (a &#8220;Termination for Convenience&#8221;). Upon a Termination for Convenience, the terminating party shall pay to the other party a termination fee in an amount equal to a low double digit percentage of the then remaining Alliance Funding Amount. Termination or expiry of one or more Underlying Agreements does not affect the term of the Alliance Agreement, which will continue to apply to the remaining ongoing Underlying Agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_AgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_AgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249631371520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Acquisition<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAbstract', window );"><strong>Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTextBlock', window );">Asset Acquisition</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7. Asset Acquisition</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2020, the Company entered into the Agreement and Plan of Merger and Reorganization (the &#8220;Myst Merger Agreement&#8221;), by and among the Company, Flatiron Merger Sub I, Inc. (&#8220;Merger Sub&#8221;), Flatiron Merger Sub II, LLC (&#8220;Merger LLC&#8221;), a direct, wholly-owned subsidiary of the Company, Myst, and Timothy Langer, the sole common stockholder of Myst (&#8220;Langer&#8221;). Pursuant to the Myst Merger Agreement, the business combination (the &#8220;Merger&#8221;) was effected in two steps. The first step was the merger of Merger Sub with and into Myst. The second step was the merger of Myst with and into Merger LLC. The Merger closed on December 14, 2020, and the effective date of the Merger was January 20, 2021. As a result of the Merger, the separate existences of Merger Sub and Myst ceased, and Merger LLC became the Company&#8217;s wholly-owned subsidiary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the Myst Merger Agreement, on December 15, 2020, the Company paid the former equity holders of Myst, (the &#8220;Myst Holders&#8221;), a one-time up-front payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cash. The Company paid an additional cash consideration of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million to the Myst Holders on June 14, 2022. The Company also issued Langer up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">725,920</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock. Of these shares, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">362,960</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock were issued upon the closing of the Merger and the remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">362,960</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock were held in escrow with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% vesting in December of each year that Langer remains with the Company. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, Langer is an advisor to the Company and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">272,220</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock have vested and been released from escrow with the remaining </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">90,740</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of the Company&#8217;s common stock to be released at the</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">end </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of 2024. This restricted equity grant is accounted for as a compensatory arrangement under ASC Topic 718, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Compensation &#8212; Stock Compensation</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;ASC 718&#8221;) as continued service is required under the agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, under the Myst Merger Agreement, each Myst Holder is entitled to receive certain payments as consideration based on the achievement by the Company of three predefined milestones. The initial milestone is the closing of an initial public offering, which occurred on July 25, 2023, the second milestone is the first acceptance by the FDA of an IND filed by, on behalf of or for the benefit of the Company, or the Company&#8217;s sublicensees for a product being developed by or on behalf of the Company or its sublicensees that is claimed as a product or method of making or using the product by a pending or issued Myst patent claim existing at the time of such acceptance, and the third milestone is the occurrence of the earlier of (i) the commencement of the first registration study for a product being developed by, on behalf of or for the benefit of the Company that is claimed as a product or a method of making or using the product by an issued Myst patent claim existing as of the time of such commencement or (ii) the issuance of a Myst patent claim that claims a product or method of making or using the product then being developed by, on behalf of or for the benefit of the Company, or its sublicensees, that is or was the subject of a registration study that has or had commenced. The milestones are not contingent on one another, and the milestones do not need to be achieved in any specific order.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Within 45 days of the achievement of the initial milestone, which occurred on July 25, 2023, the Company is obligated to pay the Myst Holders an aggregate amount equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. At the Company&#8217;s election, the Company may pay this consideration in cash or in shares of the Company&#8217;s common stock. Pursuant to a letter agreement dated September 11, 2023 between the Company and the former equityholders of Myst regarding the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million milestone payment that became due and owing to the Myst Holders, the Company agreed to pay $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cash to the former optionholders of Myst on or before September 30, 2023, with the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million payable to Langer in shares of the Company&#8217;s common stock. On September 11, 2023, the Company issued Langer </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">249,992</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Within 45 days of the achievement of the second milestone, the Company is obligated to pay the Myst Holders an aggregate amount equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. At the Company&#8217;s election, the Company may pay this consideration in cash or in shares of the Company&#8217;s common stock. In May 2022, this $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million milestone was achieved. The Company elected to pay $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in the Company&#8217;s common stock and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cash. Pursuant to a letter agreement dated July 25, 2022 between the Company and the former equityholders of Myst regarding the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million milestone payment that became due and owing to the Myst Holders, the Company agreed to pay to the former optionholders of Myst on or before July 28, 2022, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cash, with the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million payable to Langer as follows: (i) on or before July 28, 2022, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cash, (ii) on or before July 31, 2022, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in shares of the Company&#8217;s common stock and (iii) on or before January 10, 2023, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in cash. On June 8, 2022, the Company issued Langer </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">212,203</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of the Company&#8217;s common stock to settle the $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million obligation payable in common stock. The Company then paid the Myst Holders $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in July 2022, with $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million paid to Langer and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million paid to the remaining Myst Holders, and the remaining $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million was paid to Langer in January 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Within 45 days of the achievement of the third milestone, the Company is obligated to pay the Myst Holders an aggregate amount equal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. At the Company&#8217;s election, the Company may pay this consideration in cash or in shares of its common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounted for the merger with Myst pursuant to the Myst Merger Agreement as an asset acquisition as substantially all of the value received was concentrated in the acquired in-process research and development of Myst and did not have an alternate future use. The Company recognized a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million charge to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_7a312f44-81d0-4aab-b68e-4d0c368d2aae;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">research and development expense</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> at the time of the completion of the asset acquisition during the year ended December 31, 2020. The Company determined that the milestone payments are separate units of account and accounted for the initial milestone as a derivative in accordance with ASC Topic 815, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivatives and Hedging</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;ASC 815&#8221;)  and the second and third milestones as liabilities in accordance with ASC Topic 480, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Distinguishing Liabilities from Equity</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;ASC 480&#8221;). In connection with the initial public offering, the Company reassessed its initial accounting of the milestone payments and concluded that they should be viewed as one unit of account because the milestone payments are not legally detachable from each other. The milestone payments, as one unit of account, would be classified as a liability in accordance with ASC 480 and measured at fair value, with changes in the fair value recorded in earnings. Regardless of whether the milestone payments are viewed as one unit of account or three units of account, because they are all subject to fair value measurement, the financial reporting effect of the contingent consideration arrangement as one unit of account or three units of account is substantially the same. As a liability under ASC 480, the contingent consideration will continue to be recorded at fair value until settled. The adjustment to the fair value of the contingent consideration of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three months ended June 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively and was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the six months ended June 30, 2024 and 2023,  respectively, were included in research and development expense in the Company&#8217;s unaudited condensed consolidated statements of operations and comprehensive loss.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249631999504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Term Loan</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8. Term Loan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On April 26, 2024 (the "Closing Date"), the Company entered into the LSA, by and among the Company, as borrower, the Company&#8217;s wholly owned subsidiary, Myst Therapeutics, LLC (&#8220;Myst LLC&#8221; and, together with the Company, the &#8220;Loan Parties&#8221;) and BOC, as lender. The LSA provides for a revolving credit facility in an aggregate principal amount of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the &#8220;Revolving Loans&#8221;). The Company may request advances at any time the loan is not in default and not to exceed the Revolving Loans limit and may prepay any amounts outstanding at any time with no prepayment penalty.  Upon termination of the LSA, whether in connection with acceleration, prepayment in full, or otherwise, the Company is obligated to make a nonrefundable payment of  (i) $0.4 million at any time on or prior to the first anniversary of the Closing Date, and (ii) $0.2 million at any time after the first anniversary of the Closing Date but prior to the second anniversary.  In addition, the Company is obligated to pay a fee in the event of certain corporate transactions equal to the greater of (i) $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> or (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the highest aggregate principal amount outstanding prior to the transaction (the "Success Fee").  The Success Fee is due upon any merger or consolidation, any sale of substantially all of the assets of the Company, or the closing of one or more related financings where aggregate cash proceeds from the sale of equity securities and/or upfront cash proceeds from strategic partnerships is equal to at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">75.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and occurs on or before the tenth anniversary of the Closing Date (each a "Success Fee Event").  If the LSA is terminated prior to the payment of the Success Fee, the Company will remain obligated to pay the Success Fee upon the occurrence of a Success Fee Event during such ten-year period.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The annual interest rate applicable to the Revolving Loans is the greater of the Prime Rate (as defined in the LSA) and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">4.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Interest under the Revolving Loans is due and payable on the first calendar day of month during the term.  The initial maturity date of the Revolving Loans is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, which may be extended to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">March 31, 2027</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> subject to the satisfaction of certain terms and conditions as set forth in the LSA.  Upon maturity, all amounts outstanding will become due and payable.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The LSA contains customary representations and warranties and customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness and dividends and other distributions. The Company is also required to comply with certain covenants requiring the Company to (i) receive positive interim Phase 1 data for TIDAL-01 (as determined by the Company&#8217;s board of directors), which was satisfied in August 2024 and (ii) receive at least $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">40.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in new funding from the sale of equity, partnerships, and/or business development payments, in each case, by March 31, 2025. If the Company fails to comply with any of the foregoing covenants, the Lender may terminate the commitments to make further loans and declare all of the obligations of the Company under the LSA to be immediately due and payable.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The LSA also includes customary events of default, including failure to pay principal, interest or certain other amounts when due, material inaccuracy of representations and warranties, violation of covenants, specified cross-default and cross-acceleration to other material indebtedness, certain bankruptcy and insolvency events, certain undischarged judgments, material invalidity of guarantees or grant of security interest, material adverse effect and change of control, in certain cases subject to certain thresholds and grace periods. If one or more events of default occurs and continues beyond any applicable cure period, the Lender may terminate the commitments to make further loans and declare all of the obligations of the Company under the LSA to be immediately due and payable.  Additionally, upon the occurrence of an event of default, the Company is obligated to pay a fee equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% above the interest rate then in effect on all outstanding obligations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of  June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> amounts had been drawn under the Revolving Loans.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of debt issuance costs which were recorded as part of Other Current Assets and will be amortized over the term of the LSA.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249639522128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock and Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Redeemable Convertible Preferred Stock and Stockholders' Equity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9. Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Redeemable Convertible Preferred Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">From October 2015 to October 2016, the Company issued a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11,250,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of series A preferred stock (the &#8220;Series A Preferred Stock&#8221;) at CDN$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share (equivalent to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.74</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, based on a conversion ratio of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.344</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Canadian dollars to one U.S. dollar) for total net proceeds of CDN$ </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (equivalent to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">8.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million based on a conversion ratio of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.344</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Canadian dollars to one U.S. dollar).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2016, the Company issued a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">16,285,156</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of series B-1 preferred stock (the &#8220;Series B-1 Preferred Stock&#8221;) at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.77</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share for total net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. In November 2018, the Company issued </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25,065,538</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of series B-2 preferred stock (the &#8220;Series B-2 Preferred Stock&#8221;, and together with the Series B-1 Preferred Stock, the &#8220;Series B Preferred Stock&#8221;) at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share for total net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">28.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company issued a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">17,905,288</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of series C preferred stock (the &#8220;Series C Preferred Stock&#8221;) at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.35</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share in January 2019 for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">41.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company issued a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">29,285,356</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of series D preferred stock (the &#8220;Series D Preferred Stock&#8221;) at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.73</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share in June 2021 for net proceeds of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">79.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Company's IPO, all outstanding shares of the Company's redeemable convertible preferred stock automatically converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12,493,879</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock.  Subsequent to the closing of the IPO, there were no shares of redeemable convertible preferred stock outstanding.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the closing of the IPO, the Company filed its Amended and Restated Certificate of Incorporation which provides that the authorized common stock of the Company is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">490,000,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock with a par value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.001</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Shares of common stock reserved for future issuance consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock options outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,298,558</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,374,282</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested RSUs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108,899</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,945</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for issuance under the ESPP</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">453,280</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">222,287</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for issuance under the Plans</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,946,048</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,755,404</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,806,785</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,454,918</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249632996016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10. Equity Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2018 Equity Incentive Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2018, the Company adopted the 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;) which provided for the Company to grant incentive stock options or nonqualified stock options for the purchase of common stock, or restricted shares, to employees, members of the board of directors and consultants of the Company. The Company assumed all of the outstanding options under the amended and restated Equity Incentive Plan of Turnstone Biologics Inc. dated October 1, 2016 (the &#8220;2016 Plan&#8221;) in connection with the corporate reorganization in December 2018. However, there were no changes to the terms of the options requiring modification accounting.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All options granted under the 2018 Plan have an exercise price, a vesting period determined by the Company&#8217;s board of directors and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> term as determined and approved by the Company&#8217;s board of directors (the board of directors may delegate authority to one of the boards&#8217; committees) at the time of grant. The terms and conditions of the restricted shares are determined by the board of directors at the grant date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The majority of grants outstanding were approved with a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> vesting schedule with </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% vesting after one year and the remainder vesting evenly over the remaining 36 months. No further grants will be made under the 2018 Plan.  Any outstanding awards granted under these plans will remain subject to the terms of their 2016 and 2018 Plans, respectively, and applicable award agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2023 Equity Incentive Plan</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2023, the Company's board of directors and stockholders adopted the 2023 Equity Incentive Plan (the &#8220;2023 Plan&#8221; and together with the 2018 and 2016 Plans the "Plans") which became effective upon the date of the IPO.  Under the 2023 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, performance stock awards, performance cash awards and other forms of stock awards to employees, directors and consultants. The maximum term of the stock option grants under the 2023 Plan is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and, in general, the awards granted under the 2023 Plan vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period from the vesting commencement date. The 2023 Plan does not permit early exercises. The number of shares initially reserved for future issuance under the 2023 Plan was the sum of (1) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,889,435</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> new shares, plus (2) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">712,503</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> remaining shares of common stock reserved under the 2018 Plan that became available for issuance upon the effectiveness of the 2023 Plan, and (3) up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">120,949</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Returning Shares (as defined in the 2023 Plan), as such shares become available from time to time. The number of shares of common stock reserved for issuance under the 2023 Plan will automatically increase on January 1 of each year, for a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, from January 1, 2024 continuing through January 1, 2033, by </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as may be determined by the Company&#8217;s board of directors. As of January 1, 2024, an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,154,966</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> were available for future issuance under the 2023 Plan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of the stock option activity under the Plans is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.23%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.702%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.882%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.702%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.242%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Shares<br/>Underlying<br/>Outstanding<br/>Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average Exercise<br/>Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual Term<br/>(Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic Value<br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding &#8212; December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,529,982</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.86</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.8</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,912</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">189,365</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16.45</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,784</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.91</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options canceled/forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92,924</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.46</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding &#8212; June 30, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,604,639</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.42</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.8</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,605</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable &#8212; June 30, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,622,615</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.82</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.7</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and expected to vest &#8212; June 30, 2023</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,604,639</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.42</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.8</span></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,605</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding &#8212; December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,374,282</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.66</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.1</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">352</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">129,165</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.73</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,119</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.51</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options canceled/forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">175,770</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.97</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding &#8212; June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,298,558</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.56</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.5</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">354</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable &#8212; June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,955,510</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.9</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">341</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and expected to vest &#8212; June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,298,558</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.56</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.5</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">354</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of each stock option granted to employees and directors was estimated on the date of grant using the Black-Scholes option-pricing model, with the following range of assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:72.06%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:12.52%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:12.22%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.30</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.72</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.89</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.48</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.88</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.03</span></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.09</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.20</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Volatility</span></p></td>
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94.67</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85.8</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86.2</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise price of stock options<br/>&#160;granted</span></p></td>
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.68</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.88</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.18</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16.53</span></p></td>
       </tr>
      </table></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 2023, the Company grants RSUs to employees. The RSU activity is summarized as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.852%;"></td>
        <td style="width:2.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.563%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.521%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.023%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>RSUs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average Grant Date Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding, non-vested as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,945</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.71</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,384</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.75</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Cancelled/Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,430</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.71</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Vested/Released</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding, non-vested as of June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108,899</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.72</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:12pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense for all stock awards, including options, restricted stock and RSUs, included in the Company&#8217;s statements of operations is as follows (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.56%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.24%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">644</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">507</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,294</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,009</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">375</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">567</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">771</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,057</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,019</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,074</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,065</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,066</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The expense related to awards granted to employees and directors was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for each of the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2024 and 2023. The weighted-average grant date Black Scholes fair market value of options granted to employees, directors and consultants during the six months ended June 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.14</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.23</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, respectively.  The aggregate grant date fair value of RSUs granted by the Company during the six months ended June 30, 2024 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million.  </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> RSUs were granted by the Company during the six months ended June 30, 2023.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company had unrecognized stock-based compensation expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, related to stock options and RSUs, respectively, which is expected to be recognized over a weighted-average period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2.7</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3.5</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> years, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2020, Langer received </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">725,920</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares as payment related to the Myst Merger Agreement. Of the total issued, the Company restricted </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">362,960</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares to vest over a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period in equal annual installments. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">90,740</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares remain unvested, and the Company had $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million in unrecognized stock-based compensation expense related to unvested restricted stock which is expected to be recognized evenly over </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> months.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2023 Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2023, the Company adopted the Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), which became effective with the IPO on July 25, 2023. The ESPP was adopted by the Company&#8217;s board of directors and stockholders in June 2023. The ESPP initially provides participating employees with the opportunity to purchase up to an aggregate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">222,287</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. The number of shares of common stock reserved for issuance will automatically increase on January 1st of each calendar year for a period of up to</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ten years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, commencing on January 1, 2024 and ending on (and including) January 1, 2033, in an amount equal to the lesser of (i) one percent (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%) of the total number of shares of capital stock outstanding on the last day of the calendar month before the date of the automatic increase, and (ii) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">666,680</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares of common stock. Notwithstanding the foregoing, the board may act prior to the first day of any calendar year to provide that there will be no January 1st increase in the share reserve for such calendar year or that the increase in the share reserve for such calendar year will be a lesser number of shares of common stock than would otherwise occur pursuant to the preceding sentence. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 1, 2024, the shares available for issuance under the ESPP automatically increased by an additional </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">230,993</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> shares to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">453,280</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> total shares available to be issued under the ESPP.  As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, there was no enrollment offered to the Company's employees.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249633249328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11. Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company did </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t record federal income tax expense for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, as the Company expects to be in a cumulative taxable loss position in 2024 and 2023, and the net deferred tax assets are fully offset by a valuation allowance as it is not more likely than not that the benefit will be realized. The Company recorded a benefit (provision) for state income taxes of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249638823760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12. Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating Leases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company leases laboratory and office space for its corporate headquarters located in San Diego, California and office space in New York, New York and Ontario, Canada. Operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. In calculating the present value of the lease payments, the Company has elected to utilize its incremental borrowing rate based on the original lease term and not the remaining lease term. The Company determines if an arrangement is a lease by considering whether there is an identified asset, and the contract conveys the right to control its use. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company&#8217;s lease terms may include options to extend or terminate a lease. If the lease includes non-lease components (i.e., common area maintenance) that are paid separately from rent based on actual costs incurred and therefore are not included in the right-of-use asset and lease liability but are reflected as an expense in the period incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In July 2018, the Company entered into a lease agreement for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office space in New York, New York. The term of the lease is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">seven years and three months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">starting November 1, 2018. The lease requires the Company to share in prorated expenses and property taxes based upon actual amounts incurred. The lease contains escalating rent clauses which require higher rent payments in future years. In September 2022, the Company made the decision to sublease this space and executed a sublease in November 2022 for the remaining term of the lease. Since the Company is still responsible for making the lease payments, there was no impact to the operating lease liability from the sublease. However, since the sublease payment does not cover</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">entire lease payment, the carrying value of the operating right of use asset was analyzed and determined to be impaired resulting in a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million reduction in the operating right of use asset in September 2022.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2019, the Company executed an agreement to lease approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of laboratory space at Carleton University in Ontario, Canada. The initial term of the lease is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and started in November 2019 at a rate of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million per year. In November 2022, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the lease was extended for a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> period.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> In August 2023, the Company terminated the lease.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2019, the Company entered into a noncancelable operating lease for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9,423</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet located at 12 York Street, Ontario, CA. The term of the lease is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, starting December 1, 2019, and includes </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one renewal option for a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">five years</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The lease requires the Company to share in prorated expenses and property taxes based upon actual amounts incurred. The lease contains escalating rent clauses which require higher rent payments in future years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">     </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2021, the Company entered into a lease agreement for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19,474</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> square feet of office and laboratory space in San Diego, California. The initial term of the lease is </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">38 months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> with </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one renewal option for a period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and commenced in March 2022</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The lease requires the Company to share in prorated expenses and property taxes based upon actual amounts incurred. The lease contains escalating rent clauses which require higher rent payments in future years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recorded rent expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively.  </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below summarizes the Company&#8217;s total lease costs included in its unaudited condensed consolidated financial statements, as well as other required quantitative disclosures (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">). </span></span><span style=""></span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:27.826%;"></td>
        <td style="width:1.86%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.183%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.86%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.183%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.86%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.183%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.86%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.183%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">398</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">430</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">796</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">900</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term lease costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Variable leases costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">398</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">430</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">796</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">906</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The present value assumptions used in calculating the present value of the lease payments were as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:72.02%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:24.180000000000003%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average remaining lease term in years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.74</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The minimum aggregate future operating lease commitments at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 are as follows (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.36%;"></td>
        <td style="width:1.78%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.860000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Minimum Lease<br/>Payments</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Remainder of 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,056</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,110</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">105</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2029</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,270</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,204</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: current portion of operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,793</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability, noncurrent</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">411</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249639566448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13. Net Loss per Share</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Basic and diluted net loss per share attributed to common stockholders is calculated by dividing net loss attributed to common stockholders by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. The Company&#8217;s potentially dilutive shares, which include preferred stock, restricted stock, unvested RSUs and options to purchase common stock, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. Potentially dilutive common shares have been excluded from the diluted net loss per common share computations in all periods presented because such securities have an anti-dilutive effect on net loss per common share</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">due to the Company&#8217;s net loss. There are no reconciling items used to calculate the weighted-average number of total common shares outstanding for basic and diluted net loss per common share.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following outstanding potentially dilutive shares were excluded from the computation of diluted net loss per share attributable to common stockholders:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.98%;"></td>
        <td style="width:1.52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.98%;"></td>
       </tr>
       <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
        <td style="background-color:#ffffff;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
        <td style="background-color:#ffffff;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90,740</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">181,480</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested RSUs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108,899</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,298,558</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,604,639</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Redeemable convertible preferred stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,493,879</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,498,197</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,279,998</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249756372816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Proceedings</a></td>
<td class="text"><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14. Legal Proceedings</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is not a party to any material legal matters or claims and does </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t have contingency reserves established for any litigation liabilities as of June 30, 2024 and December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249632526016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation of Unaudited Condensed Consolidated Financial Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Presentation of Unaudited Condensed Consolidated Financial Information</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. However, such interim financial statements reflect all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the Company&#8217;s financial position and results of operations. Results shown for interim periods are not necessarily indicative of the results that may be expected for the year ended December 31, 2024 or for any other period. The condensed consolidated balance sheet as of December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> was derived from the audited consolidated financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements, included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 22, 2024. Certain prior period amounts reported in the Company&#8217;s unaudited condensed consolidated financial statements and accompanying notes have been reclassified to conform to the current period presentation. Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Principles of Consolidation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_SignificantAccountingPoliciesPolicyPolicyTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Significant Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The significant accounting policies used in preparation of these unaudited condensed consolidated financial statements are consistent with those discussed in Note 2 to the audited consolidated financial statements included in the Company&#8217;s Annual Report filed on Form 10-K filed with the SEC on March 22, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of these unaudited condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to accrued expenses, contingent liabilities, impairment of long-lived assets, revenue recognition, the valuation of equity-based compensation, common stock, restricted common stock, and income taxes. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_RestrictedCashAndInvestmentsPolicyPolicyTextBlock', window );">Restricted Cash and Investments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Cash and Investments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash consists of certificate of deposit accounts that are pledged as collateral for the Company&#8217;s San Diego facility lease. Restricted cash was approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 and December 31, 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company invests its excess cash in investment grade, short-term, fixed income securities and recognizes purchased securities on the settlement date. All investments have been classified as &#8220;available-for-sale&#8221; in the unaudited condensed consolidated balance sheets and are carried at estimated fair value based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments at the time of purchase and re-evaluates such designation as of each balance sheet date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company assesses its available-for-sale securities under the available-for-sale security impairment model in ASC Topic 326, Financial Instruments - Credit Losses ("ASC 326") as of each reporting date in order to determine if a portion of any decline in fair value below carrying value is the result of a credit loss. The Company records credit losses in the unaudited condensed consolidated statements of operations and comprehensive loss as credit loss expense, which is limited to the difference between the fair value and the amortized cost of the security. To date, the Company has not recorded any credit losses on its available-for-sale securities. Declines in fair value below carrying value attributable to non-credit related factors are recorded as accumulated other comprehensive loss, which is a separate component of stockholders&#8217; equity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Realized gains and losses are reported in other income (expense), net. Interest on short-term investments is included in other income (expense), net. The Company&#8217;s investments are classified as current assets which reflects management&#8217;s intention to use the proceeds from sales of these securities to fund its operations, as necessary.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, investments and restricted cash. The Company&#8217;s investment policy restricts cash investments to high credit quality, investment grade investments. The Company&#8217;s investment policy provides guidelines and limits regarding investment type, concentration, credit quality, and maturity aimed at maintaining sufficient liquidity to satisfy operating and working capital requirements along with strategic initiatives, preserving capital, and minimizing risk of capital loss while generating returns on its investments. The Company is exposed to credit risk in the event of default by the issuer or the institutions holding the cash and cash equivalents to the extent of the amounts recorded on the balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has no off-balance sheet risk, such as foreign exchange contracts, option contracts or other foreign-hedging arrangements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the unaudited condensed consolidated financial statements on a recurring basis. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy requires that an entity maximize the use of observable inputs when estimating fair value. The fair value hierarchy includes the following three-level classification which is based on the market observability of the inputs used for estimating the fair value of the assets or liabilities being measured:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Quoted market prices in active markets for identical assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2 &#8211; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3 &#8211;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Inputs that are generally unobservable and typically reflect management&#8217;s estimate of assumptions that a market participant would use in pricing the asset or liability.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized at fair value in the unaudited condensed consolidated financial statements on a recurring basis (at least annually). To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Stock-Based Compensation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company accounts for stock-based compensation expense related to stock options and restricted stock units, ("RSUs"), by estimating the fair value on the date of grant. The fair value of RSUs granted to employees is the closing price of the Company&#8217;s common stock on the date of grant. The Company estimates the fair value of stock options granted to employees and non-employees using the Black-Scholes option pricing model. The Company recognizes stock-based compensation expense, over the requisite service period, based on the vesting provisions of the individual grants. Generally, the Company issues stock-based awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. The Company accounts for forfeitures when they occur.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a) the expected stock price volatility, (b) the expected term of the award, (c) the risk-free interest rate and (d) expected dividend yields. Due to the lack of a public market for the Company&#8217;s common stock until July 21, 2023, and lack of company- specific historical and implied volatility data, the Company has based its computation of expected volatility on the average historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term. The Company uses the simplified method as prescribed by the U.S. Securities and Exchange Commission Staff Accounting Bulletin No. 107,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Share-Based </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_FairValueOfCommonStockPolicyPolicyTextBlock', window );">Determination of Fair Value of Common Stock</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Determination of Fair Value of Common Stock</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">After the Company's IPO in July 2023, the fair value of common stock is determined using the closing price of the Company's common stock on the Nasdaq Global Market. Prior to the IPO, there were significant judgments and estimates inherent in the determination of the fair value of the Company&#8217;s common stock. These estimates and assumptions include a number of objective and subjective factors, including, among other things, external market conditions, the prices at which the Company sold shares of its convertible preferred stock, the superior rights and preferences of securities senior to its common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale of the Company. The approach to estimating the fair market value of common stock is consistent with the methods outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide, Valuation of Privately-Held Company Equity Securities Issued as Compensation (the &#8220;Practice Aid&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In valuing the Company&#8217;s common stock prior to the IPO, the equity value of the business was determined using the backsolve method, a form of the subject company transaction method, wherein the equity value for a privately held company is derived from a recent transaction in the company&#8217;s own securities. The value is then allocated using the hybrid method allocation methodology. For grants made subsequent to September 30, 2018 but prior to the IPO, the Company used a hybrid method, which is a hybrid between the OPM and the probability-weighted expected return method (&#8220;PWERM&#8221;). The hybrid method is a combination of the PWERM and OPM. The OPM allocates the overall Company value to the various share classes based on differences in liquidation preferences, participation rights, dividend policy and conversion rights, using a series of call options. The call right is valued using a Black-Scholes option pricing model. The PWERM employs additional information not used in the OPM, including various market approach calculations depending upon the likelihood of various discrete future liquidity scenarios, such as an initial public offering or sale of the Company, as well as the probability of remaining a private company. In a hybrid method, various exit scenarios are analyzed. A discount for lack of marketability of the Company&#8217;s common stock was then applied to arrive at an indication of value for the common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ContingentConsiderationPolicyPolicyTextBlock', window );">Contingent Consideration</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Contingent Consideration</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consideration paid related to the Myst Merger Agreement (see</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Note 7 - Asset Acquisition</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for additional information) may include potential future payments that are contingent upon the Company achieving certain milestones in the future. Contingent consideration liabilities are measured at their estimated fair value as of the date of the unaudited condensed consolidated balance sheets using a probability-based income approach based on the monetary value of the milestone payment discounted for the likelihood of achieving the milestone and a present value factor based on the timing of when the milestone is expected to be achieved. Contingent consideration liabilities expected to be settled within 12 months after the balance sheet date are presented in current liabilities, with the non-current portion recorded under other liabilities, non-current in the unaudited condensed consolidated balance sheets. Changes in the fair value of the contingent consideration are recorded as research and development expenses in the unaudited condensed consolidated statement of operations and comprehensive loss.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Debt&#8212;Debt with Conversion and Other Options </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Subtopic 470-20) and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivatives and Hedging Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Subtopic 815-40) (&#8220;ASU 2020-06&#8221;), which reduces the number of accounting models for convertible debt instruments and convertible preferred stock as well as amends the derivatives scope exception for contracts in an entity&#8217;s own equity. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_8fb38185-ea26-45ab-b107-b14eace25cd0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ASU 2020-06</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> is effective for the Company on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2024</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.  The </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">adoption</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">did not have a material impact</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> on the unaudited condensed consolidated financial statements.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Recently Issued Accounting Pronouncements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, the FASB issued ASU No. 2023-07, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Segment Reporting </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Topic 280)&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Improvements to Reportable Segment Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;ASU 2023-07&#8221;). ASU 2023-07 requires that an entity disclose significant segment expenses impacting profit and loss that are regularly provided to the chief operating decision maker. The update is required to be applied retrospectively to prior periods presented, based on the significant segment expense categories identified and disclosed in the period of adoption. The amendments in</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ASU 2023-07 are required to be adopted for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the potential impact that this standard may have on its unaudited condensed consolidated financial statements and related disclosures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, the FASB issued ASU No. 2023-09,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (Topic 740)&#8212;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Improvements to Income Tax Disclosures</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (&#8220;ASU 2023-09&#8221;). ASU 2023-09 requires that an entity disclose specific categories in the effective tax rate reconciliation as well as provide additional information for reconciling items that meet a quantitative threshold. Further, ASU 2023-09 requires certain disclosures of state versus federal income tax expense and taxes paid. The amendments in ASU 2023-09 are required to be adopted for fiscal years beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued. The amendments should be applied on a prospective basis although retrospective application is permitted. The Company is currently evaluating the potential impact that this standard may have on its unaudited condensed consolidated </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">financial statements and related disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_ContingentConsiderationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_ContingentConsiderationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_FairValueOfCommonStockPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of common stock policy text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_FairValueOfCommonStockPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recently issued accounting pronouncements policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_RestrictedCashAndInvestmentsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted cash and investments policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_RestrictedCashAndInvestmentsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_SignificantAccountingPoliciesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant accounting policies policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_SignificantAccountingPoliciesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249631107760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured on Recurring Basis at Fair Value</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables represent a summary of the financial assets and liabilities that are measured on a recurring basis at fair value </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.949%;"></td>
        <td style="width:1.081%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.049%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.081%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.866999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.081%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.866999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.081%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.866999999999999%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.081%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="background-color:#cff0fc;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,125</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,125</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,997</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,997</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,238</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,238</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial liabilities:</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent consideration</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,024</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,024</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,024</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,024</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 1</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 2</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Level 3</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
        <td style="background-color:#cff0fc;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial assets:</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,635</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,635</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">U.S. government securities</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(2)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,979</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,979</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92,730</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92,730</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financial liabilities:</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent consideration</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(3)</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">916</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">916</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">916</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">916</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><div class="item-list-element-wrapper" style="display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash serves as deposits for the Company&#8217;s San Diego office lease. </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(2)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Included in short-term investments on the unaudited condensed consolidated balance sheets and are classified as available-for sale debt securities. </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(3)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Contingent consideration related to the Myst Merger Agreement. </span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Unobservable Input of Contingent Consideration Valuation</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following significant unobservable inputs were used in the valuation of the contingent consideration payable to the sole common stockholder of Myst Therapeutics, Inc. ("Myst") pursuant to the Myst Merger Agreement:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:29.174%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.077%;"></td>
        <td style="width:1%;"></td>
        <td style="width:19.816%;"></td>
        <td style="width:19.956%;"></td>
        <td style="width:1.38%;"></td>
        <td style="width:13.597%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value as of</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Contingent Consideration Liability</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Valuation Technique</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unobservable Input</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">'Milestone payment for first registrational study (see Note 7 - Asset Acquisition for additional information)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,024</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Discounted cash flow</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Likelihood of occurrence</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Discount rate</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.0</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair Value as of</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Contingent Consideration Liability</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Valuation Technique</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Unobservable Input</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amount</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="vertical-align:top;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">'Milestone payment for first registrational study (see Note 7 - Asset Acquisition for additional information)</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">916</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Discounted cash flow</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Likelihood of occurrence</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:middle;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Discount rate</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.5</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Company's Contingent Consideration Measured at Fair Value Level 3</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table reflects the activity for the Company&#8217;s contingent consideration, measured at fair value using Level 3 inputs (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.876%;"></td>
        <td style="width:2.02%;"></td>
        <td style="width:1%;"></td>
        <td style="width:18.104%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent consideration at December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">916</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in the fair value of contingent consideration</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contingent consideration at June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,024</span></p></td>
        <td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_CompanyCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryTableTextBlock', window );">Schedule of Company's Cash, Cash Equivalents and Available-for-Sale Securities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following tables show the Company&#8217;s cash, cash equivalents and available-for-sale securities by significant investment category </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.761%;"></td>
        <td style="width:1.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.189%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.189%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.189%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.189%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1:  Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,125</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,125</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Restricted cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;U.S. government securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,021</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,997</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,262</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,238</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Classified as:</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,125</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,997</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,238</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.761%;"></td>
        <td style="width:1.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.189%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.189%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.189%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.121%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.189%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross<br/>Unrealized<br/>Losses</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated<br/>Fair<br/>Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Level 1:  Money market funds</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,635</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,635</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Restricted cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;U.S. government securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,875</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,979</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92,626</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92,730</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Classified as:</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,635</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted cash</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">116</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,979</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92,730</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_CompanyCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company cash, cash equivalents and&#160;available for sale&#160;securities by significant investment category [Table Text Block].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_CompanyCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249631708096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment Net</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Property and equipment, net consist of the following (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.16%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,112</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,043</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Furniture</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">690</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">690</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,308</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,308</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,110</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,041</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,541</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,689</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,569</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,352</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249624692736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses and other current liabilities consist of the following </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(in thousands):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.16%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:12.92%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,187</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,675</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Professional and consulting expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">753</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">641</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,336</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,593</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,354</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,909</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of accrued liabilities and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249631691488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_CollaborativeArrangementDisclosureAbstract', window );"><strong>Collaborative Arrangement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationTableTextBlock', window );">Schedule Of Transaction Price Allocated To Programs Performance Obligation</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company determined that the notice of termination on June 13, 2022, represented a modification of the arrangement under ASC 606 and that the transaction price should be updated and re-allocated to the Development Program Performance Obligation and the Discovery Program Performance Obligation based on their standalone selling prices, as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.571%;"></td>
        <td style="width:1.429%;"></td>
        <td style="width:18.571%;"></td>
        <td style="width:1.429%;"></td>
        <td style="width:20%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Performance Obligations</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Price Pre-<br/>Modification</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Price at<br/>Modification</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Development Program</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">166.3</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;million</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">134.3</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;million</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Discovery Program</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26.3</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;million</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21.2</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;million</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">192.6</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;million</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">155.5</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;million</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_CollaborativeArrangementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement Disclosure Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_CollaborativeArrangementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_ScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of transaction price allocated to programs performance obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_ScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249633733520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock and Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock', window );">Summary of shares of common stock reserved for future issuance</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Shares of common stock reserved for future issuance consisted of the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock options outstanding</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,298,558</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,374,282</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested RSUs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108,899</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,945</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for issuance under the ESPP</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">453,280</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">222,287</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Shares available for issuance under the Plans</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,946,048</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,755,404</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,806,785</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,454,918</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of common stock shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249634339200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option plan activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A summary of the stock option activity under the Plans is as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.23%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.702%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.882%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.702%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.242%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>Shares<br/>Underlying<br/>Outstanding<br/>Options</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average Exercise<br/>Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining<br/>Contractual Term<br/>(Years)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Aggregate<br/>Intrinsic Value<br/>(in thousands)</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding &#8212; December 31, 2022</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,529,982</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.86</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.8</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,912</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">189,365</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16.45</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,784</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.91</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options canceled/forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92,924</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.46</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding &#8212; June 30, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,604,639</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.42</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.8</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,605</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable &#8212; June 30, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,622,615</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.82</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.7</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,100</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;word-break:break-word;">
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and expected to vest &#8212; June 30, 2023</span></p></td>
        <td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,604,639</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9.42</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.8</span></span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,605</span></p></td>
        <td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding &#8212; December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,374,282</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.66</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.1</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">352</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">129,165</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.73</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options exercised</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,119</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.51</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options canceled/forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">175,770</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.97</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding &#8212; June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,298,558</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.56</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.5</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">354</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercisable &#8212; June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,955,510</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8.40</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.9</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">341</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Vested and expected to vest &#8212; June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,298,558</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7.56</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.5</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">354</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of fair value assumption of stock option activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The fair value of each stock option granted to employees and directors was estimated on the date of grant using the Black-Scholes option-pricing model, with the following range of assumptions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:72.06%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:12.52%;"></td>
        <td style="width:1.6%;"></td>
        <td style="width:12.22%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.30</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.72</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3.89</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4.48</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.88</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.03</span></span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.09</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;- </span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6.20</span></span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dividend yield</span></p></td>
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Volatility</span></p></td>
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94.0</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94.67</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">85.8</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">% - </span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86.2</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercise price of stock options<br/>&#160;granted</span></p></td>
        <td style="text-indent:10pt;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.68</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.88</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">$</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11.18</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;- $</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16.53</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of RSU activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 2023, the Company grants RSUs to employees. The RSU activity is summarized as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.852%;"></td>
        <td style="width:2.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.563%;"></td>
        <td style="width:1%;"></td>
        <td style="width:2.521%;"></td>
        <td style="width:1%;"></td>
        <td style="width:16.023%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number of<br/>RSUs</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted-<br/>Average Grant Date Fair Value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding, non-vested as of December 31, 2023</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102,945</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.71</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Granted</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,384</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.75</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Cancelled/Forfeited</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,430</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.71</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;Vested/Released</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Outstanding, non-vested as of June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108,899</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.72</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock based compensation for stock awards</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Stock-based compensation expense for all stock awards, including options, restricted stock and RSUs, included in the Company&#8217;s statements of operations is as follows (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.56%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.24%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.12%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.24%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">644</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">507</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,294</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,009</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">375</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">567</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">771</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,057</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stock-based compensation</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,019</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,074</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,065</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,066</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249633700912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of information about lease costs</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The table below summarizes the Company&#8217;s total lease costs included in its unaudited condensed consolidated financial statements, as well as other required quantitative disclosures (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">). </span>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:27.826%;"></td>
        <td style="width:1.86%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.183%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.86%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.183%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.86%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.183%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.86%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.183%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">398</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">430</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">796</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">900</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term lease costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Variable leases costs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">398</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">430</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">796</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">906</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ScheduleOfPresentValueOfOperatingLeasePayments', window );">Schedule of present value of operating lease payments</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The present value assumptions used in calculating the present value of the lease payments were as follows:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:72.02%;"></td>
        <td style="width:1.8%;"></td>
        <td style="width:1%;"></td>
        <td style="width:24.180000000000003%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average remaining lease term in years</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.2</span></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average discount rate</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5.74</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of minimum aggregate future operating lease commitments</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The minimum aggregate future operating lease commitments at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 are as follows (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">in thousands</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">):</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.36%;"></td>
        <td style="width:1.78%;"></td>
        <td style="width:1%;"></td>
        <td style="width:15.860000000000001%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Minimum Lease<br/>Payments</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Remainder of 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,056</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,110</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">105</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2028</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2029</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,270</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">66</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,204</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Less: current portion of operating lease liability</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,793</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating lease liability, noncurrent</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">411</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_ScheduleOfPresentValueOfOperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_ScheduleOfPresentValueOfOperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249632007008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of dilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following outstanding potentially dilutive shares were excluded from the computation of diluted net loss per share attributable to common stockholders:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.98%;"></td>
        <td style="width:1.52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.52%;"></td>
        <td style="width:1%;"></td>
        <td style="width:14.5%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.98%;"></td>
       </tr>
       <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
        <td style="background-color:#ffffff;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#ffffff;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:#ffffff;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended June 30,</span></p></td>
        <td style="background-color:#ffffff;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Restricted stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">90,740</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">181,480</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unvested RSUs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108,899</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,298,558</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,604,639</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Redeemable convertible preferred stock</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,493,879</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,498,197</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,279,998</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249630075600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 15, 2023</div></th>
<th class="th"><div>Jul. 25, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_BusinessDescriptionAndBasisOfPresentationLineItems', window );"><strong>Business Description And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Description of the reverse stock split arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-7.9872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of new stock issued during the period</a></td>
<td class="nump">651,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Cash received on stock transaction after deduction of issuance costs</a></td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_UnderwritingDiscountsAndCommissions', window );">Underwriting discounts and commissions</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_SharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490,000,000<span></span>
</td>
<td class="nump">490,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (21,304)<span></span>
</td>
<td class="num">$ (19,629)<span></span>
</td>
<td class="num">$ (21,499)<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
<td class="num">$ (40,933)<span></span>
</td>
<td class="num">$ (21,431)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176,758<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_BusinessDescriptionAndBasisOfPresentationLineItems', window );"><strong>Business Description And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Revolving credit facility, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_BusinessDescriptionAndBasisOfPresentationLineItems', window );"><strong>Business Description And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of new stock issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Cash received on stock transaction after deduction of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_UnderwritingDiscountsAndCommissions', window );">Underwriting discounts and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_OtherOfferingExpenses', window );">Other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_BusinessDescriptionAndBasisOfPresentationLineItems', window );"><strong>Business Description And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments', window );">Funding from sale of equity partnerships and or business development payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_BusinessDescriptionAndBasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Description And Basis Of Presentation [Line Item]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_BusinessDescriptionAndBasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funding From Sale Of Equity Partnerships And Or Business Development Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_OtherOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Offering Expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_OtherOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_SharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_SharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_UnderwritingDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underwriting discounts and commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_UnderwritingDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249631788784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 25, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Description of the reverse stock split arrangement</a></td>
<td class="text">1-for-7.9872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in Accounting Principle, Accounting Standards Update, Adoption Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList', window );">Change in Accounting Principle, Accounting Standards Update, Transition Option Elected [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:AccountingStandardsUpdate202006Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 326<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates transition method applied for adoption of amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-5<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-5<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249633064848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities - Schedule of financial assets and liabilities measured on recurring basis at fair value (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 52,238<span></span>
</td>
<td class="nump">$ 92,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=tsbx_ContingentConsiderationMember', window );">Contingent consideration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">1,024<span></span>
</td>
<td class="nump">916<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring basis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">7,125<span></span>
</td>
<td class="nump">15,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_RestrictedCashAndCashEquivalentsAtFairValue', window );">Restricted cash</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue', window );">U.S. government securities</a></td>
<td class="nump">44,997<span></span>
</td>
<td class="nump">76,979<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">52,238<span></span>
</td>
<td class="nump">92,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">1,024<span></span>
</td>
<td class="nump">916<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring basis [Member] | Contingent consideration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">1,024<span></span>
</td>
<td class="nump">916<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring basis [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">7,125<span></span>
</td>
<td class="nump">15,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_RestrictedCashAndCashEquivalentsAtFairValue', window );">Restricted cash</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue', window );">U.S. government securities</a></td>
<td class="nump">44,997<span></span>
</td>
<td class="nump">76,979<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">52,238<span></span>
</td>
<td class="nump">92,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring basis [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total financial liabilities</a></td>
<td class="nump">1,024<span></span>
</td>
<td class="nump">916<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value recurring basis [Member] | Level 3 [Member] | Contingent consideration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 1,024<span></span>
</td>
<td class="nump">$ 916<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_RestrictedCashAndCashEquivalentsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted cash and cash equivalents at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_RestrictedCashAndCashEquivalentsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value as of the balance sheet date of firm holdings in debt obligations issued by the US government including short-term Treasury bills, medium-term Treasury notes, and long-term Treasury bonds, as well as debt issued by agencies. Includes both pledged (to counterparties as collateral for financing transactions) and unpledged holdings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479035/940-320-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=tsbx_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=tsbx_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249632376656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities - Schedule of unobservable input of contingent consideration valuation (Detail) - Contingent consideration [Member]<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>yr</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>yr</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value of financial liabilities | $</a></td>
<td class="nump">$ 1,024<span></span>
</td>
<td class="nump">$ 916<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=tsbx_MeasurementInputLikelihoodOfOccurrenceMember', window );">Measurement input likelihood of occurrence [Member] | Valuation technique discounted cash flow [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration input range</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement input discount rate [Member] | Valuation technique discounted cash flow [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration input range</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement input expected term [Member] | Valuation technique discounted cash flow [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration input range | yr</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=tsbx_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=tsbx_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=tsbx_MeasurementInputLikelihoodOfOccurrenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=tsbx_MeasurementInputLikelihoodOfOccurrenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249633771888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities -  Schedule of company's contingent consideration measured at fair value level 3 (Detail) - Contingent consideration [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in the fair value of contingent consideration</a></td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 1,024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=tsbx_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=tsbx_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249632491696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities - Schedule of company's cash, cash equivalents and available-for-sale securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_FairValueDisclosuresLineItems', window );"><strong>Fair Value Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 52,262<span></span>
</td>
<td class="nump">$ 92,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross unrealized losses</a></td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Estimated fair value</a></td>
<td class="nump">52,238<span></span>
</td>
<td class="nump">92,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_FairValueDisclosuresLineItems', window );"><strong>Fair Value Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">7,125<span></span>
</td>
<td class="nump">15,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Estimated fair value</a></td>
<td class="nump">7,125<span></span>
</td>
<td class="nump">15,635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=tsbx_RestrictedCashMember', window );">Restricted cash [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_FairValueDisclosuresLineItems', window );"><strong>Fair Value Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Estimated fair value</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=tsbx_RestrictedCashMember', window );">Restricted cash [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_FairValueDisclosuresLineItems', window );"><strong>Fair Value Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Estimated fair value</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government and agency securities [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_FairValueDisclosuresLineItems', window );"><strong>Fair Value Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">45,021<span></span>
</td>
<td class="nump">76,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain', window );">Gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Gross unrealized losses</a></td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Estimated fair value</a></td>
<td class="nump">44,997<span></span>
</td>
<td class="nump">76,979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_FairValueDisclosuresLineItems', window );"><strong>Fair Value Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Estimated fair value</a></td>
<td class="nump">7,125<span></span>
</td>
<td class="nump">15,635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_FairValueDisclosuresLineItems', window );"><strong>Fair Value Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Estimated fair value</a></td>
<td class="nump">$ 44,997<span></span>
</td>
<td class="nump">$ 76,979<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_FairValueDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value disclosures [Lineitems].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_FairValueDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=tsbx_RestrictedCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=tsbx_RestrictedCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249637279584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>Security</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>Security</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Security</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_FairValueDisclosuresLineItems', window );"><strong>Fair Value Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeExtensibleEnumeration', window );">Investment, Type [Extensible Enumeration]</a></td>
<td class="text">Short-Term Investments [Member]<span></span>
</td>
<td class="text">Short-Term Investments [Member]<span></span>
</td>
<td class="text">Short-Term Investments [Member]<span></span>
</td>
<td class="text">Short-Term Investments [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Available-for-sale debt securities an aggregate unrealized loss position</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities an aggregate fair value</a></td>
<td class="nump">$ 42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_FairValueDisclosuresLineItems', window );"><strong>Fair Value Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of available-for-sale debt securities in gross unrealized loss position | Security</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_FairValueDisclosuresLineItems', window );"><strong>Fair Value Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of available-for-sale debt securities in gross unrealized loss position | Security</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tsbx_MystMember', window );">Myst [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_FairValueDisclosuresLineItems', window );"><strong>Fair Value Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_FairValueDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value disclosures [Lineitems].</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_FairValueDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of investment. Includes, but is not limited to, common stock, preferred stock, convertible security, fixed income security, government security, option purchased, warrant, loan participation and assignment, commercial paper, bankers' acceptance, certificates of deposit, short-term security, repurchase agreement, and other investment company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column C)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=tsbx_MystMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=tsbx_MystMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249632717936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment, Net Consist (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Laboratory equipment</a></td>
<td class="nump">$ 11,112<span></span>
</td>
<td class="nump">$ 11,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Furniture</a></td>
<td class="nump">690<span></span>
</td>
<td class="nump">690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">1,308<span></span>
</td>
<td class="nump">1,308<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property plant and equipment gross</a></td>
<td class="nump">13,110<span></span>
</td>
<td class="nump">13,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(7,541)<span></span>
</td>
<td class="num">(6,689)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">$ 5,569<span></span>
</td>
<td class="nump">$ 6,352<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249633749936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Property and equipment depreciation and amortization expense</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 1,007<span></span>
</td>
<td class="nump">$ 1,439<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249757035344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Liabilities and Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Liabilities and Other Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ResearchAndDevelopmentExpenseLiabilities', window );">Research and development expense</a></td>
<td class="nump">$ 9,187<span></span>
</td>
<td class="nump">$ 5,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional and consulting expense</a></td>
<td class="nump">753<span></span>
</td>
<td class="nump">641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_AccruedCompensationCurrent', window );">Compensation</a></td>
<td class="nump">2,336<span></span>
</td>
<td class="nump">3,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 12,354<span></span>
</td>
<td class="nump">$ 9,909<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_AccruedCompensationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued compensation current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_AccruedCompensationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_ResearchAndDevelopmentExpenseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expense liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_ResearchAndDevelopmentExpenseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249624774640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Agreements - Schedule Of Transaction Price Allocated To Programs Performance Obligation (Detail)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_PriceModificationAxis=tsbx_PricePreModificationMember', window );">Price Pre-Modification [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationLineItems', window );"><strong>Schedule Of Transaction Price Allocatied To Programs Performance Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Performance Obligations</a></td>
<td class="nump">$ 192.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_PriceModificationAxis=tsbx_PriceAtModificationMember', window );">Price at Modification [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationLineItems', window );"><strong>Schedule Of Transaction Price Allocatied To Programs Performance Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Performance Obligations</a></td>
<td class="nump">155.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=tsbx_DevelopmentProgramMember', window );">Development Program [Member] | Price Pre-Modification [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationLineItems', window );"><strong>Schedule Of Transaction Price Allocatied To Programs Performance Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Performance Obligations</a></td>
<td class="nump">166.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=tsbx_DevelopmentProgramMember', window );">Development Program [Member] | Price at Modification [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationLineItems', window );"><strong>Schedule Of Transaction Price Allocatied To Programs Performance Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Performance Obligations</a></td>
<td class="nump">134.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=tsbx_DiscoveryProgramMember', window );">Discovery Program [Member] | Price Pre-Modification [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationLineItems', window );"><strong>Schedule Of Transaction Price Allocatied To Programs Performance Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Performance Obligations</a></td>
<td class="nump">26.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=tsbx_DiscoveryProgramMember', window );">Discovery Program [Member] | Price at Modification [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationLineItems', window );"><strong>Schedule Of Transaction Price Allocatied To Programs Performance Obligation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Performance Obligations</a></td>
<td class="nump">$ 21.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of transaction price allocatied to programs performance obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_PriceModificationAxis=tsbx_PricePreModificationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_PriceModificationAxis=tsbx_PricePreModificationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_PriceModificationAxis=tsbx_PriceAtModificationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_PriceModificationAxis=tsbx_PriceAtModificationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=tsbx_DevelopmentProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=tsbx_DevelopmentProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=tsbx_DiscoveryProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=tsbx_DiscoveryProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249638161888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Agreements - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 15, 2023</div></th>
<th class="th"><div>Feb. 27, 2023</div></th>
<th class="th"><div>Jun. 01, 2022</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Inflow From Issuance Of Intangible Asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Additional revenue recognized on change in contract modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of new stock issued during the period</a></td>
<td class="nump">651,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tsbx_TakedaAgreementMember', window );">Takeda Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Inflow From Issuance Of Intangible Asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_PercentageOfOperatingProfitOrLoss', window );">Percentage of share of operating profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Performance Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Additional revenue recognized on change in contract modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Additional revenue recognized on change in contract modification<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 19,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_CollaborativeArrangementAdditionalConsiderationReceivableForLicensedOption', window );">Collaborative arrangement additional consideration receivable for license option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_RevenuePerformanceObligationFixedAggregateConsideration', window );">Revenue, performance obligation fixed aggregate consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundableUpfrontPaymentReceived', window );">Revenue, performance obligation fixed consideration Non refundable upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundablePaymentReceived', window );">Revenue, performance obligation fixed consideration Non refundable payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_EstimatedCompensationEarningFromProjectExpenseSharing', window );">Estimated compensation earning from project expense sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tsbx_TakedaAgreementMember', window );">Takeda Agreement [Member] | Development Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Inflow From Issuance Of Intangible Asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Receivables related to reimbursable costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tsbx_TakedaAgreementMember', window );">Takeda Agreement [Member] | Development Program [Member] | First Milestone Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Inflow From Issuance Of Intangible Asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_MilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Performance Obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tsbx_TakedaAgreementMember', window );">Takeda Agreement [Member] | Development Program [Member] | Second Milestone Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Inflow From Issuance Of Intangible Asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_MilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tsbx_TakedaAgreementMember', window );">Takeda Agreement [Member] | Development Program [Member] | Third Milestone Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Inflow From Issuance Of Intangible Asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_MilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tsbx_TakedaAgreementMember', window );">Takeda Agreement [Member] | Discovery Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Inflow From Issuance Of Intangible Asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsFairValueDisclosure', window );">Equity purchase commitments by counter party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tsbx_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda Pharmaceutical Company Limited [Member] | Takeda Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Inflow From Issuance Of Intangible Asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Inflow From Issuance Of Intangible Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_PercentageOfOperatingProfitOrLoss', window );">Percentage of share of operating profit or loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_CollaborativeArrangementAdditionalConsiderationReceivable', window );">Collaborative arrangement additional consideration receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tsbx_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda Pharmaceutical Company Limited [Member] | Takeda Agreement [Member] | Clinical and Regulatory Milestones On Development Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Inflow From Issuance Of Intangible Asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_MilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tsbx_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda Pharmaceutical Company Limited [Member] | Takeda Agreement [Member] | Sales Milestones On Development Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Inflow From Issuance Of Intangible Asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_MilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tsbx_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda Pharmaceutical Company Limited [Member] | Takeda Agreement [Member] | Clinical and Regulatory Milestones on Licensed Discovery Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Inflow From Issuance Of Intangible Asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_MilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tsbx_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda Pharmaceutical Company Limited [Member] | Takeda Agreement [Member] | Sales Milestones on Licensed Discovery Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Inflow From Issuance Of Intangible Asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_MilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tsbx_H.LeeMoffittCancerCenterMember', window );">H. Lee Moffitt Cancer Center [Member] | Alliance Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Inflow From Issuance Of Intangible Asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ResearchDevelopmentAndManufacturingServicesAggregateAnnualAmount', window );">Research development and manufacturing services aggregate annual amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_CollaborativeArrangementAggregateConsiderationPayable', window );">Collaborative arrangement aggregate consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of new stock issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_CollaborativeArrangementAggregateConsiderationRemains', window );">Collaborative arrangement aggregate consideration remains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ResearchDevelopmentAndManufacturingServicesAmendedToRemoveTrueUpAnnaulInstallment', window );">Research development and manufacturing services amended to remove the true up annual installment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tsbx_H.LeeMoffittCancerCenterMember', window );">H. Lee Moffitt Cancer Center [Member] | Alliance Agreement [Member] | Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Inflow From Issuance Of Intangible Asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of new stock issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of non-vested equity-based payment instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">366,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tsbx_H.LeeMoffittCancerCenterMember', window );">H. Lee Moffitt Cancer Center [Member] | Alliance Agreement [Member] | Sales Based Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Inflow From Issuance Of Intangible Asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_CollaborativeArrangementAdditionalConsiderationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement additional consideration receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_CollaborativeArrangementAdditionalConsiderationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_CollaborativeArrangementAdditionalConsiderationReceivableForLicensedOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement additional consideration receivable for license option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_CollaborativeArrangementAdditionalConsiderationReceivableForLicensedOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_CollaborativeArrangementAggregateConsiderationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement aggregate consideration payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_CollaborativeArrangementAggregateConsiderationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_CollaborativeArrangementAggregateConsiderationRemains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement aggregate consideration remains</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_CollaborativeArrangementAggregateConsiderationRemains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_EstimatedCompensationEarningFromProjectExpenseSharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated compensation earning from project expense sharing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_EstimatedCompensationEarningFromProjectExpenseSharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_MilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_MilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_PercentageOfOperatingProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of operating profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_PercentageOfOperatingProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_ResearchDevelopmentAndManufacturingServicesAggregateAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research development and manufacturing services aggregate annual amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_ResearchDevelopmentAndManufacturingServicesAggregateAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_ResearchDevelopmentAndManufacturingServicesAmendedToRemoveTrueUpAnnaulInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research development and manufacturing services amended to remove true up annaul installment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_ResearchDevelopmentAndManufacturingServicesAmendedToRemoveTrueUpAnnaulInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_RevenuePerformanceObligationFixedAggregateConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, performance obligation fixed aggregate consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_RevenuePerformanceObligationFixedAggregateConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundablePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, performance obligation fixed consideration Non refundable upfront payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundablePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundableUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, performance obligation fixed consideration Non refundable upfront payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundableUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of arrangements with third parties, including, but not limited to, operating lease arrangement and arrangement in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479428/808-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tsbx_TakedaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tsbx_TakedaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=tsbx_DevelopmentProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=tsbx_DevelopmentProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_MilestoneAxis=tsbx_FirstMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_MilestoneAxis=tsbx_FirstMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_MilestoneAxis=tsbx_SecondMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_MilestoneAxis=tsbx_SecondMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_MilestoneAxis=tsbx_ThirdMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_MilestoneAxis=tsbx_ThirdMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=tsbx_DiscoveryProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=tsbx_DiscoveryProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tsbx_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tsbx_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_MilestoneAxis=tsbx_ClinicalAndRegulatoryMilestonesOnDevelopmentProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_MilestoneAxis=tsbx_ClinicalAndRegulatoryMilestonesOnDevelopmentProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_MilestoneAxis=tsbx_SalesMilestonesOnDevelopmentProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_MilestoneAxis=tsbx_SalesMilestonesOnDevelopmentProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_MilestoneAxis=tsbx_ClinicalAndRegulatoryMilestonesOnLicensedDiscoveryProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_MilestoneAxis=tsbx_ClinicalAndRegulatoryMilestonesOnLicensedDiscoveryProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_MilestoneAxis=tsbx_SalesMilestonesOnLicensedDiscoveryProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_MilestoneAxis=tsbx_SalesMilestonesOnLicensedDiscoveryProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tsbx_H.LeeMoffittCancerCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tsbx_H.LeeMoffittCancerCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tsbx_AllianceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tsbx_AllianceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_MilestoneAxis=tsbx_SalesBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_MilestoneAxis=tsbx_SalesBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249625698096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Acquisition - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 11, 2023</div></th>
<th class="th"><div>Jun. 14, 2022</div></th>
<th class="th"><div>Jun. 08, 2022</div></th>
<th class="th"><div>Dec. 15, 2020</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jul. 25, 2023</div></th>
<th class="th"><div>Jan. 10, 2023</div></th>
<th class="th"><div>Jul. 28, 2022</div></th>
<th class="th"><div>Jul. 25, 2022</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment for contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=tsbx_ThirdMilestonePaymentMember', window );">Third Milestone Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ContingentConsiderationPayable', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tsbx_LangerMember', window );">Langer [Member] | Initial Milestone Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ContingentConsiderationPayableByShares', window );">Contingent consideration payable by shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_StockIssuedDuringThePeriodForMilestonePaymentsShares', window );">Stock issued during the period for milestone payments shares</a></td>
<td class="nump">249,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tsbx_LangerMember', window );">Langer [Member] | Second Milestone Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ContingentConsiderationPayable', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ContingentConsiderationPayableByShares', window );">Contingent consideration payable by shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ContingentConsiderationPayableByCash', window );">Contingent consideration payable by cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_StockIssuedDuringThePeriodForMilestonePaymentsShares', window );">Stock issued during the period for milestone payments shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_StockIssuedDuringThePeriodForMilestonePaymentsValue', window );">Stock issued during the period for milestone payments value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment for contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tsbx_MystHoldersMember', window );">Myst Holders [Member] | Initial Milestone Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ContingentConsiderationPayable', window );">Contingent consideration payable</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tsbx_MystHoldersMember', window );">Myst Holders [Member] | Second Milestone Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ContingentConsiderationPayable', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ContingentConsiderationPayableByShares', window );">Contingent consideration payable by shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ContingentConsiderationPayableByCash', window );">Contingent consideration payable by cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment for contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tsbx_RemainingMystHoldersMember', window );">Remaining Myst Holders [Member] | Initial Milestone Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ContingentConsiderationPayableByCash', window );">Contingent consideration payable by cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=tsbx_RemainingMystHoldersMember', window );">Remaining Myst Holders [Member] | Second Milestone Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ContingentConsiderationPayableByCash', window );">Contingent consideration payable by cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment for contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=tsbx_MystMergerAgreementMember', window );">Myst Merger Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to acquire productive assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Research and development asset acquired other than through business combination, write-off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nonoperating Income (Expense)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability', window );">Asset acquisition contingent consideration arrangements change in amount of contingent consideration, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=tsbx_MystMergerAgreementMember', window );">Myst Merger Agreement [Member] | Initial Milestone Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Contingent consideration, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=tsbx_MystMergerAgreementMember', window );">Myst Merger Agreement [Member] | Second Milestone Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ContingentConsiderationPayable', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=tsbx_MystMergerAgreementMember', window );">Myst Merger Agreement [Member] | Langer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares', window );">Asset acquisition, consideration transferred, equity interest issued and issuable shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">725,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedShares', window );">Asset acquisition consideration transferred equity interest issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuableShares', window );">Asset acquisition consideration transferred equity interest issuable shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=tsbx_MystMergerAgreementMember', window );">Myst Merger Agreement [Member] | Langer [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting of award under share-based payment arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of equity-based payment instruments vested during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of non-vested equity-based payment instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition consideration transferred equity interest issuable shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition consideration transferred equity interest issued and issuable shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition consideration transferred equity interest issued shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition contingent consideration arrangements change in amount of contingent consideration liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_ContingentConsiderationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_ContingentConsiderationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_ContingentConsiderationPayableByCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration payable by cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_ContingentConsiderationPayableByCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_ContingentConsiderationPayableByShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration payable by shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_ContingentConsiderationPayableByShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_StockIssuedDuringThePeriodForMilestonePaymentsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during the period for milestone payments shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_StockIssuedDuringThePeriodForMilestonePaymentsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_StockIssuedDuringThePeriodForMilestonePaymentsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during the period for milestone payments value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_StockIssuedDuringThePeriodForMilestonePaymentsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=tsbx_ThirdMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=tsbx_ThirdMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tsbx_LangerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tsbx_LangerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=tsbx_InitialMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=tsbx_InitialMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=tsbx_SecondMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=tsbx_SecondMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tsbx_MystHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tsbx_MystHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=tsbx_RemainingMystHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=tsbx_RemainingMystHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=tsbx_MystMergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=tsbx_MystMergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249624658672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Term Loan - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments', window );">Funding from sale of equity partnerships and or business development payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Loans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Revolving credit facility, aggregate principal amount</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_DebtInstrumentSuccessFeeAmount', window );">Debt instrument success fee amount</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_DebtInstrumentSuccessFeePercentage', window );">Debt instrument success fee percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDescription', window );">Interest rate description</a></td>
<td class="text">The annual interest rate applicable to the Revolving Loans is the greater of the Prime Rate (as defined in the LSA) and 4.25%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate percentage</a></td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_DebtInstrumentFeeOnEventOfDefault', window );">Debt instrument, fee on the event of default</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationDate1', window );">Line of credit maturity date</a></td>
<td class="text">Mar. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_LineOfCreditFacilityExtendedDate', window );">Line of credit facility extended date</a></td>
<td class="text">Mar. 31,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amounts drawn and outstanding under credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Loans [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_CashProceedsFromTheSaleOfEquitySecuritiesAndOrUpfrontCashProceedsFromStrategicPartnerships', window );">Cash Proceeds From The Sale of Equity Securities And/Or Upfront Cash Proceeds From Strategic Partnerships</a></td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_CashProceedsFromTheSaleOfEquitySecuritiesAndOrUpfrontCashProceedsFromStrategicPartnerships">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash proceeds from the sale of equity securities and/or upfront cash proceeds from strategic partnerships.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_CashProceedsFromTheSaleOfEquitySecuritiesAndOrUpfrontCashProceedsFromStrategicPartnerships</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_DebtInstrumentFeeOnEventOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, fee on event of default.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_DebtInstrumentFeeOnEventOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_DebtInstrumentSuccessFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument success fee amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_DebtInstrumentSuccessFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_DebtInstrumentSuccessFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument success fee percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_DebtInstrumentSuccessFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funding From Sale Of Equity Partnerships And Or Business Development Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_LineOfCreditFacilityExtendedDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility Extended Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_LineOfCreditFacilityExtendedDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the credit facility terminates, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of interest rate for borrowing under credit facility. Includes, but is not limited to, terms and method for determining interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249634356048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock and Stockholders' Equity - Additional Information (Detail)<br> $ / shares in Units, $ / shares in Units, $ in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">13 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2016 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 15, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 25, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2016 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par or stated value per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of redeemable convertible preferred stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,493,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tsbx_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Number of stock classified as temporary equity issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,250,000<span></span>
</td>
<td class="nump">11,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Value of new stock classified as temporary equity issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.9<span></span>
</td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tsbx_SeriesB1RedeemableConvertiblePreferredStockMember', window );">Series B1 Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Number of stock classified as temporary equity issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,285,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from Issuance of redeemable convertible preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tsbx_SeriesB2RedeemableConvertiblePreferredStockMember', window );">Series B2 Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Number of stock classified as temporary equity issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,065,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from Issuance of redeemable convertible preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tsbx_SeriesCRedeemableConvertiblePreferredStockMember', window );">Series C Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Number of stock classified as temporary equity issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,905,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from Issuance of redeemable convertible preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tsbx_SeriesDRedeemableConvertiblePreferredStockMember', window );">Series D Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Number of stock classified as temporary equity issued during the period</a></td>
<td class="nump">29,285,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share | $ / shares</a></td>
<td class="nump">$ 2.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from Issuance of redeemable convertible preferred stock | $</a></td>
<td class="nump">$ 79.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479424/830-30-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tsbx_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tsbx_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tsbx_SeriesB1RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tsbx_SeriesB1RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tsbx_SeriesB2RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tsbx_SeriesB2RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tsbx_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tsbx_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tsbx_SeriesDRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tsbx_SeriesDRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249637247264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock and Stockholders' Equity - Summary Of Shares Of Common Stock Reserved For Future Issuance (Detail) - shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">6,806,785<span></span>
</td>
<td class="nump">5,454,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">3,298,558<span></span>
</td>
<td class="nump">3,374,282<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=tsbx_UnvestedRestrictedStockUnitsMember', window );">Unvested RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">108,899<span></span>
</td>
<td class="nump">102,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=tsbx_SharesAvailableForIssuanceUnderEsppMember', window );">Shares available for issuance under the ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">453,280<span></span>
</td>
<td class="nump">222,287<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=tsbx_SharesAvailableForIssuanceUnderPlansMember', window );">Shares available for issuance under the Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">2,946,048<span></span>
</td>
<td class="nump">1,755,404<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tsbx_UnvestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tsbx_UnvestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tsbx_SharesAvailableForIssuanceUnderEsppMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tsbx_SharesAvailableForIssuanceUnderEsppMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tsbx_SharesAvailableForIssuanceUnderPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tsbx_SharesAvailableForIssuanceUnderPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249625556400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Based Compensation - Schedule of Stock Option Activity (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems', window );"><strong>Schedule Of Share Based Compensation Stock Options Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Underlying Outstanding Options, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,374,282<span></span>
</td>
<td class="nump">2,529,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,165<span></span>
</td>
<td class="nump">189,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,119)<span></span>
</td>
<td class="num">(21,784)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options canceled/forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(175,770)<span></span>
</td>
<td class="num">(92,924)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Underlying Outstanding Options, Ending balance</a></td>
<td class="nump">3,374,282<span></span>
</td>
<td class="nump">2,529,982<span></span>
</td>
<td class="nump">3,298,558<span></span>
</td>
<td class="nump">2,604,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,955,510<span></span>
</td>
<td class="nump">1,622,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,298,558<span></span>
</td>
<td class="nump">2,604,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.66<span></span>
</td>
<td class="nump">$ 8.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.73<span></span>
</td>
<td class="nump">16.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.51<span></span>
</td>
<td class="nump">3.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options canceled/forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.97<span></span>
</td>
<td class="nump">10.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price Outstanding</a></td>
<td class="nump">$ 7.66<span></span>
</td>
<td class="nump">$ 8.86<span></span>
</td>
<td class="nump">7.56<span></span>
</td>
<td class="nump">9.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.4<span></span>
</td>
<td class="nump">7.82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.56<span></span>
</td>
<td class="nump">$ 9.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Term (Years) Outstanding</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding , Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 352<span></span>
</td>
<td class="nump">$ 6,912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value Outstanding , Ending balance</a></td>
<td class="nump">$ 352<span></span>
</td>
<td class="nump">$ 6,912<span></span>
</td>
<td class="nump">354<span></span>
</td>
<td class="nump">18,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">341<span></span>
</td>
<td class="nump">14,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 354<span></span>
</td>
<td class="nump">$ 18,605<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of share based compensation stock options activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249630318256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Based Compensation - Schedule of Fair Value Assumption of Stock Option Activity (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems', window );"><strong>Schedule Of Share Based Payment Award Stock Options Valuation Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, Minimum</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">3.89%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, Maximum</a></td>
<td class="nump">4.72%<span></span>
</td>
<td class="nump">4.48%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, Minimum</a></td>
<td class="nump">94.00%<span></span>
</td>
<td class="nump">85.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, Maximum</a></td>
<td class="nump">94.67%<span></span>
</td>
<td class="nump">86.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems', window );"><strong>Schedule Of Share Based Payment Award Stock Options Valuation Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 10 months 17 days<span></span>
</td>
<td class="text">6 years 1 month 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price of stock options granted</a></td>
<td class="nump">$ 2.68<span></span>
</td>
<td class="nump">$ 11.18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems', window );"><strong>Schedule Of Share Based Payment Award Stock Options Valuation Assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 10 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price of stock options granted</a></td>
<td class="nump">$ 2.88<span></span>
</td>
<td class="nump">$ 16.53<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of share based payment award stock options valuation assumptions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249626627984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Based Compensation - Summary of RSU Activity (Detail) - RSUs [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Outstanding RSUs, Beginning balance</a></td>
<td class="nump">102,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted</a></td>
<td class="nump">16,384<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSUs Cancelled/Forfeited</a></td>
<td class="num">(10,430)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Outstanding RSUs, Ending balance</a></td>
<td class="nump">108,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Beginning balance</a></td>
<td class="nump">$ 2.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">RSUs granted</a></td>
<td class="nump">2.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">RSUs Cancelled/Forfeited</a></td>
<td class="nump">2.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Ending balance</a></td>
<td class="nump">$ 2.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249632591568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Based Compensation - Schedule of Stock Based Compensation for Stock Awards (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 1,019<span></span>
</td>
<td class="nump">$ 1,074<span></span>
</td>
<td class="nump">$ 2,065<span></span>
</td>
<td class="nump">$ 2,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">644<span></span>
</td>
<td class="nump">507<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
<td class="nump">1,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 375<span></span>
</td>
<td class="nump">$ 567<span></span>
</td>
<td class="nump">$ 771<span></span>
</td>
<td class="nump">$ 1,057<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249624645280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Based Compensation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,019<span></span>
</td>
<td class="nump">$ 1,074<span></span>
</td>
<td class="nump">$ 2,065<span></span>
</td>
<td class="nump">$ 2,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.14<span></span>
</td>
<td class="nump">$ 12.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,806,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,806,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,454,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ShareBasedCompensationArrangementAverageGrantDateFairValue', window );">Aggregate grant date fair value of RSUs granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of RSUs granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,384<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based payment arrangement, non-vested award, cost not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based compensation arrangement by share-based payment award, equity instruments other than options, nonvested, number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based payment arrangement, nonvested award, cost not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based payment arrangement, non-vested award, cost not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based payment arrangement, nonvested award, cost not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tsbx_MystMergerAgreementMember', window );">Myst Merger Agreement [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based payment arrangement, non-vested award, cost not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based compensation arrangement by share-based payment award, equity instruments other than options, nonvested, number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Share-based payment arrangement, non-vested award, excluding option, cost not yet recognized, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tsbx_MystMergerAgreementMember', window );">Myst Merger Agreement [Member] | Timothy Langer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business acquisition, equity interest issued or issuable, number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">725,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tsbx_MystMergerAgreementMember', window );">Myst Merger Agreement [Member] | Timothy Langer [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business acquisition, equity interest issued or issuable, number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tsbx_TwoThousandAndEighteenEquityIncentivePlanMember', window );">2018 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based compensation arrangement by share-based payment award, award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tsbx_TwoThousandAndTwentyThreeEquityIncentivePlanMember', window );">2023 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_MaximumTermOfOptionsUnderEquityIncentivePlan', window );">Maximum term of options issued under equity incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_CommonStockCapitalSharesReservedForFutureIssuanceIncreaseDecreasePeriod', window );">Common stock, capital shares reserved for future issuance increase decrease period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Share-based compensation arrangement by share-based payment award, percentage of outstanding stock maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tsbx_TwoThousandAndTwentyThreeEquityIncentivePlanMember', window );">2023 Plan [Member] | New Shares Under 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based compensation arrangement by share-based payment award, number of shares available for grant</a></td>
<td class="nump">1,154,966<span></span>
</td>
<td class="nump">1,889,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tsbx_TwoThousandAndTwentyThreeEquityIncentivePlanMember', window );">2023 Plan [Member] | Remaining Shares From 2018 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based compensation arrangement by share-based payment award, number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">712,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tsbx_TwoThousandAndTwentyThreeEquityIncentivePlanMember', window );">2023 Plan [Member] | Returning Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based compensation arrangement by share-based payment award, number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tsbx_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance under share-based payment arrangement</a></td>
<td class="nump">453,280<span></span>
</td>
<td class="nump">222,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Shares available for issuance automatically increased by additional shares</a></td>
<td class="nump">230,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_CommonStockCapitalSharesReservedForFutureIssuanceIncreaseDecreasePeriod', window );">Common stock, capital shares reserved for future issuance increase decrease period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Share-based compensation arrangement by share-based payment award, percentage of outstanding stock maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_CommonStockCapitalSharesReservedForFutureIssuanceIncreaseDecreasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock capital shares reserved for future issuance increase decrease period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_CommonStockCapitalSharesReservedForFutureIssuanceIncreaseDecreasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_MaximumTermOfOptionsUnderEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum term of options under equity incentive plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_MaximumTermOfOptionsUnderEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_ShareBasedCompensationArrangementAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_ShareBasedCompensationArrangementAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=tsbx_MystMergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=tsbx_MystMergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tsbx_TimothyLangerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tsbx_TimothyLangerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tsbx_TwoThousandAndEighteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tsbx_TwoThousandAndEighteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tsbx_TwoThousandAndTwentyThreeEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tsbx_TwoThousandAndTwentyThreeEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tsbx_NewSharesUnderTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tsbx_NewSharesUnderTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tsbx_RemainingSharesFromTwoThousandEighteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tsbx_RemainingSharesFromTwoThousandEighteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tsbx_ReturningSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tsbx_ReturningSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tsbx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tsbx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249633534384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations', window );">Federal income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ProvisionBenefitForIncomeTaxes', window );">Benefit (provision) for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (100,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_ProvisionBenefitForIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision benefit for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_ProvisionBenefitForIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249623590368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 01, 2019</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>SquareFeet</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>SquareFeet</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>SquareFeet</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>SquareFeet</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Nov. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Operating lease, impairment loss | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Lessee, operating lease, liability, to be paid | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Payments for rent | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_AgreementAxis=tsbx_OperatingLeaseAgreementMember', window );">Operating lease agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_NumberOfSquareFeetForLease', window );">Number of square feet for lease | SquareFeet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, operating lease, option to extend</a></td>
<td class="text">one renewal option for a period of five years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tsbx_OfficeSpaceMember', window );">Office space [Member] | Operating lease agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_NumberOfSquareFeetForLease', window );">Number of square feet for lease | SquareFeet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tsbx_LaboratorySpaceMember', window );">Laboratory space [Member] | Operating lease agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_NumberOfSquareFeetForLease', window );">Number of square feet for lease | SquareFeet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Lessee, operating lease, liability, to be paid | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the lease was extended for a one year period.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tsbx_OfficeAndLaboratorySpaceMember', window );">Office and laboratory space [Member] | Operating lease agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_NumberOfSquareFeetForLease', window );">Number of square feet for lease | SquareFeet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">38 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one renewal option for a period of three years and commenced in March 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_NumberOfSquareFeetForLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of square feet for lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_NumberOfSquareFeetForLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_AgreementAxis=tsbx_OperatingLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_AgreementAxis=tsbx_OperatingLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tsbx_OfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tsbx_OfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tsbx_LaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tsbx_LaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tsbx_OfficeAndLaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tsbx_OfficeAndLaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249633262400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Information about Lease Costs (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease, Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 398<span></span>
</td>
<td class="nump">$ 430<span></span>
</td>
<td class="nump">$ 796<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ShortTermLeaseCosts', window );">Short-term lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable leases costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 398<span></span>
</td>
<td class="nump">$ 430<span></span>
</td>
<td class="nump">$ 796<span></span>
</td>
<td class="nump">$ 906<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_ShortTermLeaseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term lease, costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_ShortTermLeaseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249639631136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Present Value of Operating Lease Payments (Detail)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_ScheduleOfPresentValueOfOperatingLeasePaymentsAbstract', window );"><strong>Schedule of Present Value of Operating Lease Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term in years</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">5.74%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_ScheduleOfPresentValueOfOperatingLeasePaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Present Value Of Operating Lease Payments Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_ScheduleOfPresentValueOfOperatingLeasePaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249757050784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Minimum Aggregate Future Operating Lease Commitments (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2024</a></td>
<td class="nump">$ 1,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">1,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">2,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(66)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">2,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion of operating lease liability</a></td>
<td class="num">(1,793)<span></span>
</td>
<td class="num">$ (2,025)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, noncurrent</a></td>
<td class="nump">$ 411<span></span>
</td>
<td class="nump">$ 1,189<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249637264736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">3,498,197<span></span>
</td>
<td class="nump">15,279,998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">90,740<span></span>
</td>
<td class="nump">181,480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">108,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tsbx_OptionsToPurchaseCommonStockMember', window );">Options to purchase common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">3,298,558<span></span>
</td>
<td class="nump">2,604,639<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,493,879<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tsbx_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=tsbx_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140249638834512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_tsbx_LossContingencyReserveForLitigationLiabilities', window );">Loss contingency reserve for litigation liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tsbx_LossContingencyReserveForLitigationLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss contingency reserve for litigation liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tsbx_LossContingencyReserveForLitigationLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tsbx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>67
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M]G:\'2B^:RZ8UUPI7C:/6T8!M1: [S><JY>!OK/N?J-8_@-02P,$%     @
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MNRMF5W*OTR07=P51^RSCQ;\W(I4/UR,Z>GKP(=ELM7DPF5WM^$;<"_UI=U?
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MK7.2-$]^7S\9#SPY1I]$H382_0@6I,?K)^!%ZPK>N_(>>Q7^4A7O$ F^1SC
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M#L6T8TW]N4Q?.+:/S+LYY)"*XKG;]C"PZ!=XK5]M:/' =+FO*2_1CF85TXY
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M@@QBJ16P>BSA!K),"ZEM_*XUK<:E!C?':_6)B5W%\H0%W+#L%TED.K"N+)3
M')>9O&>K+U#'T]%Z,<N$^46KRK;3L5!<"LGR&E8[R FMGOBE_@X;@+L+\&K
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M1V2P7]#4\L1*\N9//9KY/&]BBH-<1:N%-G6:!M\8(-628%F&I4Z#AD-&(43
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M>4['+T @N71D$9FY[$\<P=L3^S1'!4WN+*,9YLNVY=(=65)/;MH3/X1ZF"6
MYH.%WFE?DS2UI<MJY\/3C!_NJ)>70LH2)6<N>>:)'3$&]32 HU%2V:!+VW$#
MF#KZ(0IS/A%T.*,1<(2;AHW=2C0?0Y92TB:02R[1.)LJ0Z]F5%#!C 3\F4O/
M\Q-VTO-[R)'ZDA0="/]=MG,&&>SZ>70A1I')C?I J=8S.!-]YLD*7XP,,U:&
MP2MIO1%7.DT""<?SO;04?1YX+AMZ%R'?J(RYY$23W8>H$AYLZ447N?&L^W3?
MK7<4I =SRHPN-/)<=AANUU[?=7L'/$&PJW\ HJB7ZIGZ!>)):')L#3D-312_
M7H=O>R^"C 8S9.6]V5B>AJ9?,U+/_M#)9=5T;I.LOS>SF1'8O0,4H;]E@LUC
M:*G;XV8=J+\+,E O(&4\PZ&HI/?#HEFC&1H[GWA%&@ZQB#;#CZG/$HEQD6-V
M!7.G!MM.;O?R9(3G/9,)!=%.6(/*+>'"CJB9FIW_;H\F'T1O=='MZMB11,SI
MXB'/[\/VY.$R.2AG\!7^'^"8J?U13O(E%'L=4(-GV) FSZ6/&3I OD8AI"W]
M,&F5*QXP] /SK/L]("&Z>^,S>C$B'AHECGJKH>GC<"VO3W C'6A.R=C9?"&W
M+E?V,F61-\EZ>BD!EINE+I^/E.L0>=<C>V=)9*%GPNPR/4&9)C=K!?@BCL?M
M3O+=9,_<O36$#WS[:,LV5Y]L^"S>\&L9 !#PWGN;#!W);WPCA#:Z[.@G.])%
M'U8 U3>[9_*27@F+7.>F;^W!>5$G_&X$=ZD[B6PR:JOY_3<WFV3UI;RW8**E
M&D1ZH+)1J/(8RG:=N\U0.H^4*W:>SV9'MT&!KF ;&B820_D*2M[Y,)%'<H7/
MF90!.[PNLB:<W\D,Q:S[9A16?*\Z])?WY[5E!)VRX#A:KN]W6D/3+MEXK J.
MCG0#,\%LH^,>[+-2-SEN-3K7/2OOY,DE77Y!SX22&I+$#CJ2'DJS'M/@]5[3
MS#E Q@C<O1[D-Q4@'C3>'W>4<"V&8T90:3R A(?&^O1J%\=BX#N5P63"-+\,
M)"UNN6<\.'@I<9)[O0-:XP%JZ"N:WZYZF<B,;R-YP,1YZ?Y4/UF-%#35PL.-
MYEP=>IWX>/2:.'2^YI?A.1%T4=X8+[^6]^TOY37S8;F\K \\M+;PX,:LL'4Q
M?W%^)(U[_A+=EE\Z7[H87<L?Z25#XVD!GJ\<XBA]H0/*_X7PYO\ 4$L#!!0
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MME-&HH70-4QKM"V^K=$(,6/^D<,ACBES%5[Z@QA_C6? "//)JJ..T,"!=P1
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M&^!W_@&(\(43Q#__\^Q_ %!+ P04    " #E@@Y9&$!$)7X*  #@(   &0
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M&?9;V1_2]--VE."_WD:'Q"?B>MH]<&FW5DYQ &Y2Y3+Y0YA%W0"]W%N'KLD
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MD4-D[7;U1HO2.LQ6:/0KN\SP#P*D2<#WJ1#ZL#$%VK^<Y6]02P,$%     @
MY8(.63F[;7Y%'0  K6X  !D   !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
MS3U9<]M&FN_Y%2A-=DJN@F@=MNPDMJL4.]Y1*HY=MI-YV-J')M D>XR#00.2
M-;]^OZ-O "0U3K)YL44*Z/[NNUO/;MOND]Y(V6>?ZZK1SX\V?;_]]N%#76QD
M+?2BW<H&?K-JNUKT\+%;/]3;3HJ27JJKA^>GIY</:Z&:HQ?/Z+MWW8MG[=!7
MJI'ONDP/=2VZN^]EU=X^/SH[LE^\5^M-CU\\?/%L*];R@^Q_V;[KX--#MTJI
M:MEHU399)U?/CZ[.OOW^$3Y/#_RJY*T.?LX0DV7;?L(/U^7SHU,$2%:RZ'$%
M ?_=R)>RJG A .,WL^:1VQ)?#'^VJ[\FW &7I=#R95O]4Y7]YOG1TZ.LE"LQ
M5/W[]O8?TN#S&-<KVDK3O]DM/WM^?I05@^[;VKP,$-2JX?_%9T.'X(6GIS,O
MG)L7S@ENWHB@?"5Z\>)9U]YF'3X-J^$/A"J]#<"I!IGRH>_@MPK>ZU]<K3LI
M@<B]?O:PA_7PVX>%>?=[?O=\YMW+[$W;]!N=_="4LHS??PAP.&#.+3#?G^]<
M\,>A6607IWEV?GK^:,=Z%PZY"UKO8B]RV?]<+77?@0S\[Q2>O,RCZ650+[[5
M6U'(YT<@^%IV-_+HQ=__=G9Y^MT.(!\Y(!_M6GT/!W:^.PW9Y2(+$/\H/LE2
M9.\V F2XD$.O"E%E+]MZ*YJ[["=5JUZ6\+FJQ++M!*F*>SV[;K*?VQM9+V4'
M3#G[)L_ZC71OPQ.R@[=5T[>9R$JE"WBXN\NS(EI/-&56J0)466;"K7W\][\]
M/3\__<Y Z#:EK\^^>P":T&^R-ZJJ9-.HH4YPT#E 5RRR8_BQS3XU[2ULY/!]
MVP ([?KN00Z W6X G+L,G@!@];#4JE1@@;)V=2!YCH_XN:,'B^P7$/:.R) "
M'A.'$"TSH(PGAF2<S(OTJY-2WH!IW!*1X&/1UK7L"B4J]6_8XGO5GEP^/GN2
MHOG^^M>KGTY.SQXX,K[B=8BT[[IVW8G:41+7IMV:<BAZSZALRP]J_*TJX56U
M LC+4B'?@! -/%;A4_1> >NH$M#09 G+#'BK0,9N1%&H1HGL1G6#SK:5Z-%=
M9/ /R$8IP8/@VED9@.C =K D0!].:7BK02Z9IQ!9A$JL5JI2!*U WU"58%IE
MGJFNDS=M(985?&C:Y@3L0J-7LN-O@ ?R<U$-&KQ%CM+"DHN_=$(\$&2%['IP
M>RA& 3@(_]F3[S3QZF0#Q@ !V@(<@'6'3D)[T1^Z!DQ\ QC*8M.0Q#JF 4MJ
MP"C/!HV @./*82N D^BJ!0)K*)K#D\VP O,V=/ MBU(@1_!BE[4 9'>K 'SY
M>5NUJ@^ERP#T$R-8$C(MH!F)D)$#C8*$F*MF/;&&88-;ZIUYRRT%)!-5E:V4
MK$J]L&RS7(QTJ"DG21NRMMG'4/SFGAS=P3IO,Q)\_U\XB,09\8S>GN-"3'WZ
M5!1M5XJF,-;I7ZV*=36/0"&3SA#6LB1S">P0JB/%;[0AY93:WL-XHK%S$M$>
MJMI?Q/PI90RMIJ&+LU<(##I=T14;CB[!:LJ#">Q?A74"BXPTW$VH70KC</)$
MF\;F3\+CXW_&U"9S3,O:+041\$*[).V\CS7_0M[_P>I[K!YDG*'(D';L1@-O
MNY:-Q/"!55O>B&J@3\L[XOY6=,0QQD6,)-5X>6>Q/M@MO?-]Z3:SUHNQ.%8*
M;?\=H .$UEN0'K3ZE34K4RY!9+LV&/N:* 2(7(5S#K6 :/,SDA-%>Z.TE0H2
M1 0,]D.&];?MF'R("#Y(LH./*A#JTB[AUMW*3K5E++.'Q!:)C8%EMK(?1)4(
M9R"TL2CBHJL!(]2M4.7)L/WB.$,#22 (0V:0$%O1Q"]4#3R[,=F!$5] <-YJ
M9[JM) "'0@^:@)8 F-V8M)H8@*\%"H"0.L'H-P)DL04J]:@3VPY)38$AB-26
MHN+<.'IX4,#;^*2-+_%7\!^$T'<0FC-KOSAD^#,YQJ#^Q9EE"8?VWC)ND?TS
MT:T=!@JWN]VHPN4V90O?(B.==J':L,;M\6#SS-G)CZZ]$U5_=[($;Q28J#%'
M$)!)-I  @FD!:DFM*4'L '^A(15: DV!GL!TPA4A-D:<4UQ85P^ ?BD+3-)W
M6G.?L9EGO6TT-M';O_=D<[5:@O"2C;>[A[D4;#X* O7N*!#UK)2X/3F2[=#I
M 9B142(_B@#)FP=2!VE_K:T]&D=YH0&]A?P]6\JLLX@ NQ '%+4@V/!KSVP.
M=@,Q;\F&5-(2G5)WX/*YR)"8%([VG<*@U*-_( P@'CL &+:FDB%6/0I4! :^
M-P/(! ]G]3U/0^IQ*.'$[7?E>&QUL)"*_R/>N:''5*Q/&_*OQR#RR\9\@"97
M=[%@ +6(;)17(12=!$#)-8"9.&F'WBJKW@@V4]V4,A2M[AEU4$C$F033ZGND
M)MT$F '_K6JE)#R,P+MT=3K6!C!W1F*[6+8S&4GSL#WJ>D"N@6YNPDQW8!";
MDDSP5MQ96_1U]OAT<9K5H'5(8974$%F)FKC,-+_61;+6%5B"BDK$I[FCL,\1
MG-G?VG!P)XUS]HD!+ 6RL)2=4[2OL[/' 0BPZE(R02#\]J6\D#H(EA3 ">?]
MK']@0 ]/A.>T)-(+)!SJ:PL^<4UPZU%@'"K"A,S?LXAPC.],%![?@N:^PA(E
M=7=\*L&F.]!KRBR'#C.BOQCX;P' "'ID5@4! 2TY-+VJXB*X83'S:9X8>92J
MD4MB!L(;#407F)S <A#?=>P<(!!;4=#4956KM1P39>RI/&GF[';XQ"[S[9];
M9->K&8P1O#T8-YGN$6= :-6U-4=.D$233\@HZ#&&*=05)_)YXL-%EQTCV*""
M6*WN*RHE/,B>G&;_E<;^^]ZYP'?,9G]%LAO,,=EES>"R"5C'"$LL(K"U^QJL
M8F(MQ1KL"KYJXI=BHR3G$Z&7=!$+NY'U /%)"W82%I)4%O&:M@)L^CG-HF""
MMZ"'Q78+]IAL>D@NMRS)/O"8J@P6A[/4>W@<$ AX[:17M?,2>B=F6*71*1YD
MFF=0(&!"BCZ:A>98N5JP5XEEVULK3UV5G=[GP1_+E5%A)>3/8;S1M@QTXTER
M,2]DOP=)?B<F[Z+#/4V:<PFS(:+U+,;D 4R5DH,U+FQ2N T*)L78?=%!^KMF
M9$JIBTXML<"W;#'K#8$# Q#8+9"$0J+M!".!S=<*,EG\>@, P@\2M@=;!G#U
M8BU-5HP>!\C7R-[0RGC@60>YC$V,P3JMJ;@D7,*2)><.9+DY%:>X,S=U 3)U
M3<& >)'U%I @XY1NSKI0_:X ]]Z;B%=B4&[6 ^6 6,+YDJWR$1RBZBN6)MLG
MB4"(*2Z;VHM^8;=#$@!I[\";:),"4F@?.+!IC-*%;/;_WA#I(Q#)AQJO89\=
MA='[" 8)A 8,4</56I'VH[3<3T9V0/.%8A)28.$^.8U''8%7_V6\+@_#8%6&
M0F"R)LY'CL)D%#W56)\!,3T8,X7RA\WS55L!'?2WY#I=86$L-T%FD12).85G
MLHN ,K]2K<=9LSRL7WN0)@MWP8HD+[.+NC!GU#KG2.6;4Y#*.VW(CT4X(+[Q
ML0Y9+NE'DGH?8*6BR%UQ_Q^%L),]"4#+.LI1^,GR[L3^S,6T-1 3O^6?L,RK
M; ZFU>>LIH&B&'3;A\!&!.F=^*M!?G8^"?B")!MA,?(T,:*1O6VR'P?PMF<7
ME-.>^Y2[:V\@#RTGZ'+;J1Z-D:%/).YI$F+WF>C?(0'Z ,)44[CC;;F#,AD^
MO92HQSZ4%YI1+#C3M_@LLE=>XV=9S%H56[=;D02^V&)2S2 -:>RBOEP[A3<.
M12ET.[# K<(6)>8GQBOC$Y#>;8T+\<B$B%H3/T+-LLH9NG!T)&K$NAD)QZ=R
ME*Q@X1GM,X0$71+P8]UG5/%UBX[%;&074,A$,R"-+@GVB]]#S#J)4Y^E][KC
M4L9]1.?'H7+@.2_Y@WLH1/(5@.!]YEOFWORC.3DR&X$&TVC:M2!V=%0"GAT#
M>^76AX'S%?P'80'B@#Y'TJ[@4D$X=X++N:X%:D('3DR&-2CA2GSSE B4915[
M:V3OETV54 B$8U_RL]*42A\$$<7J#757D@:/]?S"!Y14>S.3=901!.C'^K3(
MKFCW-U01O3BS8A^B7$CJ,J)P8,E[EQ"8U2$DN974HC323X(,V-8D'\[8"*W;
M0M%WKN<6EK=V[>2(MML<A>H"R!847R(X5XVH[L YQ;,76,G01@9!YVN%']9M
M:ZK:#O(=D$VXD*L/+[./[585V>4IP/(><T8P553I>8E"*E XZ-&7%+])B)Z/
MC_ U>.'(#!F4DA&4W 2&+W$SU#3J%LX  YI3FJH;!W14O9$=3:HCA '!.=2S
M!?(\+M[@)%/4_Y@@QI1KL1H4MX+B[@_"U[7#>N/;0_B:'=_D6OBLX[ *Z1[?
M,>R9O0M0?^M0MV;R.S_.$4_L!"M-X3WR)=&D:,-3%#7.JJ[:H=O3T$#4;=7W
MH&'0/4AQ1PE\D (?-HC*2O8^SK'P(*LG12)/Y($"HYBMN;,W<[SS+#8C#1Y,
M4-R23&1!Z@ZK8%)#$]PDV=N!+"J9/A"N)6E&._1;4SLO;X >")C;PPK9SC[D
M1[1?@(OQAP?2R@,F,I--3BO9(OL @E")KKK+37SP)7(VL:]O<)EGA*K1?O=V
M0(J9M5<,G3%'8OB-]'X,/\X0R=&26G:6MZ[@/47J%.'<B )XN$92!9H?IF*E
M0QAS8KD5.#6#/0-61(55O$7V0_@D9L3"/<O^S?5L(YA,0\O&@;NEP0SR<+)J
ML^8#EDJQC7O!$,^0-3=#0$E8;97*!G"[I,;!9X4''3/- ]AL)F:^5<X9O^&8
M,E-RB=N82:?0MC%=R3E&Q-442ELC$UL@W6>*)7C7(++H 6Y185T6!Q&Y48%1
MN8D5B";573#XPA3NVYX,@&BTX!D@?DWT'$2*(G"UB!WB\'1Q:9'(W<Q6Z<I<
MSME2@MR@YGS+W;3+[[+7ZK,LIYJH3^.BL37 HT;RL#T!O<&IB_MVE&F^\O!>
M,HD:)IDE1"RM:2QG'"B>FIH[%=1*UW:F7RT<KK^*CE0O03>HY)B:$G$=J[Z(
M\4X%(Z[A,9D:PSD[ F#B/]S*';R8TU"GY,NA7,L^'R6:;!DL]P>K&DZ9/<%X
MM )X-71=I,YA!([[+3#8@Y"3$A87\"+B9(1Q7E5FM>PW:8[O!9R'KWKNV=E*
M)O ]D,4 @)2FH?^;F\RYOIYTB1%=$D/41[QPMN6W0:'I(+8#$94)(I%7RKYO
M$J))S7,*-P; S_;2E*NE#[Y%)@0,6\O=5%<*'+:EL-FE>]Z?SVGXY"8U%V\$
M^&?R%7M$>&K*+.BO[!=AA]1@.^,U"!/8ID_HMYBB1B)0\%A"".6;:8C8#AN+
MW6+#'&<[MJWF<2Z(CH#OIFI-72);'@JB0X]!.( Q@4(>U/-]0XQ,R'EDB-AX
MF-X4,I4="$Y49M?-#;*#/0GL_K.\S5YU R1HW'DCM(Z/KG]^=?3 5M)_67S
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M+%M%'5>^W>+1F%5(+ZP=15%1>#JJGVK]%5QKHN-!U@7R^1_S8=9\4Z!@JZT
M$3AU5;FT!;,4^,+D'K8,GV? E$P/F+1;[PGFP<5);C/=#R7-;5]5E2&8MB'?
M1MS()%Q6S3R<S@<; YM.U V-@+TX],&K5;0IN;:5*FVYN/?.S0RWV^$'JNC*
M#=ZLA2TKS+Z"J3R($Z4TDR#H8V"UN(?.AZ#MB3P:B)SQ]F4B::5<2<-B(]M
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MS0S'RBXN+_.G3Q_M@,C)<7S3#M7OJ2]G^K_WN]@EO7,H=&CFU)-&:VSF22*
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M2G?#UI8NV=#9DQ/4H@(9*FS5DV_)"G>C6I$QN@2^N1W=GK8)6\HLNK[.5?/
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MFG[<2 &@X@/P^U4+KLI\P W<7ZA[\7]02P,$%     @ Y8(.60&9Z:U+"P
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M2-\,W1M7(=*QQ3:J'SQ$SL./4OL65<JBDVY*C)5:\$$9 RPU34"FC$]Q$]0
M ;H0Z9F.)PB^K+WE$46[&&-XM*WWL9\?6DHR-^W4T_F1Q*B-.%4H\DY$O56Q
MV'0C[BK<L<0Q):+DZ>SK^W?7'UXNCU/U1%+!^?G^P>DSM]*59'8)E$6PSK_H
MLW1'B<2)IV,!7G<;Q"\.RD,S[Y&-./1T/-A!SN"R27,&V?8(I6<3<LYZ6L\[
M4"E%H$0OKFT;9ZD8*PZN8'X%ZRN>P2=5=#80;._,M=2UOQ\)>I$JF,A]8WFN
M/60AEP_/PURW TO'3F<;#(D,9YBLUIWC[*B9!3AW5%%+ZG.'!IH(.N;N%.6!
MR:C0H!54H9L&@S9.!>I':Y(3+A:-&A<FSS%\3!J 1Z7%/J';7NH3PP22'?B<
M9H24KC'O>]9 ]S8$)R-603IR$Y#44&3!3GV:$C*QU;8>QN"1SWVK"LUI5SCK
M_<OQX!Y7QO,P88_ 1C#&7-"CSZ7YYKHV%/&VIFGNP9E%[Z+#3LI67U02?%&*
M/[MRTS/(X8"MQ,Q$/0#0-YTDFQ3<#F=MZ#>/3W%.V0^N'"G G079CB:P7A/1
MLV65-!L576&"LQR# U,@R?VX,0Q-H()J7"(3->%T]/+8GSV7P'@&^R$7^@$G
M-9&@#:Y42+E]'*3WXT9>4*)$S?\/=7&=QGX:7K-')QYSF/.'\OA[UX1A?CP!
MWST7,D<"L^AT$@I4)415,=(T5Y*]HXX[,AJHV?#?.P2M_[B#P0'7R;[J*@DV
M5U1Y3N[,XX//O89DV.H2_+R<'T=K<UP?O>_H[HR(>:YH9G[%TSJN.S2=H T0
M.9/()P[@+;LO "E? KBHX\Q &%W0_X$4?.&&Z6ETRYT_]/UG,?HBQTV:OCN"
MPLC@^'%N6!T^;5['+WJ'[?&[*%K AN:26JTANIR?G\V$B]\:XT.P+7_?RVT
M/_+/2DGXD#;@_=K:T#_0 <,'WZO_ E!+ P04    " #E@@Y9!D?*XQ@%   %
M#@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6RU5]MNXS80?<]7#+R+
MO0"JK*LMY6(@<;)H%MBL$3?M0]$'6J(M82522U+VIE_?(24K2F*[;M&^2*3(
MF3EG9C@<G6^X^"8S2A7\* LF+P:94M7I<"B3C)9$VKRB#%>67)1$X52LAK(2
ME*1&J"R&GN.,AB7)V6!R;K[-Q.2<UZK(&9T)D'59$O%X10N^N1BX@^V'^WR5
M*?UA.#FOR(K.J7JH9@)GPTY+FI>4R9PS$'1Y,;AT3Z\"O=]L^#6G&]D;@V:R
MX/R;GMRF%P-' Z(%39360/"UIE-:%%H1POC>ZAQT)K5@?[S5_LEP1RX+(NF4
M%[_EJ<HN!M$ 4KHD=:'N^>9GVO()M;Z$%](\8=/L'04#2&JI>-D*(X(R9\V;
M_&C]T!.(G#T"7BO@&=R-(8/RFB@R.1=\ T+O1FUZ8*@::027,QV4N1*XFJ.<
MFMS3E&*8%P6%*6=K*E2NQS/T#16"IC!7//D&A+6CC!<I%?(]W'RO<_5X/E0(
M0JL:)JW!J\:@M\?@"+YPIC()-RREZ7/Y(8+O&'A;!E?>086?:V:#[UC@.5YP
M0)_?><0W^OP]^G;1A#NN*/Q^N9!*8![]L8MVHS78K56?K5-9D81>#/#P2"K6
M=#!Y]\8=.6<', <=YN"0]O\CBH<-QC;\2YOOWD2>.S[;.O9(+9\$+^%KHOB"
M"@RT&X+B_?G( I5I%65%V"/D4M8H2W"7(@7P);BNY86.Y3@.R(Q@!/1'#$..
MHTNH.G/2F/N@E6FDGG,VWVYZ@<DLNV<?@2B87M^]!==&Y17B,0;@ T6&:U)0
MIC38M^#8X^!IW3+%) 5=F2 QU)M"1[!:&<2V'P0P)8RD.6&0\J(@0FI5G%%X
ML.=V^^TC8&UNF3(LXY7@":6I8=@ <^P8:T=1:/VO8$6VVRW^9Y!LN&7_+#XC
MRXM"RPU'K^-S]9-[3(3TM@,Q,@$8]P*TWVOH,L_VMUXQ7.[XFI8MF6@G&2^T
MG%%HA7ZTBX%W' -O#P/+G"/%5Q2E!-X1*C,8]E-O,+[0?]@_KHWGZCC_>-%3
M2MGPR^'0CJW8"3&\.QPS/<8MT\.P,51]V#F#SX35V&'H6,6&QFL"@6M'QQ+P
M8I.;_J[<O#Z&P/7?$1C[+PC4>)[P/G/WH!_'??28GGA:6=OG=+G1$GHOX7;V
M%1.H0#*UD@HS*6>K'I7GF\5314YZ%?DE35)C:X*%(4&]C]N=N)HS+ >N9P6Q
M;T7CN&<FX66)^(RX#?-Z(;$4M65(0T@*+C6P%I$!K;.=PD8_&._I.A)DCZ^M
M*6K[S86RQV=[,'3)L<P+S5'A?8"=::KS!,_E/44KFOQ4 UFB3[!;0!6W+.&B
MXJ9^HI$L3S(=R'6>(@N58?"U;O1DQD7^)\KW7?0B,IB7$,3F!GMQBST3,DP(
M5$0 %OF:-OGBX-7D/J48>G^W=-N9I";MEK6J=3KB>2 L,8Z6N=0T6V1+K/5\
M@^XZ/3$)JYNP:YHT==)WK1/=D>DT]D^FSXA5VA_R63;ZEA='5AA&./+' 1XX
M[^0! VOLW<\?)-YBD17%,;X]*P["DY8"69.\,(F@,7=@:PR.,"AOYK,9!"$:
MB!SP/ _?XZ.%9P5!H-K@R'*""%QK'(96X 0G(RMR1M8X"@'G86#%;K2KD1OV
M6O.2BI7Y 9'HRYJIIDOOOG;_.)=-:_^TO?E!^D+$*D<T!5VB*%YFX0!$\]/1
M3!2O3*._X K/IAEF^)]&A=Z ZTN.76P[T0:Z/[_)7U!+ P04    " #E@@Y9
MHS)=&>(,  "#)   &0   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6RE6EES
MVT82?N>OF&(V6:D*@G 1)'VH2G:<Q*EUK)*<Y&%K'T;DD)P8Q# X1"N_?K_N
M&8  14IR\B 1!&9Z^OSZ %]M3?&Y7"E5B2_K+"]?#U=5M7EQ?E[.5FHM2]]L
M5(XG"U.L986OQ?*\W!1*SGG3.CN/@B ]7TN=#R]>\;VKXN*5J:M,Y^JJ$&6]
M7LOB_HW*S/;U,!PV-Z[U<E71C?.+5QNY5#>J^G5S5>#;>4MEKM<J+[7)1:$6
MKX>7X8LW":WG!;]IM2T[UX(DN37F,WUY/W\]#(@AE:E9110D/N[46Y5E1 AL
M_.EH#MLC:6/WNJ'^ \L.66YEJ=Z:['<]KU:OAY.AF*N%K+/JVFQ_4DZ>$=&;
MF:SD_V)KUR;Q4,SJLC)KMQD<K'5N/^47IX?.ADEP9$/D-D3,MSV(N?Q>5O+B
M56&VHJ#5H$87+"KO!G,Z)Z/<5 6>:NRK+M[]6>OJ7KR!8'/QUJQA[%*2OEZ=
M5R!/B\YGCM0;2RHZ0BH5'TQ>K4KQ+I^K>7__.=AJ>8L:WMY$CQ+\N<Y]$0>>
MB((H>81>W,H:,[WX"+V;E2S4F17U2M[#M2IQ610R7RJ^_N_E;5D5\)/_'1+>
MTDX.TZ;8>5%NY$R]'B(X2E7<J>'%=]^$:?#R$<Z3EO/D,>I?9Z7'286!+XZ2
M@Z;#2?/X?3Z#5A SXBJ3.;Z*[]5,K6]5P<L\4:T4[Y;YO9!SLZE C>X]0N2$
MGG_WS22*@I>\C.[R]_#EJ=BN]&PE-H6YT_ @ <CIG5$9L82U*J%;HHB/V6>!
MH\%\*; ^-_F?M<ST0H- _VE#;E,7LQ5$%V8A9F:]AMB\T*/]L%U5Z!F)4I*[
ME!X=J]:;S-PK^K9F#92TF8C=&EG,Z<M<%P :@R<RGX-N7@(7P&R[TDGABT]=
MM95 0YPELZQ9!^0LL7&N\V7+>HV(LLQ+>"KIA@XA7B5Q>EC7H/>I+G+(EBOQ
M1IO,+/6LI%6^F/.^CV"8S!E2B(7IOG72OG5T3F+E#DZWNEHQ1S-3;$P!>N '
MR4'F^B_K2WK/87SQD]FJ.U6PYQ1*;.E?;@2L@1 L2=%$L%+%NM5:HX%"0<:"
M=+(V<UAW)AVHSTP-F?.E+RY)AVXY^PDDW"FN]3:QDM 0/M475<PT_& #@RM/
M2'$'A=(1&U5H,P>X$RN(G[FXO>_:D%02CE^6QZQ?J?SL7LF"18&-NY3HN=R0
MCW\5V9,CSK:6]Z">J2490-;5RA3D"E E6;WKI*4CSSZOJPK>?"ID956./$N+
M66W60ZT5G"_/M0LP2^]!D C\.Z"N0^JQ!]HX)B^TIZWE'Y;QAHFR%P?L*:W6
MV/4DXKDNK)H;NU'),J\S95=$(_%M^T@NP!SKA'>PE5@2*ES(1YJ%<- \ Q]W
MSF_L"GH2I_ ]2G"^^,6(15V0%S?<;C6\[Y8$F:M#7@?W1+AW99);,LI#3R6'
MQ 9'TAZ/FNGV#VCP4(CHP@8OB=0>!Z""63:*:Y[LWFO<+D/@W$)!?+B0RT)Q
MZH-(R+'Q<>3_N89.:$D/]?]]- (84%<FFQ-4]G/#T6/ZZ(-E'?2Q!C-+Q3IO
ML8?E=8);M"KY_I OATU&N54SX*90BX55B*@WP Y:2![8>/7[JX^^^+5C.L="
M/]%1P%GO[647SWTE)U4S;=&IH)+0FJ*-%YMIKF]^Q7W@#)?5T$.SG9VB_V0F
MRU7C+22K81W08W:![L:]7'4T)S5!]T6OZ[5%*:>$KE"-;]</=2)T22C'P<34
M/8+[I<I5(3.KL&/^W2%",6<CK1O-#GT7A5GS^B8R";<4%,*UV@XZ=N3F!DB4
MFXHH .$$B,%K&YAW0N<U)R12G(4N!'>ED7_OA:O;;.&QJ*L:H*.1H-D*A_C?
M2NMNR.%$\"0\12J=3*9>$H]$CHZD*2$V60T(CT[%.(R\41!W4,5QL5>+['@Y
ME,&J%6#4.;6\DSKCF":N=^PV'MXZ?:[*%L [ODV><1*?8@,Y3Q@%WC29BFL%
MZ9F_&\O?"6>Q!:.[SOM$3CW*<66-2'/2@#?3YXV-25F&$ R?1XQQ5 U]X0[9
M@M 2"="@4P/(D3U1)J)/I4(/ ";S&DVG".D()<$J^9K'=&7C<J2=UJD]RW2[
MT;8A%$7PQII44ZT*4R]7_24Q(!+ICW*/4W9E*ID]+6JO[NN43G'8$")D4?P<
M\J$,1*Q8(5B&#/;%\@?G2%LDW!Y*T$\7'LA;S.J>&LAO@.NV+H!TH1>.$F^:
MIBY5]YSR&:&$8YJYP$$DXN:=<L9NKT5[S0(N3):9;?EB\$LK_>_<CZOY6>?J
M<HF$1Y72X&-'V2Q]]+*K<18R$HC5:.I-)Y'XEYCXDU2D_@27J3<-H\''O5(S
M1-S'Z0C/P]1/1NWS!G\09B(*O?$D$:=8%/O3L%TS([UD:GX.=2V4KGCQ-/*F
MD5V,IBU)#S*-'EDU/7(,AM,@\=)XBCU3/XD<PVC6TF T>&<Y8;L<WA]Z:00:
M(4DQ]B'WR!_3_L0+@V#P&X#85;#J"]46E-.-1?&_P\]SC!"+V(O'B1>Q$<8^
M/&SLAZ2_T0$3P%HAFR#RQ_%A"V!%.+5*]4=/6" <C[SQ..#5J3\=/VF!!-Q&
MTXDW&DV8VQ&YS(BY39Y4?P+U3T<C;Q0&[&])(!*?-!<GX5?K_C%.&'H7$H7C
MG<QJU2+BP]QO#VDK"CY^5U10^J/<O.9F<J^BLC5275J@1 .:R=GGLYL9BD("
M/S[DC#HOU],IE UM76?CF9[P=(;H<:=LC?5B<*._](9-K>@#%IW\9G"MR\]G
M"Q2XR / /5(4=ZF)'P< YS-<C"-<Q/YDZKXG$_$MS-2HE\JB$^WRP2EB83+!
MLM1'_L:_*5]'P>![3>,*:.9>JVPN I_(XV_PF\F0BS*"K6E"=\_H,QWC\03$
M^- )2/"AW5YT5]8U_2QY=$JGT\6$8RCT0WL#<#.*'4QW&NZ]6KTIYJCR[!G5
M9F+<WH&L+AT8Z[_(YQ['UVY0>#1_.;MSOMKGJ WH, "P)2Y*P\&/3?"F7@QL
MY+NCP5N.1PK('[H!&:"TLO'(>VU4G%\C<FF6]00K>\$63+S)=&I)18,;TO?9
M+8_$9MV1&(5;7MI,1F.:?J&.&B.KN[.:A]4^1XTM^.WJ70FUGW]YGL,-&?%K
M4)9(:_]>FH,B>+^I2Y NQ>F+P:<5.?K!D!#/"!;1"1M47+( &G"LHQO.S(8K
M;D!@0N89!9P2@"X)?P;!=/"C+?QMESE'B:%ID,JM%A!G3+8>P>_'XY VC,:#
M3UP3E<=TSG3#J?T<LU-X@05V?*;LL8U="I5)!U1[+<<3T$6&#\4:=2,=2>9E
M%&S*#VC-MOM"]?7)NK)-9Q3;Z-DVP2#1S,AE=[YA@4\TP,>PB\CZK*H=^NY/
MK9[9Q8EY733P^DQV=X(G5/3:&I&?0M61CP7MW?X$P<HIFP*J*V _DS"^-(+T
MR\ROX->R25#J[,,S%Z;-!>8_/"!NR]K>J7W 7$GJOJ![L\P9"(^Z:^.*($B%
M0M0ZE55LX,?"Z_II']MW\- ?V=C9A2Y["?^6'+[ER/7.#]QOU\\ V_B &,F?
M\]B^6:]W:,40N#?G1S\H_D,YF$;C,Z6I%QM'(U2F0:?!V+BW*1T929,?[I%T
M/ZB"=E\VLR9??.SV1=05J'E?\QT$C5,DB[0]JREYC@T-@(N*YO^0.:</G0-2
ML\S-N [;?!IXXZ0]P0W<ZMRF#J\=%7;=@FPZ:JW,R[_&3SIJ:LYYF#6>8?[N
MK'(WG+0C-H<?SJA7S3N/QP=ZO5'=HR2ZP[IW-U=7S5L"[]C(K:WMWE]]Y(:<
M&1AY'10E.ASY#1=?-W7OS1QU;NV\1WTW['%OF<AWBPI5Z$;:\6^;,%J&S69C
MBJK.W5R]?7UD)R;4![>H2 &'!BJ:C(]T^?]H[/'<$0?%AROI>X."!\,.*T%W
MY.%F;&X&L3_[X.ZCG5"<T->V_CE]. ;1.6MG36]H7%@Z8'"S"IJ9Z5.>RH,I
M&@93C2>^/7W&Z$1N=%M"[,].^ A94GYJQPFM)CA,X)]0AGHP VZUVVK63<@T
M^$S3U$LGP5'3_F(J<IJ6$]O)P#4,UZ.[-R(TCT&Q3<4^O9.T.EGH8L<QQ6+?
M=N1YUF7M^,^]0G.O'7+3,W_K%J[.M&G>>16[ 4_K^B?PZU'W?N9O$6B8.3Z+
MVO=SG)>+K:DS-]7>4@MD9K.ZH# CMV]?>>R&7R7\A.; 2"0/7-3;<5L>'8VV
M(R2&A,,!Q>#3GW%%R!G3:=Q)1<D(338<PKKI@U,M7ML$MW?J(_4'6572'!NA
M5AB;N[!T@0=M8MV]?]FU<8=^9G#>^6'(FO(P_?RE%/S.U/Y&I+W;_L+FTOZP
M9+?<_CSG@RR6R*8P[0); _1H0_M^H_E2F0W_S.365% H7ZZ4A-"T ,\7QE3-
M%SJ@_=W1Q?\!4$L#!!0    ( .6"#EG$\R8A\ (  *P&   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;*55[V_3,!#]5TX!(9"F)DV[,8VVTKJ!&-*D
M:1OP ?'!22Z--<<./J<_^.LY.VWHI*Y\X$MK7^Z]>^>+7R8K8Y^H0G2PKI6F
M:50YUUS$,>45UH(&ID'-3TIC:^%X:Q<Q-19%$4"UBM,D.8MK(74TFX38G9U-
M3.N4U'AG@=JZ%G8S1V56TV@8[0+W<E$Y'XAGDT8L\ '=U^;.\B[N60I9HR9I
M-%@LI]'E\&(^]ODAX9O$%>VMP7>2&?/D-S?%-$J\(%28.\\@^&^)5ZB4)V(9
MO[:<45_2 _?7._9/H7?N)1.$5T9]EX6KIM%Y! 66HE7NWJP^X[:?4\^7&T7A
M%U9=[F@40=Z2,_46S IJJ;M_L=Z>PQ[@/'D!D&X!:=#=%0HJKX43LXDU*[ ^
MF]G\(K0:T"Q.:C^4!V?YJ62<F]WHW-0(CV*--(D=,_IXG&_1\PZ=OH ^@UNC
M747P41=8/,?'K*27D^[DS-.CA%]:/8!1<@)IDHZ/\(WZ]D:!;_3/]N!:4JX,
MM1;AQV5&SO(+\?-0RQWC^#"COR07U(@<IQ'? D*[Q&CVYM7P+/EP1.^XUSL^
MQK[3ZUX:QU'T86W#X0#VIPR/%<*5J1NA-U#( K0!Q_<K-[: $@NT0H'L=0"N
MV0 (@0T '$-)KJ'NIHY^ZL SPWYF('3A%R,X84YJ,-PZM3D!00&^J^QI<\<Q
M QER/1#\NM>M$C[?%Q:90N"!$32&9+C"G/6LQDE8>5;-]L5W$:UE05ZU($)F
M%SSMLE5J Z8L.0+9A@LMA6I%9PJ*74GH'+T\Z4 2'X?C_ABGY!,+9WJA0Y 7
M+A3+4&/)R2NIE!?/9JCD;RP&SXZV.U&6(WK V\::I?1^]BX<)SGA<.^L>3BF
MA->0#!*^ZTH%A=RACPS[R/\-8@"'7M-XST%JM(O@DP2Y:;7KS*2/]E9\V3G0
MW_3.QV^%74A-H+!D:#)X?QJ![;RQVSC3!#_*C&-W"\N*/R=H?0(_+XUQNXTO
MT'^@9G\ 4$L#!!0    ( .6"#EF!$0$^3P@  .P6   9    >&PO=V]R:W-H
M965T<R]S:&5E=#(P+GAM;-U8;8_;-A+^[E]!N+DB ;RV_++>]69W@;S<H2V:
M-LBF+0Z'^T!+M$U$(AV26J_SZ^^9H23+]MI7W'WK%UNB.,.99V:>(7F[L>Z+
M7RD5Q%.1&W_7786POAD,?+I2A?1]NU8&7Q;6%3+@U2T'?NV4S%BHR >C))D.
M"JE-]_Z6QSZZ^UM;AEP;]=$)7Q:%=-NW*K>;N^ZP6P]\TLM5H('!_>U:+M6#
M"K^M/SJ\#1HMF2Z4\=H:X=3BKOMF>/-V0O-YPN]:;7SK69 G<VN_T,N/V5TW
M(8-4KM) &B3^'M4[E>>D"&9\K71VFR5)L/U<:_\'^PY?YM*K=S;_0V=A==>]
M[HI,+629AT]V\X.J_+DD?:G-/?^*39P[Q.2T],$6E3 L*+2)__*IPJ$E<)V<
M$!A5 B.V.R[$5KZ70=[?.KL1CF9#&SVPJRP-X[2AH#P$AZ\:<N'^9P67_.T@
M0!>-#-)*[FV4&YV0FXH/UH25%W\WF<KVY0>PH3%D5!OR=G16X4^EZ8MQTA.C
M9#0YHV_<.#9F?>.SCHE_O9G[X!#[?S_G8U0Q>5X%U<.-7\M4W761\%ZY1]6]
M__Z[X31Y?<; 26/@Y)SV,\B?E7O>JN&H+RJ/?UTK)X,VRWK@\TJ)=[982[,5
M>1S*Y=QBDG5;(4TF[&*A4R58JT"A"QV\2*U;TR0E5BCVKZ5T03F(VA1CF=!&
M/$@CWFNUM#WQ3N8:@D;+8X68^0NJ\Y^HSE[SQ--^-4$ZS>)&9K+?LIT-%;F6
M<YWKH&&S= HLD-JET=^P/I4B%C(BP#T&P@3Q*/-2874>7)2AA R*1A=E46E<
MRRTH!>[91^5X6AR';T5?_&A$*O.TS*,1)U7OZ^KQ6 WQ2GK!I /S@A5E@ /?
M%$.J3>H4B<A<( !(&%J%,=YSQSJ]U :3=K8Q7L8&_@XEH-L=3-'X=IPS16/(
M'"RZ@"S0<](L>7&A 68E.=\BSF#83#E2MUDIZ&=<@!S-,P+?3- +#?.D]RKT
MV!0R Y)<6O3PJ+8^VD8T2([S5_ 9.5YZU>3G1H<5ZS6(*WQD[X#K<"2*2"E(
MP%SY&'%RF:+NLAT\<YE+0^E%K+?G]_??78^&5Z]]"Q</MMP2\GF9 =DU]0)/
M]JFGH"A5G8A0410J6) ([3A7PA[&F(LXE&(]:SB17NJ^ZO=HI* N@\XH*#I0
M3D:^@AX9V)6UU)GP:BTIX/E6+)PMX!L"T@0?8): )+4^9DOI',$>\4:[LE!3
MHU)9Q978 ']A%Q< .T:*!?<+:2OF9:A*:5$EJ>0PJR?T>78VICT2PF:-#5P:
M/Y6P>I0,K_<3'AXHQW8 U3JQY-*IF&W$)W*]=O9)%]'Q:>\R2=!_2[)C03L/
MA/^_4T:,=)TNK?!XH/JHC-@JZ7R%%E:OTZDG/&B&"_H75'TQ1X(/>^Q(5!G5
M./6UU"CV/=_@D5^1F; (+CBFO@JJN!1&@16 #?()0S&4Y7H73%G8TK3"V5Z3
M:@2Y L+PX)U(.IP1:2Y++I:53E>U:6*%$,-XGM$0&2RKF([]YT@]J'6(CJ*;
MCO;#54C4 0UD*M6\MR(GRWE5,BN"DX- WJDGE9:<)+LI%)P:1U+/$=ZGI:,@
M]<6#II)M&T(+@1QSR/DUD1#TLZY"?JG9]QFBA:,;2;4H-/2DS#5,FB=Z1U5H
M-*5VH2]^L!NDC$-J-&8U_E6KB<QRR1.]U;V"F- =6!7134&P6UI\KT_L;(JT
MB.%==6ZX\&2^_5;5>$/:W#CFBAW45%I "+M,T@/PI7@ADOXE&EN>QZUQ5L8M
M;E6[9U?5A]D12UL:5"-7]^R@NIL,,*VBAGU5G1]4=G)<V:W-1I58 0W?Y2K
MY-\,-N7.4YA@V=&&@$KEL%'L57ZL]%WE<ZE'4FPEZ7!&B\K8:J%BWVJ"<]C
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MWA:V59:)$^7MJG9QNE5WE=M"7BI!MZY3WX4Z4<[$D#QZFZR=5+Q3-'V3LX7
M(VU^.7C@SWMW!M#$1S?Q!V[BN[&?#NY_:AR81.%X%$&<Q>$HBP:/>VT41UF8
M32;@,Y5<#;Z]TU*0ALDD"\_/,TC"BV@47J03,ED@O7D<<\HGI<ARM_ZIIWL;
M$"?A:)*&V7@R^.ZSE](^"^/)&.+S,!E/PLDD@T-7PG#GPJY0K_RSA :H:J1M
M[^[MZ?;E<]U>^*_B[;/I"],K3HX*7))J=#8^#T"W3Y%V8U7MK_^%LO28\,N2
M7F^HG0!]7RHJAV[C#&S?@_/_ %!+ P04    " #E@@Y9[=>\@'P"  "/!0
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M>GV1@.O'OS?(MG'DUI9X@..QX8V)+@3P_<9:.A@AP;"#B]]02P,$%     @
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M)R5P+.Y$D$7Y@1L^/55RPQ2M1F[T8%6UU A.1.24N5'X5R"=F5YQH=@W'L3
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M'$55<MJ6O!BYMB=<"VF,#.VC#QSK(BW _TN)#3M](0'YD>?T;U!+ P04
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M\7V=%E!2?2DW(' GEZJD!I=J[>N- IJYH)+[41 ,_)(RX2539UNJ9"HKPYF
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MA(:WDAFNX7'*)!+ _E((O9^@@OZY._T74$L#!!0    ( .6"#EG!TV!+'00
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ML\Q8$@AYEZWZ?,-HL"@:)7%?'PPF_22(TM[U9?'8/;N^S+8BCE)ZSPC?)DG
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MTF U[SYS?*"!LA-P/)72O#3L NV3+_H74$L#!!0    ( .6"#EF:Z792I@0
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M:X#?9U*:U<2^?:JW[O@O4$L#!!0    ( .6"#EG4VE8?TP(  (D&   9
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;(5584_;,!#]*Z<,;2 QDJ9MQE@;
MB9:A,5$)T<$^3'QPDVMCX=B9[;3P[W=VVJQLI7QI;>?NW7O/E\M@I?2C*1 M
M/)5"FF%06%N=A:')"BR9.5$52GHR5[IDEK9Z$9I*(\M]4BG".(J2L&1<!NG
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M$K\=0!H#?#\70F\ZICS57R/A'U!+ P04    " #E@@Y9;1F,5;8"   /"
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M8 1-E026+_A+E1R364:YWBT6\F,X5UKBD__9EO>*.6QG-FVPIPH:P\#!/J=
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MXJPV.JN#:BZJ>:CFHUJ :B&EM8.EJ;2/3SH9^AO]X? 7MH5H,Q[5-%334<U
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M$<U%5MV@_/Q=FA;/'U03/*39]]V7<_5_4$L#!!0    ( .6"#EF!'9^'X!$
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M+4*UF-+ZJ=U5Z@;T=>$&:&\.U514TU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4
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M ?7W[_.\>OZBF> Q+[ZNG^;-_P!02P,$%     @ Y8(.67FB.54;!0  TQH
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M<Z)8&@;@OW+*F=KIJ>I5./B:3:Q*Y!UZ-M6IGODPM1^('I5J! <PZ=[:'[^
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MJ&$CVT.Q!UJ^CH10HDI2=O/O1U*R;#F*T*!L'F)*NN?HGGN/F<O,#I0]\@Q
MH&\%*?G<RH2HKFV;IQD4F%_1"DKY9$=9@86\9 \VKQC@K085Q/8<9V(7."^M
M9*;O+5DRH[4@>0E+AGA=%)@]?0!"#W/+M8XW5OE#)M0-.YE5^ '6(.ZK)9-7
M=L>RS0LH>4Y+Q& WM]Z[UPLW5  =\4\.!WZV1DK*AM)'=7&WG5N.R@@(I$)1
M8/FQAP40HIAD'E];4JM[IP*>KX_L'[5X*6:#.2PH^3??BFQN11;:P@[71*SH
MX4]H!>D$4TJX_HT.;:QCH;3F@A8M6&90Y&7SB;^UA3@#N,$+ *\%>-\+\%N
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MHG%842:"+'5K-RI+96,X$W"CB&ZJBJI?,^!R.PD&P7[AEJU+8Q?"+*WI&N[
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M.K] ;<KGF)\86;LH6$J#P>*&)48_*%N [U=2FOW$;M#]F62_ 5!+ P04
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MQ5_8HT:+'1JFWIQY4?8O><P?.QYTR'P3Q<PO@I,M\-T@_^G\+ [$3L!@="!
M+ +$4P/Z14!_+T 4#P0,BH#!7L!X>"!@6 0,]T<X%# J D;[ 8>.TK@(&)\Z
MPJ0(F)P:,"T"IJ<>):&W/7.]DT/*D[U_M@^';$^WL'^^A?&AD.T)%[(SWLV?
MB]D367)B9W89LD<2IH]/O/27+!NR^.3YZP9IXM[&8?)7-XF+9Q9-GO41^9-\
M6"S<-)4<C^A!7A#2Q'HOT=AQO3_(.^(&Y.\5VT1.L(@NNW$R>$ITY\5 -_E
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MH>D['>OSTRV\??,.W@!E\&G+"TE8(N>NTL!F6C>NX&Y*N. $W!\%NX2A-X#
M"T8M\F6W_!9C+?>M?/B]W-5IJG,5U+D*;+SAR5Q)B3AH9F$ 'RA9T92JYP$H
M#BN$!T*3 =Q1&9,4_D(BX)[H!.H1\/?U2BJAG]Y_VO)1 HS: <PK?25S$N/"
MT>^L1+%#)_KU%S_T?FO+SO\4[+M<#>M<#;NB1X]H]I $A7F>3BS?31DBM"',
M?K.+?&\<SMW=H8O.>7JZ&-4N1ITN-/BX#;Q4C0_!?=]K@'>&[@D^KL''Y\##
M-O#Q,;@W;G!W1N[)'=;<X3GN21MW>,3=S'9GW)[4DYIZ<HYZVD8].4O=&;<G
M];2FGIZCGK513\]2=\;M23VKJ6>=U)^XTGMJP1*]N?*"*4P@M;4H)\^V$+59
MFAU9"H))TU7GO#U=^=YK'?8Z?9GB<@4TRPMCB6IC>A;56C.](S<787/7[)ZM
MKYN#4X7_ ZO$ZT)9+E'Z4B=;;?DMB^2-FKXZY^WKZ_4$X'<6S6J5XD((_:A!
MSH4]B^H2]W-6@^,5]">S8=-K<%0?+\J*M&LS\5J:_>[:_/$4ZP 89Y6Y5N[C
M@CWR_29U2U7WI[,&M'MP9#7?"_=$;"B3FFBM9=[E1"='E$?PLJ-X;D^Q*Z[T
MF=@VM_JS!849H.^O.5<O'7,PKC^$HO\ 4$L#!!0    ( .6"#EF1_![WR ,
M  43   9    >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;,U876_;-A3]*X0&
M#"W019^6I=0VD#@MUJ'9#!O9'HH^T-*U1404-9*RLW\_4I)ERU:T9A#:O-@B
MQ7MTSB&O>,7)GO%'D0!(]$333$R-1,K\VC1%E #%XHKED*D[&\8IEJK)MZ;(
M.>"X#**IZ5B6;U),,F,V*?L6?#9AA4Q)!@N.1$$IYO_<0LKV4\,V#AU+LDVD
M[C!GDQQO807R(5]PU3(;E)A0R 1A&>*PF1HW]O7<]G5 .>)/ GMQ<HVTE#5C
MC[KQ*9X:EF8$*4120V#UMX,YI*E&4CS^KD&-YIDZ\/3Z@/ZQ%*_$K+& .4O_
M(K%,ID9@H!@VN$CEDNU_A5K02.-%+!7E+]K78RT#1860C-;!B@$E6?6/GVHC
M3@(43G> 4P<XYP'>,P%N'>"60BMFI:P[+/%LPMD><3U:H>F+TILR6JDAF9[&
ME>3J+E%Q<O:[6BF?F1 H!XY6">: ?D$KM5CB(@7$-NB.I(5V&JT@*CB1! 3Z
M\!2E10PQ^L@917-&\T+B<E8. >I>@[QHD-_<@<0D?:L>(72'F)A2:=!,S*CF
M>UOQ=9[AZZ-[ELE$<<@4@7:\J;0W!C@' VZ=7L#?BNP*N=8[Y%B.U\%G_NWA
M;@\=MYD/M\1SG\&[R22)^RS?=%C^ ?.,9-M3J[]\5L#HDP0JOG:Y7+'PNEGH
M=\>UR'$$4T.]' 3P'1BSGW^R?>M]ET4#@;4,\QK#O#[TH0Q[AVXH*S+9Y55%
M8%02T*_%W<SUPL .QQ-S=VK#Y3A[Y(S#, R:@2V)HT;BJ%?B$H3D)-))M9(L
M>D1?[H&N@7=.;"_42R=V(+"6:K]1[;^*3/"'-&P@L)9AX\:P\8_.A/'%"@^M
ML6>=Y<'E*#NPO<#JSH*@D1?TRGO(=BH/E(SEZJ%SX^@-?^E$#@364AHV2L-7
ML?+#(0T;"*QEF&T=JQCK1Z_]FD%K65M!$(9GJ[^?Z?]UXJ2>LWN=^"/7\@22
M#.4%CQ)5XJ*(4:HDB__<//JQ7[HDAD)K.^$<G7!>11K5-(8R;2"TMFG'\M/N
M+=:^2R*YE_64$P:C47">29<#'=_R?#?LWDGL8\UH]Q>-2XA!?0ZOU2?.G*E]
MA4NBKQ?J$Q(X_Z8ZJ_\)+Y[U@=#:?AP+3'OT.E)ET.IT*+2V:<?ZU.ZMYKY+
MJ@Q:G-9HK1W,\4(W&)\GE'ERH$"!;\MS%J'V$<6S^K1N>INSG)OR!..L_U:?
M\90'%4>8ZH#H'O,M4?M4"AL%:5V-%2U>G;E4#<GR\MABS:1DM+Q, ,? ]0!U
M?\.8/#3T YJ3K]F_4$L#!!0    ( .6"#EFY&R.L=@(   $&   9    >&PO
M=V]R:W-H965T<R]S:&5E=#4Y+GAM;*U4WV_3,!#^5ZR T";!DB:EH)%&ZEK0
MAC:IVC1X0#RXR36QYA_!=MKMO^?LI*&@-$^\)#[[ON_N/OLNW2O]9"H 2YX%
MEV8>5-;6EV%H\@H$-1>J!HDG6Z4%M6CJ,C2U!EIXD.!A'$6S4% F@RSU>VN=
MI:JQG$E8:V(:(:A^N0*N]O-@$APV[EE96;<19FE-2W@ ^UBO-5IASU(P =(P
M)8F&[3Q83"Z74^?O';XQV)NC-7&5;)1Z<L9-,0\BEQ!PR*UCH/C;P1(X=T28
MQJ^.,^A#.N#Q^L#^Q=>.M6RH@:7BWUEAJWGP,2 %;&G#[;W:7T-7SWO'ERMN
M_)?L6]]9')"\,5:)#HP9"";;/WWN=#@"(,\P(.X \;^ V0E T@$27VB;F2]K
M12W-4JWV1#MO9',+KXU'8S5,NEM\L!I/&>)L=@LEY62M50Y0,%D:\HXLBH(Y
MC?'@1K8/Q2E^M@)+&3]'C\>'%3E[?9Z&%E-P1&'>A;MJP\4GPLW(G9*V,N2S
M+* 8P"_'\9-XA"#$VGL!XH, 5_$HX]=&7I D>DOB*)X.)30.7T&.\(F')R/I
M)/U]))XO.<&W5$(PBVUB#:&R($NL%J\%9,[ D!4S.5>FT4!^+#;&:NR"GT.W
MT :9#@=QD^'2U#2'>8"M;T#O(,C>O)K,HD]#"OPGLK_TF/9Z3,?8LUME#,E[
M$5Y(%X+@NR0<GVG9/D[.Z(8Y&\R0'FV0F0_B!MLNB])P=USDF$>;>7C490)T
MZ8>/2ZZ1MFVX?K>?;PO?UN$?]W8XWE%=,FD(ARU"HXL/.!UT.W!:PZK:]^Q&
M69P ?EGAC ;M'/!\JY0]&"Y /_6SWU!+ P04    " #E@@Y9G@DS\5$#  "L
M%0  #0   'AL+W-T>6QE<RYX;6S=6%%OVC 0_BN1NTZM-#6$C$!60-J0*DW:
MIDKMP]XJ0QRPY#B98SK8KY\O#B%0'Z)]6,M ;>S[?-]]=[XD;H>E7@MVMV!,
M>ZM,R')$%EH7GWR_G"U81LNKO&#2(&FN,JK-5,W]LE",)B4X9<+O=CJ1GU$N
MR7@HE]E-IDMOEB^E'I%!8_+LY6LR(D'TD7B6;I(G;$0>+M[_6N;Z^IUGKV<?
MSLXZ#Y?7^_:+"K@DOI.T=P3I5:>#$P.(D4?'D1_BQJC[N]2;Y>>&J_$]QYP'
M1^DZ( LCCIVJ6IH0QW['X;C-!4ND'[BKT(Y8E]"O>VP\3'.Y;;606(-AIQGS
M'JD8D0D5?*HX>*4TXV)MS5TPS'*1*T^;'C?A K"4?RP<V!FT?\V3<9FK*K:-
M8']/Z^5[P&8& KD0C< NL8;QL*!:,R5OS*1:7!F?0%X]OE\71N%<T770[9&M
M0W4Q0::Y2IAJP@1D8QH/!4M!CN+S!5QU7O@ :IUG9I!P.L\EK31L/.J!H9TQ
M(>[@V? SW>%>I:U]JS9;-D,CJ!Y:&CL!_C:;Y6[3]E[$ZQ7\,==?EB8=6<VA
ML=FM8BE?5?-5V@C V .<G1:%6'\6?"XS9I,_.N!X2#=^WB)7_(^)!JTR,P:F
MB/?(E.:SMN6WHL4]6^E-.ZU27'/W!#7_VSK/F62*BK9HT_MON<HO5ASV7TMR
M]539%^S46+_PW[K(WBF(C$Y!Y$GTY. 41,8G(++_:D_-YX@,WK[(\&WNME\?
MUUIGPIT386/UX.0](C_@'"^V0;WID@O-93U;\"1A\LG!T-!K.C5_BN[PF_4)
M2^E2Z/L&')'M^#M+^#*+FU6W4(AZU7;\#=(+HN;8;V)QF; 52R;U5,VGU= S
M Q.U_H##/G)3?=P(YF,Q-P(8%@=3@/E8+RS._Y3/ ,W'8IBV@1,9H#X#U,=Z
MN9!)]<7BN'UB\W%G&L=A&$5812<3IX()5K<H@A\W&Z8-/+ X$.EYM<9W&^^0
MPWV [>FA#L$RQ3L1RQ2O-2#NNH%''+MW&XL#'M@N8+T#\=UQH*?</F$(NXII
MP^Y@'(EC#(%>=/=H%"'5B>#KWA_L+@G#.'8C@+D5A"&&P-V((Y@"T( A85B]
M!_?>1_[F/>5O_S\[_@M02P,$%     @ Y8(.69>*NQS     $P(   L   !?
M<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^O
MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
M1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2
M?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;
MZ/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " #E@@Y96"T[FK4$   ^
M)P  #P   'AL+W=O<FMB;V]K+GAM;,6:VV[;.!! ?X7PTQ;875LWIPWJ F[2
M[!K()D9MY'7!2+1-5"*]).4D_?H.Y74R:MQ!7Z9^LBZ6=#02YXQ&>O]@W9=[
M:[^(QZ8V?C+8A+ ]'PY]N5&-]'_:K3*P9F5=(P/,NO70;YV2E=\H%9IZF(Y&
MXV$CM1E\>'_8U]P-\8P-J@S:&E@8%]QI]>!?UL=9L=->W^M:AZ?)H)NNU4 T
MVNA&?U759# :"+^Q#W];I[]:$V2]*)VMZ\D@V:^X4R[H\M7B181<RGO?+0GR
M_K,$D,E@/((=KK3SH?M'MW\)C#L%?][/M<%>Z3HH=RF#^LO9=JO-.NX&SF*(
M3J.+P^%W'\1S]S-AM*N5+M6E+=M&F;"/HU-U!#1^H[=^((QLU&1P87?*B;E<
MJWA2<)19M3_! &0H7.Y<PPHWJSI&3AY3*>-5)6#*VUI7P%&)C[*6IE0"0:8$
M9'I"R']3!)D1D-E)(!<1!S9%D#D!F9\0LA?)@H L3@F9(<@Q 3GFA9S+)['S
M8JY<MWD<+)?:E[7UK<-C^XQ /.-%G!FO*\@V2R<KR'=BZIPTZW@S!H\(WQ*$
M;WD);V2 : F[$F&CQ,?6:Z.\%]+$P>TU@GQ'0+[CA5RT32/=4Z1<Z+71L)DT
M04S+TK8F8,AD1"7R$2_FE=1.W,FZ[>)YI0W<DUK68NH]. UG\H3T#;-PH(+8
M@M^?NHO\Z;]6;^,&OXL;%3 B99N$63=P95T+">?3XS:FH?W]> MWJ!,7K7,8
MD_)-PBR<Z=JI5X,YH>22,-NEN]5@8,!5]3JNQ6"44!)FHRR5:\2UE3T@2AX)
MLST^JPJNG82#1L?M8L$;I^=.K93K^2.A!)(P&R2.3QBJD(L[&3=Q/,CO+RSE
MCX19(#-3VD:)I7Q4O5% Z2)A]L6U@G!AFI320LJL!<BK<.>#5"'KBL5&]FZN
ME#)!RFR":[4&/8$/2J5B?=(+&?FTP9S_2>'WBN24RO\I<_XGA=_'I*20,DN!
M$+[X;2DQ)J6(E%D1I/3[T:3$D3*+XT7Z,7AP;/\&HU&R2)EE03JM'T%*&2FS
M,G[HM'U ,29ED?276.381<XHG62_7"='$2FO9,Q>(1\J^]TBRC+922V#NQP9
MV=4ZJ65ZF)1E,F;+T)@YQJ0LDS%;AL8L,"9EF8S9,C3F&&-2QLF8C4-CGF%,
MRC@9LW&H"N@/L<"8E'$R9N/0F%/<P*8,E#,;B"[4<$+**0OES!9"A1I<8]AA
MU4(Q=+N*W5@H.# F9:&<N]>%,:=5U;5M8 C-3+<[C$E9*.?N=7W?6>K38DSR
M[0JSA9[[3$>#B1N<.66AG-E"=*7>&T*4A?)3-LEZ3L\I"^6G:I+M!S[&I"R4
MG^RY!S![97%.62AGMA")V3;X#25EH8+90G0T\1 J* L5S!:B,"%!84S*0@6S
MA7 ;]TCJQ)B4A0IF"_W_3'XTM_>;X@5EH8+90L^8SV4'5,<OG!B3?,O/;*&C
MF)#</6P&53W&I"Q4,%OH*.8_\6NFMA'3-<:D+%0P6^A(8P8C8TS*0@6SA5XU
M_7]8R!64A8K.0L/#]UJ56FFCJALXA(?EI:S+N1/Q9_\R.2_B&Z%56]<7L.S6
M0(E6'3[_.GRZ]N$;4$L#!!0    ( .6"#EE9=@'X]0$  #@C   :    >&PO
M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-VKM.ZT 4A>%7B?P 3/8MP!&AHJ%%
MO( 5)A>1Q)8]"'A[HE"$95&<!LVJK+'E[;_Z9(U]]Y3W;=EUQW&[Z\?9QV%_
M')?-MI3^7TKC:IL/[7C5]?EXNK+NAD-;3LMAD_IV]=IN<M+Y?)&&GS.:^[N?
M,V?/GWW^GXG=>KU;Y8=N]7;(Q_++X/3>#:_C-N?2S)[;89/+LDD?^\OI,9T/
M<G6:W,P>7Y;-\/@B3:H=I!"D]8,,@JQ^D$.0UP\*"(KZ00L(6M0/NH:@Z_I!
M-Q!T4S_H%H)NZP?)'&6<$R1-L";06I!K(?!:$&PA$%N0;"$P6Q!M(5!;D&TA
M<%L0;B&06Y!N(;!;$&\AT%M1;R706U%O)=!;)R_;!'HKZJT$>BOJK01Z*^JM
M!'HKZJT$>BOJK01Z*^JM!'HKZJT$>AOJ;01Z&^IM!'H;ZFT$>MMDLX1 ;T.]
MC4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T>]G4!O1[V=0&]'O9U ;T>]
MG4!OGVQV$^CMJ+<3Z.VHMQ/H[:BW$^CMJ+<3Z.VHMQ/H':AW$.@=J'<0Z!VH
M=Q#H':AW$.@=J'<0Z!V3CY4$>@?J'01Z!^H=!'H'ZAT$>@?J'7^I]U@^]WF\
M]'RO\3OW7U)=3O?FR^//R^^3B//BC'."'V7NOP!02P,$%     @ Y8(.61?(
MS!O; 0  T2(  !,   !;0V]N=&5N=%]4>7!E<UTN>&ULS=I=3X,P% ;@O[)P
M:T;7K_D1YXUZJU[X!RJ<#3*@3=O-^>\M3$TT2EQFXGL#@;;G/;3)<\7EXXNC
M,-FU31<6616CNV L%!6U)N3649=&EM:W)J9'OV+.%&NS(B9FLSDK;!>IB]/8
MU\BN+F]H:39-G-SNTNM0VVZ1>6I"-KG>3^RS%IEQKJD+$],XVW;EEY3I6T*>
M5@YS0E6[<)(F9.S;A'[DYX"W=?=;\KXN:?)@?+PS;9K%=@T+\:6AD(^7^*9'
MNUS6!96VV+1I21Z<)U.&BBBV3;XO>C*>'-,.T_[*C\X?RHP%IID/WKJ03LS3
MX7'O1]*OGKI4B'RLQS_Q(S&5/OK[J#_MDLI?9J?M?;9^/9Q'8,/M^#W^?,8?
M]0_L0X#T(4'Z4"!]:) ^YB!]G(+T<0;2QSE('WR&T@B*J!R%5(YB*D=!E:.H
MRE%8Y2BN<A18.8JL D56@2*K0)%5H,@J4&05*+(*%%D%BJP"15:!(JM$D56B
MR"I19)4HLDH4626*K!)%5HDBJT215:+(JE!D52BR*A19%8JL"D56A2*K0I%5
MH<BJ4&15*+)J%%DUBJP:15:-(JM&D56CR*I19-4HLFH46?5_ROID[?JO?[+H
M[WEKZNX]GPU_LER] E!+ 0(4 Q0    ( .6"#ED'04UB@0   +$    0
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M965T,RYX;6Q02P$"% ,4    " #E@@Y9CKS(;1H&  "S'   &
M    @($[%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @
MY8(.6=MH4,@7$   A,X  !@              ("!BQT  'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+ 0(4 Q0    ( .6"#EE3ZY9NU0<  '\E   8
M          " @=@M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M    " #E@@Y9^0F[*[<"  "'"0  &               @('C-0  >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ Y8(.61#"[$!$ @  B@8
M !@              ("!T#@  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M 0(4 Q0    ( .6"#EG&A&,^_Q$  )$P   8              " @4H[  !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #E@@Y9.*#PG&T7
M   *2   &0              @(%_30  >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+ 0(4 Q0    ( .6"#ED80$0E?@H  . @   9              "
M@2-E  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ Y8(.
M61I_4D@2 P  +0<  !D              ("!V&\  'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"% ,4    " #E@@Y9A<Q19+X"  !^!@  &0
M        @($A<P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0
M   ( .6"#EDYNVU^11T  *UN   9              " @19V  !X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ Y8(.60&9Z:U+"P  6R0
M !D              ("!DI,  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"% ,4    " #E@@Y9#PK)9]<(  #\%0  &0              @($4GP
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( .6"#ED&1\KC
M& 4   4.   9              " @2*H  !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L! A0#%     @ Y8(.6:,R71GB#   @R0  !D
M ("!<:T  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #E
M@@Y9Q/,F(? "  "L!@  &0              @(&*N@  >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( .6"#EF!$0$^3P@  .P6   9
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M970R-"YX;6Q02P$"% ,4    " #E@@Y9."1&M-,"   ;!@  &0
M    @(%E[   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (
M .6"#EGFWTX\S (  &0&   9              " @6_O  !X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL4$L! A0#%     @ Y8(.6?&_M=H9 P  [@8  !D
M             ("!<O(  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M% ,4    " #E@@Y99*U3B.0"  !-!@  &0              @('"]0  >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( .6"#EE19OA\Y@4
M /H.   9              " @=WX  !X;"]W;W)K<VAE971S+W-H965T,CDN
M>&UL4$L! A0#%     @ Y8(.6<'38$L=!   7PH  !D              ("!
M^OX  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " #E@@Y9
M0T< S@@#  !Z!@  &0              @(%. P$ >&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;%!+ 0(4 Q0    ( .6"#ED,A<W.<@D  '-H   9
M      " @8T& 0!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%
M  @ Y8(.65\'2%NE P  _@T  !D              ("!-A ! 'AL+W=O<FMS
M:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " #E@@Y9FNEV4J8$   A&P
M&0              @($2% $ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+
M 0(4 Q0    ( .6"#EF=*2[.@ ,  /<.   9              " @>\8 0!X
M;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ Y8(.6=3:5A_3
M @  B08  !D              ("!IAP! 'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6Q02P$"% ,4    " #E@@Y9G1!UJ1$%   5'   &0
M@(&P'P$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( .6"
M#EG[&Q8+R@0  )\>   9              " @?@D 0!X;"]W;W)K<VAE971S
M+W-H965T,S@N>&UL4$L! A0#%     @ Y8(.6?X9)Q8  P  F0@  !D
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M=#0S+GAM;%!+ 0(4 Q0    ( .6"#EF!'9^'X!$  .\[ 0 9
M  " @8)) 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @
MY8(.67FB.54;!0  TQH  !D              ("!F5L! 'AL+W=O<FMS:&5E
M=',O<VAE970T-2YX;6Q02P$"% ,4    " #E@@Y9=!:=Y.4)  #$@@  &0
M            @('K8 $ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4
M Q0    ( .6"#EE7VBW G ,  &L0   9              " @0=K 0!X;"]W
M;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ Y8(.6=IMY2H'!@
M*R(  !D              ("!VFX! 'AL+W=O<FMS:&5E=',O<VAE970T."YX
M;6Q02P$"% ,4    " #E@@Y9-O85?P4$  !6$   &0              @($8
M=0$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( .6"#EG\
M%M[:7@,  /(+   9              " @51Y 0!X;"]W;W)K<VAE971S+W-H
M965T-3 N>&UL4$L! A0#%     @ Y8(.669- SJI P  S!   !D
M     ("!Z7P! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .6"#EGI L"=/P(  !8%   9              "
M@7R= 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ Y8(.
M64@D[#6& P  % T  !D              ("!\I\! 'AL+W=O<FMS:&5E=',O
M<VAE970U-RYX;6Q02P$"% ,4    " #E@@Y9D?P>]\@#   %$P  &0
M        @(&OHP$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0
M   ( .6"#EFY&R.L=@(   $&   9              " @:ZG 0!X;"]W;W)K
M<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ Y8(.69X),_%1 P  K!4
M  T              ( !6ZH! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #E
M@@Y9EXJ[',     3 @  "P              @ '7K0$ 7W)E;',O+G)E;'-0
M2P$"% ,4    " #E@@Y96"T[FK4$   ^)P  #P              @ ' K@$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ Y8(.65EV ?CU 0  .",  !H
M             ( !HK,! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ Y8(.61?(S!O; 0  T2(  !,              ( !S[4! %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&     $, 0P!,$@  V[<!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>261</ContextCount>
  <ElementCount>328</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>81</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100060 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100070 - Statement - Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100080 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Nature of the Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentation</Role>
      <ShortName>Nature of the Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Fair Value of Financial Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilities</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995485 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/AccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/Agreements</Role>
      <ShortName>Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Asset Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisition</Role>
      <ShortName>Asset Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Term Loan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoan</Role>
      <ShortName>Term Loan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquity</Role>
      <ShortName>Redeemable Convertible Preferred Stock and Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Equity Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensation</Role>
      <ShortName>Equity Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Legal Proceedings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/LegalProceedings</Role>
      <ShortName>Legal Proceedings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesTables</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNet</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.turnstonebio.com/20240630/taxonomy/role/AccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsTables</Role>
      <ShortName>Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.turnstonebio.com/20240630/taxonomy/role/Agreements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityTables</Role>
      <ShortName>Redeemable Convertible Preferred Stock and Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Equity Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationTables</Role>
      <ShortName>Equity Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.turnstonebio.com/20240630/taxonomy/role/Leases</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail</Role>
      <ShortName>Nature of the Business and Basis of Presentation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of financial assets and liabilities measured on recurring basis at fair value (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisAtFairValueDetail</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities - Schedule of financial assets and liabilities measured on recurring basis at fair value (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of unobservable input of contingent consideration valuation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputOfContingentConsiderationValuationDetail</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities - Schedule of unobservable input of contingent consideration valuation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Fair Value of Financial Assets and Liabilities -  Schedule of company's contingent consideration measured at fair value level 3 (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysContingentConsiderationMeasuredAtFairValueLevel3Detail</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities -  Schedule of company's contingent consideration measured at fair value level 3 (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of company's cash, cash equivalents and available-for-sale securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysCashCashEquivalentsAndAvailableForSaleSecuritiesDetail</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities - Schedule of company's cash, cash equivalents and available-for-sale securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Fair Value of Financial Assets and Liabilities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net Consist (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetConsistDetail</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment, Net Consist (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Property and Equipment, Net - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Liabilities and Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Schedule of Accrued Liabilities and Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Agreements - Schedule Of Transaction Price Allocated To Programs Performance Obligation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationDetail</Role>
      <ShortName>Agreements - Schedule Of Transaction Price Allocated To Programs Performance Obligation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail</Role>
      <ShortName>Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Asset Acquisition - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail</Role>
      <ShortName>Asset Acquisition - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Term Loan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails</Role>
      <ShortName>Term Loan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Redeemable Convertible Preferred Stock and Stockholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Summary Of Shares Of Common Stock Reserved For Future Issuance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquitySummaryOfSharesOfCommonStockReservedForFutureIssuanceDetail</Role>
      <ShortName>Redeemable Convertible Preferred Stock and Stockholders' Equity - Summary Of Shares Of Common Stock Reserved For Future Issuance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995845 - Disclosure - Equity Based Compensation - Schedule of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail</Role>
      <ShortName>Equity Based Compensation - Schedule of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995855 - Disclosure - Equity Based Compensation - Schedule of Fair Value Assumption of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfFairValueAssumptionOfStockOptionActivityDetail</Role>
      <ShortName>Equity Based Compensation - Schedule of Fair Value Assumption of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Equity Based Compensation - Summary of RSU Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRsuActivityDetail</Role>
      <ShortName>Equity Based Compensation - Summary of RSU Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Equity Based Compensation - Schedule of Stock Based Compensation for Stock Awards (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfStockBasedCompensationForStockAwardsDetail</Role>
      <ShortName>Equity Based Compensation - Schedule of Stock Based Compensation for Stock Awards (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Equity Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Equity Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995895 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/LeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Leases - Schedule of Information about Lease Costs (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfInformationAboutLeaseCostsDetail</Role>
      <ShortName>Leases - Schedule of Information about Lease Costs (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995925 - Disclosure - Leases - Schedule of Present Value of Operating Lease Payments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfPresentValueOfOperatingLeasePaymentsDetail</Role>
      <ShortName>Leases - Schedule of Present Value of Operating Lease Payments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995935 - Disclosure - Leases - Schedule of Minimum Aggregate Future Operating Lease Commitments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetail</Role>
      <ShortName>Leases - Schedule of Minimum Aggregate Future Operating Lease Commitments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995945 - Disclosure - Net Loss per Share - Schedule of Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetail</Role>
      <ShortName>Net Loss per Share - Schedule of Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="tsbx-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995955 - Disclosure - Legal Proceedings - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.turnstonebio.com/20240630/taxonomy/role/LegalProceedingsAdditionalInformationDetail</Role>
      <ShortName>Legal Proceedings - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="tsbx-20240630.htm">tsbx-20240630.htm</File>
    <File>tsbx-20240630.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img127454107_0.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="661">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>73
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tsbx-20240630.htm": {
   "nsprefix": "tsbx",
   "nsuri": "http://www.turnstonebio.com/20240630",
   "dts": {
    "inline": {
     "local": [
      "tsbx-20240630.htm"
     ]
    },
    "schema": {
     "local": [
      "tsbx-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 269,
   "keyCustom": 59,
   "axisStandard": 25,
   "axisCustom": 3,
   "memberStandard": 30,
   "memberCustom": 45,
   "hidden": {
    "total": 9,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://fasb.org/us-gaap/2024": 5
   },
   "contextCount": 261,
   "entityCount": 1,
   "segmentCount": 81,
   "elementCount": 695,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 661,
    "http://xbrl.sec.gov/dei/2024": 31,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage",
     "longName": "100000 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets",
     "longName": "100010 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_a8da5438-d86e-4609-9ee4-eda50bdb908b",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a8da5438-d86e-4609-9ee4-eda50bdb908b",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_a8da5438-d86e-4609-9ee4-eda50bdb908b",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a8da5438-d86e-4609-9ee4-eda50bdb908b",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "100060 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_bf315150-6fec-4edf-8d74-affc42e06301",
      "name": "us-gaap:Revenues",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
     "longName": "100070 - Statement - Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "shortName": "Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_fab6d8a7-91ff-48ba-9d83-2f673cd37dd0",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c72ae3f1-ec49-47ae-8a52-43699c15abfc",
      "name": "us-gaap:TemporaryEquityAccretionToRedemptionValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows",
     "longName": "100080 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentation",
     "longName": "995455 - Disclosure - Nature of the Business and Basis of Presentation",
     "shortName": "Nature of the Business and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPolicies",
     "longName": "995465 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilities",
     "longName": "995475 - Disclosure - Fair Value of Financial Assets and Liabilities",
     "shortName": "Fair Value of Financial Assets and Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNet",
     "longName": "995485 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/AccruedExpensesAndOtherCurrentLiabilities",
     "longName": "995495 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "tsbx:DisclosureOfAccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "tsbx:DisclosureOfAccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/Agreements",
     "longName": "995505 - Disclosure - Agreements",
     "shortName": "Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisition",
     "longName": "995515 - Disclosure - Asset Acquisition",
     "shortName": "Asset Acquisition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoan",
     "longName": "995525 - Disclosure - Term Loan",
     "shortName": "Term Loan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquity",
     "longName": "995535 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity",
     "shortName": "Redeemable Convertible Preferred Stock and Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensation",
     "longName": "995545 - Disclosure - Equity Based Compensation",
     "shortName": "Equity Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/IncomeTaxes",
     "longName": "995555 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/Leases",
     "longName": "995565 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShare",
     "longName": "995575 - Disclosure - Net Loss per Share",
     "shortName": "Net Loss per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/LegalProceedings",
     "longName": "995585 - Disclosure - Legal Proceedings",
     "shortName": "Legal Proceedings",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995595 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesTables",
     "longName": "995605 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)",
     "shortName": "Fair Value of Financial Assets and Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNetTables",
     "longName": "995615 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/AccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "995625 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "tsbx:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "tsbx:DisclosureOfAccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "tsbx:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "tsbx:DisclosureOfAccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsTables",
     "longName": "995635 - Disclosure - Agreements (Tables)",
     "shortName": "Agreements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "tsbx:ScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "tsbx:ScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityTables",
     "longName": "995645 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity (Tables)",
     "shortName": "Redeemable Convertible Preferred Stock and Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "tsbx:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "tsbx:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationTables",
     "longName": "995655 - Disclosure - Equity Based Compensation (Tables)",
     "shortName": "Equity Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesTables",
     "longName": "995665 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareTables",
     "longName": "995675 - Disclosure - Net Loss per Share (Tables)",
     "shortName": "Net Loss per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail",
     "longName": "995685 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Detail)",
     "shortName": "Nature of the Business and Basis of Presentation - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_c5cddb37-672e-4bc6-993b-61b085312425",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c6e4f9a3-9885-44ca-907d-b6658de8f0e8",
      "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "longName": "995695 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_a8da5438-d86e-4609-9ee4-eda50bdb908b",
      "name": "us-gaap:RestrictedCash",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "tsbx:RestrictedCashAndInvestmentsPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a8da5438-d86e-4609-9ee4-eda50bdb908b",
      "name": "us-gaap:RestrictedCash",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "tsbx:RestrictedCashAndInvestmentsPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisAtFairValueDetail",
     "longName": "995705 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of financial assets and liabilities measured on recurring basis at fair value (Detail)",
     "shortName": "Fair Value of Financial Assets and Liabilities - Schedule of financial assets and liabilities measured on recurring basis at fair value (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_a8da5438-d86e-4609-9ee4-eda50bdb908b",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tsbx:CompanyCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_314b4149-fadb-4ae4-82c4-63f56b1c9d19",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputOfContingentConsiderationValuationDetail",
     "longName": "995715 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of unobservable input of contingent consideration valuation (Detail)",
     "shortName": "Fair Value of Financial Assets and Liabilities - Schedule of unobservable input of contingent consideration valuation (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_09ae6d90-7a9b-443b-bc02-068850b13217",
      "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07beddb2-5e8d-4fd2-a982-9c19bd8f1784",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysContingentConsiderationMeasuredAtFairValueLevel3Detail",
     "longName": "995725 - Disclosure - Fair Value of Financial Assets and Liabilities -  Schedule of company's contingent consideration measured at fair value level 3 (Detail)",
     "shortName": "Fair Value of Financial Assets and Liabilities -  Schedule of company's contingent consideration measured at fair value level 3 (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_86fd67e3-caa9-4cfa-8107-a69bd2da8aa7",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_86fd67e3-caa9-4cfa-8107-a69bd2da8aa7",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysCashCashEquivalentsAndAvailableForSaleSecuritiesDetail",
     "longName": "995735 - Disclosure - Fair Value of Financial Assets and Liabilities - Schedule of company's cash, cash equivalents and available-for-sale securities (Detail)",
     "shortName": "Fair Value of Financial Assets and Liabilities - Schedule of company's cash, cash equivalents and available-for-sale securities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_a8da5438-d86e-4609-9ee4-eda50bdb908b",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tsbx:CompanyCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a8da5438-d86e-4609-9ee4-eda50bdb908b",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tsbx:CompanyCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
     "longName": "995745 - Disclosure - Fair Value of Financial Assets and Liabilities - Additional Information (Detail)",
     "shortName": "Fair Value of Financial Assets and Liabilities - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8",
      "name": "us-gaap:AssetImpairmentCharges",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8",
      "name": "us-gaap:AssetImpairmentCharges",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetConsistDetail",
     "longName": "995755 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net Consist (Detail)",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net Consist (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_a8da5438-d86e-4609-9ee4-eda50bdb908b",
      "name": "us-gaap:MachineryAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a8da5438-d86e-4609-9ee4-eda50bdb908b",
      "name": "us-gaap:MachineryAndEquipmentGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail",
     "longName": "995765 - Disclosure - Property and Equipment, Net - Additional Information (Detail)",
     "shortName": "Property and Equipment, Net - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R41": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesDetail",
     "longName": "995775 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Liabilities and Other Current Liabilities (Detail)",
     "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Liabilities and Other Current Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_a8da5438-d86e-4609-9ee4-eda50bdb908b",
      "name": "tsbx:ResearchAndDevelopmentExpenseLiabilities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tsbx:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "tsbx:DisclosureOfAccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a8da5438-d86e-4609-9ee4-eda50bdb908b",
      "name": "tsbx:ResearchAndDevelopmentExpenseLiabilities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tsbx:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
       "div",
       "tsbx:DisclosureOfAccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationDetail",
     "longName": "995785 - Disclosure - Agreements - Schedule Of Transaction Price Allocated To Programs Performance Obligation (Detail)",
     "shortName": "Agreements - Schedule Of Transaction Price Allocated To Programs Performance Obligation (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_c6cfacbc-df8a-46ce-911a-93257d4940af",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tsbx:ScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationTableTextBlock",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c6cfacbc-df8a-46ce-911a-93257d4940af",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tsbx:ScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationTableTextBlock",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail",
     "longName": "995795 - Disclosure - Agreements - Additional Information (Detail)",
     "shortName": "Agreements - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_bf315150-6fec-4edf-8d74-affc42e06301",
      "name": "us-gaap:Revenues",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b070210d-0df6-446b-9018-f836d7eb1564",
      "name": "tsbx:PercentageOfOperatingProfitOrLoss",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail",
     "longName": "995805 - Disclosure - Asset Acquisition - Additional Information (Detail)",
     "shortName": "Asset Acquisition - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_bf315150-6fec-4edf-8d74-affc42e06301",
      "name": "us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d28ff08-66e3-4717-8e1b-0159fd2dae0a",
      "name": "tsbx:ContingentConsiderationPayable",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:AssetAcquisitionTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails",
     "longName": "995815 - Disclosure - Term Loan - Additional Information (Details)",
     "shortName": "Term Loan - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_eea7aad0-d598-4675-97e4-495ad0d5f473",
      "name": "tsbx:FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ece257ea-a6a0-437c-89a2-7ad5c9fc8aa2",
      "name": "tsbx:DebtInstrumentSuccessFeeAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetail",
     "longName": "995825 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Additional Information (Detail)",
     "shortName": "Redeemable Convertible Preferred Stock and Stockholders' Equity - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_b283014b-e73a-4c69-9931-4985a3e59add",
      "name": "us-gaap:SharesIssuedPricePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_10aa115c-22ea-46be-bcba-a9a9cd88b729",
      "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquitySummaryOfSharesOfCommonStockReservedForFutureIssuanceDetail",
     "longName": "995835 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Summary Of Shares Of Common Stock Reserved For Future Issuance (Detail)",
     "shortName": "Redeemable Convertible Preferred Stock and Stockholders' Equity - Summary Of Shares Of Common Stock Reserved For Future Issuance (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_a8da5438-d86e-4609-9ee4-eda50bdb908b",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tsbx:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_02fa49d2-1f02-4cc7-908f-06f8c20ff1f5",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tsbx:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail",
     "longName": "995845 - Disclosure - Equity Based Compensation - Schedule of Stock Option Activity (Detail)",
     "shortName": "Equity Based Compensation - Schedule of Stock Option Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfFairValueAssumptionOfStockOptionActivityDetail",
     "longName": "995855 - Disclosure - Equity Based Compensation - Schedule of Fair Value Assumption of Stock Option Activity (Detail)",
     "shortName": "Equity Based Compensation - Schedule of Fair Value Assumption of Stock Option Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRsuActivityDetail",
     "longName": "995865 - Disclosure - Equity Based Compensation - Summary of RSU Activity (Detail)",
     "shortName": "Equity Based Compensation - Summary of RSU Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_fa91a432-14eb-479a-ab9e-c343bfe09637",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_233d0f7d-f749-402b-be07-03dbe6d24916",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfStockBasedCompensationForStockAwardsDetail",
     "longName": "995875 - Disclosure - Equity Based Compensation - Schedule of Stock Based Compensation for Stock Awards (Detail)",
     "shortName": "Equity Based Compensation - Schedule of Stock Based Compensation for Stock Awards (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_62ea4f09-347c-4795-8884-5220ce935f91",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail",
     "longName": "995885 - Disclosure - Equity Based Compensation - Additional Information (Detail)",
     "shortName": "Equity Based Compensation - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/IncomeTaxesAdditionalInformationDetail",
     "longName": "995895 - Disclosure - Income Taxes - Additional Information (Detail)",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesAdditionalInformationDetail",
     "longName": "995905 - Disclosure - Leases - Additional Information (Detail)",
     "shortName": "Leases - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_159402e9-c2a7-4db5-8c56-97648d7a2af3",
      "name": "us-gaap:OperatingLeaseImpairmentLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_159402e9-c2a7-4db5-8c56-97648d7a2af3",
      "name": "us-gaap:OperatingLeaseImpairmentLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfInformationAboutLeaseCostsDetail",
     "longName": "995915 - Disclosure - Leases - Schedule of Information about Lease Costs (Detail)",
     "shortName": "Leases - Schedule of Information about Lease Costs (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfPresentValueOfOperatingLeasePaymentsDetail",
     "longName": "995925 - Disclosure - Leases - Schedule of Present Value of Operating Lease Payments (Detail)",
     "shortName": "Leases - Schedule of Present Value of Operating Lease Payments (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_a8da5438-d86e-4609-9ee4-eda50bdb908b",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tsbx:ScheduleOfPresentValueOfOperatingLeasePayments",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a8da5438-d86e-4609-9ee4-eda50bdb908b",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tsbx:ScheduleOfPresentValueOfOperatingLeasePayments",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetail",
     "longName": "995935 - Disclosure - Leases - Schedule of Minimum Aggregate Future Operating Lease Commitments (Detail)",
     "shortName": "Leases - Schedule of Minimum Aggregate Future Operating Lease Commitments (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_a8da5438-d86e-4609-9ee4-eda50bdb908b",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a8da5438-d86e-4609-9ee4-eda50bdb908b",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetail",
     "longName": "995945 - Disclosure - Net Loss per Share - Schedule of Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Detail)",
     "shortName": "Net Loss per Share - Schedule of Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.turnstonebio.com/20240630/taxonomy/role/LegalProceedingsAdditionalInformationDetail",
     "longName": "995955 - Disclosure - Legal Proceedings - Additional Information (Detail)",
     "shortName": "Legal Proceedings - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "tsbx:LossContingencyReserveForLitigationLiabilities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LegalMattersAndContingenciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_264a7ac5-398e-4718-ac23-f5ff805f1954",
      "name": "tsbx:LossContingencyReserveForLitigationLiabilities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LegalMattersAndContingenciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tsbx-20240630.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "totalLabel": "Accounts Payable, Current, Total",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r715"
     ]
    },
    "us-gaap_AccountsReceivableGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableGross",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, before Allowance for Credit Loss",
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r248",
      "r249",
      "r927"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable - collaboration agreement",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "tsbx_AccretionOfPremiumOnShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "AccretionOfPremiumOnShortTermInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion of premium on short term investments.",
        "label": "Accretion of premium on short term investments",
        "terseLabel": "Accretion of premium on short term investments",
        "negatedLabel": "Accretion of premium on short term investments"
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_AccretionOfRedeemableConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "AccretionOfRedeemableConvertiblePreferredStock",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accretion of redeemable convertible preferred stock",
        "label": "Accretion Of Redeemable Convertible Preferred Stock",
        "documentation": "Accretion of redeemable convertible preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_AccruedCompensationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "AccruedCompensationCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation",
        "label": "Accrued Compensation Current",
        "documentation": "Accrued compensation current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accrued expenses and other current liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Accrued Liabilities and Other Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total accrued expenses and other current liabilities",
        "label": "Accrued Liabilities and Other Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional and consulting expense",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetConsistDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r159",
      "r556"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r81",
      "r167",
      "r552",
      "r574",
      "r575"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r11",
      "r19",
      "r446",
      "r449",
      "r522",
      "r570",
      "r571",
      "r826",
      "r827",
      "r828",
      "r834",
      "r835",
      "r836",
      "r838"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional\u00a0paid-in\u00a0capital",
        "label": "Additional Paid in Capital",
        "totalLabel": "Additional Paid in Capital, Total",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r715",
      "r930"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital [Member]",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r586",
      "r834",
      "r835",
      "r836",
      "r838",
      "r894",
      "r931"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accretion of redeemable convertible preferred stock issuance costs",
        "label": "Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock",
        "documentation": "Amount of decrease (increase) in additional paid in capital (APIC) for the increase in carrying amount of redeemable preferred stock."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r102",
      "r108"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r352"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r736",
      "r746",
      "r756",
      "r788"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r739",
      "r749",
      "r759",
      "r791"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "tsbx_AgreementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "AgreementAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement [Axis]",
        "documentation": "Agreement Axis"
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_AgreementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "AgreementDomain",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreement [Domain]",
        "documentation": "Agreement Domain"
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_AgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "AgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreements [Abstract]",
        "documentation": "Agreements."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r740",
      "r750",
      "r760",
      "r784",
      "r792",
      "r796",
      "r804"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "tsbx_AllianceAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "AllianceAgreementMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alliance Agreement [Member]",
        "label": "Alliance Agreement [Member]",
        "documentation": "Alliance agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfStockBasedCompensationForStockAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "verboseLabel": "Allocated share based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r393"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for doubtful accounts receivable",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "periodStartLabel": "Accounts Receivable, Allowance for Credit Loss, Beginning Balance",
        "periodEndLabel": "Accounts Receivable, Allowance for Credit Loss, Ending Balance",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r250",
      "r263",
      "r264",
      "r266",
      "r927"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable write-off",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance."
       }
      }
     },
     "auth_ref": [
      "r265"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_AssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r889"
     ]
    },
    "tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuableShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuableShares",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition consideration transferred equity interest issuable shares",
        "label": "Asset Acquisition Consideration Transferred Equity Interest Issuable Shares",
        "documentation": "Asset acquisition consideration transferred equity interest issuable shares."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition, consideration transferred, equity interest issued and issuable shares",
        "label": "Asset Acquisition Consideration Transferred Equity Interest Issued And Issuable Shares",
        "documentation": "Asset acquisition consideration transferred equity interest issued and issuable shares."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_AssetAcquisitionConsiderationTransferredEquityInterestIssuedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedShares",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition consideration transferred equity interest issued shares",
        "label": "Asset Acquisition Consideration Transferred Equity Interest Issued Shares",
        "documentation": "Asset acquisition consideration transferred equity interest issued shares."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition contingent consideration arrangements change in amount of contingent consideration, liability",
        "label": "Asset Acquisition Contingent Consideration Arrangements Change in Amount of Contingent Consideration Liability",
        "documentation": "Asset acquisition contingent consideration arrangements change in amount of contingent consideration liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration, liability",
        "label": "Asset Acquisition, Contingent Consideration, Liability",
        "totalLabel": "Asset Acquisition, Contingent Consideration, Liability, Total",
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r889"
     ]
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionLineItems",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_AssetAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionTable",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Table]",
        "documentation": "Disclosure of information about asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition",
        "label": "Asset Acquisition [Text Block]",
        "documentation": "The entire disclosure for asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset impairment charges",
        "label": "Asset Impairment Charges",
        "totalLabel": "Asset Impairment Charges, Total",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r35"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r130",
      "r161",
      "r191",
      "r232",
      "r236",
      "r242",
      "r243",
      "r253",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r436",
      "r438",
      "r485",
      "r548",
      "r622",
      "r690",
      "r691",
      "r715",
      "r727",
      "r855",
      "r856",
      "r911"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r171",
      "r191",
      "r253",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r436",
      "r438",
      "r485",
      "r715",
      "r855",
      "r856",
      "r911"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysCashCashEquivalentsAndAvailableForSaleSecuritiesDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Estimated fair value",
        "totalLabel": "Total financial assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r463",
      "r706"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets:",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysCashCashEquivalentsAndAvailableForSaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Debt Securities, Available-for-Sale, Amortized Cost, Total",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r267",
      "r547"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysCashCashEquivalentsAndAvailableForSaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross unrealized gains",
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain",
        "documentation": "Amount of unrealized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysCashCashEquivalentsAndAvailableForSaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gross unrealized losses",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss",
        "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-Sale, Total",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Available-for-sale debt securities an aggregate fair value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r267",
      "r462",
      "r541",
      "r706",
      "r710",
      "r847",
      "r897",
      "r898",
      "r899"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRsuActivityDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquitySummaryOfSharesOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation of Unaudited Condensed Consolidated Financial Information",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r424",
      "r700",
      "r701"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r424",
      "r700",
      "r701"
     ]
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Business acquisition, equity interest issued or issuable, number of shares",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of contingent consideration liability",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r829"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contingent consideration",
        "terseLabel": "Contingent consideration liability",
        "label": "Business Combination, Contingent Consideration, Liability",
        "totalLabel": "Business Combination, Contingent Consideration, Liability, Total",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r114",
      "r428",
      "r464",
      "r465",
      "r466"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputOfContingentConsiderationValuationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration input range",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "documentation": "Value of input used to measure contingent consideration liability from business combination."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r465",
      "r466"
     ]
    },
    "tsbx_BusinessDescriptionAndBasisOfPresentationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "BusinessDescriptionAndBasisOfPresentationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description And Basis Of Presentation [Abstract]",
        "documentation": "Business description and basis of presentation."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_BusinessDescriptionAndBasisOfPresentationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "BusinessDescriptionAndBasisOfPresentationLineItems",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description And Basis Of Presentation [Line Items]",
        "documentation": "Business Description And Basis Of Presentation [Line Item]"
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_BusinessDescriptionAndBasisOfPresentationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "BusinessDescriptionAndBasisOfPresentationTable",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Description And Basis Of Presentation [Table]",
        "documentation": "Business Description And Basis Of Presentation [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of the Business and Basis of Presentation",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r92",
      "r93"
     ]
    },
    "us-gaap_CapitalizedComputerSoftwareGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalizedComputerSoftwareGross",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetConsistDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment and software",
        "label": "Capitalized Computer Software, Gross",
        "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r678"
     ]
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Project [Axis]",
        "documentation": "Information by project."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r539",
      "r920"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r157",
      "r680"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r895",
      "r896"
     ]
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysCashCashEquivalentsAndAvailableForSaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents [Member]",
        "label": "Cash and Cash Equivalents [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents, and short-term investments",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of the period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of the period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r89",
      "r187"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r89"
     ]
    },
    "tsbx_CashProceedsFromTheSaleOfEquitySecuritiesAndOrUpfrontCashProceedsFromStrategicPartnerships": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "CashProceedsFromTheSaleOfEquitySecuritiesAndOrUpfrontCashProceedsFromStrategicPartnerships",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Proceeds From The Sale of Equity Securities And/Or Upfront Cash Proceeds From Strategic Partnerships",
        "label": "Cash Proceeds From The Sale of Equity Securities And/Or Upfront Cash Proceeds From Strategic Partnerships",
        "documentation": "Cash proceeds from the sale of equity securities and/or upfront cash proceeds from strategic partnerships."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "documentation": "Indicates (true false) whether accounting standards update was adopted."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r153",
      "r199",
      "r247",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r279",
      "r288",
      "r409",
      "r416",
      "r417",
      "r425",
      "r426",
      "r430",
      "r441",
      "r442",
      "r452",
      "r453",
      "r483",
      "r484",
      "r498",
      "r519",
      "r520",
      "r536",
      "r537",
      "r568",
      "r569"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r153",
      "r247",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r261",
      "r279",
      "r288",
      "r409",
      "r416",
      "r417",
      "r425",
      "r426",
      "r427",
      "r430",
      "r431",
      "r440",
      "r441",
      "r442",
      "r443",
      "r452",
      "r453",
      "r454",
      "r456",
      "r483",
      "r484",
      "r498",
      "r519",
      "r520",
      "r536",
      "r537",
      "r568",
      "r569",
      "r819"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r211",
      "r258"
     ]
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Principle, Accounting Standards Update, Transition Option Elected [Extensible Enumeration]",
        "documentation": "Indicates transition method applied for adoption of amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r410",
      "r420",
      "r421",
      "r430",
      "r431",
      "r432",
      "r445",
      "r455",
      "r457",
      "r495",
      "r496",
      "r497",
      "r499",
      "r500",
      "r501",
      "r521",
      "r570",
      "r576"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets",
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r162",
      "r163",
      "r164",
      "r191",
      "r217",
      "r218",
      "r225",
      "r227",
      "r234",
      "r235",
      "r253",
      "r296",
      "r298",
      "r299",
      "r300",
      "r303",
      "r304",
      "r321",
      "r322",
      "r325",
      "r328",
      "r335",
      "r485",
      "r580",
      "r581",
      "r582",
      "r583",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r609",
      "r631",
      "r649",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r815",
      "r831",
      "r840"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquitySummaryOfSharesOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r234",
      "r321",
      "r322",
      "r323",
      "r325",
      "r328",
      "r333",
      "r335",
      "r580",
      "r581",
      "r582",
      "r583",
      "r696",
      "r815",
      "r831"
     ]
    },
    "tsbx_ClinicalAndRegulatoryMilestonesOnDevelopmentProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "ClinicalAndRegulatoryMilestonesOnDevelopmentProgramMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical and Regulatory Milestones On Development Program [Member]",
        "documentation": "Clinical And Regulatory Milestones On Development Program Member"
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_ClinicalAndRegulatoryMilestonesOnLicensedDiscoveryProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "ClinicalAndRegulatoryMilestonesOnLicensedDiscoveryProductMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical and Regulatory Milestones on Licensed Discovery Product [Member]",
        "documentation": "Clinical And Regulatory Milestones On Licensed Discovery Product Member"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "tsbx_CollaborativeArrangementAdditionalConsiderationReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "CollaborativeArrangementAdditionalConsiderationReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement additional consideration receivable",
        "label": "Collaborative Arrangement Additional Consideration Receivable",
        "documentation": "Collaborative arrangement additional consideration receivable."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_CollaborativeArrangementAdditionalConsiderationReceivableForLicensedOption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "CollaborativeArrangementAdditionalConsiderationReceivableForLicensedOption",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement additional consideration receivable for license option",
        "label": "Collaborative Arrangement Additional Consideration Receivable for Licensed Option",
        "documentation": "Collaborative arrangement additional consideration receivable for license option."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_CollaborativeArrangementAggregateConsiderationPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "CollaborativeArrangementAggregateConsiderationPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement aggregate consideration payable",
        "label": "Collaborative Arrangement Aggregate Consideration Payable",
        "documentation": "Collaborative arrangement aggregate consideration payable."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_CollaborativeArrangementAggregateConsiderationRemains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "CollaborativeArrangementAggregateConsiderationRemains",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement aggregate consideration remains",
        "label": "Collaborative Arrangement Aggregate Consideration Remains",
        "documentation": "Collaborative arrangement aggregate consideration remains"
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_CollaborativeArrangementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "CollaborativeArrangementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement Disclosure [Abstract]",
        "documentation": "Collaborative Arrangement Disclosure Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/Agreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r138",
      "r150"
     ]
    },
    "us-gaap_CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement, Revenue Not from Contract with Customer, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inflow From Issuance Of Intangible Asset",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity purchase commitments by counter party",
        "label": "Commitments, Fair Value Disclosure",
        "documentation": "Fair value portion of arrangements with third parties, including, but not limited to, operating lease arrangement and arrangement in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r895",
      "r896",
      "r900"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquitySummaryOfSharesOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock reserved for future issuance",
        "terseLabel": "Common stock, capital shares reserved for future issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "tsbx_CommonStockCapitalSharesReservedForFutureIssuanceIncreaseDecreasePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuanceIncreaseDecreasePeriod",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, capital shares reserved for future issuance increase decrease period",
        "label": "Common Stock Capital Shares Reserved for Future Issuance Increase Decrease Period",
        "documentation": "Common stock capital shares reserved for future issuance increase decrease period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r717",
      "r718",
      "r719",
      "r721",
      "r722",
      "r723",
      "r724",
      "r834",
      "r835",
      "r838",
      "r894",
      "r929",
      "r931"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock par value",
        "terseLabel": "Common stock, par or stated value per Share",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares authorized",
        "terseLabel": "Common stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r609"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares, issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares, outstanding",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r75",
      "r609",
      "r628",
      "r931",
      "r932"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, $0.001 par value; 490,000,000 shares authorized at June 30, 2024 and December 31, 2023, respectively, 23,128,454 and 23,099,335 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r551",
      "r715"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "tsbx_CompanyCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "CompanyCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryTableTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Company's Cash, Cash Equivalents and Available-for-Sale Securities",
        "label": "Company Cash, Cash Equivalents And Available For Sale Securities By Significant Investment Category [Table Text Block]",
        "documentation": "Company cash, cash equivalents and\u00a0available for sale\u00a0securities by significant investment category [Table Text Block]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss:",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r116",
      "r175",
      "r177",
      "r182",
      "r542",
      "r561"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r58",
      "r59",
      "r246",
      "r675"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r58",
      "r59",
      "r246",
      "r578",
      "r675"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r58",
      "r59",
      "r246",
      "r675",
      "r818"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r140"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk, percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r58",
      "r59",
      "r246"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r58",
      "r59",
      "r246",
      "r675"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r685"
     ]
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Consideration by Type [Axis]",
        "documentation": "Information by type of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_ContingentConsiderationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "ContingentConsiderationCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration, current",
        "label": "Contingent Consideration, Current",
        "documentation": "Contingent consideration, current."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_ContingentConsiderationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "ContingentConsiderationMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysContingentConsiderationMeasuredAtFairValueLevel3Detail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisAtFairValueDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputOfContingentConsiderationValuationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration [Member]",
        "label": "Contingent Consideration [Member]",
        "documentation": "Contingent Consideration [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_ContingentConsiderationPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "ContingentConsiderationPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration payable",
        "label": "Contingent Consideration Payable",
        "documentation": "Contingent consideration payable."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_ContingentConsiderationPayableByCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "ContingentConsiderationPayableByCash",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration payable by cash",
        "label": "Contingent Consideration Payable By Cash",
        "documentation": "Contingent consideration payable by cash."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_ContingentConsiderationPayableByShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "ContingentConsiderationPayableByShares",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration payable by shares",
        "label": "Contingent Consideration Payable By Shares",
        "documentation": "Contingent consideration payable by shares."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_ContingentConsiderationPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "ContingentConsiderationPolicyPolicyTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration",
        "label": "Contingent Consideration Policy [Policy Text Block]",
        "documentation": "Contingent consideration policy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Consideration Type [Domain]",
        "documentation": "Description of contingent payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Contract with Customer, Liability",
        "totalLabel": "Contract with Customer, Liability, Total",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r339"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, current",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r339"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, noncurrent",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r339"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r307",
      "r323",
      "r525",
      "r532",
      "r546",
      "r682",
      "r684"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditConcentrationRiskMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Concentration Risk [Member]",
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails",
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r853"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails",
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r853",
      "r854"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r189",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r294",
      "r295",
      "r305",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r317",
      "r318",
      "r319",
      "r494"
     ]
    },
    "tsbx_DebtInstrumentFeeOnEventOfDefault": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "DebtInstrumentFeeOnEventOfDefault",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, fee on the event of default",
        "label": "Debt Instrument, Fee On Event of Default",
        "documentation": "Debt instrument, fee on event of default."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails",
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r306"
     ]
    },
    "tsbx_DebtInstrumentNonrefundablePrepaymentFeeInFirstAnniversary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "DebtInstrumentNonrefundablePrepaymentFeeInFirstAnniversary",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument nonrefundable prepayment fee in first anniversary",
        "label": "Debt Instrument Nonrefundable Prepayment Fee In First Anniversary",
        "documentation": "Debt instrument nonrefundable prepayment fee in first anniversary."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_DebtInstrumentNonrefundablePrepaymentFeeInSecondAnniversary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "DebtInstrumentNonrefundablePrepaymentFeeInSecondAnniversary",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument nonrefundable prepayment fee in second anniversary",
        "label": "Debt Instrument Nonrefundable Prepayment Fee In Second Anniversary",
        "documentation": "Debt instrument nonrefundable prepayment fee in second anniversary."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_DebtInstrumentSuccessFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "DebtInstrumentSuccessFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument success fee amount",
        "label": "Debt Instrument Success Fee Amount",
        "documentation": "Debt instrument success fee amount."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_DebtInstrumentSuccessFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "DebtInstrumentSuccessFeePercentage",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument success fee percentage",
        "label": "Debt Instrument Success Fee Percentage",
        "documentation": "Debt instrument success fee percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing costs included in accounts payable",
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Total",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "terseLabel": "Available-for-sale debt securities an aggregate unrealized loss position",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r268",
      "r693"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of available-for-sale debt securities in gross unrealized loss position",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r269"
     ]
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Offering Costs",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs",
        "label": "Debt Issuance Costs, Net",
        "totalLabel": "Debt Issuance Costs, Net, Total",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r858",
      "r903",
      "r904",
      "r905"
     ]
    },
    "tsbx_DeferredIpoCostsIncludedInAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "DeferredIpoCostsIncludedInAccruedExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred IPO costs included in accrued expenses.",
        "label": "Deferred IPO Costs Included In Accrued Expenses",
        "terseLabel": "Deferred IPO costs included in accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred offering costs",
        "label": "Deferred Offering Costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNetAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and equipment depreciation and amortization expense",
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r232",
      "r239",
      "r243",
      "r690",
      "r691"
     ]
    },
    "tsbx_DevelopmentProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "DevelopmentProgramMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development Program [Member]",
        "label": "Development Program [Member]",
        "documentation": "Development program."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_DisclosureOfAccruedExpensesAndOtherCurrentLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "DisclosureOfAccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "label": "Disclosure of Accrued Expenses and Other Current Liabilities [Text Block]",
        "documentation": "Disclosure of accrued expenses and other current liabilities [Text Block]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r354",
      "r385",
      "r386",
      "r388",
      "r703"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_DiscoveryProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "DiscoveryProgramMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discovery Program [Member]",
        "label": "Discovery Program [Member]",
        "documentation": "Discovery program."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentDomain",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document [Domain]",
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationDocumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationDocumentAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information, Document [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss) per share attributable to common stockholders",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share attributable to common stockholders, basic",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r214",
      "r217",
      "r225",
      "r226",
      "r227",
      "r231",
      "r422",
      "r434",
      "r459",
      "r460",
      "r543",
      "r562",
      "r687"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share attributable to common stockholders, diluted",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r217",
      "r225",
      "r226",
      "r227",
      "r231",
      "r422",
      "r434",
      "r459",
      "r460",
      "r543",
      "r562",
      "r687"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r228",
      "r229",
      "r230"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfStockBasedCompensationForStockAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "verboseLabel": "Share-based payment arrangement, nonvested award, cost not yet recognized",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based payment arrangement, non-vested award, cost not yet recognized, period for recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based payment arrangement, non-vested award, excluding option, cost not yet recognized, amount",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based payment arrangement, non-vested award, option, cost not yet recognized, amount",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r887"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquitySummaryOfSharesOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Stock option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Purchase Plan [Member]",
        "label": "Employee Stock Purchase Plan [Member]",
        "documentation": "Employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "tsbx_EquipmentPurchasesIncludedInAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "EquipmentPurchasesIncludedInAccruedExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment purchases included in accrued expenses.",
        "label": "Equipment Purchases Included In Accrued Expenses",
        "terseLabel": "Equipment purchases included in accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r152",
      "r178",
      "r179",
      "r180",
      "r196",
      "r197",
      "r198",
      "r201",
      "r206",
      "r208",
      "r210",
      "r233",
      "r257",
      "r262",
      "r280",
      "r336",
      "r407",
      "r408",
      "r418",
      "r419",
      "r420",
      "r423",
      "r433",
      "r434",
      "r444",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r458",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r498",
      "r503",
      "r522",
      "r560",
      "r570",
      "r571",
      "r572",
      "r586",
      "r649"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r736",
      "r746",
      "r756",
      "r788"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r743",
      "r753",
      "r785"
     ]
    },
    "tsbx_EstimatedCompensationEarningFromProjectExpenseSharing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "EstimatedCompensationEarningFromProjectExpenseSharing",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated compensation earning from project expense sharing",
        "label": "Estimated Compensation Earning from Project Expense Sharing",
        "documentation": "Estimated compensation earning from project expense sharing."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r463",
      "r476",
      "r706"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r463",
      "r476",
      "r706"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputOfContingentConsiderationValuationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r465",
      "r466",
      "r710"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputOfContingentConsiderationValuationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r465",
      "r466",
      "r710"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Unobservable Input of Contingent Consideration Valuation",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r465",
      "r710"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysCashCashEquivalentsAndAvailableForSaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r477",
      "r708"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysCashCashEquivalentsAndAvailableForSaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r477",
      "r708"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysCashCashEquivalentsAndAvailableForSaleSecuritiesDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r461",
      "r463",
      "r464",
      "r465",
      "r466",
      "r475",
      "r476",
      "r478",
      "r527",
      "r528",
      "r529",
      "r694",
      "r695",
      "r697",
      "r698",
      "r699",
      "r706",
      "r710"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysContingentConsiderationMeasuredAtFairValueLevel3Detail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisAtFairValueDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputOfContingentConsiderationValuationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r477"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r463",
      "r464",
      "r466",
      "r706",
      "r898",
      "r901"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_FairValueDisclosuresLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "FairValueDisclosuresLineItems",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysCashCashEquivalentsAndAvailableForSaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Line Items]",
        "documentation": "Fair value disclosures [Lineitems]."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_FairValueDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "FairValueDisclosuresTable",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysCashCashEquivalentsAndAvailableForSaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Table]",
        "documentation": "Fair value disclosures [Table]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Assets and Liabilities",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r473",
      "r474",
      "r475",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r540",
      "r706",
      "r711"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysCashCashEquivalentsAndAvailableForSaleSecuritiesDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 [Member]",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r341",
      "r346",
      "r463",
      "r476",
      "r527",
      "r697",
      "r698",
      "r699",
      "r706"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysCashCashEquivalentsAndAvailableForSaleSecuritiesDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2 [Member]",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r341",
      "r346",
      "r463",
      "r464",
      "r476",
      "r528",
      "r694",
      "r695",
      "r697",
      "r698",
      "r699",
      "r706"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 [Member]",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r463",
      "r464",
      "r465",
      "r466",
      "r476",
      "r529",
      "r694",
      "r695",
      "r697",
      "r698",
      "r699",
      "r706",
      "r710"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysContingentConsiderationMeasuredAtFairValueLevel3Detail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisAtFairValueDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputOfContingentConsiderationValuationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r477"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysContingentConsiderationMeasuredAtFairValueLevel3Detail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysContingentConsiderationMeasuredAtFairValueLevel3Detail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r477"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Company's Contingent Consideration Measured at Fair Value Level 3",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r472",
      "r477"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r463",
      "r464",
      "r466",
      "r706",
      "r898",
      "r901"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysContingentConsiderationMeasuredAtFairValueLevel3Detail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in the fair value of contingent consideration",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r477"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysContingentConsiderationMeasuredAtFairValueLevel3Detail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Equity issuance related to milestone achievement",
        "terseLabel": "Equity issuance related to milestone achievement",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r477"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysContingentConsiderationMeasuredAtFairValueLevel3Detail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash payment of Myst milestone",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r477"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysContingentConsiderationMeasuredAtFairValueLevel3Detail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r477"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysCashCashEquivalentsAndAvailableForSaleSecuritiesDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r461",
      "r463",
      "r464",
      "r465",
      "r466",
      "r475",
      "r476",
      "r478",
      "r527",
      "r528",
      "r529",
      "r694",
      "r695",
      "r697",
      "r698",
      "r699",
      "r706",
      "r710"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value recurring basis [Member]",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r706",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r901"
     ]
    },
    "tsbx_FairValueOfCommonStockPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "FairValueOfCommonStockPolicyPolicyTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Determination of Fair Value of Common Stock",
        "label": "Fair Value Of Common Stock Policy [Policy Text Block]",
        "documentation": "Fair value of common stock policy text block."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Federal income tax expense",
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations, Total",
        "totalLabel": "Federal Income Tax Expense (Benefit), Continuing Operations, Total",
        "documentation": "Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r397",
      "r398"
     ]
    },
    "us-gaap_FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Owned, US Government and Agency Obligations, at Fair Value",
        "terseLabel": "U.S. government securities",
        "documentation": "The fair value as of the balance sheet date of firm holdings in debt obligations issued by the US government including short-term Treasury bills, medium-term Treasury notes, and long-term Treasury bonds, as well as debt issued by agencies. Includes both pledged (to counterparties as collateral for financing transactions) and unpledged holdings."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisAtFairValueDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputOfContingentConsiderationValuationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value of financial liabilities",
        "totalLabel": "Total financial liabilities",
        "label": "Financial Liabilities Fair Value Disclosure",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": [
      "r895",
      "r896",
      "r900"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialLiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities:",
        "label": "Financial Liabilities Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_FirstMilestonePaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "FirstMilestonePaymentMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Milestone Payment [Member]",
        "label": "First Milestone Payment [Member]",
        "documentation": "First milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyExchangeRateTranslation1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyExchangeRateTranslation1",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange rate",
        "label": "Foreign Currency Exchange Rate, Translation",
        "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r493"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r740",
      "r750",
      "r760",
      "r792"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r740",
      "r750",
      "r760",
      "r792"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r740",
      "r750",
      "r760",
      "r792"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r740",
      "r750",
      "r760",
      "r792"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r740",
      "r750",
      "r760",
      "r792"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "tsbx_FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails",
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding From Sale Of Equity Partnerships And Or Business Development Payments",
        "label": "Funding From Sale Of Equity Partnerships And Or Business Development Payments",
        "terseLabel": "Funding from sale of equity partnerships and or business development payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesGross",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetConsistDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture",
        "label": "Furniture and Fixtures, Gross",
        "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "totalLabel": "Gain (Loss) on Disposition of Property Plant Equipment, Total",
        "negatedLabel": "Gain on disposal of property and equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "totalLabel": "General and Administrative Expense, Total",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r633"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfStockBasedCompensationForStockAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and administrative [Member]",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "tsbx_H.LeeMoffittCancerCenterMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "H.LeeMoffittCancerCenterMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "H. Lee Moffitt Cancer Center [Member]",
        "label": "H. Lee Moffitt Cancer Center [Member]",
        "documentation": "H. Lee moffitt cancer center."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment losses",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r35",
      "r97",
      "r707"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r98"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r125",
      "r129",
      "r544",
      "r558",
      "r689",
      "r690",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfStockBasedCompensationForStockAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r287",
      "r289",
      "r468",
      "r472",
      "r477",
      "r565",
      "r567",
      "r634",
      "r678",
      "r709",
      "r928"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfStockBasedCompensationForStockAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r289",
      "r468",
      "r472",
      "r477",
      "r565",
      "r567",
      "r634",
      "r678",
      "r709",
      "r928"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r396",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r411",
      "r413",
      "r414",
      "r415",
      "r585",
      "r705"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Benefit (Provision) for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r149",
      "r209",
      "r210",
      "r232",
      "r240",
      "r243",
      "r397",
      "r399",
      "r412",
      "r563",
      "r705"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid, Net, Total",
        "totalLabel": "Income Taxes Paid, Net, Total",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r186",
      "r405",
      "r406"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable - collaboration agreement",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "tsbx_IncreaseDecreaseInAccruedCompensationAndOtherAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "IncreaseDecreaseInAccruedCompensationAndOtherAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation and other accrued liabilities",
        "label": "Increase Decrease In Accrued Compensation And Other Accrued Liabilities",
        "documentation": "Increase decrease in accrued compensation and other accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_IncreaseDecreaseInContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "IncreaseDecreaseInContingentConsiderationLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in contingent consideration liability",
        "label": "Increase Decrease In Contingent Consideration Liability",
        "documentation": "Increase decrease in contingent consideration liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r534",
      "r829"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r820",
      "r829"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Other Current Assets",
        "terseLabel": "Other current assets",
        "negatedLabel": "Other current assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other non-current assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense",
        "terseLabel": "Prepaid expenses",
        "negatedLabel": "Prepaid expenses",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r740",
      "r750",
      "r760",
      "r784",
      "r792",
      "r796",
      "r804"
     ]
    },
    "tsbx_InitialMilestonePaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "InitialMilestonePaymentMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial Milestone Payment [Member]",
        "label": "Initial Milestone Payment [Member]",
        "documentation": "Initial milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r732",
      "r808"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r732",
      "r808"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r732",
      "r808"
     ]
    },
    "us-gaap_InvestmentTypeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeExtensibleEnumeration",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Type [Extensible Enumeration]",
        "documentation": "Indicates type of investment. Includes, but is not limited to, common stock, preferred stock, convertible security, fixed income security, government security, option purchased, warrant, loan participation and assignment, commercial paper, bankers' acceptance, certificates of deposit, short-term security, repurchase agreement, and other investment company."
       }
      }
     },
     "auth_ref": [
      "r598",
      "r599",
      "r655",
      "r657",
      "r658",
      "r659",
      "r660",
      "r663",
      "r664",
      "r665"
     ]
    },
    "tsbx_LaboratorySpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "LaboratorySpaceMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory space [Member]",
        "label": "Laboratory Space [Member]",
        "documentation": "Laboratory Space Member"
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_LangerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "LangerMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Langer [Member]",
        "label": "Langer [Member]",
        "documentation": "Langer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfInformationAboutLeaseCostsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "label": "Lease, Cost, Total",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r509",
      "r714"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of information about lease costs",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetConsistDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements, Gross",
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LegalMattersAndContingenciesTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LegalProceedings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Proceedings",
        "label": "Legal Matters and Contingencies [Text Block]",
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r518"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r518"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of minimum aggregate future operating lease commitments",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted lease payments",
        "terseLabel": "Lessee, operating lease, liability, to be paid",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Total",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, option to extend",
        "label": "Lessee, Operating Lease, Option to Extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, term of contract",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r64",
      "r65",
      "r66",
      "r69",
      "r70",
      "r71",
      "r72",
      "r191",
      "r253",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r437",
      "r438",
      "r439",
      "r485",
      "r608",
      "r688",
      "r727",
      "r855",
      "r911",
      "r912"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r122",
      "r554",
      "r715",
      "r833",
      "r850",
      "r902"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAssumed1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAssumed1",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development contract obligation assumed",
        "label": "Liabilities Assumed",
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r156",
      "r191",
      "r253",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r437",
      "r438",
      "r439",
      "r485",
      "r715",
      "r855",
      "r911",
      "r912"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Long-Term Line of Credit, Total",
        "label": "Long-Term Line of Credit",
        "terseLabel": "Amounts drawn and outstanding under credit facility",
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r120",
      "r924"
     ]
    },
    "us-gaap_LineOfCreditFacilityExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityExpirationDate1",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Expiration Date",
        "terseLabel": "Line of credit maturity date",
        "documentation": "Date the credit facility terminates, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r68"
     ]
    },
    "tsbx_LineOfCreditFacilityExtendedDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "LineOfCreditFacilityExtendedDate",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility Extended Date",
        "label": "Line Of Credit Facility Extended Date",
        "terseLabel": "Line of credit facility extended date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityInterestRateDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityInterestRateDescription",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Interest Rate Description",
        "terseLabel": "Interest rate description",
        "documentation": "Description of interest rate for borrowing under credit facility. Includes, but is not limited to, terms and method for determining interest rate."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r68"
     ]
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityLineItems",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r832",
      "r853"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails",
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Revolving credit facility, aggregate principal amount",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r68"
     ]
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityTable",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Table]",
        "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r68",
      "r295",
      "r832",
      "r853"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_LossContingencyReserveForLitigationLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "LossContingencyReserveForLitigationLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LegalProceedingsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency reserve for litigation liabilities",
        "label": "Loss Contingency Reserve For Litigation Liabilities",
        "documentation": "Loss contingency reserve for litigation liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MachineryAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetConsistDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory equipment",
        "label": "Machinery and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfFairValueAssumptionOfStockOptionActivityDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputOfContingentConsiderationValuationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r348",
      "r394",
      "r466",
      "r533",
      "r564",
      "r566",
      "r577",
      "r600",
      "r601",
      "r656",
      "r658",
      "r661",
      "r662",
      "r664",
      "r676",
      "r677",
      "r692",
      "r696",
      "r702",
      "r710",
      "r711",
      "r712",
      "r713",
      "r716",
      "r857",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918"
     ]
    },
    "tsbx_MaximumTermOfOptionsUnderEquityIncentivePlan": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "MaximumTermOfOptionsUnderEquityIncentivePlan",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum term of options issued under equity incentive plan",
        "label": "Maximum Term of Options Under Equity Incentive Plan",
        "documentation": "Maximum term of options under equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputOfContingentConsiderationValuationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement input discount rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r897",
      "r898",
      "r899"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputOfContingentConsiderationValuationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement input expected term [Member]",
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r897",
      "r898",
      "r899"
     ]
    },
    "tsbx_MeasurementInputLikelihoodOfOccurrenceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "MeasurementInputLikelihoodOfOccurrenceMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputOfContingentConsiderationValuationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement input likelihood of occurrence [Member]",
        "label": "Measurement Input Likelihood Of Occurrence [Member]",
        "documentation": "Measurement input likelihood of occurrence [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputOfContingentConsiderationValuationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r465",
      "r466",
      "r710"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputOfContingentConsiderationValuationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r465",
      "r466",
      "r710"
     ]
    },
    "tsbx_MilestoneAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "MilestoneAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone [Axis]",
        "documentation": "Milestone."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_MilestoneDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "MilestoneDomain",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone [Domain]",
        "documentation": "Milestone."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_MilestonePaymentReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "MilestonePaymentReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment receivable",
        "label": "Milestone Payment Receivable",
        "documentation": "Milestone payment receivable."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails",
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfFairValueAssumptionOfStockOptionActivityDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputOfContingentConsiderationValuationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r348",
      "r394",
      "r466",
      "r533",
      "r564",
      "r566",
      "r577",
      "r600",
      "r601",
      "r656",
      "r658",
      "r661",
      "r662",
      "r664",
      "r676",
      "r677",
      "r692",
      "r696",
      "r702",
      "r710",
      "r711",
      "r712",
      "r716",
      "r857",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysCashCashEquivalentsAndAvailableForSaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds [Member]",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r860"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "tsbx_MystHoldersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "MystHoldersMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Myst Holders [Member]",
        "label": "Myst Holders [Member]",
        "documentation": "Myst holders."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_MystMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "MystMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Myst [Member]",
        "label": "Myst [Member]",
        "documentation": "Myst [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_MystMergerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "MystMergerAgreementMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Myst Merger Agreement [Member]",
        "terseLabel": "Myst Merger Agreement [Member]",
        "label": "Myst Merger Agreement [Member]",
        "documentation": "Myst merger agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash flows used in financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash flows provided by investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing Activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flows used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r90",
      "r91"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "totalLabel": "Net loss",
        "negatedLabel": "Net income (loss)",
        "verboseLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r91",
      "r126",
      "r154",
      "r174",
      "r176",
      "r180",
      "r191",
      "r200",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r209",
      "r210",
      "r223",
      "r253",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r422",
      "r434",
      "r460",
      "r485",
      "r559",
      "r630",
      "r647",
      "r648",
      "r725",
      "r855"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to common stockholders, basic",
        "terseLabel": "Net income (loss) attributable to common stockholders, basic",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r202",
      "r203",
      "r204",
      "r205",
      "r214",
      "r215",
      "r224",
      "r227",
      "r434"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to common stockholders, diluted",
        "label": "Net income (loss) attributable to common stockholders, Diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r216",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r227"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Adopted Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_NewSharesUnderTwoThousandTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "NewSharesUnderTwoThousandTwentyThreeMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Shares Under 2023 [Member]",
        "label": "New Shares Under Two Thousand Twenty Three [Member]",
        "documentation": "New Shares Under Two Thousand Twenty Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r740",
      "r750",
      "r760",
      "r784",
      "r792"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Disclosure of Non-Cash Investing and Financing Activities:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Nonoperating Income (Expense), Total",
        "terseLabel": "Other income, net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "tsbx_NumberOfSquareFeetForLease": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "NumberOfSquareFeetForLease",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of square feet for lease",
        "label": "Number Of Square Feet For Lease",
        "documentation": "Number of square feet for lease."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_NumberOfTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "NumberOfTradingDays",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of trading days",
        "label": "Number of Trading Days",
        "documentation": "Number of trading days."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_OfficeAndLaboratorySpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "OfficeAndLaboratorySpaceMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office and laboratory space [Member]",
        "label": "Office And Laboratory Space [Member]",
        "documentation": "Office And Laboratory Space Member"
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_OfficeSpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "OfficeSpaceMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office space [Member]",
        "label": "Office Space [Member]",
        "documentation": "Office Space Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r689",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845"
     ]
    },
    "tsbx_OperatingLeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "OperatingLeaseAgreementMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease agreement [Member]",
        "label": "Operating Lease Agreement [Member]",
        "documentation": "Operating Lease Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfInformationAboutLeaseCostsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r714"
     ]
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Impairment of ROU asset",
        "terseLabel": "Operating lease, impairment loss",
        "label": "Operating Lease, Impairment Loss",
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r906"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease liability",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets",
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: current portion of operating lease liability",
        "terseLabel": "Operating lease liability, current",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets",
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfMinimumAggregateFutureOperatingLeaseCommitmentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease liability, noncurrent",
        "terseLabel": "Operating lease liability, noncurrent",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, payments",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r513"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right of use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfPresentValueOfOperatingLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r714"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfPresentValueOfOperatingLeasePaymentsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term in years",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r714"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityTypeAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Type [Axis]",
        "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r56",
      "r57",
      "r117"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Type [Domain]",
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_OptionsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "OptionsToPurchaseCommonStockMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options to purchase common stock [Member]",
        "label": "Options To Purchase Common Stock [Member]",
        "documentation": "Options To Purchase Common Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r715"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets, noncurrent",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_OtherCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitment",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other commitment",
        "terseLabel": "Commitment to spend for cell therapy infrastructure and continued research and development",
        "label": "Other Commitment",
        "totalLabel": "Other Commitment, Total",
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrealized loss on available-for-sale debt securities",
        "terseLabel": "Unrealized gain (loss) on available-for-sale debt securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax",
        "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax, Total",
        "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities, noncurrent",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "tsbx_OtherOfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "OtherOfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other offering expenses",
        "label": "Other Offering Expenses",
        "documentation": "Other Offering Expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables related to reimbursable costs",
        "label": "Other Receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r617",
      "r691",
      "r926"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r738",
      "r748",
      "r758",
      "r790"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r741",
      "r751",
      "r761",
      "r793"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r741",
      "r751",
      "r761",
      "r793"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of contingent consideration related to Myst milestone",
        "verboseLabel": "Payment for contingent consideration liability",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "tsbx_PaymentOfLoanFirstAnniversaryClosingDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "PaymentOfLoanFirstAnniversaryClosingDateMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of loan first anniversary closing date [Member]",
        "label": "Payment Of Loan First Anniversary Closing Date [Member]",
        "documentation": "Payment of loan first anniversary closing date."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_PaymentOfLoanSecondAnniversaryClosingDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "PaymentOfLoanSecondAnniversaryClosingDateMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of loan second anniversary closing date [Member]",
        "label": "Payment Of Loan Second Anniversary Closing Date [Member]",
        "documentation": "Payment of loan second anniversary closing date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for rent",
        "label": "Payments for Rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument nonrefundable prepayment fee",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of financing costs",
        "label": "Payments of Financing Costs",
        "totalLabel": "Payments of Financing Costs, Total",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of deferred IPO costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireProductiveAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments to acquire productive assets",
        "label": "Payments to Acquire Productive Assets",
        "totalLabel": "Payments to Acquire Productive Assets, Total",
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r890",
      "r891",
      "r892"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireShortTermInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of short-term investments",
        "label": "Payments to Acquire Short-Term Investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "tsbx_PercentageOfOperatingProfitOrLoss": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "PercentageOfOperatingProfitOrLoss",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of share of operating profit or loss",
        "label": "Percentage Of Operating Profit Or Loss",
        "documentation": "Percentage of operating profit or loss."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock [Member]",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r717",
      "r718",
      "r721",
      "r722",
      "r723",
      "r724",
      "r929",
      "r931"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, par or stated value per Share",
        "terseLabel": "Preferred stock par value",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r321"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r609"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares, issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r321"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares, outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r609",
      "r628",
      "r931",
      "r932"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized, at June 30, 2024 and December 31, 2023, respectively, 0 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r550",
      "r715"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "totalLabel": "Prepaid Expense, Current, Total",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r270",
      "r271",
      "r681"
     ]
    },
    "tsbx_PriceAtModificationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "PriceAtModificationMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price at Modification [Member]",
        "label": "Price At Modification [Member]",
        "documentation": "Price\u00a0at\u00a0modification."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_PriceModificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "PriceModificationAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Price Modification [Axis]",
        "documentation": "Price modification."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_PriceModificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "PriceModificationDomain",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Price Modification [Domain]",
        "documentation": "Price modification."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_PricePreModificationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "PricePreModificationMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price Pre-Modification [Member]",
        "label": "Price Pre Modification [Member]",
        "documentation": "Price pre modification."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from Issuance of redeemable convertible preferred stock",
        "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock",
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromRepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromRepaymentsOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate cash proceeds",
        "label": "Proceeds from (Repayments of) Debt",
        "totalLabel": "Proceeds from (Repayments of) Debt, Total",
        "documentation": "The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inflow From Issuance Of Intangible Asset",
        "label": "Proceeds from Sale of Intangible Assets",
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of property and equipment",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "totalLabel": "Proceeds from Sale of Property, Plant, and Equipment, Total",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturities of short-term investments",
        "label": "Proceeds from Sale of Short-Term Investments",
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r15"
     ]
    },
    "us-gaap_ProjectMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProjectMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Project [Domain]",
        "documentation": "Planned program of work."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r539",
      "r920"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r517"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, Net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r141",
      "r145",
      "r146"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetConsistDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property plant and equipment gross",
        "label": "Property, Plant and Equipment, Gross",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r158",
      "r557"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetConsistDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets",
      "http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetConsistDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total property and equipment, net",
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r517",
      "r545",
      "r557",
      "r715"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r517"
     ]
    },
    "tsbx_ProvisionBenefitForIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "ProvisionBenefitForIncomeTaxes",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Benefit (provision) for income taxes",
        "terseLabel": "Benefit (provision) for income taxes",
        "label": "Provision Benefit For Income Taxes",
        "documentation": "Provision benefit for income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Commitment, Excluding Long-Term Commitment [Axis]",
        "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or services from one or more suppliers."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r121"
     ]
    },
    "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Commitment, Excluding Long-Term Commitment [Domain]",
        "documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate such information, as appropriate."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r121"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails",
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfFairValueAssumptionOfStockOptionActivityDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputOfContingentConsiderationValuationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r340",
      "r348",
      "r380",
      "r381",
      "r382",
      "r394",
      "r466",
      "r530",
      "r531",
      "r533",
      "r564",
      "r566",
      "r577",
      "r600",
      "r601",
      "r656",
      "r658",
      "r661",
      "r662",
      "r664",
      "r676",
      "r677",
      "r692",
      "r696",
      "r702",
      "r710",
      "r711",
      "r712",
      "r713",
      "r716",
      "r719",
      "r852",
      "r857",
      "r898",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails",
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfFairValueAssumptionOfStockOptionActivityDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputOfContingentConsiderationValuationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r340",
      "r348",
      "r380",
      "r381",
      "r382",
      "r394",
      "r466",
      "r530",
      "r531",
      "r533",
      "r564",
      "r566",
      "r577",
      "r600",
      "r601",
      "r656",
      "r658",
      "r661",
      "r662",
      "r664",
      "r676",
      "r677",
      "r692",
      "r696",
      "r702",
      "r710",
      "r711",
      "r712",
      "r713",
      "r716",
      "r719",
      "r852",
      "r857",
      "r898",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918"
     ]
    },
    "tsbx_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Pronouncements",
        "label": "Recently Issued Accounting Pronouncements Policy [Policy Text Block]",
        "documentation": "Recently issued accounting pronouncements policy."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r743",
      "r753",
      "r785"
     ]
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "RedeemableConvertiblePreferredStockPolicyPolicyTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable Convertible Preferred Stock",
        "label": "Redeemable Convertible Preferred Stock Policy [Policy Text Block]",
        "documentation": "Redeemable convertible preferred stock policy."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount",
        "totalLabel": "Redeemable Noncontrolling Interest, Equity, Carrying Amount, Total",
        "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r103",
      "r104"
     ]
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RedeemableNoncontrollingInterestEquityPreferredCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock ,shares authorized, issued and outstanding",
        "label": "Redeemable Noncontrolling Interest, Equity, Preferred, Carrying Amount",
        "documentation": "As of the reporting date, the carrying amount of noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. The noncontrolling interest holder's ownership (or holders' ownership) may be in the form of preferred shares (regardless of class), preferred partnership units (regardless of class), preferential membership interests, or any other form of preferred equity regardless of investee entity legal form."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r103",
      "r104"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r347",
      "r523",
      "r524",
      "r549",
      "r555",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r627",
      "r629",
      "r654"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r347",
      "r523",
      "r524",
      "r549",
      "r555",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r627",
      "r629",
      "r654",
      "r910"
     ]
    },
    "tsbx_RemainingMystHoldersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "RemainingMystHoldersMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining Myst Holders [Member]",
        "label": "Remaining Myst Holders [Member]",
        "documentation": "Remaining myst holders."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_RemainingSharesFromTwoThousandEighteenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "RemainingSharesFromTwoThousandEighteenPlanMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining Shares From 2018 Plan [Member]",
        "label": "Remaining Shares From Two Thousand Eighteen Plan [Member]",
        "documentation": "Remaining Shares From Two Thousand Eighteen Plan."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195",
      "r307",
      "r323",
      "r525",
      "r532",
      "r546",
      "r683",
      "r684"
     ]
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development asset acquired other than through business combination, write-off",
        "label": "Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff",
        "documentation": "Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r678",
      "r888"
     ]
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Asset Acquired in Transaction Other than Business Combination or Joint Venture Formation, Writeoff, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r678"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "totalLabel": "Research and Development Expense, Total",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r678",
      "r690",
      "r919"
     ]
    },
    "tsbx_ResearchAndDevelopmentExpenseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "ResearchAndDevelopmentExpenseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development expense",
        "label": "Research and Development Expense Liabilities",
        "documentation": "Research and development expense liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfStockBasedCompensationForStockAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development [Member]",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_ResearchDevelopmentAndManufacturingServicesAggregateAnnualAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "ResearchDevelopmentAndManufacturingServicesAggregateAnnualAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research development and manufacturing services aggregate annual amount",
        "label": "Research Development And Manufacturing Services Aggregate Annual Amount",
        "documentation": "Research development and manufacturing services aggregate annual amount."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_ResearchDevelopmentAndManufacturingServicesAmendedToRemoveTrueUpAnnaulInstallment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "ResearchDevelopmentAndManufacturingServicesAmendedToRemoveTrueUpAnnaulInstallment",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research development and manufacturing services amended to remove the true up annual installment amount",
        "label": "Research Development And Manufacturing Services Amended to Remove True Up Annaul Installment",
        "documentation": "Research development and manufacturing services amended to remove true up annaul installment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r734",
      "r744",
      "r754",
      "r786"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r735",
      "r745",
      "r755",
      "r787"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r742",
      "r752",
      "r762",
      "r794"
     ]
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash",
        "totalLabel": "Restricted Cash, Total",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r821",
      "r830",
      "r922",
      "r925"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "totalLabel": "Restricted Cash and Cash Equivalents, Current, Total",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r157",
      "r187"
     ]
    },
    "tsbx_RestrictedCashAndCashEquivalentsAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "RestrictedCashAndCashEquivalentsAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisAtFairValueDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash And Cash Equivalents At Fair Value",
        "documentation": "Restricted cash and cash equivalents at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_RestrictedCashAndInvestmentsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "RestrictedCashAndInvestmentsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash and Investments",
        "label": "Restricted Cash and Investments Policy [Policy Text Block]",
        "documentation": "Restricted cash and investments policy."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_RestrictedCashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "RestrictedCashMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysCashCashEquivalentsAndAvailableForSaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash [Member]",
        "label": "Restricted Cash [Member]",
        "documentation": "Restricted cash [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock [Member]",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRsuActivityDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs [Member]",
        "verboseLabel": "Unvested RSUs",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets",
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r108",
      "r553",
      "r573",
      "r575",
      "r584",
      "r610",
      "r715"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit [Member]",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r196",
      "r197",
      "r198",
      "r201",
      "r206",
      "r208",
      "r210",
      "r257",
      "r262",
      "r280",
      "r407",
      "r408",
      "r418",
      "r419",
      "r420",
      "r423",
      "r433",
      "r434",
      "r444",
      "r447",
      "r448",
      "r450",
      "r458",
      "r498",
      "r503",
      "r570",
      "r572",
      "r586",
      "r931"
     ]
    },
    "tsbx_ReturningSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "ReturningSharesMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Returning Shares [Member]",
        "label": "Returning Shares [Member]",
        "documentation": "Returning Shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from collaborative arrangement",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r893"
     ]
    },
    "tsbx_RevenuePerformanceObligationFixedAggregateConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "RevenuePerformanceObligationFixedAggregateConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, performance obligation fixed aggregate consideration",
        "label": "Revenue, Performance Obligation Fixed Aggregate Consideration",
        "documentation": "Revenue, performance obligation fixed aggregate consideration."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundablePaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "RevenuePerformanceObligationFixedConsiderationNonRefundablePaymentReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, performance obligation fixed consideration Non refundable payment received",
        "label": "Revenue, Performance Obligation Fixed Consideration Non Refundable Payment Received",
        "documentation": "Revenue, performance obligation fixed consideration Non refundable upfront payment received."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_RevenuePerformanceObligationFixedConsiderationNonRefundableUpfrontPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "RevenuePerformanceObligationFixedConsiderationNonRefundableUpfrontPaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, performance obligation fixed consideration Non refundable upfront payment received",
        "label": "Revenue, Performance Obligation Fixed Consideration Non Refundable Upfront Payment Received",
        "documentation": "Revenue, performance obligation fixed consideration Non refundable upfront payment received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Obligations",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional revenue recognized on change in contract modification",
        "terseLabel": "Collaboration revenue",
        "label": "Revenues",
        "totalLabel": "Revenues, Total",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r181",
      "r191",
      "r232",
      "r237",
      "r238",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r253",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r485",
      "r544",
      "r690",
      "r855"
     ]
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails",
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Loans [Member]",
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash received on stock transaction after deduction of issuance costs",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_SalesBasedMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "SalesBasedMilestonesMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales Based Milestones [Member]",
        "label": "Sales Based Milestones [Member]",
        "documentation": "Sales milestones."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_SalesMilestonesOnDevelopmentProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "SalesMilestonesOnDevelopmentProgramMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Milestones On Development Program [Member]",
        "documentation": "Sales Milestones On Development Program Member"
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_SalesMilestonesOnLicensedDiscoveryProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "SalesMilestonesOnLicensedDiscoveryProductMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Milestones on Licensed Discovery Product [Member]",
        "documentation": "Sales Milestones On Licensed Discovery Product Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails",
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r349",
      "r837"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails",
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r212",
      "r349",
      "r816",
      "r837"
     ]
    },
    "tsbx_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Liabilities and Other Current Liabilities",
        "label": "Schedule Of Accrued Liabilities And Other Current Liabilities [Table Text Block]",
        "documentation": "Schedule of accrued liabilities and other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of dilutive securities excluded from computation of diluted net loss per share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "tsbx_ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of shares of common stock reserved for future issuance",
        "label": "Schedule Of Common Stock Shares Reserved For Future Issuance [Table Text Block]",
        "documentation": "Schedule of common stock shares reserved for future issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of computation of basic and diluted net loss per share",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]",
        "documentation": "Tabular disclosure of the effect of income (loss) on basic earnings per share."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r29",
      "r839"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfStockBasedCompensationForStockAwardsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of stock based compensation for stock awards",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Assets and Liabilities Measured on Recurring Basis at Fair Value",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r895",
      "r896"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Summary of RSU activity",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "tsbx_ScheduleOfPresentValueOfOperatingLeasePayments": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "ScheduleOfPresentValueOfOperatingLeasePayments",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of present value of operating lease payments",
        "label": "Schedule of Present Value Of Operating Lease Payments",
        "documentation": "Schedule of present value of operating lease payments."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_ScheduleOfPresentValueOfOperatingLeasePaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "ScheduleOfPresentValueOfOperatingLeasePaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Present Value of Operating Lease Payments [Abstract]",
        "documentation": "Schedule Of Present Value Of Operating Lease Payments Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetConsistDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r517"
     ]
    },
    "tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityLineItems",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Based Compensation Stock Options Activity [Line Items]",
        "documentation": "Schedule of share based compensation stock options activity."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_ScheduleOfShareBasedCompensationStockOptionsActivityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTable",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Based Compensation Stock Options Activity [Table]",
        "documentation": "Schedule of share based compensation stock options activity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of stock option plan activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r110"
     ]
    },
    "tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsLineItems",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfFairValueAssumptionOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions [Line Items]",
        "documentation": "Schedule of share based payment award stock options valuation assumptions."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTable",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRsuActivityDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfFairValueAssumptionOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions [Table]",
        "documentation": "Schedule of share based payment award stock options valuation assumptions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of fair value assumption of stock option activity",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquitySummaryOfSharesOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r101",
      "r106",
      "r107",
      "r108",
      "r162",
      "r163",
      "r164",
      "r234",
      "r321",
      "r322",
      "r323",
      "r325",
      "r328",
      "r333",
      "r335",
      "r580",
      "r581",
      "r582",
      "r583",
      "r696",
      "r815",
      "r831"
     ]
    },
    "tsbx_ScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "ScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationTableTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Transaction Price Allocated To Programs Performance Obligation",
        "label": "Schedule Of Transaction Price Allocated To Programs Performance Obligation [Table Text Block]",
        "documentation": "Schedule of transaction price allocated to programs performance obligation."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Transaction Price Allocatied To Programs Performance Obligation [Abstract]",
        "documentation": "Schedule of transaction price allocatied to programs performance obligation."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationLineItems",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Transaction Price Allocatied To Programs Performance Obligation [Line Items]",
        "documentation": "Schedule of transaction price allocatied to programs performance obligation."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "ScheduleOfTransactionPriceAllocatiedToProgramsPerformanceObligationTable",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Transaction Price Allocatied To Programs Performance Obligation [Table]",
        "documentation": "Schedule of transaction price allocatied to programs performance obligation."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_SecondMilestonePaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "SecondMilestonePaymentMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Milestone Payment [Member]",
        "label": "Second Milestone Payment [Member]",
        "documentation": "Second milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Series A redeemable convertible preferred stock [Member]",
        "terseLabel": "Series A Preferred Stock [Member]",
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r823",
      "r859"
     ]
    },
    "tsbx_SeriesARedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "SeriesARedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets",
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A redeemable convertible preferred stock [Member]",
        "label": "Series A Redeemable Convertible Preferred Stock [Member]",
        "documentation": "Series A Redeemable Convertible Preferred Stock."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_SeriesB1RedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "SeriesB1RedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets",
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Series B-1 Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series B-1 redeemable convertible preferred stock [Member]",
        "label": "Series B1 Redeemable Convertible Preferred Stock [Member]",
        "documentation": "Series B-1 redeemable convertible preferred stock [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_SeriesB2RedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "SeriesB2RedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets",
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Series B-2 Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series B-2 redeemable convertible preferred stock [Member]",
        "label": "Series B2 Redeemable Convertible Preferred Stock [Member]",
        "documentation": "Series B-2 redeemable convertible preferred stock [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C Preferred Stock [Member]",
        "label": "Series C Preferred Stock [Member]",
        "verboseLabel": "Series C redeemable convertible preferred stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r823",
      "r859"
     ]
    },
    "tsbx_SeriesCRedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "SeriesCRedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets",
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C redeemable convertible preferred stock [Member]",
        "label": "Series C Redeemable Convertible Preferred Stock [Member]",
        "documentation": "Series C Redeemable Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesDPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesDPreferredStockMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Series D redeemable convertible preferred stock [Member]",
        "terseLabel": "Series D Preferred Stock [Member]",
        "label": "Series D Preferred Stock [Member]",
        "documentation": "Series D preferred stock."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r823",
      "r859"
     ]
    },
    "tsbx_SeriesDRedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "SeriesDRedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets",
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series D redeemable convertible preferred stock [Member]",
        "label": "Series D Redeemable Convertible Preferred Stock [Member]",
        "documentation": "Series D Redeemable Convertible Preferred Stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "tsbx_ShareBasedCompensationArrangementAverageGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "ShareBasedCompensationArrangementAverageGrantDateFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement Average Grant Date Fair Value",
        "label": "Share Based Compensation Arrangement Average Grant Date Fair Value",
        "terseLabel": "Aggregate grant date fair value of RSUs granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award requisite service period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRsuActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "RSUs Cancelled/Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "terseLabel": "RSUs Cancelled/Forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRsuActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs Cancelled/Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRsuActivityDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "RSUs granted",
        "verboseLabel": "Number of RSUs granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRsuActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "RSUs granted",
        "verboseLabel": "Aggregate grant date fair value of RSUs granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRsuActivityDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, nonvested, number",
        "terseLabel": "Number of non-vested equity-based payment instruments",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of Outstanding RSUs, Ending balance",
        "periodStartLabel": "Number of Outstanding RSUs, Beginning balance",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRsuActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodStartLabel": "Weighted-Average Grant Date Fair Value, Beginning balance",
        "periodEndLabel": "Weighted-Average Grant Date Fair Value, Ending balance",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRsuActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of equity-based payment instruments vested during the period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "verboseLabel": "Vested/Released",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfFairValueAssumptionOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise price of stock options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfFairValueAssumptionOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfFairValueAssumptionOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Volatility, Maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfFairValueAssumptionOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Volatility, Minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfFairValueAssumptionOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Risk-free interest rate, Maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfFairValueAssumptionOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Risk-free interest rate, Minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRsuActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r353",
      "r355",
      "r356",
      "r357",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Shares available for issuance automatically increased by additional shares",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of shares authorized for issuance under share-based payment arrangement",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, number of shares authorized",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation arrangement by share-based payment award, number of shares available for grant",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, number of shares available for grant",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options canceled/forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value Outstanding , Beginning balance",
        "periodEndLabel": "Aggregate Intrinsic Value Outstanding , Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Shares Underlying Outstanding Options, Beginning balance",
        "periodEndLabel": "Number of Shares Underlying Outstanding Options, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted- Average Exercise Price Outstanding",
        "periodEndLabel": "Weighted- Average Exercise Price Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation arrangement by share-based payment award, percentage of outstanding stock maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationSummaryOfRsuActivityDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquitySummaryOfSharesOfCommonStockReservedForFutureIssuanceDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options canceled/forfeited",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r358",
      "r377",
      "r378",
      "r379",
      "r380",
      "r383",
      "r389",
      "r390",
      "r391",
      "r392"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation arrangement by share-based payment award, award vesting rights, percentage",
        "terseLabel": "Percentage of vesting of award under share-based payment arrangement",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationScheduleOfFairValueAssumptionOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted- Average Remaining Contractual Term (Years) Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "tsbx_SharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "SharesAuthorized",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares authorized",
        "label": "Shares Authorized",
        "documentation": "Shares Authorized."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_SharesAvailableForIssuanceUnderEsppMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "SharesAvailableForIssuanceUnderEsppMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquitySummaryOfSharesOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for issuance under the ESPP [Member]",
        "label": "Shares Available For Issuance Under ESPP [Member]",
        "documentation": "Shares available for issuance under ESPP."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_SharesAvailableForIssuanceUnderPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "SharesAvailableForIssuanceUnderPlansMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquitySummaryOfSharesOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for issuance under the Plans [Member]",
        "label": "Shares Available For Issuance Under Plans [Member]",
        "documentation": "Shares available for issuance under plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued, price per share",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments",
        "label": "Short-Term Investments",
        "totalLabel": "Short-Term Investments, Total",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r824"
     ]
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestmentsMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysCashCashEquivalentsAndAvailableForSaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments [Member]",
        "label": "Short-Term Investments [Member]",
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r667",
      "r668",
      "r679"
     ]
    },
    "tsbx_ShortTermLeaseCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "ShortTermLeaseCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfInformationAboutLeaseCostsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease costs",
        "label": "Short Term Lease, Costs",
        "documentation": "Short-term lease, costs."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_SignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "SignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Line Items]",
        "documentation": "Significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_SignificantAccountingPoliciesPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "SignificantAccountingPoliciesPolicyPolicyTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Accounting Policies",
        "label": "Significant Accounting Policies Policy [Policy Text Block]",
        "documentation": "Significant accounting policies policy."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_SignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "SignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Table]",
        "documentation": "Significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r188"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets",
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureNetLossPerShareScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r162",
      "r163",
      "r164",
      "r191",
      "r217",
      "r218",
      "r225",
      "r227",
      "r234",
      "r235",
      "r253",
      "r296",
      "r298",
      "r299",
      "r300",
      "r303",
      "r304",
      "r321",
      "r322",
      "r325",
      "r328",
      "r335",
      "r485",
      "r580",
      "r581",
      "r582",
      "r583",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r609",
      "r631",
      "r649",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r815",
      "r831",
      "r840"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r75",
      "r78",
      "r79",
      "r152",
      "r178",
      "r179",
      "r180",
      "r196",
      "r197",
      "r198",
      "r201",
      "r206",
      "r208",
      "r210",
      "r233",
      "r257",
      "r262",
      "r280",
      "r336",
      "r407",
      "r408",
      "r418",
      "r419",
      "r420",
      "r423",
      "r433",
      "r434",
      "r444",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r458",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r498",
      "r503",
      "r522",
      "r560",
      "r570",
      "r571",
      "r572",
      "r586",
      "r649"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets",
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r233",
      "r503",
      "r535",
      "r579",
      "r597",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r609",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r618",
      "r619",
      "r620",
      "r621",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r629",
      "r632",
      "r633",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r649",
      "r720"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails",
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r212",
      "r349",
      "r816",
      "r817",
      "r837"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets",
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r233",
      "r248",
      "r503",
      "r535",
      "r579",
      "r597",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r609",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r618",
      "r619",
      "r620",
      "r621",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r629",
      "r632",
      "r633",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r649",
      "r720"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r737",
      "r747",
      "r757",
      "r789"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering (in shares)",
        "terseLabel": "Conversion of redeemable convertible preferred stock into common stock",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r43",
      "r75",
      "r78",
      "r108",
      "r316"
     ]
    },
    "tsbx_StockIssuedDuringPeriodSharesMoffittPerformanceBasedCommonStockAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "StockIssuedDuringPeriodSharesMoffittPerformanceBasedCommonStockAward",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Moffitt performance based common stock award (in shares)",
        "label": "Stock Issued During Period Shares Moffitt Performance Based Common Stock Award",
        "documentation": "Stock issued during period shares moffitt performance based common stock award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from initial public offering, net of issuance costs (in shares)",
        "terseLabel": "Number of new stock issued during the period",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r74",
      "r75",
      "r108",
      "r580",
      "r649",
      "r670"
     ]
    },
    "tsbx_StockIssuedDuringPeriodSharesNewIssuesOnMilestoneAchievement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "StockIssuedDuringPeriodSharesNewIssuesOnMilestoneAchievement",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon Myst milestone achievement (in shares)",
        "label": "Stock Issued During Period Shares New Issues On Milestone Achievement",
        "documentation": "Stock issued during period shares new issues on milestone achievement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options exercised",
        "terseLabel": "Exercise of stock options (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r74",
      "r75",
      "r108",
      "r364"
     ]
    },
    "tsbx_StockIssuedDuringPeriodValueMoffittPerformanceBasedCommonStockAward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "StockIssuedDuringPeriodValueMoffittPerformanceBasedCommonStockAward",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Moffitt performance based common stock award",
        "label": "Stock Issued During Period Value Moffitt Performance Based Common Stock Award",
        "documentation": "Stock issued during period value moffitt performance based common stock award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from initial public offering, net of issuance costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r74",
      "r75",
      "r108",
      "r586",
      "r649",
      "r670",
      "r726"
     ]
    },
    "tsbx_StockIssuedDuringPeriodValueNewIssuesOnMilestoneAchievement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "StockIssuedDuringPeriodValueNewIssuesOnMilestoneAchievement",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon Myst milestone achievement",
        "label": "Stock Issued During Period Value New Issues on Milestone Achievement",
        "documentation": "Stock issued during period value new issues on milestone achievement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r75",
      "r78",
      "r79",
      "r108"
     ]
    },
    "tsbx_StockIssuedDuringThePeriodForMilestonePaymentsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "StockIssuedDuringThePeriodForMilestonePaymentsShares",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued during the period for milestone payments shares",
        "label": "Stock Issued During the Period for Milestone Payments Shares",
        "documentation": "Stock issued during the period for milestone payments shares."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_StockIssuedDuringThePeriodForMilestonePaymentsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "StockIssuedDuringThePeriodForMilestonePaymentsValue",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issued during the period for milestone payments value",
        "label": "Stock Issued During the Period for Milestone Payments Value",
        "documentation": "Stock issued during the period for milestone payments value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets",
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r78",
      "r79",
      "r94",
      "r611",
      "r628",
      "r650",
      "r651",
      "r715",
      "r727",
      "r833",
      "r850",
      "r902",
      "r931"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity (deficit)",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Redeemable Convertible Preferred Stock and Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r190",
      "r320",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r334",
      "r336",
      "r451",
      "r652",
      "r653",
      "r674"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock split, conversion ratio",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of the reverse stock split arrangement",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfInformationAboutLeaseCostsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Sublease income",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r714"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r526"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r526"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r526"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Disclosure of Cash Flow Information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "tsbx_TakedaAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "TakedaAgreementMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Takeda Agreement [Member]",
        "label": "Takeda Agreement [Member]",
        "documentation": "Takeda agreement."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_TakedaPharmaceuticalCompanyLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "TakedaPharmaceuticalCompanyLimitedMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Takeda Pharmaceutical Company Limited [Member]",
        "label": "Takeda Pharmaceutical Company Limited [Member]",
        "documentation": "Takeda pharmaceutical company limited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityAbstract",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable convertible preferred stock",
        "label": "Temporary Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityAccretionToRedemptionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accretion of preferred stock to redemption value",
        "terseLabel": "Accretion of redeemable convertible preferred stock issuance costs",
        "label": "Temporary Equity, Accretion to Redemption Value",
        "documentation": "Value of accretion of temporary equity to its redemption value during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accretion of preferred stock to redemption value",
        "verboseLabel": "Accretion of preferred stock to redemption value",
        "label": "Temporary Equity, Accretion to Redemption Value, Adjustment",
        "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityAggregateAmountOfRedemptionRequirement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityAggregateAmountOfRedemptionRequirement",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary Equity, aggregate amount of redemption requirement",
        "label": "Temporary Equity, Aggregate Amount of Redemption Requirement",
        "documentation": "Aggregate amount of redemption requirements for each class or type of redeemable stock classified as temporary equity for each of the five years following the latest balance sheet date. The redemption requirement does not constitute an unconditional obligation that will be settled in a variable number of shares constituting a monetary value predominantly indexed to (a) a fixed monetary amount known at inception, (b) an amount inversely correlated with the residual value of the entity, or (c) an amount determined by reference to something other than the fair value of issuer's stock. Does not include mandatorily redeemable stock. The exception is if redemption is required upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity, par or stated value per share",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r38"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity, shares authorized",
        "label": "Temporary Equity, Shares Authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering (in shares)",
        "terseLabel": "Temporary equity, shares issued",
        "label": "Temporary Equity, Shares Issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary equity, shares outstanding",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Temporary Equity, Shares Outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "tsbx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of stock classified as temporary equity issued during the period",
        "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "documentation": "Temporary equity stock issued during period shares new issues."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering",
        "terseLabel": "Value of new stock classified as temporary equity issued during the period",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_ThirdMilestonePaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "ThirdMilestonePaymentMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/AssetAcquisitionAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third Milestone Payment [Member]",
        "label": "Third Milestone Payment [Member]",
        "documentation": "Third milestone payment."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_TimothyLangerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "TimothyLangerMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Timothy Langer [Member]",
        "label": "Timothy Langer [Member]",
        "documentation": "Timothy Langer."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "tsbx_TwoThousandAndEighteenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "TwoThousandAndEighteenEquityIncentivePlanMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureEquityBasedCompensationScheduleOfStockOptionActivityDetail",
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2018 Plan [Member]",
        "label": "Two Thousand And Eighteen Equity Incentive Plan [Member]",
        "documentation": "Two thousand and eighteen equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_TwoThousandAndTwentyThreeEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "TwoThousandAndTwentyThreeEquityIncentivePlanMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Plan [Member]",
        "label": "Two Thousand And Twenty Three Equity Incentive Plan [Member]",
        "documentation": "Two thousand and twenty three equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/AgreementsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfCompanysCashCashEquivalentsAndAvailableForSaleSecuritiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government and agency securities [Member]",
        "label": "US Government Agencies Debt Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r686",
      "r697",
      "r923"
     ]
    },
    "tsbx_UnderwritingDiscountsAndCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "UnderwritingDiscountsAndCommissions",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/NatureOfTheBusinessAndBasisOfPresentationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriting discounts and commissions",
        "label": "Underwriting Discounts and Commissions",
        "documentation": "Underwriting discounts and commissions."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "tsbx_UnpaidLiabilityMilestoneAchievement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "UnpaidLiabilityMilestoneAchievement",
     "crdr": "credit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid liability on milestone acheivement",
        "label": "Unpaid Liability Milestone Achievement",
        "documentation": "Unpaid liability milestone achievement."
       }
      }
     },
     "auth_ref": []
    },
    "tsbx_UnvestedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.turnstonebio.com/20240630",
     "localname": "UnvestedRestrictedStockUnitsMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquitySummaryOfSharesOfCommonStockReservedForFutureIssuanceDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested Restricted Stock Units.",
        "label": "Unvested Restricted Stock Units [Member]",
        "terseLabel": "Unvested RSUs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34",
      "r137",
      "r139",
      "r142",
      "r143"
     ]
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputOfContingentConsiderationValuationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Axis]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r465",
      "r710",
      "r899"
     ]
    },
    "us-gaap_ValuationTechniqueDiscountedCashFlowMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueDiscountedCashFlowMember",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputOfContingentConsiderationValuationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation technique discounted cash flow [Member]",
        "label": "Valuation Technique, Discounted Cash Flow [Member]",
        "documentation": "Valuation technique calculating present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r710",
      "r897",
      "r898",
      "r899"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/FairValueOfFinancialAssetsAndLiabilitiesScheduleOfUnobservableInputOfContingentConsiderationValuationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Domain]",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r465",
      "r710",
      "r899"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/LeasesScheduleOfInformationAboutLeaseCostsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable leases costs",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r714"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of shares of common stock outstanding, diluted",
        "totalLabel": "Weighted-average number of diluted shares used in computing net earnings (loss) per share",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r227"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.turnstonebio.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of shares of common stock outstanding, basic",
        "verboseLabel": "Weighted-average number of basic shares used in computing net earnings (loss) per share",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r227"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(f)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "63",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-63"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Subparagraph": "(12)(c)",
   "Section": "S99",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Subparagraph": "(16)(c)",
   "Paragraph": "3A",
   "Section": "S99",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-4"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 3.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(14)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(15)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479428/808-10-45-3"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "326",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-3"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-3"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10B"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-5"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii)(B)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479664/932-10-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477385/932-360-S50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "SubTopic": "320",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-1B"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479035/940-320-45-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>74
<FILENAME>0000950170-24-097065-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-097065-xbrl.zip
M4$L#!!0    ( .6"#EG!<FK/'A8$ )P[!@ 2    :6UG,3(W-#4T,3 W7S N
M:G!GW+P'6%/=MC:ZZ-)$>B<H($U Z4B)J#3Y $'I)2H@38@("$)($*5(%1!0
M4%"*2)->!"3204"4WDM D28)2%B0=L.W]SG[['O^_=]SSWWV/O]SUY,)#RLK
M67/,.<8[WW>L,:%,4A:!$U<,30P!&NIQAN8, %!F@$L '2WMT8MZT%-?#,<8
M&.CI&5B8F!B/L;&PL;&RL+*R'^<ZP7Z<\S@KZPF^$YS</+R\O&P<_ )\/ )<
M/+P\1U]"0T?]##T#,P,#,P\[*SO/_^N#\@G@/,;HP/&:CN840,M)0\=)0^D$
M( ! PT#SYP'\]:"AI?:1D>D8,PLK]8*Z$P M#1T=+3W=4:^I[X93WP?H.1FX
M3I[39^2VO,ETRI]'^6'*FV,2%ZO:>*V^8255;MV+9&;AXQ<0%)(Z+2TC*Z>J
MIJZAJ77^TF4#0R-CDRO7KEO;V-K9.[BZN=_V\/3R#@@,NA\<\B#TT>.HZ)C8
M)W&I:<_2,S*?O\C*RR\H?%OTKKBDNJ:VKKZA\4-3>T=G5W=/;]_GX9'1L?&)
MR:GI)<SRRO<?JS_7UG$[N[_W\/O@P>&1730 '<V_'?]+NSBI=M'2T]/1,QW9
M14,;?'0!)SW#R7.,7/J63#?]N4\I/SS&<S'E354;LX2*%9;WUKUO+'R2JDM2
MN"/3_K3LOV98Y'_+LG\W[&]V30-L=#34R:/C!*  Z0).@Q@?VD *-:4 KX6(
M-TA-,\&Q"&D*X)(&(8;[X%&=%&!'87UA;TV#'.&#>X3?I  I\>VNT)TU* H_
M,=]4N=!IJ-;*B/AHP&-;?9>!Q_+"OZI!#) =11#NNOR7J,XL\S".A4N##Z#=
M\ /Y'%4*4#FX0$[RWLN=A).O1-<EH2>' RB [U*%%#B8"SKFJ Y!<5K-%.#;
MH%,56?4C.PS[K<?2@'?4C<?2 /@_N?'NH3N@F7@EG/Y:>@O^%]IB@R2_$G>X
ML)3;3Q (>;W,Y+OJHETQ<OB;*)_5VC\F-#)W")&D6C;\?ZQEX;X$1P2:D0P!
M0@;L?E. Y)OD4-L^M3WTEA\*,TB$,HG_BH]$K<T0\16I\MD<1!4'](E_B4'A
M&@26",1-#!Q6:40!\AD0%& Y>FX9=D)D]7Q4&P7H381=(+=_H "/FSN)$!"7
MO$:N;D7B>HA)K>*K4-S91JI[)3I](ZNV&E:#G$^H\6'RU-* !_AG-MOQA;J&
M?BQ\"<N4T)5L >(AJX6(-)@C>7R5?&:A WOO^,]&:?(K])#WCV*BL5#'4LJ.
M 8^E\VE] YZK-/_,!C,CM[^&"(1D3VQR4H"?;3!EVY'<RO>H)44<E(FLXWJ(
M*GN/,,).%4(3(="0I8:0B4XFK2]O[J)V)&RD?,%ELA'L1$ N^-P)];.[[,JT
M]BFQ)0,>ZV,R>7' /[,=SN#KEQ<G.K <PGEK(V3=F(,UF.0$=9!;H4MF1+WN
M\UT)KN3P*$2:TR1J*6L,C(R3>9\FGA<G _P/-;KUH<E+9#WB'14*<*9<<ZAE
M#CVT :OE@^"6X3/[/L0HI!*9ZKNX@V7](=G;Y_W';Y*H(&]!#3MAOW.$NJVD
M]A8G(YS]3RN0\UKGPE^07^DOR+_A.W\2FTL*_0.%VZN8H@#<U!!H*$5-%"P<
MTE1T<\S4D V5F!,H0'\!B0+,P$)#X)B3-J#@SAZ/I4O?IW\II/ 3CE. /O-Q
M]";U]Z&>T X\86''5L>+ MS,1I-$QC:@E=O$9UOP$8*0!0G"_D#C[Y>-[\FX
MPI_>%" Z29TZG_G_D_/Y7VH5Y:V"RV2!CB[-GKF6(;T-*HI"TX_"GJ@R1#R'
MBH/.M:R'CW\HW?QH6:Z[\.9?%/+_S<8T3@'JT!#J@I"4J^KD"MG9HH:<[=')
M'F(*.F:Y:)!?^ (%R+QY8-O'.QA#%BR'Q5)#=4V9128OXI_9]%Z2HE K<!R4
M%-(S0\X*G1B:U]3"-<0R;Y#>^$^0F]3"Z0@LU)A8P+A2 /-S> KP-J=N=S\)
MNA*(8T)1H2NPA_@;?N5'#*YP1RWS4\(5F;RF/ZB \9KVG]E:&TCE(*B!)08>
MY"T+4,<-?N7@%/7D>^A*(A$JJN?9.,U$;.;X_*$$Q<58";HA4OXU"Q45_2N(
MB60JTZP0(*!&+!P.DEK_.L#G*$#17\ZM=J*8LZZ!WZBC>!SABZ$-I0">3D$4
MX'VB77K#<O*!J([^ ODTORCU$[K"PU7RGIL)\T?KPC^UZ]1&0V4G_CUM5&_4
M/,@["*$ N?#=Z5;CBG*T3_*!1"Y'CT66HB;UK#\YI"+5YS^2%E[=\J@Q@O*,
MH]G=ZVZQ3^OU&M_)O\-R="D)(.1'<RA &_GTF(Y&T.D%M=J9HL=_\'RW,6 Z
M_CIMIU(BY]FK0YID"G#L5RD%N- _1&1"84LF;#34%;E^S#O>O_FT^HV5484:
MH8K CP@9I0Y4<L0A+"ZHV6YK[WE1FD5+"*-$CG$]><\6#&:DK[@0D'3N*GDR
MMWK^!<&"J))F3BL,Y?-Z\TO5[(I^LJ(5XT^G9;WKSX'#$^6/&IAB-FPRSZ0G
MY;H&!0ZU>S?#\];YKY95VCF;<8=/242]L-!<?+@N!^<.\;B.A<>JB;(Z5F6;
MC?T^F)Y>'_:/B3/0E$-UW@V-P\.G:O"58"+6M3N'O[X29U@4M&3GAXE$<<S-
MUM;?GBMDO)RD/GM*.N!$+PW]:H[^9MK]%O,@GZD<N7G(&*>I>G9(2;[D<Q&:
M0VL6 H',8D^P#"&8@F,H['8'^50K=COF=[,,0V>HTQ9]9JH95^^\:S&;K4_)
MYI?S*R(3GU2+^S[+F1TW,9BB2@<'KK^M%BY=!#GRE^F*+5F<CSEVKBS (*^]
M/Z!LG3.!U?$J\@YW]S[AG=;*JH#-*7<IWONJV?>-DKXY+_0DLZS-,X SR]O'
M/7$"JJ^DG3]6U3XI4+026 TT.&,B&06XO3R<8#;3+CW"IAN\?F:G#T7E%JZE
M?EE2G7E2T!"-R[_)D]K];OA4ZUG[RU6I3.+G5]^]VSSCIV:ZX2.OZ?+C%\8@
M6L#5>5"BBN;Z\954!F0]T9,4KU"&NA$&I5\;+]6(0\CZDEJJ.Y4G^-_8_QKE
M[&>T2;F.JCI!YK0;?5=<FVNUS"0_28S/BY._]3<\D*\%M;"9,' )QV^$#8Y1
M&)B.?B-C\RS2M3X6599U:8KSGD4%X/:4Q>_SIL97S-J%,Q?H)'_S4B5?O71[
M./<B:HL.P\$0$FA&2G_K.%FBUIF]$ARFZ6+DNOYE8'*1;1$X9[3I@>%@!6WQ
M.6!X"=AMZJG*&H97MGB0?%KP#_/Z'2T=&?L$LT9L\SW_A-'=L);>4I_;=^?E
M0=WE(5I/_'3#$QW^BI]"SGVL[#^*WIK!N:N^ !Y7E2]('B\(&/[ 0EHC5>K8
M+[%SX#UQLSER336^*E>__5(H/_4B/7&LOQOYI3(9$TX0X-R__VM15@+K4)UO
M/696ZVQ\3YLZY\Z,^HXY'%BE6/))[^4KV-9'Q2'Q5E,_A)T5ATV?T-+2W'K'
MS,(LZ/II\.;$NA*1BZ-SGB?F$UGUZV7\4W#:^0]JGY[6S-K%6KK.Y#A;64 U
MORR<]1".OE>J8:YHPG]L]TK/#_@3':4R4,,NUV3B=_86M_4C,=^D?#^LF9BA
MX<K=8[WBO[?MTP^%*0 # J?Q>,^"+X3[2F7.^$;7=* &;!KF(3>L[_=#@NU>
MRL(I0VN=B,Y%)GKR TMS)YR5IU7RF3*JMWH;_QT,P<S) ]!JMUR>5GZ$*9B&
M,?5:PJ)C:MDOFJFLGB/57$V:F[,34Q&Y3/L J+),I8L[B'MC8E+;Q/XVO3U.
MIO3$T7=8QYN=W[ZZ@'>T?W_?-3A-\(['V[NZB;;O-Y:@W=O"1,X)B5&B*$:;
M)-CR\T=C;>1]OHDPYNF:KE?5BH+1 B)^FMU>VC,7]K1@H%$0[)#1!;6H30&B
MK@9ZSJ6,ELJVV0B(']K^+H1]F>CF.)!W4:?2J^_[Y&>Z 9;E6XXV5757$*_,
M#8\(UHF_$E<H&:KC2P&<RL^-D+.I\-FQ2WI=>41-D0O-L!5Y' K/0?UK2%B$
M2Z=9!S?QHI$<1-"_Q3(Y$WGVLL_(3_FN3A1O3I320QZB&04X-5]. 5Q2J6*#
M$2T ]:N?PT"8*<!$00\%@#B0<G'0O^0]S/Z:]VB&KMS"/A\B-EDLD.KVBZ+)
MIWCA#W.5J*"]^?)?2G^^H?[DICX1%GCM9>C>O- .+ %-):\>5/(:_R=YA?UY
M@2<%&/W_"7LE"^(( B'YD+G_D-&862HBOD#%J8SXKL*#B!M_2V9\^S\\F>'D
M3Y7?( 7P5IP\8JG3K2855$?T0>JQ_X5NK9+#8RK _Q'N>A>G0>6N7Z!K1>4(
MTA%]4J, A&-.@4>$"G8!V8[>T0"SR2T2%.!;^BX%H'(N'PS=!)5@00[/E69!
MNS-[QV&TY_XE'6:A*N\&"I"J@05=(:K.511 L:/N2-(@QV<1PB!2A6A))8-#
MZ(,MIS'H$SH[A+*>"76M*^C]9V<$Y->&)FW)1AS<J(D$Q/*1#!@(^KVP*4\!
M)%!/T!OM4)*@$YB\5',%):2'.DH&95$ TF/%\Z@)P[(K,[BVH43$!6K/.]N7
M*8"AVBV;;U."'ZEX7/)/3PQLP*<7R,8+';A>*F5%;4VB<M)WS,+A!,>5H_'D
M@/RIM;:/M)8Z!+Q=AQ3_]^$D7&M#\5)=)9**,!4="_S@K=W-T/I<G-QMF@])
M@>I6VT]Z MT7DSMO1!BMY6[NXK8[%FH].DPY^'YR?.<G#>)S-H4<Y9_2A&1/
MO#O9.%L@PK:(M A)H4XI_23V>:\@& ^%X+\KW$57P[>TRL@#$.Z3XUN(F06.
M^:V&\<!""?ZS'MLR.LS7I)[AYDPZU.Z:)]>:E?_Z\GSTNY=N\E<X*#.QZ4,!
M6 ,Z=A%&V*!8N)#76531U">T7K'WHW=TVV8"(L'NP@].,B M0#C94$&>W(JA
M %^[4)?G67$9B3C6]B;8$QU=%%]1OO=5A:ZZ4>F8:\18+7HQ?7HQ R059=LN
M0%UAX 5$D!?.MJU>$_LE_UU[4*EPX$$@(3/EP@LCSP+7WI_OPT48$G1]D+\,
MK&.FC9Z@VDPHP,J.CO\(R2:7 A2<#9L8&!\?<7$R@,.YAW3>2R3)C-9H<T>\
M/FXB71>N0B4%,E#<"S'-5<UXBVVJ>CP;1@%B]O3JJ&/T"A1U7>:(%:+ZC*[+
MF-]-['"/[UO)TF<$MS?Q5Z#3B?QTNFR?DJYSCA9M_BS6Z^W)S/(584\F<N^L
MMD&/W\2ANRL@7A2 ^?>3*2Y6K3.YEJW!?C8J;'<:[[VN'U/\3'.&WZM#!T6]
MS_[8%IFW"P=9"DZXTRH?8O+&)\9'7J.V^5A!C'O4B_T[<I<4+T7J+:V*Y5-[
M&XGSG>OI5*()<1VZZ>I3V%_\0")*V53%J/'PI?[#G!>:ZS[CJ,6GH:/[, :B
M>V&?O(YZZ/XK(0WL@Z>&QYA&SJV*?=#=8++RSBI%I12=<?IP!ND4 KU<A9-^
M<J9VSM2E!CN8WG;C\/T;D6%]1IZ4QHM)Q*?\)\U9:>_22&R6\Y.9M9>'N+SX
M0M^G+V\S>I_W73'5K9LKV^<R4+VC7%9VJHT^F'=EH6&_/1OZ.+>.*>Y,8']@
M[;":OEB5%UR I:JL0UF&+B+/.A.XRT]7%ZY+M3V/5  ;^ AJOW?FLY(<U=$9
MYO)/^-A5N5ID?YUF^I:%N$V=M)Z%%ZV$P.Z]WH, _!-2,AQZ.V3S#<XB&:&E
M7A5:JE"?[BHZFV;"F>9JFBM]JV0'>9M^2Y,>YQQ$G8D?^U=!1X[.6+)""!^4
MWE0P12W^A=]B[-* ^UTL(T<+[Z3AUJRKVB$K(1#95X3/Q;H\5BW-=M;H;%+;
M>0[WJY8@2):5WBTS<J=Q@^P-/$R<JAB 3=<L&V9C9K;XER8>_I*$1;4RQ6\*
M7=Q>OOK<XTMKFHB*\??/+^^6&;-^C#(XG_HN/>?CE6?7A9N^KB)YR5^:8KJ3
MXZ^%J+3KG1P.TA8.Y)X-2;HD5??R_K+?&NT?3V1//A=W?B'][5X'/AL?1,HA
MRA(TB7KUV-7H4]PZ#V^CQ]PL5Q<&D_>2C/1)8R(R>Y)I1/+$;WLLFFR2^QB]
MR4EUMCRKFJX R?3?<HGO?T,UD>=1;1HMMLO)\6):.%]T,@+BX56ROI\5Y^@\
M.W#ZB63Z2XF'@@<1FN)BL[:KB:&96Y8]6^=PMN3N1--ZZ/<?5W:F-]\69+S_
MP>5]>(1)5AS%T!M*=#^W<-QV8#$&<Q(+ZPB#;L47VU^"-VOQ597D5'RPGX#T
M"'%@> D610LSZ_5\$_4!"EV% Z:J*H;WWB?0V#!]C61'GD=^9:4 ;&L$:9!I
M<<6^ 6<4+XAPQA32QQC<8?7Q$*VJNO>1;F8E?)U@2F9^@FL@\P5ODG.$6AMW
M@RH8/S>%,4K6V%<JW.F9!' T:\?V*I0X^=6VSHL^RY5?@5+%OR_\(07 OD%Y
M6G#^S*C_P<YR0 'J5%\J\CC^83+9^JTQA (L OL5S!430Z!<\"<* -I!&'P1
M\**9@ZR>QU+*9E7WANT^6[L+T+U*D$"&6'.)_4"+;U0_)A5P:ZT;91@5DX<H
M .W$\GY<3'2YCOL;T,/Y5>3DU,;%)>3T_:J;P@5W(B+RO]]F:&!_O0N[#.:3
MF2_AA-M;!<?VFI/Y0!>?</4O/GT23WX%5W=']0K&%[/"H.1>]$X@A/4<!;C$
MFTE.="#-X,8_2D>U<&)$O66L,,X:YHTMQ@6$]ZY/7LKB-;M<7<K6^F2RKCUV
MR_98F?@$!:46DI%G0I S,)QY!5.$:G-C9WVEDT/=V.^X"W*#QU<XBYD2AYK'
MC 2[2<70Q9?D,Z171#FR_(A:8XO74FEXWF&(+WMY5XXY7:WCK.H#<3[VIQ9R
M3&K="';P^W*N('(*PD&T+0U)PF\XC.F8>GCYRU^9T1OROYO21_O^;M7FO3=,
M@*NH//X1YD<B4VPK;TB_Z8=$]X:6;Q4*<R)N)[XVKNX6%UL5:I5^%%@^]D6Q
MET@+NF(G','FY42E]ARQ)*8Q-2:YQ*#S'6S>)?8KP7ZT)=&N"6D)@ E 'D?V
MHJI1T=#;,/K'E1FB\,[#5-G1O3U+PB^,#+J9*V?.+B'G$Y+7=IM_\Q(%./T*
MVT]N,Z4 ;^ITK$=MFAB$G0["\$VDB!8S7/_R:FR+QUMPI'W:[.WKC)*,T%>=
MQ3I(YQ9_T4\G19[U]MR27]Y^3 &J=1;X]4[YY-"/D$^&N'1T-=U^\^!6EN]B
M,R-.X8M8B)O=%>67YUB;D9Q/KFJ5#X&R&L0<HR341D[N#/GEC3+X).,ER-9#
M[&PICVOPW1:Q#[79$CN#7F*>PQ\/.15MM1V+UQ:XH(N9Z!-D$:(>CBDN",(/
MWMNV^*JZD7C1-,1EY4.2I)?@58%*YK;U"WTK^Q7QI?L$/)7%IKF#Y5^@F.>C
M5 8S43.Q#-E,QCI D]$0Q+DE^8\=QJDVS:,O3)@VJV2#G9+T$<?:-IV$KGM_
M,/@<SF3%HB#S*N839-*V&RW4HJ24L*=PL>,3$FA(+,KL%/HFKB,CT'?&$O?A
MFE>_]JF]#A&1T(9(Z&*VGC XM"3\T6<IN$=4HRMZ;'[:X,/7[S7ZFO11B,]#
M0D]M7R6FI*H,M]93Z4FZCQ$UC*H9"PO7CC4%%>[-9:163K].E(B@*D^%"Y^L
M9XXY'3_7<PDFC&JCNCAU96<E<N,:X@*A NM/\M;T3D4R/;KZ03-2/I;MN2WT
MDZ [_#GN&;#'RU)XY6E \JSM&5<I/D0SSF>)(P[)!&*VVW/.CCB:CI6W]^K=
MP)EQ>]RI:ESZNKAS_H0^S4.Z-0[J+&+-E4X@W+$#+C)8:.?VL8WS%CE?X]\Q
M;%J(O-.7Z\7*Y[,]ZF5B,%Y\Y PE\JHLVT;HG0E)^U3OPCY^AV@0GM\1C-^Z
M9/[4U(_O&D>F0 K25KSGI.:BG\B._S8$:ZSABH5V7S&](W9*4NF&6:T6]#4Q
MRFG=8DIVLR_!=>@S0HI@2>[3DR*E^^EH06+W7LG;A@?YB7&_?6$^)-G3?/^W
M2ZMGM\K751%;=ZP*GFD,Y9G,UEJS.!1+YFKEPZBUUCQU,=)]EI3=\H'W-62+
MO3]=RM%+L^(!=9A[.4E%V-<>N=+7J#2JG#J,D1I5Y&&P4JLGK3#7==>9*MR[
M,VLSJU9;W_1#O#Z'5'1N@Z<S.ZF$QE9,L+:^91AA^<[G,!D?]/']L^$?*M];
M$L\D2GJ7"I5P.>K8EH? R<Q,864A""=GA-T(OXV5E6.XAJE/J>>*Z+4O*A)B
M_GT7C K#J<#-H /65!"52+E;Y2VZ@8?A0[%!4L._E&[>2^WQ<WT@>C5)/SRN
M@ ($5F[WM.5BS2%Q#ID="]./.K+<-.!BR1BK0Y<W/LTKSYX%T+F^_?Y,D<-)
M)1FC=B[=?F35?%RVFS-7(5F#E >]#1$F#\Q+Q?R!<RZX9S\7[</NT!<_/?=N
MG3>6P<[-78!6F4,\$I&!?@#UY7A\?T$0[0$1\!R"KZZKVR27K#WF>.'WVB:0
M]:=S<,_OIQ/+Z,VT!TNZ4/Q3+,-$TNF&!NSH^=0^?[5YG6=/Y078'F-/F'WW
MD_Y.)XG+&D_W"U'?OVR>>Z8LV(6/%(TPX7CH2X3C5#J;H.U0%B?E\I;I X^/
MC;,:'(IC>K>,V>Z?L_TD[:=5X82%$+DMVJ$"+2K^Q<3SX-Y;L' KJ<\Z\-()
M(RT925@M?[RX6$G HZ3TO4PB3T9'F\/^9DW)'!A-'A>>>7"J&4OLESNH<>9C
MX3LY-I8R<U>0!@E?HD=0UQKZ!TF;(1L8R;BT\(>U,^[!+(@:\?3ZR%"_MCL<
M%WT@/EK7@KCK$K5.%>2[+E<DH6LH0 +: R:0>QSL;A//N;SK"_>UZ_,)AES$
M:=&)BQT3/_N+T2!T:!-&$)A##F<->Q^.%S(F+H9IOV'H.+.NN%T J.C3>DA$
M?K@O(!S]M?.$7C_5TYH]ZS-A $*AI(4S>P/*941_K5)X7,OW/5LL1[Y OB2J
M4E=^46DRDVS>O)1,BAJA /K>XVI25IGJ X-=AO>A7BVV6+1Y\B(L5H^J<>;[
M.Z8#I]GGTVX]EX5[2SY<MKD3$.$8(%:4UJ=V((KKP-/AE#X-14\7)=0I"8&V
M-K65GM9EOV>>.& N298*3 N=/<ZZLOM5B.1+RM<BY9"E'U& BZW%,]"=-064
M[EXTK\G<6Q^'SY][3+';2^@GU-ANZNG0XQ[V& \J[>ZTP2[>./Y^P/BZY=SS
M".VLPT>="Y7)D:V<LYZ'1EW)R><U'B$L2XQ^&!1.>8YX,W.E1>Q<$54_J27\
MRMK$INVDN5XW=31N$(]7@0^P? O=MGR?$4:8'SZ9KR96XP9%"L[)DM>FW9<K
MGJOL&T*UT+[;_,Y@/[X43 X*TK; Z]J8J8N'2MX''\O0O3[@P)CHI#F6)!4:
M"31+NG_.YY4>G205H6\=>7X]UGL_8"8DLUWCN$2\TTAZ9'?/K[)O+Y_WWQ>O
MSF'<Q,'.3_Q";U(9GQW"DQ2/X'\#ID*W6-EA[=BU"9<;#'%ER*LWC D;M6?]
MWD3XU1U8$!3)0T48C2U8(4)OXL9N66"YX5+=\[8#!WFK[LO0S>:\GAXHU*_V
M6GF0HN]7\YS2S.)9Y!<HUFPA%B)*A'IAG*T.%SZ1!5N<\34+GW:=9XN\7!L8
M4/<?=&B_-V2)+!#Z"J93'77+5[W'&A4-X29"<19VWS!>=9#C:UL\H<_D6L[9
MI7H%GT ]WM*-7HY 444:53J*.%%AY#E2?"/+M:[P>VN&KV]AC-S7EB^5$N_/
M\RI'<MQB0 J 3#U9"QT002\Q6>SWWUGWZPJ_-/#MOOEUOI0#8R-H<ZU#5ASK
M+6M>Z/@9+^>?<*8,91A$W$+ AH@*%<(>%?@_\YZHRW7$3:(+!4BM6?8[1@&>
M?-^''8*A_4S-BJV]*^_RXGY_N?"W3"C":X3DG*,;.CA"/+2E$D_U-7R' &D8
MJWU7MQ3W",\!7<M1W]LIZUN>OX/*#27ECG3/"-]@!!)#NK59</Z03H\WIHL&
M%MRHOSRC1__E&7UY0TA,.VIOC;K^]8RC/8@6_Y8G34/])4TZ="#0<IJJ1Q73
M]JD4-GQM"1T;Y;CHT3]J:1 F#5!_-+3#IJC.-"657A'5XKL85GYK?=*97<S7
MP7B;\_XO]W///[A#0F0UV[8&_RC(+Q4RVPPQX\5[$,^CEF%$4H@M!6"TH@"X
MK'P.(M?J,OM>0:90. 5X7&>06,];,];_ZM-BPO-/]&$Y8[GU1<2N,*W[>OIY
M'RLP19L>N.3%^6R](HP%@XMB"DMFFM7(O':OA/[8RCD5@8FY]HDXF[@K#F]-
MS?QX+ VN_C,?JW+D48";0P=R0D.DAPL4P*C#Q127#<4VZ'CEH&?X48=:I>/H
MFPL'LM/C(9#)8=1/T*</J8+J<\*]I;*F.]3E\>>/]W840,@EN@+T7*9.^[HR
MB_RE"\.VSN-EM?OHFN'Q'Y:"+:,B!2=6P5<1DC)XQM8,,/S(K<&'.,?+OK!V
M,3DL-#9P]&G[/M_YEB2N"S0R'7V?ZX]I:FJ>RK-*0)Y6XU=(SO"LJ(*C%ZGA
M(!#8;//AXY@.Q,NOT/IMKG7*";X;)<SG7%,OB!4\O+YG 4KU],@+6^JFOWU4
MSFBV7G^^)'(^0M":">H4-AKFC1JPK<ET7?&6;P0+L48]N0Q!DE4X=%0=!X>I
MA'*7U$#8ZY?O-1X$R)[K2TC8<DV(6]JX/C+&6;]DP'/M[U-0M2T:>16Q=?VZ
M:GORHB?](#=;1PL\MY867S;+5=$E?=JK*$%H4XWL ,LQ6UQ#=M_4AAC6IZTQ
M#S+VZQV:^WE*7[K;WQ+?.7;XR%*V&\HM:]#ONG)%GHKPGDI3"UVP&EA\&4(+
M,S&R,JITQO;JD]JI+#MB?<HRD&%]4"/LG_2\XFR)F8DSUUCMS?_4LY??FDIJ
MY.4J/Z=JZBS'^?XEF7MM*=KT17ZTP+2]VXTG0K)G!LP!($AR8A3"AE[,ILZ>
MWBFO*N_,+.O,R-HB"XTML=.-ZK].!)WFM4G19-HN(3N-7K%,JG:UO#=Y<"_N
M,!4R&6S>.(:ND0"IK/#%=D-LIX0S5"45N'K_1KWYV>,!75?!4JKQ.' ,6V21
M:Y79@07S32/\4G<[ K);.+8?&-A8,5E=O''<A%=OF+_N\TH&7L\[[UED0>19
M(TL3AZ?_V[2T[4UL\I)%+%*=>&$8(;P4'[(ZML?O;O@BSH!++N.!Y!W1DA)F
M'>Y)6F.FG^AI83)SPW)R! 4X_DO'G>]#44C1'Y4LT\]L_'6N.9Z\T7K#YLMO
M^L3.$X8!#32Q@Z,)#O&AS_*FFXQZGUD:>!K_=YZFVXXOL%& E7[B-?+6:L!Z
MW5%.$CL$Q7:195:2,W;131-JX9DE:D7-O_6,_YJ1;*)221C'+3#J@;_W_!GL
M:M3WY-O=.-Z9&2/UK:EIC+IE8KYV'&DI8??Q7!W=T[S6;BH5B;0ANH[>66RN
M'45(!/OH^)Q1:2OI73MU]G-U90P]9^2QC10[%SWJ90'$2Z#CZ_H&S )/"*3C
MT*$QUFG!>\?P_:JF :-(S0GF3_3+TE7=+M/"3F@/Q9[/H]:)5P:\#J/&2F8O
MW1=/S^/G&W"0O9^J<5*<JTB0_F%;A3.H13CKO2"2;5Z'74UH$19K0%2K.HB]
M*6[A1Y^\DYAC2;]U<=+*?"2G1TA+IK3:"GXY9(QW;R*6 BP^1_/J0/)GUZ=_
MH1=?"9LV"&;M7QUW..8J^&EV^P2=-%W:K&W__%GL-&C4:1MZQ?OP=E/]=Z.9
MWP^F?>SOO6DUDBM8UM0)8GSF(8@XXZ>H_9R*X/8G_^YAD\/PYHC5:+F"9/,C
MBZ0'-J>;F^:^7V2F"]NR\<W7TJ1?O,L>KH#=)C/CEG/C'>XTD(_C4!%$(Q]6
MN8%QH?[>KS5L#T\=:#]-R1%@6QR]<@5Z8M2I7@^6U]H/!Z4@W056@P^6KE]5
MMJ^3O4"WL ]=Y=VU[81%^R-TSHGC,J.(%MI77$.(VF%2$YD1R%L_U"Y^$/A<
M1?Q0*)22V=Z-6?[0^<V ]\W?^AN6295V4_R=N;52)1#FD/QV9>\<TUF3O+EU
M.._O<Z7/SGQ[8)2PM<)U=N/E[694[ +6;"@>RDID+0=K[!JQ&VNANC5SL_&.
M!V(7XR>\GT=;8,Z/FQ=PUX2F]Y^N</WN+5/1H,-/#<!\,!E3$:,^+]XT4?N*
MV[ZYWC$[G.67%EN<H*F<F;A XE#_)_:$ET\-93_[QW2VG[LW"2;%H3'L3%>Q
M[S^^^]E45SJYGA4TD)%YO]HUT*J[R_FX=C0]DO=BV=.\.-F(O[F]IN$/]:?R
M/%8\]9KTJW30A\1$0#U.?A,:@<;^0>4CQ#L@W&-9.#','%N74PAY]79Z_I)D
MC848TEY 45V"+5TG]:Q_)/OE(@'YOJ1S][Y!Q"R=+;HXHINVVRB V(8>!TZA
M>GKC_/7YZ[V)'P1XV9)BFJJK*W7N=H@'OG<HV1\[JIJ\\?^U9!?5)PPB&3G.
M!5. HIM'-9$4H*X5M61&A&XD?CLZZ;>W8Q!PDP)$^]AB6/Z^U$E^CLR-[ U=
M[>XK*R/*+Z/HYM;W;4J#22F*I9+!_L57!\JBQ>R5@QFDA2W\O-VE1.V&X:[M
M,A4UT"4JW@M1@-6-]GPRQHJ &H'LQKVA,HF-9=Z]9YGG@_8?UUD;3ML,V2H&
MT]((GHOJ7=723:[SV"K>EY_JK]KAY=V"\D)=80DPQMJU/2@7>!JG&JO_0$U!
M=[DE4E74Q?!)=C\LF-5%P4%6UON%@EJCI0'OQ?_T9$I^#4[5]I70I%:-$%^U
M"J:0[+:LCY7,JUUB)3]\;-W9)%[0VQNN$$2+Z,>5MA@(/,2+I"RB]$T,A&\P
MW^1F6&@])[OZUG?_DXDK@HQJRYP-6AOV!&-8QF%ZO[Q+S\-O+C%8R*+'$ZAG
M<FP]D@/;=%%)*O&]=%/3K<KI3\_GSCRFO<LJET!KXBZZ,0WU&@*E*Q+0MZF>
M6Q&?;5^%,WS(D](1KE:@Q):1L")7(^_&HWC1CTG+?3F'R4K.J7R=1:$T5\[R
MWR.+%P_]- 2>MDAJ52:J5>$2N]%OP5OL5IS^;Z>H'E<]R$E(U9L]-A8ST#AK
M++YX.^]: N_*YP1JF&OF-:&>Y!X/&GJ,U!EO@6!,;WJ5>ZD<<.?5?[\3T;L>
M5BHA+_NI]Z93E_5VB>3?N9MM*X*#E$!T)%S\^6.WC2R)31P<]3]H$++N?KL6
M=J<Y[I'D194(8Y%(HP&M(3J?90TB]SX&]2DW)C0W4<=([]'IY*):4^7)^3Y)
M=$OZ+2?91/V#5V&_U7)KHP[@Q4[5=9N($0,>F\=1_W&?@#GRSRKMCLZ%O64(
M.8'W[VKR_N[99^[!W60*8&@[1-:D "DCG:(4 '/3?X3<I!9@! X?"/4O&DK]
MX]K)(#$:K [R_*A';5IG$T<THN"XHAJA*%*6^89ZJ9R&SNI+-KK!\'/Y%*!-
M@:P(QIC4C/X>=&P[C'[U@&L('NQ;:B)IU?V)-^@FWS'QU5,UZ<8]&'>9#W<0
M*(/P&'_J#->":(\@7U__$O \:_;+@[/]I>=;GLL=_WJKK\W]BZ[1NR]*3]"+
M+]!B+;IT@TPQ9]1&_\@0NEW$?(?F9=33-] +S/AB_"@%>([\XIR<_JX<SA-B
MX8C5:_#/!V.,/W[=<[Q'7^\0U7Q)SN/IE4HF^GL<_BXI6'Z\QP25896^V&PY
MA^%@F][@K&$8#O+5?]W\POJ2H,2%Q(^&82()(@ELXTDF\M56OI,[0O+K5 Q"
MM:DB%1':6)=F3*+5:H?O6\_Q:[#9^/"+AD][N%3JO]X"7BK126CQ[D3)?%$!
M[30;?U%]P^X?DW;Y5M ,*]RS(%)WR74QEPWF$R7L-F'YMM_SN JA+_M8C$B$
MHW2E:K:)<S1!A)UW"U+;L-E00>Z?F!<<:3$JL5L7RJARVT_FRQ'-;Y@FW(??
MT,AY_))F;\-%Z8JRE>TEKZ+;_U SM-:3RG<I  M\B6R!,^@A-;,<G#XZETRT
M1\<0'^T:S)!?Q:@-7EM^6*8G^+\M3H#I(V1)\40CW'OK>FQ,8@M[R3KTMF.Q
MZMA8@>/SIUM]G@-:!Z: <2\3^H^!OR@G!,$@_ 65B>6"U$F NO!"]KDR9\C/
M*<!+&P04:XI.<(C.:6AR7WV\%RLL[-!CJWC\@LZY!*5+5#SQ#O^,O[>)B#&@
M2HXN^!0$L]KFR#^J8[]8NJ&KJ >SJG-KKM=_2;MS<4"B;PTMZO.YMIFS>/U^
MAF\ P]/&%Z<T-/ZPD6DX*SP;86SY,I5F4>B;B8FSLH./H75>:Q-VE<C-CVE(
M4-76];@TH2-8NJ;QY(?C_)3W]AFK]\:?*^.94I)=VW[Z+RU ]  P%W\75R;&
MCW/+X/*^9B]UJ/Y**P.J,/?5+=WJN*O?N1'><\6"VJ<U!*7N)ZM3^=W%B__8
M"1:@'NC)- QJ2]2'5/AZ[:N7F,A!Y$;62"W?<.4=WGCOFL_W!-ROOY/3O^%]
M5*O7G18J\>EG11/"C!H\B6!VX9I20#Z8W=$TAU%<=FUUO!] &KU]L8 "M%P/
MF^@64Z9Z*W:W<V)>#*>8'I2W8:/T?=9^KMORZQ[3G'$;F_(Q\4A]QK=J$M"H
M)$O_.8':?T1X_[JOX>R?M19_[AOI.=K\\'?XHHOZ#P4".>+;%(";-2EW[ULI
M5SV1&NH21;':?Y8(%)$"O3O+\ZM/_OI?.^A1Z>C#9=QXOFY!CM17A,IW<7__
MBCD=3F-3FCI[RP^K.HLWQ+PT?.U$/O+B&:EWIF\ FS&BIX>NC:C!F=:%@E9,
M=3_.U9=+II@* ]9CC^W$'[V,"^\A<HU@2*_&ZNJZ2Q=_*OH%K'0HEJWOW'BG
MK1\OS9"IN2>6KQ7F'=Y_Y& /#,*O8>#@:7A/!<>%7?VE?O8@;JGH%\7MCH#'
M23<9BZ^TX:4_AOX?H<96L!O&*M75$^CVS>7C?QUU)MZ!NV3F?%S TD+DW@*/
M=Z:>L*^*8746><5QG4LU6C/E5?VC$_1+(8*"O07K%Q4'U]4$U0*3GU'7HZ]/
M_W&I1'/>SZ:8)VIANO)7JAM'Z[3[;%A]M.T&4@<E1.1*DDRD*U^S7+>=T:.A
MJ@4+A W.,(6=_+'DIPN75^;=J@_IOQ2O375Z7T4>MWC'NPJMY=]DP!GAP[])
M3FR_KL9)1V,$&T=K3<3TO54B;B>.V1L1+B@G*7]Z:2-7)ESMOF,B/WE0'2=3
M'OL/ZWBHT(->223J]="=0ZV=K4CUV4!-+^0^0G'T"@KGK9+GHA I_[>M*-8V
M*9'OS@S<!00EOS*-YDA2*=GQ2>SS+RHX/L0J^I"G;F<LG( 9FFKHQE.U*95^
M<ER89MC9N.\B">>:\T*:AK_5-C*YR7:K>S/*<T5"D,5$LZWGDW6BEG18L*)7
MJ1.!@\R\3W"'?K+@33X64H)+[B#=NDF8<DQ47*K465H3OBMR?RGFHC">#_^Y
MWV5XM;8I6IBDM\,M4F5,UZ-ZYZR^Z#%Q<AUQ9F(MALAM@?]"^.,^E*G%-YPP
M*@:+WA..AIRE +G2KK.H?AW\Y_L7'OCSP F]V5;%>/M=#R+/:PK0[1:R_!*C
M $63--NVR9!14B+5S1^U-* >MBK7NO@MXX1-I0F)/H#%F%BK%G7*GD' @621
M@)<&1?M'9>:Z%*#C,*>#S!Q/N&1'E 0;4$O.R(,S""BF=SE:ZX=FDOR*=)\D
M!3AV]]?CPV=#=&H!\>D,?KW/FZ\'ZV4??1WR*XR7 GC,N7Z:R*'#J?S,,JQ@
M&+4]A_)PF*W(Y3:\Q)<A+7>E?T13FT/4!S,$ANQO<5,  PX*()-%9<D2$QNP
M+5D"]"<%J"UJ;Z8 3-XC=8_+3\W9>9L(I)3]NGHBE4'23^"VC5-":26]".=!
MF@:1:QL#C0F2C\_E Y/;R6+8H%B5!3"E0LAXJ<'%?ERYI*OJFZ.G=&)[=;Z<
M4WVJK6JQX#Q.[P[X 5?:C1)M,85C.$0V(#.A'S_F3?;XX^T4<"S-3>\G+7F6
M"@)258:<:.R0S#ADZ2('_\]YR:^_A"9LA]\O-]<]"WC"^1!(6O>/U(XT"OVI
MIPH^:I_>3RJRH/?R*01-S:)UM<T4!!SC&_,%"-9MG^94R^R_&-%$)O'8?D-5
M)V\N%X,:;=,48(MN&<8VZ_13CZLJW.+BM_=Y;N<+I]FZ5([GS:M/=U4]2DB(
MNA'FE"^PWFITWMP*ZD3D?S\7DMU^7KT4]=8LSYL_XZK3G%<PD_+4%5QIK1)Y
M.*-M,7 -%@=KB-G<HP!L!-R,9?W(%C&7U2>[SDS">TG"T/7'!6WDU@ZP4=EM
MX7 ()3-G$BS S"Z8$ *V!.59</)>[4I4;\ED4UF9?R=VFPF;WPGT&.Q87A"L
M*$/Y64RUD+]1  ;%3=5)5SB?YT"0J.AS8-B8)Z9A-I39-LE8^+$;MF[U(AC:
M4G$[R'2_L@G*MG%X!H11 ,F1=AC^6"T%^"8+^_*C\.W<S\.HKD12V;A&_:];
M6=,_5$12-#7E/E\0?S0Y\9N&H [N7@%3L-)M0C]2@D3'6K+,6I0?:YVS$/%.
M[>S046ZJE)AIU"JO"COM<>D^4A(Y!MD)@/"B-CU'FU$C ^G?Z_ 56TH$83#7
M!)S"07MR5+(6.A;8'<B[=F9WG=IW7 3C37D+6[0?J6YN2G0P6$;?,@8:NJRG
MS*]8VIQ-]5KGW4972;<+6\11 %'5@[HA1:5C(;?Y<8P?_*&'A?4-'0RN(VP$
M&LC<?)CM8_NI66_;I]/3^E)CHU\DX@2N-O=V+LJ]6TD-8R'Q4?6>/PZUN4$-
MPFU<"W;-5GZY@N]C;=:L>N^0OWL1,[!C#+NLZ+;\4#6"-#MJG2G78'-=(AC9
M0X<K[4)7;_>@GH3V)"+TERE K/_Z^;2W-Q[]$?/Y(2<OERH#,PNO$=+<9"7-
M.7,S#<>/]P4Y<;>F=]MS='%E^Z'3BBE2]55%E^L3?QAG"WY^)U_7_FKNH>Z3
MBB^',H'7DA7F'DW[A$&&%3_D386D&8RJ)EZ94U+=(#Q0\/-=$;2_%23W,SPN
M%2I$#F_51LBV@B=Q 9UDYM8SVP5SM7<'EE^\OB$FJ$G^?2=QTT2T%+^--\61
M*W"7\/Y8_B=J/T_'V#:/1#K5KEO_\'R5MSM$"N1\HGN6:/L9AK6VF*K>[\K2
M2\-=Z\@*;&@XO Z[.;Y4?_&7K[*#+#[I6U60:]_,J;2HBT:,8BY?_-C62L4\
M=R66(%/\9/-'2QZD!!O8H9K//F19FI@*$4%-LA H@,D\^@0%<-4]O6M'*FX5
M-'#WE1I]NI&QKWS&V_&.?V-PP$_:8DF"[2^+SD0YW["EA3C5&<]IQ_A!N?5Y
MS67"P!"K#-ULFFT<B#&#1.4^@M8H$5]FMB<3A -S26?BT&$Z#RC *8W8FA'"
M^=4BTCUOXBE2^F]14RO2.SW^R>G)(;7OZ">;TED,"=M)FGY<)B]B;L0F]7R5
MK9A'<:_M>,\+CY6]$<SZ,>QYK6C>33QH7_56JTR4Z OBPL1_+(^0/RJ/0'(Z
M3P_=#%*K&U!VG&W?$JD<*'119V*P$].G/Z%?,5,!2L<DJU8((3_G<-17-B4Y
MSG%IJ<X0[B)#)$T$WMW,Q5Q,X+@[W\GNCZ(]%=.)]$.UF:"/:NXH@%,M>>'W
M,L,MY"<W*K[?0*AWHY9WD$:DT$'8%?(,NFHH@2R.',D:2I)*[3$$_1_X^ 04
MA^3M_%*-,8L3X)*]U&V<DKO_P-I:._Y=[RI\B*KV#9.F,[=R%SM>S\R[K-4'
M!V?JW4EY*'F_E/Z-6Z:@-529[HO&66 E8=;ME2CDHH-WT0#)DU2*6IE"RE&
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M86+98")'4]3#[17?LY\:S2:].ER3J ^/*=PE)!.Q,_LN9#G'CX.MQ0=E;(9
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M\T_F;3^Z]O_<R+ON4H<;)G?_-32X1SP42^8J5VM[TY5R7O$6NZ'P_7,:8JB
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MBZD ;=;!YT%'^&N>4R2Y<ZXNW'."5FZ4R(3L_V'_\^WO'O(YUU^/>:N'?RX
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M,C/3DDY-%L+JZ=(+8U5JS X)C6)+4;'+EU,L1?"9(=*%A\!DT/^# 9_BC2X
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MCZ)>,+CO4TC65HAAQ5LJ%[\<C,J>(ISCL9.X-5H7;ACCZ8^UERRZ=UXRTWT
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M>&?1<$HF2 5O&PP/ZWRGH3N2_XNW]PQK*MK61J.HJ(@H"$@-"H)*$ZE*B:*
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MT-I+_AABE'.%^ZF;A",O-[ B\;G-B6="._C]OP(DWCM+@3;?N_Z RTE7N#;
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M[HX$\F>D=;-TJQ)T4^^^J!LM&2IUYNCG/GE=DYI@L T')*S^B>./_XGC9!-
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ML7Q8'!062(*2,P+#A!-6_WOU$V%'4)(?NJM0R%T=_SVREA6XM/]5.Q#8GEH
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M]D0.*VP,[#WS?@"7P*E 9_[CG=:_KB7[_],/^V]4:0(=&8C#KA6S<!P[A<4
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M.7UO0P\"?EO&5\):IGQO##\C4;Q;3G)TN\GVA+5;NGAM27\(RMH"\#17(-*
MHK=J1!$W&["]H$3]+7@N:?_16Y2<+O'0JV%GKWQ?_O!WI,&R)A/JZ:;J>'Z8
M&G!K14L*H8PF1+Z&59S#T=6)M]XIWD 1&ATXM8^<4( D"W&'D]3O'6I9M$+N
M1]RL!@PIZ):F2XW5'M]DH>:OYHBGF^4><D:.<PF%)NG5"L=7M9C9J]177&ZJ
MT5O/10ZA#C38S$2MKVF=#;PS?ZVQVBF+HU?WE',<CE/XS97C1\S#A.36?**!
M2);,6'U NX(X NSDC](ODV]>=8GPFDN:L*7DS]1F^.E:CLI:6KG<NK'C]&O?
M1:[O!J&HJZXEUH1<H<+W5WLW83Y,B"L^&L^&/(LX2I&+(9I$C<O8'BIX_.W3
M0)6:G-P/*QO'C9P[/:MU_'_& _N,<_]*4UW)Z' -<]KM1:3D$%TG-Y"]&2F
MD]DZWQ5;-1$H?^[5!8UVBV-W]<7?/9TX-"QWR">6/J%S[SQ-K;:@[O*7GB%7
M!GT$Y9H0=G4N ?6IE^+8#!I-<MO]8$)X1=);ZU,T@II>887H4!JL@"[/@>*
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M <B,'^(TZY)JU_+WN,[%R%0\%OL96V!:X8&W\U>UM^\+5#F3XC0MV73,)DS
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M!L1Z'=Z0A;/!;P"]V1\VU^LF7/55I;_DQR\_#RMYVNN*/N7XI;?S ?R?A(2
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MW'F/(,W6?50'*[=[J-!G^?S1@.S+"U[E7KE"C97=3F$L^3D@ZJPCIA@?^EF
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MNYL.UBD '?X;</I GJ ["H-@[5MSQ,;5/2=U5G;,>'24Z?,9CK[?NV@J&[?
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M8<C3U4&@C[3WBMP0X05+(2/8RMDB!DYN2:0,MS<7#G]U3K_3WZXD6DB$-<6
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M2B^80$KI(&!8J"^.?W4$S)](!,SZ0FX+:<\XTOM;# [Z!-+XKU?"*9.RI1%
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MU<;L-I-/COP '(07M>S[8L UN()H0'(X6%J1>+2+#B:5WY[:H]6%1"XA3]G
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M"0F ;(UA\7F;4[$O?CVZ;0>L@8G9.;VD>;P'"X!]"MA"KF/I4&+DM3[6<TR
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M#39B1EY.PEHP.V8M?@8H5;^WF1U^D^+\6)%0N\WWI;A#@'^?MESU#8[K+7O
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M*1X ^*-'P)IM@"325JM+<RW;:\F$<VE=KVC/!B=M_:*#9\<NOVGL&>JV5VR
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MMM-&UJ>4*><6EDB?SE(&"%MV7])132?O;\?LRJ*3?R&+ROZ6+/K)CL-X!<K
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MLS)B%]=*]0C@URSMT#7Y,7N9>RKP ./;A% U$W@8-]&+X*?XM!J'2O='A'V
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M5X@L4'4;)0=U)S.!KZ23=045E:@"UWSK(/#O5/;8\W=B?(7:V&<5W@!T6W,
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M'B;8L(; TC: B<W-N6W$)G+[1_+6XBH%N<ZP$$Z."*&#L32236K0*NL/Q#-
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M5RP'$AF2BY3=H]A-VI^6%SFYQT%FHZ,T!B1]AV%<M[N-3D^>6P6,Q 0RJIF
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MG%",VR(6X"1FX@X@XLM#"\,8?2B<ZODSI4ARN$8BOR*(RG.PO_@^MPA!!\I
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M&[[D[W1 =8.R\I\7.G-TS>49K$'P/LE:(\+%!\H_" ^\\YM?KU4]TW,U$:>
M5#)=!)>49YT%$)V2I+.[E-S 3A Y#K;4^!/I649@IK'KJ)"=PZ[LT@88SX]_
M>0#60'/1%T,"%\)FDV!;-G1@G8<.U-7LWX9D(?'&R+TR.K#+QN"GXU2Y3P3)
M+J<A$F\Z%L+N8G#TQ^Q@M;S0]I325,&3\@<#G4IKTCC9Q*I*U%,"Y#4(;Y/.
M(,R'L9?@>Z^Q.-#VKO\&%60P4_YZ[Z#I9C"(\-+AA# =>.L@H4H'P($.C-%L
MK=WQG..SFU4!S3+^=]-/$T)4MJ<#B[_DB1)(B?_DPT0;PJ&4=J@>K.T.:'[1
M';;JP& L@U48,SK PEBF-"Q.F2QH1P>N/JCPI+&WT0%90S<&V]XIHB7E-H))
M,I*43!XAQEO1KC.S;W78'[D+2TVA-(/NK&P*TMA[9D-AW+0?XPY(MV.)0='&
M"7:QS*(+,>.G9G;7'DC&0)MM?M,!BL"Y? 8(K\*FI>Q\Z";527;\,4R&L5;H
MJ5+G-,OQ$N:,D721RGUG)<=M49><'0M)7Z:OZP1M;<9;7/O<DSS/_VC_ZBA9
M'1()KZ0#XR!L,4V ^KJ605Z.'OYX0W4S.#IHA3HU2EZP>6&=]6@0NB0VC'+C
M3+]^T)+7?M[G4&EDFID^P$]J)MNY0,^2R,YSX'%Q#E!4<DN89J'=FV^/OL2;
M)N 01S8]V(;,CFPC?FQ,#,\9%V*1SVIS6?$=@@1$I_P(?CWSA'O-,Y]C2C+$
MFXG2"@9+;\&NZQ6@QS,\9N0+=6VOV-5@JY#5KGJ5Q+U9#T%=&'(!2J8N)U@2
MK;-7]OC5T>OP).07Y6X,B9FPU6%P-L-1('F(&F?M8.JF;7KW*'/ZY[67W&LB
MF(VG/@J59?ELQL+65B\OK<OOM1(TXSPIDG/7;2Z/WM=HS'WKK_AZ1/:33_=O
M<1@K*](9-IM#!T3I -8+.M!HG[0Z9Q_:_M4OM G^=LZ(#IB\)$SK*06?SG><
M;E2YV6AE?,N)>'?G=!AC50X?TZ(FT4YMI4S=W451D';DE*V5H98D1 YR]@.;
M9"6RT\&;7&9 H@.9*S!O6GB(#1<HV:#H"DT *J:AD9.80$NK1NX='B-2>V&+
MIY#95CEBG+FCU-,N82ZUT76OWN#$8P(=#7K0AB6N"6<1:BOL\KUA[N1;86=(
MWG,O9KB#LE&V#BD5=Y^2C9(Z0&\EMN\*:EF-BMLM&CV@ QU>?\WBTX$9,!WH
M'-TT6T[5ZVM8OTU9#+M*>#9SK.54$+Q+4'BKYMV-A9OW0X._5.%^<?U"U4 W
M2<XXYRB::I!CY]JL\O&QH 1[@]%G_2[USQVNP)0#+BY;-(;8;"T+G6<1B_Z!
M@1[7\&GHMU]SW#]*?<-P[9QC>+@T&XU7419$8N.'2M&&#26K4[I2R*+^GE2%
M#*0WS%G FIK;(OA**@]?FW$K.C7EBU$"18?ZD4$[N:0)CGITH,NN#+;TJ/KS
MC%B<'=9DU695$">?(@;M@7!O>,##N\K3EY)6:X?U>.G O-;P%L)_%#0O&#RQ
MJTP'WF?M.=..1HL-TK[M\UWU22F&J#GT+?"N4&='=S2*38>5ONF"TRC[81_K
MEUTL$*I!E+,T=R2GS;8Z7I9F"NM DP7]-JAGDI&YD Y^*M?!%*9)XK=H75.Z
M=, LOV(5TIX<(EK5\"%!_KM.^T$IGE/_58E&_O;_ZDPEL%C\3P!R_N],OI7R
M2)5L]*3)>:%N;34<B?X7&7PL[$FY8"+E0!=?MT?\]SHLS(0BVI$>.,G54P+V
MJ]*7#A3^K"$K0F)F\-= K"1T]TRU;&*Y'@^!W3-.I""$J_/+LM<B<?QMEG+-
M1#1OLM>M0UUV7@OSW5[7H>\8_C*"^I[Q5,A:%3N"MD\NB:O0-LJ!,$:D.-Q-
M!U(=L8+WJ%66&ZC)NC5("/2['!_1E72M]'Q^NXXILQ#CI=,JV]RBL7?A-^8T
M(RGZ^#&*/^'QPMR]0$'-/G>Q\<.Y;Q2%+;E6N>H/[S[R&NN>UL$L2ZXRD,T9
M##X[$=;% -ITP,/[)MOW@RJT= !8DCQ!DX'V3_-@\M/<1>T(ZOU)0X8G33:G
MS[;)F1@+?].2XD6+22;HB<Z!)6!MLC#7LG(^.[,=..#Z^QK-E#VK,'9.NO'Y
M\<MH7MFS8/N^=Q4(2#AT K3I!?\2L4('^'.:8!-:=  -[K0IA6(DOV#B8&X\
MSW:A@J// D+Z6U:2!.^.-9ISY-R7T%:IF_);-.:9OBW%/!IV<FY-$C4M.$0Q
MP:Y=%K>Y,JHXM#RP.9F6UMTAE;BIWP9$O[QXJN4!QH3BKMIQCX\."'SQ>(><
M>[1# *W*DV^2XHBRI)Y2RA%2ZZ.A)K7=/\ N^-7@AN1A)YLEHDNDM>QZ4I]4
MJQ)X?!_+Q9CY:_@^YC:2C0J;-AOM#'@H0@=,.HN)W)EY#JE$=-K+=GSN\2\N
M$-CM_LF;D2L:^J;H]<5E4].Q"+&T]]PUFS84/E4:.\\LG"M,>]" )\RP^46'
M8(BCF4!JA?UY.]TW\Z\+>*]13_HKM:H^$+[8Q]J],9) V:<B&#'908C4' Z;
M0\;L6D^S$V[-]WL7?'_F$OA%HN"P<)WCR&O.(N9YEHSW/,T[7 8=G>.*_:\G
M;RZ+..1Y_.CG>X#+%3X1:[7\J8!ZJ8*9Z$ER]L>#9VV>-?&7@%DP(OSYMDWX
M2I4O\6*Q/<RE+X.7]C&XE [XN"Z1P9ZC?$A#,^T.\L/^;/A5CSLDB,-#8B O
M<VRH?&2]5 ]([<I'W)8\;P+5$Y^)"N<A)E+?^*>(D03F>XC](H3#58G]3D&?
M-19E+"BNG7[DUC+.6)8(J$.8+ 9"I#"^_,W=%=M%=ZNV_?#)W=I:&V UY5KU
MY,_*$TMQ+SOMP2Q]9WQS),?W*0P@'77>S -> ZT]<^\;[?C7.SSYU-(?#* 2
M%D=9(0Y$L&]Z'J%PO6B#5-ND&$B[E'MRI22JE1N(DF\K_E'?J;K:$J!2+7^9
MD-PP^0SWIS^D_P03B?'('78EH3Y1[E#S*+IXDTL- </;@35W/VU>!I?:,WVN
M-<";%C[G,93)K=E'X5'8]11\-G8CKDG\O5UY;>J',1/G0W(X+XNHM>7O/M_!
M,I6RZ9!XF'!A$!V8+6N_?M\S"7K*Q=A(*K%529'(#5O*':=.O#_4E#V':?W5
M(D4!DRQP7S7J:C%Z?&5@E:R'K7V.WNXR5NWGN>]4QL<&B0H]\D#<_1"AYTDL
MHA8W*9//4+3BNJ9EJUM&'!N;KQL,H6[<OM"O*MURH?/PS<I*!?#]\V:'&CTC
M02)J/.-\6.MHW ;GBS?;2;::CV(WSZ=?69(VD?%@DI9;[)!ZZ?W25-UM;J$-
M?I@2B _+%2#\B?2<4^3Z8Q[IKMOD+E;V\HO,\][%5E6NWE;L&S\9:V1D$]?[
M,#5\[EML"L>2]?Z9R(]=\^-WQBN.G^Z1G4SKK'QH)I-F)I,%3/TODDDR+Z!9
M&6$&,5<QLU07CCQ@<W &S=(;]6OY3_*WB ^MC*B\60DZ9F'$OY@3"3D._0DZ
M L/ZA043#%YX\F1_LJ6HIE@. S?O3':5-+#K3YDSG*#[X? Z!QX)&/;K&3KP
MY2DCFLFEW!N=*^(7',VV2G_A+OEFI@K2%4>2)^1W0,\$RA>A0&,UAW=JTN=?
MX1IN!D8N1R'=/KR5C3\=_]-TDM7&ZF7KYA']+J@!P^$QKFU!"?GYH2:Z=] ?
M0<J^XRYY]N[1+6F)[$?<P.K7<+=UY5\88E0E!NFTYZ\(W:+*MFELVBXK='IJ
M$$Q:!(%<0D1.KJW&#@+$)GO5)U^ZB%<BJ#3U LCU:9@#H1N)325O\(3IX<OI
MP'-_%0I7B;G;J3'CZ<3XQ@<[ZGL;>%;^>A(!/RTK;*9G_K$LG&OD/F:)+3),
M&>;,>,BN,5X1R<PY3S$7G:+GGI?FN\1JA\)S>6=<C:K80P0>0'(@51A*YD8L
MG*CJ M^_+>[X_&>!S'[6(.E1IN'NH2]A9G-3/&VUDAZ8G7<@PR\#,]7+-A83
M*/CU@8O]LHEZ5HZS,/85B9.CPNDWAM9.-]<_P?@&>^<%M*Y[:8D/R&^29W,;
M@LD.T%^VUW>3D7,NA9[U32+7.IN;SIN(JMV4PWFTTAQF3=!;'CV.#N6NT_W=
MY^RK8M\9^,T339;J8EJD@\ HY0M!GETBFL\E>-_:F(^<;#@+&O^%DDSRF+(W
M='17[.JLG)AHCS4[_3KJPUEA!;-90+L'@690WKB.*66LY/,F-AR<V;8+JVA[
M5[8NX[J >HT]8?5)@840H"'<IM]J,=Z227T+/6='&X%533#BLSF[O?WU$_L"
M7SF?.O+].5\Q<V:HY9'/N3WOJ,Y#*E?YL[,+3Y>*E8S+N3EBT:2S=<D@K!*)
M5)LQGABX;YWY\1)7W=C"\2O"6S*)YTTGS8%0RHO<USMUSUI8P[09L,IY)L8V
M\+G']>[\#T\$6NR6-+]E:I!GG^MH=7 >?]&AS.*=[(:%36ABD7$&)R@!(Q1]
M['4M%ULUC8RAPL^Y9I_1QQ[K%CQV3 O-HO)24Z <),U6&#M%<:Z<PYC,W8Q8
MU/!9MH&Y9H'UL]1] G1?0]ZD;T;>.V'U+KBD@/Q.721)J[YJ7IET5BDO+PB*
MQB(BPL2#/:;Y!JOW/B:/]RY>RW4T^#%@*(Z.<:S?(G?OJ*]!JB0[E ]1@JDI
M82=GD2<F3?1^V$\[&!TNG$,%LD3]\1+COJ'1,!MUWG?1;4%R8F$6'0UE)VUU
MV 9&JWFNNNGVJU3(IJRI@ELNR2NM]JZ: 'ZMB&+8+!QTF"+JCL_L /$Z#M:2
M>F<=)OI*PDL=&U6\98(V=_<<?]\6YLC5?_*Q4.%:ODPM14UL_);5M5;26S)W
MF!A!(S7O%\D956MP[.O0!S<7CS/UL3L5(PUAO1_OT($@8?3W(T)2[JU"^[!9
M2 ><)^P<"9(?Y-F^.S.>=;VT09#VT-3CD?,9$X4FG]^Q;!>!M2S*!B,0O0JR
M,<&C4(JGMY.4,-=H/P:E&QL%4A7<U*;#EA_=;_(X>8MOAEE]![/JB&T&=8,J
M/6/4KEN?<QY&Y(V<K$\0C9=R-H1YL6\DO6Z5CH[^)N.G5;[8*]>4)S16X&0!
M>ESP.V\64H=9\W:9$W5+B85R(,E&63U)GI9U3PL*P0*#GY??;\[[2REYUTLV
M->GBN-ALDH>&.NR&$1Y9QZX(['I_FP<N!$3GRA-@Q&A\1>8L+*E%[8>:.:32
M101:I-A<CGRS&>Q=,NOA<X=J=@9I29$G"U,D\//N@1^#KIK+9Y>=J<EZXA^*
M7SOQ(E[0 ,84>PGUT"0D1_]JC5S_5YC-+W_'(^VRW_];!AA-?/8?!Z@34*C8
M7',PP"=%D0T]CJ0TMYU0;.!J.;X.Z]'@- ?A($'(JG;)AU[X4_/\-9@KA-S3
MK!TN;>?S6!9>K?+LV_DE;\S[[&GH80N,>AF(:[$QMKQXH'8\/*8ITX9/TQ1G
MI/ =&L%G4[;@.;';*2C"LXJ<<ZIUD0[=<W^:F%K+GG\M<99\H>P<'0AI%DF;
MC\YT3%/YDV:R4(123IJ6I99!%6P[>',5#?YLZHKS7'$YFBR^RGN4.5HZC4-3
M-H<;X-_/QVO.9L;1F$G'^SK&Q:NA7D9NU(MG3C?#F?V2P5H# 0@CMD-(.9"C
MFY8GTF4F;A!=]W"9U:+ID8?I%(8PF2]!0HR5;GG)P[,^U3@_/KTYSO&PHJ1P
M;,76?P!>;'LIW-$G5KO<P_'NJ=?@VT[W#7D>RO\&1<P Y2V':)A<Y>HAQU0]
M]4]![HCM'V.G>(GU5UYZ:,LZ,B7FK#D-@-5W:O@7>[/2+9>337NZU"?=OE7F
MZWZ^8I'VW0O8J5!23@9Q*ZGS#\^1(K'!RN/@L[85-4^=E'/<)Y#:1$0,<C8?
M5FU<6!S42CD_J.Q<->2WF';]_I6KX:6!-U=$CT&?C K?T!%P3-U,V#T*<T(P
M:ZZZJ@UCFPWTO<,NJ(/6O%VCMM;:9P9F_N"@'$E??7<-'%ZCUR:+S@Y#CB*J
MKLI9AL)M;-IF\+?]V0Q)'EZ:'-F$7)*\Y\;:TCT$A:^(F/A3D>(DV,'E0S-?
MD]@_*FI*-LS02#<N'#\M2Q)F%B^8Y1<B=S<B2')UE BH&,]^,%*61HJ>V;=6
M=Y/[Y6(F<CF[Z*[1NTS*\5V:*3>2#CBJHVAIXS8]2/S-""1^5$)6#NBOB0>1
M. 2;PYWH $LS@_4R(^C KWYO.E!0^WHSD')"B@YT6P5EYM"!#[_HP)("E Y@
M[XTBIZ3<P*1-T#68,V)/"L0%6KT[#-K.T%EN,IKKYVDC7MYR^.E'/3ZL13;.
M]Q=O@NT.OY2/()F7WEN$?4%'J\O+:XQX/J4(.WL?SKF?D7NETO@.ZNLQ-AR$
MC8:B7<C&Q:V9Z"%YJY\T!?N6C-V[T%=Z6>GDL+"*E%-\Y!5P9A^SF. ]QYS=
MWKJJFU%3.;UP3;5&Z>W #M"))D&<>7<U?O=%M7C(DHUW]+41;(,7FU6-4(Z-
M!20-5J<9[0=_!JI^R(A@PJXM(B:5M2/Y*=<<#TT,W.U>C$K]O27T5.F\6;?\
M=ADQG/ QC\ @+-%Z1J5?>DIFEBK-?$]%L*0QU<"!^QYR=LR167YNC>FOM15O
MEEK]3D@;@Z=)5DL[$]-(40SRJZJ_ =[?"Z$F$TPZX4=($D_F")()?A">/JE>
MDU+7\Q.J//=752%),]67,ZGY+:<./TP,,P]C]I>B%NXA?FPDP#[/1.X@8PU.
M->2XBJ [>2K- NG 42/J-L+7.R U0_1E709O0LPOP=]6D=_ZO1XX:37F,!C+
ML$[9V1KNQ^&Z1:[665V)FK6"-Z?'!K[.U=>]-!-[L?R)^\C^[2Q*/C6"INN*
MY*8IN^3RYJ[-XU'QSF2%C#3-'JYA3B,Y[N]WY,3\.573RAS(#*(@1OW@+\EZ
MQP7)W:0=:@"'E5XB]ELN3[[R=KV;>M):+&FUPDY(]Q:W8:I]95?WK7?6M=J_
M+U\->[Z/N$D:PV^8CA0,(YI"L2\4+VO^(F:*=#7YE,'\\L*BUQ)6I>H3EH7^
MQ!IE"9^X8";*:FWU32KY0XL9-94./$8PD5X0[PS%(K'E((L1/7.6K6E7/COI
M>^]=Q*4W"YRF)$:.& _O?IE:^9/RJPBW7H>'X<2+(OP5+YO#V5WKUCXV?_H>
M]M7M8WAJOY#V1&;[9R$6#;#<V?V.%RG5MJ;Z:9F:\K^H^J--MS\LJLKHY"(>
M%%U=:7;\VF#Z!J$7T>G=1BD>"K/(=QMJLGV,<"SN$YI<<O%)>RW<;6KII0K1
MI -M1DWJ!<N0JHK"LDD7XK!K8_AH277S$\S <[7>Q%)JP,L%Z2+#9"9) 5KG
M0E<()D4=?82D0R;S6!($WA%#DX+./1Y:L^CH4W ]<L8P)BE8Z(*S5,0EJ^-+
MH[?60I\]*3',75@N1W:"V1V",L#<$R2X,;R3=WVF %5\!>-6[51US+V#&2%F
M8PB!SW <E..14"=YDPV#8 ZTZ>&-)OF"F8_OU:76Q+^W<6/Y#*-C'P(@%?N"
MG/3-GRF4$WUSJ!=ZZG3@R,(SM;?KU<W,MVK2_FPR%I3LR#8V+R#9GL]I@WS3
ML'B.^M"BZ-Q(TB?E1X6GA73A]LL0T1;Q)W5HI^(@<CM1\[G7SUV=_FJ?<]MR
M T<JJL CY>IN0IX*'GG-56\#NPX*U6I";M_W,AEJD6LAW9Y5%H&V=G0NM(I
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M<44?AU<_;53T*7"QF8=3^.<9-/12T$UGFE-0$)JJ/Q5*!\#HNN64%TV>V!G
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MT<+X6$"7%\_!R-@SY5?F6(ET))2V]C*8!CSU?(V<NEX\&>BQ,["UN);:3["
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MO@)UY8R;/@R>(J)OD@R[U-^*B<9Y&@P89;BTI&\DZW/[2=0-7/I]*$.261)
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MXANXNS_CN>AAX[,7_^R X/<T?LT6(Z!52GA <='DG7Z0;WD-93"SY%>_>-6
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M89KB)UW'#_6_.3<+6GL0S:*BN#.HFN(G63WH$B_"BUO?GFC*V9R,G>X"%T;
M"-?#IH58CR\81_%O3L,PC550%+Y?,M_*1_V>!YA+R(%FV0:U;\Y#?'.#8D7&
MLNW!M<F&,0Z_.1'U[0TJ.T<;_G@V/Y[-CV?S73R;[7W8![VC+S4(I9]BW(+6
M(5./L[?I-N5H23]=)GK8TO+_45WT7V4(\.UN_%"&?ZKO5"]VL4K#'D9?!1V
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MYTZS7 C]2O^$19B5X+-2'A $[@*S%]EN<(P]A,@B1QY@D02.++8&QK+OQ_&
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M+@^\/4<$!9^N*OU48A@04C()(=,[!6X.YNT8)"/*1T>K45W_@F87RYRZ'M;
MB&&[?J5(GLWY/J*N<-I. K161B78/8P_SQW2)#!!<D/1@XN^&X,V2FOL<UFR
M-U&+4V IY,^VA+6+6A-)]+9[/("[JA4<.H :R-+DKV;Q#/ZIMP5F5HM-SW-V
M7\#S@+TS"-8Z#//B.Q"*&$%-;0&"!8V#N#Q@M23?-V^M@$'[LZ"-&@X\(#,
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MKH,8N1T%V5D21(65;"=T!^U*&K*GH:%'2EGY1/)RE5SR6H*H\Y)GF\,B+ %
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MI7\1'>/T_T8 XA,(U"\#,AVV'EB'G/I=+2%1\O1Q6+GBB7UT+X:.$CH@$.0
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ME$V$GPZ+A#Q+]()GY=5 Z6O_E-K;=IX@&-'*G^]OVB7.\U.>*<ILXH!?TWL
MN..=7%3J'5][_NF4-Q<[#]_D1C =L_B2'B,[X+4L\6VG$=I@:+X;!E]-=O%H
M/]"0RIWI&+R9KO'JLUPYCR)NSEM?<?>RON,*7F=NY /81(?"V'<SZ57%>@0U
MG&JI1F.>\<B?QV/[7U3BU T?N45Q+,OHYU<I2"C'33&>;!O1 Y#VR'943=XV
M&TF:;$1X4(-3B/R\F64:+9>N55"\.6&DK%@>,?+3VJP<HQ6F"#D=WLZRO_J?
M[%7P7V<,_AWXMWF%_]JEH-('I]8E!L&:AOIB!,'T@Q<4-H.ZH);2OOZ3A7]*
MJ%+V$>:BZ8]8I)HU#]'4DRJ+P7XXP2TZ^#7";RG:NK(>_[)GW:$XUNGIP[=;
M(F;$*G*),>4^PT2(=MDB#4C ."_,NADU$H:CR(^+R:R@DY=L_9&VP(RV9GUI
M24_"G97DU8X>1;'K'SG-0HJ K3PA.E?\":]:>[5#-B]US14##Q=GGRH$!$FE
M*.<8F[*$2NAYO%0^G=P8\DTSYQ,K^@P=T#BBVJ^2>;'H*$WI]IW7?E7^3W9N
MN9P=51G\R.;D(YI2&W8AKTC^PQ3S,XGSPH^FYHY\2UR(XE(C'L\J<5%FHP=L
M+R.=LR&B^+XBQ3SSI](;'$" TU;XTI G#K4U1A=K-U*BE81L*G-9<&UIG.+2
MRO ( 0!&1CSZ,5J9DHT4FD<(@B)8*./"$'_W1)2S^REG&^]&GLL/OK.8G\[5
M7,TAU!!?X4V_BDEU;'9GQ<4&E7Z7>_%%Q#2TLHY#_XDN=_NQI^^60W/Y!,P,
M9149UI4M^N<5Z2\5:H.X5%,U@?##PW%.X:T7_,[F3ZIPJ,XM-?QZ_O%%PDOG
M:.KZX1<&=*&.*-D0/]R-9EFG7L1'5GE6_A;<L)[?'<\I9F$OXCKY^718.0,3
MEVX^)!2V6+K WP9#"./G,TM^VVF.D6&+<VYF&;<-M:^X$F?>^%^7=#3^^-*]
MVWSW\6Y5+21; ]U$97(5#&SX2M>?C,F_2G8+MOY^M[-PJZOZ*58.;L[3.=--
MCI(I1LNI<&YZS'"'+8>"@J$T0.+2$=VLRP^(\*\Y^F-ZE.PV<?B&X"5+2VM_
MT]NYN%7<55&SGG2O&JVJK^9FK)*+P'G&CC9UQ&5*4=W.K,A7<0D\+#:K%RM7
M/'V[]$G#>R%N@;L>*6[/5K%%5R.>B7T(&7"?@\,G^V<RR'R=B\L+ JUR^+V.
MC,E<U0G?(;M90Y)C*I> ZI!LF3@QLV\/F,N;8V$1TPNVUSV.?(%JOZ=S$8$
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M0W7Z8^/+88HL-S=UE!!(_'"[4*VEBK.OG!-\TLG-5J0SBZ.@>=SW A^S%U\
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MS)G0E)2^D=:DAY\^"JC=8RN[U/[D=V"8Z<0"WCCQ\#(L$OZ7]Y^3E[D  [*
M03=W/Q[6CCPVUFD'YG7-GXLHW^^34#31]C(X6_^506//L<&,11(C]IMQGBRX
M)$' $'GK".+-$N/R!\/'OJE(.T_R#+@+R^O8A2B5B;Y )\ 68Q8@M6(^G6UJ
M!)T/'RNHZ**-I.YBDQ>WDJ<S7NVD2,(NWM3GZV/>QIP_+<"RO<""4,I>7-AR
M<U\LB^*!.[=QIDRL8[7>_&)[H/A&VR$@HFH[YI"->B+\+#02SFO&O<KQ9#QM
M6/U2O3H9LJ(K@L%;#[.Z^.75[+S2-B0FT0!W2_\4K?.>)ZEXFR'WYZ/ZD +G
M)\]057!#9">2<41;B:1"UIDH+Q_?S#V-I^8%?]IH8!^SG3><^&V0*9.R5:)S
M_^&V'G#^6*LTE4W7BW3^-R(T3V#&=X<:ZS?:EDY)H '+8U0(:JKX(VI=]@7#
M(8G0>[,!#R,+:'T5M!:]4&Q<]M#EKQK*R3;,($OC3.9KL3F&7T'_D@+W$2-0
MFVWB@T7%R:(?)>#FU_2^-*1)FEV7Z&A_LU:%'C*="=-+I+(QX-^U7(R?43_\
M8MP'D G4 /08ZG7>KBF9KN"/6M 4OG&&PTD:P'2%SH,AN()><M=6$&KL0C &
M30-L48OOX5S:CTG*R!DH*U+]ZGO5)JP<S,!=9O!9N8G,E1^-K_K#))+?YUB)
MM'V/XPXU!<_LD%^C^#EAJ]+VL]1,XVT*ZHB^A)MV,'Q>%R1.7 (4P[GS]-YC
MZ7S9O#-=)Y;:B6+*X+U^4<CJN?;'&-YW[PX+(V93&%9.0;:Y\3;_G )ZTKD,
MI#8'*7,%;C>ZTA#,9OW:(-A%?G3D>W+ZK-J;C11&D4O'F0W1#F#58KPCB>A&
M0+W2OG(^&Y[=X1=H_NKM].I#$?T818U#HV>/UN+^=B.?4^<Q>)-XP<7$5[[0
M..@)7YDAYMGKZ3)E0ZS%+U6_]GV2KLW3&B]4K'H@N73.TOTD<A#D(!FY_<W[
MS)E-2.U^*6TQ6;O .;\A^-Q38)4\H]TG^ODNU\#GLA2^D(>+]C' (2.1D6Y)
ML?[P1<_0%W1^#!6HW1P^:9S_ZY?UK!O,\4FR1^9<0<MK#D)SWU9+6'*<Q\G[
M-<A0,@STPP:;+G$V$ H[ GOR2J? AJLU8RNIMR[(JGEZ2G[P0*P\$7H[?;;W
M\<G)XX0:HBZH0GH&JMTFF$_DUL_D5CSFG\_!#4&?6;B+]%0()\65#S8XSRPN
M.ERPJR/ M]3>DW4I22C/;8-%_@DTI0$;?Y=UI7&W7>!/F?.DZM]88>F!I C+
MMPZ475;WDG&&WS"\3874#[(,Z(9:UI?'3E0^-CH6WRX9Y1-W)!!O])>?^)?.
M)WFM06FB$W[AM6=:?'HRELWM\.<ED<&8?MN0[\S/BRMA)\$&*AL=IT@Z8=<H
M4<LT8-0)7466P?(3=K8*B_QMI_2S)L,*QHPO7^0S>2(QS"BQ\Q(: 2#NT;7Q
MS<\='16$&;A"B.U6I+,]05<U@?I8K9R>>6'V:FVCU&0A;MU/FL<C=-=[9S!U
M?NTMD$1XS4Z\MECPJ=J&!SRF]JI?AX[_NOXM3&^GLX1%Z)RQ?(#*82_]BP,)
M+Q9.(G40MT!CG#-G6N6&6>6L6R3#Q)\.HP>6P)]9J>2VI%1X.5**<#SC5:M:
MF5O6FW[W8I?T5+M?0Q+NEKAXMA;>J>-W?72AV0MXO<2XK,1H;<$E5*1UT8)+
MU8\L.0-C(YTGR;>_2\>./?+59YRP0&M3"EJ/%_ICZ*;XWEGMAV&6Q^<)V SW
M].V)G><<T9SEOZ\#&P4B3#Q%"8>5"]03>?@8>@CZ00XB7"0R-U3]%)<3,9$]
ML7?C1K]6W('M$$_X1H)FN"4-$'*X3U>S$7_9EN,BY8*K5X92 <VC/ ],/(",
M1MP!/;%EPR%(&?P3YW357&'WDQLCRH,V#@DG[+E51T1=@;O%[(T])Y@>Q4UV
MP/#7*=:KGE$T@*^V_J5J^LR'M&\N4]K)AI4&35S%RS+[ICAI<BI=VJ@I^<UB
MBK<K>9$^\#\=#:L(?I7(Z8_$I3\/_?(AX_^7;8(4_K5:I0'PRR?Q:(7N$2*"
M''-5UXF=0I11O-9_8>^]HYKZMK7AC4%"CU*D$Q44%!%1D9Z "H@M6$$I45$1
MD2Y%" E%06H4%)06%!$L@$B7$GI I"B])B$@'1)*"*2]\7?N]]U3[CUE?.=\
MY]SWGC_F<+@98V?N5>9ZGK7F>J:'\8<&_-W-WV"*&\,A(<W-V%0*EE/UFYZE
M\K9^!8MGE7PQ'H:_BI J5<OW/":QX_^CN-:8QA.]]0@HSKT&?;2ZE&:A+-?3
MH@>]F9)*8?PJ08I8M0:Q"U@=O].SY +&F([UVDQH\#0'H[U^WI<+P%CG$Y9]
M:HW"<+.<H* <X/RI4,@W0;T.=.42'#;,@>]&U^%NT<2+:;C&SZR-M^_&RC,3
MVIC3PHOW0<; P4]-B^1S<9N#;EM"YS8T[L_WXZ[I=QR;1J:IC;U]Q11#=SL<
M^=1S>"C-HJ9:O8SSX\1\_X/0/8I?6H3<1'9/[[REZN2N6=,,GBJ9*XQOC3<(
MF\6ATB'H &%6TZ]+<RP/=WF4>2E5.<4;;T$=(/JJP%5+YV!N#[$C'^XI';AJ
MZE!(B^8(VY/+*E6\G:D+K>?*:4K?KN_$=V_?:NKT%'MH<\L#F<_S0PFI3X[@
MVJ-;6U9%RA?R;@=&OQS)2G26+334;KF!.&^I=ICO"/;-J,M&<6)2MFW5Z*M
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MJTA+="@Z,,6OM.6*Q/3+$J5^UUH1"<MAR#=T"DUFCDWB K(HA4K&]3%!'^/
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M $4[FS GWX+7YQ?M%W_O)R]VUBM]>1ZE$VO9(I@ANM%[23O^G?*%$]>[[0F
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M8)K>HA4Z<MR&.FZ,.EAV:E/IO&OK[H\\"!UJHMR,!L6<"4L["G+B_8P*KVN
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MY)H7AS^A@%W\IH#5;]:;;V.!;*[P#[8KW$BN3#>!G7#NYXD7ON%DYCZ+:%6
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MM?SP7M$:0>8+"DKK?<LO/"-.&+JG&-SB<)(W*8\TE 9<Y'KO,.UD"NQG'KY
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M)*<7K5>X(<JV+N+,"3669(D?*AO]A3H+33-DY (4PD+[3A,C<FZ5E0]HG?)
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M]X 12Q7$27P\B#0Z7CR4[-F58*&NV228^&&T@B/CFCD'^BB_F52_*P*M')C
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MV!)N+NYTT^55D)*X5W2!SAY7X[U^8'2\,1)"4GK/,I&<0Z GH@"Z4GPPC2@
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MM/=05Y0=^UH; 7H.+0#<. T?%V8$P$6G0^U6AG"<?I)QM?BYFW11VN56??*
MSJ^@L#%YJ/4&RV4HNO8Z$_X9\RS4R--W^W@G'M+L!;5TT9#UV?-)]%""H9<B
M?0L6_Y-24E9K'#(X0]A?RO),XWC)R!\+]"F4/*@<?EHO[IYAHQ_B@%Z(W?-V
M$]A= 5"\N8&\EN/&7X6B$6\;/JSL@&\<LBIP4#CG-(E*T__0LB=ILV^9FD*S
MXFO9/CU/.LQNZ?ULHNOC@^S'''06I[?ZN' Q%M:VZ[SN[B58/\MIA+RIVQ>5
M>'AMIE]UN=R%)X01H7J $E8*?W:N,I 975O*E^"D4C5PFST<[!;DG:IZ[=&#
M)J?BAW;<*FLT])ZW9Y7ONXCK!8N/D>J\XYS4P7CD)ATUKMCS,R-OOG%.?K!!
MT(M+4Y*L'C'N7USSHSQ>OVOKGML"8 OE_L*MDEYSPME:#XE*VYZR%=H_1'XJ
MR)%4I_-UA*B]&!!ZB=D51_3VCH+N9_:5.0B J% -*$Z)GW7^LDKB/M/<8]>W
MW+ZQ^,EBVY1A>OS7A8?@HE6H=D?H"KB;WMUKM,&&I,,NE>:[?AQ)?"B_W=%K
MKYCH6$.(B^Y(B7""A)8E:6CB%K.+1JZ[7.G"QDGV8)Y0/A6]^[*K?^OTID'\
M1S?)M_8OHT6I2D_=5"#C%*8#ZB9!A5582XD>T&S7R7]\$L7\VC+C<,<A*['@
M\_#9L<1[_L77%*Q<@#?T FS""1.8%O8C\NW]LD54K[O,3[34=7 MY]+'VH!W
MKQBLES['?%]K!BP$G?XT?[7B\"DQ,R#\\VZX%EN;5R$TRI2T'#B!+)M1;XF:
M'$9:! >L,[PI71 W7MQ_A&]U+"*OO>R!B,K.XRO\*OFQ'3NBC&[W&)QPC8N2
M4W1=_U.HIUSY7YRDF,3Q[L737#74S16[L,9BS1Q2@\/5HU=WC1]*M/*6> >Y
MFBQV-BYOWZ>\?;57>0:Y!9[GBVYL*8LRPIR\%;]]5?X,Y)G5_SRQ\'<%#:NF
M?G=_Q 0Z_P](O_E_EL9#SOBC!,AS>G]TNO0_28O40-<:RG468GW,7J)U[AHM
M:-'(WT_N5,LO>MK[1H\K-IB383^I))'8^FT=KH6('TQV:G_^[?GC*PF9]'S8
MZ0D/H]K@(]V]+S\].I>ZLKRA?@::4H;>=_OE:"-;K>.XJ=D&NZWE_P2G</]N
M]*]]800EHXCQMC4@+:A4"H#J-:%W!KTYL^]A$^ ^?C!X8X%11X(J?+7VY<=H
M(9D0]#;.6;ZQ5_0B_I, R,!330PED)T&C!27V7D<?8$7!IFVX(U)%3*QB(Q^
MY#;4;'SP=WL>UF6>3T0?N@1ULE32)B-K. ( Q00".BH I:<T;\13VL2LD<7\
MSZ_SV0W6VI'%JI!("E_4M[J18?6A%'M\7P2F>O[&>,TD@W1%^QU@  \TX*\?
M"UX-NQJF!KA=JI6I7<'?%N*F%,;S;R(['F>\C6GH.VSDHECVFN_"A3S.HXPE
MXCDKQ W8QHO7QH\T3_N4ST_ID^2\SW-)J$:15<%:JLH3<_.O$9/S?(N!&D;&
M?.M>\9-X=E4P6^[I146FN)>YX02)*9ST@]^W8Q1OS-T>Z>"&+%RK![0&6JWU
M=J.<>*A!G#\/DM+LJ1Y,DR6KL"'<%^RGNZ8B_$R=@F:;D#@8/?/T2?)'67IB
M682?OBQL/"1@9@/@LB9^;8BSZPSBP>0D-]?QQHVN"'']45^2$[\?U$7/1HH;
M(/$#<G.\8/Z&KXOE6Z#[RI1\LKEA2.CS<.W0$[BB@_&/2-XN"UU?,\0%0*)&
MK0!@2Y4)@'8/]$Y.#A^>15+&R F <*$&X[_]7Y,;N80OT).L8O9E9N"XA&LG
M5"?U7-7G<\<MGSEX!)XN]=O@^9&\VBMW>/]:>ZAMF :2BAM+I4IU#YA#(>?\
M+=X$.03I='9.Y!0G';@E6;+[NZ1SO"\^)4PL1/>/-[<=&906C@GNA@#83%!%
MXD)MJ5^_O)TOU>WL[1Z*&$D\D&TEK7]ZBSK.G/1)GG#S2?A.]_>[\8-5.\A'
M/E_UG&G9V[H]HJ>U=7NLK,N)6X?, /4;U8!MSU^;'/TO<9>SAK!^K%,+;I:=
MAYWW^O[.7YT_EKWN =D_ 4,Z..D4*0!6C6K-SW0(@$F* '#A^SH%,J7X1S;'
M(ONPE)FN$7[03&%H0;:#[^FC+1UW'W<+-\>']W?X83HL 7!5 "S"IF.1@^?,
M!  B#2, 2D$>;KX^<(,M[T*.7]@](T4D5R.72.] P=AD 5 D /2S^1N_H*='
M<G"+;@+@FP!(M_,U@]F_Z#->;OQ?-!8 1!#-QN)3+KOSI8XA!BT/*]^P9BDJ
M Z4A=U>-Y+ZXGK/]4L.+>@]GH5$%.?Y/L.3^'>E?.2:6L4.?.9"W5)TDZ-?J
M))L_4%B,:\@^OAM7Z-1#9KMBXN%Z>>DTGK032%U!,&.6<8/[I>:0#P6 ,;(Z
M_)HT^-*_2YW$F(:19Q<6M+9&:R*<<WRWS,*AF&'7X?C@X+:ZS2X)YM8HIV'J
M] CY9)MS1Z#8B:@>NZS&F?$O\1:,7AT@ZW53<ER6L$GXL&M\G^]/1$G2SJE6
M\\.*K(Y;;.' _G0D:MZP #(VR)!;QK_X&+HRD2LV]L,D\:G*DD(AW;[Q+5A
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M3VY*[?/%A=KY_Z<S/AY/ +2Z0WZNTJ +@"6>>$[.>>0<A4B<;_GM*!+)LOX
M3A)!<#H-6/@E5NA^+KF==/[.;RC>W.0DW__70TDR]^1K_.(DA<+]$8X(?T(
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M^_MVC$PPJ7/S[',<3%-.S\>CH]TC4#_U_VW'\-O)O,W)FS'\]4^P;DNCQLT
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M&9-Z&V>_/PU-G6H/XN0'^5(_\<7;-_>Q;<=7BJ^_T/1N9//<.(E%E;+"8YQ
M;%"66*6<8X8K9WL;%GF_Y]?;[: 9OX !-U$3SSA@+YL3\<&"P%.O-:56<M6S
M7*(.L^!#$4PQ18DN&>Q73H789"3QI43),]6"KEU8UNJY=X?_B@3-(A+1R>)Y
MH <?7F6 Z"482V5FG/76TG>:==4S979#ELY*&^B]<?$C#<8%F8')>,; LT+
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M6!PTO4B1<UKR-DFQGTF*O1%XRFQRA7I2&,8F:!:)IRH1$11EX%PD&WIWGO!
M5SYUN>J\>.D2H+Q"<0L^&KSMJ4 'Q4:0V\)*;W?'KL!DSXZ.!Z.3G%M$-KL&
M?F.HH03WE+7)W5B(!/&(0JUJ7<C:9I7Z)P/?X/4MJWEHMSJ1^6J3T)NC$*KA
M=4X[@O=/ 6_J0)S-A23I-!8GL\GT]I)V=.$O,LFGT<'A:-KX80)B'7R"%YX<
M' *#SC ;P"_L]F/&GW;FUET"V5_G3S/4WB+TI5$M#6G=ZHMU5-&4&EUH# K@
M>@83KJB;.?C<Y9QI$9Z;_AJ3X?W7KEO?-N\=SMVZBBBB)G!IG2.*AHQ;?XF
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MQDA<3HQ$(VSV6J8D>NNH?J<Y#'?UD[H#X\XFCO?<EH2WK(%%()XR!OJ/1Z<
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M)E'FB'6W*/&9X[&-+,X ;@'7JV^K/E-&"[]XV91X^.[T0?-FN'3LMEJ9N@?
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MM@;N^6A<30YS]:^%!%:S$X(J#U-.-^#TFSJ]0K.$PJV25I/@C$*8SHG36"-
MZNR"M=S2SC3+VW8VSV:G(.?TRM,$WY CZ.40?T:2/R$GV8])'O:",O\Q'>9*
MT,?KH4'A+ M*$XG!>2)Y$,2*S$F.P@2'%QSYTA4-GM<-J,1_P-H^AV^:7JPN
MGI3=I/;7[4O=(RC]1K35FW<;386-/9G8N@9;UV#)>&@95#(^D.3:.E[4$9_
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M\F=?E^@*U/"^F1Q-WH_*^]$QSF/4O <S_!ZC8A\0.)QM&B!B>'.<9R]L6HB
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M>CP:OF_RL!Z-X9^%(;X/3/#[? C5'S $  $XA"4LL+7[6[N_M?O;%=H"@"T
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M\DKW^K(+0V&YHAE3%D_N25"6M%+:MLJ&X'4%(V* *")"\MD444U1)'J.YVZ
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M6_QX?]LU;[)OK^XR8LH=E0'[&@??FO(_,UDR63)9]G>PT8B43>WR'+""4=8
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M^KN;6QX?1O/1<O7YZ>GE];?M92Q_S39GPOWILP=RR^?RB52_]_'O?!:?*//
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M[FEP5PU>&[(.,L8 )A0)D42 8'4@(4JM<:UXOJK&N" BE*RP\1TYB-A%[W7
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M$SX3_KZXWU2<<E)8\*&KFI)U!-0B02RN-M?;9QEZJ=*XAP1]QW%_CH;TOUW
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M?KEW^_S:UNUO]*^+T;P-] W-/HPRK3(0?J,\?3=9WF69C-!3WH$<"N-.._6
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MP8[%MAE"5'1"8&WN1$8PS@N(C3+ :J.L<L847#_95'WRV;GV==.N,;)"E+6
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M@BUKVF-0P^#%536'56^LV+HG0=7%*SND<$AQ *2@?LI Z\U($ <QH5)*PJ+
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M0>2K2&3A7LRR!T4P&CUC8>A70>3.2'N8Z$ I:T/)UCJKKXO5-1IMFRN@:@]
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MWJPH<99C!V1N<X\,R Y5T8LKZB<AR56<$TK]F# .$.GKC&K-HBC(]E*M8+_
M^%4\C$*7[^GLT <5N/MXR#G2]C@4TK$KQZX<N]J?;4A*Y?M91'0B,D*S."%"
MTIP YTF!=^4LHWM)@]K!KKHS_@O^W8?Q[UN89\=5*<S5*G HZ5#RT"BI9)PF
M01X!-HJ$T#ABA >2DH3FD5*YCN1SA9<<""7#XZI&]EKJ%IRNA-]':2_X+09-
M.8;E&-9),*P[XA>#.-8)#PG-I0"1.@](EFJ?L"3-DBC)6>+SYPW$_FC/X?X*
M7(:G[IQU\.4V]^C@ZS#R-H\SJ706D$CP@% : ;2E (Q!*E2:IYK[4?2\X=P/
MAL/[R=G1+(R<0<(9TU^F1)@K"N;XF.-CKE&;.\EN<X_F)!_(3Y9@5%N0$^$S
M[ T<4\(X_!-2QB*=9YE*GA1#;:K5;HNCWRIZ]0R9(9DS!3M3\*$[5*PT%L$9
MFF&; EB5";OF[<\N!L3QME/C;;MY4:!SEBM.B?:SA%"51(2'7)-,LT#QR->)
M3I[<56*G:00/XKAG_7FI3-1A^],OPQ'=6S=[2H\K^-!)[0[9'++=%3R=\CB+
M TT$RR*,1DL)]W5.9*!8Q/) QN&6&VP/4O9+(!LVL3QU#YDS !\P?1'(C+@4
M1L=L'+/I^HHF*J"ISPB3"98_CW,B8I'"GSJF+-%,T6>J[F$.Y&]5*9\SBY&=
M.G=Q4.8V]^B@[$#6;BJH2&1"%$\"0A.$.0U_AG[ (YVD <WVTAEB[]#X=6-"
M>ERF!&?:GKKD_5;G&NA8>;6^T>7*13GOD4T)(#Q=]X,]BQ=+KZGFA?*ZK3IF
M1O;MV;]Z5K?O$ U','?,WD*['SE,<21RY)AR&/$Y#J(DD*$D:48C0OU$$J&P
MMV3 ?1FR.,[E5E+U?L1GC!?!L?R?8GEUL6I@/77]?,$B;!;YS]@L;9*G<<KQ
MSH^1L:<O1/^FEY[DS967SZO/C;=J0)Y>[YD&='?C D,<+W2\<(*\4#+&<RY(
M$E!&:!JGA(E4DAC^2;FO\CP+]F%E!Y2X )#X6%<WA=+JI]L_ 2=&^?/G/4CL
M/:<GFD79,UJ6)GD0#U^'Q"DPKY56'&B_-M!.I4XUIP%AL?8)S7*.Z>@1R5@:
M92E-_"C<B_W_!4$[F&5)X$#[^1T&NZCQO@K-J]%=S-L^V_40U5S=N;CORQO=
M&*WE_-Y:RXDH**X)KINNH^N3W.C7/UUGVWMDP[E*:JT:+Z^K:P_$M55M6*)7
MY5YS5=5+ G1Q[16&:V+#9F?B<Y%>IQ'I=4?0:NZK*&0YX6'(0,L*<R*TYL0/
MTS3).4^R8"^%PKJ#^0[.Y2=0M#[DG_ X_@&G\?UP&/<4F$7]&2S/4<5FN7!5
M!V(.Q.X ,1%0/Y.!)CQ. ,1DGI$L9)HH$81<L#2(Z5YZ9!P4Q*)X%I\\B#U[
M7.F1BL&K6EYAHPLG]CJ.<=H<XS .CES'P&:X)"H,?. F.2<L2U(B=9Z%>:J2
M)-IR<#Q*C.:WYOC^49W+?ZZ*6C\C TIF*3TN_N.:73AL=-AX:&RDL?9IEE.B
M H!%*K.<B"B+B:+:SQ7U_33<2_3J(;$QB&=AF#EP=,;JO1FK&R!#E-<7-4:B
M+F]-R3(-A+Q PG4\R?&DD^!)NWF(5!$/XYB37$BLK8"%,Q,&_,"/@CS-HB1@
MSV2F_M@>QX]S7B[/2_5S=R+WE41\7#G$SD[M4,RAV!THEG&?)GF>@D#+ ,6X
M#@B+>$XHB,-4I0&-Y%;L^G[LU,^-8@&+3AS&G*7Z29;JQHF^+I[?Q?._$I,.
MSVD,*KPF82* *5&6$JQ83W@F.8MTDF1LJW_I7LS=SRZ-TV>L5C_)P^<2KQQ0
M.Z ^5J!F,LGA=M >F**$LCPBC#/XDP>1Y$D4IME6:?>]V-Z?&Z@9>T;7Y"0/
MG[//OW"AB$6;5>B)VS:2QA6+<.S/L;]]UNM/A)#45QA!D\,_*2.@&@1$BT!&
MOE"!5%M=L?98W*%/IGQ,GO"W:CKXT:F5-IK">7$:A2.1DX94'499A*VOTYB'
MA/H CRQ4C- @BWRJPRQ4V3.67G@^2 W8C#YG >8C.2^NT,)^"BV\*TI>2E=H
MP26DGV9"NJ-KM]''.%UG&WN<W[XU^*+;/N]9HZP:EUKF@KQ.),CK0+YVJ5C.
M?$K",.:$1CP@/ L92<,D$'D>I6D>[=/7_B'O1=T+/,[[<M@<5_LPETKFL-!A
MX?,U5WD5F^UB/I\B.Z+HB%\"H\&_X&-3*%.H%7A?K>=\J96WK+Q?;YNE!T/6
MS;(J7<LKAZ@.4=UFNY-\BIO[.D_RH4J0I(H+ID@J,-0O2C7)<A$2H72 #:*D
MU%LQV4\(]7M7U1<]\[X8\^Z^/U2O1^[=]Y<QEWOO[)=[DD%5UU3U_<</SH+I
M.-,)<28G8[J3[#;W&$[R861,'8=!EODQB?TP)92'.6$L2DCF9YGDF6"^W&LZ
MR8?\T[*2?[UOFA5(DGJ?_H@P><9,OQ>7A0[4B^>T1<BU\DWZBZYET99<1:+U
MJ@42E1,F70RSBV%^*MO)&*54$YTR3JA*?,+3C!$NHCC(N&*1OY_JJN.Z*7B&
M/]@C_'-[MM6^^A-0%[;L,D$<BDZ-1(X;15F4R\Q/*,FHBD!X#R*0P85/=!;F
ML2\9#_1>FG >"D4SET_G@EN?1;+?2/Q> <UZ13F*<W5)WXXO.;XT42,5#8-
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MN8+7FA(%EWP)KV@6*%NA"ZX=HJ&0_SCS?H'I_%KE0/A+[\(\U;LP J5YSN_
M0'@ML=X!/&JY6NH9?)1G,^_[[]J[OL,=EW4%S.<)PU[?>>,L27]LS.W_7/$:
MQF,M,\#X#3$5I?<)X.!MH2^K&0Q\7L!"E@4_@*EE7VPMR(Z4K_T.9[:&<V%R
MC[Q/BWFQ=.QM@NSM0^G]YPH@.J S+_3#:-:J8Q;M-# % XC<V[5[#WC_'9I%
M)B*6AUJ1) EC0G/."4_2@ 2AIDKG-!/^5M";C*52(DI)DH:@60B9$,8B09)
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M6VU,!*ZJL2/IQ?*.0-'M. !T[&S%I6*1]^6N(-V1?WUP_!NH[DO!FV"*!B.
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M?3=($S#=>ON&,8\,T-8),(I[,\E2JRZ6>:ROM=/#N@0&"6L4#3#J#;Z]W2H
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M,^_=Z.E#?7+>M(RW167C.1M7@Q2CWBHV1[BMMFD_ZR_%<N=-"UY8^SIFUV"
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MC??^XP?T(%D-UFBOVT:^-8W71"*V]0C4R +U-<OC_]IM<_R--XK_T_O[O!+
MK'XU:C?V%VV[=.(E,#PSHAIT-[W1D+-SC5F8&ZR417EE&47KHMIRR>V.E/N:
MGM_W![VS9&3?@<<K5Z9HCXDK[(TBI1K;2-HT_K66LI9/=2$QMG$ZNBYK[#+:
MFB0&&^&LB\8T)=&7'>,>\80&CH_7H.33=&5/Y*CK^<)TRZ@[0XQ]7K,RRG,-
M'!%.H)WDHF_)89XS2KAL=-GNU";7V"BJ,NN+,<R+O_2\N*J,?@Y?RZM"FVP9
M/DK.,2DK0QH"+]L<FWEGDZA0$L"[T&S?]G8?3=TR5%,%AJ]),VN&]W9)[R3R
M7<S<F@%@'5;+N2'_KB&(;095FKH?F$=C\=!6:X/+/MIQM[H_&I"[Z@HC<P"N
MT7_U#NJ_8Z+4;/2%Z396W)BJ:^0_4#3H=OIGV]9^9()XCU9H8ZX8^Z.\[W&L
M;06@CZ;T%IS4\T)-K5W(*05HO"\-"7:D^55CXV(7,K8%.M:QK.LIW[94V@'7
M@LN_ ")N.J*&PVCJN/4B:IO6V/5?&$=J=W=\1ISM\LS&HS!!)3A<2Z[>%9*K
M'%+6UIH\F6@.$Z$Q>D7[5+FQ'-AU:UQ>Y8\VJ*,K;5-B+$LEC4EPF.O5K:B+
MP8AGKQ@F8OIGGV%)\]:[ ]B@S HT,"MM(Q(^87\@6XW-U&@+,M,$?/>6C$R)
M\+[U]Z^586E_&9>P^?#QUQXN <%$&SS52D5M*5^C*=@<P6Y:7?^?C__GY]]_
M[4^T-:"NS=^\&!96;'!$<Z-Y-0S!WFC&TBZHU3C0IX;A0MT,[>*W\^^*\!JN
M8\V&>J1"#35[3+"E!7S>NAMZ)C,;PLO,3Y85S0:]J$TIM86$D*$UX\OLKF.!
MF[JP' N#WM9U+?.-N0$7PTQ!]3?>UR5IE\OJE,VX(_BX]QYJLUU/@'9SQ[;Q
M;L%:7M2SK,X\8"0+VQK>=&19=/$T8S;:/P4S4VK3Q6]E>HT/'+6!\X47-4_@
MJD9=_ZRQKU^S29QX::VOVXS;_N1WQQ=+46P?@V[8)A^E'Z&)N^*PCK?_HQ6&
M(^&LD$4:4.F\*G;!-G(COHJ=GWD'$(.A FO5H7"VM*NA1E7B!AQK86A;(WY%
M 4B/5,8557$>\I@$(96@C&<A$6GH$YYG0<)D(%GRI-[(1AF_J+IZY-@C"HYX
M/6JMY;3QKQ:4Z JYKZV<4[TG*.:M[9"UTHWBB1!C?KUMEMZONKX$$>,<HS^-
M@?'[1NOG!YP'[)_I,Y-ZQ#LW\=WGTH;6/)'NGHB+1M[<R8%_,-U5.^6\K]O1
ML<B%M<F/0GY'[1%Z=CN$T'3J:A?W ,,$W;)J"_S9+ Y\\)DW.IUR;>_78JKK
M/K95M3IS4>\NG,K[8*0N4NM>(=0;95H[(6<L6+9Q!;;H4R^"K&<DP@R7V%YW
M3<GH)]\M8\^K]=#$=EU4&59P_0'&FM*U ^V8KS&2K ]DB0W>+O%)7=32Z"&V
M%D9K;3>V<OLZE"/NM1T;=]LBNZJ+=@Y"7(?E%6Q;;T?;KOMJRZ_;B5BYKS.\
MKV4J]28%4^2Q,\VWA3W[ZAFV,JFU":W=/K[K<15[84E,A,) N%L&,7G7FFU6
MG\39FGY/N(WC\(ZNZ\C#RX;>JVKH"8EB.4]4$K*<:*:PG(22)%,1(UQ'6LJ$
MJXCG^X@%AX&,^OG550D?I7;M-N[9;@/M&/-;[UQ5IIOPN+7?VEHZ&6V",AHH
MJ>>KRQ6(8:$?^M:2@]V4;5 O[.:G/TVH%OY*_&1V@%B"A_CFA,W2"7_$CY;!
M7 SV$6/7,8SD0^NQ>#GP_/[32BQ-V6R:^B3T;7/L::VFL6!@42\SMO]HBQFA
M&&'K'0%'^]E4E.C-#1\^EYTI?@I+FP4QH;"TH[[B'>5VUL%97Y)3K61KX!N\
M5Z-\P5$I_K$/22&AC9/*!IO<3B?3V(($7*=LP]O5:+%!?ER8VB;:&M[:5PZ+
MWE?R6+,)MT6J=R[\PYCO^$[2:$F*+^2J4 ![;][](\M%E 593#0/$T)C+H@(
M_!3^H1IV,HRE\E_(M3OL;H_>:_]Y 1$)Y7'30\^X/->CJ5&@?_IF[6Q+EJ0T
M5HDFN<PXH3P$J4=E&4E%GK$DY[[,M@IO/:;_CQ6?WY=C<:GM>#Y\]6D)1P)3
M-?Y<H(!KY (@Z[?P>;UM#OY*C'J!;R&*WY);D*F)+E^$G/Z3ERO4]VQ(.^UI
M:5/0?2G:.O.\NY(FGDY!818D(%S[).:1@%/.%&&Y9B1-),^UBH&,MMHM'92"
MM%HG'M-0AK0"^.$W@[=4/3DJ>2Z$X0Q&S7PB S\BE E*,ID(DD5)*H-,LHQN
MZ6*'HH_WUV@YJ@L^_]E [Z0(115JB%C%:A)VI*:UBEQ.CWRJ)]0I>'3@Y".3
MQ4$AXWG ?:*U"@B5,25,41_HS0]%'BNIHR<EB[?=.*V":^-+G*'@R8:"-E#'
MV0E>F9W@M^K&!H,,(9-W6 HBXJ?3LA1\TK:@R.]]PZD75%=M]ZPP\W]HC1=3
M6JGWUY@OH?ORZ';%3,Y$MXAO;3503*1^04:UH>,CS0T10*,O[ZR*V14U78NO
M;?3EAA7?\.DV13XOEGUGDG'-G\O5G&-ISS;5I/=OHBLF'U5;QP:AQC*%O=AK
M&U.S6J@V[Z(=:._(:8,V:KVLJZ$%IDUIP0@LF_39#)Z7C=S^K\RK+X6#,S3E
MXFS_$O1E]+5>N_*G?6YI)_2VP:9HS>@ZT4] X'5IG"Z-\R 4%_@NC]/E<1[6
MR&DXF64VZTRB];J9 B<%-JOVT(:&U8YA+C8TT7CN^\;*03PNV6"2_XKKGI>T
M?O\'/8J>>3\;]M?Q!V1F"PR_7B[U1D66HN^0-<>D!QOIWX9&#)$JENE:#@OC
MP=HR5N,WD2U&E6[S]AY73\\6F[&A2&J09J;B6S^Q7(">GNZC6+ #5(QX@#KX
MWH80_<&_O*PP;'6*E+X*G6)8M,GJ$FR7+L'NH4MT%6_& G:;+=+[A98P<9-L
MC0%% $[SHF^NW;D*^Z3UW3'V"/?]S2;56U^W@[K&J"R.W:)P:+; #9;C;[#%
MT9GW;E6C1WRV>UI=C-\(%&W%,QPMNM57C9=K#(J:=]%S.)E.JS Y''@43+3G
M#C5A[:W[9&=?YT%M2PBLDKJ;(9B5,WP%;;6WL(*FC[Q%H*UYP%*V[2,Z'<T6
MX1G4M+:^ )\OX=++JW4=SMXE^=18Y<L=P$<QZ;N-S#N_!1E\O]9GG6=9&(F,
MA(QI0FF>$L;2A/ DR]+<5TQ+M==N1R.L/"43\UU$$YUMY.(/S0O/ARK-OPPA
MI"]@6'9FY UMQK"3_UR5NDTI#*G9I1[.H[Z@W*[L)NS5"&!HD[Q,A/9M7[EN
MA:$U?6/?5H_9[BFYT4/2O-U4,^M+G8RRO9%#K:7*=1U+;$W =;SN^P W!FX[
M-@EZ?BG7G]J5G@[- [HT_W+H0F18)9;$69F@X.ZMAI[;WA9J5??,8-,.>/;U
M&8G*+)65KL<%W2XQT['LB]3AM=B@X=8DSMYY[9GW=V!J;4!U;;)',56QR\^_
M<RA+TUBS2_OD$ML5%T-VVU!R?%>/BS:ESQSSK<X9,UO:<[,>>S,LI+D1\./N
M/>K7R99R-346^A4;)@]G!%DH2C#&(@5#;/1:$<AW('<4VON5PSS>P77*_"'[
MB7=C^ \4IGZIX$3^Q,N_SKQ/!0:NWSW"H;>!JHS4TJYGTVT"B@WPU];.;L_5
MS'!HKJ6_%(T5U&U="[/6HVZ<WUC>L%M>ITT??.)C/+KBRON7)T:#W&/4=PVE
ME9G>U5UVNQ6:I) 1"P*B5"!!:$HSDOF:DBR($NGSD/M^LBDT)6'&\D G) T%
M"$U<!)@'( AE<2 2KFFJPDVAZ:>V&,#%D/-]1])E)R#<?F?J5YMW_OF//S^]
M_<Y#_0.>"0-"Q\TUGS?_^SL2KX>7E*MKHJHE::_X[M^#,[\30+NYOV0\!UP]
M[V*A)T<-89)D*@,1FNL@)U0H1;(D2&&/$\Z"5"<@5&]2@\2\C\B7)!-"$1J(
MF( <3HE(M/*UD'XJDNE0@W_&ID@-17EWIM-:LIZ1UUYNP/>2%$'LZ;VCLWNE
MF+8E$>Y:@39KK&F3(Z\-4S<>4)/XU^O>V\F QJ3>K.4WCG+,)IK8VEH,7TER
MZZX6 5_-W"N:47;I@U(\IYO:.=2 &<HU?)V8UPH[CB,#VO+F*$'>U>6G3YEH
M9X3%5+I^8./VI-]HD?,@;2?ZNH8S$=ERKP8EI4+FTX21P ]CX($!<,,@3 D+
MHCP)PRA2V9/J0/:];^255JLY=L_N3$O68')>JI&YI&T4K3Z4OW>=IWY"J^8?
M2"#W,$ ]I[B-QH_)"-RCMK>X-,UP4+ FS^KZ&B&F*\%W[TYB/0_9V?QKG;%,
MB:E\;Q"@6C4PL^:'ESNG4VCP^_A7/S968HQ.;=3)O]GHO788X]:5?+6L?FQC
M1G H&$("BBQ>3N;\%O#81L__:-_$XC/_;]WU,)TY7S3Z3:,7')U9W0DU-:;L
MH[\; E^6?> +MIFQ(O:;[AFC"^%*U<>3F+?2[(Q1]C<,C+G[(E"ZLN!;UWSK
M=WC(MU]T@(%D9UF2L-'_N3&]T)C^[5^7]2X:;N.OT(^"IE&L\ETJTI[PW/S?
M[A/^&0Z/C?IZ8V._\(L=G&S7($V&*>B@[966$]X1YY4=/H3P =%;2W5B$P3*
MP%__]W<!"&-?G6T?P=>%F2Z6GO'0>AWG>(GU>(R7[%XJ_>/)8IH+=="3\94E
ML!CD1Z]]$1P OSR9'<,$>P .3QY_6Q^H0UZ'O.[8//38A.[8N&/CCLU#CTWD
MCHT[-N[8W/_8#(&M[N2XD_,$#=GX,!Z@">_6?+=U; EKE\L?-Y8=ENHE$D^?
M$)?T;L,?]^8^Q';?Y6BI<,?H)Y+VO5^P?ORR#$-^SH4QGJD#X9%;"W=<W'%Q
MQ\4=%W=<ID0B;BW<<7$DXM9BVUUZ&L?E/NKRW1[E!ZC,X^C7NY7P;^C/XV ]
M\Y#Q4_VOA--.1;W^=2M%]SXT>I^E.E+ZO&L9RNHKB_#B)I>[YOHOS[?;+XC,
M>T^#$XQ'7%%.),/DMQB3VX)8D225D1^'.95B*RE29#Q5:2H(EY(22F5(>*(%
MB2.>ARS)9.QG6\6U>7-U7BK\S\]#3OR.^A)W)K]%:\EOT3>2W])9$,9WIK^]
M5M+?[\%V^#;)37;X]BA\VR@^]EIWWQUQ=\3=$7='W!WQU[W)[HCO44N),<68
M"46TT)Q0$6F2Y3HA/E<LS&@0!NE6MY4HH((&E,&DE""48Z67$/25),KC1 22
MJ8 Y+<7AV\3P[5Y!-?N(GW%60GS.[^LU^;Z=/8V#)_0LR<;9GRR^:_V&%4C.
M4KAH4=D")V],K9CB1M^=S![\\"0'PPF?H0>OS_$AZ)[)XIB$B5RP(!(L)EB\
M#>M]!43$,B,J!!F#1SS->/84DV?;NJW#E=TRQ?FRERKV)$L$0?(H2<(=$(>;
MCBP<;C[.SN+(Y)63B8,/1Q<./EXWF3CAPY'%T:#''7$JTM=2BH@PE@6$1FE(
M6.9SDN;:CVD>QYK1IUB G=+V.@_(UPKNG 9NNK#2@QJ,-WM:#,TLIF0[#N]E
M.S[A4_,H7]ICT]HGCJH/((-OK\"1RA\^3V+-0Y_0-.6$^C(AF4@#HD"4"$22
M!))NR1^/B9/MD\+?ER"+K$S3FP^?2ZW^_/3W'G1 ,CDWK70^"%@"4VO]&603
M2F>,I<_KG78GZCYU(ASX.E(Y#?!]C@@_1S@/Q)CCLT8[6G$@XT#&@8P#F<G3
MRK& S!UF[#1-L;\@2646$LJBB'#.-)$AS7SEA\+76UT''Q/([-1(=Z*.'WT/
M%BO]&$OW]$W9?U1+/M]J"^;\UU/P7Z^?Y_ LQ .MJA6VTWI!3-MC5M,^:.@^
MJS0-U-M_%+.,62J93V3*4D+3B!.>:T8HC<(@",.0R:V.C8\Q2-OVC,^7 A6'
MLS#*7L@)/M%3-HU(DJ\NSDG8IH^6P!R,3]KJ=+1TYX#- 9L#-@=L1T=W#M@<
ML#E@.S)@VZUX9S3CF:\X$5FF0/$6E#"5Y83%0:*9G\>,[\6$[Q3OXX#QAT>H
MGR:,/RV.?=<X'F+Z?_7&_*&;T+S@HIB;D/1[M10Z(?/\O=N\38-W/9.0Y*;L
M:/SD-_P$I^QH_,0V_ 2G[&C\Q#;\!*=\%#3NZEP>5#V\@$]%>8D9R_!E4RA=
MFX#/*24M1Z[@Y01-X!.)IIVT ?PH(]A?T*\W$9J;HE?O1$*[3X"Z'*(Y1'.(
M=HHU#XZ4N!R@32-"0?D)9U2D)/23D%"9180G0I!<:>T'5-(X$YL1"K[.1:1T
M1&0:^X1JD1 6YRG)\Y3Z?A8%*A2;$0H_K9JBU$US45V+HC3JY*!F7HRUS%]:
ME^3MOLKFS?R03B)T82)'S^&ZPW6'ZT>.ZS3.@R@4G,1!GA,:L( (2E.2I1D+
MA*89C?4FKL=:Y4"^G/A*Q7!/$!'A [@'@OFIRJ(D#Z3#]<D>O2D&I)T&KA^L
MK.IIY):/@M)<9=+G+BDSF7C:EVF">1+!Z<]?Q&HR5/2"A53N$7Q]?/;VUTXO
M#G4<ZAP[ZCA19V+DXD#GP-80S@*?43\@.N$1H3FEA(=13)0,=<;].!)ZR\H=
MZRC/>$Z)U,HG5 498:&.2,:9B',:B##G=Y;2^V5089XO*^_Q%I#7?H <WCJ\
M=7@[7;Q-(E_K2(8P0(8>0LI(E@>,)(&?9E+RE/E/ZL#E\-;A[9'A[=B&#)\Y
MS/;P^_R-*&WS[J^^[KY3[R9JYKDK<)ZOEE5'"3B>HKS$X>/E9,YOJ]427O%%
MJQ_MZUA\YO^MNQ[@;,X7C7[3Z 6O^5)WRV# SS[ZNUWV^INB*:R/ZDWWC+L,
M\>:M,;SSNW_]R@7!61!^ZY)O_,[.OG7%-W]W@YCT(+[A/<KV5,M@^^C?/Z%H
M-[AFKP5;3V."?1)@0+^1!?A8]_7SKL<]I%#SOL_V7(AJKNY<KK=:ZFNA:R\*
M9E[HA]'C26.:BW70TW$?G_XK7P0'PB]/9L<PP7MG8D\35O:)P;_H&SWW H>\
M#GG=L7GHL0G=L7''QAV;AQX;)^>[8^..S0..#7I+/.,N<2?'G9PG%^%Y:FG5
M.U,S7GV0^[N-UFGW*K=ZW^4XYO#V'6#]^&4YO@!<MQ;NN+CCXHZ+.R[NN$R)
M1-Q:N./B2,2MQ;:[]#2.R\%RPEW-6GS.KU6I;SUXWU]ZZ>6PHBYU_!GB^U_<
MY'*HV/UI(//>X_)%$-#$3WV217Y,:):D1/@\(I'*HBC*@B@,U&9</I<LC!(_
M(30-.*%1#G<+E9,TBKF(<I4+'FS&Y5_PYNJ\5/B?G_^Y*F[X'$;UG)'Y\2R)
MXN<-S3_VL'L'< [@7A' /4=VN3OB[HB[(^Z.N#OB[HB[(_YR:DJ4!T)I14F>
M85'B+$T(DTH3$;(X"E26*3_?5%.2,(6?$D%\D6G052).LC1.2)KF-%<J2C.V
M5;S2J2D.X%X:X%QOJX/:"7_7S;(NY%(K3\*QGU)+J\"UM)I$7>U7B:![)HMC
MDB8RD3%?Z81P'C%"8Q$3H?T$!(4DYBEC/-UN<? 0H^>R$5_>#+BR6Z@X7_9B
MQ;Z$B2!YH>K7[H XW'1D<42X>=!>5XY,3B/:P]'%JZ(+!Q^.3!Q\.+J8BM86
M<:;\-!8DU5$ 6EL 6EN6,A+X@<R2B(I,9D^Q 3NM[74>D(=W))K& 7&AI:_5
M9/SGV:<S[[*":9;7\(W7:+FJU[H33<%Z'-[+>NR,'0_SIAUIH[='5^,]H0Z*
MN<Y3QL*0!)1)0I6@A-%,$)&D<:9$3"67^XB5[1/#WY<@C*P08IH/GTNM_OST
M]QYT0#0YO]2EO/T@8 E,/\5G$$[29,92=L@*U^Y$G4:'1$<J#GQ?JDN4(YQO
M8LQQZ$6.5AS(.)"9!.$XD'&T<FH@LUN-I)2FE&4^Z( R(C1,<R+27)% J80F
M,4VH>)(=VZF1[D2=#OH>+%KZ,9;NZ9NR_ZB6?.[E&Z4(7?C<%!S8$VW]ML?$
MIGW0T DW5<Q4ZH<\DB0/*4H%<42$8#X12HB(^AF7B=Z'0?K<@,+S94&Q<)9&
M_@MYP2=ZRJ812G*:G1=/@L <C$_:ZG2T=.> S0&; S8';$='=P[8'+ Y8#LR
M8-NM>(=Q(+-0*A*J+"*424&X##+" M_7L9]$4;R7<B1.\3X.&']XB/IIPOC3
MXMAWC>,AIO]7;\P?.@K-"RZ*N0E)OU=;H1,RS]^[U=LT>-<S"4ENRH[&3W[#
M3W#*CL9/;,-/<,J.QD]LPT]PRD=!XZ[2Y4'5PPOX5)27F+$,7S:%TK4)^)Q2
MTG+D2EY.T 0^D6C:21O CS*"_07]>A.AN2EZ]4XO0_A(B<L!F@,T!V@.T(Z&
MN!R@32-  32UE"<R);Y,-:$LRPFC44A21?U497$<Z>U2-4&09)%,2)SKG-"
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MJ!'A$$DDHD:$0R21VYLZFQ6:^XH]GXTQ=$<TN!X"XR"8H[L#TK),?4XYT;P
MTUX4@FB7YZ2@Q@G+J.14[D3UM9%.B9P8A0U,*=Y=.DX* 4^RN3(R-R^Q&>D+
M(I,XDNA>M)1$*105M:BH144MDLBX4"/"(9)(1(T(AU=%(O>S8T;3D.EILO5?
M<8\SGE)3"F=)P3)->*D]D;I0!$<,<\.E+=A.,]\7UN/LN=/,_:U_^(Q]EO_1
M@>^7U9E;5 9^M]7%XV]H+UIOO?O*U]T8(/W.A@D(_"3/LF^NR$(HKGO_T7T0
M1]C\^SJ9^^0_5C.79.DD82GCD]Z%,5S.+=YU?$]D7A1<6$9R9Q3AA6)$6^&(
MSK+2.Z:%H7Z;&Z546.E313Q5$NZAAJ@TMR33>4JM4%9HN\V-MD9(;#4:7W<5
M_VE>U[_-ZPJ7"$2AW>)7W_V^.6>B?=KED&E]_.7'ZQ*8#N<O/3Z&('Z,#R&T
M+&E!<416@:[IC"AI4D*E<EI(7A1V1SP)Q4Q:2DF8LBGAEJ5$* &HP9TTI<U3
MMBN>1H,08F0(,5\M$M6!@\#:20T @3WIX<CUY(M;N*2:)2KYC'WY 1 =Q)(I
M_G[>P@@?^7^-#<D$+TOM-*@RGN%  UX260I/M+129(53,LVWD4P)JW*>"6)%
MX0 [4TFD<YPX^#K55LM4[ QCNPN2'52/B@WU*+\&K]*3P[K1$R 67#U%^'^I
MEMCE)E&?/R_<9[5TB0<-,;E %7&4J.*$X%IF#"!+X=BUX$2RO"2YMZS(I+%E
MN3-0_2ZHLHT<:[391*(CH0=GH\2/DZ316KYWQB&O33(:-)=L?)J+,3F84A)L
MHIR!YN**DHB4.\)D7DA'.0BRG5[11I=."DM)JE%S23/07%29$6,H6%'4F=3+
M<0@J JP>L0:#?+6;O?G';#XB= &5=KY:CE%]R;/" SX88JP$]45J3)I/4U+D
M1C&PF[/<["3:ER56V:>>^ *M:\TIJ+^@""M;\-QYK3/NQH$5NWR$O7#UY21)
M_NNT@@?4>Q/ $P6/V7W=)*F6254GL_DR.9O#)=/J+S>]3):G !+\$C[@#Y=\
MF)\!F"Y!+DZGB7;) AN_+6 5RSDL%[[#BX8OU,[C Q?.S"_<XA*W#)> "%7=
M6#S KGJ9:%6[>I( J,UI<J8N\>%PC.&(@<O"DP_L"$"T@ ^PVE,WM<FINNAO
M1,#!^Z8. !2V,@="O'1J<?*$9WY_ZYZRYVC>?QI@S\)=5.Y+?>A( 6.2"JZL
M%OA[8N$L9Y\3IP S%NX<T09^/7>+:FY/D@^ ?8"]2 6NP6_$M<^S@%JK<T1,
MQ$E MQ4\"]!53;OO;.4]T-7,.,"VY1?G9N'K@8:'_0W;N[>0%:@%_XCO6MC0
M*#ZHB=/I_(O"!^(>S,;2JN;IJYE:P;?A47C@=?,II.@H_%JK:7A"?>H< */1
M0.$20//Z'&[!S2O[WZL&6K@7P.@9?%N?)']NL@57-Y2+4$$R7KAI> 7<8ZX"
M&S(:8U9GJ^;R.:P;=@.'MW"GL.(*2 QOW/>^P*CP736@6^4KHV"-"(QMQA"H
MM85)BQ=AKD_Y'7*SQ=(#0.8(UFVGT!/2+IYXA\-X9I5U@?<A+CDSK6:!1P/Y
M_>66+0:U6Z_=D)L#_(&]G2] )BU@ 8E:+A>57@4?9SA0>/C\K#+AA>WC$%L:
M,9@L5#B0P-*:<R3=R7H0:O,%G R0&QQ$>QK;XF*-C>UN_JT>G,T0_,M=U38\
M^Q 8%E7]%SE?S#W*H(;7PR4K#$><JT78_ JP?I&\_^-#DK%B@KB"&-W@*3ZP
M04Q\$ Y8GILJ;"R00;T"%@ K;* ().BJ (G_<8MY H"> 26$7S;V/S:=2_FT
M-(P7A"I*47]R1.C<D)1S4*MR[VVVHXF[PA42C7^EC43M71%I##Q"NL(KY:C1
M8F]$XV//1S^<@EBXPB"[*IRQHUX?,#Y5)AS67!I6HHTA<E *TX)X6OHT-ZZD
M?,<[R@JN2BS;S*0 X[.D@BC#,N(!$ *@067.GWYG4A1,@Q5$*.<YX1P+4ITJ
M29%A=,JZC(H=/9EYS@L!QK0U:'&EKB!2.4/ TE::,C"NTEVS^M%WYBGS&0>]
M'^C< C9:P*Q<<:+*0MJ,&R>8V-Z9]AG-:0YF@L?]..N)L"7<X[WAS*7%OF&9
M#[BSO<;>';YX,L$RT'9:_@S<S'T]=TT7I@U9/1#B%<C1>W*W+5T004NJK^2T
MLJ";O/OQ_[,YE8:QE&CT:G/G#5$.#$1:%#1%!Y'(Z;4/ 7Z7E2F7I* ::#QW
MC AF&2DI4Z4!R"JEGD8KW:^!]CKZOG^> #U:#1B%Z=.M8GFZ<(U&7%=?P4R<
M+4]! ,]0^=W0S\(EJ"@\W5+'8M_MC5;_KR3Y._Q[-UK=>&#GPS&9S$&A &&$
M[ML4^++*,PIB5%!/3:9%MA."NHO4_6TQ!Z-K>?D;V"?+]S/[ YC^YT@OZUR)
M3_"&?T[GYJ\WB0-&?HZF[6+E;I9S0,73V+5?FG("/9_:8V  /TDZ2 52Z,$T
M@9N7]\',(R]T U6/BI&,F\SGN25>H-!(4]!PJ1'$T=0KZQWC^4Z\ZJ@8>0,\
M?,"$BJ)K&/'4/I<-/'1K/)PU]F1=U<O.2 -[;SK_@E+F[<,SS^92?/*[:@E
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MEF,D]YOB-IS3#.FBO0K1"_% >5]-JX ?0'3SQ=3"2]PDJ18+=S$W:/5/ *4
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M@XROD36;6M87M>4 1Z!5LY5K0=,]=%W\M6_?M5M<5*C^P@.^5%CPC"DLK76
M5YPD?YZWJNQZ,\.-=JKFSM:ZH^H5KF$CBHVR[K[C0G].=B?/ <O84$\$TV2Q
MY?C'FH:=:J;^H9'Y/CWWVF:^V_I*9+TC9;UJMD+.402*SH[!?!?N3%4A ?1
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MWS>C'BZ)1Q]U-SRA,1?5= K8#$9\U[CYHFES5<VVMZZ2C4VT 8SV\O^> _4
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MH7D7SR^D#R4E$8F6.A/)+2=60ZR4I9>,<4&M:Q7_629TL4H0A0-R98;/>,;
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M'HL)/&Q%]P"7"J$=521) Y&M-HD$'[!Z.W)C1;$NM*8">XB&(7YEQ":)1[
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MS]Z?G8U'<4TI=55HN!I^MN7HXZ^_S3"$^;T"@I\/UK/S5J$$:/^/G9Q9S[R
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M>3+=NM@-Y71+Y*^F /@*&CRN=MR;MV.^:O:A[QM]9(B^1STNV-Y&8T3@Q7P
MKFEEG,5B@]]SG96:!J]01PH@=L-L_':RGAE4OZ2R FR&J"U.(1JHHSB6B]/I
MK+;[;ZOO9<ZFNU,B'[[L0+JL \0*J=;5Q<2(+99A9;ZD$)LZ*]JU,C9Y)84E
MR>H,H$\=F@Q),KQ,0PJ.VG 9]!MMJLK4 /W+S9+=,>R4KO:C=K<G=4<B&FY!
MY)$8?,*NA4Z&!Y0:J9W)Q-$(KCX+B7B3-4D)ZRP3=::TPH,["L5O?O9NUC#)
MUVZ.0T:6UU7STQ-*.]7KL0DM=XSQ0<>UXE!6980G(=<AB5:1$(PC*5B>&>R9
M*G>B JE9J/?Q-*<E\I^VU!_P-L\^Y?1F.GNS7"QG>1T>_H'.R@T(0NXS9$%S
MV D3]_YJ$)FM%J\F&TI=OFW^FLE\-$=3MJ$O'8_K,,H7W0@[F]3_X,^+ZI:N
M;F.U ;C4+S!J^FF5NL=;P5L'GP/?3L;^')Q5N/J7G'YJOLFI$_K]^OT1T>!L
MGE_,,V L ,5Z:V?5"ZN7_FY]"W /F_.'3Z/YJ!E>_V)]C:TWPCO3)JU?OU7K
M$Z?-]ZNITWO>Q$Z8ONXMU_U=G AU[?=T\C[^_*?%[*JE7IW68. 0?/SWA]ET
M.4ED)8BE_N]J0426M>:,Z$5S4H0O[-FE&NN ,5CI<*/95VGU%3&.??CCQEN<
M]2S2,W]@D!3\:TT9=_[AOR5,W+<V:YK(7AQN_,#W^X W/O7MI?WVTOXZQZ;Q
M1+!>XA_8IK97K2LJ]^0QI6,V=%-"LZ[R.EL,ZJC:P5K+'SO.;',NWUX8NKD^
M#ZH/7UF"!GFH>!*+T.O,MLZ(7F>^U4K7-$K;3$?0E!)O%>5>><^7%AV6ZAC5
MCW?(2K_:.4,Y6\V_N#BCO(GDW61E;N4B'J,(^>Z(O7W9R?0KBW $"3GLT]U\
MDR\VX#Z?N"8<#Z@4^RCA<Z'8X6Z,BT0Z)DE KB27I!&!V6A%:S@]Y<5+9%5@
M\%&DA#?$45L(U<5&3DMA17WEJ.:5/\,3Z6OR^'>NTQ!#[NQ0J?T%7+W<]^#6
M;_(3!K><6?!4%1(Y5T06)*!4TA+&/+>&LNACJX5-*<5]]HH _!G\C"%6>(X,
M((!L5&6;OG8._6#@)HP<<LM[<+N#P[S.:SU[A_D?=:YM3H/?W_]CWAN0WH#T
M!J29_*=]*%1;$D,E,-2U,KF LYR<"-D[Z]H,QD(&BM,"$W>"R,PL<0#4)!O%
MI:12.]X! \*H'5JWOX2YE_H>VOI-?LK0Q@6V]QG":^#O4R0NV$2TCUBY6WP1
MK3;25!AE-B:2K9!8P!>(9RD34[24/D3&3>X"M/&AD_NI0)Z7U/>IY#LISZJ"
MTG_RHW&M-\22R4VMY,4@S%_>__9;;UUZZ]);EV:^0PJ6!8/V 6<U@+$A/AE+
M##,I>EVLMJWR\)(E=XEY\+,3,EA&1;PW'*Q+%JIX+Y5L]0(^O'612@RYW=\J
MTDM]#VW])C]A:#-*.REL)HGB0&0#[K"+&L)]E2F3BFF16P.QA.-&JY"(21FY
MU.#MEE-&>#96%Q^$_6ISTP-!&^<<H&T_Z_SSDOH^I?P@CO-O8S_I4\[W8%Z^
MM4BJ@ZKXC6)P_0H\51,569*):9*8 4\Z<D6<RIYXFX6V(@7*6OVW6OOLM+*$
M&O"Y)3C;!(R2(,%8&X.@GD?1 1,U=%(/J;SGHHY>=VY2D]O#;"\JSQEFN<W,
M! 5N? %?OI:7V.0EB070,G#IN6N--[/:2IZX!M>? <S6*87.)L)=%B$XG9,T
MQX=9-C1*#>'N>ICMHX6C=2[VCO\!M(J?<%2K-%UB$/;H].H@-NGJ-7BB5JDH
M:CB2,7'JP,)PQ4EP@9) 0W31J&AD:];#'<EW'L@JZ:&E>FCL/1_M]OISS1KT
M 4 O+CW<KH, ;JUE@@%62@L.O1/$:1=)$L%YEYD5G+>XLST3P>) G1(!HGT&
M[T\G0:3Q5E"K@E?E^' + 8"20\<>--?RR/5G7QCP8#Q%3\OU?T9>_K?0M!P1
M1X^UX<_PD7L9?V8;_C0>>=L4PL]X!OR7M2>QXA+]R];@H=:K\-%NF+%+W_W5
MK[OI2N'#7<W'>AW3Z'=7\[%JQZ-,7I#"M<:I0(%8$PH),O((_F22K#74]S9\
MK&LW]/5HC@39X&=64M:S/)E7:NO?\QBY=U]-YXN&2O=G/\_I-W_^$59@?@,^
MUOT[_+@(XO>) *,G@V:8TJ NS6![]8[ #W\[-OC]NW,DZO=[9\7GE-GUAKV=
M("2//C75*CV9_[WLZ)W)_#=\?[AUNYS]/DW/L+T57]N_L3N#O.K;\-7-Y*X=
M\OZ&.WG[.Q;3P8>9GRP&H\U%+Q'0S 8 V_^]A*4JHXO1&:N_KB]WMIS%4P"(
MRZ3-0_P\Q/ +P'Q\E":B'^+7YH]GX^EYQM\^UA78#)P)4S^K/,[-*,XI_ 6'
M%2#%\W*\@)N]/)KF9+ ]#,_/YV!D4C/5IGG?]G";]:U?%'/YK8D(L_5$A*O7
M&J[WQW(V@6>;Y,'/(Q"2#Z,XQW>=#%+]W#NX8=Q.-L0]TY=W1^_NSFC/-(?5
M](4,]S.=??"3T?]K1C&,+@G,R>#_3#]G\,TN#T.!W9A\P&$-S?04\,P^;E9M
MO0*S#,^(HV@&'Z>IF?Z W^%CA)!_L3T5Y>$UX]E.;'J)4KO:H*J9(%,7HKK1
M[\&I!YF$?_.7/(NC.4ZW&<4\'/@!-L7CII[5 4.#E''S1Q.X3CC?UAH40F9^
MFN_3MSO.9]CC\CFMJ0!/C?B,_1+%2.*T"41(ZJO[EFR+W8)Q'I,HD@C*/9%1
M!G#Y@B"J4"]]L([+5N;QPIW;=EE>SF:H%^C>_7S>\OA>?H:%J/_Y'55C#CO\
M/L\^-2/_8"W93NZ1S'-\D98S3'/-\^0HT@+_D//L9QMMN1R3'$U_4>@ BK?%
M#X7*GZ$INI4L_K#')GSTYW#U<?Z .+F:1;.H%@W!>=N6S%>7KZ9IM%B T:DC
M+2LRP@/AFZNN-8:D <N5R4FCE1ULKM>R90.<A=C6L:MTJOG"QMRBL>CA]>$?
M'/?WH_]7(RKK;=^AV6M,Z$9.5Z-K[@<,LXDE>V]("#P &'I*K+21.)D=+_!7
MG<OQP?"?C4'I*@:6Z7+641!<F^+Y:B1,(TU=&WR4<RRNF$**\BB%V1#'BB;*
M..J*S$F&%IO>-TMAN%X*P]>D\'<,1><@B^B7^P^[!X80AEQ,0R+\5H-V]]=G
M/+S@?+^1G#H5OAHTE/!JE!HS]-&/JE>X?B,$ 9,Q0-JGE:?8O /_(C3X]Y/%
MZ?QD\.MT4)8SC!36P/=Y!/YF0$Q,^2H_\V0P> DQU38^>MR-*YQ3]$&Q+::Y
M9O/]@_DR_ OLWU5QR&C61$CX3)OO@V@0C.H9!D2?\OA\N'8:QA"=X-EJ_?*!
M_S#+56+FQ[2A?=+I@A:Y3SH]&A?H+0[N!JC ;=M)./W'WE"PYG).82<P2[.;
MEMJW]9<2'_"VK<1'@V/3#[E"T2;M45%@!0=-HF1>7_^N_OC=.ID5<@2[,LBE
M-# Q6)Z!+<,WIM7\RM4(3 "O?VQ!VNH>=I-L&$4T+OE.9FNX^A7]0# 136:D
M'CXU"+4) IHL%S+0#3'BKC8&>P57'Z]8N?N7Z.>G:Q#%AYW61< _5V3<_N"E
M/-G>?%@3MWST7T8?EQ^;T&NU"ML/M<;\97M-#C"D<X^+:XJ4L@A-G-&"2)TM
M<=XQ E:>I^0BE@VUV"R+ESH42P(UU;F0Q*N2B(XL1>9=3I'NC-S[>_/D?\"#
MOROOFAVL.]^(YD8R\5$[Y[_"/]6XS[OGOX*8#3'G^"%/\LR/&\W99_^WI F=
MDL85N:_(23,;=-2::!0,:;0CP3M%N"XB@>RPX,5=Q*J/G(XK>:OD99E-/U;9
M6KNYF,')H,ZXSDT2I4+?A>BE*7S!9+K *WP<+0;P=&#KUEG2%5*"]X\9=$3;
M)HD#GO)B5,?5?W7*Y%6R_MDW1FJ^K*#[ _NQ<P$>54HQ;QAQR4* )V4DEJ=,
ME)19V:*DUBT,QM-UZJDCQ5D'02%3)-@2"?=%2&&8".UJSV]6EE_K?KPKJR')
MZ^[[-]/97Q%E[C@KF0VM=4,INA3A#2;PEO5IV-EX.1_\P+LG.,Y+9U7TA+*(
MA$@TD""S(U1DQIS@FLMV?8;P@9D020P94%96TZ\\L9X)ZH/76?-'(CB&\:&B
MHDMB<Q'6[QFUO<&OJPZ-ZNCVE?N\C^-B[4MOW.M)GF_2WUM.-+J@/X@?X0/H
MI79-<J7ERF:A"$.6&QE*)L'D2&0VQDIA4V(M#MP@F?(*((\:"3Y%<(98G3FA
M*>>,'Z&A1>754<EEG Z=W$^4>P3)_3V#+:V2NR)9^:&>#I5Z:C*:[(K7CT,\
M.YHO(=I;R3E([717:JMK@*<WF%N"?_>8]J^.D?ZZ9<<\%LY.AG7&TD?P#D:3
M.,NUS@&":#]9^MGY@.%79 ^WBJ[4L%[7KQT8^-,]Q57>.<I!6#D5(-8B*N)B
M%H0JD:(O+D33ZN#PV&(G$B/1XF0!JS0)FN)Q@_5)&<6RY#MQU:W;-]ZNUN=U
M;OYM/-_..;[=#;F&C5QO9 NK2+BL^SB:+%%[%J>SZ?+#Z>Y;A!CBR6/74#A2
M^+\MX$1FIE'@P/&T.0' YJB%B5;)=!<AO3,*7YPCO"OO+G+<5>)7285#'3!T
MR?O\?FW/%U/0Z>LQ<Z=^:JL$2;#UA3!+ENO?<6TFR<]6:%C!< PN!+R]]3V^
M.<4/5YV@7U\9<#)X66_UDK*@:S+PJ3FXAZ?KFE)HFKE+D:%#8@&Y-3C(TE?W
MVOFB;)2BE;J@FC+GM"/@6P/:*QT(Q&>%).ETR#K:9%I%SUUU388,&_2T[I ^
MK,[\=SSB&\3^72G@@'7,7^)XF?)?:GU^'/LY[,09P!J93"'07WWNN[_LE.^/
M\Q?2*!.L_@NX[^7'R4]I-#\;^_,7^->?SE"-)A^VN$Y&S2VM"$*:%_ZUG"]&
MY7S]+?6C!##@IS#]@H\)5WBQZ9?\TJ&FH%LT,-R\F^3AG^UA)(ZSG9Z9I@5F
MTPBSD;^MGYLVFC^?;OI)JT VO:'U7/N%'W_VY_.?OOO3CF"NI:XNU=4B=Q3)
M^I;>F\/)U15K?74OSC<&%%X9'YTIQ H+)D8[3;R.E#@O<U(08/CB#]&+\WY5
M"[.R+RT#57VOU1G.2TQ C!;G?R JWZ =YSX+V/"LMQ/GMR\QU?P1'9ZKSOC\
M:LDNDY7B"9_'@OWQ>/IY_J(;EFO=:%?[[#8][,VRXP*_P.A[W6N/MX(*#SJ)
M;R=@I< OA:M_R>FGYIN<.J'?K]\/CS/V9_/\8I[//!;3KS>T'N,VE_[NJK;W
M3Z/Y*(S&L(@OUM?81VM5OU71$PZ2!BBV_SWLCG]W)X;RNW['";OK)>R)M7>^
MC:>Q%.Z$R]M=XQJV-?M5LK6;,RZT0>KF_;Q76]!',X'\>3S@C1O2NSEQ_EL*
MP/:MUJ_KC,*?P^Q/*_;N^F.M_AB?X]AT_'4KM]/\WO@7WRY'W5S:!U6EFY#M
M/H5%Z-5MLUK_5=^3$ZE*]!*6 2*ZP2^KXHKZXF_8AM;K5:]7O5[=4:_JS[^O
MS_OK;Z_@$Y@M7?KQ (L=ZXL__%\\R?JQU[E>YWJ=N[G.O?SP859[1ZL2O07%
M&DWFHSCXIQ\OF]=^J%4)T^4<',=>O_IIG?<U=&@K.*D-$XS_M'W$6D\U><\Y
MWI/@]B2X!SV(]X5Z;Q@E@@5%))>4A$ =82))E4KBAK4.XD-.U)FHB6?8]XK%
M+#Y8223U6E-J)5<MSO%O/HA?92FV\*')=]SQ!)X/%7=#9WE/D=LSDG<&C(]N
ML_<]Z__J)XS>"$UI<#(ZA^U4 2G%/0F*.9*+" ;^P#UOL0@<&4W78?<JX%[G
ML6H*:P=C_P$_YO0>F<'F[\K+>FSN7^/9X*SAC=S4!-+;E 3:$[N_"NJQ*E4_
M.N<9(.<S&LF\MZTY..T8$3%3(G/0Q":J"56<TY@$#JV\C'99) #)[ C6QN"\
M> G^IN;$Q1 $3\DSG,%\(,Z4:]%NDUG<2BIB3I%?6:V/Q;R'LR#ZQ%Y3>=\K
M1H]^G=WDWF\\H-]H10#$-)$8Y6S3E6]5YL3RDL UE,K$5H_(D?W&3;*XYHIW
M/<7WKS>^H-CV!8FX=DZ88_<<D3\:/'RPN93;!:/UJM^28=XN6*P7V;XJ_4H%
M:F<2T+M\L[V5>A)6ZAGYZ/=FG 28HA 9)V"DL%=+4.)T#,1FQC+2QI3<-DY%
M,,44);K4AO-4"+9G$5]*E#Q3+>C5;OX=C%-MS)J_G33]MG^=3>?SN[9I63<4
M^IZ'5CXCK>BAKW?0'R<&\LQI2A3P+"6&J0Y!/#)O<>N3E+$X5EHDQ?>"@?-;
M@>"QD[M,G\@>/GOXO$$)UJ/#F <P*?TZ]"K2JTBO(L<H,^RS0MM9H35W9I\7
M>AK!T3,$H3MHP0_?V"E_NQ@KR>B\])%X6221T5 2?%;$IV*5X R"I\/$6$@5
M@&1M.;U>SC;4Q$WCY#;SPCI<2G>M-61#8^63"X-NEF"X4<] CYA/9+?[=-*-
MH*ZP'%3PG!1M,I%<.6(-C<2*Q(UQ5L8KF%F/D4Y:0V!G,DKBQ+$GAZ1]M-Q'
MRWVTW,EUZ%6D%XTGO0Y]F=%1$DH1^53'.?T)O)V21WW%T0,TM]Z\Z_SI>'O7
MKT W$*WSV2E/'0LA")*Y"$1Z*X@+3!&6J?2*49MD:]; ,:J@WC1XLIQ=Q&QW
M3%\Y/G3\GM-7G534XR2X;D+#TH-[GP1[1 B]9SQ12H;2H(@Q&IL>E"%.1D]4
M*I1K&9)@K!-)L"L@]=AI,$9/9-\VVSO(?9#?!_F]BO0JTJO(HRFL>C[\;?^Y
MG.2!H)6[3?30U'.W]=QMAYU,S)/VHG B4N!$*D&)S;80YY4NUK,H3:N*()4L
MM;66N*05!%T0>7FK!.$05.%$-F?-X28+WAMWFZ9RJ,7^T:Z]=O7<;7TZJD]'
MW8J#PWAGBT[$%L6(I)(29Q(GR( 9/-=2LU;YZ9'1]-A9*'<B>[:.WHWM-[G+
M@'DU=QM/1MJ0&/'2)0*.8B&6FD0\Y09\2F^,.EQ#<\_=UBM&CW[=V>3>;SR@
MWQA#,#HG1Y1 )*4:_$:K)5%11:J$2BZ;COF-]\+=QBR$Y3W9PUVRR=]05?DT
ML\FK2*9.Q.VSR7TVN1OYKJ>=3;:%*R9=(5H*1V1PCCA&"W&&"DV]9)FV:-Z.
M8<>VL.$@V60VU)P/-;MGT]5K5Y]-[K:GTT<%AT13ER$LH(J(G"$J2(81GRTE
MC$FC(H_"Q$YDD[?0]-C99'-RW].8GCJ^]LCYO#:Y,]GD8KD2445BM/!$"N6)
M]\&3S+)A7/,<=>Y"-GD_VNW+)K,'R":K$]-GDWOT>ZR;W/N-AR1;%ZQ8FB0!
M].-$4I9(T#R04I)G ++:ZL/5=!T&27>SR>Q0Z60Y9)3V_N"-T\FWR1KO+V1^
MDNGD?^8Y6/J!GZ1!_G*6(_ZRF X^P<O?GE[>G[[O3=:-9>QYILSNI'Y]IMJ%
M@-5XC"A1,I'!:^*4-J3PZ'1VDB;6B4QU SLO)^F7%>C\,<67NE4.W:OI\=3T
M6:2\[RY@1W<V[A33'$**GBB04^$$M;X0*GU QE]-0H9@1[H0DU#&"]4:E]U-
M(#]V[OR;*[$?I79V ]I[T.[%HG-8O6=2MZ!4&LU)"HX2*3PCSC!!: HT%>TT
M%9W(S]\::(^9MK];$7BO83WP/A6QZ+WEA_"6 :IE4%80PW4!']D$XIGBA)7$
M36$T*BT>A[?\\L.'6?X +G#7"M$?I?8=]DCA=FGM.Q$ /PJNWWO"^6=DV:X@
M7.HR;A]KPY_A(_<R_LPV_!D^<B_CSVS#G^$C]S+^S#;\:3QR'P+U(5 /*SVL
M]#+>RW@OX[V,]S+>RW@OX[V,/Z-'[GF*#LYZ_SK'C%7= \%ZKJ*>JZCG*KH/
M=@W+71#*$1:3(M+'2()SGD1O,TM9T!1:A</.,Q%L8,25R.$S&3LKDR#2>"NH
M5<$CXVFWF>_%4!@YY/?-D]%K5]^XT>TVVK[G_)#]=(R7DA@CVD5#I/....X!
M&:4TB4NK !\[AJ;'[K<P)[H?O]B[L?TF=QDPK^Z%2$XI:I0G3"C *VT$L4:!
M \FI#5IPG[1MH9UFTGK+B$TQ$$FS(S: T\F9S2'%K#15SX/YWIRPGJNH1[_'
MNLF]WWA OS$I+Q55E"B9*:*B)@"&G!BJ!"M.F!QXQ_S&>VDX$*KGK;Q+.OD;
MAJBV"FF^);_<C>J:NZ2?&_D>? !- />@MU%/PD8](P_]WDQ3]F!]6 DD.30N
MHACB10!+5711AH&54>ZR:>):>N.C(L+9# :)6>(C%Z2H4BQ5A3DE#VV:_HJ:
M.W\[^0U<Z&GZZVPZG]^5SIZ[(=/]')8>^A[A)O?N^0$Q4$G-LTO@4ZEBB>2%
M$\N1F=GF0(T*C.?P(!@XOQ4('CNURT^,Z-&S1\_KRZ(>'<0\@$7IUZ%7D5Y%
M>A4Y1HUAGQ3:3@KEE>/4IX6>1FST#$'H#EKPPWI![C7$\IR7G(P@TI=$9,Y(
MM,0-L0FB)L5#M/XP::;%-/[[[7R^S.GU<C::?&A"I1KES.L?=\<RY'173FDW
M9.S;"*6[K$,WRR_\V"/FDT#,/IMT2/8Y7BP@'2.6.4.DHH4$J3)A13 M$Z=&
MMBA$CY)-6D-@9Q)*[$2Q)X>D?;3<1\M]M-S)=>A5I!>-)[T.?97141)*T4]B
M'N?T)_!V2A[U!4</T-E*3[#M;#X=C](S[;R[:@6Z@6B=STYER4PJG,$#ZPCA
MEU#$6T^)YM:QY+DL[2[98Q1!O6GP9#F[B-GN6@1EU-"8>YX>VDE-/4Z&ZRM+
MT;?*]EFPQPC1>R:622^*"888*Q*1/A1B;?+$Z4BM*\FJ8#J1!;L"4X^=!],G
MSO1YL-Y![H/\/LCO5:17D5Y%'DMAU?,A;_O/Y20/!*W$;;*'IIZXK2=N.VC\
M9))1)F1-G$N22"H=\5)98BBWBM(0M=&7XR</ 9:2PI)D-<1/FCKB<I8DP\LT
MX$13&[I/W,:='2IE>^*VGKBM,V!\='O=9Z/NA*8EZ9Q-$D3[R(AD(A'+I,:&
MOZ2B809PLF-H>NPDE#E1/7%;[\;VF]QEP+R:N"TGIZA6DE".G [@08+O: 4)
M7M(H:(I:LX/EWI\<<9L^43UQ6X]^CW63>[_QH'ZCL9PA?Z5QE$A)/?%& CZ*
MR(JQ48K4(FX[LM]X3\1MLO<%[Y!*_H:2RJ>92EZ%,1YS#'TJN4\E=R/9];13
MR39QQEAPQ.8@B2RV$&>X)+RXD@WEAE'?!2.VA0T'226SH5-JJ-B#5C?VVM6G
MDKOFZ?0AP2%# N]]X I"@J0]3O[06-BH 2.=SBI$SVF+%?_(:'KL5+(]D?>,
MP4\=7WOD?%Z;W)E4<BB&1NX+\0%G@'B*OJ-7Q&C)4F:!^_;$HV.DDO>CW;Y4
M,GN 5+(\<7TJN4>_Q[K)O=]XR"A<6T!,FDDI#KQ%8QGQ+"?",P^&19VX;3%@
M?;/?>!@DW4TELT/EDF5/\G*77')?EKQ:W'_F.9CY@9^D0?YREB/^LI@./L'+
M?6ZYSRUW)/OUM'/+RG":>$PDAPCQ ?49K)I5A(K@3!!42]&)PKH&*UY.TB\K
MI/ACBB_UU<M/4^GZE',?.CP=D&66L:1R)%RX0)"KA%CN-<E2>)FU=Z&TDC#=
M!-EC9Z+[HN;>Z>TWN>,X>G4FVBAAG%*2Q(CS4"-SV!IG28F6"JZ%LZ431<VW
M!L%C)JC[6N<>%!_Q)O=>YB%#>1;!8U2>F!@-A/*6DJ!2)(5*&E5B167Y.+S,
MEQ\^S/('<!W[6N@'RU_#SWAD<(4=2:-/?_DS_&?/(WWM*;[;XPH8QVC*EG!9
M*!8T*N)B"@1,.\_*.8B6#D/7&$]S6H[SNW*U0&[/$T$):P1Y/E]^;%[[ U?D
M#[B'G\?PQN\&&>3M#*Z_F($P;FWR-L^M/%%"?/\5LEM]S9KM[KQ>T^C>*0-_
MBRW;)TE_G.9!\:/9X!.JXF!:!MG'4[@'6)G!M*[7>CHW)O'SQ[/Q]#S#I3&]
MGT8ST/3I;#[X[.>PC O01'PC?&8!UTWP"UZQ?GZPG"-/";[^\]C'?Q/8Q>D8
M+M1\"3D#.<(W?)RF/!X./H\6I_7-!8++Z6?\2P4BO)Z_V,H7W\A#>H"5&VRI
MWUK9JJYME+?9\<J;[)>+Z3HUAK<"SX/:CV\G8W\^72[@ZE]R^JGY)J-.Z/?K
M]T<,K\_F^<4\G_D9K.E:EJK]:2[]W57G59]&\U$8C4>+\Q?K:^P[B&J^E9]0
M_?U/W_WI*^]A)]>^@Y\H?HBK\-VK7',J9[]Z*'>5#-SFI.[&AW+V'JW!/7F2
M=_&=#_6X#TQ#)K[[^L/?BL'Y:,MS4YS[W&A(F([3WM5[/_HR^#O\=CH?_ (6
M+VU.:+_QD+Q7QUX=[_3 ST\%;UH*<=\,UKT0/6XA$O?3(WM7S-Z.INI7/?6Q
M([^/YO\F99;S8(2[CN5/Z+W?1)H?YUIUT"#><V[WX,F^%)+F-',2A-9$1AZ)
M5\:2% 3.8]5>EG#4B1=O_&A6LW9;^104]#<@YV]78OX[2/G?1Y/1Q^7'G=S>
MV7+K?)CP[>R>O":Y)T_$_E:E ^W(]P,R./ E]TRB%$X;8PTQ+L,F8_>OTTR3
M2+.,T1:?J'H<F^R_'':3#;_W37[DB--C[-W+=D+(2BI..-,<52F2H)@C3 2;
M>'246G%9_4(13#%%B2XY@LJF0FPRDOA2HN29:D'98\=8<6+W#\Q^;!B;A%6.
M24M@YPJ1/!;BP((2$5B1)1GOVX/-N[G)A\98N;\(]KXQ]FZ-%7T <FM2GW7W
M19Y]'/PPF@RP2F5^H]E9CW.QGH]UO/H$5AINE$3<,@4\2Z<R\=(9<!J9TXXQ
MRG-IH5[*6=H<B"G2$ZEC((%J1ZA.$(T(XZDQ!RO&N@KU-O4"#U1<I4ZLO::Z
MZD#?1+:O=_6.<<<*=]$3D;,@,@E.K <//X4@D\V%YK8SHEG0,C/P78IW2'41
MB.6.DBRI91S^;ZE[4CNF3ZBX9L<>F?KV@-6(OZ,2'#$>B<[8?4LC.&Q2*<*T
M4J)D!XC5&J?@HHT104Z#(!%IC2*>.X_*$UU*-)FHGIKX7\=7<*!O:B1LUT7?
M@UM9:*L2V J-<P0I,G JL!J*%^>=<]3ZEJ6QFJ=LC"5:6PN6AGL2A&*P<4RZ
MR+37[&E9&GW"Z2UQJ\_1/ZB+_'KT:00WFP;GHSR^T3CPQ[E$S\?.W%M&(4KM
MLHX*V7;@/]HKP+["B$K6>J=BUJR543AZUG:->&LYQXS"35,)UQ7<TI/[3\D_
M<B'LU>[.:B>%2C4I9R,6%<=<B&,!HB0C"N-9V^1:Y>]'3^3=1>VNZY4\GM+U
MZ;N'Y5&9CD$&L7RW]TMZ@-P+D#0&2;T.$ 3KB!,)"PF)&Z*CD<FFR$ILS4+H
MC%]R(>/?<*!UG8/BY -X*.1!CK.D3UG:Z(D.V1-9I"'6!4<2S8YZ(Q7CK31A
M5S?YL =:L,G:]'YH[X?>LP;R(+04QA!C6 *?DE'B>&2$:\<M5]1JGSKKA]XK
MS%IU<O]'R@]5-R BM9192ZQ$&O$L<=*O<410KP1UM C:XG3IZC;?#FBOW69]
M<KSJK#XM>HQQ0'F 79FUYW*[(73^YS#[T\I,K'I#^PBE-YT_;5$ZW*\I5BFX
M: +AWH%CZY@GME !]CCQ !&/I;R5$@),3ZY03PK#,W/-(O%4)2*"HBQ9GVQ(
M]XS1#\RIQ4_TO9OE]7GAP^R[$CHES2.$/HE!I%L2<9H:4K1V4918O&T5QUO/
M(S7.@:PD2F3B%.LKL&HB@P@E1;DJ3VW?[;?17'88DGH0[AX(6QDIQ#S$. '*
MJ*4D08E$5!3">Z'4%0RSQ@<L#7#$6%J(M-*#CXQ9#%-\8%%D+I^8,C)VPIX8
M"F>FP<@*V.ZH)9Z#&JP7#,1#3&Q#M"+(5BK*>,V4Y(PH'2%XC@&,M161<*8"
M<[D$K:^N_'B\&Z]/E+@Q#-^9L8==(C'YCU< +F$V^H_AW$_F9 Y7*!<[>FDL
M.?6Q\*R)CPDV1UH(7RU#PFCPLFC*CMK6Y*R[T?;\.IU\JFQ1O\-_X4;J!D!\
M@7LQ?PE+]0E"V'MAZ6'\<=+TO)QC$/8ZQXQLV,B:+X:5'@=UPT_.&XZ=^>#W
M]_^8[_#TG R0X0=>'OC5N@Y&\P'H!3PHW%$:^/F*8N>"2^?)$-IH=F*OY:+A
M)U1>1T9SW=_%B=+BCA=!VIQKO^BZO^L3D(Q;7:1+/![/E>OB\7.7;)AU>,^L
M<VGUF@$& -\U:X8 _=3Y++I"\;'A/;EZ$5RO7T]!O]:TS:3JUXJ\>?#7RCGX
M&AD(,1X8U("@5[Q[GH&U/G!Y]C.PMEAOAP.(N,BGU5"L73]>L#H!:R]CSS<R
M(1]AK8[-<MV/WGG6\ZY,\ED)RT@QFA+)123>.T4@I JL**H\;26EBG?,2\$)
MDSD0:9PG/KA,HI BE$R=%H=+2OWRWTL(6]].YHO9$E^<OX/H??;'J9^LB(HW
M.9&##+QBE ^=5/VXJVZ,N^H!N2O"<9S1!,\8F:.RC.E,B;%84"63)'AR1"0V
M\4:GC1,MLJN.(O.E 3$UQ, (8W/@\##'N^:>Y_1V5'/[6;Y'B&.:Q=W^[U]O
M7O#51RQ/8IQ(/XYGIQ-#!A-"=H2YP(E4#.R9 %-5@M B".Z8:!6?<2$2+29!
M="(=D90'$C(UA(H4LDY<.J8?SIY5#9Z_G?P&%FF:[AIHZ*&P_>"='OPZOZ7]
M4+)#>O7%,!TU)8E91B3CCCC&(\":#X53[W-I]Z-U& 6[XMK?<\;FT2!I?_QP
M8+?]E9_$/![G]*<WTUG)H]Z%?T[J]%R-UP\/4A'+!,N:BT*$R(I(B<Q WBJ2
M8^;,"E5$;,\][)0QW&#"#:."M[^^N?8 8BB_0MG_6-7O9D[DC1AV>VA]E'O;
M!P@WPD2=L^<\.Z*-#T3R  &"2O ?DZDUW&:JVZPD7<3$)4!?5Z*#>T[\/QIW
MYKA$5$\P.FAF=__I]SS.J">'KF1^5);J?DHMCXCM72G'[1?E]C7*O>;T0O)T
M%Z7/\MUCD?%Z@//@IG-E^X#TV53%]&5LMXUGO0E>&:6)]=P3Z6@A+J5,@LE>
M)\<9HZT<7Z%*6T8U208Y9YC,Q..T!!'A,[H(Y;5_O 7&=FC=_GEQO<[U!<;/
M$I#[ N,'1F;%> HQ!\*2$D0:G8AS7!)G) Z44:*H%F-C1Y&Y*WG&_3R/3UES
M#QO#/#1IPIX%8P]M :YEH7E8$H6GM0 WSK \A\7H%^"Y+T"O#KTTM(SP-_&G
M74<+MH<Z37MFF$Z4<%,RD<%P$A+CQ,>0K<B):=YB)+T;==HO*V*O]WGV:13S
M'J=T/)[&^M.[\GN.TP\3I/IJ*GM>3>>+>4^KUDA599TC=78D[-+% @[R%_PY
MHZ<\\./QH*&_]NC.SX>#T22.EYAV71-B#P>S#9/=^KV35-G8UN^&/XPFVY1M
M__M_6L[,3W-X/WCP-3# M.WT#'S_>E$D:KM@9QM\:RW;+9:I>2M>^<5H 7L3
M]RY<?93I$A0WS>__OO;66;TXWG</MK#H:;#E*7JB]'7<<2?L.CZ]ZSCJW F_
M,]]>?Q='O8LN<0;N/[9[3/QY7W7>GABUU*[KKGM"LTNK]\?I+.?!W^'WT_G@
MEPEZ#NNSW)[ [(&K<I[BHO2JMS\>&'WI%>]^BWIZYZ!W#GJVTV]&J)L6<SWF
M]>J]@%['CJQC-V)D?<SKU>M8KV.]'7M<XM3K6*]CO1WKNU&ZV8WR>YYG/XNG
M]>0SY4]Y/#W#4\W[ZY=_<O,HN]RIW;,C'+!FV1:EN<N::%&01%)*8@-CQ/%B
M* ^<,F\NUXUHGKTLU!$A34129$6LM9(HSFG,3JCB6E/F5X4@.5U=)_)+4^6P
M6U7\_O6F;EALUPV3ZP;$:]GS0/;0]@@WN8>V0T[BD,'2R J10EKD>X_$&>9(
MD,%[*FEQWE^&MA0,CRIG0JDR1 *B$(]C2*/404;JA,\MOO<'A39%30]M/;0]
MODWNH>V T):8"3SK0(KU&;PV4XCUWI,0E05DTRJFULCS1$UV.DO"301HTRP1
M:S(E.,8B4\>HCN*HT,:&W/5^6P]NCW"3>W [9!NMXL(6H4@T"?PV%A)Q3'N2
MM3<N1Z>X:86DW-G$)5>D) >?H:H03R&,E8[#!Z)E+!XW)&5#2N^9H^#1@%L_
M">=.6O/7/,DS/Z[939_@7:/Y ALU/MUHJFQO36ZG5=<?/AQ=>HY#[=!=7K"#
M6Z12F#(\"I*" 9M28B0VNTBTCRQE67QTK4R"!YMCDP3OG#$!%BD8$I041(3L
M#0/C)$,\JD42]SWBH9.:<T3&G+N<A/<@VX/L$P=91[7.X. 3:7&<6;*<>,T=
M*3%X&KE7NK@6R()WSQ,OQ$;A,<^KB'/2$2835=E(E5TY;KI6WW.ZMI.:TX-L
M#[*/3%2>-K9F%ACEQ9.<H@1GE ;BE I$T&)T5,98PRYCJQ R.94\<9XZ(CVC
MQ.I2B%?,""LEC>*X^6+SL..'>X7IL;47E1Y;6Q54U&E=F",JTT2DAO^X% IA
M+N<0L\S2M<;**RE-UM*3Z'PAD@M!?!8&'%['*.!KLN:X909L2%7ON7:N7G>;
M"JE>]5LRW-MT,/4BVU>E7^%6ZDH"_(_IPJ^(D*Y@3.J3X#W#<<]P?$]U)Y&6
M4%PD3BN-U<*!^ #_ 1LH7(F.*=D:MIQUUJYP"!Q"A#@B:X@H8M1H'W7Q/K,8
M[+%M'>OIXSM"']_#;7?%I8?;AZZ$\9'+Z!/)HD!H$0(C-BM+5!0^F60<+:US
M1UZDU(#')$4<#T*S)L[G2*2P/C >@Z'AV'!K[KG,KZ/ZT\-M#[<]W'87;I-G
M3@1/"?>% 6 J 7YNI$1[2SV50:1VEOQ;.)0?%&[YD.H'+?3HC/[T<-O#;0^W
MW85;ZIPMG!FB)."G](H3GP%SE3:>*^.B,2W*^E $4TP!)A?T:7,JQ"8CB2\E
M2IZI%O2X==X(M[J'V[O-2^C$ +E+W_W5K[OQHX-<Y"^5A+^9_Q#'?@YB=>8_
M9#*9IKS^\'>[XR'&^0M)HUFNTH0<ZLN/DY_2:'XV]N<O\*\_G?F$8P"VCE-&
MS7VMSB":%_ZUG"]&Y7S]+?6C)$\2R-07?%9D@]^(UY<.F:>M;[]VP,.--^/A
MG^UA!@)POJ-M==C(ZK_;\K?U\T8;3S=G5U4DFP,I7^!17OCQ9W\^1_+U;=%<
MRUU=K*N%[BBR]2UJ?CC)NF*UKYX!\R!#3@YQ%G< L?SC-&^FF<SR&"WR8#%=
MC3(9?, 1@\TK>3599MX0^%3<F\[F@\]^/MCX7]OW?XN;.[@7PXLMP01/D$Z
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M;3%BGA/J06H:P+M\KD>F$>JQE3A!8D>1[WB'4!X_\#.6?V0-X$[]IDC>PH+
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MO%R*>9Z7VH(G60QLDGA( [RN(:*,6UA\"5*+>"E)')'^UK0+8$@@9);+JKQ
M[KI8M 5Q"K9$/T;%Y41'V%L-,,I2V!W^+;D 04ELI^/(]#KZ !C?>'F0DVTC
M!%>_!YZ1BI*4Y*6$5RQ+'+@)<OT'CI)$WD0B?(GG! Z/L[%'/!_N!^"$LX[D
MLS6?:__ F98@3R[$^+%%63<K>X[/@9'RXDS,+\+=XE( &T:3DM:/+HY5CP"7
M"<X*>Y"CS$@A^*;%/,\[K@X[P_EH\-9_<2&/FH;%WP6$$!S=9-)+/G!&T''H
M.QTV%=-FY*)S[1M\FR25X.H9#M@LHYPO9O@\HLP2!!7GI) Q*34X#H&B,:UX
MJPS>A<B Z\.90.EHQ+QQ+;]:+,_+^*K!<:GPY;?W'VJ"(JZ[@E@@1LYXT0UJ
MA=]I YA =M<\1XDII[P2W,4L*NWE@K."]B;'1B&"XGRX;@"HV%9WA[\(]6TK
M*'; [2N]&PXK=@\",/O.A:SKS\_EY0!"76G4@0!> R*T$U91FW^GYSN11;\F
M/V#"%[ QA!C26_1/+O;4;9BPI*?9!D5UW8UWU?)L08JN.&-SM:2QM!O@19F^
M<@I2=/MA7B.Z8G%52NF^8/\LJZRY6J<UNC_:>7-><1PU>U;B2SY3!P9S8Z\I
MW?N[-Q]TPQRKDTQ;@"J2 5O#87X4,NC4[Q4Z)_8(6T?;!!D"H/<Y:EBDQW/
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M.QH59+ST9QJY+B?(LT] B_M[7D9PM2NXT=_.*'EFC&IPHYQJRNLEM?)L"YD
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M)! ^,:TB7LME8"G*2I*K\+2 Q0!"V11$MN.,__[Q\UIQ \(QQKOIFDAN:W=
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M>+T$4=3%9_=,C2@PS-RK;N3V[_XR7B$NVSS1%AS=JUH-(,K0JX5?T%Z[K8I
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MG/9C1YX#=P-Z_@UEOMQ8O7Z)'6=^,OVYK\'*.;::P=_B)U;_R?V;SLS@<QR
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M[#'3?]'C<V@GXI??B"C\5B\#?NSQ(#-XE ]PBT?X7@O\8XH7)H\HWV7KFOM
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MXX.H'RC:@1P83\2-43+GCH<3.)DKZDJAB^:I=?QX*YTZ4S'1*J:A@%>VG+O
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M6Y?;/9D]A/84QR)$6.2RV+;%/]MNC6[9_\&_!9BLD%Q(H.:5I,[ "<@V0U]
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M%F841F1G"!8J(?WKMN=U4VYW)Q06(LIGH ,O8HO=S8<79GH?WKHY"8;TMU3
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M0&GI9SI(TT':UY(JW(21/YK"W0W )!#_9><[H4(L(,%-N12#54K.DI-F))&
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MQHHL@A\8;(/$:A5\VOWZ9SIKTUD[N%3@$9X"_91<2M&$@9UI F+K7470L:T
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M<Z4I$U\>IJ2&PAOSG@57$'PO(-HP^=RH:Y;-NS4*9 @9ZDO?G"%)"-QK+4>
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M+L*#_FD7=SPJ<&I$F!H1/DXCPJ.I$>'(&A$^3\?%ZW%CG@++L#6]PCRV,'/
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MM/&?&V,]X&CEWI6&+\H@U#V7"5UN[ZD-_"G7J!1_3'2\CH5S7N,9<%+Q8.^
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M1S\D_ A7!T<,->=)Z#9S)(5-K%9_LF<'$7O-FKK0>>NA5!V]%G&GV+7E%\$
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M89?>%SZ7_\%<WJZ57O[01G?3N;N!)(,WDUL.6O'(S6-8-\=R<.!!<AEV&HR
M0OFE;&P2YF7;=J*H5% FW3+IEL-;BJPH:9D;HZNU$T.E*P^H1)YO6ZYGF'8D
MQU^_$"J[&@Q[P-U;-SH>A02;5D&!+HG[1'LUR>P-:=:D BI4MS+WF M<$,#
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M8 D7,K</-T<Z*)*C2L--T'.*4B?E#;!A'2MIZ&[* [5)G%?W%8!AA(@ !2-
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M&'N>E-B@3SQU$.YXL'C+9$5MG?H&)B'GO<VC0'(EJ9$.L'#).Z,A[$KZZ38
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MNC/W))T7W:P"%>,*7.L@CAL@-51V<2E+#K_%E]"ML13RFYQB-!8^EI@?6L@
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M;4]"MSQZDL5*.B%3Q].#*(I^Z@!4%.N"(!3B!3>M5)O@3'C.37" *KU*@ZH
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M&8*<JM-.=R"APFD6) ,VTI=/7!6D8F =V,$EBRB/-U1/T+G ?"GY,$J_XH-
MDWIUD@\.QCGLQ*_#N45ML56?=8<<@NZ_YI%=3PHFZ81N]''],!^=1IK,Y,&L
M%6S[T:D1S]FN<#V/<2&XS\) ];N3C^>M7P#V.NXO-[N*F+3H SF3(ZA<S^DI
M2=!;),<F'T2J?&9/%%UNV]&L\"$ZUF?.%?.KP/AQ\78V8XE"?)NFSS7U6!9\
MWM/.]I3[E\'(>*44 DX:N*!+!URK]R:"FH#,8+%%9X@)0+.Q1&XD2I+2M* @
M[$HK8JCA<L?3HM8&R=8>;FR0/9!GV HC%S:\>[,RCQ&<=HJ>:U !@]+RF/H\
M=X)&' (<">20P3Z(=E W[F /VJ! S%!^LH_Q?/P[)=I#7[&B.,W+*IEL$*IC
MI05: P3?^&)O&/L8!,O.>4P7'P3]4?6YC>9WC[*;XZBU3V@H:AC"\RH-+0FC
M_N@VN%(G61DHN"G]&=TLA^4EN;X*$:#/6((*9O#Y763NGI\VRFC%_';D^(K"
MJD8#N\2&7'74M>[Z"GP6;;>NMD(VN2=>RQK=O6\E?SJ<NGA1'%I.F4@Q_3BK
M7GMH73HQI<E@G"#_'*^=:!9Y[73EMB++/-Q0AK:/85^Q.MR<>SPDLK4B#0?(
M%^UY$.* %+4NO 7&DZ,22!EN'VIZ/'J@=C?QVIXW]]E#E;W)W$S$"\@9MG 7
ME:8OF3$^X&4\S/(>?=0THS=ILY>"*JMQ]2*$F3."P/U8_ Y3I#EX;NI.+>MS
MAO-:<:LQ6P-V.'N5I5\(2LF:"2E)_]G*"AA:88FRFU#6,>0@Q(L4YA$F2D6H
MF+YY2M/[$Y-QM]!1 M)#1.>B5^K;+B_E<R9D$63!591M%3?3 +F<I@%MFV>H
MB+&/G3$+L83HGXXG\14'B?VFJ];!.S^[B/&;?2G0DOP\>FCCQN'S/NB8^5YB
MT55EB#SBF<TDV>3SZ5%="M\U4KP^E7@Y8;CAR]XHH+]X7 Z>M6HZLXT;7X<6
M <O58)Q$]1'RG3@G(C@Z_%(6U#M>-]9ZFR2O47TW#M/I$;Z7.'3I*;P'[.')
M BEJI7<@BMHF68I"H2AFQ3G8<(PRQ*__AC'3GWO1A0D=8K]A"(OY4H61S4)1
M?+P8]RLM3O9:;F+(S=R1[4Z8RC6AZF;C**[PRE%/S9XHJ^@NXSU2;0D8:]4.
MXG@&V"$J].9>%_MJO,#"L5P1;Z9FI!*0[59.0L:5;YNX0!8 VT=;(S]J*9BR
M+UC#7/9U3P,I(VQ%*K>+9K0N-V]&Q0FM:M^3YD/2AUQJ*F,; =M@\%E2Q^W%
M(@D"H4LY'7>6,/#*YW$-$;L9M-L0:#&JM+=)\B3A*+Q$=*NG-:DXEJN_?)?=
MNEOL3\?N%PC9 B'[,!"R+Q8(V0(A>P^&A'UH:H/2_8D=LU3@)N-\[F)1+#+L
M2=^_-22TP..V,HDJTR:2Y+I9Z"G?-$JTC-_KO6:XDT0*E[:LF)?U[2"SD]I^
M4B:6S:P9U3;GKI.O\9YKN\@<<,][80ELNBZ&$+0Y:D/G*AA?SC@Q?I_-^=[+
MTB\;L 0R[=%222RYQ, (G>Y(1+6I,)CJ, _N9W#V*HIZS!K(Y*K:JO*\3?0%
M&^K3*J1QP;A[URG5;+2@!8T!%.]CDH$* 8IO25?D?5G<_%N5+#MI.I6*YW-
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M6JJ378.:H6/8F5A%:M 8L%X![>BTVB'CZZL1&;NHY=F:&4I=D\<!]WR)E^M
MD]GV]SDE'*N3[=LZ;$XU=<LVY/V[U6VYV3!4RX(N=UXY92JSB$@2%,*8Q)[6
MJ!2[B3@)/UJ,U><((BG)4!B6)#//5H]Y%02[EVTP@\D$>H%4.!@%FJAN@%V.
MVF:;KNV9B*QM-OP>A5(6?*(T-)\>CB\\HY,L#R?=QQ.J#'Q*2Y=0#/N6 81[
M>L?0T> T0@NT.0N>O#D42T_4X#LS)XE0L*+_F*I>9\]P'"U^W]KO;]IH<$U(
M'[2&D_U&W7O\7+NI@>RCXZ\K0?UM4$9?MULFVT)08U]V"UVI,\!.K:5F^R#
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M43R-NUO=KN,YFG"D6B%=@=PCU0P$=4K-A+@CK*M6VNCY8A/!@8+!7H--@:Y
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MI2BD.+G0N/?$QT6\=I03I0W,T[$44Q$?>3<.&]R3WY6W;9>,J_!J4(.78\
M%H*:/'&\"686-\*6P8)*@Z/36.*J9Y_$0ROVJJ8X ?&H" 9W.+05O<#K&$QX
M7D"8/G0\E5YI\J*]WW=R(S/(4GZ/?(ZA_[ZO=OR P8!"Z ?4OU:='W! 6!O$
M6)  \,Z5T*E/,:CX1+G#O&;9H-FOT\0#U5K OT1LBG/-<5D^I[7N8_X2GIT.
MHDRM@RRB!V4..QZ4%+^PO3NV 8\G33[+?6"A^'JB0>SSGCN1:=^Z[MH[U=%E
MJYM#QG?MZ?IF7H=>IXA5&$IC&9@:1SINMTNL40.BKE*OD"]@+(\RYPSO@IUR
MH >Y1TT#&?S?3V3-Q\K)C],6,9!Q$Q]?)'%$W<NR&HY%A;DR'!V">+,VRIKE
MV/?N$:1#3$&@ ^SP+'A(NEAYG.9K'"IN5?7]223>RHX"K^UPH5L0)9'>O3>?
MISK9G?,[C4<=:.)=ODT7*>IEDP7).SD7X_DBF=PNIBR-ZPSE<2(8D-?F H*J
M43E)W2@G*2D<2S7S[FH,P3&;:/SA;.-S4-C#@3L:_K]_MM[?WT8]=^<_83O]
M*05Y?R4$0(/@[2<3O/P(F]Y[?%4?:3_[X+O]ZYMI!AHMY,\W +0O]',#(L57
M1ZZQ6]7[U^@Q^ZWJV,<,)*D*1]]!(5359!RO=6BNCS>LGCSL'%3-3; OQT=$
MQRW-7TEFA;PZ.M!!OR.1J*.,.T6B/N/TTCS;K.=>8KDG&LN]SH:G;*O,MO,B
M[F/$"X$]U-YYW(KX5TRFB78+_GMY4I'J'FX*/N4 ZPHTG)L>I!+QJ/L3ZR&7
M!^'F+%:;>,Z5_:Z0>H4)Y$*Q% V?)"#L17+O68K3*@8@0U5FXP,UO(Y'C1!%
MT>*<S5_.+/E3C$_J"8%;+D;\Y;OG7"#2:\V%%J9%:OD;#]9C2+2N/',1;JOV
MU-=G%74+6[D0&3F-EU%XQ8C)B]!9\,$59*=]CJ."A58.91_S=X/>)!M$<.]R
M-EF(GJ7TW+9<;4DC%UF]R@A-)LL^?;F+3O)P$CYMKD>O/FM1_.(H^@]<6J**
MQS;T%9-';.7B'WB/#!3+[M.[8'_Q^<#\)B8@M)#.(XE=;IN1)FUOU,)RBZGW
M/"M'A4OAABFU07WQC[R,LJ$EG:JG&#E^ GVCUZK53?9S4_8,SI4U)DU>9;>*
M%Q?@5;B CMQ YFP)TT(>;_5\>UOUY!Y>8/+\&$(A0BK5FJO6K,4<LXYXW')S
MUH8L+11)N0(E8O0GK$-D=TPQK9Z-M=K;0URN"5$\=>:RCC="=0$4?2NAPD/:
M\W3,;0%3+F#*#P.F_(\%3+F *=^#(3'A?AY1B-A6,]+;F@A"+["PWEE-+9&A
M*CL<A0ZCPMK5ZI6$0=NP$6@,ZHJT@='X2_DF(#:_1T*,-AJATN;#\1TM8<C'
M@:_XJO&PE"HD?ZZ8Z6:<&&9V6])H])GQ<F4_Z (EB@_12?,MT87Z?QGQ>[(C
M?NQ-AW+G[,;^8<GH.ERSN&*V<+0#+W-VRT3U8G6/&9Y@?!;OZX1LM69/QB F
MIF?@<AF/CK?0-.1>X<$7TUM,[\%"T\1OYQ6DII"!C&2-,257CV(4]^*G'_J)
M/FR,[M!^SVB&DF3L>J;*ZT<J%(-R2ZA %P)3OQ0(=IKL07,D780[]V+[B^T_
M>K-/4\A'+@Q/6#7E.!"S-N+OU<N?_@*FH+;G88QPO*&VQT8+8EHR6XQR,<J'
M.^1-=ZK0 K')@4/TC "6YK 9&8.A*7N"!&ZJ YH@0!#!;#V8B*%#BR$NAOCP
M(A0CP,3V7'/)]#RZ<#QUK(1Y(*3:D21J9!J-E/Z>G0Z+Q2T6]U!^G8E0DJJ5
M%<.6N:NN2C/'-EY4H:3+A_I,'T&8^M<7/^:4Y32BTK6' WA.3C(@A0,MQKD8
MYP.-L]QN8R+><ZO^K&Y1VZCQ<YO0-29_XC"W7%U76N1AT6BQP,4"W\X"XQ]V
M=;71,5,:3&J=(G1=WLF4L0*HEBQDL;4'I\;334:49F1^3ST@ 5=IFUVL:[&N
MAWLR<E%C>3\MX46_M1C38DP/,J8<$HE1HET5R%'1W"[ULYFZ<//7[W_L/0K6
M[8S"RX/BR0C_L'!C_I\?Q=>'IHMY/1+\JA\@5)B*12'3QVHO6D]#= '&&WH;
M6Z>RZA[,E$KE\BV/[Q=C!5&9LNI//2JP0V@".'VY]_#RI[\P]<"@(IN@M543
MC?]XDFF-1IH4@'_KA7;$%(3Y/9X_%-J*:6#W9?B+\%U@H@Q73I?!]]&KD$I2
M0U&H^]>OOO^+?%(OJXAI!2;P)EAPLD%<!EZ(D#*@0-DT2"H08O82LYXB>C*M
M^R5S,78 3<%Q5@45&W?00/DUS;'1C68E];=YFFX 3\R-1A?Z*C$$V07<M'5\
M:R?"8X>>:)\D89,)20*S\#A>O" "J\,JXSVYY[<-^WCEF/DG2NO0A+@XN!IQ
MXFA\BFW%*4E?VW@8NKG)Z^#L\:57.#KHG#;VE[K<O,'- +A[-&GI3!M[_+"-
MK20-!WG+:G>%,< XF6N4]O3OR"X&;W!^TC87,+0FX<51*AV!&K-8)(H,%WX:
M X<>2IDX]#B34*7!;&RII X]:T7R+6LR-7!2.'#&\T*3N#1S7[=WJRVQP_A;
M&\Y6C<;*Z)=>AF*"\8G>E!Z/&2NFR$>>(E[N=S/P^?!!LU]"IJ$H^='D'/$R
M2?<O%NS0K ,ONYI?(S6$R9EA;H/F)>*V&%^MD.[I:)"; :/$1J?@0 UI%D(!
MLW:+,6W!1>V[-KKLNGXF T U^<$?;\CU_-OTH#OY@SK<4MR53M3D?] $_= >
M9,>YFCWH\7P0DD@1<%C=Q-VF"UN<3WM A2)X/;EF+\+4H @YAU(T;Z5;]!3]
MU2<0L/_@0S5YQTHLH*1,XRF?;+^\R%RDCD^IY:<\WPX,;J!+&"&$R5"Y14B3
M"T_'1I;RPE)>&&,S'YV?T!)3:4V3$\>TZ35RO8J<(Q("3^HU6+!+074QT@<:
MZ5T8DQ/YM%7FP/MH;OVNS%+U1]LV.IPSFP/&^&."K6.E A9UM$=,1F=TOVGP
M>C'WQ=P?XY,=3=(PT-$ 9Q\"5[UJ2L^AKDT.MV>^[A3%;IP(T]M6I':.E7*Q
MY,62WY?CGG>VPHZ^RB@UF/]$:I0]H9U0*1"W*[5/T$$N1KH8Z3\W!%:U7:\?
MOW-5$$\/TQ]CGLCU^;>(BA=:AX76X3W2.OSG0NOPSZ1U6#:@90,:;T#8)TA[
M@%$#3)CV4#Y@3T3O!FC>:UJ<:)-8(G2]K_K>&M+$*=9V7O:(C^H^5S5VCIQ+
MLNWNZ3%-TM01^D'5+Y=@;UEK'SK8TY: :!!,T-5),SP(,XAQUZF,_3,:8_,,
MU*1SAM"1P3G"50XEOYV/#&4<7B$(M [K*BSRWHOE/YJ%P8 ;;4V;Q!!"_];;
M T09LF%V!@CQC"8/9\;O$E*1QY2<>6/KJQHOK>.J30M <<AGI"](63(>_H;D
MG7"U9&P+=$#J[7N#D/)-:$J&+WFF=]9WH>%(H'=&2F\#[BY MR[+ YB3W=Q4
M8:;O*@!!F/.:/+'! S4 N8-DG]'=*M;M;J&G_WVBE41'AM\5!):PJ]X$XNO<
M4-,&NH?;((*XAYMS'RV^E!?K-^=#>2;U.D/B&IE'(CY:D8##LS?5YLVZW+PI
M8JA>GK8,BUN?1+*,XV!W 1A7<K3D+"SC%Q.Q4ILHS:8C?#'M]='DY,.;ZC8N
MCD-<B35#;C58.,&'[F-^#OL]G+CZ1.C0LML+N35@F#>L"X7:J9-A"F5'-!$+
M9.NINO^_35AR\0 SGN41M\R)F)7.0/A6>R*DZ5K6S^46E."Y$W%-O*D^VN9!
M4\F!1JP2B[.RJP@$>$LKNXYV("<?.;5(BZE[P6X7 [%V3\N8V':R%;/NVG);
MG_TZ?>>%*4JJU*L8BF93A&_[0797?"SOC%1,R*+\Q&./80&O:T9D]44B;'>T
M])E640\P$]-BQ*ON"GEA?-Q+<&8H#M7U2JB9XT?V+8<5"92;^-,O*-STTU1'
M>)Z,!&$>9XT-\#:*E?K-'O>Z>[:-KV(@KTP/&73J5++8$"_[:TA 3[TJO*.D
M-(M+O:G657QXT;ZV\9D@XB%3C9\ 77-\HM'C-JH?X#4 _-,X=J><NWPOA8S/
M^C\0P3\+7JA%$O8KWB5?-^N&^H:5::U[2Q$0)HE"/4]"F>ZI'MUM$QVI8A=E
M(J"C  5C/?'V/"6[ZO(D_+N.9RMF4EA83%AY-!3TFI,%6TIA2Y=:H,/,*TG#
MS7O6$O\2?3[0JJ:8RP>*!P:!"]=\$1_8T:0,H$Z\4&LNZ?733Z]EF:R>4X3X
M?\738=\]T<P,;P#JH?IIR?(W#4"C]=G$=$2%#%D:>RV&I>*?+9'%P55WM%/J
MP$<7]J=&TI?59PF82G]+H>LZ[BQ!9K?6<0'^@;PC]0U9G8W02_Q3_$S,FHXJ
MVL;_+C!H4O8W_-EX7)(^@8 P"7.*DK$CT2E6H9)[#<+UKXS..%?<_4_D9%0=
MXA3WLI)2N3K@/^@499-F230]WM=UVVX++;S1U<5E@H'(T-W&?02.3EY!>8;K
MDS!_7Y+/P9 <A3]\V;2Y%C);6=J;S<,5\O-)IY*N^7N2,BI%G8-_J+:V)9#Z
M1G0,/4_$!0C!*7'@KB5EY>M353-!YFW5JIXEU=O9AA S$<>+A/UD+'78\@[G
M/T>W?0@;*L>@*<W= #YF]+-']O 7[17R#6N:*;.NMB@SQ'T!;CO;S=;A>$<?
M'H2$>;53V+A)?_L&@5F**=<<T\H[[T1DES8U"G!0-HT9CCL&6=)2^%_\\UOX
M9TZE$=9IHKV+80_-&I;5GF.6$9Q?OOLM/OB"/_B<@\YO7SP?>O=IYYZ\7&\>
M / Z:O<EST]+(DB$2@ZWY$%,\./J'P-\'5T+Y2(47)\PLB.WL./]8,\KO\A4
MI==G\U.%.:E4/KO@[++]:5^^P17RQ8VND[SJBN?.2:^)KY4\=\>JU11)BA?F
M278>^YV])U;P=,*[S QXYIG;F 7','$5GWDX:WE0[R,-J.(F\QU6 VGZ\;:M
MMG(OVX#A2+TSXC_21&7B$NXY[=7J^\P-BLN_"?4VAK>(L'FC06GWQ7-6KXX)
M>L/ZU:) S_)7^H9MIZ8)TJ30./'23 <;6N!$@PL_CJ7[^5<00\:_O_AJHK<[
M;V/# 51Y36G9P ^Z'=@/-L/B2]WE4F/Z\I:$;)S&VBE3O6 JL/Y31_6!U--X
M\9QW/7K R*=8)*WG\L<M)R"Z/C&J3*^;_BQ/*J[P_EB'==W>A<Z>&-4>\$EM
M9].[O2GKW?"6W$N*61\175^G^_>7R>6<=M7?T L#,0V;V!$EFH  [+SL?<O>
M]Q9[']<2X]+M3QVPX3^VW5%S<3*\YQN41_17V.)VJR_^\S__!._YMY<_/K?=
MCGPDY/C$"]!&JGNLE;!Y[?:F7\SUF;D\)_P6-B?;^LICM*>#RKKSWZBWL^I)
M:4[PQ%KH.WOGIT0&X@2QNZ$N4H"2(Y2\Y*9\"$+=II=R.F^W6AGD$E/TCRBF
MV="'[ #\5U(SB_^^:P"XQW>2>T?%:"N)%,9AC91@_NH+D=FK47OD,Z(NNOKL
MP]=$'EZB#U?7'Z]$<T790]R9-_P6X-#_P%G$G*W1RX^K6U3<;(O7')?^?3HP
M,?:92F/$6-&!LG,3T-:6P&57<AS($9'HC//?Y"PAQ3O"S] TPBGBYN?JBAR[
MDEAH^(;,>6P;?3&YP6K2V/JO[&D==4[L:!"JS!0LRK?,5OG,*YR:%Z?FI;P.
MX$/>6RZ[0*87R/0_U]7\^?,%,KU II>(]FE$M#]J'WSU(^^8_>K5B7JO34#T
MBBR?MEV=2G?Z5[[=J\JT?;L/P[HEZX''C_+F'_^AO"3*^;9''26A,R?*S40+
MQS)(EO"/ZS!:_7YQ4]7;+C0R!]=/!.X2V7Z&"$([DN$WTK:A^_H#,U@P"4;3
MG!",R,:?0P*^#E3M9G6<G9Z(;NIOI_@<5J\DNN#X_V^OBH$ M$K?Z8WVJ92$
MPLQ.'N%M69^D+D0?3O"%SV(,7TF_6/6FMZV@N@C748&<JCU0KS7&8?CIT&ZK
MDG_@4MY-%4/OCL%@KD7;M,TS.Y=TE>G"Z:(^T]I]^D#T,O&0I;;R&[1.LV])
M4'E4::&;MC]08)QWURG\[P@ P/;7W(:>GS"JZ8&N&O6?&%V.@!P$SZOV9%$@
M1L/2B 9&?'C+8./B)!_J)"T5C\[@1" %(C64K(,,[=3LRHI1OH&M6RK?[+84
M4B.N,@A8(M[6AIG\;I/TJ?N1TWP(TW/^ Q2:7L."6E]L^%%<RDT9M]GVU$]
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M2AU<HS!O^#5@>>+*8V&,W>J;$Q6B2RHUQC79 3%NW^@U/^I.-9>YG0/59<T
MS?2G>*0MM].4<CD'TQMCAW[,WYA^YVKUK:=NSOQ+;T0UO'(8&,\]0T82.6P[
ML7Q8Q9?LM8HO;TL.,Z<<=H#Y'9P0\Y/%K[?<F_V$:12I&VH X\N0[@'@US5\
MLE<VVHW3UI8PP@P">/8FA -*[_$-TE_HGWU,WLIK]F)]V)PZJCEG9T %>)MC
MBVE)GAK5L8Y_(R]V"9_^=("DGYJY<>""&03:-S=!JP[0)>7*OX*>*](VT#0>
M%I$,,%Y2M75#AMQ:XX&#T-Q67=OHD=U>V@7:JZ,/FL<S^\M:MV!I 2LL82XQ
MV*BTV9JH]YN.^I5G1F%/; 3N_%.;P'#V@0-0 M_5@K=S5/A<1Q#T"15!NK9'
MOY1'A-IXYSHOE(D76/AE[E"6V/%8IZY4ZMUP;"L;P=7J&PI':1%/(]F]'W>H
M\0$T/"N/1*]^:(WP_=#&;6*-T1-_?[3U>=2$%QR01A3)?SX3M\,ZXL\XU53@
M/A/U$&(5J'.&$=+A+&JEWE@#]\=LQ00NU-$_G8#0^UX\QSMYCG>]]8\P>8NR
MK=DGPNDLGQNZ,C]S"YI]:BRCHFED9[:(;,3%"#S\2E)W1N $'I]2*$46L#'R
MCGUF@NJ*[//<+)05:.\9W["970XZQ;.Q<Q D5CSD=4D_09T$#?9@PQOQ:\2)
ML#N!Q6,;=H'7/"92ZEN1J.AC\GS4N?".FEZ8 :/I+CTEQX+PQ+DN2XSET'UO
M!H.\.7HS%]#(&+X)"UHDN J>T6P(:7.6\*@8)KIN.W8H'MZ9A9A%LI_P6[RJ
MWGQ-$C96AA3)=%,^1[(88;A7"!9S>D0__7UB0M1R\&A=<5^M-9G6%-I-?:7Y
MY\QS9Z$?9<#XBD$B)8NE(6MZD80]O"/,PH:Z*CZ"C%?7Q:]SM>,8KA'J@4\M
M2_#=KY!S]QB! H N >>HRN)J"2ZA(*.^6CV/%BP$.-26&:(.>]V@@+N,5YS,
MMCZ+U1+>EHT0@$D9.XQ6=NHR>Z+KJCD[[^5QR_;SKEL/-7R G=)5;^],8(><
MNU/;*=[_MBOO>+I"G >7#G@"F$/ZS3(0_SL=B ?0+45 +&GHVIX/D_ @AT2C
M&IZN:;5MXQ^8?A;%Q[BGW26EFMS?M^NW/R_6?D84M8RG/]&\[I]B;M>GN,W%
M,X:1S2FQK-"-H$HJ(IXS;&+ ;8X,#*D7\3L88X@J2=UORU.73C&=!"P--JM;
M%>#2&::I(ZFDDJX!4HR#\&U)\(6T12D+S'6'7K4;9,ZT6B:DN_*H888N9I:M
M#;7)?<P+YYFP9L>J#;HZO"A./BG>RU?\ZGGV6+94[%[=4H.!IVL&ET8H ,P2
M\ISTJ#(UB.NZ<%M%XR8AL79+ Q4T2\FSZNV>0]EK )P[=%HT))UB5?#QI@N0
M'L;Y2E'5\%>FR3=K6L+W5VX([\%EXOEW.>5.:7P#6)<!'=]<G7O*FM@2UL$H
M#!!?60N,JRA4=*%.F>;LV6=1JJMD)_%7DJZ/LAM18J,I_N0!N!:(2O)-=(QA
MJ,FF<_/]@,F%Z8B>3JRR %47H.J' :I^L0!5_YE U7_%FMS;VM8OTJ<$]1]/
M)F9!2*W*)VG_L5;DU>JGV:UJ>C>2R"'?D*0P[W9YSQPH+<BQ.*=GW,3^)56W
MN+DP%VVZC[FX)(6\4[1[<@&]4?3YNL3$%RYV/7UQ@04^"X0JQ/QCA7S6J6.9
M9_G%)$,?:F$T=41/Q1494INO2=PVZ6VQYJJR\PUA(7-W4@EU@+6=^;GB O\7
MTSA 7<W5*<=A;,]2;4?:W]7"+/3O C%-;*=$53L:YOD'AS%4Q]&O&C+M0B*B
MAZ?NX9#T<"F7_.[*)=](2G47+@K^"<W(%*M65@&Q2#-F*.T@81S6257I>)LO
M(LI+/!1MVANX1$/JC59_'Q,8IL9?-;N8+XAC.[WE4T. $U2MN9H8%^Z^3R(8
MBQ;LO\P>?B\A*]!(QDX'$H&'&?IH5QY4".IR3:# ^*]X4V_*:X_^*-C)'BO&
MA&0<=;27"@52AB%12!+M^7$O?.9V$DV\!4'@N U8,*B@JDQ<49NS ^#A(+)E
M.(2?S_/CJ[R9:-@,M\!I!L9\?>T>3N0[8%V8]CS)K0RCC\U?O_]1'H6,@N97
M,I_\QZ_\]<6/$^'6A+ZX)NCZ5O TGV#B_2G%ZSD%"5=JW6\4O>>(ZQDQ(\IQ
M@ZTBH;D>1T6=>X8,'Z88$QC/WT\E(CF=D<^OU^CVN2(8/T0K%-<(^Z:ZDIFW
M:V8_[]'(QK+1F-$X]X?$_'.K"HU/5 YYLH>&DWE'I^H2"0#T,\LNNZQ1;9+X
M6.D+_*3W3,_8,WQ9BM9_^>YY(0YJ,M<JE%'KMB+(/(-L^B"M2KW0&(406MT>
MRH9<*>;CTX-!Z7F0*]VUW1M-F-B_,"G# 46X:(8%TR#P542GRO!H:M:2+95P
M=,XFTD/R=C#8* XI5Z&C#NQB\24?Q9<\;\Y3(7)R_!I'#PJR0\V:?'V!Z5.;
M^KQQ6JE8E%3COTY]-ESI^PD&^)=.=VM$!Y9RP0;U>@MEX>!>T6!C\S-,E%]3
MA2!%!?!4A%4C(TW6RPKT?UQ]EFUY?QB7_!&,=+<ANIE25GU</-51QC]%RU 6
M$D<G<]T3H35Z&\T&5'!T/*!<_?3-]Z\2Y\CTT5BZ\;H2-N$R/5O_:"_$E-X+
M5OT;AXN@GC+-O0RIT>D%U>,75+=4B0S=WGAM67/]V>E W!4\D8L+PPR*8\R&
M@STU^N=#73*BPF=4BHLD%X=I');^/5&6I1!\16"$;8ZCWH?XF F,G@AW,76A
M82B[<+[[:!?[ZA]*)];6PPBORB0YR@?OL[)T^EDJ: T=FS#>WH?AJ4' $J>8
MF7R*J?L45$^'TEQ22_,R' D3B,B09S:<LKCVCP;2?BM7 H@=4[0%E"HW7<CA
M2/1O;MY:VWPWBI3F<DA)L)IMV6T!#0<&11K][.NK7:I&M!L"9J&;D3G-CG#F
MH9>F-=GDU>H[M'C!"R[\.Q9"Q?5P:HB9IGE0H2-O Z-0B(8]+Z*\<-('HA@Z
MGIE\*MYJ#/Z8+,I.,"\;-4RHD_A4P>I3DS,V,\^V&-28Z-Y[#6BS75BS=AD!
M@5J,K/>,@+Q+I'GKFH8MU^UO2IAWQVH37PTPF3[AOM J3R&V.[<H_O)DCSMF
MYI-SM)RB"[/?*MNOWP;OW06O5C^(F]/",I8 WF=0/QFF^$ 7/O-E\/K)#EX/
MP:7)80I%6NY_!GVD8H!!]2[8H*ZRVFE7L,%A/O"6G51RVM$#/$P;>;'>Q7J)
M^H+A^;+7K.H _CNRKINVWL*@WT)X>S&NQ;C@&G>GGGFTWTHLT:F('F0>)L-+
M4(),+%(I ;4 +/O<KJH9]W>2[_34!)0 + 9Q[<8&"7C$-@E +N:^F/M#S5UW
MX3Y4_S!4M,ZMP-)X.1R54=LFKKJCM([QK[F"T,((M)CC(\RQ:GX]-4XZ?#3=
MQ^H.Y)%UIL^P#PN123SE# ''-S]C'<;_? ^F.6[\.A89XT/2@KKTVP>!5#'(
M#%*QW;6LA*K!]B?4:OE=&71[J$2G]4=),-!^%VPY&FBH]6 <PDBYIT_HBBP\
M89CP9W/5I[Q DL\1%)<MCL7K$OR&:]I&<PA$W\"-&I/%O8^:.QQ\T[-WJRXW
MI61:;45:E3X@'AX<,QI+Y)D<"GA5IM@P>]IC>^2O8,JUK)]DM6/!VR]X^_>(
MM_]RP=M_%+S][VV/]KG<SF$@BJRF/=QJQ_7R0E'(0.>EBAXU*BR,*E;YZ219
M-,:L3"@K[6Q/QY]_2M&;]N<>#KF"JBS>_)C,=8#%S'"7H]%-"\TX'&3U:(+?
M9^5A\!3PYP2/P0?!YT@.0X+V(;3#,-$48 &2E'$Y,$62=9G';:F$@GC<HP%U
M+>'YA<4%AYZ4LE7M&B45R1Y.N]L]PW4P0 41J? ]G?F!5;W(9A 7)4VN..FQ
M](CRPXQ!,H_D+B%Y,<Q$\.,Y0$4T)+6I\>.ZT.(5NBT^C2$E'$/34)DY7GIT
M%\!'X!%P["O#* 4#?M*4]:.FQ:]6O]!D:$-MX'A &LWA-U>]B<9\ RW0ICQ*
MP0)P1830DU?K!(H[(A1%BT)X,TBIJZ]38S-_OJ6X95$VG<3[TK? W:J#-+1T
M^KJ]8V4@G5\OM^7A*,.LS34/0X7?JEZ<=X['A_UO6U-BIV[H\#/ZL@MICCM>
M'CWGU*2\A^7)*$$-*A[(VHS&S!7R9>/N)C^M",NWG(X1:Z&!X<',3=@.AN+C
MAY\?NIB#??FG8O7EYU_^&T\+&P?F"U/OYH<&14):?"UE7$ QXPE^S9'^+=OX
M3\X^6NZ*LW>PMS+@%W2FPL1)<BZQ"F!4^:R"IA=6N<D+U<OKYTX>,W6X*;;H
MAZ;5@TQ6A0X!,8T+JW1YM[(5W0*E<* JWJD1P<IY7)_<K)03]N4;7/:>7CB>
M(V3/6:5I7;6*!/,DY*'LZDJ&[LEK"A%6S>5V<%TQU9SQ[6(.3#F4\NES<&;U
MLRR?G^"XTPNR%R79S!^6^&R57&?W9)(5;C90@1KA.L'Q9B$Q.S="XG%]L(VX
M =@THPXPTC8'MJG)<2OPRL9[7-?G9;#H"4>IP@4TOX4/3&,;J!N6H+]L=SS0
MB0D99[;E-NYU/&WC[5>@!4.&=1\K1/-6(Y:09'8U&,&,K0!(L=%N0>BR>'J*
M&J,S)K$WC@@- X00YQ2$2F0>"5OV@)8^Z%(\ZGYX6=E:\5OR-EY(W1Z4"!RP
M[/[A#Y.H1PB3T>(BQP_V1P:X]J2=OG),IDD0YT@4*BID)YRI#HZ-[0 8ZXX>
M)U[^\#2\ \JU89Q JHH:QO+X<WR6[:;"AJ!90]6E\P\F'1[\"#*ZQTD>/H4#
M3ZJ_%QI@[T.' $?NB38VBJTW7/.E\$/?'W.Z4 2V)-D?Q7W]=9)T5K@3Q_H-
MIB(DZ@W"[JXB#I[Q'0%W:)#:MMUUV4BT!J&C#8W>\0X)N2D^H=IO[^8O8;S&
MY5CN:52?IVN<^5ZM+FSUI&HYOAEQ&9CH.1TH7';DP[M2))ER;LW108S>D-K$
M':6F*<<"^:@GIJH6&.32;7ZZW>;R_['WKDMN',>V\*L@3H2_L")Z9HN49,E;
M$5\$3=&V]K$M'E':^MT#%&9:!+JQN]$SPGGZ4[GR4EE] 8>4:,)F_U&( Z"O
M65EY6;D6+S7"V8@D+X.$*^AW84G3],@"IUDLZK&E_7(;"B$"U$J#Q$HQ_JD#
MQ<SE(N^^6-3C?12E4(>6Q0)U?E 5DV4";3&GQ9P>:4Z43%V9?UK0>8OQO(7Q
MU-((8;X@29IKZC]X98]RMR#QB'YGDDFV;F*,67&S@#HXX^K7H$C1./XV= <Z
M&3:;*M@\ZU WIP9 X4B-SQQ_FE 8I9%R2I)O(JLDY6.6:LG%672L7CB/78]0
M9]*Y&BQ%)<QBEZRH+"!YT1_HUK3)T897) B$GB$Y,ZANH,NA^Z3DHQD''M)>
MG.+JYG3%YXINII*I)GI!*-OQW/ZH<C=32])JHK;'KE>.=TRXJ^TXW)*ZI4O6
MZ]*&$;TY[@CZHZO&=,O<"I!>4(9@O9Y472?EXG ?9&H I]:BNM1;6VD4\5M8
M-U>YM.)!RW[;"D*R4K&Z(;G7>.YH9M8?IEK;1$DO*9[$6RZ8HY!?\EPMCFJO
M:>3?1OU7@:04I95H=#7\L98HY"U/=9&M@$EUN[Y&^Q@H5_QFNFX;O\8D+_*V
MJBZ5/<?KAXQ?;PF86Y1NLD8^S#A!*LEHSW6^?R"J&- :NV.85!8X=DR'<KP8
MSRQU;B3O3@E:89)I*U;"2;T:UE]#W[VDDG/\D%;XZN&._SE\X;!_K7'Q-#((
M:1*B^*R'FWL6&5>"Z&L1;WQ5WM;Q,<8(^ BQ[63*LZ?I2 9=]<!*U)=M5O$-
M5Z=E;3W]H#',O4[1BW?/])5V/^](T 1-?R.R/^^5"X]:AHKH(TY8\$M(PK83
MCVO!=7T@>JZF#>P*16 .G%C@4!KHH,G.-K'$9MGF&'Z"5UX>&&Q.Q*FY-%TG
MZ #6MT%-.ZM0&T4/0^\SVP3RACI-HR(TEL>,4Z&?"HF,1B0H<6=[P^36H-O=
M.<_ 7I*$]&Y(AL\]5L-I</GE<@Q^ :8OP/3W TS_; &F+\#TW\"0O-0AR+UC
M<#6][PQC/%0DXW9S8CEU4O)@XAK10(S1D-0L-6=@]WT?V'^#+P?("D#F?KQ^
M1?W-^K8UB>FJIA!/&[4*M!.%1D:ACNE:/;QS$RB@1MP\Q==2K&X LV<P!(FY
MQ]V76'OH]OQ-%;J_^F">%-77;<6(36[O<BM)40.%TDIRGB<XVKOJD"3%Y9D-
MR3N-9BQ!$CA@1!'!I>C*:3- ?8&M#-&B0/MP>3&)8TBM/C1L\!2?K/ZKC]OY
MTT^?/N&D]$]Q;\ZGXL"WLV.9W))@K!"I1<:YH1A'R(%>,H(ZWM)SA_\3<WJV
M)YQ@_/6+:'[-_E08@Q!9UI[2X,,NPX67T8@WE(V,GS42!>7#I/?U,OZ#+OO(
M5V\]Z]&EQB.\(H4==,'_6,AM__6OK]P=XO+;<">4J"]W)0L-QBP8YAEO\*_1
M,ZZ^(2-YV4+R4^1 CSO,6,176Z_I?M(+L-<M[[%DP5Z0],93TB!>8&A4@AWY
MR,:PWCB3+A7%8,>WWP>OZY@.,@EQ[G#+]#J.@'027OE>*B 8<+0;,+O1!0:K
MT2L#82O#WRT@HQ(0L3IMLM6(68"]T""$'(KO5JI1Q Y2(/KY. =*2S2!&%A4
MJ&D=6Y]?'E2RBL^B E,66,)Z_.^0(4=A91[%TPWG6.$-Z""[!L O1G@X5Y(H
M$!$<5[D&DK_O^/48^J+^@%G[,@E)#N0V^%GTN]?TVF.N2<]\2?,^E&H*E<9Y
M2W2D^FD[#$ $LA)'4]="V6MC,"IM#Q3<+,?FAE&"@.>TK)'U4+8;X=KT<K*%
M:()8<E35VQVXRY)V^CG4$@Q:.%0E*HA>')Y#B8UM4L1[)QERN$0S_ @QX=\)
M@[^7@\Z3Y'PT'AN2NBH>G+D4790%UOW^ELSS-)GD=N-BI<+D1LBA,N0VB>(&
MF=(N+E0(HN#ME=%U8H9'L&ZT$X&->YLF?_YS]?LGG]B\%)5.^R$Q7=FV]"EZ
M%U^O?O_T$W-(S*+9;)!R6(5+G:D.1<;??/:)SNH(]!A! '/!3XDHQ9]\_LF0
M]C9Q9 M7E)">&J%N_//OO_ADE<EK>XV+;+PKUV77!_ 06@6',QNK:G9\'-)%
M'T'X,-TQ'J;*7EE(AP4<CM=[=K];2RQ-,>RP,#R8MXO?^'L9(\F8##WYE",(
MZ:/1\.\Q)+[^9U3!WJ!+\9R.]HP:F53QW4-373G4_LIQQG,%S[^("XG7UO=Q
M$=0D2<'_?,9$*'Q>K*3=+N@$+[+&Y\^(]Z_3C"*>0%,?G3[J^AMB$E9J=_4>
M\<</-,/(EX)[KSJQ?3X0ZMZC0KRBOA7N78B\BK7F=B?Q<7P25"X&R4JTVCYF
M$S*EBWN8JC_(''"8RFS8>SD2VI10W] $9W0.5PC6TM0=72IGJ$AB:00AU0).
M]#-^8&VXX7F5!WX..1<Q5S'HSG3D@?/<[_$K,@C4'&!+Y6[=<VO2R@QIFKRJ
M[V)PBZ1GVW?\/W'3V/'?]H2SE:FTJN;'8,V2P"T(D*GW^W0AO\V54P&)!H@W
M<AH^JE53(*ZQJ>ZK34_^/=0M&27&/NVX&GC#K 8A=,PCXP*INCL42R PL@TZ
M;E#^$I!=#OB?MY9NWL3];8.FRK#F(9,GD##6]VLC*B^IO?E-ZN+<E@=+;I,$
M0#R^JI#YT[/^<UQ4++Q-NLFK+S_]732_N/-?-=LK9"F6*],W2 .[.5:B&88*
M",L%:!,3]Z$F$7.CZ&DK_!VXZ[C[()/=J$8,]UO=Q;.,\TB30($>_@:LV-/T
M1\WY[<0WP2#?>7U.'MFR\WV0G>]51=$2P>Y1R^4>N"NY&&4Y^T]?.$[D"5;<
M*U8_]S0:;2@A7T=.W?CKU7=4[*S#ZLF7A2MXPH6_Z@\4C<7MI6]1TZ');75$
MY&BE4FV'TXR<+H\'O"%@1!0*+1%#F"N\[>4P],V*_!1J4-6Q/VJE6Y[$,0:$
M1YK9Y:8M_49*J\DC":%R2 3LA(8XA'*7;X^T]_2BLTTG!E8@WF$)'4^5KI=3
MRTPV9MIC<!"?P!T52TU"=>8IM3T3C0RJK_$FNWZR5"S4&1REP(M)'T'<+)>U
ML?2Y]/7G<-/VQ"3]Y M^8_$(\>G>WJV>];?DMNSOP,WU+<7)'/0:[,+/;R%(
M-T>CQ])GQ/$]:%!XZQY>/@N04P&1U=S58O,H(B>'=>I2E +4]*048I*H![2Z
MBZ_U.ZWS<H=>:H_$-.(J/4Z<( 47B/PILN-[MQUK$_9<^#P*&P$M(C[=0UE1
M8]Y2%WE'S&@'E:A<7@!14E:-YDTI&K;-.ZQN8J96A7: @!G>R+F78I<N+C^^
M("Q@??',#?%T;'U:4XV_^;;>[C3P5$X!BSGIM_'8WW[_C)XEP2%*D^F<"M<X
M:*!U>L<Q)$6>U4:[+#YH2(79,S<:[69@=)W=/$5'JU,H6[K.+]@8XX6R 88=
M&&*.$N:*B]@T=7\D0FQS#<. *,4)&NO<Q-RAKD4:F<Y$'B2/=1%J*O(N[=X4
M?/V"Z"SNNA0C')HU<0@@)F4,"=])*7 1'Q9EW:YAF*+8M.@F=_0 [HA9!2_"
MI3'#FI5 [:9:5SR77I\$+C51GUAB@ \2 [#0QD05V>WV6=MW0,"2-ZB[2KI7
MO-N5G7:)O=-X2C[CB?8Y^PV)4#^7AE/*19],I6OJ$>-EW,8-]I8AK>)48("V
MR!*XUK#.'.0__1UM;C$)[2C3H^6MA*+N2 _2C&]TCS8ZG">X^L^DER1- 7)"
MD"<YYC5>RLC%8</NX_([N8U?E^?33S][J@A85ZS*6_&EL+%TZ!;6'$?%-4QN
MX*E>5-;D_:'\)3Z%>*_?1V<5MN[A/L6[$1\]<+O3:?*6PY&5RH-//F?%$QQ/
M!W8']N"'Z.5&JQU/GF@0>&8'L3OZ/N9CO32#TQ;R9+1S#)PSUU*IS)ZV8DI*
M)>E<EX?",>)T ?!;FO]@?#Y]U_*;4C:.'"Q V1>74=%\C:>,OFT=A'RM;NZI
MRI\:[/*II)2V 5R."UQ0<PMJ[OV@YCY?4',+:NXW,"3=^GC_^-PES$<.TZ?W
M,6INL;=B] UH8J2*QGQ#C%Q)Q4!VZ%?>96= F&ZNMD5?HN88]XTZ*YQ.E<#^
MY/AM4H8 ^8>X8Q)M.5^7UF83UHD>+  &PI$GW.BI>H/  P CB3H0XE-8@0(_
MQB$E^7 Q$2C_KE<^;/NC\@#2<R/FIQX)&#-$=D8<M*W:^(_XEGPM>D+ZF6](
M'SZ7;2FUL&* /0U#;F5?M_PIH[/SVK<Q/LPK3YK L::&&8 AHFA35TW8_"%J
MI$:JITSC2-++!PZ+45_0%FQAY5&NL/#CC">GDQ%R'MG^D'L*Q1I\U!^HL&0G
MHO/8U7!I '7]!.+25"T] Y^TR6*P%^#17S<Q5:WPVS2BA:@_GZ1*$3#6QUR7
M90 &G,L$+9#Z;GULJ'M&-8!)B& J.WWN+<]!!%GG5!!_G!Y3_1Q-EQBP[+@F
M()+"VA=[CMV//S(3^__*_>'K%!V^"NT]U=-1FWC^]U=%O#L$<61W? #5\);G
M*A-SQMQ;$4$I#_Z1*5+^GD%7)?03DEJIR53\BT)Q>M S4GEN<DGQ4H>9^<-=
M$ <7]*;UFN(#)=>Q4:ESJ8(,T_8,&.#\:+R1;\*:09I?>@[026QJ<@C$,&DM
M4(\FS-SK!';75P)EO'!/2<(582-H/_?MI3^5I[NK;YH=^I](ANQBO_(7^P^9
MCHYOD,N]..XKDSVE1_U#6-_5W* []%H?V3*H@.=U5]^T,0Z)QS@B^B=4X5]T
MA?XYKLJ $AW]Y+D4%[5:\^(7XBCCNT'*<Q47RO=\-VQ"ZB_$<=+ GZ2Y7?[(
MTJ0P.9\Z"'L4/7"Y)LJ1Z,E%HZAY,%"418->Q>"!7J]^NJMVHS^S&Q >8%5M
M12U #T1]0K5#V2BAJEP.B?72&Z-EN=5GM91[/A2)9,=4W.QD! W$L&+\08#I
M9\I\PF@Z9.+%D8J5[*#:XLPU7AP.QTHMUM*5D&E49MSV(NBF'SZ0(9=:0@G:
M^Q1V1IG[5@+'>4!G$KS/?SG)F2U+5$6%&3PJ96HGY)V?@Z>8X>=NA/LUKIQ+
M-/V/$)_YXD<.+!V>;#2'/"1?)U;2EC$N#N_E-GHA\94^4T ]U1,09*0(B=9Y
MSQL7EN&OJX0O4,WW"C0'9GO#M<[PVC&VVZL_3^$]GB,6WX.>$HY)@T_Q?QO,
M*80=8Y-4<.'GOJVZC5,<\:R1+WY4-GSQ9$D4OLY89R>/=I9P^B%,I7#<(QUJ
M.N!6B=T^.SP2!,Q=Z-EMEJ)@.2N",;6 G#7,G<[W5)B/%]&R"09VXFU(EY4U
M@C7X3%N+O"A_R9Y"^] ?;63 DAXW)=9WM)C/4$DPH+ +V0W* 7RZRWO(;-?:
MYH*T7<V\!!0>LBY;ZNA.2 ADX:)=W?7J%29?;(K%6&# 0#(0&>'#JL@(G[0<
M>$@*,L&M;T/AZ$YHLD7)VGV9/*F7P#@-F";4=QI3+X/^RETX0WBM'!B@5\V;
MIC.DUS;P?HY_8IKT^AQ'/\\D<60DB@KT$ Q<X*(M#X<<!%>7&!M\!&'Q2VUB
M[<N-<'^<.FJQUYYI> PT]/S]PVV<$7VDU4,IY3H:I,RH4<DF45, \L<GAS]P
M9VZV5$73PZ"1)4X.^3/!@F**9EA[NM+_:-KD V0-VA'30.;^L&M.=':BF"$%
M[Z!R$3+2NK6VH[]?/0.O[$E-&RD".JC4*+RQ;JN35LEHSL7UUYJY<[JBE:9X
MH1L>B\BN4_ZZ56W'C,UE+M):S0AW'L=7J!Q:FLRT(6X4>H5QGWM=R(NF3]J*
M &+  F=SGZ;TI3I@!%G9QZ]W#;: 9?E_J!& M V1% <5Z2;"E&&XI?QASDR2
M<DPV;SS>8NZILADOANJNV&[X/$(BA/\=3 B(!<LRH?)SBMNHFIU['Q2E>9J6
MKQ(Z4]/A4\J$N7)I*V^$F^I.'5%$6MPPH+6K-Y/UON[,>>_Z/1>MKE??AVUH
ML]'-7L8-:#"[Z;NQCP4,KB2Q@[ ;Z/B1)VQOJB.V>!WW)WXS7!*#68A83?\]
M/':!""S'/<CM7*^>C?P]1_&B05\ZLEA4[PPR/7P(\ "L$D.0QE *PH8.@6>-
M8C$:5BO!M^'_Y1EW*4+-N.:4](RUT@C7IE8[<06YU-S?Z1<#R>*.\Q,&A0JM
M<F)6J-HA<Y[ <*7(,G[SN6@-]QQJ':8R=-B,[M#*,@FW-"6-NK'EJ);(]=+$
M8-@=^\TI$2O2/Q.$$I)MB6-BP'+8;-]042*8)8Z:=$3HG^6AX@Q0X+<*QF1*
M0%,+RUCCVN0Z9#NG?3/NUC+6XTK6S[HN7AU^]GN!(?[UAV>"/_QD/F.Z"?%^
MV3GEQ %4]:;^FE,#F?=C[EWK8/W0>'+'V6!GI0R+L-9BE3'SN[743#IU\2:,
MQK+24KB<#&0)N&]YPNA'%:L 7HNX[) Z-.LJ4%JE!K4U LCQ*A@&'2[D4Z<W
MCFW,4=/U-OUQ3;</,\'5(S?A*"Z-@)]_G&SC+#^M;(,4BTR\0@GO4MPVB,/R
M&"Q[(PJLQL_B.7@USE^59GG2?-1[2;-F\6;EZ9CC&S_BU*&\Y\D3]<KCR_O6
MM7,8'N:4X_[17../__'TZ5=/R4V<6Q/8".+U%8S&H_M+DG2$,_R/IY__!VWE
MA(B3FK8L-2=FZ)I]3/6'+=LP",#?/?U"RD,\\]+P%+_-?0H<8;2%5?7E!'T+
M[&N!?;T?V-<7"^QK@7W]!H;$F[Z;Z3BJTQ]D:#QY.PX\A<?LOK(\#CS4TNYW
MWOJH"1>3<-+G/],LIB/#MDU&Z_L=Y&!+V5_=_D')9(<!5,:H7 %C!98B;8G*
MQ)7!@QBD--XOA$=9@C3:>8]-0[+D&>>8W:@&9^6Z;3A:0N)*/7C&!MPR?@0M
MTYX#4KX)_S1G[SP%18R/N0]3+R9Q[2"U3B/5$IEM$U-4/"V?+/&/HP+>[XY6
MK(]9XHW)\!&6AS(U;LAL[I%NT>Y,C\:%1/%V-G+ 1*&Q#V3CD\8$6!;_@L6D
MH>&=?X5D54^J1@?  WWE/FZ&,:A'J2H9%,7[G!RPA7P[7R*;U"84<%5EZH2V
M$NJFOK)7\_MP?7N= N$"47"YBW\YWM$7/HD_/ #^F+B(\C4D&K.H85C<U]3S
MX>$E5JTNQ+6_ZWV-7/N[E^1^T_O]IZ%4P&Q0D]V/I0$H";=J&?WACH4",=>G
M99%A30)#G&6JF UPC)95<8Q/3/>K;7G?J(#[L,QEB\%QX<Q@3@C[677'IE4:
M3CO7KNSK]5VJ>!,DH0'LBKGVY:9XTM6/V(W;R$GS4RINVJ>FCNUXEO!Z]1+%
M:O.$B5@ *=VH\T5W-I"NWP7FO]82V533-$R]"?+;O"7(?>O+I+:&NZS4LK5"
M#QK<^NRIZ\NS.GW=Q9]TC(<[Z1E8HGU$QY]C,+I,CSG^1)6:J9JQCNX;MPXU
M2!:=%1G:CC<9;D_&9];C?/0%5/O#+82BVF.M:I5X)+;QC>IUYRM+UE-/K=L'
ME7*O:0Z.P=RFY?XOY9'_;2%&WU1=VTN57N+)/W_SS-FU59O0'9:&@R.7'9#$
MY?  +8XK/JZ[(\;*6UYRM[OF)A7PB>\G'E.[6'=5G<;?'7HI+GM0YFIQ<A.H
M3[AZ'7BQ1TLFZMQT^11[$9_BKK""*K!Y!ZR1(V)P(P3S)/58.C>!0PR.XC9%
M(K-7Y"W$?0W!#.S##H0S-7/8TUZPV^7%9+<:?NLIXP5;]7[5S0?="UTJ7)57
M56XLD9DUD1,]:#/&R4!W&E1XB$;&^SLAR.O6XPU/*S.6@U<=[S7*UQ>OJ'!7
MYW@:C!6KT)M+(Z5N\4_?F7QUN%;%/V"YTB*U]<CW#R -[SNB[1!O,'J-%EQ(
MA5O(6*[2! $2=@IF.[SD1[^7B:N/5PK<2]O$^*L&QE=A8L\$E:/])1C0P'L^
MWB306]KN*'XJ95<7#AF,Y7BEC $<R;UV?=>T/^-Y>1?M[8^>'WV9CA@PWPP"
M)G9Q_'4J//.W<] :AP>[RL+1M:-7JR@"H* 8$5R\G8H+!7TM>D'T**Y7[[;?
M9'+<U.8C"^AV,CP$P%FB%!'I$3?]-L7X:)X\?4V36'JIW'U-6!5>A^DDTX]7
M'\;#FYD7!YUS:)YPFZD[VI0Z#, O=+JWS[Y8;<I3YT@Y_!C,4QZT_\I1%KEK
MI32DN^N/,8A_2.3Z8L!U(JJ9-M6D>2[OK6#CO;,H>X?I&%.XIU<K2!XY04PR
M#NGS9&J7& Y^#+ 2P6"2PEHT<6<I9"4PDF:][EL>,XNIRDS0IN&4KF=K7L_X
M/(&3H/6=F-WXRU3H0_V' <2\'KMB^IAF0!CVX?AJBH21<9;CW?M-%TINCV,Z
MMVUKRY=S+?M==)5$!L:7/48/&#3?4 1I;/'2:68^PLSHNT>,Y,QA[0EH+-M*
M#EG>EFMMAS-18=<T-?.=43$A>L7J4/[:['A) MYO$O GBQ@@ZI&IF)![<(.X
MQ@#SZ1_AP/[T\OFW<=<T=L[X@YL;\BS\3[6?: -WQ$J[G5;T6QEY:F)U!6:G
M90YN#N,1>Z*K$4\3?=U5?*6A[J"IH2BV\<&O5S^F 5:^VK)6H*IQ:Y;^S+I*
M5,"-)S#VU3'!0^!K^VC?.V[A<&2;RW5NF-] HL+6(>WX\(1^X %4NQ'!=L2#
M#R)C>/MLT.#\]0)4;5 J=URYZ"=/]9)5&A)7:["+QUYQ#("5RC0&S$^><I--
M^FH@3(^17D=;&A(S+2TR1@Y!+S'CVAR"NA+JZ,0=Q8F)CB^F<BDKA[245VS[
M>+@__>V9P?_2$<WY-;5.<3!Z)NYOC6-3?:"^2[#N#H1VD5- <1>"P3K/P--$
MN]V5%,&)B])^>*2]$3MN(B$43'FY#?1 #CW-9$C">L20(]]N92_U$C?/CR".
M_$&U:4L S5,39+Y>;'D5\ML)S1X>RRYAG9Q0T6(%U\#V9/9Z=@WQ4*P*U?H/
MUEJ:1DDR$(V7$*6MIRC-?.VP<$?E]82&#$M7"FWG//KR9F)M:FM_L/)H*$NK
M\81YI$U#5V$#$>R^IGNA'Z.Y@C[TFV,+-]IQG,#8>5])% OK8.^J\"-VPE6P
M23VEVH;.)FX1]5':U)@WE+C=;..*2]WFKO5.[ RZYU />6HSC(>B9W\B5DGB
MFR@20$&&KB#MG9CP'9/FL'PMM;6TP;*_E?(("2A1=T<?,GT3,^$BQRN8V8E9
M-]G(E8'=G@^R]_B\_"!CM77/.^L$,7P8"$Y7EO&OG!L^E*1G?.^&;2B/%+"6
M]3']ZCZDMIAYUJ-/4\BJ>:C\HO+T!0FX( '?#Q+P#PL2\-*0@/^N589G5/4'
M>4<,8,#&$/=3GOCKAB-_;EH0L?7!1%<*EB-9GT0N<LV!,D\E#C6;'*N0EKY&
M0X3O(AI4+,)>_WI1NQ9T!P853:?>=.OR@*">QH,VQ,U]W^SNP>0OM! \;3P3
ME\2 *[0T$@?$8)&I\&IC1RW4S]D.N!K2N"*GIZS\0S;?4RR>5#4!"Z#0A3[+
MU@&!=M!W!,\$=?6$!T_;&>Z/0A#%LUIRMBE5QD':&N-"I:WCP^0+S0LHF_8Q
M'E_BM1/1A<169:Q;C,SE7J)Q&.$%K(G3C&/?3;SY=D^=2H!=!;7*X_SG'$%A
MSN=P3 6$:N 6Z&F@C#TL5J^>U2?U6)-N3)!' U\FQE#(9&+\H3<)1F2YJZ53
MHK0%&+(707#X80$WH;8 W:5D.A)&KP6..F,0HPEJ16H(Y@M5&=<CJ>I[(NZ[
M=:)I_D67VL*(46JU3[ UYA*1Z]^4^Y)%0CAOTI'M 4W5NS02IOWT^W'32^GD
M5U#V3/M/RJH=!D202HZA;.RS'\;N$R^[=+RLT2^N6X(TG!B?)"Z34\?I+I@2
MQ@P5Z/[Z[<MGS^9UW;YU*\L-OI%;>^&'()^K*Y7?02UNH/(F)RN4JG::.M<(
M<<WYLJ(Z,PP*XI/BI,(VAX)''*1QQ[2Y\3E!_XQ*+.(NTJ0BM10%I0^/; /H
M=K-48.F.?CS32.9]+]\ &%52^9$"LS68I**@<E7C<Q5<I<@X:\>!H#<(FA/H
M=[=H.'")#4]6:1;C207@2TJ8X3[8A@@I-YN/++EQ*[I;S"Y,3X6+;B;I&=-S
M O<?@S^7@$U[W@'I7)R<[^Q*\VO#[#1[0)BRD_(C+,&>YV>4N((**/'[KVNT
M%G!,ICE[FW<HA6L^_Y7>X,0KY:UJ_"83[)ONC[&_!##$ :UXGNVQ6Q$9%9'P
MM[6ZQ7U_$''<Y'*."N8"1$G))QT0;#9)&WIM$M"*YC3IT"=(S@;"NXZ-@K3B
MCS[7F^/R*G@]6HTY*SQ3W!9^\?JU((-FB^WE\#'PD&ASW7?Q!2FH?(PUGR -
M>4Y%_2;&:B78:2ESH.8JGE;2!/F*R8Z?OX1'&,N?Y(3KG_*(&WU=&JZ='SC7
MER%TLB#&35>QEJOH1!\C<9K/O,8F!H@:"%(3@EPAH_OJ#:F?)=6ZB<#37:EQ
MIZ E$"_6>S;ZVWW56%A<=FBGL1=615+<$)J>:ZN=(U3@?4U!@&B('#B\@ WQ
M+?JOK@CK=RM7F)'7NR>EKTD(@W7S?OZ2^.W3S,>;W]=G_$ S\ X""W[J>#K"
M.@VR^C.14/8R:MN?=%?*QS#=<?2MJU%(RD#?]\,Y1 =-9^SQ"05F93S4<>S-
MB;P%1^M>XQ<":#V $%Q>L9A%+WIT7<"\Y3V_"%!IPYVH!;.@IWO^PWL7GF59
MV_]7WB[(VVW?O ^C&'&8^J1PT9N[WR'-]%W.$QV7='7@N^ -19(W'O._*W+@
M57P,S\DW1P]9K'X\EG?%ZMOF@9O&SR7-7O>,89Z0>+(I14>P(\TX+3$ \4SI
MSQ8!)+WD&.8Q5.<AQH7,,4E4//4MI^1\BZ:,Q,.0HY!72"E4BA+ORQRU2]%R
M[UEO=]7Z.!3SEK@*/]HSB:*Y5U4$X(837X@"[%(P-I\K2-2DRT;^+Z[(A'?;
M1 \=@Y5U]GJG,@I.1..%"7@.@=%VEI0LOT<3*G!/:+*VN.2CEQ+0_,3&!:<S
M6]L;5@1G+&>6?762WG4L-_ZBCXL^\8KIC-J/_WOU%]Y85M_0>9WZ^/?N/+^G
M>>240,I!_O+-R^]Q)#I*_/^O;<"<OT)_^V2%[8]WFI50E(V\NRLH(2S0C1W/
M(HO>LU%"OJGX6BT)?A8]+3;-%R\ MS(&PQ__]S70965MV'UP+0[7'.YID.4[
M=^*W0[P,< &F'1#>L&UN^BYC0?6U+)J_'+SB4=4V=8Z9.5":]OY"MJO^0/83
M$Z#/_O#YUT\_747;W-'1$@F_?T?4-?KLZR=?7G\Q\45Y@?3@/O^= I]$2EO*
MVC8)*9^ZRSDJKDJPNH2%IZ#H%AMMFP'*$LD1[HP*QP?2W^@F9SD J.B@KH>P
M@#=.A31+;*%S-P\J?LK$6R&:7$LQ$9=2XT+%4$_)44>Y0ZL(%%8SY4R\I354
M52DH/Z)TY.^:$0Y?)[OA\"+N4HAV9\-(#7K$"VC4( &3YODZ7K%K-K>RI1%]
M&#TR0LB:_C+9S49KH%+E "0!8[(6M>XQ+,A1">8?:/-)$;"^5KJ/Z]5/6B08
MJ/BXS9@"P5UY.."I4;8=_XT(8*)NFX5GY42?+EW']>J9JT;E,KCVG+6TT7'%
M:2MBC_F;&XS;X(?X?ZH;I\E:*2Z( @;BHRV)23LIR82Z<VL60I#$H^5/.F2-
M'(0\WY(8=GQVE%))) %5YWCM_T5X"%[7RMI!H?]_T?_HD#)T63-&6GY)<8<@
M\.')GL;@21C2\L6/_Q']HLE+9W/E-\1)>!^WS$V"1FE"\NJN"KO-2/!9V@@2
M\=NKB*%=0RZ4@AQZ:'A,Z45QV$VSW!3S27G16@T@6MN5G _$\[UZ_KQCNBZ1
MN);"J+G^Z-2UXD@21\++ MHN,%DS)FK.2"AY8$KL0%O&V'=>K[[+GCB7V1X&
MQ(-I#R&<&)4+_$8!'*9O*;D\R80V8(=U"#K'[[6;F*2#N0/Y"]%KJHP5'B_A
M.F][U&G9;H\ZR*<W3]>:W[N!='=,SLT:G:S2#/MXA1,C6C"Y'[P\M[/%_V4-
MFR/7K=%]8T 8,\6(284L</F:;#D(;HY09_&@+WZ\BF>4*(3M+HGM:/4/ZS.3
MM0JGIIX4/A=)T6@O0['1:"JJ1\521^"5>P&1:3+]5^EADLGGZ^15/"R%(:0.
M%+?16T#SGJ7IJV29J!@-87&)9,7)R,J"I-6>.-;A%,19L(-BLO72J%ZQ+Q*^
MC2(L+5[9>L0[=HOR67<Y6< ".%L 9^\'</;E CB[-,#9OV3N/I>6</E/67!,
MN+&IAYOK+U KW >:(*JZ?6?9*#0XR9?35C,.EEV'KNNW%,QE5=6. N&4#.A!
MW0XS@%(TK69:\E7NZ0%O9(/_?:W ZYD04LE;42%$@)XB:-GAM""1.J[ 200W
M3NKX!837PW]?HVW0ZI@F(WWY-I :Y@&49C$?4B(C^AH+P\M^R;@/$2%1(E^N
M$RNTCNN.2 9 P\UUB4RL3)C7N$9'OTX5.\QS2U63B0W<,]*"HLZTEDGP9\!4
M3:HSU+]@W+P/!IVU'#-=3DA)HK!8N?FD^!3+6[&>HR&VJ#-0H_'I"@96X:!8
M:U2 H.J2$.'*]6H@BS?^#AC&!1MS4?[LF8KMDK@31=3SB-@1Q$V:CPGEYJ!A
M2.4'13'.W5F1UWU62'(VT@*QTF>99'641JA(+5E)A'"EJG-*^3:MU@Z#-^)4
MD._2"(VOB8*I@L< "SN1=A0L=[-)0:ONCV[#JP'2\DY5Q$<C^ 1>9WP.1>)(
M!T@.+IZ?+^AIE!*S9N>_VY4QT"CY,[O0'! W>+U($O-^0FME#5K7FPU-KDPW
M9)6;H$#GA#:0OD:-A%[/L-LUV*T&#A1\IH5"]<8XO3?X&MEK)MS-);J5CQ&$
MG][^).0BX4CS9-7M&^\.FU]0\_]BFQ+K%VHP'4-FA;^X=ZH5NBDRS,(<\ :B
MLL=A)!>/M1X[0X/33YIH]&%H666;1Q:G[DKL)A+?<D3Y9VG#/6]:8F5:O31H
MNL(X,.(JN)2[&%XB>#\QKY #TWC('S:R0WG"H$!#R0"/# @@ >@B)?MJ[0M"
M, DD)_T_B94#WB_ 0*<L@V9>@^O0/F(\2L4<PHZ@"N2@C1NNS&9>&&6H.X]B
M[:52S(5BUI#@/1Z(1V8<3*4N1>?3)0CXT6NHE!WM\5)2G'Q6]&W32$1&I/](
M /L?]!5P2Y;W=*)7M,;@ W@W9>>K;+"@<]K'>3EP8%JIR8'\2$:0[Z7DQQMP
M&L!@,@+(B8HPS$W3O%:37#<HYV)^EIB#9*<&"KEJ@<8$* .]+.1MVFXQ1:"6
M6F"\MZ;&1.YYJ0Q9;:JR-3IHE*OOP0?GZL[@KM ^2%(KLE$"=\?&R[MMVED_
M?XD;]D>0!SR?R BQ) 3$)MU6))KD">(N.U!LK9Q*6O*+:_9[\)7,LK=N8O;Z
M?YD(-*85^PE>$7&'"'P[=Q9#[033TATP.*L^8$&(BA+C2Q@7-[)H6'-<S ?:
M?7D9B[^V%E("<++=;QJ>6$^N37_OF=?:I-'JI'K5:T8GHS#6@\I,$G^C7<B;
MYY_<^:7UH;BM#6E'NOX0]1G:[#QNHL:N*(&_=OQC//6)+NVR(C_(BOQO 1A/
MI]V#KI:0-F9B?WVG"[;K B'XN1QV-FZ2/;J+JXH\=K9W$3L$HA+UVO3];3[=
M1;T;IOD%-,4V$TT9M4V< 6L-MZLL#-AM:)PET=WD4R9-EV@O5.[:A8GL.M;A
M#3=;'1GJ+?FOS-"]5<B8H'>%8J<4BD=U!+#V]!L<&D%;HKD@J>.Z)S:,GJ,W
ME"UW.9#9/Y )LI,WQ,!NK U0 3R;V[9Y((79Q$'AT->2><_0EJ+*O'B##S9(
M/ ,)A;7-)= 6!Z>96#+,5)?))GT A@?J:#SS@])/WR$4:(09_"9NOD&ELMTF
MHU4JH&OITE^]>.YH97$4,'S?$!<EM4Z,^(MX:HC'/(7:\61P.^$7(4\>@/2-
M;#+N7XF;>"K0OD3;_0B+03^-P-7J\/">,UKB^ JO4@Q9\!_V34UL]"50.7">
MTE:3#*-8=66MH\$I;"+;"C/30#^QU @/OP4=[4FL/ .;6TI'%^HG/4IP3[TO
MJH5_*+/2/9B3@S1JR^14TO2+ = /.,+?$$5H%<@5'R2PJ++.  VAH.RO68)M
MVQD4L)!&!7G#CB8VQ#%JSR!K(+C60KH]TR_A><U48RJ2():O0IFN&JE.8:1?
MPQN>$@66?:;F)*]$%='S/(8YT+A\%79<04(-2\8S9+QZ71T@(689(@NRLY@N
M<+=Q;XDW>;WZ[VP+22\!GF!FA]1]D?'7V"KS";(BTW+G?';7L' P6PI=1A7?
M"GW7MM#XQ?*7%05A)B=7Z(P8Z]GCW; 5MV6_<9-CQ2K3H:>,V+_ C%R,'!V2
MO@DY:40.6BOBSE>6+*9L-U[1#/M]XP<@K\KX^QTSKUJJ6ZSZFGO5QRH7(,@,
M%U>*D(%GZ!":6@KB&/3]9!USO$=7@5]K03;4MR" R!IA@!Z/,VS,!1C/7&*C
M9R$^3*F!9Y16:HGF(D$<,($Y] M^TE]8ZCI/*T+9^EW8<1MLE^3!W2+@ \4<
M!6O8W;22/B;M%?4'35JQJ2^71L[CP\2:W+GY-?H-#U7%?:_%6/<N;%@HGOE;
M+I%$?L$*+EC!]X,5_&K!"EX:5O!?*Q6:>PC?5]WK;O6]-,;B-D,,^ P8#PR9
M>8F8YWCZ .G%;YBY?J#,X9\B6! W1*#XF/@642;MM\H,Y>6-9-I"F;7L)1_D
M)6/TO.I21T4&OKKC;G0 ^@WI4U$L(J/S5B4%Z8]%%HYS7<&;@OHS&F^!]RU)
M[*4FL0CP3'#H,V%O *P!@C&M,6U3-BDAZ>K)$QV&0HS,\2G;R9=?Z4>: NNG
MT7Z?_-%K:_[D.8C.G>U+2GI0K'.G\SH&0/:U0322K Q'D6S^I8?&#I57+U\^
M_V'P7=S,Y_;U_&ZR[^+.GHRU0[_KO;"@K6?/9EW1='5[&]+*-@2!;WTSSN+(
MV1NE=D1+S<L2B5[,,]MPS%@SMJ/%G$E)IP;&L-9?&&6@#ERC0-#4'/53"R95
M'>(G-]KOH=LO#\BT6!N\6T$S$N@";4# -^SYYN1+2%=#>90^:.K6R /CR<)-
MV,J;X,Z'V=QM24Q-*R\BFYJW_!*<JX1F55][1HT\6:/4GN6HB922BPO<+$FE
M!Q:)X?E=PF\+L]B,EJIZ<#*;_B!JM4.B]@=)EL7C\A0@)M<\%2$S#\F= Y>Q
M5K$Q:L&Y&;!O#6.?D/6H= \P%6+.SG*4 5YOA7+%1/A&^1TW:E1%"ET\5J[E
M?XP/R2?>*+L[3154D%N/[_6F;<J-(GH3%3LWD^14LELYB<Z)#AY?GQ+1T[6!
M8PM)-P@9-67.#2(_K+]Q]PYEL]/+$83P$"%XF4*X'TG+BJU.NC#PLR,\"95K
MKGC*W1/?3H0Q6V+/DU8H&2_U:$D6PHHTZ$EU5>L6Y&A+H%]DG!@0D$7EK>$U
M"7@RZF)#N5FOZY"V!![W3NMJ_+O"Z]2JF3HR&=5$:$R$4\97#5&/XK-0Z7HY
MN: $%R0D%QUY73C=WP1YI:*0H?;6\>9=KS\>J&$^,OU"7Q..P&9[ON^[KF+N
MH!]?MS1J/(#LN+=UB NZ1T$I\2H.W(Z\ YO'82V'+O$P10LY-/&4>.LR.X/=
MF?J?*/<Q39]@WL@H&CT17F")+=**9+/][*8_TL3-3: H@M  %543F]4.JCC-
M["U<K_S4!"H5S+M%Y4E'+RCT#5N^WI+GAF[;($A[5%AUAWNX:X39CL,1"O_?
M]8Z2J0RF"13X%T;# @(DZ.#_:;9H^(WGWW]'__W[=\.N072W- WGX4G9WFTL
MNQH@M*8=+^5MV2;3@Q'0"CW&H!,*#.N65U5.+&YZ>60+&T1*;8C+ZN?0Q--M
M&! [V&# E3'Q9GF'WL04'8@V*E^#VVI\0AE+</LCSM]-7YT$&%VY9RWYI,V2
M=DFY.Q1K;56A(UD:UT-V"P@<M R-$(5H"::\IYBR71IM_Z!?2&=G_W2]>I%J
MQE2DEA^ ,L EFVF 3;VS'9EV7KO>+ 899JOHC61?E&-&QZ60TG$>/(J,N61_
MLVO6K_W;L&"DF58*,@$:)^_6TT1\<O+4_2$FF'75KOL]=8'6BBZ7!\P#^'=*
MYL+J1N2OA<<P$#,EFXO:DMO )">83)WXKBPD3#$<5N"]A+SI_:FKU/R,IYU:
M^[=QG'AN;+K_Z(E!6R,5#/Z^;$?RXXLJ_'],,13!<INN4D/ACK;E&@/Q0EA6
MCH>= HUMC\SUQQ0VQ+W5<"9MP.U1I6J8B3 "[W@Z<"LJJ6EQ?GAG5ZBG<;^G
M;8]8DVA M]WHF &GG:)-'I>@_Z<_FO&7]-P +NT6M7U&6R5#$/F8,KY*%^O6
MVJ8)G/:HKF[NR%.^*8F9Z4W9^93B<YC09!>$2<2-;@+Z$\\N,Y&DN4M/KDA;
M>3X=DYY>J; "ZL<W1U?HL^N@ZSI228,'%C;)S1SN3AWU>&M#+'8Q0+P)NE^K
M$R5DU=-/OX[)]E6,"\+N&G]X\G6*A>PC/8B(D&.>NMZ""9))QZD4<],?@Q*<
MZ*?*@[:?>ON%>%2&L=%CI"11",5A=-EALKHJ-A%^S[P9</JP.+4/2NB<JF&W
M;;E70Z&AWS!=PF*JOK$_3'6KH<?@KJ_1,8T/J1&' Z-Q8PZ"A1J"<\R5"8Y(
MF$D1F^5TF<$Q(\1#T^XV\2$LMO;ABA =$=/> L[BR][D3N+NZ4/@\0:Z!<.9
M6&5G1-T"R"#/DU*F_^F)8,/H?AGA86(S#(2=JDIHY";%]G@G&K-Q L!9KR,.
MYDJ^WHH,BT  Q54?9PJ?X!-GFNVXM6RGI]>X^L'9G);870E=4P07D])>E%6&
M<9'%(.3$;+V6@?%S%%,A$F'%5%&0;V5KE M5+-T0O>R"C9M .W1=MFWSP P!
MB62,("[T)OO:%6V-<GN/51S2;9VD2&L7JT*1KJ<R]2HU+7 C]&]L _*6)+L3
M78W-"H#H@X*.%LR#J ;A/2-/A?W&%'I#EMWF5I["+8G ;+IIZJJIS-WL-FQ)
MTF$81C-Y[9SZ.B5\I*-QH4&3GAH?";J(&TFE!)LIT5$+J5ES,LB'/%L*+F:N
MR9&G<^H::M@KT3!3+L]SH/T(\E4HKZPHVU+9;K5A 6EK :R%01J*T#//A%L#
MXVK7@])EMB'^9*E%?Z!MX%4%I=SIDO#8_R&@0!DX[Q[JF)^5]$2J?6! P -)
MOC^N%F!F#W/-$"Y/A>W35.&H36B1-Y@^.[$Q,^'P=@63O-OII@&N%9JMED'
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MGSZU3KD[[KY<#/R^ 4)I<[,:I_;8?9@7(#;,SY5#+!K ]<-6&@QI_(,@EDA
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MB;;GZA[[@S3>FB0LPU>EOH?P(3'IB+LQ+HP#PU:KISM!3!Q1&<4/%?BQOFN
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MVC;>)0::HY>GOA>5$=Y_5/46*P]7B=<2N@\8[D7G5H6'@BI>1V;GM3\Q((,
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M9E,=,=BI*<TBRT#P+2FG>@BSLEBY68@N6F.IP[R-\$R!?RO\DDBFK?^ >FH
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MD_AJ$,'$Z^"OJKH HD#-"*JA7!=@B19"6O LE@#&^OMRUY\1V]9,L:4Z7HR
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M!6% XT!@KV+H:B8$0KQCS]0_V-<PH^H$)3A47#DJ%W^3R0B>VU*F8+ 3(%7
M5W?,K<I9X8;;WCI^& .LZK +*G/-%C]1JR@XZ1FT"JD,T77.B1/1T&VE.4D[
M_X"C_^B@XR+-[S7&";->I 1F/#,+=U8+!I)]N18_-/W09GP='D!7> _6,G]!
M3"<C5T01Y:9L-X2"<YQHYQZZ7E*,1W\6+*MC?>>A<NGENW$<#DI]QL+%(:T^
M8A*3W7V53Y3)C*!SJ,1QQJ,XGNA-Y,KAZOBNUVV%I%-S;UH*6:.)768JH8YP
MOXOK^D!@JF(4L!93D!"**M;'/)#2^._-\>ADS.:5L8'6UJ*%K[/'B^^I6F8#
M813B<5F!*FT"JT[+_$46,>:!^-0]C"C]'[$NBZFC3]^DTVR@!TKI'@OUN!32
M'F-<M>%X% %0XT_* FND&%.OC.!,E+F&D?O'8S0UB'3KQ6@OL2J6%N78:XO@
M4^?&"4 /JZ\P@5<>?)J0OAV#JG#@U\DCXCL\'496/=P)NWKV6AY SDUTZ_S2
M9+C"ODQY!;XD5+]20!U<,-V0.B PW74578_T;T;V,2@@O;U)ZYL<OH+%N7VH
M?#RG?->YULXEO'ZROK;EG\2!9BW!49EWX[7$O&4XX>JQ4D2*>;P\2:++&I*_
MJ$<3?EE=B%K3;RA)-,5#;G-F#$0VJ%[Z!O<)CE6;N!4' V*IN)\M!7=!3G<<
M<^].8N"\CI$L,2D!*/O%@!7AC( 18X3I:50,%)Y;]_FOI5UC-#J+J_]0DCU^
M:O#!TQ30P"CK[TP8A;ZY =%FFH+D2E":[U-"AF8[+*KQD&S\838_NMC#!YEX
M?LMZ:.[TN*[GVN<I"PE"A><JG5;7U,JEPW#[D" SK3?II<WXL//2:;^5V[X<
MFUU@H0LL]/W 0O^XP$(O#1;Z[PHN$$E-R-A, TT\!D#19Q2/I^U@CAH(Q0RB
MC].C)5T/ZJHN6($+#5!>2O8@"#_%C1%'/5V,8,]&@W.$A]SM1D3\+/;(4YC$
ME\_UB)H$&F.N%?.[*NEO&S"N<M#AU=-/5Z=0:LN3FO;Q7[N*RA<H=(#X5JGI
M"?KDN'=9-Q+J>]>K_Q;^?(PG,I& UC4.:1U$>Z5]=J^MG?\ LX3^(LV-:@V1
M>7V/PN+O;R-%YGXJ%;VEZ&,[L$;*TV4""ZK0E6@ E=D5V>E7-R7E>4VMO!V$
M-.2BY?"R9H;G_MH\!$9AUM3775'+?I>J/='6;F1^<R,*&:%$+5Q1XE!XNM?0
MC@+6F=_B! WN!H[ 3L6.PB-"<ZX8IS3B5 8@]# @*!L\'-/P4B&U"N/,=#T
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M^OGG"8%T+%_+?&F#MG^/J9+3RAI)<QM:MIFY[2#U )HVP82FRY&V>@3]78]
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MB<JY-G)S;:"NIQ!OJ3E(9L#?C5S$JE\.Y\AV1;XX ZLFM0H;,>;"E& Q/)R
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MEG^-EXOWQI+)3G9+I)V533593;A<U#UDX2,X[T5+KMHZ85!)>1]V=),GVP0
MZWU3ZF<6P'VVK=9R>GUE\*B2OD:L2GSE8OW%I4)-3$9C+6+%.B$SV[]<GTA3
MR'(M^E<"TS(3J1TQL6^V-(58KTXLQR XN;UGU]P;;-,ZFM3F'LA648:*7_&"
MF^9Z(6IMD"<R4T7!P0F-J!@G1\N'NBNP*%+?%K(=8A)D3*$M1F=D>#P>VBRL
MJXS$Y%T0=!$6ULHK[TINZXEK6ZPI_N25E"[RLC$T7;!S$[!:=&3IW:@;37ZN
MU]?.MYR_8R$$TG]J$@]5+),?;F6WUQ\FI+.YH\M].T?8E=V5=V3[TWRH:@/=
M0&)JSG*$2]2*S-IW A2H,VJL+%"[@VB;R"&J=K@T5O:Y9&T[9 ''@]IR*T31
M;$'W!(%ER)Q)D05ZYXK!U,"(:UO54,[M#AK5^/#$_;8KSHGKTK$F775.-L:\
M]M_YUC&^+CA&UD^0L#=9"#O=G?7^,(,6V+<2OB=\O_M6[EB!6G6*9@&R#Q9D
M:!A4@#E%?+6R\&U\H*1.#;R\696C9]X)/B&ACFT+LSYBLW#9+:X.+(A-@?-*
MK5J>(AAT^[0*5Z[3JE"+:W1)\3R2^]:3K$-$<4K+5SH99QMPX2UPV]X:BG5F
M>'&X2^OWU?UQ5V[!QLO?"8X2H759LZSB9VD;GIBJR"JES;<Y8[88,^>A*N*B
MWDJ!8"R)'2N^O"C-$C3%[V9#P"!>PL6[W&=I?:_A3O#/[ *!.]S,[(H&SCR$
M2,\TJ2;I#46DFR*W3D-X A.MFS ?L(09,HJZK=O7'2^>-%7ZHV5O))SX0>O2
MT*5UEC5QQV=Q58WXH<2,B&WAPB@PN,/2,5VRZQ8.T6<ZQ5^0;'%%M2JK0M9;
M(C1K?NV&:[CLBF 6H4XTDVK@0'/""Q83;@IWNVU:V**[W!FV<EDQ<93$4#(0
MA0W8FJ9I0E60K$PUF[8+[AX.BP[%#06#X7ZH$2]=J%TCK&=Z&DE=12D] TD[
M@2M&M"AHDD>Q 7.MN*06@MA#S5I]N<%XC51<"')K =+Q)E2S<8XJB*=;Z]52
MAY,4+NKQ/"CF!0+77SJ!,\<E:2IH9RE--+;E#$X>930RTT\7+'H37"_GP8X(
MU7XP[>=H9/K(9SFQ%1JI$GL2&Z.;#M15:L(2Z*=3NQK+2;?Y]B)BS,CG@[(P
M?=SK*WB8<AL&L'&<"ZV^H()BA[5QNC7\(]9,''?C"[U!6L,$.>AK50R^L^[6
MY@\TR KX7%/$C8E+%_PMXV>1:<SW=D-T;<AI782*R!N+23""JZ\PI_*^SAWW
M(KWYY6.QUQ0Z60S-F2U=NZ'SV]AGAJ^(!C"$(6+^!);/]2-R?1[KBV(#A0*R
ML3U:P*,=/=KQ?M".NQ[MZ-&.=U'31]=:.)<T$)JM9<.O6-39TJOGNO:=S1[5
M+9,KL$%(!WM2P//M%<GZW615$7W!B(N6Z_AQ;,-)XTJC(<QQ=8+7M35 /L*<
MBI>6+[&;7E6,4W"3XEE>VQL"R;&17?,T8\=;=PX;O"SA/'A=*+M@V@[SZC,U
M'X,"C/\7JAD&,V4/?-A_.P+([ZALQ&(#&@B;VH&SA3^F+E%X"(1W7N>Y,,^J
MD"W(40Y.F@^=;ZGZE-#Y I*.:4+AA&\.J>.0 $9<N/!.JI"N%2=2<JK(T(>@
MLKHJM_2?=8@"(QGT;!-3C=,:82?H/&8KQ&JNU?$0]##PMJ!V#@+O08U?I52H
M)+%3$]-H26P'RWHQVD!#!F<P0M[7*>PE=87C[^ X)+PGSAUA77D5"^Y71YE3
M^;1.>N,,W40$NX/7+UL+8X53C*KEP22[(!Q@F] )\;D,2^ W,%YLA6=BXD1?
M;A=<M[A >UB N5[B+5>8W+BMQ\U(,A">:\;9O!E(?J:ZW$8M_CAB%W0<)ERQ
M3>6,%L-GG'$,)JJ$(32TL7]4T9B/,N(E0#P12M@65FAIG3A255+.#6TN_(CL
M\"B[2+F[8H:6EV5HQK)>,BSX"B#3 GQU]44O($":'2+HDT4<@%@38,$@E*;D
M?)[)1UL5H 3=)J"123RC:R<GVF0.2ZJ**[E)S=0);6HD/Z^QE"K'$ G\KI R
MV/H 8FF_C5,BQM<>2--@,LY!I>!-Z/)$4/\Q2KO(+4A )@%.M/![(!U86,E
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M='C0L"9 D.3_1ZF;6#>9A([]7S6"P;Y0R86:%R^?/+?B:;_)PD4KLEJROHL
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M6B60H%>?CI6NFK1E+FGG"K\'&E@)Q.O\\,T.T;&!JJ;EL2%[[P?+''9='J0
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M+TZ8K>!="D%(W(Z0Y+4.PY \6&M1%?30G#[X=01LAT29OL?N.O3_D7';56\
M?J-C6STF[YW72X^LOK_R75:=M?UQU]1^8D##+K-'L='TFU=18G,$21XCT;7Y
M6OM:W3S\P+O%6ZBU0;T::59W@[4VGQ!\H/08+SW!%^FI$\<[,M,V>(RA5 X
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M-',>L '7&,&3A^HH'AOGL+@,% 8O%08!]F 9HG/!W-DA,M<.@R!7L;R"9DL
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MO7#7/M'2QFY\61V6UAI38,@S<F^B+[L"9HZ3CVGC_6Q=,/(2!@&P,1$;E+^
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M2!"DLB&-7]C7^,5^*>.%%VW3*6H9V^*:?V)DF&8>CR8H0)9#;2X\C[1)3GU
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MD@(:>-@[V3TD4/[K,H32[@"'Q*Y=?W]\-G5G2;(HIWOX'/+ENP:C#42PBJ'
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M,K FLA,O0\#:)?L'MF;",.K&!Q]5O;AO@$UQ,K='P$P!]%>7^'][]S#J6="
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M34.-GE'Z@>44ZKO>"^6'M.NEO&$OHRU/!++@!#LD*JD]?6LI,XMA>6Q<+,;
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MG&TC(I\PF]MA$5>SHE7H@V8O)L%:>4(9\O'CYQI0C1/BJS2+@Z]^O%V"K1;
M[ICO0C;C49"S.-[Z$0VEZ/?XIWU[0=DYF=JUV#UW1,F$,$R?C,#SR1".BC]1
MC35"OQ[NV*OTS-U*,J_HVZ.=LZ111\6:AD_G(*MG.G!U:L/$+!),XU^1#V_P
M8!X_0<0QC)B&]:?\3TB!FD%]ZOF.%JLX_.>6N< -[I?Y&B=OP#&B>".(Y[J\
M8UXQKI-D(MNK@E:%C81)%8 73U9DT;-7=CVA1V@I^[WXW^\"/+AP&2[(@(8P
M<T*<6;75B8R>;"T,8#V8QFVCWW@C<:@3*E^+K2=HF.]BW#DYC!DJ2R_,8>G^
M&7TV1J&K>214=.="^S; 9<J#@(F63VB3I"QH*-_N^Y!BYP#W@2H:]6BK8T]D
MP[Y>LZK/\BL_37=X0&1&>DJL4QC")Z(L:A!%/"T(3&S#Y6+DQ\A4DREHYSO1
M/5&(_@/*2[U] 4[SD@BYW)C%&D2:15__#["4FYC'+[PWZ.[0J=?Z"YP,&Z*2
M Q7#3@GQ!.2+N?X*\B^G(+^OZSU+UP"$3!.F('1XYLT8\0?"J-T*,0!9?+:@
M03[D83G <YPTZ@FM'@P5D8( _-2=#JM'&=]9>CP,,DWR"-8+JR&L Y 85:F3
M![.*CI)31;1^W65Y_Z!\:&6:,/;]QQL=SE!K*MG*D,?'R&WX2?/S_Z]AOKK:
M8LEM7<8[]5)17/.@A!1]H'A\\,>126,K3!'1Q+NBZ>AY9Q=%1-<DIMY;?,3X
M$60 NL6_]#;QTN8\:,\C#5J( \ G]=#>+E=2GWT:0$$<0'Z<V@%D/+HCD>3F
M.QU()MU0>+J[8R!9?*YWIWLBE<4^H$2S@&)<7N-_V\ >XOU[,("IY6L%<OT@
M%Y4*N/ZB"#X>W8UY;')5KXP+I9ER@JMKLKD63H3].##1J5 -#NVM>&]$N_[7
M3[_[].DS..93#)?_\#Y_NOCTB?RO&0J+C\G<^]_;&'D_?;KPOGSZ\@=R;F*Q
MA\BJWD^?R:\_74"H&P <A!\HPJPJFF*)V^N H7X&]IW.#1\ \Z,ZWUDX+D^&
M3O@Q;FP<_B5<D)QC3^A]&_EYDNZ^AA&^WI(89?-8\#MA:(&]WEN\/Q9]RGOT
MRBZ]>5SQQV&]3O-(FXP=]<A!SI995[;0[D=ERKW$>Y* !P8HV$>VJ-$.S0.^
M9MV9DG<QJO@P"H%LK1\?8>)E<<]\8&M SA[BU 5C4[</FCJ,^BY'ZWT?1B(@
M+ T)E2C?:28!GE&\A%0G+".]3X7].@%C-$"O-#"86$FJV0!%!/ZL0-\?79=U
MN<TPE5DF2',]/-MY:U4E_*C^[+79Q7)#ACG/_&N*2+)[4#(-E3"N B=)NBM=
M;LK8-=(EMRQ-X3<U(2=4"WQ>Y\A<PY&QH_Y!JW<%>.DI\J^28._W/IQ3T(8'
MC8PZ>23Q?.&I];Q=+/!>ND40^+, ;K_WNIU(9J6P:-[+:/O>$I&@)M;#@1$8
M";25+7NL:8AG\!X/E;;:+C.;O]%O#(J.A:^N%*T +/L#27Q&&IFS9L$_ME0]
M>(F628J>T"+RLZSPW"V_9P\HGR]?_._]?"->8[QE(WB#4V<C?!'YK3FW3I9W
MU0SU!>?>_3#F;DIG!IJ$KE_=77A&N?I^)JPE_D\7WAL9EE>.X\+SEX#_@$=R
MLBP558XC\'5D?:1!KECF,M7/$->2,!8\G:@J\0 )C1HT2M/]>I?,F^L0:>R8
M +B<S]$O>B'0:=\P6F$'4[!:"XBT_<DH=%=%0].$R,IT%J)KI:BS*"*]9EFV
M76]Z9]]5*74JGI(UK4X9;28,8A*H?BN<,M3R;!C'?,*QJIKGH^"87PYF](UM
MA-'<?Z\?(#!U7P"8(R<WJE+:BK\]26X\:A&\)D'7%,>47L17),%K1F!PKLID
MK_NG;ZZ^+\OF8<,;)I:M17<0]-,DCA%-_$7<WL(8#P[OGLWV+0H7N&W< "C/
M?@AC=O%/DW)P,K;6I-GN3 WC&EN/BS_\0B:TTEX]VBU#(^90U<0+0V"?T+OP
M:AI3VWJ?+/SH<97$_5"L23,>:6>B@.ZJ=OQNO?'#%"[M?4#LJL=$V19,R=/\
ME>*_'Q)!%8#^0ID?0<,77EC2!VJB0Z(KJI-T3TD2INQ^ I)D:/9":I,1H/HO
M1%>B R,OJE-61>N?'RQA--O531PTYDY)X85W0[W!+OT(,H(>),7/N9_F76B^
M1.]A'$](]BS.PR",MN!"5]ZC-]\!'!\%MVFR!NWIEKX#Y\LZXO9]3_<*L7OA
M'O?X "C.JS $N&AD.-WWX[M:%#H7.$DA>!>?I6GR07$U?DY[7CY%JW#K%,T>
M#BU1G0RQQ0N/M#DN,*B9D[ 0*)L53O8$LXJ(M*/YD%._8E]P'5FHM*&^,$1O
M47CD4V0MXH)ESQ_=559'(I=%!QVE?ET<G2?$/11<5M8<W>_=52;7\9XG6-+E
MBAY?<Q@$A K\RO/#X"Z^\C=A[D>]-GW1Y'_[+Y__].D_L.P=_!C&](\%;?]
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M(N4C\F)$8?O@5_@W2>B\A>L;<ZT,LO&+T8P>[.L"ZR(IUXK!0("F1X?#$@W
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M1P_S[!CG#CN)=3R0;&[F/GDBBWHJD<K4L_-$V#ZHD+6O1^F)\+J7)*:=D9/
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MOC^NWB$*#"ZAZ[4>'X*["?'D@8S2*/U  7ZNWFXA+1U8PF ==SDP]F[5#7'
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M^"YMJ,6TXJ_T\(5QV,4PO[@7;\ZL5[F1+3Y"D 3HP6)<:_JX>;=:??E[DIU
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MDV_Q 1 KX2K<Q^"+5NQ[^GKSP-9%Z&30I):;\]2^I=MMG.?H3]L4'G$KGKN
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M"&-#MZW "F9IXZY4Z35\"Y "&ARJ_][  +U>(>>MF[ZN0VRJM,SB[2?Y*LL
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M[>RKS_L734J#L)%]3$1!BS^X#"JM87I 0E*$1#9,)G.0)_6[RT+I7U+<0N*
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M$;G,1K"Z()566U:U$40O2]TUF*5M!/O+T&SG2?#VK)O8"[ZZF8O-PUZ0V G
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M.(@5YC'ZYQM:&T H=P:R\QV[(](W_.Y,7X 3/V?RBXZA<3*KF1S:,_W!0>=
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MD9_O$(@#!X;BP=7S-+\E8WP,PU=EQ"K&X5!T"L@ I;:D0\3'L/RK</G!;(?
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MWBWD<L*GUJ^/A[OTHXEW/QWN^I];_!]02P,$%     @ Y8(.6<=,L-)6"
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M=G_EI%,Y&4]D@&V:W%^ AU\U26MK]@],M9\VL&\ ><&@Q6'!RW'UM/K"I!?
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MI_UTW/=5#KN6C/^/GYZ.=[X37*OGN&_LR'Q)F^5I58T?(7PKY_P_[/=VSV[
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M,C R-# V,S N:'1M4$L! A0#%     @ Y8(.67;S[_;A;@$ =(@6 !$
M         ( !J,T' '1S8G@M,C R-# V,S N>'-D4$L! A0#%     @ Y8(.
M62F=VQ(^"   =3$   \              ( !N#P) '1S8G@M97@S,5\Q+FAT
M;5!+ 0(4 Q0    ( .6"#EG'3+#25@@  #DR   /              "  2-%
M"0!T<V)X+65X,S%?,BYH=&U02P$"% ,4    " #E@@Y9B%EH@CX&   M(@
M#P              @ &F30D ='-B>"UE>#,R7S$N:'1M4$L%!@     &  8
*=0$  !%4"0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>tsbx-20240630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:tsbx="http://www.turnstonebio.com/20240630"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tsbx-20240630.xsd" xlink:type="simple"/>
    <context id="C_80bdbeb9-b4a1-45e1-87bb-ef7e5bd3a405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">tsbx:DiscoveryProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tsbx:PriceModificationAxis">tsbx:PricePreModificationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_80fd60e1-4de1-4fea-91cc-497c425d7782">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tsbx:OfficeSpaceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tsbx:AgreementAxis">tsbx:OperatingLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-01</instant>
        </period>
    </context>
    <context id="C_8136f853-5792-4e82-a119-8cc35daccd6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:RemainingMystHoldersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:SecondMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="C_82a867ab-5d5f-459b-8a82-12bbd36560a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesB1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_83258d10-36fd-47d8-8435-ebb348293175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_838eb810-3507-46b7-b156-72691850ae36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_83c6962e-9c53-4e63-b1ff-31ca5d0d2f3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">tsbx:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_862de778-6688-462a-b351-4d149c16a617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_86842d26-2e12-4042-998d-29e3bb96ed47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tsbx:SharesAvailableForIssuanceUnderPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_86fd67e3-caa9-4cfa-8107-a69bd2da8aa7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tsbx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_87d12abd-fd41-4556-ab97-906718a6de21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">tsbx:DevelopmentProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tsbx:MilestoneAxis">tsbx:FirstMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="C_87edcac5-f97d-43c3-9877-1d9fda334fd6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">tsbx:RestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8916fdbc-eab2-44d0-8e8f-7bb4a95aae54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_8a2c0799-2ad0-4d20-8a89-44e9c7d5025f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_8a4b4f37-0658-467b-8161-438bc3405ed1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesB2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8aa8eff8-bf22-4098-92ea-223279b190c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_8b5fa308-adf1-4661-99fb-c63ef4adc638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="C_8b8a1ea1-2432-469c-84b7-3b0a47c7f036">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_8eddfc98-0dbe-49c8-9be7-73a81bdcbff8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesB1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_8eeaadf6-6367-4498-a18c-12b0327753e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_93377237-7cd1-48a2-b8a5-b9a2243d15e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_96148a81-8dcb-40e9-8bcc-218ebdce5605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_971026b7-966d-464b-8792-32c68702fcf6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:H.LeeMoffittCancerCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:AllianceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="C_9755dc24-1227-4784-baf5-a2b45b159779">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_9800e42c-8612-4c53-9cab-3c07fc9a6fbb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9c8cc4df-6000-4875-a29a-4d3c9dd0d7c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_9d04382e-1108-4cb1-91e7-16fb7b6fd93d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="C_9d04f62a-8f18-4763-a524-2381aeebe491">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_9d84a11b-47e8-4e33-b8ab-f05dc1707a83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_9e1380fe-5300-44d7-addc-af012845a913">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:MystHoldersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:SecondMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="C_9e6ce855-a23c-4318-9cf7-7b65d716e1a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_9f42a392-3c59-43e9-a2a2-d060b68b5b79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9f5bac87-6928-4532-8588-a3d080f1d32d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:RemainingMystHoldersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:InitialMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_a11683c6-5fef-4195-864f-a7d508bdc2d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tsbx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a12fbc8f-79f0-4426-843d-ec27ad6e7c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a282ba00-b430-4f99-a7fb-75b6613249a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_a2c92d2f-8c3a-4345-9949-14d05e745e9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_a4224032-80db-4207-a62f-06fddc1f3e8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">tsbx:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_a72293d1-c825-4856-b60c-948ad5751e42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsbx:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="C_a8118d4e-4113-40b7-b543-3bea71a014bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_a8da5438-d86e-4609-9ee4-eda50bdb908b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_a8f26943-f1b9-49c8-b166-c849e9c3a34e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-15</startDate>
            <endDate>2020-12-15</endDate>
        </period>
    </context>
    <context id="C_a963c822-6da7-4671-af23-c5e6b30f3e6b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tsbx:MilestoneAxis">tsbx:SalesMilestonesOnLicensedDiscoveryProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="C_ab5c8887-9c0a-4afb-8d68-eae695a3dd3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_ac0cf97a-5db0-4110-a9ce-20faacb87521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesB2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="C_ac923606-471a-43f0-8bdf-735ab3fdfba1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_adb55f11-8d4b-474a-b9d9-4cbcb3d9be20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-26</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="C_b070210d-0df6-446b-9018-f836d7eb1564">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-30</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="C_b169253e-4db8-48b5-a2f6-a9d18d0f3f36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_b1d0d042-927c-480f-9792-c14b9cf5f6d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-10-31</instant>
        </period>
    </context>
    <context id="C_b283014b-e73a-4c69-9931-4985a3e59add">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
        </entity>
        <period>
            <instant>2023-08-15</instant>
        </period>
    </context>
    <context id="C_b34ba69f-3f68-4be6-9f1b-44db7d637865">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tsbx:TimothyLangerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_b3dc0960-b79a-43dc-b52d-544a4f88fb55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">tsbx:DevelopmentProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b415a509-074d-4b97-86e2-0deee38dd0b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tsbx:ReturningSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsbx:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="C_b49bbb74-b521-4de0-8223-a4c6342ce9da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">tsbx:DevelopmentProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tsbx:PriceModificationAxis">tsbx:PricePreModificationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_b4bc9727-1662-4540-9335-43dccebbd817">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsbx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="C_b5d7d3a5-05a6-4a7d-b86b-89c61ed59b35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tsbx:PriceModificationAxis">tsbx:PriceAtModificationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_b61d7932-d1b3-455d-a3a5-9627e4bd93da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tsbx:TimothyLangerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_b6215fc5-849f-462e-86bf-6b597390fe38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_b6c3ec3d-2d98-49dd-9189-5cbaccf94ce2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b8a7d77b-acc4-44c2-a6eb-53af2968c508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_bbc99879-3c57-49b9-b3a2-7c36543a3a7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_bdee48eb-7f4a-46cb-b069-06ddbd37a077">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_bdf52929-1966-47f8-aeba-19d09b7e879d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tsbx:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tsbx:AgreementAxis">tsbx:OperatingLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_be0f70da-b5dc-4227-b5d4-1a3bd3c8a13d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesB1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2016-10-31</endDate>
        </period>
    </context>
    <context id="C_be5fa637-0934-415e-a76d-cef88c5177de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-25</startDate>
            <endDate>2023-07-25</endDate>
        </period>
    </context>
    <context id="C_bea27948-4ee5-4b9b-8b58-855991725981">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_bed097c6-a12a-48ed-ab84-40a66008425b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_bf315150-6fec-4edf-8d74-affc42e06301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_bf4bea3d-6d81-4dab-a5e9-0fb7804e121d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:LangerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_c0b79b4e-6d2e-4c6f-9298-ac7fa6a0af9c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
        </entity>
        <period>
            <instant>2023-07-25</instant>
        </period>
    </context>
    <context id="C_c2fc5443-940d-4d73-8fd5-8bcdd4605301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c5cddb37-672e-4bc6-993b-61b085312425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
        </entity>
        <period>
            <startDate>2023-07-25</startDate>
            <endDate>2023-07-25</endDate>
        </period>
    </context>
    <context id="C_c5e178ae-25e5-4b12-b4f7-11636d959e09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tsbx:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_c6cfacbc-df8a-46ce-911a-93257d4940af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tsbx:PriceModificationAxis">tsbx:PricePreModificationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_c6e4f9a3-9885-44ca-907d-b6658de8f0e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
        </entity>
        <period>
            <startDate>2023-08-15</startDate>
            <endDate>2023-08-15</endDate>
        </period>
    </context>
    <context id="C_c6f26a23-43b5-452a-9c94-f293c2677e84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_c72ae3f1-ec49-47ae-8a52-43699c15abfc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_c762659f-a398-4da4-b6b5-fb1c73edfefd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:LangerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:SecondMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="C_c9641d36-9a68-4e01-bcd1-21dd6a75222f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="C_ca9e9c5b-5d60-4a1b-8ad7-f5f5e30eeccd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:MystHoldersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:SecondMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="C_cad3a30c-8bbd-41b5-8824-b6ed0ebc07b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tsbx:MystMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cada1dd4-e094-4155-bd2f-9d9d53838f8b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tsbx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">tsbx:MeasurementInputLikelihoodOfOccurrenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cb7e98d1-0ba9-403c-aa73-cc10851ec0f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cb80c5db-70c4-46c8-b391-908e60dc4392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tsbx:AgreementAxis">tsbx:OperatingLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="C_d07e96e4-27c7-461d-87e0-bfe0e09106c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_d0a34fda-1a97-4930-aa8e-a5ab1c515de5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tsbx:OfficeSpaceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tsbx:AgreementAxis">tsbx:OperatingLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="C_d347b544-ac7a-4849-8e58-614bec001e25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-30</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="C_d3863644-3003-48be-ba26-f907692ad408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-25</instant>
        </period>
    </context>
    <context id="C_d4a98e5a-d94e-4f1c-b7cf-4ba20e9be13c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_d7168d5d-e7a5-46ff-9b87-4e0562cb00e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:LangerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:SecondMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-28</instant>
        </period>
    </context>
    <context id="C_d917210f-1291-4dbd-86d6-3aa84bc8ab10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesB1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-10-31</instant>
        </period>
    </context>
    <context id="C_d92a8a59-80bf-4bc8-8d8b-2f30a155d5e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tsbx:LaboratorySpaceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tsbx:AgreementAxis">tsbx:OperatingLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="C_d9bf8d53-5a76-4443-ae16-8d541daf5ad2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_db72c5ee-0057-4dec-a48f-c46b4c093ae7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_db819b3e-1792-4c62-b813-10d6991af201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_dc19bbcb-5619-4e9c-8fd6-1b3767d599b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:H.LeeMoffittCancerCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:AllianceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="C_dd6315d5-b691-40c0-8822-66150720e552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:H.LeeMoffittCancerCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:AllianceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tsbx:MilestoneAxis">tsbx:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="C_dd66f43c-636a-4989-849e-33408277fa05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_dde16e3b-95a2-4acb-a8f5-4219383626cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:RemainingMystHoldersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:SecondMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="C_ddebe139-151f-44ec-8890-0c2c9c33904a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:MystHoldersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:SecondMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="C_de5bd2cb-2a69-4ca4-88ea-be6ca6b3d91e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_df0e855c-ac6b-4b9c-86e6-10fbdce55a16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_df1018cd-e834-471b-a1de-7f644abc127e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tsbx:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_df3730e6-4b3b-4511-9b22-d73a3cb03c8b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:LangerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-14</instant>
        </period>
    </context>
    <context id="C_df7b7c66-464a-441f-91fd-4ca59bed28ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_dfe46888-9d65-4c68-a853-215029dc9872">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_e1930a00-b656-4b09-88f7-718672d19d95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:LangerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:SecondMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-10</instant>
        </period>
    </context>
    <context id="C_e1ea96db-9cc4-4129-9e50-4fac54584f5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">tsbx:DevelopmentProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tsbx:MilestoneAxis">tsbx:SecondMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="C_e2186eec-5e5a-4c75-b0fd-9b1fdf69034e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesB2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_e3da0be9-f805-4bd4-bb62-9cbb32dda1e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
        </entity>
        <period>
            <startDate>2022-12-31</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_e72bcdb4-17b9-4881-84a9-0f4fe4e39f0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_e83e1bee-c31a-4456-a69d-f9eab649bf3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_e8c17d3b-ae8b-41f1-a20f-40ff4625b247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tsbx:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tsbx:AgreementAxis">tsbx:OperatingLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_ea03660c-6f74-4aa0-a083-02a3316775a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:MystHoldersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:InitialMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-11</instant>
        </period>
    </context>
    <context id="C_eab032e1-3425-462f-8d5e-286e582b438d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:LangerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:SecondMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-08</startDate>
            <endDate>2022-06-08</endDate>
        </period>
    </context>
    <context id="C_ecd3cf07-fefb-416f-8ca3-3ebe03141ea5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_ece257ea-a6a0-437c-89a2-7ad5c9fc8aa2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-26</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="C_ed2ba762-cc53-4aa6-ad18-93928a0e9e83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_ee135c52-c1b2-4ad5-911b-acfb5c8e8f2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_eea7aad0-d598-4675-97e4-495ad0d5f473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_f0568106-d7a9-414e-a63d-3cea66f35a6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_f13a602c-d40d-43cb-af5a-1b863d53488c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tsbx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_f25cb532-a515-4fa7-abaf-0947b47f1a2d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_f29d5b9e-4d61-4151-a985-c2091e0f2865">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tsbx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f3098a29-f113-4e61-967a-00d2ad37159d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tsbx:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tsbx:AgreementAxis">tsbx:OperatingLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_f4165f52-0752-4cfc-8c7f-a573ebe98155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tsbx:MilestoneAxis">tsbx:ClinicalAndRegulatoryMilestonesOnLicensedDiscoveryProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="C_f6268a98-55de-42e4-b33f-cf7c0879c342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_f744bbe6-544a-4cb6-9ffc-e06c7c098585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f8d09b91-2147-483c-b5ae-6de7be334706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tsbx:AgreementAxis">tsbx:OperatingLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-01</endDate>
        </period>
    </context>
    <context id="C_fa91a432-14eb-479a-ab9e-c343bfe09637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_fab6d8a7-91ff-48ba-9d83-2f673cd37dd0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fbbc94d3-e5cf-4af0-9f58-49c609a48ce9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tsbx:LaboratorySpaceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tsbx:AgreementAxis">tsbx:OperatingLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="C_fde9996f-abc3-46c0-958f-c7d1eb86e821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:LangerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-14</startDate>
            <endDate>2022-06-14</endDate>
        </period>
    </context>
    <context id="C_fe429d1a-4bd7-4dc5-aa72-7fe35faa4549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tsbx:SharesAvailableForIssuanceUnderEsppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_ffd72f23-b073-4049-978f-aa0c05133c6b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_0041f20c-fe1a-4d2b-a3bf-ab3dc220fe5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">tsbx:DevelopmentProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_018d9f0a-f1a9-461c-a05d-3b501d8ad8bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_02fa49d2-1f02-4cc7-908f-06f8c20ff1f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_0532a010-4fab-45c5-a50c-f89be68e5dbd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tsbx:MilestoneAxis">tsbx:ClinicalAndRegulatoryMilestonesOnDevelopmentProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="C_06019969-ab1c-456b-98ef-d496be6c8d74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tsbx:NewSharesUnderTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsbx:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="C_076f0cb5-40e9-4509-958f-29eee0f3a275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_07b24899-50be-4afd-9968-9f3387fa7317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_07beddb2-5e8d-4fd2-a982-9c19bd8f1784">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tsbx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">tsbx:MeasurementInputLikelihoodOfOccurrenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_08eea265-04df-4ba5-a0a1-6754a009edac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tsbx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_09ae6d90-7a9b-443b-bc02-068850b13217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tsbx:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_0acb4150-37ee-4c10-8006-d0790fa8f0f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">tsbx:DevelopmentProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tsbx:PriceModificationAxis">tsbx:PriceAtModificationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_0d77c486-d172-4aa4-894b-cde28b23636d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_0e39171b-0288-4a90-bd4c-4de866d982ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-30</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="C_0efb3de3-c750-4eb6-95f7-ff7400831d2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tsbx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_0f2177db-5b60-476f-a730-1c8f81312684">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="C_109f55ad-7a48-4c7f-a7ed-d02672f14dbb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_10a10b4c-098b-47f2-b0cd-44fdb0c3ed0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-14</startDate>
            <endDate>2022-06-14</endDate>
        </period>
    </context>
    <context id="C_10aa115c-22ea-46be-bcba-a9a9cd88b729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_122cd3f4-302a-4c4b-acb3-5f0a4ab8924f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsbx:TwoThousandAndEighteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_1326cf13-b619-4a7a-8459-199edf00cef7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_15263df3-916f-46a0-9832-65fb7bc16128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_159402e9-c2a7-4db5-8c56-97648d7a2af3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="C_1608bf2e-2722-4b3b-ac28-7d680ca451a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-26</instant>
        </period>
    </context>
    <context id="C_18a36a9d-0182-4470-abc8-5f7ff7b3b4a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">tsbx:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_18e0b921-32c2-4a24-b203-fed3d74f4d65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_1acb574a-2c4a-4dd0-8d44-95c2caca0d22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_1b2bcaaf-9d3a-490e-8d00-989c002af276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_1c334911-8a35-4c3d-9e49-91814e062e98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">tsbx:DiscoveryProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tsbx:PriceModificationAxis">tsbx:PriceAtModificationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_1ec4e76a-cfd9-4b97-8d2b-92c62767f896">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_21d1e869-620d-4a35-abc4-05dbceb24181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_221e8d7b-e069-4751-b775-170cde6f9416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_233d0f7d-f749-402b-be07-03dbe6d24916">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_234b0297-d293-4e18-9282-e7524404692b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tsbx:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_23ab17bc-cbea-4436-975a-8a130aba6e62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tsbx:RemainingSharesFromTwoThousandEighteenPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsbx:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="C_2475957a-da36-49a5-8126-8a055410a470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_250b5a1d-34ea-4e70-805a-18bd6081b49c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_25efe362-0a08-4b30-b273-8685627ec35a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_263ddd8f-936b-4629-ac81-de82901400f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:LangerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:InitialMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-11</startDate>
            <endDate>2023-09-11</endDate>
        </period>
    </context>
    <context id="C_264a7ac5-398e-4718-ac23-f5ff805f1954">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_277bc5e6-e420-49a1-a481-ae8acaf14f5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsbx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-01</instant>
        </period>
    </context>
    <context id="C_278e12a5-7809-4e31-81fa-b5ac9fed8247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_29034bc0-6cf8-44cc-9ed1-c738ea64dd3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_298d2425-fd98-405f-a011-492c95c811c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_2b4f6127-8d59-412e-b50f-15f6bca69e60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tsbx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_2d28ff08-66e3-4717-8e1b-0159fd2dae0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:ThirdMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-15</instant>
        </period>
    </context>
    <context id="C_2d44f350-3d07-4146-ae3c-42824895d484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_2e92c815-0887-42a5-9aa2-1aa6d38a8788">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2016-10-31</endDate>
        </period>
    </context>
    <context id="C_2f446809-dc2a-40e6-9aec-438ab12cb70b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_2f5ca510-92ae-4c6d-88c6-32a100f28ecc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:SecondMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-15</instant>
        </period>
    </context>
    <context id="C_2fb9dc1f-ccec-4fe3-83bb-464c06488b6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesB2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-30</instant>
        </period>
    </context>
    <context id="C_2ff3278e-16d8-4b68-bf2e-7b39955581f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesB2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_314b4149-fadb-4ae4-82c4-63f56b1c9d19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_31b4b1f9-e730-4c51-a000-a2794909b7b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_325b972a-88a3-49e4-a865-f3c3e4c449cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_334d95da-9a09-4a10-86ff-a51738440c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_33626c55-fab2-4ed6-af8d-d98851be5b39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_33faa779-ce8f-4e4d-a219-c041b650a61c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="C_34b78f7b-64c0-4260-933e-8c293a3cde64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
        </entity>
        <period>
            <instant>2024-08-12</instant>
        </period>
    </context>
    <context id="C_385dcdbf-07bd-4e19-a166-84748a852d48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsbx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="C_390d4d0c-2d69-4485-b251-e5c588a82858">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:H.LeeMoffittCancerCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:AllianceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-01</endDate>
        </period>
    </context>
    <context id="C_392765bd-7ded-4967-8201-2e786fab388b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tsbx:SharesAvailableForIssuanceUnderEsppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3960fbc2-6191-4efe-80f0-27545067aa20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_396a19e8-3bfd-4308-a62d-934e7ca98d70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_398e0a09-f989-4f15-b8fc-2af343713b5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tsbx:NewSharesUnderTwoThousandTwentyThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsbx:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="C_3bc9ea85-cac7-4114-b7e4-68f51d5ac95c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_3ffd6a05-a9be-4e07-b29c-81b2bc74d344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">tsbx:RestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_44bd7a65-8c40-4525-b754-f1b5eaea0d39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_4519aa8e-1238-4faa-8345-635ebb5bc098">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_464ce7dd-76e3-4b22-9015-b1330a849be8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_47ec3535-df3a-4de3-bfc4-2765e79fb6a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="C_488ff119-253a-4f13-ab67-fcbecef54a44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_48fa1a69-511d-4e0c-b236-6692208f9dc3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:InitialMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-25</instant>
        </period>
    </context>
    <context id="C_497bd5df-0910-478f-aa44-aeabd848571c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_4bae3e9b-125f-4503-8c73-cdcf17ef0bfe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:H.LeeMoffittCancerCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:AllianceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-31</instant>
        </period>
    </context>
    <context id="C_4d3b7a6e-20dc-4532-aa88-976e8d769182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:H.LeeMoffittCancerCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:AllianceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-27</startDate>
            <endDate>2023-02-27</endDate>
        </period>
    </context>
    <context id="C_4d689c27-7fb0-4851-9baa-5648a27e5506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsbx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="C_4dcd6724-0338-4288-a92d-f40147c40f0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tsbx:AgreementAxis">tsbx:OperatingLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-01</instant>
        </period>
    </context>
    <context id="C_4e19f9b2-a9f6-479d-8fbf-5061721bee44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">tsbx:DiscoveryProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="C_4ed0c192-f7ce-4ccd-88a9-1326c9ea54ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_4fb7b644-c91b-460a-90e4-f747ea99d23e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tsbx:LaboratorySpaceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tsbx:AgreementAxis">tsbx:OperatingLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="C_507a33a4-3fb5-40c4-b2ec-c9dcaad76c3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="C_50d1f298-b372-40b5-b6e4-1d4f6cc1d536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_538d2283-b280-4bac-8832-abf9afae8b56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tsbx:LaboratorySpaceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tsbx:AgreementAxis">tsbx:OperatingLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="C_5447e64a-c9af-4233-ae37-a6910517d877">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_5552aea5-73b7-4fb7-83a2-8300ff05e8db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_58806346-af8a-4a1b-852a-6954a4cb63e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:LangerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:InitialMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="C_5987e3e3-0cab-4166-bca8-581516776417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_598b88c4-d183-499c-84b9-3e796e6520bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_5a226ff4-7fbd-4466-ad8e-193443f07e2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:LangerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_5b06c6b4-e689-4fe0-a090-8bcd1ee5595a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_5b35fa61-bbf8-46c2-a6fc-1e914819fa92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_5b861034-a720-43d5-8699-9c7302265892">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5cf56eca-80aa-4857-a57f-478d4c936a9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_5e3f8af4-ced0-4d18-92e3-8a9b5f41b2fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_5edf160a-0dd5-4113-b0b6-1b907d836f1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tsbx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_5ee261db-0283-4149-9229-b37f40e4e1e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5fa46bf8-b07a-4c44-a5fd-6c1dc1a9edc0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tsbx:TwoThousandAndTwentyThreeEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_611eb55b-b1d8-48ea-b1bf-f13c75cd2c4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tsbx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_61b64e12-4fa9-444b-8290-e40812121809">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_622828de-17f7-43ff-8529-65876283fc2a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_624dbdac-4327-488c-b421-114825296f78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:LangerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:SecondMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="C_62731d6b-0b8e-473a-8756-77f4fdd3789c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6289f1e6-72be-4ab1-8d3b-4951b6ae47d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tsbx:MystMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_62ccdb6f-2ce4-4c14-88c5-56ab718bbe38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_62ea4f09-347c-4795-8884-5220ce935f91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_656dbf1c-1dcc-431d-8fe9-c0de04b2841b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="C_66ae9658-0772-4454-88b3-b788cb30a2c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tsbx:SharesAvailableForIssuanceUnderPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_686637a7-6c9d-4004-a3a1-f62abb9c5a0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">tsbx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_6b9ab1b4-ace1-409a-beef-b24a105df524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:H.LeeMoffittCancerCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:AllianceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="C_6d290ced-5d11-4542-b2af-bb92860ccf5b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_6f6523cc-b1d2-4b30-81f0-6490c4ab9067">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:LangerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:SecondMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="C_7442ee75-92a9-41e2-98c5-9ab8b76e128f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:H.LeeMoffittCancerCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:AllianceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_761632b7-6a3d-4167-8e38-3551f8b5bd83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_77f50463-e1af-4144-8629-1e583e752cb2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="C_77f8cd0f-f6c2-4b41-b3a2-ad645efbb34e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7a327960-116a-4bd1-8648-b5f38a13e8f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tsbx:SeriesB1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_7a433f77-f757-4637-ac62-b0d9f32aca2c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">tsbx:MystMergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_7a615421-56cd-4cb3-983c-215b19efb667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_7ab99909-780f-484a-afb9-d7fab1c3e24f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_7b886516-c4ec-4600-ae2d-8f4f97019128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tsbx:MilestoneAxis">tsbx:SalesMilestonesOnDevelopmentProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="C_7c898406-56c5-4ae7-8aa8-5701d037862a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">tsbx:LangerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">tsbx:SecondMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-25</instant>
        </period>
    </context>
    <context id="C_7d7ff18f-d96f-4bfd-81be-511ab4a4637d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">tsbx:DevelopmentProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tsbx:TakedaAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tsbx:MilestoneAxis">tsbx:ThirdMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="C_7faec367-2bfd-418b-b55d-ce16bab8f5a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001764974</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_CadShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:CAD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_CAD">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_SquareFeet">
        <measure>tsbx:SquareFeet</measure>
    </unit>
    <unit id="U_Security">
        <measure>tsbx:Security</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Y">
        <measure>utr:Y</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_04344c20-4f24-4f81-a6b4-dbe7d774840c">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_2da71bec-8891-47e7-82f0-640f16d3fc7b">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_07e42a2d-d157-44e6-9324-6a4e16ecf7d9">0001764974</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_00e4de9f-3d92-44e6-a456-7faa198b006c">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_8fb38185-ea26-45ab-b107-b14eace25cd0">http://fasb.org/us-gaap/2024#AccountingStandardsUpdate202006Member</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateTransitionOptionElectedExtensibleList>
    <us-gaap:InvestmentTypeExtensibleEnumeration
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      id="F_d519c220-b9c0-4efc-ae00-16610eda5851">http://fasb.org/us-gaap/2024#ShortTermInvestmentsMember</us-gaap:InvestmentTypeExtensibleEnumeration>
    <us-gaap:InvestmentTypeExtensibleEnumeration
      contextRef="C_dfe46888-9d65-4c68-a853-215029dc9872"
      id="F_07c37049-61be-45e2-82d2-712a7c000aaa">http://fasb.org/us-gaap/2024#ShortTermInvestmentsMember</us-gaap:InvestmentTypeExtensibleEnumeration>
    <us-gaap:CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="C_325b972a-88a3-49e4-a865-f3c3e4c449cb"
      id="F_86aca0ff-7597-42fd-ba5f-977c1204204c">http://fasb.org/us-gaap/2024#Revenues</us-gaap:CollaborativeArrangementTransactionStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="C_d4a98e5a-d94e-4f1c-b7cf-4ba20e9be13c"
      id="F_7a312f44-81d0-4aab-b68e-4d0c368d2aae">http://fasb.org/us-gaap/2024#NonoperatingIncomeExpense</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <dei:DocumentType
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_9e3567e7-8683-493e-9064-762e8fb878dd">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_7062510c-3dc9-4dec-86ca-1650883790ec">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_bf285486-b975-4932-963b-446e9b88280c">2024-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_f21e300d-cb9a-42b3-83e2-ec37b9b280af">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_64b5d7ab-d927-4809-ad9a-6cde4feff26d">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_fe212df8-e168-47d7-a66c-2443d181d7b8">001-41747</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_477fdc43-ec34-4182-9453-45312af682d2">Turnstone Biologics Corp.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_84c969b8-a29a-4b99-b70c-2afe78947c91">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_8b9ff3ed-f39d-4992-8802-5c8b3ff65bd9">83-2909368</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_5f2680dd-5fe6-42e9-8fc1-fa18a7688515">9310 Athena Circle</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_f400b547-993e-4b94-a7b7-32e475335bb7">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_d358db8f-ec99-487d-8f74-fdf6cab69c85">La Jolla</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_348947dc-9b91-4686-9f59-49a811d61049">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_5199ab16-9c5d-476f-b8a1-52c761f6c6ac">92037</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_cf98e4a5-8664-4d03-96a0-25d8f49b9af7">347</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_336f193f-34ad-421a-a23b-8ef19987f536">897-5988</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_8b49a69e-4d55-4e07-a033-37cd45b500a0">Common Stock ($0.001 par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_df3b1b9b-8ead-4346-a012-5db0fab444d4">TSBX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_f3d13689-3043-4d22-8f61-cf3e3cf165a7">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_c1a7cb8a-4555-4c73-9b59-44eda54f3422">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_8be84bcd-8546-4035-a73f-847e23b88361">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_43ed3bb7-83ab-4ee6-b743-d69bbee0f1bb">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_c2ae9d10-bbdd-4f93-bf48-dc23945c9b68">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_6d9696c7-6ff4-458b-bb37-e7b23595e292">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_6e84c988-8d97-4cf7-90d1-65ddf9b1684f">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_bf0a7b76-375a-43b4-b7da-1a6e5efbe0eb">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_34b78f7b-64c0-4260-933e-8c293a3cde64"
      decimals="INF"
      id="F_1986c7f3-4df9-4fbe-bb09-bf8ac7256a5b"
      unitRef="U_shares">23128454</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_5cfd9195-5d3a-4518-a83a-b3c0c92df455"
      unitRef="U_USD">17401000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_e0f6fc40-3896-4efa-8714-2af97ba46aaf"
      unitRef="U_USD">17798000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_9a36ee6b-c4b5-40fd-8475-ac909c1b195d"
      unitRef="U_USD">116000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_20536b7a-2578-4dec-8a63-9e4b90331ae5"
      unitRef="U_USD">116000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_4c5eaf2b-08dd-4f07-828f-9d5e951ab973"
      unitRef="U_USD">44997000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_b8b1ed5a-891c-44a4-828f-cd8695ad73dd"
      unitRef="U_USD">76979000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_203e453e-41ef-4b91-a441-cbc80ccd77e1"
      unitRef="U_USD">194000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_c06b7774-77c1-4ca1-9a6e-202935576b9f"
      unitRef="U_USD">3542000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_930706d5-20c3-4e34-b110-9950053cbed6"
      unitRef="U_USD">4655000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_0b074fb1-ac10-45d0-a111-e199d7f2255c"
      unitRef="U_USD">2348000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_05687719-25db-49dc-b740-97d109c35f39"
      unitRef="U_USD">2812000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_a4539dd6-c526-4964-b523-61385147467f"
      unitRef="U_USD">68404000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_d57e4c6b-b517-441e-910f-563967a5bd24"
      unitRef="U_USD">102554000</us-gaap:AssetsCurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_95003aab-e2a7-4f96-b992-503504486e25"
      unitRef="U_USD">1051000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_15115496-873f-4098-909a-b7c4d0f4d2e0"
      unitRef="U_USD">1143000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_015e9c52-668c-4e2e-a260-1addcc2964e3"
      unitRef="U_USD">1853000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_1ba143ce-d70e-43d3-9086-5e49e8814954"
      unitRef="U_USD">2766000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_c99a00bf-a1ca-4f3a-a4ae-ff0052b7d13a"
      unitRef="U_USD">5569000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_6889fed1-4fac-469b-bf29-dbb0c80e3566"
      unitRef="U_USD">6352000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Assets
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_5bfb9c46-4cc2-4839-a908-d4980bd42aa7"
      unitRef="U_USD">76877000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_46b05dd6-fca5-4fd2-bf1c-34161314fb58"
      unitRef="U_USD">112815000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_823409fe-ade6-4d85-a372-ce9d8188a5a3"
      unitRef="U_USD">1486000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_0dd95d98-b1f0-4c60-8539-b73e286b9593"
      unitRef="U_USD">36000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_ad5de9fa-8fe3-4166-a773-c1aae8be37cd"
      unitRef="U_USD">12354000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_53059698-1d44-4030-8c4c-4f3a0a7fda49"
      unitRef="U_USD">9909000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_44984ff1-69b1-4de8-8084-77491fe65b57"
      unitRef="U_USD">1793000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_c1dadb8e-a6b0-468f-86ef-9a5ae654b36c"
      unitRef="U_USD">2025000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_8be01f43-fe85-4d88-a12b-ac45ac17c2d4"
      unitRef="U_USD">15633000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_c689a2b9-0445-43a1-8b7d-080f98f15e1f"
      unitRef="U_USD">11970000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_ab64ce40-6bcb-47e2-bc1f-3e615b8cdbf2"
      unitRef="U_USD">411000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_490df26c-4a04-4171-8faa-b2684e449f88"
      unitRef="U_USD">1189000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_d17a78be-58a6-4c83-900c-c9937c122f51"
      unitRef="U_USD">1097000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_5e244cff-ae53-4989-a940-22601a983481"
      unitRef="U_USD">989000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_66d428fc-b365-4691-95ab-cf0421f50211"
      unitRef="U_USD">17141000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_d9966797-0581-42cc-b566-9a84014449e6"
      unitRef="U_USD">14148000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="INF"
      id="F_174e2434-c840-4403-bf65-c530f60c8c69"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="INF"
      id="F_d3599fe4-bcc0-43af-a5b4-60c93a786a0d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="INF"
      id="F_36f69ebb-2d71-4f64-bd7e-0afe25744754"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="INF"
      id="F_b4884622-1856-4604-8c80-17976d2fd1d8"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="INF"
      id="F_ec434524-cf2d-4a80-b8af-af7f76342059"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="INF"
      id="F_6246cbcb-ae6b-4a52-bd03-41a91c31043f"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="INF"
      id="F_883e15eb-10cf-4870-8997-eabb63169aa2"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="INF"
      id="F_1c4e5b0a-b974-4d51-8073-c58448e9330c"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_4284e823-d350-4ed0-b914-4bfb76a71d7d"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_8cd62986-7125-4fe6-8fe1-1978eb43f3dc"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="INF"
      id="F_a63507fc-3cc4-4876-99f7-04cd307131b5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="INF"
      id="F_9b98a163-3e5b-4487-ad48-ab97d1d0f384"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="INF"
      id="F_dce31fc4-6f29-481c-872a-15e5cec0d704"
      unitRef="U_shares">490000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="INF"
      id="F_7daef1de-afe4-4545-92c5-1c4d53399bcf"
      unitRef="U_shares">490000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="INF"
      id="F_77dce3e6-aac1-497a-bbb5-78c812278e92"
      unitRef="U_shares">23128454</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="INF"
      id="F_719e5c8c-fe93-4af2-a77e-8749213435dc"
      unitRef="U_shares">23128454</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="INF"
      id="F_4c517531-527b-4b4b-bbd8-ddc1af935379"
      unitRef="U_shares">23099335</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="INF"
      id="F_6b37f63f-5b85-441f-83f2-124a7cbbbd68"
      unitRef="U_shares">23099335</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_249398a1-6a60-416b-be16-c87a9a1347a8"
      unitRef="U_USD">23000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_c5755a02-7095-4668-8ff7-cf2313fdc2b2"
      unitRef="U_USD">23000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_7a997c05-345f-4493-bf2d-e6f6243805b8"
      unitRef="U_USD">277630000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_41d4ead1-a995-41c4-8f42-454375217c20"
      unitRef="U_USD">275521000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_cd78bacc-0db1-47ae-8f46-d690b67c1ab2"
      unitRef="U_USD">-226000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_e40bc4f8-ddaf-4254-a341-4badadea8a3c"
      unitRef="U_USD">-119000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_6fb2def4-5461-460b-a035-32aaa70b0724"
      unitRef="U_USD">-217691000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_ff49bb5b-f9a5-47b7-a2ee-77068445f2bf"
      unitRef="U_USD">-176758000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_5eb07376-e974-4dd2-a159-2ed1f917c211"
      unitRef="U_USD">59736000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_874d6f31-fc36-42f3-9589-75b5bdfcf569"
      unitRef="U_USD">98667000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_bad25d58-9b6b-4617-8ce5-e42c39327ddb"
      unitRef="U_USD">76877000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_a56a6a8b-45ba-411d-89e0-d7e6a6567729"
      unitRef="U_USD">112815000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_21305cbf-d218-4e7d-9698-6b829eeb94d8"
      unitRef="U_USD">19306000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8"
      decimals="-3"
      id="F_51efd694-7885-40a6-a01d-bf96944b9326"
      unitRef="U_USD">17730000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b"
      decimals="-3"
      id="F_f8734e56-ca98-48d1-9e08-8538e00dff91"
      unitRef="U_USD">17193000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_a6b84be0-83c1-4978-bb57-8760977860da"
      unitRef="U_USD">33520000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_29d761a4-b2ca-4986-a17a-c2c621bf1d45"
      unitRef="U_USD">32861000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8"
      decimals="-3"
      id="F_5f112f5a-5d03-4e86-8245-054fcfe70f0c"
      unitRef="U_USD">4327000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b"
      decimals="-3"
      id="F_5513184f-feda-4cf9-850b-214698b72fdd"
      unitRef="U_USD">4659000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_20148618-960d-4a84-b9ae-dc2288c62700"
      unitRef="U_USD">9228000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_de801798-3ca3-4dc3-89a1-a89050f2280c"
      unitRef="U_USD">8691000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8"
      decimals="-3"
      id="F_862551f1-29d1-4570-9744-d382a5d5f738"
      unitRef="U_USD">22057000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b"
      decimals="-3"
      id="F_cfcd5197-71a9-4846-8013-5dc6f0c40ad9"
      unitRef="U_USD">21852000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_9b7a39d3-5165-49d1-96af-71ba93204fe5"
      unitRef="U_USD">42748000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_4e4be213-05c7-4a05-a2c6-2d3263ccb1b4"
      unitRef="U_USD">41552000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8"
      decimals="-3"
      id="F_4ddc371c-36f6-4938-b86b-9ff928e8d8a9"
      unitRef="U_USD">-22057000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b"
      decimals="-3"
      id="F_3877afe9-d15c-4aca-9881-b9778d5b85d6"
      unitRef="U_USD">-21852000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_4c1306b8-c23d-447a-96fc-743d26f214a9"
      unitRef="U_USD">-42748000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_cb3a3649-08e9-4295-808c-e604749aad41"
      unitRef="U_USD">-22246000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8"
      decimals="-3"
      id="F_b32d55e5-89ec-40b5-a39e-a98252dec2a3"
      unitRef="U_USD">755000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b"
      decimals="-3"
      id="F_a0910ff5-2ffa-4922-9ccf-11d07077dea5"
      unitRef="U_USD">347000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_ccb00d69-d087-430a-93b6-1c887781fba6"
      unitRef="U_USD">1833000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_10540d3e-7529-4988-b260-9b03cf6c0036"
      unitRef="U_USD">727000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8"
      decimals="-3"
      id="F_3a7ac47c-2b5a-42b1-8bb7-bed75e9a1066"
      unitRef="U_USD">-21302000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b"
      decimals="-3"
      id="F_7ca4f495-228b-4669-8a58-dd19dec0b852"
      unitRef="U_USD">-21505000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_b50047df-8b20-4cf7-8de9-3a24c5ea7374"
      unitRef="U_USD">-40915000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_5f2338e2-ea33-4c40-adfe-dc31df886571"
      unitRef="U_USD">-21519000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8"
      decimals="-3"
      id="F_f36e038c-798f-487d-8e47-1c06afe5a3be"
      unitRef="U_USD">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b"
      decimals="-3"
      id="F_67665376-40a3-48ba-b3d4-829c3670b5f3"
      unitRef="U_USD">-6000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_deb809b0-e2d3-4e1c-a424-7085ed0cda16"
      unitRef="U_USD">18000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_8dc17d0f-475f-4b9e-a03c-d1d12c2897a6"
      unitRef="U_USD">-88000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8"
      decimals="-3"
      id="F_ff71d2d2-7f05-4b07-8ec4-8c3e2de6d132"
      unitRef="U_USD">-21304000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b"
      decimals="-3"
      id="F_cb51c858-d560-4cf9-8dc9-630420b8a790"
      unitRef="U_USD">-21499000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_a89edbc5-9df9-40fa-8410-a54bf3d9a3fd"
      unitRef="U_USD">-40933000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_97f9d543-87f5-4c17-9b69-dd0508b53e55"
      unitRef="U_USD">-21431000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8"
      decimals="-3"
      id="F_8fd37877-c7ba-4b66-877f-8ed11783eb0a"
      unitRef="U_USD">10000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b"
      decimals="-3"
      id="F_6a50ebd5-98e2-4f13-abaa-21bcb6606073"
      unitRef="U_USD">59000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_7afd0ed3-cdfe-462b-a157-e2074a44e900"
      unitRef="U_USD">-107000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_ed626105-7876-4c39-a30b-9d6f6077c181"
      unitRef="U_USD">180000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8"
      decimals="-3"
      id="F_640bee6b-f258-41ab-aa54-983eaa7ad325"
      unitRef="U_USD">-21294000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b"
      decimals="-3"
      id="F_6d981916-cccd-47df-938f-47f2e862dd1f"
      unitRef="U_USD">-21440000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_ea3ca55e-a5e5-4be3-bb5c-ba69f4c732e4"
      unitRef="U_USD">-41040000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_b825333f-4cd5-4505-bbc5-d252669e78d4"
      unitRef="U_USD">-21251000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8"
      decimals="-3"
      id="F_d12453d9-f6f3-40f1-9fb5-59b5a81c95c0"
      unitRef="U_USD">-21304000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b"
      decimals="-3"
      id="F_3ea994d6-5e5e-45e8-9065-f7b08be80c7d"
      unitRef="U_USD">-21499000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_599e97e1-568f-46f7-bd9a-9ef5d9255791"
      unitRef="U_USD">-40933000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_e5382ef7-5630-435b-87f7-78a35d049ad6"
      unitRef="U_USD">-21431000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b"
      decimals="-3"
      id="F_0627cf60-6cb9-4d08-9880-ef7ee5ca33f4"
      unitRef="U_USD">19000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_add4eeeb-c8ac-4144-b25c-1c01117680ca"
      unitRef="U_USD">39000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8"
      decimals="-3"
      id="F_0e77fb3d-24e6-40f3-a1b1-0680d204c227"
      unitRef="U_USD">-21304000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8"
      decimals="-3"
      id="F_1c503748-d08a-4ce1-b46f-71ce3741f43a"
      unitRef="U_USD">-21304000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b"
      decimals="-3"
      id="F_9da3a067-40d9-4383-9204-258e25d7bfe8"
      unitRef="U_USD">-21518000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b"
      decimals="-3"
      id="F_f12f0657-4e63-4e4d-b5d0-3ab2c0971ba4"
      unitRef="U_USD">-21518000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_c6e23d37-193d-42ba-9455-4a86e3f49961"
      unitRef="U_USD">-40933000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_a6f87be6-1312-41a2-bdd0-5054395a1af7"
      unitRef="U_USD">-40933000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_2e6eea2b-6f71-44bf-850a-21fee7e72636"
      unitRef="U_USD">-21470000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_bdc457f1-fa33-41e2-b5ff-6d8c72fb2db0"
      unitRef="U_USD">-21470000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8"
      decimals="0"
      id="F_7578e036-c009-486e-b38c-e120301dac2b"
      unitRef="U_shares">23037714</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8"
      decimals="0"
      id="F_55c8c7e8-c9e1-40e6-8d55-f94700bc41d8"
      unitRef="U_shares">23037714</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b"
      decimals="0"
      id="F_f5f56460-91ed-4286-99c5-afc886e15692"
      unitRef="U_shares">2847675</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b"
      decimals="0"
      id="F_6867e74a-e6c1-4485-8d2a-bcd9b4d2d2a9"
      unitRef="U_shares">2847675</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="0"
      id="F_d84fc9bf-b3f5-4206-a051-fa61d43d0321"
      unitRef="U_shares">23024754</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="0"
      id="F_0d21aef6-f8d5-4cd5-992f-fe2432f798e2"
      unitRef="U_shares">23024754</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="0"
      id="F_9124b3ec-a5ac-4efe-8e56-2491767f8ca5"
      unitRef="U_shares">2817008</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="0"
      id="F_c9630a02-9e02-424f-8ee6-9728257a341d"
      unitRef="U_shares">2817008</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8"
      decimals="2"
      id="F_ca468369-79bf-4733-ad60-4e97329a8e25"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8"
      decimals="2"
      id="F_c6c32a04-02cb-4705-a6cc-8009be838ddc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b"
      decimals="2"
      id="F_a11adf5f-083a-4481-8c76-ef1752874377"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-7.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b"
      decimals="2"
      id="F_77a978ae-4994-4936-86f7-6f7909527d6c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-7.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="2"
      id="F_dda57c13-8997-4585-9be1-2044bbc248e9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.78</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="2"
      id="F_06404574-9576-4373-9223-bdd242e18793"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.78</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="2"
      id="F_4472a1f7-9260-4d20-aa90-e9b8630e6877"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-7.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="2"
      id="F_07f85521-7b9f-478f-83d9-97dde6798ef7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-7.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_761632b7-6a3d-4167-8e38-3551f8b5bd83"
      decimals="INF"
      id="F_c7e58068-b4d9-4b11-ad7b-da3ae9d31b2d"
      unitRef="U_shares">23099335</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_761632b7-6a3d-4167-8e38-3551f8b5bd83"
      decimals="-3"
      id="F_2a64f3c5-6213-4641-8f9d-f985bf57c2a9"
      unitRef="U_USD">23000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5b861034-a720-43d5-8699-9c7302265892"
      decimals="-3"
      id="F_91949c60-8411-4538-a8ae-43e4f457b25d"
      unitRef="U_USD">275521000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_62ccdb6f-2ce4-4c14-88c5-56ab718bbe38"
      decimals="-3"
      id="F_33f75a9e-5bd8-49c6-b763-f2b3dd328e95"
      unitRef="U_USD">-119000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8eeaadf6-6367-4498-a18c-12b0327753e8"
      decimals="-3"
      id="F_98504a65-8973-417c-94b6-c86de803f525"
      unitRef="U_USD">-176758000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_cb1381f0-e750-4ac6-a311-41ec607fa4d1"
      unitRef="U_USD">98667000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_f6268a98-55de-42e4-b33f-cf7c0879c342"
      decimals="INF"
      id="F_38da18d6-0913-428c-a1f0-5a7dabdd338f"
      unitRef="U_shares">29119</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0d77c486-d172-4aa4-894b-cde28b23636d"
      decimals="-3"
      id="F_a77c7e50-78ff-4982-9a94-65b7b7052494"
      unitRef="U_USD">44000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_93377237-7cd1-48a2-b8a5-b9a2243d15e5"
      decimals="-3"
      id="F_c3bceb51-7f75-41e1-8ccc-610cb2eb083d"
      unitRef="U_USD">44000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0d77c486-d172-4aa4-894b-cde28b23636d"
      decimals="-3"
      id="F_1c25da6b-9662-43c7-9558-21321b31d6e4"
      unitRef="U_USD">1046000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_93377237-7cd1-48a2-b8a5-b9a2243d15e5"
      decimals="-3"
      id="F_dab80ec3-9334-4bca-a1a9-f546544a44d5"
      unitRef="U_USD">1046000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_bbc99879-3c57-49b9-b3a2-7c36543a3a7a"
      decimals="-3"
      id="F_f4a4d45f-1987-434d-83fe-9d028e7945bd"
      unitRef="U_USD">-117000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_93377237-7cd1-48a2-b8a5-b9a2243d15e5"
      decimals="-3"
      id="F_679a46be-e8fc-4bfb-bcf6-08a12e92782b"
      unitRef="U_USD">-117000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_dd66f43c-636a-4989-849e-33408277fa05"
      decimals="-3"
      id="F_204d865a-dcab-46a0-81bd-b09e51e9fb24"
      unitRef="U_USD">-19629000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_93377237-7cd1-48a2-b8a5-b9a2243d15e5"
      decimals="-3"
      id="F_57c3a70c-2167-4d31-b487-ee1327cfa51e"
      unitRef="U_USD">-19629000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_b169253e-4db8-48b5-a2f6-a9d18d0f3f36"
      decimals="INF"
      id="F_a47479a9-6f45-411e-8aa5-6128fac3c208"
      unitRef="U_shares">23128454</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_b169253e-4db8-48b5-a2f6-a9d18d0f3f36"
      decimals="-3"
      id="F_29278280-72c9-417a-b717-0120ec278a3b"
      unitRef="U_USD">23000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_df7b7c66-464a-441f-91fd-4ca59bed28ea"
      decimals="-3"
      id="F_0fa600af-8aca-4670-9782-534252644da4"
      unitRef="U_USD">276611000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_db819b3e-1792-4c62-b813-10d6991af201"
      decimals="-3"
      id="F_44eb12af-ac95-4763-8556-72b0c2fddace"
      unitRef="U_USD">-236000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e72bcdb4-17b9-4881-84a9-0f4fe4e39f0b"
      decimals="-3"
      id="F_ee727958-f98d-47f2-8d59-5bdd683227e3"
      unitRef="U_USD">-196387000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_18e0b921-32c2-4a24-b203-fed3d74f4d65"
      decimals="-3"
      id="F_25c1489f-1548-4c67-9095-957fb86ffbb0"
      unitRef="U_USD">80011000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_7faec367-2bfd-418b-b55d-ce16bab8f5a3"
      decimals="-3"
      id="F_ec8ce985-124d-494e-aba4-c2ea9c1fcf4f"
      unitRef="U_USD">1019000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8"
      decimals="-3"
      id="F_cd331e99-43cb-4abe-8c92-45c279955270"
      unitRef="U_USD">1019000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_1acb574a-2c4a-4dd0-8d44-95c2caca0d22"
      decimals="-3"
      id="F_e9cbc5e7-f92b-49e1-81ad-cd900c577e67"
      unitRef="U_USD">10000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8"
      decimals="-3"
      id="F_1ccfa41c-a367-4e53-aae8-cd5750cc3b3a"
      unitRef="U_USD">10000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_ecd3cf07-fefb-416f-8ca3-3ebe03141ea5"
      decimals="-3"
      id="F_c64a3e1f-0f4b-4a6a-82a8-74d4ae74272e"
      unitRef="U_USD">-21304000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8"
      decimals="-3"
      id="F_48486e4e-a97a-47ff-8d0e-e97cb0b8d000"
      unitRef="U_USD">-21304000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_250b5a1d-34ea-4e70-805a-18bd6081b49c"
      decimals="INF"
      id="F_ea339148-375a-4011-9211-9cc31478a9a7"
      unitRef="U_shares">23128454</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_250b5a1d-34ea-4e70-805a-18bd6081b49c"
      decimals="-3"
      id="F_c3a4a982-d9ab-4ac9-83eb-8733f4bb120a"
      unitRef="U_USD">23000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_25efe362-0a08-4b30-b273-8685627ec35a"
      decimals="-3"
      id="F_ec23d125-d4f4-4654-8711-0bfb70bc63d1"
      unitRef="U_USD">277630000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ee135c52-c1b2-4ad5-911b-acfb5c8e8f2b"
      decimals="-3"
      id="F_de0d9fd5-9318-43dd-a535-170f6b6bfd1c"
      unitRef="U_USD">-226000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8916fdbc-eab2-44d0-8e8f-7bb4a95aae54"
      decimals="-3"
      id="F_f0653681-c402-4291-9f39-7426726e7148"
      unitRef="U_USD">-217691000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_16e58284-dbeb-46a9-b0aa-ffe8b7e2df44"
      unitRef="U_USD">59736000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_fab6d8a7-91ff-48ba-9d83-2f673cd37dd0"
      decimals="INF"
      id="F_51ee462a-374f-4ca5-a619-67680c18ee41"
      unitRef="U_shares">11250000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="C_fab6d8a7-91ff-48ba-9d83-2f673cd37dd0"
      decimals="-3"
      id="F_717de24b-030e-4c2a-9d94-7c77e5e47e34"
      unitRef="U_USD">8643000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_82a867ab-5d5f-459b-8a82-12bbd36560a5"
      decimals="INF"
      id="F_0df9d0da-53ee-4f10-b426-192485cae3d8"
      unitRef="U_shares">16285156</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="C_82a867ab-5d5f-459b-8a82-12bbd36560a5"
      decimals="-3"
      id="F_aae87542-8a1e-489d-ba82-f8537685b790"
      unitRef="U_USD">12611000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_8a4b4f37-0658-467b-8161-438bc3405ed1"
      decimals="INF"
      id="F_6eb114be-55de-47f3-b411-70481b1a3500"
      unitRef="U_shares">25065538</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="C_8a4b4f37-0658-467b-8161-438bc3405ed1"
      decimals="-3"
      id="F_6a4b0935-bb02-4f59-90bb-c1cbdd5161d4"
      unitRef="U_USD">28860000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_838eb810-3507-46b7-b156-72691850ae36"
      decimals="INF"
      id="F_672bca04-9fab-41ce-b685-f6ff30ac8a69"
      unitRef="U_shares">17905288</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="C_838eb810-3507-46b7-b156-72691850ae36"
      decimals="-3"
      id="F_43cdabfe-f13e-4036-8368-fb9d19b1a7ce"
      unitRef="U_USD">42100000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_f744bbe6-544a-4cb6-9ffc-e06c7c098585"
      decimals="INF"
      id="F_691b2334-a704-41ef-bbcd-6daa44103470"
      unitRef="U_shares">29285356</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="C_f744bbe6-544a-4cb6-9ffc-e06c7c098585"
      decimals="-3"
      id="F_953b337e-0d5a-4827-af23-c295cd1c7a2c"
      unitRef="U_USD">79730000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_9f42a392-3c59-43e9-a2a2-d060b68b5b79"
      decimals="INF"
      id="F_043f27ac-7047-4a32-ab1d-ad13aed7491a"
      unitRef="U_shares">2915757</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_9f42a392-3c59-43e9-a2a2-d060b68b5b79"
      decimals="-3"
      id="F_63114e69-3084-485e-9cc7-135a3c547be7"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5ee261db-0283-4149-9229-b37f40e4e1e5"
      decimals="-3"
      id="F_d280d529-249c-4f12-b53e-52e71212bb30"
      unitRef="U_USD">20501000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a12fbc8f-79f0-4426-843d-ec27ad6e7c70"
      decimals="-3"
      id="F_55642301-02af-437a-bca7-6f4edc0cac0b"
      unitRef="U_USD">-413000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2475957a-da36-49a5-8126-8a055410a470"
      decimals="-3"
      id="F_5cab766d-12a0-401c-b5fa-2ce9fb481122"
      unitRef="U_USD">-121558000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_bed097c6-a12a-48ed-ab84-40a66008425b"
      decimals="-3"
      id="F_c763f5a4-a7fb-4c47-8238-b16a7d191906"
      unitRef="U_USD">-101467000</us-gaap:StockholdersEquity>
    <tsbx:StockIssuedDuringPeriodSharesMoffittPerformanceBasedCommonStockAward
      contextRef="C_e83e1bee-c31a-4456-a69d-f9eab649bf3a"
      decimals="INF"
      id="F_07e98e1a-baf5-486b-86de-95fc1a0eccf2"
      unitRef="U_shares">91721</tsbx:StockIssuedDuringPeriodSharesMoffittPerformanceBasedCommonStockAward>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="C_c72ae3f1-ec49-47ae-8a52-43699c15abfc"
      decimals="-3"
      id="F_8a4599e4-b185-4fa3-8041-6e49f881687a"
      unitRef="U_USD">20000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
      contextRef="C_47ec3535-df3a-4de3-bfc4-2765e79fb6a6"
      decimals="-3"
      id="F_d4fb7e9d-c020-42e2-b1b9-eb19057e9f23"
      unitRef="U_USD">-20000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
      contextRef="C_278e12a5-7809-4e31-81fa-b5ac9fed8247"
      decimals="-3"
      id="F_cee728a7-bc1b-4e61-8310-2a3fc232abeb"
      unitRef="U_USD">-20000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_e83e1bee-c31a-4456-a69d-f9eab649bf3a"
      decimals="INF"
      id="F_e031c900-4a00-47d2-a804-e0937e21c601"
      unitRef="U_shares">20658</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_47ec3535-df3a-4de3-bfc4-2765e79fb6a6"
      decimals="-3"
      id="F_02802e97-8e62-4d15-8c96-92fc1594dfc8"
      unitRef="U_USD">83000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_278e12a5-7809-4e31-81fa-b5ac9fed8247"
      decimals="-3"
      id="F_2c96dc68-4243-4034-9907-de1587e6024f"
      unitRef="U_USD">83000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_47ec3535-df3a-4de3-bfc4-2765e79fb6a6"
      decimals="-3"
      id="F_0da52ef8-94e5-4b55-8809-954054baef85"
      unitRef="U_USD">992000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_278e12a5-7809-4e31-81fa-b5ac9fed8247"
      decimals="-3"
      id="F_d8c410f2-0d0f-41bd-a0c9-a5fe8b438cab"
      unitRef="U_USD">992000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_df0e855c-ac6b-4b9c-86e6-10fbdce55a16"
      decimals="-3"
      id="F_6a18dde5-b4e4-4747-a54e-e7dc1164c94b"
      unitRef="U_USD">121000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_278e12a5-7809-4e31-81fa-b5ac9fed8247"
      decimals="-3"
      id="F_04486e24-289c-4e24-bb3e-a1214f633904"
      unitRef="U_USD">121000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_d9bf8d53-5a76-4443-ae16-8d541daf5ad2"
      decimals="-3"
      id="F_af5292f1-f2a8-4f6b-9346-cffc318a977b"
      unitRef="U_USD">68000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_278e12a5-7809-4e31-81fa-b5ac9fed8247"
      decimals="-3"
      id="F_dae60949-601a-41d3-80c7-18c21bffed60"
      unitRef="U_USD">68000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_656dbf1c-1dcc-431d-8fe9-c0de04b2841b"
      decimals="INF"
      id="F_2905935f-9b9d-43b8-be24-d6e316cf926e"
      unitRef="U_shares">11250000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="C_656dbf1c-1dcc-431d-8fe9-c0de04b2841b"
      decimals="-3"
      id="F_3a12a37e-e7e7-4f90-93a5-d845ea65f926"
      unitRef="U_USD">8643000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_8eddfc98-0dbe-49c8-9be7-73a81bdcbff8"
      decimals="INF"
      id="F_6ccca8a3-4002-423a-8566-406775917f45"
      unitRef="U_shares">16285156</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="C_8eddfc98-0dbe-49c8-9be7-73a81bdcbff8"
      decimals="-3"
      id="F_c8708c5e-e1eb-4b39-a3c3-da0a5aa7825f"
      unitRef="U_USD">12611000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_2ff3278e-16d8-4b68-bf2e-7b39955581f3"
      decimals="INF"
      id="F_71348374-f280-426d-921f-ca7621fda382"
      unitRef="U_shares">25065538</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="C_2ff3278e-16d8-4b68-bf2e-7b39955581f3"
      decimals="-3"
      id="F_7b07ca3d-06ab-4787-b140-b054e23c31f6"
      unitRef="U_USD">28860000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_8aa8eff8-bf22-4098-92ea-223279b190c9"
      decimals="INF"
      id="F_a55a34c9-a3e8-4e42-b6c4-70eebe82d87e"
      unitRef="U_shares">17905288</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="C_8aa8eff8-bf22-4098-92ea-223279b190c9"
      decimals="-3"
      id="F_b59de50e-fea9-4264-826c-ff6cf2831b40"
      unitRef="U_USD">42100000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_ed2ba762-cc53-4aa6-ad18-93928a0e9e83"
      decimals="INF"
      id="F_f392bdad-f77f-4b0f-b82e-e6c89e680418"
      unitRef="U_shares">29285356</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="C_ed2ba762-cc53-4aa6-ad18-93928a0e9e83"
      decimals="-3"
      id="F_3f436732-988d-4b61-9de0-e21a5a2ea011"
      unitRef="U_USD">79750000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_15263df3-916f-46a0-9832-65fb7bc16128"
      decimals="INF"
      id="F_3b7f3fa2-a9ad-433f-ac47-3e99ec976509"
      unitRef="U_shares">3028136</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_15263df3-916f-46a0-9832-65fb7bc16128"
      decimals="-3"
      id="F_1dfeb55e-e09d-4261-ab8a-35da6af6b6e8"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_07b24899-50be-4afd-9968-9f3387fa7317"
      decimals="-3"
      id="F_e54f95ea-5e41-4652-b616-b3d88b8219b0"
      unitRef="U_USD">21556000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_622828de-17f7-43ff-8529-65876283fc2a"
      decimals="-3"
      id="F_16d917f1-f90b-440e-a1cc-07a17df9dc75"
      unitRef="U_USD">-292000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_33626c55-fab2-4ed6-af8d-d98851be5b39"
      decimals="-3"
      id="F_c4ca1b17-ae22-4b5e-ab45-5c17a10ea8e7"
      unitRef="U_USD">-121490000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1ec4e76a-cfd9-4b97-8d2b-92c62767f896"
      decimals="-3"
      id="F_a964d7a3-be06-46f0-b91b-d589eb6b6176"
      unitRef="U_USD">-100223000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="C_497bd5df-0910-478f-aa44-aeabd848571c"
      decimals="-3"
      id="F_cba0a3db-dd83-4179-81b0-c04e0711481f"
      unitRef="U_USD">19000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
      contextRef="C_109f55ad-7a48-4c7f-a7ed-d02672f14dbb"
      decimals="-3"
      id="F_e5956ec0-5f89-4a4c-acaa-57cdb08130a4"
      unitRef="U_USD">-19000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
      contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b"
      decimals="-3"
      id="F_e41daa48-8820-422e-911e-b34a0a668847"
      unitRef="U_USD">-19000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_3960fbc2-6191-4efe-80f0-27545067aa20"
      decimals="INF"
      id="F_e90e5276-592d-4a2c-8b78-9a5a1623d564"
      unitRef="U_shares">1122</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_109f55ad-7a48-4c7f-a7ed-d02672f14dbb"
      decimals="-3"
      id="F_982fa5a4-f2eb-4cf2-b86e-13e78575962c"
      unitRef="U_USD">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b"
      decimals="-3"
      id="F_1a962fa4-dfaf-4f1e-9530-6d847ed423ea"
      unitRef="U_USD">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_109f55ad-7a48-4c7f-a7ed-d02672f14dbb"
      decimals="-3"
      id="F_a81e440c-fa4c-46d4-bb86-587c574a8392"
      unitRef="U_USD">1074000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b"
      decimals="-3"
      id="F_02fc8ed7-e9b3-402b-83b9-f47d5f308927"
      unitRef="U_USD">1074000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_ab5c8887-9c0a-4afb-8d68-eae695a3dd3b"
      decimals="-3"
      id="F_19753735-9a5b-458a-acd5-5ccd939804cf"
      unitRef="U_USD">59000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b"
      decimals="-3"
      id="F_e5626acb-30c0-4cdd-a11c-52eab31e1abb"
      unitRef="U_USD">59000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_5b06c6b4-e689-4fe0-a090-8bcd1ee5595a"
      decimals="-3"
      id="F_fc327435-c87c-412f-acd6-6bf9f69830f3"
      unitRef="U_USD">-21499000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b"
      decimals="-3"
      id="F_d7307a9c-d6fa-414f-b1a0-3233fb4f3966"
      unitRef="U_USD">-21499000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_44bd7a65-8c40-4525-b754-f1b5eaea0d39"
      decimals="INF"
      id="F_0c2996a1-5a66-44d2-be93-b61307166996"
      unitRef="U_shares">11250000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="C_44bd7a65-8c40-4525-b754-f1b5eaea0d39"
      decimals="-3"
      id="F_634773d3-a42a-41b8-8f87-0ae8ca70f3ea"
      unitRef="U_USD">8643000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_7a327960-116a-4bd1-8648-b5f38a13e8f4"
      decimals="INF"
      id="F_1e3c57e3-57d9-411b-bffa-84089c8b100e"
      unitRef="U_shares">16285156</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="C_7a327960-116a-4bd1-8648-b5f38a13e8f4"
      decimals="-3"
      id="F_559ee5bd-13dc-4a68-9dc8-0a4107b5c39c"
      unitRef="U_USD">12611000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_e2186eec-5e5a-4c75-b0fd-9b1fdf69034e"
      decimals="INF"
      id="F_ca9f28e1-f293-4764-ba59-0589a026c13e"
      unitRef="U_shares">25065538</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="C_e2186eec-5e5a-4c75-b0fd-9b1fdf69034e"
      decimals="-3"
      id="F_812e5f4a-4af4-4e65-814e-cc31233c44c8"
      unitRef="U_USD">28860000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_b6215fc5-849f-462e-86bf-6b597390fe38"
      decimals="INF"
      id="F_7386dc9d-0eee-40a8-84b1-2bb431fc4239"
      unitRef="U_shares">17905288</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="C_b6215fc5-849f-462e-86bf-6b597390fe38"
      decimals="-3"
      id="F_b86d7a9c-fc13-47d2-b922-553d13971050"
      unitRef="U_USD">42100000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_1b2bcaaf-9d3a-490e-8d00-989c002af276"
      decimals="INF"
      id="F_e25fe011-34b0-4777-9f35-85531e968c72"
      unitRef="U_shares">29285356</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="C_1b2bcaaf-9d3a-490e-8d00-989c002af276"
      decimals="-3"
      id="F_e8d5c4d3-0982-4dd4-b173-23e94a04c04e"
      unitRef="U_USD">79769000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_6d290ced-5d11-4542-b2af-bb92860ccf5b"
      decimals="INF"
      id="F_97f6349a-abe4-4b6a-95bc-78c6f13cdde2"
      unitRef="U_shares">3029258</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_6d290ced-5d11-4542-b2af-bb92860ccf5b"
      decimals="-3"
      id="F_9275ebd9-af98-4d2e-81ec-032a6e30dd10"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2d44f350-3d07-4146-ae3c-42824895d484"
      decimals="-3"
      id="F_40795c48-1515-4ccc-9310-886582fc5eea"
      unitRef="U_USD">22614000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ffd72f23-b073-4049-978f-aa0c05133c6b"
      decimals="-3"
      id="F_39abc0b4-e982-43fb-91f1-65fa02c68437"
      unitRef="U_USD">-233000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1326cf13-b619-4a7a-8459-199edf00cef7"
      decimals="-3"
      id="F_eb33a5a4-8ccc-43b7-8237-fc3c866d1374"
      unitRef="U_USD">-142989000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_dfe46888-9d65-4c68-a853-215029dc9872"
      decimals="-3"
      id="F_cb1c80ed-ddcb-41f5-ac97-44643a0004b0"
      unitRef="U_USD">-120605000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_ae3e1e2f-0291-4db6-99ae-c5934821d9ad"
      unitRef="U_USD">-40933000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_cecaba1b-2ebd-49c0-8daa-c38127f1dde9"
      unitRef="U_USD">-21431000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_c3f2a65e-8fee-4070-9cde-3ee9ca0bf264"
      unitRef="U_USD">2065000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_7fcc966c-4809-498e-a266-132cb31893ce"
      unitRef="U_USD">2066000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_2bf132a5-ba72-464e-8c20-150fbfc86298"
      unitRef="U_USD">14000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_05ba2f39-6b47-4b2d-a370-27854406f921"
      unitRef="U_USD">1007000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_f718c7df-49dd-4441-9402-c59130d3b82e"
      unitRef="U_USD">1439000</us-gaap:DepreciationDepletionAndAmortization>
    <tsbx:AccretionOfPremiumOnShortTermInvestments
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_e5838652-479f-46b4-b218-ccd52e0de5b9"
      unitRef="U_USD">1385000</tsbx:AccretionOfPremiumOnShortTermInvestments>
    <tsbx:AccretionOfPremiumOnShortTermInvestments
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_38db0e05-c863-4e65-a448-02c97f041b91"
      unitRef="U_USD">468000</tsbx:AccretionOfPremiumOnShortTermInvestments>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_b7274bfa-55ce-4036-a747-bd62b2bf87e5"
      unitRef="U_USD">108000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_4de1ff1c-c498-41a8-b5e7-b08475b49bc7"
      unitRef="U_USD">876000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_0292c51f-172e-4592-956f-5d33de77de57"
      unitRef="U_USD">-194000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_4ed83222-a03e-4f1a-a446-946c4541cf10"
      unitRef="U_USD">-8478000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_7c018b29-6a0e-4841-b260-675e32ed3eff"
      unitRef="U_USD">-1233000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_679775e2-c1e1-4fae-9d94-69197813bb12"
      unitRef="U_USD">-652000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_570e06d4-6da0-4253-af07-c04f12f87ade"
      unitRef="U_USD">-464000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_2bad4062-fd5f-4405-9aa0-0e84ee93318e"
      unitRef="U_USD">325000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_6ccd0083-e6b8-4856-bc4f-ffc7405f9845"
      unitRef="U_USD">-97000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_dc5761f3-bcb6-4539-a1c4-64f3ddfe3c10"
      unitRef="U_USD">-29000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_4155e6a2-4fcb-47f1-87e0-9678636f960a"
      unitRef="U_USD">1422000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_a58cde81-3ba1-4438-a7cb-17bd7f7ea033"
      unitRef="U_USD">-3237000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <tsbx:IncreaseDecreaseInContingentConsiderationLiability
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_6612f81f-b099-4954-9a54-24993ef88d62"
      unitRef="U_USD">-1289000</tsbx:IncreaseDecreaseInContingentConsiderationLiability>
    <tsbx:IncreaseDecreaseInAccruedCompensationAndOtherAccruedLiabilities
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_1ef9fda4-e086-4d63-a2ae-8e91da30e6e6"
      unitRef="U_USD">2445000</tsbx:IncreaseDecreaseInAccruedCompensationAndOtherAccruedLiabilities>
    <tsbx:IncreaseDecreaseInAccruedCompensationAndOtherAccruedLiabilities
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_27a5851e-b983-4857-a0ef-c1d939f1c52a"
      unitRef="U_USD">1002000</tsbx:IncreaseDecreaseInAccruedCompensationAndOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_f6d14709-9c68-415f-b5b7-9ce5496e9d4f"
      unitRef="U_USD">-92000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_64b4b6c6-da61-4618-aec6-201a3e671487"
      unitRef="U_USD">275000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_51361c2c-7843-406c-bd47-b1a0c2955fc5"
      unitRef="U_USD">-19306000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_5c99afab-6149-4757-9b7c-5b7c7a0dff81"
      unitRef="U_USD">-33385000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_7ce7ea41-95e0-48fa-87e3-897387460327"
      unitRef="U_USD">-31861000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_ff0d329f-a229-4e2f-beea-02776faa681a"
      unitRef="U_USD">40000000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_b1408c1e-a569-4cf8-829e-db12ab97154e"
      unitRef="U_USD">35500000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_fe5971ac-d210-4efa-9867-cef82f7d6637"
      unitRef="U_USD">6740000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_45e048f4-d1fa-4c8f-b385-d4e0fd400725"
      unitRef="U_USD">15228000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_cd3a255a-fbc8-411f-b694-a031f783619a"
      unitRef="U_USD">25000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_8a046ff7-4e98-4ae1-93af-43854d7143c1"
      unitRef="U_USD">193000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_af45cffe-26bc-4497-88d6-a8ca93e66890"
      unitRef="U_USD">249000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_9c6face0-69d4-49f3-9a90-6a13ca632786"
      unitRef="U_USD">990000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_26bbc40d-4eff-4e79-8051-eb1c30bd1cd2"
      unitRef="U_USD">33036000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_e2383e81-75a2-4018-92d9-418304e282d8"
      unitRef="U_USD">19475000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_acd9f904-225a-43a1-a829-7261bff377f3"
      unitRef="U_USD">92000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_fe7dab9d-7bd4-437e-8fb2-bde15fc5cce0"
      unitRef="U_USD">898000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_e5218805-5027-4a2f-9936-8088ca8b90c6"
      unitRef="U_USD">269000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_e589444e-e79a-4d60-a789-ab3518ad9307"
      unitRef="U_USD">44000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_93fc8064-84d3-4a13-afb0-e82f50c9a1e7"
      unitRef="U_USD">86000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_4211cf56-7619-40d3-be28-c8b7ff712b59"
      unitRef="U_USD">-48000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_8840d3e9-78b1-4404-b313-3aa7cb6ba3a2"
      unitRef="U_USD">-1081000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_937bbdcc-579e-4682-b2fd-0106a14e57ad"
      unitRef="U_USD">-397000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_a332d678-5070-4312-b80b-40056b05a594"
      unitRef="U_USD">-13467000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_e7c2ba39-df47-479b-bdb3-b6994333128c"
      unitRef="U_USD">17914000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_bed097c6-a12a-48ed-ab84-40a66008425b"
      decimals="-3"
      id="F_28570aad-ed8f-4cf9-ad90-80fa7ef1daa2"
      unitRef="U_USD">35113000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_708f8f84-8e54-45f2-a60e-27f81945cea3"
      unitRef="U_USD">17517000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_dfe46888-9d65-4c68-a853-215029dc9872"
      decimals="-3"
      id="F_b484f04d-e7f7-4547-ad92-356937c77fa8"
      unitRef="U_USD">21646000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_8aa1c7d4-d197-493f-ad75-ce99627fef19"
      unitRef="U_USD">119000</us-gaap:IncomeTaxesPaidNet>
    <tsbx:AccretionOfRedeemableConvertiblePreferredStock
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_f5bcaf27-3767-43fe-beae-512bb48ef70c"
      unitRef="U_USD">39000</tsbx:AccretionOfRedeemableConvertiblePreferredStock>
    <tsbx:EquipmentPurchasesIncludedInAccruedExpenses
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_126b27e7-413f-419e-94fb-06119dd12673"
      unitRef="U_USD">186000</tsbx:EquipmentPurchasesIncludedInAccruedExpenses>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_fec40025-2dcb-42cc-8779-f86de640e59f"
      unitRef="U_USD">28000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <tsbx:DeferredIpoCostsIncludedInAccruedExpenses
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_5bffcc0a-bddb-4881-9e00-6f380939d697"
      unitRef="U_USD">2286000</tsbx:DeferredIpoCostsIncludedInAccruedExpenses>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_ad59e2c3-77c9-472a-836b-a3ee39de45c8">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1. Nature of the Business and Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Organization&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Turnstone Biologics Corp. (the &#x201c;Company&#x201d; or &#x201c;Turnstone&#x201d;) is a clinical stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. Turnstone is pioneering a differentiated approach to tumor infiltrating lymphocytes (&#x201c;TILs&#x201d;), a clinically validated technology for treating solid tumors. The Company is developing next generation TIL therapies by selecting the most potent and tumor reactive T cells (&#x201c;Selected TILs&#x201d;). The Company has three ongoing Phase 1 clinical trials for TIDAL-01, including a multi-site trial for the treatment of colorectal cancer, head and neck cancer, and uveal melanoma, and two investigator sponsored trials with H. Lee Moffitt Cancer Center and Research Institute, Inc., ("Moffitt"), across colorectal cancer, head and neck cancer, and uveal melanomas. The Company&#x2019;s headquarters are located in San Diego, California.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Reverse Stock Split&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On July 14, 2023, the Company effected a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;1-for-7.9872&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; reverse stock split (&#x201c;Reverse Split&#x201d;) of its issued and outstanding shares of common stock and redeemable convertible preferred stock. All share and per share amounts included in the accompanying unaudited condensed consolidated financial statements and related notes have been retroactively adjusted, where applicable, to reflect the Reverse Split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital. Shares of common stock, underlying outstanding stock options, and restricted stock were proportionately reduced and the respective exercise prices, if applicable, were proportionately increased in accordance with the terms of the appropriate securities agreements. Stockholders entitled to fractional shares as a result of the Reverse Split received a cash payment in lieu of receiving fractional shares.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Initial Public Offering&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On July 25, 2023, the Company completed its initial public offering ("IPO") pursuant to which it issued and sold an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,666,667&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock at a price to the public of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. Aggregate net proceeds to the Company were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million after deducting underwriting discounts and commissions of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and other offering expenses of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. On August 15, 2023, the underwriters exercised their option to purchase an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;651,608&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share. Aggregate net proceeds to the Company were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million after deducting underwriting discounts and commissions of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Upon the closing of the IPO, all outstanding shares of redeemable convertible preferred stock automatically converted into shares of common stock. Subsequent to the closing of the IPO, there were no shares of redeemable convertible preferred stock outstanding.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the closing of the IPO, the Company filed its Amended and Restated Certificate of Incorporation which provides that the authorized capital stock of the Company is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;500,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares consisting of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;490,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of undesignated preferred stock, both with a par value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Going Concern&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of this uncertainty. Management is required to perform a two-step analysis over the Company&#x2019;s ability to continue as a going concern. Management must first evaluate whether there are conditions and events that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern (Step 1). If management concludes that substantial doubt is raised, management is also required to consider whether its plans alleviate that doubt (Step 2).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;However, the Company incurred a net loss and negative cash flows from operations during the six months ended June 30, 2024 and management&#x2019;s cash flow forecasts indicate that based on the Company&#x2019;s expected future operating losses and negative cash flows, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern for 12 months after the date the unaudited consolidated financial statements are filed with the SEC.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s ability to continue as a going concern is dependent upon its ability to raise additional funding. Management intends to raise additional capital through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements.  However, the Company may not be able to secure additional financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company&#x2019;s existing stockholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its current and potential future product candidates and programs on terms that are not favorable to the Company. As a result of adverse macroeconomic and geopolitical developments, recent and potential future bank failures, actual or anticipated changes in interest rates, economic inflation and the responses by central banking authorities to control such inflation, the global credit and financial markets have experienced volatility and disruptions, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. If the equity and credit markets deteriorate in the future, it may make any additional debt or equity financing more difficult, more costly, and more dilutive. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce or eliminate its research and development programs or other operations. Even if the Company raises additional capital, it may be insufficient to continue its development as currently planned, which could have a material adverse effect on the Company&#x2019;s business, operating results and financial condition, and the Company&#x2019;s ability to achieve its intended business objectives. If any of these events occur, the Company&#x2019;s ability to achieve the development and commercialization goals would be adversely affected.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Sources of Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Since its inception, the Company has devoted substantially all of its efforts and financial resources to organizing and staffing the Company, business planning, raising capital, discovering product candidates and securing related intellectual property rights, and conducting research and development activities for its Selected TIL programs and product candidates. The Company does not have any products approved for sale, has not generated any revenue from product sales and has incurred overall net losses since commencement of the Company&#x2019;s operations, including a net loss of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;six months ended June 30, 2024 and 2023, respectively. The Company has financed its operations through the issuance and sale of shares of the Company&#x2019;s redeemable convertible preferred stock, from collaboration revenue received pursuant to certain collaboration agreements, and most recently, with proceeds from the IPO completed on July 25, 2023 and the exercise of the underwriters option to purchase additional shares on August 15, 2023. As of June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;217.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. The Company expects to continue to generate significant operating losses for the foreseeable future.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On April 26, 2024 (the &#x201c;Loan Closing Date&#x201d;), the Company entered into a Loan and Security Agreement ("LSA") with Banc of California ("BOC") for a revolving credit facility in an aggregate principal amount of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million with annual interest at the greater of the Prime Rate (as defined in the LSA) or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%.  This LSA includes a covenant requiring the Company to (i) receive positive interim Phase 1 data for TIDAL-01 (as determined by the Company&#x2019;s board of directors), which was achieved in August 2024 and (ii) receive at least $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in new funding from the sale of equity, partnerships, and/or business development payments, in each case, by March 31, 2025. If the Company fails to comply with any of the foregoing covenants, the Lender may terminate the commitments to make further loans and declare all of the obligations of the Company under the LSA to be immediately due and payable. As of June 30, 2024, no amounts have been drawn under the LSA (see&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; Note 8 - Term Loan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for additional information).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company intends to fund future operations and future capital funding needs through equity and/or debt financings, as well as possible asset sales, licensing transactions, and collaborations or strategic partnerships with other companies. The sale of equity or convertible debt could result in additional dilution to stockholders. The incurrence of indebtedness would result in debt service obligations and could result in operating and financial covenants that would restrict the Company&#x2019;s operations. The Company can provide no assurance that sufficient financing will be available on acceptable terms, if at all. If the Company is not able to secure adequate additional funding it may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. Any of these actions could materially harm the Company&#x2019;s business.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including non-clinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance and reporting capabilities. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_c5cddb37-672e-4bc6-993b-61b085312425"
      id="F_8b39f2ed-6625-4faa-a671-12e4def48b0f">1-for-7.9872</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_be5fa637-0934-415e-a76d-cef88c5177de"
      decimals="INF"
      id="F_f6aa0bcf-65c0-48f5-a37e-d3922a0f6e88"
      unitRef="U_shares">6666667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_d3863644-3003-48be-ba26-f907692ad408"
      decimals="INF"
      id="F_fe58e037-a85a-490a-9324-3bf3991e4791"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_be5fa637-0934-415e-a76d-cef88c5177de"
      decimals="-5"
      id="F_901f7188-ca37-4d1e-add6-ab7ba53e69a8"
      unitRef="U_USD">68700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <tsbx:UnderwritingDiscountsAndCommissions
      contextRef="C_be5fa637-0934-415e-a76d-cef88c5177de"
      decimals="-5"
      id="F_19632725-189e-49f5-96c2-081235f14c5c"
      unitRef="U_USD">5600000</tsbx:UnderwritingDiscountsAndCommissions>
    <tsbx:OtherOfferingExpenses
      contextRef="C_be5fa637-0934-415e-a76d-cef88c5177de"
      decimals="-5"
      id="F_4211929b-88fb-4e2c-aa2e-333a04c6ab03"
      unitRef="U_USD">5700000</tsbx:OtherOfferingExpenses>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_c6e4f9a3-9885-44ca-907d-b6658de8f0e8"
      decimals="INF"
      id="F_c7e15348-c86d-4cae-9627-d82d8870e7d2"
      unitRef="U_shares">651608</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_b283014b-e73a-4c69-9931-4985a3e59add"
      decimals="INF"
      id="F_4148ec17-4c4e-4080-8355-93c683d1635e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_c6e4f9a3-9885-44ca-907d-b6658de8f0e8"
      decimals="-5"
      id="F_f90f34be-1ab4-4d2a-96cd-07ba4a04c723"
      unitRef="U_USD">7300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <tsbx:UnderwritingDiscountsAndCommissions
      contextRef="C_c6e4f9a3-9885-44ca-907d-b6658de8f0e8"
      decimals="-5"
      id="F_721116c5-2fea-4b39-82ec-87c4bf52bad9"
      unitRef="U_USD">500000</tsbx:UnderwritingDiscountsAndCommissions>
    <tsbx:SharesAuthorized
      contextRef="C_c0b79b4e-6d2e-4c6f-9298-ac7fa6a0af9c"
      decimals="INF"
      id="F_ded2d0eb-fe16-4efe-b161-3a02b8b7d121"
      unitRef="U_shares">500000000</tsbx:SharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_c0b79b4e-6d2e-4c6f-9298-ac7fa6a0af9c"
      decimals="INF"
      id="F_fa5972b7-faae-4355-aea6-de275d7e02b2"
      unitRef="U_shares">490000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_c0b79b4e-6d2e-4c6f-9298-ac7fa6a0af9c"
      decimals="INF"
      id="F_90ced1e5-3e15-4ec7-8002-1165c38ebc3c"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_c0b79b4e-6d2e-4c6f-9298-ac7fa6a0af9c"
      decimals="INF"
      id="F_b3e24be3-ff3b-4677-85d0-a6e454feb511"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_c0b79b4e-6d2e-4c6f-9298-ac7fa6a0af9c"
      decimals="INF"
      id="F_97716f82-1be9-4b72-a15d-12a9487a5c51"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:NetIncomeLoss
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-5"
      id="F_49e3451c-1b0f-4df1-be40-cb64db599e9f"
      unitRef="U_USD">-40900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-5"
      id="F_bae56052-054f-47df-8fbb-bd4d552a67f6"
      unitRef="U_USD">-21400000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-5"
      id="F_4d003491-522c-4f18-9b1c-289a50fb8268"
      unitRef="U_USD">-217700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_1608bf2e-2722-4b3b-ac28-7d680ca451a6"
      decimals="-6"
      id="F_1f3b1076-adf5-46e7-910b-c73df340de06"
      unitRef="U_USD">20000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_1608bf2e-2722-4b3b-ac28-7d680ca451a6"
      decimals="INF"
      id="F_3346dd5a-b514-4367-8c44-caab2ca0c83d"
      unitRef="U_pure">0.0425</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <tsbx:FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments
      contextRef="C_eea7aad0-d598-4675-97e4-495ad0d5f473"
      decimals="-5"
      id="F_e28508af-e07c-438f-8b92-9841aadee1af"
      unitRef="U_USD">40000000</tsbx:FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_011e7618-e5a4-4797-b0a1-a43fc4d6d1b7">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation of Unaudited Condensed Consolidated Financial Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for interim financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. However, such interim financial statements reflect all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the Company&#x2019;s financial position and results of operations. Results shown for interim periods are not necessarily indicative of the results that may be expected for the year ended December 31, 2024 or for any other period. The condensed consolidated balance sheet as of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was derived from the audited consolidated financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements, included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on March 22, 2024. Certain prior period amounts reported in the Company&#x2019;s unaudited condensed consolidated financial statements and accompanying notes have been reclassified to conform to the current period presentation. Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The significant accounting policies used in preparation of these unaudited condensed consolidated financial statements are consistent with those discussed in Note 2 to the audited consolidated financial statements included in the Company&#x2019;s Annual Report filed on Form 10-K filed with the SEC on March 22, 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of these unaudited condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to accrued expenses, contingent liabilities, impairment of long-lived assets, revenue recognition, the valuation of equity-based compensation, common stock, restricted common stock, and income taxes. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Cash and Investments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted cash consists of certificate of deposit accounts that are pledged as collateral for the Company&#x2019;s San Diego facility lease. Restricted cash was approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024 and December 31, 2023, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company invests its excess cash in investment grade, short-term, fixed income securities and recognizes purchased securities on the settlement date. All investments have been classified as &#x201c;available-for-sale&#x201d; in the unaudited condensed consolidated balance sheets and are carried at estimated fair value based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments at the time of purchase and re-evaluates such designation as of each balance sheet date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company assesses its available-for-sale securities under the available-for-sale security impairment model in ASC Topic 326, Financial Instruments - Credit Losses ("ASC 326") as of each reporting date in order to determine if a portion of any decline in fair value below carrying value is the result of a credit loss. The Company records credit losses in the unaudited condensed consolidated statements of operations and comprehensive loss as credit loss expense, which is limited to the difference between the fair value and the amortized cost of the security. To date, the Company has not recorded any credit losses on its available-for-sale securities. Declines in fair value below carrying value attributable to non-credit related factors are recorded as accumulated other comprehensive loss, which is a separate component of stockholders&#x2019; equity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Realized gains and losses are reported in other income (expense), net. Interest on short-term investments is included in other income (expense), net. The Company&#x2019;s investments are classified as current assets which reflects management&#x2019;s intention to use the proceeds from sales of these securities to fund its operations, as necessary.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, investments and restricted cash. The Company&#x2019;s investment policy restricts cash investments to high credit quality, investment grade investments. The Company&#x2019;s investment policy provides guidelines and limits regarding investment type, concentration, credit quality, and maturity aimed at maintaining sufficient liquidity to satisfy operating and working capital requirements along with strategic initiatives, preserving capital, and minimizing risk of capital loss while generating returns on its investments. The Company is exposed to credit risk in the event of default by the issuer or the institutions holding the cash and cash equivalents to the extent of the amounts recorded on the balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has no off-balance sheet risk, such as foreign exchange contracts, option contracts or other foreign-hedging arrangements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the unaudited condensed consolidated financial statements on a recurring basis. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy requires that an entity maximize the use of observable inputs when estimating fair value. The fair value hierarchy includes the following three-level classification which is based on the market observability of the inputs used for estimating the fair value of the assets or liabilities being measured:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Quoted market prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3 &#x2013;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Inputs that are generally unobservable and typically reflect management&#x2019;s estimate of assumptions that a market participant would use in pricing the asset or liability.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized at fair value in the unaudited condensed consolidated financial statements on a recurring basis (at least annually). To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for stock-based compensation expense related to stock options and restricted stock units, ("RSUs"), by estimating the fair value on the date of grant. The fair value of RSUs granted to employees is the closing price of the Company&#x2019;s common stock on the date of grant. The Company estimates the fair value of stock options granted to employees and non-employees using the Black-Scholes option pricing model. The Company recognizes stock-based compensation expense, over the requisite service period, based on the vesting provisions of the individual grants. Generally, the Company issues stock-based awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. The Company accounts for forfeitures when they occur.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a) the expected stock price volatility, (b) the expected term of the award, (c) the risk-free interest rate and (d) expected dividend yields. Due to the lack of a public market for the Company&#x2019;s common stock until July 21, 2023, and lack of company- specific historical and implied volatility data, the Company has based its computation of expected volatility on the average historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term. The Company uses the simplified method as prescribed by the U.S. Securities and Exchange Commission Staff Accounting Bulletin No. 107,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Share-Based &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Determination of Fair Value of Common Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;After the Company's IPO in July 2023, the fair value of common stock is determined using the closing price of the Company's common stock on the Nasdaq Global Market. Prior to the IPO, there were significant judgments and estimates inherent in the determination of the fair value of the Company&#x2019;s common stock. These estimates and assumptions include a number of objective and subjective factors, including, among other things, external market conditions, the prices at which the Company sold shares of its convertible preferred stock, the superior rights and preferences of securities senior to its common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale of the Company. The approach to estimating the fair market value of common stock is consistent with the methods outlined in the American Institute of Certified Public Accountants&#x2019; Accounting and Valuation Guide, Valuation of Privately-Held Company Equity Securities Issued as Compensation (the &#x201c;Practice Aid&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In valuing the Company&#x2019;s common stock prior to the IPO, the equity value of the business was determined using the backsolve method, a form of the subject company transaction method, wherein the equity value for a privately held company is derived from a recent transaction in the company&#x2019;s own securities. The value is then allocated using the hybrid method allocation methodology. For grants made subsequent to September 30, 2018 but prior to the IPO, the Company used a hybrid method, which is a hybrid between the OPM and the probability-weighted expected return method (&#x201c;PWERM&#x201d;). The hybrid method is a combination of the PWERM and OPM. The OPM allocates the overall Company value to the various share classes based on differences in liquidation preferences, participation rights, dividend policy and conversion rights, using a series of call options. The call right is valued using a Black-Scholes option pricing model. The PWERM employs additional information not used in the OPM, including various market approach calculations depending upon the likelihood of various discrete future liquidity scenarios, such as an initial public offering or sale of the Company, as well as the probability of remaining a private company. In a hybrid method, various exit scenarios are analyzed. A discount for lack of marketability of the Company&#x2019;s common stock was then applied to arrive at an indication of value for the common stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Contingent Consideration&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Consideration paid related to the Myst Merger Agreement (see&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; Note 7 - Asset Acquisition&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for additional information) may include potential future payments that are contingent upon the Company achieving certain milestones in the future. Contingent consideration liabilities are measured at their estimated fair value as of the date of the unaudited condensed consolidated balance sheets using a probability-based income approach based on the monetary value of the milestone payment discounted for the likelihood of achieving the milestone and a present value factor based on the timing of when the milestone is expected to be achieved. Contingent consideration liabilities expected to be settled within 12 months after the balance sheet date are presented in current liabilities, with the non-current portion recorded under other liabilities, non-current in the unaudited condensed consolidated balance sheets. Changes in the fair value of the contingent consideration are recorded as research and development expenses in the unaudited condensed consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt&#x2014;Debt with Conversion and Other Options &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(Subtopic 470-20) and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Derivatives and Hedging Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(Subtopic 815-40) (&#x201c;ASU 2020-06&#x201d;), which reduces the number of accounting models for convertible debt instruments and convertible preferred stock as well as amends the derivatives scope exception for contracts in an entity&#x2019;s own equity. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_8fb38185-ea26-45ab-b107-b14eace25cd0;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ASU 2020-06&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; is effective for the Company on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January 1, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.  The &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;adoption&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;did not have a material impact&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; on the unaudited condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Reporting &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(Topic 280)&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (&#x201c;ASU 2023-07&#x201d;). ASU 2023-07 requires that an entity disclose significant segment expenses impacting profit and loss that are regularly provided to the chief operating decision maker. The update is required to be applied retrospectively to prior periods presented, based on the significant segment expense categories identified and disclosed in the period of adoption. The amendments in&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ASU 2023-07 are required to be adopted for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the potential impact that this standard may have on its unaudited condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (Topic 740)&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (&#x201c;ASU 2023-09&#x201d;). ASU 2023-09 requires that an entity disclose specific categories in the effective tax rate reconciliation as well as provide additional information for reconciling items that meet a quantitative threshold. Further, ASU 2023-09 requires certain disclosures of state versus federal income tax expense and taxes paid. The amendments in ASU 2023-09 are required to be adopted for fiscal years beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued. The amendments should be applied on a prospective basis although retrospective application is permitted. The Company is currently evaluating the potential impact that this standard may have on its unaudited condensed consolidated &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_e9c90140-7a49-41ac-9960-cbdaee3d32ef">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation of Unaudited Condensed Consolidated Financial Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for interim financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. However, such interim financial statements reflect all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the Company&#x2019;s financial position and results of operations. Results shown for interim periods are not necessarily indicative of the results that may be expected for the year ended December 31, 2024 or for any other period. The condensed consolidated balance sheet as of December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was derived from the audited consolidated financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements, included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on March 22, 2024. Certain prior period amounts reported in the Company&#x2019;s unaudited condensed consolidated financial statements and accompanying notes have been reclassified to conform to the current period presentation. Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_346eb260-23c8-4fd6-84b2-74e649adf6db">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <tsbx:SignificantAccountingPoliciesPolicyPolicyTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_95a09511-6f29-4f59-949e-ce9583cfad76">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The significant accounting policies used in preparation of these unaudited condensed consolidated financial statements are consistent with those discussed in Note 2 to the audited consolidated financial statements included in the Company&#x2019;s Annual Report filed on Form 10-K filed with the SEC on March 22, 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</tsbx:SignificantAccountingPoliciesPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_31a3e1e7-03b6-40de-ae68-cb23595d3820">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The preparation of these unaudited condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to accrued expenses, contingent liabilities, impairment of long-lived assets, revenue recognition, the valuation of equity-based compensation, common stock, restricted common stock, and income taxes. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <tsbx:RestrictedCashAndInvestmentsPolicyPolicyTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_1742f4bc-f41f-4759-a32d-6c0bdc378f4b">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Cash and Investments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted cash consists of certificate of deposit accounts that are pledged as collateral for the Company&#x2019;s San Diego facility lease. Restricted cash was approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024 and December 31, 2023, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company invests its excess cash in investment grade, short-term, fixed income securities and recognizes purchased securities on the settlement date. All investments have been classified as &#x201c;available-for-sale&#x201d; in the unaudited condensed consolidated balance sheets and are carried at estimated fair value based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments at the time of purchase and re-evaluates such designation as of each balance sheet date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company assesses its available-for-sale securities under the available-for-sale security impairment model in ASC Topic 326, Financial Instruments - Credit Losses ("ASC 326") as of each reporting date in order to determine if a portion of any decline in fair value below carrying value is the result of a credit loss. The Company records credit losses in the unaudited condensed consolidated statements of operations and comprehensive loss as credit loss expense, which is limited to the difference between the fair value and the amortized cost of the security. To date, the Company has not recorded any credit losses on its available-for-sale securities. Declines in fair value below carrying value attributable to non-credit related factors are recorded as accumulated other comprehensive loss, which is a separate component of stockholders&#x2019; equity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Realized gains and losses are reported in other income (expense), net. Interest on short-term investments is included in other income (expense), net. The Company&#x2019;s investments are classified as current assets which reflects management&#x2019;s intention to use the proceeds from sales of these securities to fund its operations, as necessary.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</tsbx:RestrictedCashAndInvestmentsPolicyPolicyTextBlock>
    <us-gaap:RestrictedCash
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-5"
      id="F_16f975f0-6013-43d8-9cec-c53cd9dfa8e9"
      unitRef="U_USD">100000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-5"
      id="F_f39017ee-4b87-4fb7-84a8-c354fc3e425e"
      unitRef="U_USD">100000</us-gaap:RestrictedCash>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_9a97a666-0745-470d-afa8-2f863adc7fe2">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, investments and restricted cash. The Company&#x2019;s investment policy restricts cash investments to high credit quality, investment grade investments. The Company&#x2019;s investment policy provides guidelines and limits regarding investment type, concentration, credit quality, and maturity aimed at maintaining sufficient liquidity to satisfy operating and working capital requirements along with strategic initiatives, preserving capital, and minimizing risk of capital loss while generating returns on its investments. The Company is exposed to credit risk in the event of default by the issuer or the institutions holding the cash and cash equivalents to the extent of the amounts recorded on the balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has no off-balance sheet risk, such as foreign exchange contracts, option contracts or other foreign-hedging arrangements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_c4c827b5-57ed-4d9c-85cd-65ddabeb19cc">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the unaudited condensed consolidated financial statements on a recurring basis. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy requires that an entity maximize the use of observable inputs when estimating fair value. The fair value hierarchy includes the following three-level classification which is based on the market observability of the inputs used for estimating the fair value of the assets or liabilities being measured:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Quoted market prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3 &#x2013;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Inputs that are generally unobservable and typically reflect management&#x2019;s estimate of assumptions that a market participant would use in pricing the asset or liability.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized at fair value in the unaudited condensed consolidated financial statements on a recurring basis (at least annually). To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_47b3b454-e22d-438f-9d8c-6b983070f9a2">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounts for stock-based compensation expense related to stock options and restricted stock units, ("RSUs"), by estimating the fair value on the date of grant. The fair value of RSUs granted to employees is the closing price of the Company&#x2019;s common stock on the date of grant. The Company estimates the fair value of stock options granted to employees and non-employees using the Black-Scholes option pricing model. The Company recognizes stock-based compensation expense, over the requisite service period, based on the vesting provisions of the individual grants. Generally, the Company issues stock-based awards with only service-based vesting conditions and records the expense for these awards using the straight-line method. The Company accounts for forfeitures when they occur.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (a) the expected stock price volatility, (b) the expected term of the award, (c) the risk-free interest rate and (d) expected dividend yields. Due to the lack of a public market for the Company&#x2019;s common stock until July 21, 2023, and lack of company- specific historical and implied volatility data, the Company has based its computation of expected volatility on the average historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term. The Company uses the simplified method as prescribed by the U.S. Securities and Exchange Commission Staff Accounting Bulletin No. 107,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Share-Based &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <tsbx:FairValueOfCommonStockPolicyPolicyTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_e1fc98ff-141e-49ce-a327-7e4ddbc75600">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Determination of Fair Value of Common Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;After the Company's IPO in July 2023, the fair value of common stock is determined using the closing price of the Company's common stock on the Nasdaq Global Market. Prior to the IPO, there were significant judgments and estimates inherent in the determination of the fair value of the Company&#x2019;s common stock. These estimates and assumptions include a number of objective and subjective factors, including, among other things, external market conditions, the prices at which the Company sold shares of its convertible preferred stock, the superior rights and preferences of securities senior to its common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale of the Company. The approach to estimating the fair market value of common stock is consistent with the methods outlined in the American Institute of Certified Public Accountants&#x2019; Accounting and Valuation Guide, Valuation of Privately-Held Company Equity Securities Issued as Compensation (the &#x201c;Practice Aid&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In valuing the Company&#x2019;s common stock prior to the IPO, the equity value of the business was determined using the backsolve method, a form of the subject company transaction method, wherein the equity value for a privately held company is derived from a recent transaction in the company&#x2019;s own securities. The value is then allocated using the hybrid method allocation methodology. For grants made subsequent to September 30, 2018 but prior to the IPO, the Company used a hybrid method, which is a hybrid between the OPM and the probability-weighted expected return method (&#x201c;PWERM&#x201d;). The hybrid method is a combination of the PWERM and OPM. The OPM allocates the overall Company value to the various share classes based on differences in liquidation preferences, participation rights, dividend policy and conversion rights, using a series of call options. The call right is valued using a Black-Scholes option pricing model. The PWERM employs additional information not used in the OPM, including various market approach calculations depending upon the likelihood of various discrete future liquidity scenarios, such as an initial public offering or sale of the Company, as well as the probability of remaining a private company. In a hybrid method, various exit scenarios are analyzed. A discount for lack of marketability of the Company&#x2019;s common stock was then applied to arrive at an indication of value for the common stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</tsbx:FairValueOfCommonStockPolicyPolicyTextBlock>
    <tsbx:ContingentConsiderationPolicyPolicyTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_d4d5f2a5-124c-4982-b720-af8169c1c967">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Contingent Consideration&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Consideration paid related to the Myst Merger Agreement (see&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; Note 7 - Asset Acquisition&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for additional information) may include potential future payments that are contingent upon the Company achieving certain milestones in the future. Contingent consideration liabilities are measured at their estimated fair value as of the date of the unaudited condensed consolidated balance sheets using a probability-based income approach based on the monetary value of the milestone payment discounted for the likelihood of achieving the milestone and a present value factor based on the timing of when the milestone is expected to be achieved. Contingent consideration liabilities expected to be settled within 12 months after the balance sheet date are presented in current liabilities, with the non-current portion recorded under other liabilities, non-current in the unaudited condensed consolidated balance sheets. Changes in the fair value of the contingent consideration are recorded as research and development expenses in the unaudited condensed consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</tsbx:ContingentConsiderationPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_fa6d629f-e9dd-4ddc-8d39-ae3ecc6ad3af">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Debt&#x2014;Debt with Conversion and Other Options &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(Subtopic 470-20) and &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Derivatives and Hedging Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(Subtopic 815-40) (&#x201c;ASU 2020-06&#x201d;), which reduces the number of accounting models for convertible debt instruments and convertible preferred stock as well as amends the derivatives scope exception for contracts in an entity&#x2019;s own equity. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_8fb38185-ea26-45ab-b107-b14eace25cd0;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ASU 2020-06&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; is effective for the Company on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January 1, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.  The &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;adoption&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;did not have a material impact&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; on the unaudited condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      id="F_16745d6e-fc8a-4a28-ad88-7bf896fa0c8c">2024-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      id="F_28168d30-5a3b-459d-9fe9-76cafed5896e">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      id="F_1a900090-c103-49b4-8c6b-8367c18c984f">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <tsbx:RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_533af1a0-eed1-4c54-9d40-d802bf5dce32">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2023, the FASB issued ASU No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Segment Reporting &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(Topic 280)&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (&#x201c;ASU 2023-07&#x201d;). ASU 2023-07 requires that an entity disclose significant segment expenses impacting profit and loss that are regularly provided to the chief operating decision maker. The update is required to be applied retrospectively to prior periods presented, based on the significant segment expense categories identified and disclosed in the period of adoption. The amendments in&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ASU 2023-07 are required to be adopted for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the potential impact that this standard may have on its unaudited condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2023, the FASB issued ASU No. 2023-09,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (Topic 740)&#x2014;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (&#x201c;ASU 2023-09&#x201d;). ASU 2023-09 requires that an entity disclose specific categories in the effective tax rate reconciliation as well as provide additional information for reconciling items that meet a quantitative threshold. Further, ASU 2023-09 requires certain disclosures of state versus federal income tax expense and taxes paid. The amendments in ASU 2023-09 are required to be adopted for fiscal years beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued. The amendments should be applied on a prospective basis although retrospective application is permitted. The Company is currently evaluating the potential impact that this standard may have on its unaudited condensed consolidated &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;</tsbx:RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_ef8823b8-299e-44f7-9976-a6887f0d9ecd">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3. Fair Value of Financial Assets and Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of June 30, 2024 and December 31, 2023, the Company&#x2019;s highly liquid money market funds included within cash equivalents, restricted cash and U.S. treasury securities are valued using Level 1 inputs. The Company classifies its federal agency securities as Level 2. There were no transfers in or out of Level 1 and Level 2 during the periods presented. U.S. treasury securities are bonds issued by the U.S. government and are fully backed by the U.S. government. Given the frequency at which U.S. treasury securities trade and the accessibility of observable, quoted prices for such assets in active markets, they are recognized as Level 1 assets. Federal agency securities are bonds and notes issued by government-sponsored enterprises, including Fannie Mae, Freddie Mac and the Federal Home Loan Bank. Since Federal agency securities typically do not trade as frequently as U.S. government agency securities and no exchange exists to price such investments, they are recognized as Level 2 assets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company had $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in contingent consideration liabilities as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024 and December 31, 2023, respectively, related to the Myst Merger Agreement. The contingent consideration balances are comprised of one potential milestone payment and is measured at fair value (see&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; Note 7&#x2014;Asset Acquisition&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; for additional information). The fair value of the contingent consideration is estimated based on the monetary value of the milestone discounted for the likelihood of achieving the milestone and a present value factor based on the timing of when the milestone is expected to be achieved. The value for the contingent consideration balance is based on significant inputs not observable in the market which represents a Level 3 measurement within the fair value hierarchy. There were no transfers in or out of Level 3 during the periods presented.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables represent a summary of the financial assets and liabilities that are measured on a recurring basis at fair value &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.949%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.081%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.049%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.081%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.866999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.081%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.866999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.081%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.866999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.081%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Financial liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92,730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92,730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Financial liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted cash serves as deposits for the Company&#x2019;s San Diego office lease. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;(2)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;Included in short-term investments on the unaudited condensed consolidated balance sheets and are classified as available-for sale debt securities. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;(3)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;Contingent consideration related to the Myst Merger Agreement. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following significant unobservable inputs were used in the valuation of the contingent consideration payable to the sole common stockholder of Myst Therapeutics, Inc. ("Myst") pursuant to the Myst Merger Agreement:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:29.174%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.077%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.816%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.956%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.597%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value as of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Contingent Consideration Liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Valuation Technique&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unobservable Input&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;'Milestone payment for first registrational study (see Note 7 - Asset Acquisition for additional information)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Discounted cash flow&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Likelihood of occurrence&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value as of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Contingent Consideration Liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Valuation Technique&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unobservable Input&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;'Milestone payment for first registrational study (see Note 7 - Asset Acquisition for additional information)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Discounted cash flow&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Likelihood of occurrence&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table reflects the activity for the Company&#x2019;s contingent consideration, measured at fair value using Level 3 inputs (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;in thousands&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.876%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.104%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contingent consideration at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Changes in the fair value of contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contingent consideration at June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables show the Company&#x2019;s cash, cash equivalents and available-for-sale securities by significant investment category &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.761%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 1:  Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52,262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Classified as:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.761%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 1:  Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92,730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Classified as:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92,730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of June 30, 2024, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of our available-for-sale debt securities were in a gross unrealized loss position of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million with an aggregate fair value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. As of December 31, 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ne out of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of our available-for-sale debt securities were in a gross unrealized loss position.  While short-term investments are available-for-sale, it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be maturity. All short-term investments currently held have maturities of less than one year.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company reviews short-term investments for impairment during each reporting period. Credit losses are recognized up to the amount equal to the difference between the fair value and the amortized cost basis and recorded as an allowance for credit losses in the unaudited condensed consolidated balance sheets with a corresponding adjustment to earnings. Unrealized losses that are not related to credit losses are recognized in accumulated other comprehensive loss. Unrealized losses were not significant for the investments held in the Company&#x2019;s portfolio as of June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and Company considered the decline in market value for these securities to be primarily attributable to economic and market conditions rather than credit-related factors. There were no unrealized losses in the Company's investment portfolio at December 31, 2023. The Company considered the risk-profile of the counterparties under ASC 326, noting that any credit risk associated with such entities is either zero or near zero. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; impairment losses or expected credit losses related to its &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_d519c220-b9c0-4efc-ae00-16610eda5851;"&gt;&lt;span style="-sec-ix-hidden:F_07c37049-61be-45e2-82d2-712a7c000aaa;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;short-term investments&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three and six months ended June 30, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_6289f1e6-72be-4ab1-8d3b-4951b6ae47d2"
      decimals="-5"
      id="F_ecbc3911-dd1c-4478-80e4-8136c0a2a006"
      unitRef="U_USD">1000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_cad3a30c-8bbd-41b5-8824-b6ed0ebc07b6"
      decimals="-5"
      id="F_2668d8b8-ae1f-4bdd-8617-4a6a917e64f7"
      unitRef="U_USD">900000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_dd290469-1025-4a1d-8127-913f62233d80">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables represent a summary of the financial assets and liabilities that are measured on a recurring basis at fair value &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.949%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.081%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.049%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.081%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.866999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.081%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.866999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.081%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.866999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.081%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Financial liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Financial assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;U.S. government securities&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92,730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92,730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Financial liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:4pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;Restricted cash serves as deposits for the Company&#x2019;s San Diego office lease. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;(2)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;Included in short-term investments on the unaudited condensed consolidated balance sheets and are classified as available-for sale debt securities. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;"&gt;(3)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"&gt;Contingent consideration related to the Myst Merger Agreement. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_b8a7d77b-acc4-44c2-a6eb-53af2968c508"
      decimals="-3"
      id="F_b9a3ad4a-c917-450c-815d-67c3052f4cb6"
      unitRef="U_USD">7125000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_314b4149-fadb-4ae4-82c4-63f56b1c9d19"
      decimals="-3"
      id="F_5398e9bd-ebea-4b3e-8fe6-0ad928412172"
      unitRef="U_USD">7125000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <tsbx:RestrictedCashAndCashEquivalentsAtFairValue
      contextRef="C_b8a7d77b-acc4-44c2-a6eb-53af2968c508"
      decimals="-3"
      id="F_fb913b95-47d2-4a61-b5c8-d28e9a3a78a8"
      unitRef="U_USD">116000</tsbx:RestrictedCashAndCashEquivalentsAtFairValue>
    <tsbx:RestrictedCashAndCashEquivalentsAtFairValue
      contextRef="C_314b4149-fadb-4ae4-82c4-63f56b1c9d19"
      decimals="-3"
      id="F_bc0eccb3-9981-4372-980a-7fe054f55e94"
      unitRef="U_USD">116000</tsbx:RestrictedCashAndCashEquivalentsAtFairValue>
    <us-gaap:FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue
      contextRef="C_b8a7d77b-acc4-44c2-a6eb-53af2968c508"
      decimals="-3"
      id="F_0a65ea20-477a-40c6-8b71-df561b661c44"
      unitRef="U_USD">44997000</us-gaap:FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue>
    <us-gaap:FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue
      contextRef="C_314b4149-fadb-4ae4-82c4-63f56b1c9d19"
      decimals="-3"
      id="F_b7776a91-7c82-4933-aa9e-c2480d02b0e7"
      unitRef="U_USD">44997000</us-gaap:FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b8a7d77b-acc4-44c2-a6eb-53af2968c508"
      decimals="-3"
      id="F_fc597c90-c797-473a-afe9-4432112229c0"
      unitRef="U_USD">52238000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_314b4149-fadb-4ae4-82c4-63f56b1c9d19"
      decimals="-3"
      id="F_848a80da-b88d-47b4-9d8f-9516e90f59a7"
      unitRef="U_USD">52238000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_0efb3de3-c750-4eb6-95f7-ff7400831d2b"
      decimals="-3"
      id="F_d06a94b7-2062-4c83-a6bb-fdee014c458b"
      unitRef="U_USD">1024000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_5edf160a-0dd5-4113-b0b6-1b907d836f1c"
      decimals="-3"
      id="F_45f132ba-51ff-4191-b447-87891be4845e"
      unitRef="U_USD">1024000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_5e3f8af4-ced0-4d18-92e3-8a9b5f41b2fa"
      decimals="-3"
      id="F_a9109401-e6a3-4f44-a235-dc2e8a053beb"
      unitRef="U_USD">1024000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_314b4149-fadb-4ae4-82c4-63f56b1c9d19"
      decimals="-3"
      id="F_630ee3c2-fa90-4e49-8f19-61078cca7904"
      unitRef="U_USD">1024000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_ac923606-471a-43f0-8bdf-735ab3fdfba1"
      decimals="-3"
      id="F_b1146070-8305-4867-b0a3-3d833381321d"
      unitRef="U_USD">15635000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_62731d6b-0b8e-473a-8756-77f4fdd3789c"
      decimals="-3"
      id="F_3f1bded4-f862-4876-9cde-b29531d88d0f"
      unitRef="U_USD">15635000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <tsbx:RestrictedCashAndCashEquivalentsAtFairValue
      contextRef="C_ac923606-471a-43f0-8bdf-735ab3fdfba1"
      decimals="-3"
      id="F_8b890de6-aa39-45b5-be06-0b65a799a78b"
      unitRef="U_USD">116000</tsbx:RestrictedCashAndCashEquivalentsAtFairValue>
    <tsbx:RestrictedCashAndCashEquivalentsAtFairValue
      contextRef="C_62731d6b-0b8e-473a-8756-77f4fdd3789c"
      decimals="-3"
      id="F_3a9d075b-7e31-4515-b879-101c8634b8c8"
      unitRef="U_USD">116000</tsbx:RestrictedCashAndCashEquivalentsAtFairValue>
    <us-gaap:FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue
      contextRef="C_ac923606-471a-43f0-8bdf-735ab3fdfba1"
      decimals="-3"
      id="F_fef79922-149c-4db4-948b-b6758db54cac"
      unitRef="U_USD">76979000</us-gaap:FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue>
    <us-gaap:FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue
      contextRef="C_62731d6b-0b8e-473a-8756-77f4fdd3789c"
      decimals="-3"
      id="F_44474980-73c3-427f-b7fd-1dd6465464b8"
      unitRef="U_USD">76979000</us-gaap:FinancialInstrumentsOwnedUSGovernmentAndAgencyObligationsAtFairValue>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ac923606-471a-43f0-8bdf-735ab3fdfba1"
      decimals="-3"
      id="F_8d702a3c-f24e-4753-bb90-bdbb3408ac6e"
      unitRef="U_USD">92730000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_62731d6b-0b8e-473a-8756-77f4fdd3789c"
      decimals="-3"
      id="F_251c82cd-2d83-49cb-ac18-9100e506335f"
      unitRef="U_USD">92730000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_a11683c6-5fef-4195-864f-a7d508bdc2d2"
      decimals="-3"
      id="F_6897a6c7-0c7e-498f-9432-7d407d8553ec"
      unitRef="U_USD">916000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_f29d5b9e-4d61-4151-a985-c2091e0f2865"
      decimals="-3"
      id="F_c23f96c7-2ae6-4bb4-a775-8c7c869c6702"
      unitRef="U_USD">916000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_29034bc0-6cf8-44cc-9ed1-c738ea64dd3b"
      decimals="-3"
      id="F_2de0b87a-55b2-4db4-aaa3-e7694ad19b2e"
      unitRef="U_USD">916000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_62731d6b-0b8e-473a-8756-77f4fdd3789c"
      decimals="-3"
      id="F_ed05d301-fb71-490e-9a5d-12dabd1adcf0"
      unitRef="U_USD">916000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_e41ea288-0f1f-42ab-bb9b-b05b689d136d">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following significant unobservable inputs were used in the valuation of the contingent consideration payable to the sole common stockholder of Myst Therapeutics, Inc. ("Myst") pursuant to the Myst Merger Agreement:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:29.174%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.077%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.816%;"&gt;&lt;/td&gt;
        &lt;td style="width:19.956%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.38%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.597%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value as of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Contingent Consideration Liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Valuation Technique&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unobservable Input&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;'Milestone payment for first registrational study (see Note 7 - Asset Acquisition for additional information)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Discounted cash flow&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Likelihood of occurrence&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair Value as of&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Contingent Consideration Liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Valuation Technique&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Unobservable Input&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:top;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;'Milestone payment for first registrational study (see Note 7 - Asset Acquisition for additional information)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Discounted cash flow&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Likelihood of occurrence&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:middle;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_09ae6d90-7a9b-443b-bc02-068850b13217"
      decimals="-3"
      id="F_43cd3d9d-035c-4c26-84c1-f18fd818a4f8"
      unitRef="U_USD">1024000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_07beddb2-5e8d-4fd2-a982-9c19bd8f1784"
      decimals="0"
      id="F_208d3a56-2f71-4652-bc03-a2920db7054c"
      unitRef="U_pure">10</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_2b4f6127-8d59-412e-b50f-15f6bca69e60"
      decimals="0"
      id="F_8e575ca2-2c0d-40f1-a14d-baa2c6164f4f"
      unitRef="U_pure">25</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_f13a602c-d40d-43cb-af5a-1b863d53488c"
      decimals="1"
      id="F_160853f9-bf71-49dd-908a-6890909ae23e"
      unitRef="U_Y">3</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_86fd67e3-caa9-4cfa-8107-a69bd2da8aa7"
      decimals="-3"
      id="F_29e460a6-fb0e-4139-874f-6d7eb1b5a371"
      unitRef="U_USD">916000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_cada1dd4-e094-4155-bd2f-9d9d53838f8b"
      decimals="0"
      id="F_f400f6df-8323-4578-a703-90fe686f2249"
      unitRef="U_pure">10</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_611eb55b-b1d8-48ea-b1bf-f13c75cd2c4f"
      decimals="0"
      id="F_19b7ec98-c26c-4e2c-b167-ef80bd11c4de"
      unitRef="U_pure">25</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_686637a7-6c9d-4004-a3a1-f62abb9c5a0b"
      decimals="1"
      id="F_4ee69752-32f2-419b-b3bf-e3ab5d794e9c"
      unitRef="U_Y">3.5</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_a84abb79-1974-4944-80dc-f4bb79ed171c">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table reflects the activity for the Company&#x2019;s contingent consideration, measured at fair value using Level 3 inputs (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;in thousands&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.876%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.104%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contingent consideration at December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Changes in the fair value of contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;108&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Contingent consideration at June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:top;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_86fd67e3-caa9-4cfa-8107-a69bd2da8aa7"
      decimals="-3"
      id="F_fa8b9342-a0d7-4b59-9feb-200ee05ef54f"
      unitRef="U_USD">916000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_08eea265-04df-4ba5-a0a1-6754a009edac"
      decimals="-3"
      id="F_cb79e74f-b46a-4c28-9244-bce3e274db19"
      unitRef="U_USD">108000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_09ae6d90-7a9b-443b-bc02-068850b13217"
      decimals="-3"
      id="F_99c1e2c8-8638-46d2-a3c1-3c22281c2295"
      unitRef="U_USD">1024000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <tsbx:CompanyCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryTableTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_f657948c-f9c6-452f-b839-bdf4c4b3a68d">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following tables show the Company&#x2019;s cash, cash equivalents and available-for-sale securities by significant investment category &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.761%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 1:  Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;45,021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52,262&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Classified as:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;52,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.761%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.121%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.189%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Level 1:  Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;U.S. government securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92,730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Classified as:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;76,979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92,730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</tsbx:CompanyCashCashEquivalentsAndAvailableForSaleSecuritiesBySignificantInvestmentCategoryTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a282ba00-b430-4f99-a7fb-75b6613249a7"
      decimals="-3"
      id="F_3ba74156-28e3-4cae-9016-5c0b2357dd9c"
      unitRef="U_USD">7125000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a282ba00-b430-4f99-a7fb-75b6613249a7"
      decimals="-3"
      id="F_b9c2adcd-1ff2-4ded-81b3-74c2a82c0f11"
      unitRef="U_USD">7125000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a4224032-80db-4207-a62f-06fddc1f3e8d"
      decimals="-3"
      id="F_8a550a4e-f190-4b61-b877-2145af513f39"
      unitRef="U_USD">116000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a4224032-80db-4207-a62f-06fddc1f3e8d"
      decimals="-3"
      id="F_9ee0feae-de47-4db7-abbd-75ee3b30b2f4"
      unitRef="U_USD">116000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_598b88c4-d183-499c-84b9-3e796e6520bc"
      decimals="-3"
      id="F_c6d08bb7-ba5e-4048-9bb0-a2b13665ca4f"
      unitRef="U_USD">45021000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_21d1e869-620d-4a35-abc4-05dbceb24181"
      decimals="-3"
      id="F_58813075-d4f7-4a4c-b937-a622b9a42801"
      unitRef="U_USD">24000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_598b88c4-d183-499c-84b9-3e796e6520bc"
      decimals="-3"
      id="F_180841d0-b158-4b70-8b51-f714eac925db"
      unitRef="U_USD">44997000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_be3b1095-e3af-4cf4-b48a-e0b02015a93f"
      unitRef="U_USD">52262000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_124609e1-aaea-488b-a5b0-d4225445529a"
      unitRef="U_USD">24000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_2d88ce83-7b9f-4e54-b890-e2a98bad533f"
      unitRef="U_USD">52238000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9e6ce855-a23c-4318-9cf7-7b65d716e1a5"
      decimals="-3"
      id="F_4d180956-226a-4982-bcae-59bdf833c6a7"
      unitRef="U_USD">7125000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3ffd6a05-a9be-4e07-b29c-81b2bc74d344"
      decimals="-3"
      id="F_ebe21b98-5049-4c97-b7c7-f9f7689352d7"
      unitRef="U_USD">116000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_31b4b1f9-e730-4c51-a000-a2794909b7b3"
      decimals="-3"
      id="F_2fa92296-f6b4-4d80-9ee0-3929804fc422"
      unitRef="U_USD">44997000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_e8f4e804-c2d8-482e-bbbd-91292373f7bc"
      unitRef="U_USD">52238000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_5cf56eca-80aa-4857-a57f-478d4c936a9b"
      decimals="-3"
      id="F_98dfc62f-2201-4865-a945-edfdb05a8b7b"
      unitRef="U_USD">15635000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5cf56eca-80aa-4857-a57f-478d4c936a9b"
      decimals="-3"
      id="F_59211168-46df-47db-90d8-32f6f47b7fb7"
      unitRef="U_USD">15635000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_83c6962e-9c53-4e63-b1ff-31ca5d0d2f3b"
      decimals="-3"
      id="F_3fa66e03-08e6-4cb9-89f0-c1195b0d0de5"
      unitRef="U_USD">116000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_83c6962e-9c53-4e63-b1ff-31ca5d0d2f3b"
      decimals="-3"
      id="F_cf3a4c4d-f01d-4eeb-9f6f-58fbe7b6756e"
      unitRef="U_USD">116000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9800e42c-8612-4c53-9cab-3c07fc9a6fbb"
      decimals="-3"
      id="F_cf7e7b26-2e0a-4f3b-aed4-a3fe4b680df6"
      unitRef="U_USD">76875000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_b6c3ec3d-2d98-49dd-9189-5cbaccf94ce2"
      decimals="-3"
      id="F_40f5fa14-d77b-49f2-969e-91bbd61ea377"
      unitRef="U_USD">104000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9800e42c-8612-4c53-9cab-3c07fc9a6fbb"
      decimals="-3"
      id="F_4b05cdd4-42c7-46ed-a5e3-2de56c465b43"
      unitRef="U_USD">76979000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_af03debc-66dc-4ec3-97a2-d677485c82a7"
      unitRef="U_USD">92626000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain
      contextRef="C_c2fc5443-940d-4d73-8fd5-8bcdd4605301"
      decimals="-3"
      id="F_1763a897-e8cf-40be-938c-34dea866b5e0"
      unitRef="U_USD">104000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedGain>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_a2dd7f3e-ff79-453e-b263-6bcfa4daa727"
      unitRef="U_USD">92730000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_396a19e8-3bfd-4308-a62d-934e7ca98d70"
      decimals="-3"
      id="F_f8cd495d-5daf-41ee-9621-4c973e99ab9b"
      unitRef="U_USD">15635000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_87edcac5-f97d-43c3-9877-1d9fda334fd6"
      decimals="-3"
      id="F_dbb9b01c-daf2-45b4-b7cd-3967ce3d0cf1"
      unitRef="U_USD">116000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3bc9ea85-cac7-4114-b7e4-68f51d5ac95c"
      decimals="-3"
      id="F_0770f514-b46d-4868-be55-61ce8d219419"
      unitRef="U_USD">76979000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_401c78ed-623b-47bf-9b6a-67564c49d620"
      unitRef="U_USD">92730000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="C_018d9f0a-f1a9-461c-a05d-3b501d8ad8bd"
      decimals="INF"
      id="F_056648d2-5eca-46a2-bd8e-b337fe2b8c1f"
      unitRef="U_Security">16</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="C_8a2c0799-2ad0-4d20-8a89-44e9c7d5025f"
      decimals="INF"
      id="F_05b97161-46e6-4863-a9c0-19aeb89466d0"
      unitRef="U_Security">18</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-5"
      id="F_8477beb2-4f2f-4047-978f-b9d9836ea905"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-5"
      id="F_e884b932-de1e-4b84-9257-5fd2639cd776"
      unitRef="U_USD">42000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="C_cb7e98d1-0ba9-403c-aa73-cc10851ec0f9"
      decimals="INF"
      id="F_cc540191-952a-4e67-804e-29569e1405b7"
      unitRef="U_Security">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="C_77f8cd0f-f6c2-4b41-b3a2-ad645efbb34e"
      decimals="INF"
      id="F_536f52ac-cd96-49b3-9800-65ca2aed35c1"
      unitRef="U_Security">28</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8"
      decimals="-3"
      id="F_af07c246-1a11-4b4e-8b5c-044cd05ffd37"
      unitRef="U_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_ea38e877-c27a-4e85-ad06-f17f05ce714f"
      unitRef="U_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b"
      decimals="-3"
      id="F_9862b0ba-1445-44b4-bea7-631c78de3181"
      unitRef="U_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_f12f34b3-eced-4bda-95a4-a769d34ce828"
      unitRef="U_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_5c395c24-636e-4050-a531-ac81f1c3b830">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;4. Property and Equipment, Net&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment, net consist of the following (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;in thousands&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;690&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;690&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment depreciation and amortization expense for the three months ended June 30, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively and the six months ended June 30, 2024 and 2023, was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_24c3f55d-f8c0-400e-81c8-e10fadfe2455">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Property and equipment, net consist of the following (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;in thousands&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Furniture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;690&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;690&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,541&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,689&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_b1a88eba-10f5-4670-94c7-f775a961f4b8"
      unitRef="U_USD">11112000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_3523f446-fb47-4cbb-b215-0bc1d9a83a81"
      unitRef="U_USD">11043000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_b88ae029-8a2a-41d6-811b-8b575cf69a17"
      unitRef="U_USD">690000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_c2c730dc-d312-4724-9def-1b7d82edd5b9"
      unitRef="U_USD">690000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_3d31dadd-2771-4a71-ae60-cae2a0b13e7d"
      unitRef="U_USD">1308000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_475c8aeb-b994-4324-95cb-b1322e33e8c2"
      unitRef="U_USD">1308000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_7398402d-3815-4559-a1b1-837baa16aaab"
      unitRef="U_USD">13110000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_ad3d5de5-96ad-43cb-8130-c40519a47f16"
      unitRef="U_USD">13041000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_3668c102-def6-4215-a4fb-b8fe7d93a273"
      unitRef="U_USD">7541000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_34cbe711-11ea-41f6-b441-7e11b1dd2b70"
      unitRef="U_USD">6689000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_1d4d411f-da8b-49c2-afdd-13a6d5eda6bc"
      unitRef="U_USD">5569000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_ede64720-ba62-418c-b918-37f99c7a4e44"
      unitRef="U_USD">6352000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8"
      decimals="-5"
      id="F_aa5904af-41e9-4912-ba4b-ef3a3faceea0"
      unitRef="U_USD">500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b"
      decimals="-5"
      id="F_22f8c689-b631-4ca1-aa9a-debbe4bb644f"
      unitRef="U_USD">700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-5"
      id="F_f5939ceb-4d17-4f44-823e-859d095823e0"
      unitRef="U_USD">1000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-5"
      id="F_4bfebcde-585f-4b86-9d19-94a1c75fb0f0"
      unitRef="U_USD">1400000</us-gaap:DepreciationDepletionAndAmortization>
    <tsbx:DisclosureOfAccruedExpensesAndOtherCurrentLiabilitiesTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_eb72bba7-22d1-407a-879c-58e70a93012c">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;5. Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consist of the following &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Professional and consulting expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,593&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</tsbx:DisclosureOfAccruedExpensesAndOtherCurrentLiabilitiesTextBlock>
    <tsbx:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_7678a9f4-cbde-4b8a-8ddc-224b624ee0c4">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accrued expenses and other current liabilities consist of the following &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;(in thousands):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.92%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Professional and consulting expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;641&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,336&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,593&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</tsbx:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock>
    <tsbx:ResearchAndDevelopmentExpenseLiabilities
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_7dc8e4a5-2a26-4fdf-88bc-abbe82f16765"
      unitRef="U_USD">9187000</tsbx:ResearchAndDevelopmentExpenseLiabilities>
    <tsbx:ResearchAndDevelopmentExpenseLiabilities
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_ab5daea9-268c-4764-bb9d-7c5b6f5c9684"
      unitRef="U_USD">5675000</tsbx:ResearchAndDevelopmentExpenseLiabilities>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_ccdf0e04-235c-488f-9ae0-0138db7a7989"
      unitRef="U_USD">753000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_27f97d25-8c4e-416b-9c24-0ea17add59e9"
      unitRef="U_USD">641000</us-gaap:AccruedProfessionalFeesCurrent>
    <tsbx:AccruedCompensationCurrent
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_8b2f8c4d-e631-455a-8c2a-7a7984f2e4e1"
      unitRef="U_USD">2336000</tsbx:AccruedCompensationCurrent>
    <tsbx:AccruedCompensationCurrent
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_979a62c5-bda4-4cfa-9a3f-79ba2e2bdd94"
      unitRef="U_USD">3593000</tsbx:AccruedCompensationCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_24488d78-65bc-4b13-92f0-456bee6c2556"
      unitRef="U_USD">78000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_94843045-f06a-41a5-a417-9481806deacf"
      unitRef="U_USD">12354000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_ebb2857e-5205-4396-b227-f47dbf230116"
      unitRef="U_USD">9909000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_aca71098-9849-40e4-9779-95d578cd1cfe">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;6. Agreements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Takeda Pharmaceutical Company Limited&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Collaboration Agreement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In November 2019, the Company entered into a discovery, collaboration and license agreement (&#x201c;Takeda Agreement&#x201d;) with Millennium Pharmaceuticals, Inc. (also known as Takeda Oncology), a wholly owned subsidiary of Takeda Pharmaceutical Company Limited ("Takeda"). Under the Takeda Agreement, the Company agreed to collaborate with Takeda to co-develop and co-commercialize TBio-6517 (also known as RIVAL-01) (&#x201c;Development Program&#x201d;) and to conduct discovery programs to identify additional novel product candidates based on its vaccinia virus platform for independent development (&#x201c;Discovery Program&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the Takeda Agreement, the Company granted Takeda and its affiliates a worldwide, irrevocable, non-transferable, co-exclusive, sublicensable license under certain of the Company&#x2019;s know-how and patent rights (&#x201c;Turnstone Technology&#x201d;) to make, use, sell, offer for sale, develop, manufacture, and commercialize, or otherwise exploit TBio-6517 (&#x201c;Licensed Compound&#x201d;) and products containing TBio-6517 (&#x201c;Takeda Licensed Products&#x201d;) in all fields. Takeda granted the Company and the Company&#x2019;s affiliates an irrevocable, non-transferable, non-exclusive, sublicensable license under certain know-how and patent rights of Takeda (&#x201c;Takeda Technology&#x201d;) to make, use, sell, offer for sale, develop, manufacture, and commercialize, or otherwise exploit the Licensed Compound and Takeda Licensed Products in all fields in accordance with joint development, commercialization, and medical affairs plans under the Takeda Agreement. Under the Takeda Agreement, the Company also granted to Takeda and its affiliates a worldwide, non-transferable, non-exclusive, sublicensable license under Turnstone Technology to conduct joint discovery and research activities in all fields in accordance with joint research and discovery plans. Under the Takeda Agreement, Takeda granted the Company a license to Takeda Technology to conduct discovery and research activities in all fields in accordance with joint research and discovery plans. The Company also granted to Takeda and its affiliates an exclusive option to obtain a worldwide, irrevocable, non-transferable, exclusive, sublicensable license under Turnstone Technology to make, use, sell, offer for sale, develop, manufacture, and commercialize, or otherwise exploit (i) selected discovery virus candidates generated and evaluated by the parties under a joint discovery program (&#x201c;Selected Discovery Candidates&#x201d;), and (ii) any corresponding licensed products containing a Selected Discovery Candidate (&#x201c;Licensed Discovery Products&#x201d;). Takeda may exercise this option with respect to two virus candidates and within a specified option exercise period. The Company granted Takeda and its affiliates a non-exclusive, perpetual, irrevocable, worldwide, sublicensable and fully paid-up license under certain of the Company&#x2019;s know-how and patents relating to manufacturing improvements developed under the Takeda Agreement solely for use in connection with the manufacture of products that do not comprise or incorporate, and that are not based on, an oncolytic virus. Takeda granted the Company and the Company&#x2019;s affiliates a non-exclusive, perpetual, irrevocable, worldwide, sublicensable and fully paid-up license under certain of Takeda&#x2019;s know-how and patents relating to manufacturing improvements developed under the Takeda Agreement solely for use in connection with the manufacture of any and all products. With respect to discovery virus candidates for which Takeda does not exercise its option, Takeda granted the Company a non-exclusive, perpetual, worldwide, sublicensable and royalty-bearing license under certain of its know-how and patents that is necessary or reasonably useful for the exploitation of such declined discovery virus candidates (&#x201c;Declined Candidate License&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Responsibilities for the development of Licensed Compounds and Takeda Licensed Products are delineated pursuant to a joint development plan under the terms of the Takeda Agreement. The Company will be responsible for all activities under the joint development plan prior to completion of a Phase 2a clinical trial and Takeda will be responsible for all activities in the joint development plan upon and after completion of the Phase 2a clinical trial. Responsibilities relating to manufacturing, medical affairs, and commercialization of Licensed Compounds and Takeda Licensed Products are delineated pursuant to a manufacturing working plan, joint medical affairs plan and joint commercialization plan, respectively. The Company has the right to reduce or opt-out of its share of responsibilities for costs and expenses of certain development or commercialization activities for the Takeda Licensed Compounds and Takeda Licensed Products. Responsibilities for the discovery and research of Selected Discovery Candidates are delineated pursuant to joint discovery and research plans under the terms of the Takeda Agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the Takeda Agreement, Takeda paid the Company a non-refundable payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in November 2019 and an additional non-refundable payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in April, 2020, for the option to license up to two Selected Discovery Candidates, with additional consideration of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to be paid by Takeda to the Company for each exercise of such option.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the Takeda Agreement, the Company has the right to reduce its share of funding obligations with respect to development activities for the Licensed Compound and Takeda Licensed Products (the &#x201c;Development Opt-Down Right&#x201d;), or to opt-out of all further funding obligations with respect to development activities for the Licensed Compound and Takeda Licensed Products (the &#x201c;Development Opt-Out Right&#x201d;). Unless and until the Company exercises the Development Opt-Down Right, the parties will share evenly in any operating profits or losses with respect to joint development activities, joint medical affairs activities, and joint commercialization activities. If the Company exercises its Development Opt-Down Right, then starting from the effective date of the exercise of the right, Takeda will bear (and be entitled to) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% and the Company will bear (and be entitled to) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of the operating&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;profits &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;or losses with respect to joint development activities, joint medical affairs activities, and joint commercialization activities. Takeda is obligated to pay the Company (i) up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;200.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in aggregate upon achievement of certain clinical and regulatory milestones for the first Takeda Licensed Product to achieve the applicable development milestone event, (ii) up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in aggregate for one-time payments upon achievement of certain sales milestones for each Takeda Licensed Product, (iii) up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;240.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in aggregate (if Takeda exercises both options to Selected Discovery Candidates) upon achievement of certain clinical and regulatory milestones for the first Takeda Licensed Discovery Product to achieve applicable development milestone events, and (iv) up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;300.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in aggregate (if Takeda exercises both options to Selected Discovery Candidates) for one-time payments upon achievement of certain sales milestones for a Licensed Discovery Product. If the Company exercises its Development Opt-Out Right for the Takeda Licensed Products, then in lieu of the profit and loss share arrangement described above, the Company is entitled to receive tiered low- to high- teen percentage royalties on net sales of all Takeda Licensed Products by the Company or the Company&#x2019;s sublicensees during the royalty term, which commences on the first commercial sale of a Takeda Licensed Product in a country and ends on the later of the expiration of all licensed patents covering such Licensed Product in such country or ten years after the date of the first commercial sale in such country (&#x201c;Royalty Term&#x201d;). For Licensed Discovery Products, the Company is entitled to receive tiered high-single digit to low-teen percentage royalties on net sales of all Licensed Discovery Products by the Company or the Company&#x2019;s sublicensees during the Royalty Term. Royalty payments are subject to customary reductions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Takeda has the right to terminate for convenience as follows: (i) prior to the expiration of the option exercise period related to a Discovery Virus Candidate, Takeda may terminate the Takeda Agreement related to such Discovery Virus Candidate and the Discovery Program with 90 days&#x2019; notice, (ii) prior to any commercial sale, Takeda may terminate the Takeda Agreement either in its entirety or on a compound-by-compound or region-by-region basis, with six months&#x2019; notice and (iii) after a commercial sale, Takeda may terminate the Takeda Agreement either in its entirety or on a compound-by-compound or region-by-region basis, with 12 months&#x2019; notice.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Termination of Development Program&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On June 13, 2022, Takeda provided six months&#x2019; written notice to terminate the Development Program in accordance with its termination for convenience rights, with such termination being effective as of December 13, 2022. During the six months&#x2019; notice period, the Company was obligated to continue providing the necessary Development Program services to wind down the program. Upon the effective termination date of December 13, 2022, Takeda&#x2019;s co-exclusive license to TBio-6517 terminated and the Company is no longer obligated to pursue development of TBio-6517.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Termination of Discovery Program&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On January 6, 2023, Takeda provided six months&#x2019; written notice to terminate the remainder of the Takeda Agreement, with such termination being effective as of July 6, 2023 (&#x201c;Effective Termination Date&#x201d;). On the Effective Termination Date, all options and licenses granted under the Takeda Agreement terminated (except for the Declined Candidate License) and Takeda granted the Company a non-exclusive license under the patent rights and know-how controlled by Takeda as of the Effective Termination Date necessary for the Company to exploit the Licensed Compound and Takeda Licensed Products in the form existing as of the Effective Termination Date for any use worldwide, subject to a royalty to be agreed upon by Takeda and the Company. As of March 31, 2023, the Company ceased all work under the Takeda Agreement and there were no remaining estimated services associated with the obligations under the Takeda Agreement as of the effective termination date of July 6, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Accounting Analysis&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company assessed the promised goods and services under the Takeda Agreement in accordance with ASC Topic 606, Revenue from Contracts with Customers ("ASC 606"), and determined that, at inception, the Takeda Agreement includes the following performance obligations: (i) research, development and manufacturing services under the Development Program for the completion of clinical trials through Phase 2a for RIVAL-01 and a co-exclusive license to exploit RIVAL-01 (&#x201c;Development Program Performance Obligation&#x201d;); and (ii) research and development services under the Discovery Program to identify and optimize four Selected Discovery Candidates for further development (&#x201c;Discovery Program Performance Obligation&#x201d;). The individual promises under the Development Program including research, development, manufacturing for clinical trials, and the co-exclusive license to RIVAL-01 are not individually distinct as they represent inputs into a combined output of advancing RIVAL-01 through the Phase 2a clinical trial. Therefore, all promises under the Development Program represent a single performance obligation. Similarly, the research and development services under the Discovery Program represent a single research program aimed at generating four Selected Discovery Candidates and therefore represents a single performance obligation. The Development Program promises are distinct from the promises under the Discovery Program, as the benefits under each program are separately identifiable. Each program has a separate work plan and the promises to be provided under the Development Program do not relate to the promises to be provided under the Discovery Program.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company concluded that Takeda&#x2019;s license options under the Discovery Program do not represent material rights, and therefore are not performance obligations, as the Company is entitled to an additional $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million payment for each license option exercised, which approximates the estimated standalone selling price of the underlying license.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The total transaction price at contract inception is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;158.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, comprised of the following components:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fixed consideration of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;80.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million including a non-refundable up-front payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in November 2019 and another non-refundable payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million that was due on April 1, 2020 and received in April 2020. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Variable consideration related to the expense sharing under the Development Program. These amounts are determinable based on the Development Program plan and budget, and the Company has a contractual right to the payment of costs incurred under the agreed upon plan. Consistent with the expected value method, the Company estimated that it will receive $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million under the expense sharing through the completion of the Phase IIa clinical trial. The Company has concluded that these amounts do not require a constraint and are included in the transaction price at inception. The Company has evaluated this estimate at each reporting date and updated the estimate based on information available. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Variable consideration for the development milestones under the Development Program. The Company uses the most likely amount method to value this variable consideration as there are only two possible outcomes of achieving the individual milestones. Under the Development Program, the first milestone of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million is due upon acceptance of an Investigational New Drug Application  ("IND") by the U.S. Food and Drug Administration ("FDA"). At inception, the Company concluded that achievement of this milestone was highly probable and therefore the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was included in the transaction price and was received in March 2020. The second milestone of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million under the Development Program is due upon the initiation of the first Phase 2 clinical trial for a licensed product. The Company has determined that the most likely amount is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, however, the Company will not include this $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million milestone in the transaction price until it becomes probable that a significant reversal of cumulative revenue will not occur. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Additional consideration to be paid to the Company includes development and sales milestones, profit and loss share, royalties and option exercise payments. These additional payments are achievable only after the completion of the Phase 2a clinical trial under the Development Program or exercise of the license options under the Discovery Program and therefore are excluded from the transaction price. Additionally, Takeda&#x2019;s equity purchase commitments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million are at fair value and therefore no non-cash consideration has been included as a component of the transaction price.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company allocated the transaction price to the separate performance obligations based on their relative standalone selling prices. The Company determined the standalone selling price of the Development Program Performance Obligation based on the costs incurred to develop RIVAL-01 plus the estimated costs to perform the research, development and manufacturing services through the completion of the Phase 2a clinical trial, inclusive of a reasonable profit margin. The Company determined the standalone selling price of the Discovery Program Performance Obligation based on the estimated costs to discover and research four Selected Discovery Candidates, inclusive of a reasonable profit margin. Significant inputs used to determine the standalone selling prices of the performance obligations include the length of time required, the internal hours expected to be incurred on the services, and the amount of third-party expenses that will be incurred to complete the performance obligations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognizes the amounts associated with these performance obligations on a proportional performance basis over the contract term using input-based measurements of total cost of research and development incurred to estimate the proportion performed as compared to the estimated total cost and remeasures its progress towards completion at the end of each reporting period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 31, 2021, the transaction price was updated to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;192.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to reflect an increase in the variable consideration related to the expense sharing under the Development Program from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million at inception to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company determined that the notice of termination on June 13, 2022, represented a modification of the arrangement under ASC 606 and that the transaction price should be updated and re-allocated to the Development Program Performance Obligation and the Discovery Program Performance Obligation based on their standalone selling prices, as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.571%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.429%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.571%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.429%;"&gt;&lt;/td&gt;
        &lt;td style="width:20%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Performance Obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Price Pre-&lt;br/&gt;Modification&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Price at&lt;br/&gt;Modification&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Development Program&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;166.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;million&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;134.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;million&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Discovery Program&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;million&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;million&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;192.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;million&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;155.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;million&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Additionally, the Company updated its measure of progress for each performance obligation as of the modification date and recorded a cumulative adjustment that increased collaboration revenue by $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;on the partially satisfied remaining&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;performance &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;obligations, as the remaining services to be performed under each of the performance obligations are not distinct from the services prior to the modification.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Costs incurred relating to the Takeda Agreement consist of internal and external research and development costs, which primarily include salaries and benefits, lab supplies, and preclinical research studies. All of these costs have been included in research and development expenses in the Company&#x2019;s unaudited condensed consolidated statements of operations and comprehensive loss during the three months ended March 31, 2023 and in prior years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recognized the remaining deferred revenue balance during the three months ended March 31, 2023 as the Company concluded that there were no remaining estimated services to be performed associated with the obligations under the Takeda Agreement. The Company recognized &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_86aca0ff-7597-42fd-ba5f-977c1204204c;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;collaboration revenue&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; related to the Takeda Agreement for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;six months ended June 30, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.  Receivables related to reimbursable costs expected to be received from Takeda for research and development services performed under the Development Program at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024 and December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;H. Lee Moffitt Cancer Center&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Master Collaboration Agreement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In January 2021, the Company entered into an amended and restated master collaboration agreement (the &#x201c;Moffitt Agreement&#x201d;), with Moffitt, to amend a then-existing master collaboration agreement from November 2019, as amended March 2020, between Moffitt and the Company&#x2019;s now wholly-owned subsidiary, Myst, with the intent to continue to work collaboratively in the research of cancer immunotherapies.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Each party granted the other party a right to use its research materials for performance of the research plans agreed to by the parties (the &#x201c;Research Plans&#x201d;). Each party granted the other party a non-exclusive, worldwide, sublicensable, perpetual, irrevocable, royalty-free license under all inventions invented in performance of a Research Plan and invented jointly by the Company and Moffitt (the &#x201c;Joint Inventions&#x201d;) (with certain exclusions) to make, use, sell, offer for sale, import products and services and/or otherwise practice such inventions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company granted Moffitt a royalty free, non-sublicensable, non-transferable, perpetual, non-exclusive license to use and practice certain inventions invented solely by the Company in the performance of a Research Plan for its internal non-commercial research purposes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Moffitt granted the Company (i) a royalty-free, sublicensable, non-transferable, perpetual, non-exclusive license to use and practice certain inventions invented solely by Moffitt in the performance of a Research Plan (&#x201c;Moffitt Inventions&#x201d;), (a) for internal, non-commercial research purposes outside the field of ACT and/or (b) to research, develop, make, use, sell, offer to sell, or import products and/or services in the field of ACT and (ii) a royalty free, sublicensable, non-transferable, perpetual, non-exclusive license to use and practice certain inventions invented in performance of a Research Plan or through the use of specified Moffitt research materials.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Moffitt granted the Company an option to obtain, with terms to be negotiated in good faith under commercially reasonable terms, a royalty-bearing, sublicensable exclusive license in the Moffitt Inventions, the TCR Inventions, and/or Moffitt&#x2019;s interest in Joint Inventions. The Company can exercise this option at any time within six months after Moffitt informs the Company of any new invention, and upon the Company&#x2019;s exercise, the parties will have a period of six months to negotiate the terms of such exclusive license.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Moffitt Agreement will expire upon the later of (i) four years from the effective date of the Moffitt Agreement or (ii) the termination or expiration of all Research Plans in effect under the Moffitt Agreement, unless extended upon mutual written agreement of the parties. Either party may terminate the Moffitt Agreement for cause upon any uncured breach by the other party or upon the insolvency of the other party.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Moffitt Alliance Agreement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2022, the Company entered into a life science alliance agreement with Moffitt (the &#x201c;Alliance Agreement&#x201d;), in order to further expand the Company&#x2019;s relationship and support the Company&#x2019;s existing agreements with Moffitt (the &#x201c;Underlying Agreements&#x201d;). Pursuant to the Alliance Agreement, the Company will have priority access to Moffitt&#x2019;s scientific research, manufacturing, and clinical capabilities for the development of novel TIL therapies, including expedited clinical trial activation, enhanced patient screening and data sharing, access to Moffitt&#x2019;s cellular therapies research and development infrastructure, expanded&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;molecular data sets and biospecimens for research, and allocated cGMP manufacturing capacity for the Company&#x2019;s product candidates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the Alliance Agreement, the Company is obligated to use commercially reasonable efforts to further develop TIL Products, to manufacture TIL Products, to obtain regulatory approval for at least one TIL Product in the United States and to commercialize TIL Products in all countries in which regulatory approval for a TIL Product has been obtained. For purposes of the Alliance Agreement, TIL Product means any pharmaceutical, biopharmaceutical, or biotechnology TIL product that has been developed by us or Moffitt and is advanced into clinical development under an IND sponsored by Moffitt.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Pursuant to the Alliance Agreement, the Company agreed to pay to Moffitt a total amount of at least $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million (the &#x201c;Alliance Funding Amount&#x201d;), for research, development and manufacturing related services that will be paid equally over five years on June 1st of each year starting on June 1, 2023. The Alliance Funding Amount will be calculated annually at the conclusion of each payment period, and, to the extent the Company&#x2019;s annual aggregate payments to Moffitt of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million exceeds the applicable annual installment amount, the Company will receive a reduction in the amount due for future installment payments based on a predetermined formula agreed to by the parties. To the extent the aggregate annual payments are less than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, the Company will prepay the remaining amount due. On June 28, 2024, the Alliance Agreement was amended to remove the true up of the applicable annual installment amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.  The Alliance Funding Amount remains $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million over the five year term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the execution of the Alliance Agreement, the Company issued Moffitt &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91,721&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its common stock. As partial consideration under the Alliance Agreement, the Company also agreed to issue Moffitt an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;366,884&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of its common stock in the aggregate upon the satisfaction of certain clinical and regulatory milestones with respect to TIL Products. The issuances of common stock are treated as performance-based stock awards. On February 27, 2023, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;91,721&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares were issued due to the achievement of the milestone related to the start of the Phase 1 trial. In addition, upon achievement of certain thresholds for aggregate net sales of all TIL Products, the Company is required to make tiered sales-based milestones payments to Moffitt of up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. With respect to each of the equity and sales milestones described above, TIL Products include any pharmaceutical, biopharmaceutical or biotechnology TIL Product that is developed by the Company or Moffitt and is advanced into clinical development under an IND sponsored by Moffitt.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Unless earlier terminated, the Alliance Agreement will remain in effect for a term of five years and may be extended for additional periods upon the mutual written consent of both parties. Either party may terminate the Alliance Agreement in the event of (i) the other party&#x2019;s material breach of the Alliance Agreement that remains uncured after ninety days of receiving written notice of such breach (or in the case of breach of payment obligations, within ten days), (ii) the other party&#x2019;s insolvency and (iii) a pandemic event resulting in government lockdowns or orders that legally compel such party to cease operations or that result in material disruptions in the available workforce and prevents such party from performing its contractual obligations for a period of more than six months. At any time after June 1, 2025, either party may terminate the Alliance Agreement without cause upon sixty days prior written notice to the other party (a &#x201c;Termination for Convenience&#x201d;). Upon a Termination for Convenience, the terminating party shall pay to the other party a termination fee in an amount equal to a low double digit percentage of the then remaining Alliance Funding Amount. Termination or expiry of one or more Underlying Agreements does not affect the term of the Alliance Agreement, which will continue to apply to the remaining ongoing Underlying Agreements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="C_0e39171b-0288-4a90-bd4c-4de866d982ec"
      decimals="-5"
      id="F_70141c81-1f46-4bc7-82ec-ede9861051f8"
      unitRef="U_USD">50000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="C_d347b544-ac7a-4849-8e58-614bec001e25"
      decimals="-5"
      id="F_7d82af3f-b611-488b-b968-baa4a3ccd604"
      unitRef="U_USD">30000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <tsbx:CollaborativeArrangementAdditionalConsiderationReceivable
      contextRef="C_0f2177db-5b60-476f-a730-1c8f81312684"
      decimals="-5"
      id="F_210a9c5a-a0bb-499b-88aa-2dcb98dd7b54"
      unitRef="U_USD">15000000</tsbx:CollaborativeArrangementAdditionalConsiderationReceivable>
    <tsbx:PercentageOfOperatingProfitOrLoss
      contextRef="C_0e39171b-0288-4a90-bd4c-4de866d982ec"
      decimals="2"
      id="F_cc462a8e-9d14-4d73-83f8-8efddc6f9adc"
      unitRef="U_pure">0.70</tsbx:PercentageOfOperatingProfitOrLoss>
    <tsbx:PercentageOfOperatingProfitOrLoss
      contextRef="C_b070210d-0df6-446b-9018-f836d7eb1564"
      decimals="2"
      id="F_4e7c5962-6e4f-462b-b1d3-9e707901d36e"
      unitRef="U_pure">0.30</tsbx:PercentageOfOperatingProfitOrLoss>
    <tsbx:MilestonePaymentReceivable
      contextRef="C_0532a010-4fab-45c5-a50c-f89be68e5dbd"
      decimals="-5"
      id="F_404e2a04-6dbe-49ac-9ef0-981cfc4b004b"
      unitRef="U_USD">200000000</tsbx:MilestonePaymentReceivable>
    <tsbx:MilestonePaymentReceivable
      contextRef="C_7b886516-c4ec-4600-ae2d-8f4f97019128"
      decimals="-5"
      id="F_696ec4e2-ecca-43f1-a562-7a06b2c3e9c1"
      unitRef="U_USD">150000000</tsbx:MilestonePaymentReceivable>
    <tsbx:MilestonePaymentReceivable
      contextRef="C_f4165f52-0752-4cfc-8c7f-a573ebe98155"
      decimals="-5"
      id="F_cadc0e21-bdb0-4b4f-84ce-9ac4513490fe"
      unitRef="U_USD">240000000</tsbx:MilestonePaymentReceivable>
    <tsbx:MilestonePaymentReceivable
      contextRef="C_a963c822-6da7-4671-af23-c5e6b30f3e6b"
      decimals="-5"
      id="F_8ddff85e-e7fd-4afb-ae69-1d0a49673697"
      unitRef="U_USD">300000000</tsbx:MilestonePaymentReceivable>
    <tsbx:CollaborativeArrangementAdditionalConsiderationReceivableForLicensedOption
      contextRef="C_77f50463-e1af-4144-8629-1e583e752cb2"
      decimals="-5"
      id="F_fa0baecd-0a15-46f7-9363-018703f8a30c"
      unitRef="U_USD">15000000</tsbx:CollaborativeArrangementAdditionalConsiderationReceivableForLicensedOption>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_77f50463-e1af-4144-8629-1e583e752cb2"
      decimals="-5"
      id="F_1e3822b9-9971-410d-b7b0-b3722c6bd591"
      unitRef="U_USD">158600000</us-gaap:RevenueRemainingPerformanceObligation>
    <tsbx:RevenuePerformanceObligationFixedAggregateConsideration
      contextRef="C_77f50463-e1af-4144-8629-1e583e752cb2"
      decimals="-5"
      id="F_a41ec8be-9ad8-42ae-a9b4-0ac675b49c58"
      unitRef="U_USD">80000000</tsbx:RevenuePerformanceObligationFixedAggregateConsideration>
    <tsbx:RevenuePerformanceObligationFixedConsiderationNonRefundableUpfrontPaymentReceived
      contextRef="C_8b5fa308-adf1-4661-99fb-c63ef4adc638"
      decimals="-5"
      id="F_6f51cd7c-5ed5-40b9-831c-1e9b522486c5"
      unitRef="U_USD">50000000</tsbx:RevenuePerformanceObligationFixedConsiderationNonRefundableUpfrontPaymentReceived>
    <tsbx:RevenuePerformanceObligationFixedConsiderationNonRefundablePaymentReceived
      contextRef="C_507a33a4-3fb5-40c4-b2ec-c9dcaad76c3a"
      decimals="-5"
      id="F_ad739ac9-de6f-4109-aaec-27b67325ede4"
      unitRef="U_USD">30000000</tsbx:RevenuePerformanceObligationFixedConsiderationNonRefundablePaymentReceived>
    <tsbx:EstimatedCompensationEarningFromProjectExpenseSharing
      contextRef="C_77f50463-e1af-4144-8629-1e583e752cb2"
      decimals="-5"
      id="F_4fe003eb-0d91-4335-8762-4be072fb2f4f"
      unitRef="U_USD">58600000</tsbx:EstimatedCompensationEarningFromProjectExpenseSharing>
    <tsbx:MilestonePaymentReceivable
      contextRef="C_87d12abd-fd41-4556-ab97-906718a6de21"
      decimals="-5"
      id="F_26b5445e-1b0c-4e84-8ee3-46d794cfc11e"
      unitRef="U_USD">20000000</tsbx:MilestonePaymentReceivable>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_87d12abd-fd41-4556-ab97-906718a6de21"
      decimals="-5"
      id="F_1093ca8c-7267-450a-be75-a1765cb92645"
      unitRef="U_USD">20000000</us-gaap:RevenueRemainingPerformanceObligation>
    <tsbx:MilestonePaymentReceivable
      contextRef="C_e1ea96db-9cc4-4129-9e50-4fac54584f5a"
      decimals="-5"
      id="F_6d2e528b-e248-4d56-92a7-3aac956b260f"
      unitRef="U_USD">15000000</tsbx:MilestonePaymentReceivable>
    <tsbx:MilestonePaymentReceivable
      contextRef="C_7d7ff18f-d96f-4bfd-81be-511ab4a4637d"
      decimals="-5"
      id="F_c95be751-c0cf-4a0e-8286-80358956a096"
      unitRef="U_USD">15000000</tsbx:MilestonePaymentReceivable>
    <tsbx:MilestonePaymentReceivable
      contextRef="C_7d7ff18f-d96f-4bfd-81be-511ab4a4637d"
      decimals="-5"
      id="F_441419c3-ddeb-4bec-9da1-611173110ab3"
      unitRef="U_USD">15000000</tsbx:MilestonePaymentReceivable>
    <us-gaap:CommitmentsFairValueDisclosure
      contextRef="C_4e19f9b2-a9f6-479d-8fbf-5061721bee44"
      decimals="-5"
      id="F_2c4ae4c0-4ce5-45d8-9350-ec9c65f63a95"
      unitRef="U_USD">20000000</us-gaap:CommitmentsFairValueDisclosure>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_464ce7dd-76e3-4b22-9015-b1330a849be8"
      decimals="-5"
      id="F_60ce74d6-53b8-46bd-b13c-07dfa47a71d5"
      unitRef="U_USD">192600000</us-gaap:RevenueRemainingPerformanceObligation>
    <tsbx:EstimatedCompensationEarningFromProjectExpenseSharing
      contextRef="C_77f50463-e1af-4144-8629-1e583e752cb2"
      decimals="-5"
      id="F_8e972cb4-5a57-4119-becd-eb73d0660cd5"
      unitRef="U_USD">58600000</tsbx:EstimatedCompensationEarningFromProjectExpenseSharing>
    <tsbx:EstimatedCompensationEarningFromProjectExpenseSharing
      contextRef="C_464ce7dd-76e3-4b22-9015-b1330a849be8"
      decimals="-5"
      id="F_48556180-ca46-46fc-927c-4ff953029862"
      unitRef="U_USD">92600000</tsbx:EstimatedCompensationEarningFromProjectExpenseSharing>
    <tsbx:ScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationTableTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_20d4a678-95aa-4840-9892-715f0dc9abff">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company determined that the notice of termination on June 13, 2022, represented a modification of the arrangement under ASC 606 and that the transaction price should be updated and re-allocated to the Development Program Performance Obligation and the Discovery Program Performance Obligation based on their standalone selling prices, as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.571%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.429%;"&gt;&lt;/td&gt;
        &lt;td style="width:18.571%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.429%;"&gt;&lt;/td&gt;
        &lt;td style="width:20%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Performance Obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Price Pre-&lt;br/&gt;Modification&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Price at&lt;br/&gt;Modification&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Development Program&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;166.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;million&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;134.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;million&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Discovery Program&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;million&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;million&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;192.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;million&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:middle;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;155.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;million&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</tsbx:ScheduleOfTransactionPriceAllocatedToProgramsPerformanceObligationTableTextBlock>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_b49bbb74-b521-4de0-8223-a4c6342ce9da"
      decimals="-5"
      id="F_b9b7d212-aa7f-47c9-95d1-1c89cf5e1b08"
      unitRef="U_USD">166300000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_0acb4150-37ee-4c10-8006-d0790fa8f0f9"
      decimals="-5"
      id="F_f74c2e87-6326-4fbb-bb02-e283cc6dd6c5"
      unitRef="U_USD">134300000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_80bdbeb9-b4a1-45e1-87bb-ef7e5bd3a405"
      decimals="-5"
      id="F_fea76e95-67ff-42c3-ae44-c4701b21f4ff"
      unitRef="U_USD">26300000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_1c334911-8a35-4c3d-9e49-91814e062e98"
      decimals="-5"
      id="F_325344ff-9632-4732-9724-e953f7ae1e77"
      unitRef="U_USD">21200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_c6cfacbc-df8a-46ce-911a-93257d4940af"
      decimals="-5"
      id="F_97c0ba47-96ea-4945-8ea9-222237b0ebdb"
      unitRef="U_USD">192600000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_b5d7d3a5-05a6-4a7d-b86b-89c61ed59b35"
      decimals="-5"
      id="F_1d3e7ee0-1a3f-4325-b7ee-58fa3daa6f35"
      unitRef="U_USD">155500000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:Revenues
      contextRef="C_c9641d36-9a68-4e01-bcd1-21dd6a75222f"
      decimals="-5"
      id="F_8114d2c2-e1c3-4fda-8747-27f4e6b7cae6"
      unitRef="U_USD">31600000</us-gaap:Revenues>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="C_325b972a-88a3-49e4-a865-f3c3e4c449cb"
      decimals="-5"
      id="F_8c7f2c8b-6970-4157-ac2e-44cd8a6460a8"
      unitRef="U_USD">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="C_83258d10-36fd-47d8-8435-ebb348293175"
      decimals="-5"
      id="F_ad7bbd0a-e8e4-4881-8711-ecbd2107d913"
      unitRef="U_USD">19300000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:OtherReceivables
      contextRef="C_0041f20c-fe1a-4d2b-a3bf-ab3dc220fe5a"
      decimals="-5"
      id="F_cfbbbdd5-e84b-4c70-ab61-3e3c5ba52640"
      unitRef="U_USD">0</us-gaap:OtherReceivables>
    <us-gaap:OtherReceivables
      contextRef="C_b3dc0960-b79a-43dc-b52d-544a4f88fb55"
      decimals="-5"
      id="F_2f41f056-54e1-48e4-a6db-074a7730e09c"
      unitRef="U_USD">200000</us-gaap:OtherReceivables>
    <tsbx:CollaborativeArrangementAggregateConsiderationPayable
      contextRef="C_4bae3e9b-125f-4503-8c73-cdcf17ef0bfe"
      decimals="-5"
      id="F_6e0fe5b9-7d01-421c-8051-e591ad69e182"
      unitRef="U_USD">17500000</tsbx:CollaborativeArrangementAggregateConsiderationPayable>
    <tsbx:ResearchDevelopmentAndManufacturingServicesAggregateAnnualAmount
      contextRef="C_971026b7-966d-464b-8792-32c68702fcf6"
      decimals="-5"
      id="F_79ff054d-1e1e-4485-be74-0f9d088f45c6"
      unitRef="U_USD">3500000</tsbx:ResearchDevelopmentAndManufacturingServicesAggregateAnnualAmount>
    <tsbx:ResearchDevelopmentAndManufacturingServicesAggregateAnnualAmount
      contextRef="C_971026b7-966d-464b-8792-32c68702fcf6"
      decimals="-5"
      id="F_e089b1b8-0134-4be6-ba47-309ac2fc745a"
      unitRef="U_USD">3500000</tsbx:ResearchDevelopmentAndManufacturingServicesAggregateAnnualAmount>
    <tsbx:ResearchDevelopmentAndManufacturingServicesAmendedToRemoveTrueUpAnnaulInstallment
      contextRef="C_6b9ab1b4-ace1-409a-beef-b24a105df524"
      decimals="-5"
      id="F_2fe6f06e-d45a-4720-a96e-f44032266526"
      unitRef="U_USD">3500000</tsbx:ResearchDevelopmentAndManufacturingServicesAmendedToRemoveTrueUpAnnaulInstallment>
    <tsbx:CollaborativeArrangementAggregateConsiderationRemains
      contextRef="C_7442ee75-92a9-41e2-98c5-9ab8b76e128f"
      decimals="-5"
      id="F_b1ae6177-138d-4a87-9dcd-5e140c43ad88"
      unitRef="U_USD">17500000</tsbx:CollaborativeArrangementAggregateConsiderationRemains>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_390d4d0c-2d69-4485-b251-e5c588a82858"
      decimals="INF"
      id="F_fbc2eca2-0b9c-4359-adf7-bd6c20992e09"
      unitRef="U_shares">91721</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_dc19bbcb-5619-4e9c-8fd6-1b3767d599b1"
      decimals="INF"
      id="F_da31ebe6-a3f1-473d-88a6-5f472e0f83cb"
      unitRef="U_shares">366884</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_4d3b7a6e-20dc-4532-aa88-976e8d769182"
      decimals="INF"
      id="F_8aba55d7-c1f6-4e09-af04-d82a8888763f"
      unitRef="U_shares">91721</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:OtherCommitment
      contextRef="C_dd6315d5-b691-40c0-8822-66150720e552"
      decimals="-5"
      id="F_65b26bfe-4c9f-43d1-ac5d-6a3d064344ec"
      unitRef="U_USD">50000000</us-gaap:OtherCommitment>
    <us-gaap:AssetAcquisitionTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_c2ef8e23-3454-409f-ab9b-9bc362c4ace3">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;7. Asset Acquisition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2020, the Company entered into the Agreement and Plan of Merger and Reorganization (the &#x201c;Myst Merger Agreement&#x201d;), by and among the Company, Flatiron Merger Sub I, Inc. (&#x201c;Merger Sub&#x201d;), Flatiron Merger Sub II, LLC (&#x201c;Merger LLC&#x201d;), a direct, wholly-owned subsidiary of the Company, Myst, and Timothy Langer, the sole common stockholder of Myst (&#x201c;Langer&#x201d;). Pursuant to the Myst Merger Agreement, the business combination (the &#x201c;Merger&#x201d;) was effected in two steps. The first step was the merger of Merger Sub with and into Myst. The second step was the merger of Myst with and into Merger LLC. The Merger closed on December 14, 2020, and the effective date of the Merger was January 20, 2021. As a result of the Merger, the separate existences of Merger Sub and Myst ceased, and Merger LLC became the Company&#x2019;s wholly-owned subsidiary.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Pursuant to the Myst Merger Agreement, on December 15, 2020, the Company paid the former equity holders of Myst, (the &#x201c;Myst Holders&#x201d;), a one-time up-front payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in cash. The Company paid an additional cash consideration of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million to the Myst Holders on June 14, 2022. The Company also issued Langer up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;725,920&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock. Of these shares, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;362,960&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock were issued upon the closing of the Merger and the remaining &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;362,960&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock were held in escrow with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% vesting in December of each year that Langer remains with the Company. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, Langer is an advisor to the Company and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;272,220&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock have vested and been released from escrow with the remaining &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90,740&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of the Company&#x2019;s common stock to be released at the&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;end &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;of 2024. This restricted equity grant is accounted for as a compensatory arrangement under ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Compensation &#x2014; Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (&#x201c;ASC 718&#x201d;) as continued service is required under the agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition, under the Myst Merger Agreement, each Myst Holder is entitled to receive certain payments as consideration based on the achievement by the Company of three predefined milestones. The initial milestone is the closing of an initial public offering, which occurred on July 25, 2023, the second milestone is the first acceptance by the FDA of an IND filed by, on behalf of or for the benefit of the Company, or the Company&#x2019;s sublicensees for a product being developed by or on behalf of the Company or its sublicensees that is claimed as a product or method of making or using the product by a pending or issued Myst patent claim existing at the time of such acceptance, and the third milestone is the occurrence of the earlier of (i) the commencement of the first registration study for a product being developed by, on behalf of or for the benefit of the Company that is claimed as a product or a method of making or using the product by an issued Myst patent claim existing as of the time of such commencement or (ii) the issuance of a Myst patent claim that claims a product or method of making or using the product then being developed by, on behalf of or for the benefit of the Company, or its sublicensees, that is or was the subject of a registration study that has or had commenced. The milestones are not contingent on one another, and the milestones do not need to be achieved in any specific order.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Within 45 days of the achievement of the initial milestone, which occurred on July 25, 2023, the Company is obligated to pay the Myst Holders an aggregate amount equal to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. At the Company&#x2019;s election, the Company may pay this consideration in cash or in shares of the Company&#x2019;s common stock. Pursuant to a letter agreement dated September 11, 2023 between the Company and the former equityholders of Myst regarding the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million milestone payment that became due and owing to the Myst Holders, the Company agreed to pay $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in cash to the former optionholders of Myst on or before September 30, 2023, with the remaining $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million payable to Langer in shares of the Company&#x2019;s common stock. On September 11, 2023, the Company issued Langer &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;249,992&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Within 45 days of the achievement of the second milestone, the Company is obligated to pay the Myst Holders an aggregate amount equal to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. At the Company&#x2019;s election, the Company may pay this consideration in cash or in shares of the Company&#x2019;s common stock. In May 2022, this $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million milestone was achieved. The Company elected to pay $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in the Company&#x2019;s common stock and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in cash. Pursuant to a letter agreement dated July 25, 2022 between the Company and the former equityholders of Myst regarding the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million milestone payment that became due and owing to the Myst Holders, the Company agreed to pay to the former optionholders of Myst on or before July 28, 2022, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in cash, with the remaining $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million payable to Langer as follows: (i) on or before July 28, 2022, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in cash, (ii) on or before July 31, 2022, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in shares of the Company&#x2019;s common stock and (iii) on or before January 10, 2023, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in cash. On June 8, 2022, the Company issued Langer &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;212,203&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock to settle the $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million obligation payable in common stock. The Company then paid the Myst Holders $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in July 2022, with $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million paid to Langer and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million paid to the remaining Myst Holders, and the remaining $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million was paid to Langer in January 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Within 45 days of the achievement of the third milestone, the Company is obligated to pay the Myst Holders an aggregate amount equal to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. At the Company&#x2019;s election, the Company may pay this consideration in cash or in shares of its common stock.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company accounted for the merger with Myst pursuant to the Myst Merger Agreement as an asset acquisition as substantially all of the value received was concentrated in the acquired in-process research and development of Myst and did not have an alternate future use. The Company recognized a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million charge to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_7a312f44-81d0-4aab-b68e-4d0c368d2aae;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;research and development expense&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; at the time of the completion of the asset acquisition during the year ended December 31, 2020. The Company determined that the milestone payments are separate units of account and accounted for the initial milestone as a derivative in accordance with ASC Topic 815, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (&#x201c;ASC 815&#x201d;)  and the second and third milestones as liabilities in accordance with ASC Topic 480, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (&#x201c;ASC 480&#x201d;). In connection with the initial public offering, the Company reassessed its initial accounting of the milestone payments and concluded that they should be viewed as one unit of account because the milestone payments are not legally detachable from each other. The milestone payments, as one unit of account, would be classified as a liability in accordance with ASC 480 and measured at fair value, with changes in the fair value recorded in earnings. Regardless of whether the milestone payments are viewed as one unit of account or three units of account, because they are all subject to fair value measurement, the financial reporting effect of the contingent consideration arrangement as one unit of account or three units of account is substantially the same. As a liability under ASC 480, the contingent consideration will continue to be recorded at fair value until settled. The adjustment to the fair value of the contingent consideration of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three months ended June 30, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively and was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the six months ended June 30, 2024 and 2023,  respectively, were included in research and development expense in the Company&#x2019;s unaudited condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;</us-gaap:AssetAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="C_a8f26943-f1b9-49c8-b166-c849e9c3a34e"
      decimals="-5"
      id="F_bccae9f7-54fd-4822-9646-7d1782c2236d"
      unitRef="U_USD">9000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="C_10a10b4c-098b-47f2-b0cd-44fdb0c3ed0c"
      decimals="-5"
      id="F_20c63314-d434-4875-972b-d7e05e280a3f"
      unitRef="U_USD">1000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <tsbx:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
      contextRef="C_df3730e6-4b3b-4511-9b22-d73a3cb03c8b"
      decimals="0"
      id="F_b8794415-fede-4ab9-9662-fa5cf67ccb71"
      unitRef="U_shares">725920</tsbx:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares>
    <tsbx:AssetAcquisitionConsiderationTransferredEquityInterestIssuedShares
      contextRef="C_df3730e6-4b3b-4511-9b22-d73a3cb03c8b"
      decimals="0"
      id="F_54601acd-01f2-43e0-81da-132f757442e6"
      unitRef="U_shares">362960</tsbx:AssetAcquisitionConsiderationTransferredEquityInterestIssuedShares>
    <tsbx:AssetAcquisitionConsiderationTransferredEquityInterestIssuableShares
      contextRef="C_df3730e6-4b3b-4511-9b22-d73a3cb03c8b"
      decimals="0"
      id="F_816b4a8c-ff3e-4131-a13f-bbfad0a64b99"
      unitRef="U_shares">362960</tsbx:AssetAcquisitionConsiderationTransferredEquityInterestIssuableShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_fde9996f-abc3-46c0-958f-c7d1eb86e821"
      decimals="2"
      id="F_b177234d-7366-4e07-8373-165154192849"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_5a226ff4-7fbd-4466-ad8e-193443f07e2e"
      decimals="0"
      id="F_78d2a1c9-5724-461a-8be5-1e6aefa164fc"
      unitRef="U_shares">272220</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_bf4bea3d-6d81-4dab-a5e9-0fb7804e121d"
      decimals="0"
      id="F_7ddbbfcc-3f10-4ecf-a5f6-60f0659321ce"
      unitRef="U_shares">90740</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_48fa1a69-511d-4e0c-b236-6692208f9dc3"
      decimals="-5"
      id="F_b94bc050-0b53-4b1f-a8e8-7e4be5602921"
      unitRef="U_USD">3000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <tsbx:ContingentConsiderationPayable
      contextRef="C_ea03660c-6f74-4aa0-a083-02a3316775a5"
      decimals="-5"
      id="F_34332e78-60ff-4c71-9c59-4585360cf79d"
      unitRef="U_USD">3000000</tsbx:ContingentConsiderationPayable>
    <tsbx:ContingentConsiderationPayableByCash
      contextRef="C_9f5bac87-6928-4532-8588-a3d080f1d32d"
      decimals="-5"
      id="F_d021a049-e542-48ae-83a8-2f4263d464da"
      unitRef="U_USD">200000</tsbx:ContingentConsiderationPayableByCash>
    <tsbx:ContingentConsiderationPayableByShares
      contextRef="C_58806346-af8a-4a1b-852a-6954a4cb63e1"
      decimals="-5"
      id="F_88d2352f-fb4c-45a8-8351-88c4391987c4"
      unitRef="U_USD">2800000</tsbx:ContingentConsiderationPayableByShares>
    <tsbx:StockIssuedDuringThePeriodForMilestonePaymentsShares
      contextRef="C_263ddd8f-936b-4629-ac81-de82901400f0"
      decimals="INF"
      id="F_a7db16cd-9e96-4f95-91d5-f8f66cedce39"
      unitRef="U_shares">249992</tsbx:StockIssuedDuringThePeriodForMilestonePaymentsShares>
    <tsbx:ContingentConsiderationPayable
      contextRef="C_2f5ca510-92ae-4c6d-88c6-32a100f28ecc"
      decimals="-5"
      id="F_722c0009-0a5b-469d-be30-ff50599f7bf8"
      unitRef="U_USD">10000000</tsbx:ContingentConsiderationPayable>
    <tsbx:ContingentConsiderationPayable
      contextRef="C_ca9e9c5b-5d60-4a1b-8ad7-f5f5e30eeccd"
      decimals="-5"
      id="F_bb1b15ef-fe14-44f6-ba2a-aebd9d2e9665"
      unitRef="U_USD">10000000</tsbx:ContingentConsiderationPayable>
    <tsbx:ContingentConsiderationPayableByShares
      contextRef="C_ca9e9c5b-5d60-4a1b-8ad7-f5f5e30eeccd"
      decimals="-5"
      id="F_5b89a90e-2f8f-4a70-af7a-f613cbd023f2"
      unitRef="U_USD">5000000</tsbx:ContingentConsiderationPayableByShares>
    <tsbx:ContingentConsiderationPayableByCash
      contextRef="C_ca9e9c5b-5d60-4a1b-8ad7-f5f5e30eeccd"
      decimals="-5"
      id="F_914e7f0e-4829-427a-aabf-a056ccfaa88f"
      unitRef="U_USD">5000000</tsbx:ContingentConsiderationPayableByCash>
    <tsbx:ContingentConsiderationPayable
      contextRef="C_9e1380fe-5300-44d7-addc-af012845a913"
      decimals="-5"
      id="F_f700c5af-dc0a-4cb6-819b-2a7131c2adfb"
      unitRef="U_USD">10000000</tsbx:ContingentConsiderationPayable>
    <tsbx:ContingentConsiderationPayableByCash
      contextRef="C_dde16e3b-95a2-4acb-a8f5-4219383626cd"
      decimals="-5"
      id="F_439a8941-f627-49ce-a161-66a407a506bf"
      unitRef="U_USD">600000</tsbx:ContingentConsiderationPayableByCash>
    <tsbx:ContingentConsiderationPayable
      contextRef="C_7c898406-56c5-4ae7-8aa8-5701d037862a"
      decimals="-5"
      id="F_80388b04-5d97-43e3-b20e-10ed9e2c70c4"
      unitRef="U_USD">9400000</tsbx:ContingentConsiderationPayable>
    <tsbx:ContingentConsiderationPayableByCash
      contextRef="C_d7168d5d-e7a5-46ff-9b87-4e0562cb00e5"
      decimals="-5"
      id="F_91e7becf-7687-49b5-9ff5-07f7c0ce7f29"
      unitRef="U_USD">2200000</tsbx:ContingentConsiderationPayableByCash>
    <tsbx:ContingentConsiderationPayableByShares
      contextRef="C_c762659f-a398-4da4-b6b5-fb1c73edfefd"
      decimals="-5"
      id="F_604c9618-b534-4f70-947c-cfcb9c34cb43"
      unitRef="U_USD">5000000</tsbx:ContingentConsiderationPayableByShares>
    <tsbx:ContingentConsiderationPayableByCash
      contextRef="C_e1930a00-b656-4b09-88f7-718672d19d95"
      decimals="-5"
      id="F_7b918b45-1c8b-4f6a-a3ab-dde52fd0cdbf"
      unitRef="U_USD">2200000</tsbx:ContingentConsiderationPayableByCash>
    <tsbx:StockIssuedDuringThePeriodForMilestonePaymentsShares
      contextRef="C_eab032e1-3425-462f-8d5e-286e582b438d"
      decimals="0"
      id="F_57e2f052-25b2-49b2-af49-ffbc6b8716b6"
      unitRef="U_shares">212203</tsbx:StockIssuedDuringThePeriodForMilestonePaymentsShares>
    <tsbx:StockIssuedDuringThePeriodForMilestonePaymentsValue
      contextRef="C_eab032e1-3425-462f-8d5e-286e582b438d"
      decimals="-5"
      id="F_c5982288-0b8c-4733-9f59-bb281d967392"
      unitRef="U_USD">5000000</tsbx:StockIssuedDuringThePeriodForMilestonePaymentsValue>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="C_ddebe139-151f-44ec-8890-0c2c9c33904a"
      decimals="-5"
      id="F_7263bbf5-400d-48b9-a306-a44685d9aaed"
      unitRef="U_USD">2800000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="C_624dbdac-4327-488c-b421-114825296f78"
      decimals="-5"
      id="F_6336d077-ad20-4ee4-9d32-7a56444395d7"
      unitRef="U_USD">2200000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="C_8136f853-5792-4e82-a119-8cc35daccd6d"
      decimals="-5"
      id="F_4abfdd3c-646e-4282-869f-e4a41123089a"
      unitRef="U_USD">600000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="C_6f6523cc-b1d2-4b30-81f0-6490c4ab9067"
      decimals="-5"
      id="F_aa2a438f-29c8-44b6-98a0-2d1b3a608014"
      unitRef="U_USD">2200000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <tsbx:ContingentConsiderationPayable
      contextRef="C_2d28ff08-66e3-4717-8e1b-0159fd2dae0a"
      decimals="-5"
      id="F_f8eb358c-08f3-4ed7-984c-05fdcd46d348"
      unitRef="U_USD">20000000</tsbx:ContingentConsiderationPayable>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="C_d4a98e5a-d94e-4f1c-b7cf-4ba20e9be13c"
      decimals="-5"
      id="F_f2c2f796-4a43-419e-a8dd-c45d49e8247e"
      unitRef="U_USD">19400000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <tsbx:AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability
      contextRef="C_9d84a11b-47e8-4e33-b8ab-f05dc1707a83"
      decimals="-5"
      id="F_fae80eb5-c918-45cf-9cf1-9e5aa4123a33"
      unitRef="U_USD">100000</tsbx:AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability>
    <tsbx:AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability
      contextRef="C_5b35fa61-bbf8-46c2-a6fc-1e914819fa92"
      decimals="-5"
      id="F_6bf5e60f-bcec-4114-8b67-810ec8006c6a"
      unitRef="U_USD">300000</tsbx:AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability>
    <tsbx:AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability
      contextRef="C_9d04f62a-8f18-4763-a524-2381aeebe491"
      decimals="-5"
      id="F_7c1dd899-8030-4c82-82d9-f5e483da459a"
      unitRef="U_USD">100000</tsbx:AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability>
    <tsbx:AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability
      contextRef="C_7a433f77-f757-4637-ac62-b0d9f32aca2c"
      decimals="-5"
      id="F_80fa6991-aec2-4fcc-894e-74f65d665508"
      unitRef="U_USD">900000</tsbx:AssetAcquisitionContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_2db5eacd-df49-48e1-a1e5-a9dee8934b86">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;8. Term Loan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On April 26, 2024 (the "Closing Date"), the Company entered into the LSA, by and among the Company, as borrower, the Company&#x2019;s wholly owned subsidiary, Myst Therapeutics, LLC (&#x201c;Myst LLC&#x201d; and, together with the Company, the &#x201c;Loan Parties&#x201d;) and BOC, as lender. The LSA provides for a revolving credit facility in an aggregate principal amount of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million (the &#x201c;Revolving Loans&#x201d;). The Company may request advances at any time the loan is not in default and not to exceed the Revolving Loans limit and may prepay any amounts outstanding at any time with no prepayment penalty.  Upon termination of the LSA, whether in connection with acceleration, prepayment in full, or otherwise, the Company is obligated to make a nonrefundable payment of  (i) $0.4 million at any time on or prior to the first anniversary of the Closing Date, and (ii) $0.2 million at any time after the first anniversary of the Closing Date but prior to the second anniversary.  In addition, the Company is obligated to pay a fee in the event of certain corporate transactions equal to the greater of (i) $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; or (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the highest aggregate principal amount outstanding prior to the transaction (the "Success Fee").  The Success Fee is due upon any merger or consolidation, any sale of substantially all of the assets of the Company, or the closing of one or more related financings where aggregate cash proceeds from the sale of equity securities and/or upfront cash proceeds from strategic partnerships is equal to at least $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;75.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and occurs on or before the tenth anniversary of the Closing Date (each a "Success Fee Event").  If the LSA is terminated prior to the payment of the Success Fee, the Company will remain obligated to pay the Success Fee upon the occurrence of a Success Fee Event during such ten-year period.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The annual interest rate applicable to the Revolving Loans is the greater of the Prime Rate (as defined in the LSA) and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Interest under the Revolving Loans is due and payable on the first calendar day of month during the term.  The initial maturity date of the Revolving Loans is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, which may be extended to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;March 31, 2027&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; subject to the satisfaction of certain terms and conditions as set forth in the LSA.  Upon maturity, all amounts outstanding will become due and payable.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The LSA contains customary representations and warranties and customary affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, prepayment of other indebtedness and dividends and other distributions. The Company is also required to comply with certain covenants requiring the Company to (i) receive positive interim Phase 1 data for TIDAL-01 (as determined by the Company&#x2019;s board of directors), which was satisfied in August 2024 and (ii) receive at least $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;40.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in new funding from the sale of equity, partnerships, and/or business development payments, in each case, by March 31, 2025. If the Company fails to comply with any of the foregoing covenants, the Lender may terminate the commitments to make further loans and declare all of the obligations of the Company under the LSA to be immediately due and payable.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The LSA also includes customary events of default, including failure to pay principal, interest or certain other amounts when due, material inaccuracy of representations and warranties, violation of covenants, specified cross-default and cross-acceleration to other material indebtedness, certain bankruptcy and insolvency events, certain undischarged judgments, material invalidity of guarantees or grant of security interest, material adverse effect and change of control, in certain cases subject to certain thresholds and grace periods. If one or more events of default occurs and continues beyond any applicable cure period, the Lender may terminate the commitments to make further loans and declare all of the obligations of the Company under the LSA to be immediately due and payable.  Additionally, upon the occurrence of an event of default, the Company is obligated to pay a fee equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% above the interest rate then in effect on all outstanding obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of  June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; amounts had been drawn under the Revolving Loans.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company incurred $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; of debt issuance costs which were recorded as part of Other Current Assets and will be amortized over the term of the LSA.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_1608bf2e-2722-4b3b-ac28-7d680ca451a6"
      decimals="-5"
      id="F_efecd91f-a56d-4ca8-85c5-518f77150218"
      unitRef="U_USD">20000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <tsbx:DebtInstrumentSuccessFeeAmount
      contextRef="C_ece257ea-a6a0-437c-89a2-7ad5c9fc8aa2"
      decimals="0"
      id="F_d9f1824a-2137-478b-b21e-7aac486f9f6a"
      unitRef="U_USD">50000</tsbx:DebtInstrumentSuccessFeeAmount>
    <tsbx:DebtInstrumentSuccessFeePercentage
      contextRef="C_ece257ea-a6a0-437c-89a2-7ad5c9fc8aa2"
      decimals="2"
      id="F_8908ed9d-6641-42ee-9257-0697260cba10"
      unitRef="U_pure">0.02</tsbx:DebtInstrumentSuccessFeePercentage>
    <tsbx:CashProceedsFromTheSaleOfEquitySecuritiesAndOrUpfrontCashProceedsFromStrategicPartnerships
      contextRef="C_adb55f11-8d4b-474a-b9d9-4cbcb3d9be20"
      decimals="INF"
      id="F_d0336905-d479-467d-bab8-66c2783f89bc"
      unitRef="U_USD">75000000</tsbx:CashProceedsFromTheSaleOfEquitySecuritiesAndOrUpfrontCashProceedsFromStrategicPartnerships>
    <us-gaap:LineOfCreditFacilityInterestRateDescription
      contextRef="C_ece257ea-a6a0-437c-89a2-7ad5c9fc8aa2"
      id="F_88a204b2-03aa-47dc-9da5-a9becfc3274a">The annual interest rate applicable to the Revolving Loans is the greater of the Prime Rate (as defined in the LSA) and 4.25%.</us-gaap:LineOfCreditFacilityInterestRateDescription>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_1608bf2e-2722-4b3b-ac28-7d680ca451a6"
      decimals="4"
      id="F_1a3cfc9e-5f9a-4305-aab9-8ad277b89af7"
      unitRef="U_pure">0.0425</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCreditFacilityExpirationDate1
      contextRef="C_ece257ea-a6a0-437c-89a2-7ad5c9fc8aa2"
      id="F_bdd0c927-a58c-4560-bc5b-cbf4c668be6b">2026-03-31</us-gaap:LineOfCreditFacilityExpirationDate1>
    <tsbx:LineOfCreditFacilityExtendedDate
      contextRef="C_ece257ea-a6a0-437c-89a2-7ad5c9fc8aa2"
      id="F_c33be942-dfd7-4eb2-b646-e344505da35e">2027-03-31</tsbx:LineOfCreditFacilityExtendedDate>
    <tsbx:FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments
      contextRef="C_eea7aad0-d598-4675-97e4-495ad0d5f473"
      decimals="-5"
      id="F_cb20a2f3-e15d-44fa-91fb-01351b42de58"
      unitRef="U_USD">40000000</tsbx:FundingFromSaleOfEquityPartnershipsAndOrBusinessDevelopmentPayments>
    <tsbx:DebtInstrumentFeeOnEventOfDefault
      contextRef="C_ece257ea-a6a0-437c-89a2-7ad5c9fc8aa2"
      decimals="3"
      id="F_9063f297-3eda-436b-91f4-5bde17ea55b7"
      unitRef="U_pure">0.03</tsbx:DebtInstrumentFeeOnEventOfDefault>
    <us-gaap:LineOfCredit
      contextRef="C_4ed0c192-f7ce-4ccd-88a9-1326c9ea54ba"
      decimals="INF"
      id="F_673e725c-caf6-4b56-bfd5-b4ee57ff17eb"
      unitRef="U_USD">0</us-gaap:LineOfCredit>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="C_4ed0c192-f7ce-4ccd-88a9-1326c9ea54ba"
      decimals="1"
      id="F_310db7b6-2d72-4493-80f4-595267f5f742"
      unitRef="U_USD">0.1</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_25c71509-bd44-4b5a-ac2a-d837a65a88d9">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;9. Redeemable Convertible Preferred Stock and Stockholders&#x2019; Equity&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;From October 2015 to October 2016, the Company issued a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,250,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of series A preferred stock (the &#x201c;Series A Preferred Stock&#x201d;) at CDN$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share (equivalent to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.74&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, based on a conversion ratio of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.344&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Canadian dollars to one U.S. dollar) for total net proceeds of CDN$ &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million (equivalent to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million based on a conversion ratio of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.344&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Canadian dollars to one U.S. dollar).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In October 2016, the Company issued a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,285,156&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of series B-1 preferred stock (the &#x201c;Series B-1 Preferred Stock&#x201d;) at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.77&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share for total net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. In November 2018, the Company issued &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,065,538&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of series B-2 preferred stock (the &#x201c;Series B-2 Preferred Stock&#x201d;, and together with the Series B-1 Preferred Stock, the &#x201c;Series B Preferred Stock&#x201d;) at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share for total net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company issued a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;17,905,288&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of series C preferred stock (the &#x201c;Series C Preferred Stock&#x201d;) at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.35&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share in January 2019 for net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;41.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company issued a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,285,356&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of series D preferred stock (the &#x201c;Series D Preferred Stock&#x201d;) at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.73&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share in June 2021 for net proceeds of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the Company's IPO, all outstanding shares of the Company's redeemable convertible preferred stock automatically converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,493,879&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock.  Subsequent to the closing of the IPO, there were no shares of redeemable convertible preferred stock outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Common Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In connection with the closing of the IPO, the Company filed its Amended and Restated Certificate of Incorporation which provides that the authorized common stock of the Company is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;490,000,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock with a par value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Shares of common stock reserved for future issuance consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock options outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,298,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,374,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;108,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares available for issuance under the ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;453,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;222,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares available for issuance under the Plans&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,946,048&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,755,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,806,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,454,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <tsbx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_2e92c815-0887-42a5-9aa2-1aa6d38a8788"
      decimals="INF"
      id="F_8d0d7d28-1cf0-488b-9587-b8410f5c4532"
      unitRef="U_shares">11250000</tsbx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_b1d0d042-927c-480f-9792-c14b9cf5f6d2"
      decimals="2"
      id="F_446210d7-df32-4c6e-8fe1-2ab5eac3cd17"
      unitRef="U_CadShare">1</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_b1d0d042-927c-480f-9792-c14b9cf5f6d2"
      decimals="2"
      id="F_5e344fc7-a0b4-4f87-b6cd-1f31897dd808"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.74</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="C_b1d0d042-927c-480f-9792-c14b9cf5f6d2"
      decimals="3"
      id="F_599b9e4c-99a6-42c3-ad51-e172c96f9a71"
      unitRef="U_pure">1.344</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_2e92c815-0887-42a5-9aa2-1aa6d38a8788"
      decimals="-5"
      id="F_afaf7d6f-4153-48be-9462-528b45fc80b4"
      unitRef="U_CAD">10900000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_2e92c815-0887-42a5-9aa2-1aa6d38a8788"
      decimals="-5"
      id="F_fb7afa78-cf23-46df-a256-8a123f93c89e"
      unitRef="U_USD">8100000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="C_b1d0d042-927c-480f-9792-c14b9cf5f6d2"
      decimals="3"
      id="F_16792cad-8c0e-49a2-96f1-8ccad897b99a"
      unitRef="U_pure">1.344</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <tsbx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_be0f70da-b5dc-4227-b5d4-1a3bd3c8a13d"
      decimals="0"
      id="F_532a529c-1c69-4bcc-a4d3-ea252e74c910"
      unitRef="U_shares">16285156</tsbx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_d917210f-1291-4dbd-86d6-3aa84bc8ab10"
      decimals="2"
      id="F_08add21d-89a9-4659-957c-394c8e4caccd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.77</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="C_be0f70da-b5dc-4227-b5d4-1a3bd3c8a13d"
      decimals="-5"
      id="F_ae2f89d2-433a-4e7e-a25c-ae53f6099314"
      unitRef="U_USD">12300000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <tsbx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_ac0cf97a-5db0-4110-a9ce-20faacb87521"
      decimals="0"
      id="F_07b72de3-88e8-42c0-8302-d99e26665b19"
      unitRef="U_shares">25065538</tsbx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_2fb9dc1f-ccec-4fe3-83bb-464c06488b6a"
      decimals="2"
      id="F_c050c044-f6b7-4df4-9447-b9896b5b57ae"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.15</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="C_ac0cf97a-5db0-4110-a9ce-20faacb87521"
      decimals="-5"
      id="F_7fe612d5-c443-4fdb-8c34-bfdd7b76eebb"
      unitRef="U_USD">28900000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <tsbx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_33faa779-ce8f-4e4d-a219-c041b650a61c"
      decimals="0"
      id="F_df88a50e-da0b-4742-be56-e0e49853153a"
      unitRef="U_shares">17905288</tsbx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_9d04382e-1108-4cb1-91e7-16fb7b6fd93d"
      decimals="2"
      id="F_255c2941-db54-4e7c-bbc0-f82ee61bb7c5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.35</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="C_33faa779-ce8f-4e4d-a219-c041b650a61c"
      decimals="-5"
      id="F_8b53c2b5-2e5d-49e7-a02d-de12d1b3bde7"
      unitRef="U_USD">41800000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <tsbx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_221e8d7b-e069-4751-b775-170cde6f9416"
      decimals="0"
      id="F_1c849beb-196d-42de-8dec-45f4c9f3c5be"
      unitRef="U_shares">29285356</tsbx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_9755dc24-1227-4784-baf5-a2b45b159779"
      decimals="2"
      id="F_709c17a8-1053-4a1f-a4a7-c1c4f6b162c4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.73</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="C_221e8d7b-e069-4751-b775-170cde6f9416"
      decimals="-5"
      id="F_5fc4851a-3dd9-4c8a-98a0-62b55291afe6"
      unitRef="U_USD">79800000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_10aa115c-22ea-46be-bcba-a9a9cd88b729"
      decimals="INF"
      id="F_11277a40-9eea-448a-adf7-0ae57f838cf4"
      unitRef="U_shares">12493879</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="0"
      id="F_c49e6ba7-d291-4cd1-8f81-9aa402de9839"
      unitRef="U_shares">490000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="3"
      id="F_0074697e-90c9-41bd-a7e6-dd8ab1d097f6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <tsbx:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_dee8573a-be6d-4c85-bb79-db82e1da55f9">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Shares of common stock reserved for future issuance consisted of the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Common stock options outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,298,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,374,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;108,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares available for issuance under the ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;453,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;222,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Shares available for issuance under the Plans&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,946,048&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,755,404&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,806,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,454,918&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</tsbx:ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_02fa49d2-1f02-4cc7-908f-06f8c20ff1f5"
      decimals="INF"
      id="F_31ef02c0-779c-4914-b792-9d473b18c83c"
      unitRef="U_shares">3298558</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_5552aea5-73b7-4fb7-83a2-8300ff05e8db"
      decimals="INF"
      id="F_ee1ba05f-c225-4fbe-9548-11a28701cac7"
      unitRef="U_shares">3374282</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_234b0297-d293-4e18-9282-e7524404692b"
      decimals="INF"
      id="F_96abf068-cb69-4b6a-a9af-77d93bea9894"
      unitRef="U_shares">108899</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_df1018cd-e834-471b-a1de-7f644abc127e"
      decimals="INF"
      id="F_923c1c47-279c-4adc-9b8d-6aca402faf3e"
      unitRef="U_shares">102945</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_fe429d1a-4bd7-4dc5-aa72-7fe35faa4549"
      decimals="INF"
      id="F_fdb81b7b-a187-4923-ad78-717dca6f8689"
      unitRef="U_shares">453280</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_392765bd-7ded-4967-8201-2e786fab388b"
      decimals="INF"
      id="F_7569438e-d0ce-47cd-9c67-d5e0145163e1"
      unitRef="U_shares">222287</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_66ae9658-0772-4454-88b3-b788cb30a2c3"
      decimals="INF"
      id="F_7c1d4d16-d177-4c25-95ea-a8e3683db016"
      unitRef="U_shares">2946048</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_86842d26-2e12-4042-998d-29e3bb96ed47"
      decimals="INF"
      id="F_28e17b51-2f01-4fbe-8da4-cf0a2b24a290"
      unitRef="U_shares">1755404</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="INF"
      id="F_f5072291-2092-4252-b9b0-b0bc9c75c745"
      unitRef="U_shares">6806785</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="INF"
      id="F_22888131-ed48-4093-969c-d3b9a9e18322"
      unitRef="U_shares">5454918</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_692c4da3-f266-42db-87bf-b4c2cba5d41b">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;10. Equity Based Compensation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2018 Equity Incentive Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2018, the Company adopted the 2018 Equity Incentive Plan (the &#x201c;2018 Plan&#x201d;) which provided for the Company to grant incentive stock options or nonqualified stock options for the purchase of common stock, or restricted shares, to employees, members of the board of directors and consultants of the Company. The Company assumed all of the outstanding options under the amended and restated Equity Incentive Plan of Turnstone Biologics Inc. dated October 1, 2016 (the &#x201c;2016 Plan&#x201d;) in connection with the corporate reorganization in December 2018. However, there were no changes to the terms of the options requiring modification accounting.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All options granted under the 2018 Plan have an exercise price, a vesting period determined by the Company&#x2019;s board of directors and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; term as determined and approved by the Company&#x2019;s board of directors (the board of directors may delegate authority to one of the boards&#x2019; committees) at the time of grant. The terms and conditions of the restricted shares are determined by the board of directors at the grant date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The majority of grants outstanding were approved with a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; vesting schedule with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% vesting after one year and the remainder vesting evenly over the remaining 36 months. No further grants will be made under the 2018 Plan.  Any outstanding awards granted under these plans will remain subject to the terms of their 2016 and 2018 Plans, respectively, and applicable award agreements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2023 Equity Incentive Plan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In July 2023, the Company's board of directors and stockholders adopted the 2023 Equity Incentive Plan (the &#x201c;2023 Plan&#x201d; and together with the 2018 and 2016 Plans the "Plans") which became effective upon the date of the IPO.  Under the 2023 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, performance stock awards, performance cash awards and other forms of stock awards to employees, directors and consultants. The maximum term of the stock option grants under the 2023 Plan is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and, in general, the awards granted under the 2023 Plan vest over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; period from the vesting commencement date. The 2023 Plan does not permit early exercises. The number of shares initially reserved for future issuance under the 2023 Plan was the sum of (1) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,889,435&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; new shares, plus (2) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;712,503&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; remaining shares of common stock reserved under the 2018 Plan that became available for issuance upon the effectiveness of the 2023 Plan, and (3) up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;120,949&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Returning Shares (as defined in the 2023 Plan), as such shares become available from time to time. The number of shares of common stock reserved for issuance under the 2023 Plan will automatically increase on January 1 of each year, for a period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, from January 1, 2024 continuing through January 1, 2033, by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares as may be determined by the Company&#x2019;s board of directors. As of January 1, 2024, an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,154,966&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; were available for future issuance under the 2023 Plan.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A summary of the stock option activity under the Plans is as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.23%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.702%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.882%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.702%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.242%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;br/&gt;Underlying&lt;br/&gt;Outstanding&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding &#x2014; December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,529,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,912&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;189,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options canceled/forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding &#x2014; June 30, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,604,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable &#x2014; June 30, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,622,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested and expected to vest &#x2014; June 30, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,604,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding &#x2014; December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,374,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;129,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options canceled/forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;175,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding &#x2014; June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,298,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable &#x2014; June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,955,510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested and expected to vest &#x2014; June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,298,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of each stock option granted to employees and directors was estimated on the date of grant using the Black-Scholes option-pricing model, with the following range of assumptions:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:72.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.22%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.72&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.89&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.48&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.88&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.03&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.09&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.20&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;94.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;94.67&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;86.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercise price of stock options&lt;br/&gt;&#160;granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.68&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.18&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 2023, the Company grants RSUs to employees. The RSU activity is summarized as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.852%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.563%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.521%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.023%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding, non-vested as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Cancelled/Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Vested/Released&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding, non-vested as of June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;108,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:12pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense for all stock awards, including options, restricted stock and RSUs, included in the Company&#x2019;s statements of operations is as follows (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;in thousands&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,009&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,057&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,065&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,066&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The expense related to awards granted to employees and directors was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for each of the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;six months ended June 30, 2024 and 2023. The weighted-average grant date Black Scholes fair market value of options granted to employees, directors and consultants during the six months ended June 30, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.14&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12.23&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per share, respectively.  The aggregate grant date fair value of RSUs granted by the Company during the six months ended June 30, 2024 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million.  &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; RSUs were granted by the Company during the six months ended June 30, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, the Company had unrecognized stock-based compensation expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, related to stock options and RSUs, respectively, which is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; years, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Stock&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In December 2020, Langer received &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;725,920&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares as payment related to the Myst Merger Agreement. Of the total issued, the Company restricted &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;362,960&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares to vest over a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; period in equal annual installments. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90,740&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares remain unvested, and the Company had $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million in unrecognized stock-based compensation expense related to unvested restricted stock which is expected to be recognized evenly over &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; months.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;2023 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In July 2023, the Company adopted the Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;), which became effective with the IPO on July 25, 2023. The ESPP was adopted by the Company&#x2019;s board of directors and stockholders in June 2023. The ESPP initially provides participating employees with the opportunity to purchase up to an aggregate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;222,287&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock. The number of shares of common stock reserved for issuance will automatically increase on January 1st of each calendar year for a period of up to&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, commencing on January 1, 2024 and ending on (and including) January 1, 2033, in an amount equal to the lesser of (i) one percent (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%) of the total number of shares of capital stock outstanding on the last day of the calendar month before the date of the automatic increase, and (ii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;666,680&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares of common stock. Notwithstanding the foregoing, the board may act prior to the first day of any calendar year to provide that there will be no January 1st increase in the share reserve for such calendar year or that the increase in the share reserve for such calendar year will be a lesser number of shares of common stock than would otherwise occur pursuant to the preceding sentence. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On January 1, 2024, the shares available for issuance under the ESPP automatically increased by an additional &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;230,993&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; shares to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;453,280&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; total shares available to be issued under the ESPP.  As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, there was no enrollment offered to the Company's employees.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="C_122cd3f4-302a-4c4b-acb3-5f0a4ab8924f"
      id="F_96603ff8-aed7-4f74-967b-340a805f1d87">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_122cd3f4-302a-4c4b-acb3-5f0a4ab8924f"
      id="F_e7cfeaa7-bb2b-4fa0-848c-94e92fe7c6ef">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_122cd3f4-302a-4c4b-acb3-5f0a4ab8924f"
      decimals="2"
      id="F_eecf9f7f-f5ab-4fe7-91f6-57909f4ed4bc"
      unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <tsbx:MaximumTermOfOptionsUnderEquityIncentivePlan
      contextRef="C_5fa46bf8-b07a-4c44-a5fd-6c1dc1a9edc0"
      id="F_7f444f36-9763-46e8-9a91-eba2dd9c5ba5">P10Y</tsbx:MaximumTermOfOptionsUnderEquityIncentivePlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_5fa46bf8-b07a-4c44-a5fd-6c1dc1a9edc0"
      id="F_618b6c66-65fd-4769-ba95-26f3d6bf1ba3">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_398e0a09-f989-4f15-b8fc-2af343713b5f"
      decimals="0"
      id="F_05551a71-9d8b-444c-82de-544e58f54665"
      unitRef="U_shares">1889435</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_23ab17bc-cbea-4436-975a-8a130aba6e62"
      decimals="0"
      id="F_9a4985ca-01c7-490b-b4e9-03e11932624b"
      unitRef="U_shares">712503</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_b415a509-074d-4b97-86e2-0deee38dd0b9"
      decimals="0"
      id="F_48258e35-1c67-4bfe-b7ec-4e778438dd14"
      unitRef="U_shares">120949</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <tsbx:CommonStockCapitalSharesReservedForFutureIssuanceIncreaseDecreasePeriod
      contextRef="C_a72293d1-c825-4856-b60c-948ad5751e42"
      id="F_7a990209-203c-43c5-9ce3-053dcaf9bc72">P10Y</tsbx:CommonStockCapitalSharesReservedForFutureIssuanceIncreaseDecreasePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_a72293d1-c825-4856-b60c-948ad5751e42"
      decimals="2"
      id="F_c0c0c8f9-fe16-485c-88ed-07ec637c854d"
      unitRef="U_pure">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_06019969-ab1c-456b-98ef-d496be6c8d74"
      decimals="0"
      id="F_60e29dc1-b7e8-4366-94a7-4909af58c433"
      unitRef="U_shares">1154966</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_a57ac97f-838c-4696-a6c0-9a4ed543cafa">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;A summary of the stock option activity under the Plans is as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.23%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.702%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.882%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.702%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.242%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;br/&gt;Shares&lt;br/&gt;Underlying&lt;br/&gt;Outstanding&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding &#x2014; December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,529,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,912&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;189,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.45&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;21,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options canceled/forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding &#x2014; June 30, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,604,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable &#x2014; June 30, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,622,615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;word-break:break-word;"&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested and expected to vest &#x2014; June 30, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,604,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,605&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding &#x2014; December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,374,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;129,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.73&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options canceled/forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;175,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding &#x2014; June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,298,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercisable &#x2014; June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,955,510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Vested and expected to vest &#x2014; June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,298,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_bed097c6-a12a-48ed-ab84-40a66008425b"
      decimals="0"
      id="F_af0aa710-31b5-4240-bb09-13d45dfd2713"
      unitRef="U_shares">2529982</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_bed097c6-a12a-48ed-ab84-40a66008425b"
      decimals="2"
      id="F_a0b94c99-6c1b-409a-b519-ef3b74c92a2c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_e3da0be9-f805-4bd4-bb62-9cbb32dda1e1"
      id="F_7f4b9691-3ce0-4eb6-8d06-05220cd3a8e3">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_bed097c6-a12a-48ed-ab84-40a66008425b"
      decimals="-3"
      id="F_83b20c7c-7598-4c44-85e2-82fd7c6457cd"
      unitRef="U_USD">6912000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="0"
      id="F_385ebc12-3b28-4330-96cb-8e11ec1dcfed"
      unitRef="U_shares">189365</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="2"
      id="F_2e20dd00-6dd1-4eb3-ac66-28ad44cf91ff"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="0"
      id="F_d4c9a4ac-a4f4-4c70-bae5-adf853218d7f"
      unitRef="U_shares">21784</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="2"
      id="F_f1eb5ba2-f67e-4259-870c-83d277984c14"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="0"
      id="F_a091bbb3-e23b-4a83-9b15-1e04a5108d42"
      unitRef="U_shares">92924</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="2"
      id="F_4dd700b5-7768-4c57-94ca-5df0264bd311"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_dfe46888-9d65-4c68-a853-215029dc9872"
      decimals="0"
      id="F_92d6a3f2-3db2-4530-8e8f-9a56f8a1c474"
      unitRef="U_shares">2604639</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_dfe46888-9d65-4c68-a853-215029dc9872"
      decimals="2"
      id="F_87a98f6d-8f51-4040-97d2-2713ba26461f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      id="F_2d748bd1-a49d-474f-807d-a027a3fa775f">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_dfe46888-9d65-4c68-a853-215029dc9872"
      decimals="-3"
      id="F_cbb76ed9-539d-4060-9864-5c5c0535d9e7"
      unitRef="U_USD">18605000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_dfe46888-9d65-4c68-a853-215029dc9872"
      decimals="0"
      id="F_8f25149f-6439-4b99-910f-970360a41e0d"
      unitRef="U_shares">1622615</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_dfe46888-9d65-4c68-a853-215029dc9872"
      decimals="2"
      id="F_89eb7605-3eed-4d71-ae80-11475c2c37cf"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      id="F_f8253c5c-763a-435a-aaba-e1e71262ec6e">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_dfe46888-9d65-4c68-a853-215029dc9872"
      decimals="-3"
      id="F_331f80d4-3012-401d-b62b-ffda12536864"
      unitRef="U_USD">14100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_dfe46888-9d65-4c68-a853-215029dc9872"
      decimals="0"
      id="F_9bb64611-53fe-4ba6-9567-f2c96e940d1d"
      unitRef="U_shares">2604639</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_dfe46888-9d65-4c68-a853-215029dc9872"
      decimals="2"
      id="F_039308af-04ab-4c76-be2b-49bcd357a35c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      id="F_73004762-db90-43a1-9713-0db0df69603e">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_dfe46888-9d65-4c68-a853-215029dc9872"
      decimals="-3"
      id="F_b0d4b583-726f-497b-a152-1fd27f10c563"
      unitRef="U_USD">18605000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="0"
      id="F_8829b359-1cd5-4acc-b99a-ca8e1de30dbc"
      unitRef="U_shares">3374282</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="2"
      id="F_912ffd11-69c7-49a9-92a3-4447d2485830"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_96148a81-8dcb-40e9-8bcc-218ebdce5605"
      id="F_d955075a-1353-4673-875c-b208b632ad68">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_9a13b8b1-9fc2-4aed-b6d3-47a83085ba5f"
      decimals="-3"
      id="F_d5a45050-54e0-40e6-bdc2-70531f937eb2"
      unitRef="U_USD">352000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="0"
      id="F_ea37e1fb-d9d3-43f7-a3b0-5f6f571ba559"
      unitRef="U_shares">129165</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="2"
      id="F_5462e9dd-b5f8-42f2-825a-a8eb075b12eb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="0"
      id="F_a22fed73-4afd-4ee8-9d27-8dac252bc8a9"
      unitRef="U_shares">29119</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="2"
      id="F_b2f8d731-8197-450f-b45e-1f3164d2074e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="0"
      id="F_e417df21-fa6c-4735-a8a0-62891da24fbc"
      unitRef="U_shares">175770</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="2"
      id="F_04a3f7b7-783d-4abf-88da-96c089fd85b7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="0"
      id="F_7d757be6-99d4-4049-a458-7028500bc676"
      unitRef="U_shares">3298558</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="2"
      id="F_fd6ee7d3-6ac1-413d-8146-b5fd5c7179ee"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_ed950654-02d3-499d-a483-ba40c30dc661">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_fd7821cc-2790-440a-a74e-43c1f78c43d2"
      unitRef="U_USD">354000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="0"
      id="F_8d2111b9-8eb4-4f8f-9724-2f9fe702710a"
      unitRef="U_shares">1955510</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="2"
      id="F_faaab25c-2d6a-4446-88d6-4696e5bca208"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_bf70c2af-ab53-4a0f-97a5-7641de1b2a30">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_8681de0e-ff96-4781-a1ed-2e2b71c6d289"
      unitRef="U_USD">341000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="0"
      id="F_5720d2cd-ebc3-40ae-a185-03b97b30643e"
      unitRef="U_shares">3298558</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="2"
      id="F_1811d5ec-239b-417d-82a6-e43a4e6a9bf0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_75379554-ccc2-4c19-99d8-fc80326398f1">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_51ca545a-7cc7-4080-b5dc-f040c5d1f5e4"
      unitRef="U_USD">354000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_77910de8-24f0-4f85-9cdb-c232e59911dc">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The fair value of each stock option granted to employees and directors was estimated on the date of grant using the Black-Scholes option-pricing model, with the following range of assumptions:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:72.06%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.6%;"&gt;&lt;/td&gt;
        &lt;td style="width:12.22%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.72&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3.89&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4.48&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.88&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.03&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.09&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;- &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.20&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;94.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%-&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;94.67&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;85.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;86.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercise price of stock options&lt;br/&gt;&#160;granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:10pt;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.68&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.18&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;- $&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="4"
      id="F_dbd620e2-b366-4c2c-a578-db3c2526a4fb"
      unitRef="U_pure">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="4"
      id="F_b3967787-79e6-4eb4-9616-c0e4cc8fad05"
      unitRef="U_pure">0.0472</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="4"
      id="F_1bbe5452-2162-471c-b519-13b8d2c90083"
      unitRef="U_pure">0.0389</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="4"
      id="F_d3859148-bf3f-42cf-9c25-3b1f4fd7aaa9"
      unitRef="U_pure">0.0448</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_bdee48eb-7f4a-46cb-b069-06ddbd37a077"
      id="F_472754df-87f6-495e-a497-3919691102ef">P5Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_61b64e12-4fa9-444b-8290-e40812121809"
      id="F_291f29ca-3ee3-4d32-8a8e-dbb4d8ef0e83">P6Y10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_9c8cc4df-6000-4875-a29a-4d3c9dd0d7c5"
      id="F_904aa92c-6e96-40c8-b455-16553fe91026">P6Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_862de778-6688-462a-b351-4d149c16a617"
      id="F_2e3685db-b63d-400a-a569-52f9a99908af">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="3"
      id="F_c469e6c5-4a05-46a5-b6f1-5d88a95ce619"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="2"
      id="F_435d5150-8cf0-4cef-91b2-873f12e68d94"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="3"
      id="F_0cb40a6b-a26c-404f-bd27-6c74d8dc1fc2"
      unitRef="U_pure">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="4"
      id="F_4ade48ca-6bea-4f47-89b9-d0e90a745123"
      unitRef="U_pure">0.9467</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="3"
      id="F_2b364377-771d-4e10-92c1-2692825086ad"
      unitRef="U_pure">0.858</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="3"
      id="F_3c080188-846a-4e46-9979-30a53090f300"
      unitRef="U_pure">0.862</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_018d9f0a-f1a9-461c-a05d-3b501d8ad8bd"
      decimals="2"
      id="F_25db9c7b-2a9e-491a-8f03-92d2b8dc8024"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_8a2c0799-2ad0-4d20-8a89-44e9c7d5025f"
      decimals="2"
      id="F_536dd62c-89d1-40fd-9607-f669c3fcfa8b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_7ab99909-780f-484a-afb9-d7fab1c3e24f"
      decimals="2"
      id="F_284c06ad-7931-4644-b53d-5c33aa35543e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="C_7a615421-56cd-4cb3-983c-215b19efb667"
      decimals="2"
      id="F_e16b8d34-bc64-46a7-b06b-a4e18bc83b43"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_e0acf2e6-acdd-448f-881e-a1b9c0de9088">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of December 2023, the Company grants RSUs to employees. The RSU activity is summarized as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.852%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.563%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:2.521%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:16.023%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Number of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding, non-vested as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;102,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;16,384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Cancelled/Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&#160;&#160;Vested/Released&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Outstanding, non-vested as of June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;108,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.72&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_fa91a432-14eb-479a-ab9e-c343bfe09637"
      decimals="0"
      id="F_7dae5381-f760-423c-aa95-521b1f505a03"
      unitRef="U_shares">102945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_fa91a432-14eb-479a-ab9e-c343bfe09637"
      decimals="2"
      id="F_c58116e0-786a-44d4-84c0-48cc4c967935"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_233d0f7d-f749-402b-be07-03dbe6d24916"
      decimals="0"
      id="F_44b7bbe9-19b2-4514-8332-fb363b329134"
      unitRef="U_shares">16384</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_233d0f7d-f749-402b-be07-03dbe6d24916"
      decimals="2"
      id="F_cf716c60-d181-4129-912c-beabf20aaef3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_233d0f7d-f749-402b-be07-03dbe6d24916"
      decimals="INF"
      id="F_131e623f-33e5-44a5-ba85-ece21835f3cc"
      unitRef="U_shares">10430</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_233d0f7d-f749-402b-be07-03dbe6d24916"
      decimals="2"
      id="F_6eea22e9-67ab-42b9-95d9-97e08728e062"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_f0568106-d7a9-414e-a63d-3cea66f35a6a"
      decimals="0"
      id="F_a7ba5756-8a2a-490f-9dde-b7ea6d92110c"
      unitRef="U_shares">108899</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_f0568106-d7a9-414e-a63d-3cea66f35a6a"
      decimals="2"
      id="F_512dbceb-1d53-476d-9924-974a61753f50"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_6a1716d0-27fe-4b72-bd12-acbe83ed162b">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Stock-based compensation expense for all stock awards, including options, restricted stock and RSUs, included in the Company&#x2019;s statements of operations is as follows (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;in thousands&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.56%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.12%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.24%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;644&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,009&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,057&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,065&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,066&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_62ea4f09-347c-4795-8884-5220ce935f91"
      decimals="-3"
      id="F_8f5629e6-63f2-4544-8b11-92f702b201a7"
      unitRef="U_USD">644000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_db72c5ee-0057-4dec-a48f-c46b4c093ae7"
      decimals="-3"
      id="F_74b80c1f-4348-44dc-9719-b4baa040f9aa"
      unitRef="U_USD">507000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d07e96e4-27c7-461d-87e0-bfe0e09106c3"
      decimals="-3"
      id="F_d17b2e6b-f8ae-457f-8aaa-bc5804065cde"
      unitRef="U_USD">1294000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_298d2425-fd98-405f-a011-492c95c811c1"
      decimals="-3"
      id="F_55238f35-c7d8-41bd-916a-e6a79ec95277"
      unitRef="U_USD">1009000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a8118d4e-4113-40b7-b543-3bea71a014bc"
      decimals="-3"
      id="F_ff1572c3-db71-4fcc-8e9c-6ac1de4fac9a"
      unitRef="U_USD">375000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a2c92d2f-8c3a-4345-9949-14d05e745e9f"
      decimals="-3"
      id="F_9066e79e-48b2-4d82-a629-fcba0c2a56f9"
      unitRef="U_USD">567000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_334d95da-9a09-4a10-86ff-a51738440c33"
      decimals="-3"
      id="F_e1b102fa-edc4-400b-955b-30f76c577871"
      unitRef="U_USD">771000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5447e64a-c9af-4233-ae37-a6910517d877"
      decimals="-3"
      id="F_80966f19-5e0d-460d-9dbf-19eebce4e495"
      unitRef="U_USD">1057000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8"
      decimals="-3"
      id="F_dc0fbf9c-9656-454b-ab4b-80939fc91543"
      unitRef="U_USD">1019000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b"
      decimals="-3"
      id="F_5ac24cad-e3fd-4bb1-8e58-5c3ad7d790fa"
      unitRef="U_USD">1074000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_da193ba0-2af1-4353-96c0-6a80a04b3d71"
      unitRef="U_USD">2065000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_0998f217-54c5-4a52-ae53-567a2579c77b"
      unitRef="U_USD">2066000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-5"
      id="F_2f8fb7ba-f9aa-4173-b451-5f0a6cacc813"
      unitRef="U_USD">2100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-5"
      id="F_3456cae0-82d9-4b2e-925f-c34ea5bcc1aa"
      unitRef="U_USD">2100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="2"
      id="F_f60ea101-4424-4d8b-8e93-3cc38cd23180"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="2"
      id="F_695b03f3-87ab-40af-b74c-85933657744b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <tsbx:ShareBasedCompensationArrangementAverageGrantDateFairValue
      contextRef="C_233d0f7d-f749-402b-be07-03dbe6d24916"
      decimals="-5"
      id="F_6f40f36f-6532-42a2-a67a-91a71a187b73"
      unitRef="U_USD">0</tsbx:ShareBasedCompensationArrangementAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_c6f26a23-43b5-452a-9c94-f293c2677e84"
      decimals="INF"
      id="F_83ad28da-e53b-4e71-a06f-4d9a6dfe2359"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_50d1f298-b372-40b5-b6e4-1d4f6cc1d536"
      decimals="-5"
      id="F_badae1e4-8001-4784-8346-eea229710796"
      unitRef="U_USD">6200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_f0568106-d7a9-414e-a63d-3cea66f35a6a"
      decimals="-5"
      id="F_6fc2f273-4985-4718-8bd3-61674322902c"
      unitRef="U_USD">300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_5987e3e3-0cab-4166-bca8-581516776417"
      id="F_596793ee-a517-4fc5-8369-ed1d4fc45c9c">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_233d0f7d-f749-402b-be07-03dbe6d24916"
      id="F_b591b235-25d8-4cdc-b921-e4e21f57a04e">P3Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="C_b61d7932-d1b3-455d-a3a5-9627e4bd93da"
      decimals="0"
      id="F_7c1017e8-5596-4840-bcd5-3763f2eb77c1"
      unitRef="U_shares">725920</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="C_b34ba69f-3f68-4be6-9f1b-44db7d637865"
      decimals="0"
      id="F_34c94df6-ae39-4ae0-80a4-ce7284abf9c5"
      unitRef="U_shares">362960</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="C_bea27948-4ee5-4b9b-8b58-855991725981"
      id="F_4a078329-a533-47a3-a8d5-edc938c1d58d">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_4519aa8e-1238-4faa-8345-635ebb5bc098"
      decimals="0"
      id="F_112ee6f6-2362-45f7-9f7c-d554c4120b7a"
      unitRef="U_shares">90740</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_4519aa8e-1238-4faa-8345-635ebb5bc098"
      decimals="-5"
      id="F_e6bf3eaf-b5c4-4caa-b17b-a29d6e2665e5"
      unitRef="U_USD">500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_488ff119-253a-4f13-ab67-fcbecef54a44"
      id="F_204a9dbc-55ef-4cf6-98cf-e94ebf4f1875">P6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_385dcdbf-07bd-4e19-a166-84748a852d48"
      decimals="0"
      id="F_481ccf8f-6009-4856-86c8-8a6415eef52b"
      unitRef="U_shares">222287</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <tsbx:CommonStockCapitalSharesReservedForFutureIssuanceIncreaseDecreasePeriod
      contextRef="C_b4bc9727-1662-4540-9335-43dccebbd817"
      id="F_360230bf-ae7c-4b68-96d3-e0fc2245a0b4">P10Y</tsbx:CommonStockCapitalSharesReservedForFutureIssuanceIncreaseDecreasePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_b4bc9727-1662-4540-9335-43dccebbd817"
      decimals="2"
      id="F_dd78d74e-896c-41f0-b6dc-b63e527d0372"
      unitRef="U_pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_385dcdbf-07bd-4e19-a166-84748a852d48"
      decimals="0"
      id="F_839cc2fd-9cf1-4857-a995-c4d4f0c31854"
      unitRef="U_shares">666680</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_4d689c27-7fb0-4851-9baa-5648a27e5506"
      decimals="0"
      id="F_120ec430-d0dd-4705-a30c-67f62b712381"
      unitRef="U_shares">230993</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_277bc5e6-e420-49a1-a481-ae8acaf14f5e"
      decimals="0"
      id="F_c91a5dae-bd03-4247-b936-914075698c9e"
      unitRef="U_shares">453280</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_000737a2-53f9-41c7-a046-06c04ed89dcd">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;11. Income Taxes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company did &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t record federal income tax expense for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;six months ended June 30, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively, as the Company expects to be in a cumulative taxable loss position in 2024 and 2023, and the net deferred tax assets are fully offset by a valuation allowance as it is not more likely than not that the benefit will be realized. The Company recorded a benefit (provision) for state income taxes of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;six months ended June 30, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="INF"
      id="F_338ba0c5-9b2f-4a38-836e-cbaa95bcc189"
      unitRef="U_USD">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="INF"
      id="F_c0a31911-f872-4c51-8a84-8e92e1812a7f"
      unitRef="U_USD">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <tsbx:ProvisionBenefitForIncomeTaxes
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-5"
      id="F_772a9088-e7f5-47a8-958d-f35f31c5595e"
      unitRef="U_USD">0</tsbx:ProvisionBenefitForIncomeTaxes>
    <tsbx:ProvisionBenefitForIncomeTaxes
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-5"
      id="F_e16fe49a-03e1-4e99-9b57-1fdd132ab84b"
      unitRef="U_USD">100000</tsbx:ProvisionBenefitForIncomeTaxes>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_91b9b712-4b24-46a1-a5cb-6c5a6325f0ed">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;12. Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company leases laboratory and office space for its corporate headquarters located in San Diego, California and office space in New York, New York and Ontario, Canada. Operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. In calculating the present value of the lease payments, the Company has elected to utilize its incremental borrowing rate based on the original lease term and not the remaining lease term. The Company determines if an arrangement is a lease by considering whether there is an identified asset, and the contract conveys the right to control its use. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company&#x2019;s lease terms may include options to extend or terminate a lease. If the lease includes non-lease components (i.e., common area maintenance) that are paid separately from rent based on actual costs incurred and therefore are not included in the right-of-use asset and lease liability but are reflected as an expense in the period incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In July 2018, the Company entered into a lease agreement for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet of office space in New York, New York. The term of the lease is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;seven years and three months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;starting November 1, 2018. The lease requires the Company to share in prorated expenses and property taxes based upon actual amounts incurred. The lease contains escalating rent clauses which require higher rent payments in future years. In September 2022, the Company made the decision to sublease this space and executed a sublease in November 2022 for the remaining term of the lease. Since the Company is still responsible for making the lease payments, there was no impact to the operating lease liability from the sublease. However, since the sublease payment does not cover&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;entire lease payment, the carrying value of the operating right of use asset was analyzed and determined to be impaired resulting in a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million reduction in the operating right of use asset in September 2022.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In January 2019, the Company executed an agreement to lease approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet of laboratory space at Carleton University in Ontario, Canada. The initial term of the lease is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and started in November 2019 at a rate of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million per year. In November 2022, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;the lease was extended for a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; period.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; In August 2023, the Company terminated the lease.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In May 2019, the Company entered into a noncancelable operating lease for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9,423&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet located at 12 York Street, Ontario, CA. The term of the lease is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, starting December 1, 2019, and includes &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;one renewal option for a period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The lease requires the Company to share in prorated expenses and property taxes based upon actual amounts incurred. The lease contains escalating rent clauses which require higher rent payments in future years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;     &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In June 2021, the Company entered into a lease agreement for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19,474&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; square feet of office and laboratory space in San Diego, California. The initial term of the lease is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;38 months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;one renewal option for a period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and commenced in March 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The lease requires the Company to share in prorated expenses and property taxes based upon actual amounts incurred. The lease contains escalating rent clauses which require higher rent payments in future years.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company recorded rent expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;six months ended June 30, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, respectively.  &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The table below summarizes the Company&#x2019;s total lease costs included in its unaudited condensed consolidated financial statements, as well as other required quantitative disclosures (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;in thousands&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;). &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:27.826%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.183%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.183%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.183%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.183%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Variable leases costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;906&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The present value assumptions used in calculating the present value of the lease payments were as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:72.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:24.180000000000003%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Six Months Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average remaining lease term in years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The minimum aggregate future operating lease commitments at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024 are as follows (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;in thousands&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.860000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Minimum Lease&lt;br/&gt;Payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Remainder of 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: current portion of operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease liability, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <tsbx:NumberOfSquareFeetForLease
      contextRef="C_d0a34fda-1a97-4930-aa8e-a5ab1c515de5"
      decimals="0"
      id="F_4f4f803e-ab02-4c85-88de-4292b8aae9bb"
      unitRef="U_SquareFeet">6500</tsbx:NumberOfSquareFeetForLease>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_80fd60e1-4de1-4fea-91cc-497c425d7782"
      id="F_14ece8d6-0f21-4404-bb2a-d52044b391ce">P7Y3M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="C_159402e9-c2a7-4db5-8c56-97648d7a2af3"
      decimals="-5"
      id="F_74db5c51-69b6-47f3-abda-211b4fd005c8"
      unitRef="U_USD">500000</us-gaap:OperatingLeaseImpairmentLoss>
    <tsbx:NumberOfSquareFeetForLease
      contextRef="C_4fb7b644-c91b-460a-90e4-f747ea99d23e"
      decimals="0"
      id="F_f60c102b-e56e-4e18-8f93-eacda5e37139"
      unitRef="U_SquareFeet">6000</tsbx:NumberOfSquareFeetForLease>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_538d2283-b280-4bac-8832-abf9afae8b56"
      id="F_0c9aef3d-2f07-454c-a918-b7546e70e252">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_538d2283-b280-4bac-8832-abf9afae8b56"
      decimals="-5"
      id="F_b62a9f1d-171c-457a-9138-df49363ef2de"
      unitRef="U_USD">100000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_d92a8a59-80bf-4bc8-8d8b-2f30a155d5e5"
      id="F_b8e01e04-9277-4ba8-b8b2-fc9d60911306">the lease was extended for a one year period.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_fbbc94d3-e5cf-4af0-9f58-49c609a48ce9"
      id="F_41e67c3a-729f-4eb4-9ff8-147ef774fa7c">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <tsbx:NumberOfSquareFeetForLease
      contextRef="C_cb80c5db-70c4-46c8-b391-908e60dc4392"
      decimals="0"
      id="F_684d04ac-9795-439f-ab8a-f38690357b34"
      unitRef="U_SquareFeet">9423</tsbx:NumberOfSquareFeetForLease>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_4dcd6724-0338-4288-a92d-f40147c40f0a"
      id="F_c491e39e-4a45-48a3-a905-47258e72f900">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_f8d09b91-2147-483c-b5ae-6de7be334706"
      id="F_159dd3de-163f-486b-ab8d-945bc50236b9">one renewal option for a period of five years</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_4dcd6724-0338-4288-a92d-f40147c40f0a"
      id="F_3e9e623a-8a6c-4674-9c02-aba4b68908a0">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <tsbx:NumberOfSquareFeetForLease
      contextRef="C_e8c17d3b-ae8b-41f1-a20f-40ff4625b247"
      decimals="0"
      id="F_46c37b58-8a0d-4a7e-a223-167a01fc6163"
      unitRef="U_SquareFeet">19474</tsbx:NumberOfSquareFeetForLease>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_bdf52929-1966-47f8-aeba-19d09b7e879d"
      id="F_e087c3bb-2c37-4263-997f-dad3755213c8">P38M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_f3098a29-f113-4e61-967a-00d2ad37159d"
      id="F_c0af435c-9f63-4d9e-bc9b-ecefc9e3fe32">one renewal option for a period of three years and commenced in March 2022</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_bdf52929-1966-47f8-aeba-19d09b7e879d"
      id="F_c177e416-1214-4586-8f07-ecd79ff85b48">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:PaymentsForRent
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-5"
      id="F_bc1b8d36-de03-4275-8ae4-3d9ff12e6e3c"
      unitRef="U_USD">800000</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-5"
      id="F_acb18432-f4c1-4e3c-ad1e-ab243477ef9d"
      unitRef="U_USD">900000</us-gaap:PaymentsForRent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_71cf6fbc-3b13-459d-b3f8-7f789a76be89">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The table below summarizes the Company&#x2019;s total lease costs included in its unaudited condensed consolidated financial statements, as well as other required quantitative disclosures (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;in thousands&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;). &lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:27.826%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.183%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.183%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.183%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.86%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.183%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Short-term lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Variable leases costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;398&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;430&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;906&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8"
      decimals="-3"
      id="F_3ca518a4-0072-479f-b62c-207af535f346"
      unitRef="U_USD">398000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b"
      decimals="-3"
      id="F_76fe9061-68af-4890-8c2c-30b2cf109b40"
      unitRef="U_USD">430000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_986851f2-2750-4b28-af8c-240b562287db"
      unitRef="U_USD">796000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_0aecf52d-69cb-43eb-8be8-0ed6d8be6f8a"
      unitRef="U_USD">900000</us-gaap:OperatingLeaseCost>
    <tsbx:ShortTermLeaseCosts
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_8e6ae1e0-6854-46b3-bc7c-1aed4e270b4e"
      unitRef="U_USD">1000</tsbx:ShortTermLeaseCosts>
    <us-gaap:VariableLeaseCost
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_27e8142c-bccc-4beb-998a-473d95c83e98"
      unitRef="U_USD">5000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8"
      decimals="-3"
      id="F_598d7d15-77dd-48ee-ba2a-c763f7374299"
      unitRef="U_USD">398000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_2f446809-dc2a-40e6-9aec-438ab12cb70b"
      decimals="-3"
      id="F_2d600589-6b52-4df3-b77c-38178e398769"
      unitRef="U_USD">430000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="-3"
      id="F_fca1f8c3-af72-42ca-819c-1ed4165a1e14"
      unitRef="U_USD">796000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="-3"
      id="F_34b1991e-36bb-4791-a0fd-611a7685d725"
      unitRef="U_USD">906000</us-gaap:LeaseCost>
    <tsbx:ScheduleOfPresentValueOfOperatingLeasePayments
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_3ba090ec-3104-4f74-9550-a4443962d96a">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The present value assumptions used in calculating the present value of the lease payments were as follows:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:72.02%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:24.180000000000003%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Six Months Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average remaining lease term in years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</tsbx:ScheduleOfPresentValueOfOperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      id="F_9bcb1ac9-4ecd-40b6-89c9-030a0ae6d54c">P1Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="4"
      id="F_46059433-1ae2-415e-b211-71bd0c5644f6"
      unitRef="U_pure">0.0574</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_0d1dbfc9-893d-4f00-be11-31b2239c2fe3">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The minimum aggregate future operating lease commitments at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024 are as follows (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;in thousands&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;):&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.36%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.78%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:15.860000000000001%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Minimum Lease&lt;br/&gt;Payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Remainder of 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,110&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Less: current portion of operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Operating lease liability, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_0c99d809-2af1-4e06-b4d0-8d18163d6c76"
      unitRef="U_USD">1056000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_c903273a-0a55-4e11-b90f-e1246e928e32"
      unitRef="U_USD">1110000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_0f4fc657-5436-4f16-9243-ac5fd108581d"
      unitRef="U_USD">105000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_e2cbfbce-9a22-4eb3-bbc5-1978045e5b15"
      unitRef="U_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_0b8f27ae-e864-427b-a63e-6218891d832c"
      unitRef="U_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_7b0c7b0f-5365-47ef-8bf3-702720ff1529"
      unitRef="U_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_60a07187-d0d3-4cc9-b841-b1c30b73b823"
      unitRef="U_USD">2270000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_2bafeac6-79ba-4eb7-9fc5-7e5c521ef91c"
      unitRef="U_USD">66000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_97486c4a-7b79-4d6c-a6cd-bfa2885a86b9"
      unitRef="U_USD">2204000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_522def20-8def-497d-9934-ee99b6219273"
      unitRef="U_USD">1793000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_a8da5438-d86e-4609-9ee4-eda50bdb908b"
      decimals="-3"
      id="F_4112431f-22bb-41ab-ba7e-a29da1b76e2a"
      unitRef="U_USD">411000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_7eacee74-57e3-47bb-abaf-e7b9243ee0e0">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;13. Net Loss per Share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Basic and diluted net loss per share attributed to common stockholders is calculated by dividing net loss attributed to common stockholders by the weighted average number of common shares outstanding during the period, without consideration for common stock equivalents. The Company&#x2019;s potentially dilutive shares, which include preferred stock, restricted stock, unvested RSUs and options to purchase common stock, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. Potentially dilutive common shares have been excluded from the diluted net loss per common share computations in all periods presented because such securities have an anti-dilutive effect on net loss per common share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;due to the Company&#x2019;s net loss. There are no reconciling items used to calculate the weighted-average number of total common shares outstanding for basic and diluted net loss per common share.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following outstanding potentially dilutive shares were excluded from the computation of diluted net loss per share attributable to common stockholders:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.98%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="background-color:#ffffff;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;181,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;108,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,298,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,604,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Redeemable convertible preferred stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,493,879&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,498,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,279,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_a30baf78-ef59-42ec-b7da-2ddbe3f11eaf">&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following outstanding potentially dilutive shares were excluded from the computation of diluted net loss per share attributable to common stockholders:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.98%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.52%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:14.5%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.98%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="background-color:#ffffff;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:#ffffff;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#ffffff;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:#cff0fc;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Restricted stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;90,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;181,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Unvested RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;108,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,298,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,604,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Redeemable convertible preferred stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,493,879&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,498,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,279,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_8b8a1ea1-2432-469c-84b7-3b0a47c7f036"
      decimals="0"
      id="F_5b65f654-1f50-453d-8507-d19303f13b6d"
      unitRef="U_shares">90740</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_de5bd2cb-2a69-4ca4-88ea-be6ca6b3d91e"
      decimals="0"
      id="F_212207ac-de70-45ba-9d70-894f2e85aa12"
      unitRef="U_shares">181480</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_076f0cb5-40e9-4509-958f-29eee0f3a275"
      decimals="0"
      id="F_7834dc0e-9022-4cc6-b91f-833e5a12258a"
      unitRef="U_shares">108899</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c5e178ae-25e5-4b12-b4f7-11636d959e09"
      decimals="0"
      id="F_03012fc0-564f-48fd-a11c-2ac825e2db6b"
      unitRef="U_shares">3298558</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_18a36a9d-0182-4470-abc8-5f7ff7b3b4a5"
      decimals="0"
      id="F_22f3020d-675f-4a5d-835a-45ab51f352bf"
      unitRef="U_shares">2604639</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f25cb532-a515-4fa7-abaf-0947b47f1a2d"
      decimals="0"
      id="F_d4e1f7ba-44da-4252-9b18-11c877bccd90"
      unitRef="U_shares">12493879</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="0"
      id="F_6b935a30-d7eb-4818-a556-1b76d1b72fc5"
      unitRef="U_shares">3498197</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_bf315150-6fec-4edf-8d74-affc42e06301"
      decimals="0"
      id="F_0c7e2212-74f1-4c4f-aca5-907f8628cf91"
      unitRef="U_shares">15279998</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      id="F_818ba649-8f10-4c7e-b109-c2d48d3bb746">&lt;p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;14. Legal Proceedings&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is not a party to any material legal matters or claims and does &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;t have contingency reserves established for any litigation liabilities as of June 30, 2024 and December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <tsbx:LossContingencyReserveForLitigationLiabilities
      contextRef="C_264a7ac5-398e-4718-ac23-f5ff805f1954"
      decimals="INF"
      id="F_ecf7099a-46c1-4b7f-817f-dc71d5b1f936"
      unitRef="U_USD">0</tsbx:LossContingencyReserveForLitigationLiabilities>
    <tsbx:LossContingencyReserveForLitigationLiabilities
      contextRef="C_c2fc5443-940d-4d73-8fd5-8bcdd4605301"
      decimals="INF"
      id="F_82445838-cf0a-4347-bbb8-746b719448d2"
      unitRef="U_USD">0</tsbx:LossContingencyReserveForLitigationLiabilities>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8"
      id="F_7d9913e7-a350-4f0e-b4af-f188c651d696">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8"
      id="F_3d184698-485a-4f06-9514-ce0220ad69f6">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8"
      id="F_10961851-7d38-47ac-b6e6-70a46ff0cb4e">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_e6e69f2f-abc9-4e6a-9cc6-19e6faae1cb8"
      id="F_df7f33b6-f91b-452e-8c79-5650032a7fa8">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
